0000950170-22-004847.txt : 20220329 0000950170-22-004847.hdr.sgml : 20220329 20220329073105 ACCESSION NUMBER: 0000950170-22-004847 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 78 CONFORMED PERIOD OF REPORT: 20211231 FILED AS OF DATE: 20220329 DATE AS OF CHANGE: 20220329 FILER: COMPANY DATA: COMPANY CONFORMED NAME: HCW Biologics Inc. CENTRAL INDEX KEY: 0001828673 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 825024477 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40591 FILM NUMBER: 22777367 BUSINESS ADDRESS: STREET 1: 2929 N COMMERCE PKWY CITY: MIRAMAR STATE: FL ZIP: 33025 BUSINESS PHONE: 954-842-2024 MAIL ADDRESS: STREET 1: 2929 N COMMERCE PKWY CITY: MIRAMAR STATE: FL ZIP: 33025 10-K 1 hcwb-20211231.htm 10-K 10-K
false0001828673December 315,792,302FY0001828673us-gaap:OfficeEquipmentMember2020-12-310001828673srt:MaximumMember2021-01-012021-12-310001828673us-gaap:CommonStockMember2019-12-310001828673us-gaap:GeneralAndAdministrativeExpenseMember2020-01-012020-12-310001828673us-gaap:AdditionalPaidInCapitalMember2021-12-310001828673us-gaap:RetainedEarningsMember2020-12-310001828673hcwb:TwoThousandTwentyOnePlanMember2021-06-212021-06-210001828673hcwb:TreasuryNotesMember2021-12-310001828673hcwb:TreasuryBillsMember2021-12-310001828673hcwb:SeriesARedeemablePreferredStockMemberus-gaap:PreferredStockMember2020-12-310001828673hcwb:SeriesARedeemablePreferredStockMemberus-gaap:PreferredStockMember2019-12-310001828673us-gaap:FairValueInputsLevel1Member2021-12-310001828673hcwb:SeriesARedeemablePreferredStockMember2019-12-310001828673us-gaap:FairValueInputsLevel3Member2021-12-310001828673hcwb:SbaPaycheckProtectionLoanMember2020-05-200001828673hcwb:ConversionOfSeriesCRedeemablePreferredStockMemberhcwb:SeriesCRedeemablePreferredStockMember2021-01-012021-12-310001828673us-gaap:FairValueInputsLevel1Memberhcwb:TreasuryBillsMember2021-12-310001828673us-gaap:DomesticCountryMember2021-12-310001828673hcwb:WugenLicenseMember2020-12-310001828673us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMember2021-12-310001828673us-gaap:AdditionalPaidInCapitalMember2021-01-012021-12-310001828673us-gaap:CommonStockMemberhcwb:SeriesCRedeemablePreferredStockMember2021-01-012021-12-310001828673hcwb:TreasuryNotesMemberus-gaap:FairValueInputsLevel1Member2021-12-310001828673us-gaap:PreferredStockMember2019-12-310001828673us-gaap:FairValueInputsLevel2Member2020-12-310001828673us-gaap:FurnitureAndFixturesMember2020-12-310001828673us-gaap:SeriesAPreferredStockMember2021-01-012021-12-310001828673us-gaap:CommonStockMember2020-01-012020-12-310001828673hcwb:WugenLicenseMember2021-12-310001828673us-gaap:PreferredStockMemberhcwb:SeriesCRedeemablePreferredStockMember2020-12-310001828673us-gaap:RetainedEarningsMemberhcwb:SeriesCRedeemablePreferredStockMember2021-01-012021-12-3100018286732021-07-220001828673hcwb:SeriesBRedeemablePreferredStockMember2021-01-012021-12-310001828673us-gaap:FairValueInputsLevel3Memberus-gaap:InvestmentsMember2020-12-310001828673us-gaap:LeaseholdsAndLeaseholdImprovementsMember2020-12-310001828673us-gaap:SubsequentEventMember2022-03-012024-02-290001828673us-gaap:CommonStockMember2021-12-310001828673us-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-12-310001828673us-gaap:AdditionalPaidInCapitalMemberhcwb:SeriesBRedeemablePreferredStockMember2021-01-012021-12-310001828673us-gaap:AdditionalPaidInCapitalMemberhcwb:SeriesCRedeemablePreferredStockMember2021-01-012021-12-310001828673hcwb:ConversionOfSeriesBRedeemablePreferredStockMemberhcwb:SeriesBRedeemablePreferredStockMember2021-01-012021-12-310001828673hcwb:SeriesCRedeemablePreferredStockMember2020-01-012020-12-310001828673us-gaap:CommonStockMember2021-12-310001828673hcwb:SeriesARedeemablePreferredStockMemberus-gaap:RetainedEarningsMember2021-01-012021-12-310001828673hcwb:SeriesARedeemablePreferredStockMember2021-12-310001828673hcwb:ProceedsFromIssuanceOfPreferredStockMemberhcwb:SeriesCRedeemablePreferredStockMember2020-12-310001828673us-gaap:RetainedEarningsMember2021-12-310001828673us-gaap:FairValueInputsLevel3Memberhcwb:TreasuryBillsMember2021-12-310001828673hcwb:ResidualApproachMember2021-01-012021-12-310001828673us-gaap:StateAndLocalJurisdictionMember2020-12-310001828673us-gaap:FairValueInputsLevel3Memberus-gaap:MoneyMarketFundsMember2021-12-310001828673us-gaap:FairValueInputsLevel3Member2020-12-310001828673srt:MinimumMemberhcwb:TwoThousandNineteenPlanMember2021-06-212021-06-210001828673hcwb:RedeemablePreferredStocksMember2021-01-012021-12-310001828673us-gaap:SeriesAPreferredStockMember2020-12-3100018286732020-12-310001828673us-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMember2021-12-310001828673us-gaap:CommonStockMember2021-01-012021-12-310001828673us-gaap:FairValueInputsLevel2Memberhcwb:TreasuryNotesMember2021-12-310001828673hcwb:TreasuryNotesMemberus-gaap:FairValueInputsLevel3Member2021-12-310001828673us-gaap:CommonStockMemberus-gaap:IPOMember2021-07-220001828673hcwb:CommonStockOptionsMember2020-01-012020-12-3100018286732022-03-220001828673srt:MinimumMember2021-01-012021-12-310001828673us-gaap:ResearchAndDevelopmentExpenseMember2020-01-012020-12-310001828673us-gaap:SeriesBPreferredStockMember2020-12-310001828673hcwb:SeriesARedeemablePreferredStockMemberhcwb:ConversionOfSeriesARedeemablePreferredStockMember2021-01-012021-12-3100018286732021-12-310001828673us-gaap:CommonStockMemberhcwb:SeriesBRedeemablePreferredStockMember2021-01-012021-12-310001828673hcwb:USGovernmentBackedSecuritiesMember2021-12-310001828673us-gaap:MoneyMarketFundsMember2021-12-310001828673us-gaap:FairValueInputsLevel2Memberhcwb:TreasuryBillsMember2021-12-310001828673hcwb:SeriesBRedeemablePreferredStockMember2021-12-310001828673us-gaap:RetainedEarningsMember2021-01-012021-12-310001828673us-gaap:RetainedEarningsMember2019-12-310001828673us-gaap:LeaseholdsAndLeaseholdImprovementsMember2021-12-310001828673hcwb:SeriesARedeemablePreferredStockMemberus-gaap:CommonStockMember2021-01-012021-12-310001828673us-gaap:SeriesBPreferredStockMember2021-01-012021-12-310001828673us-gaap:AccountsPayableAndAccruedLiabilitiesMember2021-12-310001828673hcwb:TwoThousandTwentyOnePlanMemberus-gaap:CommonClassAMember2021-06-210001828673hcwb:ClassBConvertibleCommonStockMember2021-12-310001828673us-gaap:CommonStockMemberus-gaap:IPOMember2021-07-222021-07-220001828673hcwb:WugenLicenseMember2020-01-012020-12-310001828673us-gaap:SeriesCPreferredStockMember2020-12-310001828673us-gaap:FairValueInputsLevel2Memberus-gaap:InvestmentsMember2020-12-310001828673us-gaap:CommonStockMember2020-12-310001828673hcwb:RedeemablePreferredStocksMember2020-01-012020-12-310001828673hcwb:SeriesCRedeemablePreferredStockMember2021-01-012021-12-310001828673us-gaap:FairValueInputsLevel1Memberus-gaap:InvestmentsMember2020-12-310001828673hcwb:SeriesBRedeemablePreferredStockMember2020-12-310001828673us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMemberhcwb:TwoThousandTwentyOnePlanMember2021-06-210001828673us-gaap:MoneyMarketFundsMember2020-12-310001828673us-gaap:SubsequentEventMember2022-01-310001828673hcwb:SeriesARedeemablePreferredStockMember2020-12-310001828673hcwb:SeriesCRedeemablePreferredStockMember2020-12-310001828673hcwb:SeriesARedeemablePreferredStockMember2020-01-012020-12-310001828673us-gaap:FairValueInputsLevel1Member2020-12-310001828673hcwb:SeriesBRedeemablePreferredStockMember2019-12-310001828673us-gaap:AdditionalPaidInCapitalMember2020-01-012020-12-310001828673hcwb:SeriesARedeemablePreferredStockMemberus-gaap:AdditionalPaidInCapitalMember2021-01-012021-12-310001828673hcwb:LaboratoryEquipmentMember2021-12-310001828673us-gaap:RetainedEarningsMemberhcwb:SeriesBRedeemablePreferredStockMember2021-01-012021-12-310001828673hcwb:SeriesBRedeemablePreferredStockMember2020-01-012020-12-3100018286732022-01-310001828673us-gaap:FairValueInputsLevel3Memberus-gaap:MoneyMarketFundsMember2020-12-3100018286732020-03-272020-03-270001828673us-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMember2020-12-310001828673hcwb:AccruedExpensesCurrentMember2021-01-082021-01-080001828673us-gaap:PreferredStockMemberhcwb:SeriesBRedeemablePreferredStockMember2019-12-3100018286732021-01-012021-12-310001828673hcwb:SeriesARedeemablePreferredStockMember2021-01-012021-12-3100018286732019-01-012019-12-310001828673hcwb:SeriesCRedeemablePreferredStockMember2021-12-310001828673us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMember2020-12-310001828673us-gaap:FairValueInputsLevel2Member2021-12-310001828673hcwb:CommonStockOptionsMember2021-01-012021-12-3100018286732019-12-310001828673hcwb:SbaPaycheckProtectionLoanMember2020-12-310001828673us-gaap:USTreasuryBillSecuritiesMemberus-gaap:IPOMember2021-01-012021-12-3100018286732021-06-252021-06-250001828673us-gaap:InvestmentsMember2020-12-310001828673hcwb:ClassBConvertibleCommonStockMember2020-12-310001828673us-gaap:RetainedEarningsMember2020-01-012020-12-310001828673us-gaap:DomesticCountryMember2020-12-310001828673us-gaap:GeneralAndAdministrativeExpenseMember2021-01-012021-12-3100018286732020-01-012020-12-310001828673hcwb:LaboratoryEquipmentMember2020-12-310001828673us-gaap:AccountsPayableAndAccruedLiabilitiesMember2021-01-012021-12-310001828673us-gaap:PreferredStockMemberhcwb:SeriesBRedeemablePreferredStockMember2020-12-310001828673srt:MaximumMemberhcwb:TwoThousandNineteenPlanMember2021-06-212021-06-210001828673us-gaap:SeriesCPreferredStockMember2021-01-012021-12-310001828673hcwb:AccruedExpensesCurrentMember2020-12-310001828673us-gaap:StateAndLocalJurisdictionMember2021-12-310001828673us-gaap:OfficeEquipmentMember2021-12-310001828673us-gaap:IPOMemberus-gaap:USTreasuryNotesSecuritiesMember2021-01-012021-12-310001828673us-gaap:CommonStockMember2020-12-310001828673us-gaap:FurnitureAndFixturesMember2021-12-31xbrli:purexbrli:sharesiso4217:USDxbrli:sharesiso4217:USD

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-K

 

(Mark One)

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2021

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO

Commission File Number 001-40591

 

HCW Biologics Inc.

(Exact name of registrant as specified in its Charter)

 

 

Delaware

82-5024477

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer

Identification No.)

2929 N. Commerce Parkway

Miramar, Florida

33025

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code: (954) 842–2024

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange on which registered

Common Stock, par value $0.0001 per share

 

HCWB

 

The Nasdaq Stock Market LLC

Securities registered pursuant to Section 12(g) of the Act: None

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. YesNo

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. YesNo

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. YesNo

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). YesNo

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

 

 

Accelerated filer

 

 

 

 

 

Non-accelerated filer

 

 

Smaller reporting company

 

 

 

 

 

 

 

 

Emerging growth company

 

 

 

 

 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YesNo

 

The aggregate market value of the common stock held by non-affiliates of the registrant as of July 22, 2021, the closing date of the registrant’s initial public offering, was approximately $91.4 million based on the closing price of the shares of $4.77 as reported on the Nasdaq Global Market on such date . The registrant has elected to use July 22, 2021, as the calculation date because on June 30, 2021 (the last business day of the registrant’s most recently completed second fiscal quarter) the registrant was a privately held company. This calculation does not reflect a determination that certain persons are affiliates of the registrant for any other purpose.

 

The number of shares of the registrant’s common stock outstanding as of March 22, 2022 was 35,779,489.

DOCUMENTS INCORPORATED BY REFERENCE

Part III incorporates by reference certain information from the registrant’s definitive proxy statement (the “Proxy Statement”) relating to its 2022 Annual Meeting of Stockholders. The Proxy Statement will be filed with the United States Securities and Exchange Commission within 120 days after the end of the fiscal year to which this report relates.

 

 

 

 


 

Table of Contents

 

 

 

Page

Part I

 

4

Item 1

Business

4

Item 1A

Risk Factors

39

Item 1B

Unresolved Staff Comments

86

Item 2

Properties

86

Item 3

Legal Proceedings

86

Item 4

Mine Safety Disclosures

86

 

 

 

Part II

 

86

Item 5

Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

86

Item 6

[Reserved]

87

Item 7

Management’s Discussion and Analysis of Financial Condition and Results of Operations

88

Item 7A

Quantitative and Qualitative Disclosures About Market Risk

100

Item 8

Financial Statements and Supplementary Data

101

Item 9

Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

122

Item 9A

Controls and Procedures

122

Item 9B

Other Information

122

Item 9C

Disclosure Regarding Foreign Jurisdictions That Prevent Inspections

122

 

 

 

Part III

 

123

Item 10

Directors, Executive Officers and Corporate Governance

123

Item 11

Executive Compensation

123

Item 12

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

123

Item 13

Certain Relationships and Related Transactions, and Director Independence

123

Item 14

Principal Accounting Fees and Services

123

 

 

 

Part IV

 

124

Item 15

Exhibits, Financial Statement Schedules

124

Item 16

Form 10-K Summary

126

 

-i-

 


 

Special Note Regarding Forward-Looking Statements

 

This Annual Report on Form 10-K contains forward-looking statements. All statements other than statements of historical facts contained in this report, including statements regarding our future results of operations and financial position, business strategy, product candidates, planned preclinical studies and clinical trials, research and development costs, regulatory approvals, timing and likelihood of success, as well as plans and objectives of management for future operations, are forward-looking statements. In some cases, forward-looking statements may be identified by words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "could," "would," "expect," "objective," "plan," "potential," "seek," "grow," "target," "if," and similar expressions intended to identify forward-looking statements.

 

We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy short-term and long-term business operations and objectives and financial needs. These forward-looking statements are subject to known and unknown risks, uncertainties and assumptions, including risks described in the section titled “Risk Factors” set forth in Part I, Item 1A of this Annual Report on Form 10-K and in our other filings with the Securities and Exchange Commission (the "SEC"). It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the future events and trends discussed in this Annual Report on Form 10-K may not occur, and actual results may differ materially and adversely from those anticipated or implied in the forward-looking statements. Forward-looking statements contained in this Annual Report on Form 10-K include, but are not limited to, statements about:

our financial performance;
the sufficiency of our existing cash and cash equivalents to fund our future operating expenses and capital expenditure requirements;
our ability to obtain funding for our operations, including funding necessary to develop and commercialize our drug candidates;
the ability to receive FDA clearance for clinical trials;
the ability to secure clinical sites, enroll patients, and initiate clinical trials;
the ability of our clinical trials to demonstrate safety and efficacy of our drug candidates, and other positive results;
the success, cost and timing of our development activities, preclinical studies and clinical trials;
the timing and focus of our future clinical trials, and the reporting of data from those trials;
our plans relating to commercializing our drug candidates, if approved;
our plans and ability to establish sales, marketing and distribution infrastructure to commercialize any drug candidates for which we obtain approval;
our ability to attract and retain key scientific and clinical personnel;
our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately;
our reliance on third parties to conduct clinical trials of our drug candidates, and for the manufacture of our drug candidates for preclinical studies and clinical trials;
our ability to establish our own manufacturing facilities domestically;
our ability to expand our drug candidates into additional indications and patient populations;
the success of competing therapies that are or may become available;
the beneficial characteristics, safety and efficacy of our drug candidates;
regulatory developments in the United States and other jurisdictions;
our ability to obtain and maintain regulatory approval of our drug candidates, and any related restrictions, limitations and/or warnings in the label of any approved drug candidate;

2

 


 

our plans relating to the further development and manufacturing of our drug candidates, including additional indications for which we may pursue;
our plans and ability to obtain or protect intellectual property rights;
the scope of protection we are able to establish and maintain for intellectual property rights covering our drug candidates and technology; and
potential claims relating to our intellectual property.

We caution you that the foregoing list may not contain all of the forward-looking statements made in this Annual Report on Form 10-K.

You should not rely upon forward-looking statements as predictions of future events. The events and circumstances reflected in the forward-looking statements may not be achieved or occur. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, we do not intend to update any of these forward-looking statements after the date of this Annual Report on Form 10-K or to conform these statements to actual results or revised expectations.

Because some of these risks and uncertainties cannot be predicted or quantified and may be beyond our control, you should read this Annual Report on Form 10-K with the understanding that our actual future results, levels of activity, performance and events and circumstances may be materially different from what we expect.

This Annual Report on Form 10-K contains estimates, projections and other information concerning our industry, our business and the markets for our product candidates. We obtained the industry, market and similar data set forth in this report from our own internal estimates and research and from academic and industry research, publications, surveys and studies conducted by third parties, including governmental agencies. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances that are assumed in this information. While we believe that the data we use from third parties are reliable, we have not separately verified these data. Further, while we believe our internal research is reliable, such research has not been verified by any third party. You are cautioned not to give undue weight to any such information, projections and estimates.

3

 


 

PART I

Item 1. Business.

Overview

HCW Biologics Inc. ("HCW Biologics", "HCW", the "Company, or "we") is a biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. We believe age-related, chronic, low-grade inflammation, or “inflammaging,” is a significant contributing factor to several diseases and conditions, such as cancer, cardiovascular disease, diabetes, neurodegenerative diseases, and autoimmune diseases. The induction and retention of low-grade inflammation in an aging human body is mainly the result of the accumulation of non-proliferative senescent cells and persistent activation of protein complexes, known as inflammasomes, in innate immune cells. These two elements share common mechanisms in promoting secretion of proinflammatory proteins and in many cases interact to drive inflammaging. Our novel approach is to treat both of these elements. We believe our approach has the potential to fundamentally change the treatment of age-related diseases.

We have combined our deep understanding of disease-related immunology with our expertise in advanced protein engineering to develop our TOBITM (Tissue factOr-Based fusIon) discovery platform for the design of category-defining immunotherapeutic drugs. This modular and tunable technology has allowed us to generate a novel pipeline of internally-developed product candidates capable of activating and targeting desired immune responses and blocking unwanted immunosuppressive activities. Using our TOBITM platform, we have successfully developed over 30 molecules that can be administered by subcutaneous injection as well as used in adoptive cell therapy approaches. Our focus is to develop immunotherapeutic therapies administered by subcutaneous injection, and we intend to out-license cell therapy based approaches. We have selected two molecules as our lead product candidates: HCW9218 and HCW9302. We have chosen these product candidates because we believe they have the potential to become transformative immunotherapeutics for the treatment of a broad range of age-related diseases, and both can be administered to patients by subcutaneous injection.

In response to physiological or environmental stress, normal tissue cells enter a senescent state of irreversible growth arrest accompanied by the release of Senescence-Associated Secretory Phenotype (“SASP”) factors. SASP factors, including proinflammatory cytokines, chemokines, and proteinases, drive the inflammation cycle, including activation of inflammasomes. As our body ages, senescent cells accumulate and increase the release of SASP factors leading to chronic, low-grade inflammation, and organ/tissue damage. Studies have shown that strategies to reduce or eliminate senescent cells can delay, prevent, and improve age-related dysfunctions, including cancer.

The bifunctionality of HCW9218 allows it to function as both a senolytic and senomorphic immunotherapeutic. HCW9218 is designed to treat the impact of accumulated senescent cells and the SASP factors which they secrete by eliminating senescent cells (i.e., senolytic effect) and reducing SASP factors (i.e., senomorphic effect). This molecule is a heterodimeric, bifunctional fusion protein complex comprising extracellular domains of the human transforming growth factor-β (“TGF-β”) receptor II, as a TGF-β trap for TGF-β neutralization, and a human interleukin (“IL”)-15/IL-15 receptor α complex for immune cell stimulation. Together, the activities of these domains drive senescent cell clearance and SASP factor neutralization. The Company published a paper authored by our scientific research team in the peer-reviewed journal, Molecular Therapy, entitled, “Bifunctional TGF-β trap/IL-15 Protein Complex Elicits Potent NK Cell and CD8+ T Cell Immunity Against Solid Tumors.” The paper highlights preclinical data from in vivo studies demonstrating the potential of HCW9218 as a novel immunostimulant with the ability to simultaneously lessen immunosuppression in patients with cancer.

As the first line of defense to infections or tissue injuries, the innate immune system activates inflammasomes to initiate protective immune responses. Similar to senescent cells, activated inflammasomes promote the release of proinflammatory factors. Unresolved activation of inflammasomes due to chronic infection or persistent tissue injury leads to chronic low-grade inflammation which perpetuates this cycle.

HCW9302 is designed to activate and expand regulatory T (“Treg”) cells to suppress the activity of inflammasome-bearing cells and the inflammatory factors which they secrete. This molecule is a single-chain, IL-2-based fusion protein. Inflammasomes are expressed in innate immune cells. When these cells are stimulated by various signals, the inflammasomes become active and the cells release inflammatory factors. In certain conditions, these signaling pathways persist leading to chronic inflammatory responses and associated tissue destruction. Preclinical studies in mouse models have demonstrated the ability of HCW9302 to activate Treg cells and reduce inflammation-related diseases, supporting the potential of HCW9302 to treat a wide variety of autoimmune and age-related diseases.

4

 


 

To date, there has been limited clinical success in targeting senescent cell accumulation or aberrant inflammasome activity using small molecule-based approaches. Studies have found the immune cell activity in young individuals is capable of limiting these processes, which we believe indicates that immunotherapeutic approaches that combine relevant stimulatory and inhibitory components may provide a means of treating age-related diseases by addressing chronic inflammation.

HCW9218: Novel Senolytic and Senomorphic Immunotherapeutic

We have selected cancer as the initial indication for our clinical development. In cancer patients, chemotherapy treatments cause therapy-induced senescence, or TIS, which drives tumor cells to senescence, resulting in increased drug-resistance, immune evasion, disease relapse, and tumor metastasis. We believe the bifunctionality of HCW9218 will allow it to be effective against solid tumor cancers because it simultaneously provides immunostimulation of natural killer (“NK”) cells and effector T cells to enhance the cytotoxicity of immune cells against tumor targets, while reducing immunosuppression associated with solid tumors by capturing and neutralizing TGF-β.

Chemotherapy is the current standard of care for treating most forms of cancer. However, these treatments inevitably result in toxicity and unwanted side effects. Multiple studies have revealed that increased normal tissue cellular senescence can promote tumor progression, creating a link between aging and cancer. The persistence of viable and metabolically active senescent tumor cells after chemotherapy has been attributed to worse overall survival in patients. Tumor cells can undergo senescence and secrete proinflammatory factors, or SASP factors, in response to chemotherapy. SASP factors promote TIS cancer cells to re-enter the growth cycle with stem-like characteristics which can result in disease relapse and metastasis. One of the key SASP factors is TGF-ß, well known for its immunosuppressive role in cancer progression. In healthy tissue, TGF-ß is transiently activated in response to tissue injury, resulting in collagen production and, ultimately, healing of the tissue. However, when TFG-ß becomes continuously active, studies have shown that it induces pathological effects associated with inflammation.

The U.S. Food and Drug Administration (“FDA”) has permitted two clinical trials to proceed to evaluate HCW9218 in difficult-to-treat cancer indications. A Company-sponsored clinical trial will evaluate HCW9218 in advanced pancreatic cancer, and an Investigator-sponsored trial with the Masonic Cancer Center at University of Minnesota as the sponsor will evaluate HCW9218 in other solid tumors.

Company-sponsored clinical trial. In October 2021, the FDA permitted a Company-sponsored first-in-human Phase 1b clinical trial to proceed with a multi-site trial to evaluate our lead drug candidate, HCW9218, in patients with advanced pancreatic cancer. The Company has identified several potential clinical sites that are National Cancer Institute (“NCI”) designated Comprehensive Cancer Centers. These Comprehensive Cancer Centers are completing their internal review processes for study start-up. We expect to initiate this trial in the first half of 2022. The Phase 1b portion is planned to be a dose escalation study of HCW9218 as a monotherapy in refractory patients with advanced pancreatic cancer. If the initial phase of the trial is completed successfully, the Company plans to have the primary aim of the later phases of the study to evaluate HCW9218 as an adjunct therapy to chemotherapy. We expect that the Phase 2 portion of this pancreatic trial will include a cohort of patients receiving HCW9218 as monotherapy and a cohort of patients receiving HCW9218 as an adjunct to chemotherapy.

Investigator-sponsored clinical trial. In January 2022, the FDA permitted the Masonic Cancer Center at University of Minnesota to proceed with a Phase 1 clinical trial, which is a single-center, Investigator-sponsored clinical trial to evaluate HCW9218 in patients with advanced solid tumors with progressive disease after prior chemotherapies. We expect to initiate this trial in the first half of 2022. The Masonic Cancer Center is the Twin Cities’ only NCI-designated Comprehensive Cancer Center, and they are designated ‘Outstanding’ by the National Cancer Institute. This trial is planned to be a dose-escalation study and is designed as a “basket trial” and may include patients with breast, ovarian, prostate, and colorectal cancers. The Principal Investigator of the clinical trial is Melissa A. Geller, M.D., M.S., Professor and Division Director of Gynecologic Oncology in the Department of Obstetrics, Gynecology and Women’s Health at the University of Minnesota. The Co-Principal Investigator is Jeffrey A. Miller, M.D., Deputy Director of the Masonic Cancer Center. If the initial phase of the trial is completed successfully, the Principal Investigators may design later phases of clinical trials in solid tumors with the end goal of estimating the response in select solid tumors in combination with disease-appropriate anti-cancer treatment.

The timing of the initiation of the Company-sponsored clinical trial depends upon completion of an internal review and approval process required for each site in order to participate in a clinical study. If any of the clinical sites we have selected does not receive approval to participate, then we will need to identify other potential clinical sites which may cause a delay. The duration of both the Company-sponsored trial and the Investigator-sponsored trial is expected to be approximately 12 months once patient enrollment begins; however, the timing depends on site preparation, how quickly patients can be enrolled in the studies, and the number of dose escalations that will be required to meet the primary objective of the studies. If all of the currently available lot of HCW9218 is used in the initial phase of the trial, continuing to the next phase of clinical trials is contingent upon obtaining FDA

5

 


 

approval of additional lots of cGMP material. Since we plan to have product release of additional cGMP material that meets FDA requirements by the end of 2022, we do not anticipate any delay in advancing our clinical trial to the next phase due to supply issues. However, we cannot assure you that supply will be available if and when it is needed owing to, among other things, the ongoing macro supply chain issues arising from the impact of the COVID-19 pandemic, which are beyond our control. See “Risk Factors -- Supply sources could be interrupted from time to time and, if interrupted, there is no guarantee that supplies could be resumed within a reasonable time frame and at an acceptable cost or at all.”

We have selected difficult-to-treat, chemo-resistant cancer indications for our initial clinical trials. We believe a well- designed clinical trial in such challenging indications will demonstrate that HCW9218 can improve the efficacy of chemotherapy and minimize its side effects by eliminating TIS, that is chemotherapy-induced senescent cells in tumors and normal tissues. We are leveraging the extensive clinical expertise of our team to structure clinical trials with clear, objective, and measurable endpoints. We intend to manage initial clinical trials internally and will not use a clinical research organization to assist us.

HCW9302: Novel Immunotherapeutic for Treg Expansion

Our internally developed, lead product candidate, HCW9302, is an IL-2-based fusion molecule that expands Treg cells in vivo and ex vivo as an injectable or cell-based strategy to reduce inflammation through deactivation of inflammasomes. Preclinical studies have demonstrated the ability of HCW9302 to reduce inflammation, allowing for the potential to treat a wide variety of autoimmune and age-related diseases.

We expect to complete activities required for submission of an Investigational New Drug Application (“IND”) to evaluate HCW9302 in an autoimmune disorder by the end of 2022. Upon completion of IND-enabling activities, we intend to submit an IND for a Phase 1b clinical trial to evaluate HCW9302 in alopecia areata. We have not submitted the IND for the planned trial, and we cannot provide any assurance that the FDA will allow us to initiate our planned clinical trials on a timely basis, or at all. In the event that the FDA does not accept our IND, we may also be required to seek feedback, and the feedback may be unfavorable. In the event we do not receive feedback on a timely basis, or we are required to change the design of our clinical protocol or address other feedback, clinical development of our products would be delayed and our costs may increase. Moreover, if the FDA does not allow our initial clinical trial to proceed, we may be required to conduct additional preclinical testing or other IND-enabling activities, which would result in further delay and additional costs. If we successfully complete a Phase 1b study, we plan to build on the safety data established with alopecia areata and expand indications in Phase 2 clinical trials to evaluate HCW9302 in other autoimmune indications or pro-inflammatory diseases, such as atherosclerosis.

Out-Licensing: Strategy for Monetizing Non-Core Assets

We have internally-developed over 30 molecules using our TOBITM platform. In preclinlical studies, several of these molecules show pharmacological activity when administered as an injectable as well as a cell-based therapy. Our core focus will be the development of our lead product candidates, HCW9218 and HCW9302, as transformative immunotherapeutics, administered by subcutaneous injection. We intend to out-license certain rights for other internally-developed molecules with commercial potential that are outside of our focus area. We signed our first out-license agreement at the end of 2020, when we entered into an exclusive worldwide license with Wugen, Inc. (“Wugen”), a company that specializes in cell-based therapies for cancer. Wugen licensed limited rights to develop, manufacture, and commercialize cell therapy treatments for cancer based on two of our internally-developed multi-cytokine fusion protein molecules. Our clinical-stage molecule, HCW9201, is currently being evaluated for generation of memory-like NK (“ML-NK”) cell products in two Phase 2 studies with patients with relapsed/refractory Acute Myeloid Leukemia ("r/r AML"). The studies were initiated by the School of Medicine at Washington University in St. Louis and are supported financially by Wugen. HCW Biologics is currently assessing opportunities to out-license rights to HCW9302, our molecule for Treg activation and expansion, under terms that may include an upfront licensing fee, milestone payments based on performance, and a royalty based on sales of commercial products.

6

 


 

Our Approach

We believe we have an innovative strategy to treat age-related diseases. Our unique approach is to utilize our internally-developed TOBITM platform to create novel multi-functional immunotherapeutics to rejuvenate our immune system. With our platform technology, we have generated product candidates that are designed to direct the immune system against solid tumors, therapy-induced senescence and the adverse side effects triggered by existing standard-of-care treatments for cancer, and hematological cancers. We have also developed product candidates that are designed to direct the immune system against inflammation allowing for the potential to treat a wide variety of autoimmune and proinflammatory diseases. Our approach is to develop immunotherapies that eliminate the main drivers of chronic inflammation by addressing the underlying development and sustainment of these factors, as depicted in the image below:

 

img111359907_0.jpg 

 

 

The Science of Chronic Inflammation

While inflammation is part of the normal repair response for healing, when it becomes prolonged and persists, it is damaging and destructive. Several common molecular pathways have been identified that are associated with both aging and low-grade inflammation. Our view is that there are two primary underlying processes that drive chronic inflammation: Accumulation of senescent cells and SASP factors, and activation of inflammasomes.

Senescence is a form of irreversible cell growth arrest accompanied by phenotypic changes, resistance to apoptosis, and activation of damage-sensing signaling pathways. Senescence is considered a stress response that can be induced by a wide range of intrinsic and extrinsic insults, including oxidative and genotoxic stress, DNA damage, telomere attrition, oncogenic activation, mitochondrial dysfunction, or chemotherapeutic agents.

7

 


 

Senescent cells remain metabolically active and can influence tissue hemostasis, disease, and aging through their SASP factors. Senescence is considered to be a physiologic process and is important in promoting wound healing, tissue homeostasis, regeneration, and regulation of fibrosis. Senescence also plays a role in tumor suppression. The accumulation of senescent cells, due to the aging of our immune cells, also drives aging and age-related diseases and conditions. The SASP factors can trigger chronic inflammatory responses and consequently augment chronic inflammatory conditions to promote tumor growth. The connection between senescence and aging was initially based on the observation that senescent cells accumulate in aged tissue. The use of transgenic models has enabled the detection of senescent cells systematically in many age-related disorders. Studies have demonstrated that senescent cells play an adverse role in age-related disorders.

An increasing body of evidence has shown that chemotherapy and radiation, standard-of-care anti-cancer regimens, cause the accumulation of senescent cells both in tumor and normal tissue. Paradoxically, cellular senescence protects non-dividing cancer cells by limiting the effect of chemotherapeutic drugs and radiation and contributes to chemoresistance, radiation resistance, disease relapse, and systemic side effects. Cancer chemotherapy efficacy is based on the assumption that treatment-induced apoptosis or necrosis of tumor cells results in prolonged patient survival. However, in addition to cytotoxic activity, chemotherapy also can cause tumor cells to enter a TIS state with SASP characteristics. The persistence of viable and metabolically active senescent tumor cells after chemotherapy has been attributed to worsen overall survival in patients. Chemotherapy targets rapidly proliferating cancer cells, exposes a stressor to normal cells which drive them into senescence, paracrine effects of inflammatory factors, or SASP factors, secreted by these senescent cells, and epigenetic changes induce these cells to more aggressive cancer stemness.

Systemic chemotherapy has also been found to elevate normal tissue senescence. Multiple studies have revealed that increased normal tissue senescent cells can promote tumor progression, creating a link between aging and cancer. Breast cancer survivors who received chemotherapy as a part of treatment have been found to have accelerated aging and increased incidence of cancer recurrence. Survivors from childhood cancers post-chemotherapy treatment also have been found to have high rates of developing secondary cancer, spinal disorders, and pulmonary diseases in adulthood. Furthermore, it is well established that clinical use of chemotherapies is associated with long-term damage to normal tissues and organs resulting from accumulation of TIS cells and proinflammatory SASP factors. Therefore, we believe that therapeutic approaches that alleviate chemotherapy-induced senescent cells and SASP factors in normal tissue may lead to a better quality of life for cancer patients.

 

 

SASP Factors Secreted by Senescent Cells Trigger Chronic Inflammatory Responses

 

img111359907_1.jpg 

 

8

 


 

Inflammasomes are large, multimeric protein complexes that are another contributing factor to chronic inflammation. Their assembly in innate immune cells and other cells is triggered by a variety of stimuli and culminates in the activation of Caspase-1 which then cleaves pro-interleukin (“IL”)-1ß to IL-1ß. To date, diverse inflammasomes have been discovered. Among the various inflammasomes identified, the nucleotide-binding oligomerization domain, leucine-rich repeat-containing receptor (“NLR”) family pyrin domain-containing three NLR (“NLRP3”) inflammasome is best characterized. The NLRs are recognized as the key sensors of pathogens and danger signals known as PAMPs and DAMPs. The NLRP3 inflammasome has a two-step activation mechanism: “priming”, which entails induction of pro-IL-1ß and NLRP3, and “activation”, wherein a functional inflammasome complex is assembled following uptake of PAMPs or DAMPs. The pathology of various diseases, including Alzheimer’s disease, Parkinson’s disease, and atherosclerosis has been linked to hyperactivation of the NLRP3 inflammasome.

 

 

Inflammatory Factors Secreted by Activated Inflammasomes Trigger Chronic Inflammatory Responses

img111359907_2.jpg 

 

Our Approach for the Treatment of Inflammaging

We have identified two lead product candidates that are immunotherapeutics designed to rejuvenate the immune system in order to neutralize or reverse the two primary pathways of inflammaging. Without addressing both processes, a chronic, low-grade inflammatory environment will persist, resulting in a diverse range of pathological manifestations including cancer, atherosclerosis, diabetes, and neurodegeneration.

 

Senolytic for Senescence Cell Clearance and Senomorphic for SASP Neutralization

Senescent cells are caused when a normal cell is exposed to various stress factors, many of which are simply a part of living and aging. Other stressors are brought about by medical treatments, such as radiation and chemotherapy, resulting in TIS. The damaging part of senescent cells is that they secrete so-called SASP factors. SASP factors come in many different types, depending on the stressor and the cell type exposed to that stressor, but one thing they have in common is that they drive chronic, low-grade inflammation. For example, TGF-ß is considered one of the key SASP factors that induces or accelerates, and maintains a senescent phenotype in various cell types including fibroblasts, bronchial epithelial cells, and cancers in an autocrine/paracrine manner. Thus, to neutralize these pathways, a drug must be a senolytic agent that reduces senescent cells, as well as a senomorphic agent that eliminates SASP factors. Current clinical efforts to counteract TIS and age-related senescent cell activity have focused on senolytic chemical drugs that selectively induce senescent cell death and senomorphic chemical drugs that reduce the secretion of SASP factors. Despite the promise of senolytics and senomorphics, their efficacy in early phase clinical studies reported to date has been limited. Further, the specificity, toxicity, and optimal treatment schedule of these pharmaceutical agents in the cancer setting have yet to be determined.

We have developed an alternative approach to eliminate senescent cells using well-characterized protein immunotherapeutics including those that stimulate effector immune cells and reduce TGF-β activity. This approach is supported by our findings that TIS tumor cells upregulate NKG2D and other ligands on their surface for efficient recognition and killing by effector NK cells and CD8+ T cells. Additionally, suppression of TGF-β activity enhances the anti-tumor/anti-senescent responses of these immune cells. HCW9218 is a unique combination of a TGF-β receptor, that neutralizes TGF-β secreted by tumors, combined with IL-15, a potent cytokine that stimulates the NK and CD8+ T cell cytotoxicity. In our scientific publications, we reported that HCW9218 can activate immune cells to infiltrate into tumors to directly eliminate TIS cancer cells. This activity leads to robust anti-tumor activity of HCW9218 following docetaxel chemotherapy (“DTX”) as measured by reduced melanoma tumor growth in mouse models. Therefore, TGF-β neutralization combined with activation of effector immune cells should be considered as a part of the strategy for

9

 


 

senescent cell removal and reduction of SASP factors. For a more detailed discussion, see the Company’s pivotal scientific paper entitled, “Immunotherapeutic HCW9218 Augments Anti-Tumor Activity of Chemotherapy via NK Cell-Mediated Reduction of Therapy-Induced Senescent Cells,” published in Molecular Therapy.

 

Deactivation of Inflammasomes by Activating Treg Cells

To date, therapeutic approaches to reduce aberrant inflammasome activity have focused on inhibitors of various inflammasome components (i.e., NLRP3 and other NLRs, ASC, Caspase-1) and downstream mediators of inflammation (i.e., IL-1ß, IL-18, gasdermin D, etc.). This approach is validated based on the regulatory approval of three biologics that inhibit IL-1ß activity (anakinra, a recombinant form of the naturally occurring IL-1Ra; rilonacept, a soluble chimeric Fc fusion protein of IL-1R1 and IL-1R3; and canakinumab, a humanized monoclonal antibody specific for neutralizing IL-1ß). Together, these molecules are approved for treatment of cryopyrin-associated periodic syndrome, a multisystemic IL-1ß–mediated disease due to a gain of function in NLRP3; rheumatoid arthritis; systemic juvenile idiopathic arthritis and other auto-inflammatory diseases. We believe there is considerable interest in therapeutics that specifically block inflammasome activity upstream. However, these product candidates are still in early phase clinical testing and their bioavailability, off- and on-target toxicity, and utility profiles are still being evaluated.

Our approach is to deactivate inflammasome pathways in monocytes and macrophages through the immunosuppressive activities of Treg cells induced by our immunomodulator molecules. This approach does not rely on inhibiting specific inflammasome components but rather utilizes natural processes of the immune system to attenuate and rebalance chronic self-perpetuating proinflammatory responses. In relevant animal models, we have observed encouraging results using HCW9302 to activate and expand Treg cells for treatment of atherosclerosis and diabetes.

HCW9302 Reduces Atherosclerosis Plaques Induced by High Fat Diet in ApoE-/- Mice

img111359907_3.jpg 

Our Strategy

Our goal is to develop transformative immunotherapies to lengthen health span by disrupting the link between cellular senescence, chronic inflammation, and age-related diseases. Our strategy for efficiently validating our approach includes the following key components:

Focus resources on internally-developed intellectual property, including molecules, TOBITM platform, and manufacturing processes, without relying on third-party licensing for key intellectual property.

Our TOBITM platform is a new approach to construct multi-functional fusion proteins and fusion protein complexes, using a novel TF-based scaffold platform. Multiple protein targets (e.g. cytokine, scFvs, ligands, etc.) can be packaged as a single molecule to engage immuno-stimulatory functions and address many signaling pathways simultaneously. Fusion protein complexes have ex vivo and in vivo applications for stimulating NK and T cells.
Over 30 molecules have been created and characterized internally for ex vivo (i.e., to support cell therapies) and in vivo (i.e., as injectables) activation and expansion of NK, CD8+ T, Tscm, and Treg cells.
Fusion protein complexes are readily purified using internally-developed affinity chromatography. Purified fusion protein complexes are highly stable immunotherapeutics. Large-scale cGMP manufacturing runs have been demonstrated.

10

 


 

Focus our resources on the development of two primary internally-developed molecules for which we can establish strong IP protection, best activity in animal models, and a well-tolerated safety profile when administered by subcutaneous injection.

The activity of HCW9218 has been established in multiple in vivo animal studies, including reduction of cellular senescence and SASP factors in naturally-aged mice and elimination of cancer senescent cells caused by therapy-induced senescence to enhance efficacies of chemotherapies and remove the off-target effects caused by chemotherapy.
We have completed in vivo animal studies demonstrating the activity of HCW9218 in reversing Type 2 Diabetes and as an anti-fibrotic agent.
We have demonstrated the activity of HCW9302 to treat autoimmune and age-related diseases in relevant animal models.

Focus on cancer indications in initial clinical development of our lead product candidate, HCW9218, in indications with high unmet medical need or where side effects of standard-of-care therapy diminishes health span.

Cancer is our gateway indication. We received FDA clearance to proceed with a Company-sponsored Phase 1b clinical trial to evaluate HCW9218 in refractory pancreatic cancer. The Masonic Cancer Center at University of Minnesota received FDA clearance to proceed with an Investigator-sponsored Phase 1 clinical trial to evaluate HCW9218 in patients with solid tumors, such as breast, ovarian, colorectal and prostate cancers. We expect to initiate both of these trials in the first half of 2022, but we cannot provide any assurance that the clinical sites will be ready to initiate the planned clinical trials on a timely basis, or at all.
Clinical trials will allow us to evaluate the development of our novel immunotherapeutics as we attempt to augment the efficacy of chemotherapy against cancer while minimizing its side effects. Our clinical trial design will be designed to have clear, objective endpoints against which we can measure the success of our cancer treatment.
Because of our highly efficient design for neutralizing TGF-ß, we have targeted cancer indications with TGF-ß mediated immunosuppression and a fibrotic tumor microenvironment (i.e., pancreatic, breast cancer).
We plan to advance well-characterized immunotherapeutics with multiple mechanisms of action: effector immune cell activation, suppression of TGF-ß, reduction of senescent cells (i.e., senolytics), and reduction of SASP (i.e., senomorphics).

Focus on autoimmune indications with high unmet medical need in initial clinical development of our lead product candidate, HCW9302.

IND-enabling activities and toxicology studies required for submission of an IND to evaluate HCW9302 in an autoimmune indication are expected to be completed in the second half of 2022, followed soon thereafter with an IND submission to evaluate HCW9302 in an autoimmune indication. We have not yet submitted the IND, nor can we guarantee when the IND will be submitted.

Leverage established clinical trial network.

Our management team has extensive experience managing clinical trials, enabling us to reduce dependency on a contract research organization for our trials. Our founder and clinical development team have a track record of success in developing immuno-oncology therapeutics from bench to bedside.
We have selected leading NCI-designated Comprehensive Cancer Centers as potential clinical sites for our multi-center, Company-sponsored trial. We are working with these institutions and Principal Investigators from these institutions to complete the required internal review processes for study start-up. Because the discussions with these clinical sites and Principal Investigators are not finalized, we are not certain we will be successful in reaching an agreement with any or all of these institutions. The course of these discussions and whether we might need to identify alternative clinical sites could impact the start date for our clinical trials. Any delays in our clinical trials could increase our costs and slow down the development and approval process, which could harm our commercial prospects.

11

 


 

Expand clinical evaluation of senolytic/senomorphic product candidates to other age-related indications following establishment of a safe treatment regimen in cancer patients for HCW9218. We may need pre-IND meetings for other cancer and non-cancer indications to determine if additional nonclinical toxicology studies are required.

We are conducting preclinical research studies to evaluate HCW9218 in liver cancer and NAFLD that we believe may support a future clinical study.
We are conducting preclinical research studies to evaluate HCW9218 in metabolic disease indications, specifically Type 2 Diabetes, leveraging our ability to reduce senescent cells and reduce SASP factors.

Out-license limited rights for certain HCW molecules outside of primary focus.

We intend to continue to seek partners for out-licenses for our internally-developed molecules with strong clinical potential that are part of our clinical development focus (i.e., adoptive cell therapies). We consider this an attractive source of nondilutive financing.

Explore co-development or regional deals with big pharma for lead molecules.

We are actively seeking co-development deals for the further advancement of our lead molecules, including clinical development, and commercialization.
We are actively assessing whether it is advantageous for the Company to out-license rights to certain regional markets. Our primary goal is to enter a co-development deal on the best terms possible, so we will not enter such a transaction if we conclude it is optimal for the Company to enter a big pharma co-development deal for worldwide rights.

Our Programs

Our Internally-Developed TOBITM Platform

TOBITM (Tissue factOr-Based fusIon) platform is a new approach to construct multi-functional fusion proteins and fusion protein complexes using a novel TF protein scaffold. The extracellular domain of human TF was selected as it has a rigid elongated structure comprised mainly of ß-sheets with its N- and C-termini located at distal ends of the polypeptide, permitting genetic fusions of other protein domains without anticipated steric interference. This TF domain does not interact with the cell membrane phospholipid bilayer and, as a result, does not exhibit procoagulant activity. This TF domain is expressed at high levels by most cell types and is not expected to be immunogenic in humans. Consistent with these properties, we found that genetic fusion to the TF domain promoted increased production of difficult-to-express proteins, such as IL-15. Additionally, the TF fusion proteins could be readily purified by affinity chromatography using an anti-TF antibody and low pH elution conditions, like those used in Protein A-based affinity purification of therapeutic antibodies.

To generate multichain protein complexes, we also incorporated genetic fusions to the human IL-15 and IL-15Rα domains as shown in the figure below. When co-expressed in CHO cells, the fusion proteins form a soluble stable heterodimeric complex through high-affinity interactions between IL-15 and IL-15Rα domains. This approach offers an alternative to immunoglobulin (Fc) and other

12

 


 

engineered protein scaffolds, which typically require introduction of multiple mutations or other non-human sequences or complicated in vitro assembly/purification methods to generate bi- or multi-specific complexes.

 

img111359907_4.jpg 

 

 

Using the TOBITM platform, we have constructed more than 30 fusion complexes comprising various cytokines, ligands, receptors, and single-chain antibodies, including disease-targeting antibodies and immune checkpoint inhibitors. The modular fusion components are carefully selected to stimulate, inhibit, and/or target specific immune responses using a knowledge-based disease-relevant strategy and in many cases, are designed to provide synergistic and balanced activities for optimal therapeutic benefit. The resulting fusion proteins are rigorously tested in state-of-the-art cell culture systems and disease-specific animal models to verify their utility for the intended clinical use and targeted indications.

TOBITM also provides a scalable approach for generating large-scale cGMP-grade heteromeric fusion protein complexes to support clinical applications.

Our internally-developed TOBITM discovery platform was featured in an article authored by the Company and published in the peer-reviewed journal Cancer Immunology Research.

Pipeline and Overview of TOBITM Product Candidates

Our focus for clinical development is our two lead product candidates, HCW9218 and HCW9302. The initial clinical trials to evaluate HCW9218 are in several cancer indications. The FDA has permitted our Company-sponsored, first-in-human Phase 1b clinical trial to proceed to evaluate HCW9218 in patients with advanced pancreatic cancer. In addition, the Masonic Cancer Center at University of Minnesota received FDA clearance to proceed with a Phase 1 Investigator-sponsored clinical trial to evaluate HCW9218 in patients with other types of advanced solid tumors with progressive disease after prior chemotherapy. We expect to initiate both of these trials in the first half of 2022. For HCW9302, we expect to complete IND-enabling activities in the second half of 2022. Upon the completion of IND-enabling activities, we intend to submit an IND to evaluate HCW9302 in the autoimmune indication, alopecia areata. For our lead molecules, once the safe dose level and regimen are defined in initial clinical trials, we intend to expand into clinical trials to evaluate our lead molecules in other age-related pathologies. For HCW9218, these include fibrotic diseases (e.g., non-alcoholic fatty liver disease, or NAFLD), liver cancer, and dysfunctional metabolic disorders (e.g., Type 2 diabetes); and for HCW9302, these include autoimmune diseases and other proinflammatory diseases, such as coronary artery disease.

We have out-licensed limited rights for our molecules, HCW9201 and HCW9206, to develop cell-based therapy treatments. Our clinical-stage molecule, HCW9201, is currently being evaluated in a pair of Phase 2 clinical trials for a cell-based therapy treatment for r/r AML by our licensee. The School of Medicine at Washington University in St. Louis is the sponsor for both trials.

13

 


 

The pipeline for our lead immunotherapeutic programs is summarized below:

 

img111359907_5.jpg 

(1)
This is an Investigator-Sponsored clinical trial with the Masonic Cancer Center at University of Minnesota. The solid tumor clinical trial is a “basket trial” that will include patients with breast, ovarian, prostate, and colorectal cancers.
(2)
Available for license from HCW Biologics for ex vivo Treg cells expansion.
(3)
Wugen licensed HCW9201, a clinical-stage molecule, from HCW Biologics for limited rights to develop cell-based therapy treatments. HCW Biologics has retained all other rights to HCW9201.

HCW9218

Advances in immuno-stimulatory and anti-immunosuppressive therapeutics have revolutionized cancer treatment. However, novel immunotherapeutics with these dual functions are not frequently constructed. We have used our TOBITM platform to construct a heterodimeric bifunctional fusion molecule, HCW9218, capable of immuno-stimulatory as well as anti-immunosuppressive activity. HCW9218 is comprised of extracellular domains of the human TGF-ß receptor II and a human IL-15/IL-15 receptor α complex. HCW9218 potently activates NK cells and CD8+ T cells in vitro and in vivo to promote their proliferative and metabolic activities and enhances their cytotoxicity against tumor targets. This fusion complex also exhibited TGF-ß neutralizing activity in vitro and sequestered plasma TGF-ß in mice.

 

In animal models, HCW9218 displayed strong anti-tumor activity mediated by NK cells and CD8+ T cells, and increased infiltration of NK cells and CD8+ T cells into tumors. HCW9218 was well tolerated in preclinical studies, with a half-life sufficient to provide long lasting biological activity. HCW9218 may serve as a novel therapeutic to simultaneously provide immunostimulation and lessen immunosuppression associated with tumors and other age-related diseases. The figures below show that HCW9218 has the potential to augment the efficacy of chemotherapy (doxetaxel, DTX) in the presence and absence of therapeutic antibodies (TA99) in mice bearing melanoma tumors (upper left panel). These results correlated with the ability of HCW9218 to eliminate TIS cancer cells induced by DTX (upper center and right panels). Additionally, HCW9218 reduced TIS and SASP factors in normal tissues related to therapy induced adverse effects (lower panels), indicating that HCW9218 acts as a senolytic and senomorphic agent.

 

 

 

 

 

 

14

 


 

 

Preclinical Studies in Animal Models

HCW9218 Enhances Anti-Tumor Activity of Chemotherapy and Therapeutic Antibodies

and Reduces TIS Senescent Cells and SASP Factors in Tumors and Normal Tissues

 

img111359907_6.jpg 

 

In our published scientific reports, we also observed in preclinical studies that HCW9218 could enhance the anti-tumor efficacy of immune checkpoint blockade (anti-PD-L1 antibody, α-PD-L1) via T-cell infiltration into the tumor avoiding immunosuppressive factors in the tumor microenvironment, or TME.

 

HCW9218 Enhances Anti-Tumor Activity of Immune Checkpoint Blockade

img111359907_7.jpg 

 

15

 


 

Moreover, HCW9218 enhanced the anti-tumor efficacy of chemotherapy against human pancreatic tumors in a xenograft model. Induction of senescence tumor cells in human SW1990 pancreatic cancer cells was observed following treatment with nab-paclitaxel and gemcitabine (A+G), standard-of-care chemotherapies (left panel). Further, HCW9218 treatment significantly enhanced A+G chemotherapy activity by controlling tumor growth and prolonging survival of SW1990 tumor-bearing mice (Center and right panels). The results of these studies support clinical development of HCW9218 in combination with chemotherapies and other immune therapies in patients with solid tumors, including pancreatic cancer.

 

HCW9218 Enhances Anti-Tumor Activity of Chemotherapy

in Mice Bearing Human SW1990 Pancreatic Tumor Xenografts

 

img111359907_8.jpg 

 

Cancer

Two clinical trials of HCW9218 have been permitted to proceed by the FDA. The first is a Company-sponsored, multi-center Phase 1b clinical trial for a dose escalation study of HCW9218 as monotherapy in refractory patients with advanced pancreatic cancer. We plan to enroll up to 24 patients in five NCI-designated centers, with the primary objectives of the study being to determine safety, maximum tolerated dose, and the recommended Phase 2 dose (“RP2D”). After determining the RP2D, we expect the Phase 2 portion of this clinical trial to include a cohort of patients receiving HCW9218 as monotherapy and a cohort of patients receiving HCW9218 as an adjunct to chemotherapy. The Phase 2 dose expansion portion aims to enroll up to 42 patients at the RP2D with primary objectives to determine the 6-month progression free survival rate and safety. The secondary objectives of this study are objective response rate, overall survival, time to progression, and duration of response. We have identified several NCI-designated Comprehensive Cancer Centers as potential clinical sites, all of which are progressing through their internal process for review. We will not be able to finalize our selection of a particular clinical site until the internal review is complete and approval is granted to participate in the clinical study. If any of the sites we have selected declines to participate in the study, we will need to identify alternative sites, which may delay the initiation of the trial. Once we do proceed, the time required to complete the study will depend on the number of cohorts required to determine RP2D and the time that is required to enroll patients to participate in the study.

The second clinical trial of HCW9218 in a cancer indication is an Investigator-sponsored trial for the Phase 1 portion of a clinical trial for dose escalation study of HCW9218 as a monotherapy in solid tumors, such as breast, ovarian, prostate and colorectal cancers. The sponsor is the Masonic Cancer Center at the University of Minnesota, a leading NCI-designated cancer center. The trial is designed as a dose escalation study of HCW9218 to identify the maximum tolerated dose for future evaluation. Depending on the toxicities observed in the treated patients, between 12 and 24 patients may be enrolled. There has not yet been a decision on the design of later phases of this clinical trial, if Phase 1 is successfully completed.

16

 


 

We believe, based on the results of our animal studies that HCW9218 has the potential to be an effective immunotherapy against pancreatic cancer, a very aggressive malignancy which is refractory to other immunotherapies including immune checkpoint blockade. TGF-ß has been shown to play a major role in promoting immunosuppression responses and fibrosis in the TME as well as inducing epithelial–mesenchymal transition (“EMT”) of pancreatic tumor cells, which facilitates their migratory and invasive capabilities. As a result, elevated serum TGF-ß levels have been shown to correlate with a poor prognosis in patients with pancreatic cancer. Early phase clinical studies have provided evidence that strategies to decrease TGF-ß levels or signaling can provide clinical benefit, including objective responses and prolonged survival, in certain patients with advanced/metastatic pancreatic cancer. Studies in pancreatic tumor mouse models, including research performed in our laboratories, support evaluation of combination therapies including chemotherapy to enhance antigen presentation by tumors, TGF-ß antagonist to reduce TME immunosuppression and immuno-stimulatory agents to augment anti-tumor T cell and NK cell responses.

We have targeted advanced, chemo-resistant solid tumors in our clinical programs in cancer, all of which are difficult-to-treat and have large, unmet medical needs:

Pancreatic Cancer is the 11th most commonly diagnosed cancer in the U.S., but it is the 3rd leading cause of cancer-related deaths. It has a 10.8% five-year survival rate. Long-term prognosis for pancreatic cancer depends on the size and type of the tumor, lymph node involvement and degree of metastasis at the time of diagnosis. Unfortunately, pancreatic cancer usually shows little or no symptoms until it has advanced and spread. Therefore, most cases are diagnosed at later, more difficult-to-treat stages. In the U.S. in 2021, there were 60,430 new cases and 48,220 deaths from pancreatic cancer. The average age at the time of diagnosis is 70 years of age.
Solid tumors represent approximatively 90% of adult human cancers. In 2022, in the U.S. alone, it is believed there will be an estimated 1.9 million new cancer cases diagnosed and more than 600,000 cancer deaths, which are increasing with an aging population. The Investigator-sponsored trial being conducted by the Masonic Cancer Center at University of Minnesota to evaluate HCW9218 is focused on the treatment of advanced solid tumor cancer after failure of initial treatments. Various studies have revealed that 95% of cancer drugs for solid tumors fail. This research highlights the high unmet medical need for novel therapies to treat advanced solid tumors.

Age-Related Diseases Driven by Senescence

We are conducting extensive preclinical research on HCW9218 for senescent cell removal (senolytic) and SASP factor reduction (senomorphic) in various relevant animal models, including those for solid tumors, metabolic dysfunction, and chronological aging. Our initial data suggest that HCW9218 functions as a potent senolytic and senomorphic agent. We plan to determine the dose level and regimen from our cancer trials and then we intend to apply the dose level and treatment regimens to evaluate HCW9218 for age-related diseases, such as NAFLD and diabetes. Type 2 Diabetes affects approximately 30.8 million Americans, and another 88 million American adults have pre-diabetes. Our ultimate goal is to use HCW9218 in combination with HCW9302 to address neurodegenerative diseases, such as Alzheimer’s Disease, Parkinson’s Disease, and age-related Macular Degeneration.

HCW9302

Treg cells are essential mediators of peripheral tolerance and the global immunoregulatory potential in hosts to self and non-self-antigens. Treg cells achieve this immunoregulatory control through multiple suppressive mechanisms. Alternations in Treg cell development, homeostasis or function can predispose these cells to affect a variety of disease conditions including allergy, autoimmunity, graft rejection, cancer, and response to immunotherapies. Current research is focused on developing novel therapies to enhance Treg cell functions in vivo through use of cytokines and small molecule drugs to support endogenous Treg cell proliferation or activation, ex vivo manipulated Treg cells in autologous adoptive cell therapy to promote immunoregulation in settings of autoimmunity, or antigen-specific Treg cells, including chimeric antigen receptor Treg (“CAR-Treg”) cells, to strengthen tolerance in allergies. We have employed our TOBITM platform to create HCW9302, an IL-2-based fusion molecule, to expand Treg cells in vivo and ex vivo as an injectable or cell-based strategy to reduce inflammation and to treat a wide variety of autoimmune and age-related diseases. In relevant animal models, we have also observed encouraging results using HCW9302 to activate and expand Treg cells for treatment of atherosclerosis and diabetes.

We are currently conducting IND-enabling activities required to prepare for submission of an IND for a Phase 1b clinical trial to evaluate HCW9302, administered by subcutaneous injection. The timing for this submission will depend on the completion of nonclinical toxicology studies and availability of research material, as well as finalizing the clinical protocol. The nonclinical toxicology studies are expected to be completed by the end of 2022, which we intend to follow with the submission of an IND for a Phase 1B clinical trial to evaluate HCW9302 in an autoimmune indication in the first half of 2023.

17

 


 

However, we have not submitted the IND for the planned trial, and we cannot provide any assurance that the FDA will authorize us to initiate our planned clinical trials on a timely basis, or at all. In the event we do not receive feedback on a timely basis, or we are required to change the design of our clinical protocol or address other feedback, clinical development of our products would be delayed and our costs may increase. Moreover, if the FDA does not allow our initial clinical trial to proceed, we may be required to conduct additional preclinical testing or other IND-enabling activities, which would result in further delay and additional costs.

HCW9302 exhibits increased biological activity with an extended half-life, compared to IL-2. The three graphs below illustrate the results of characterization studies:

Left panel: IL-2 activity of HCW9302 was compared with Proleukin, the currently approved IL-2 drug, using a standard CTLL-2 cell proliferation assay.
Center panel: HCW9302 was found to have >5-fold higher IL-2 activity than Proleukin.
Right panel: We observed the half-life of HCW9302 was 6.2 hours in mice following subcutaneous administration (3 mg/kg) versus 20 minutes for Proleukin.

 

 

HCW9302 Exhibits Increased Biological Activity with an Extended Half-Life Compared to IL-2

HCW9302 Half-Life is 6.2 Hours versus IL-2 Half-Life of 20 minutes

 

img111359907_9.jpg 

Autoimmune and proinflammatory diseases

We have conducted extensive preclinical research on HCW9302 for deactivation of inflammasomes to temper the pro-inflammatory environment it creates in relevant animal models, including those for atherosclerosis. Our data suggest that HCW9302 functions as a potent agent to stimulate Treg cells that suppress the activity of inflammasome-bearing cells and inflammatory factors. We intend to determine the dose level and regimen from our initial clinical trial in an autoimmune indication, which we have primarily determined will be alopecia areata, and then we intend to apply the dose level and treatment regimens established in initial clinical studies to evaluate HCW9302 for other autoimmune and proinflammatory diseases, such as atherosclerosis.

HCW9201

We believe NK cells are a promising cellular therapy for cancer, with challenges in the field including effector cell persistence, functional activity, and tumor recognition. Recent research has shown that priming blood NK cells with a cytokine cocktail of IL-12, IL-15, and IL-18 (“12/15/18”) results in ML-NK cell differentiation and enhanced responses against cancer. However, the lack of available, scalable cGMP-grade reagents has limited the advancement of this approach beyond early phase clinical trials. To address this challenge, we employed our TOBITM platform to combine IL-12, IL-15, and IL-18 receptor engagement in a single protein complex (“HCW9201”). Further, we have developed cGMP-compliant production cell lines and scalable production processes to allow the generation of large amounts of HCW9201 that meets product quality characteristics for clinical use.

18

 


 

HCW9201 has been extensively evaluated for its capacity to stimulate activation and proliferation signals in human NK cells. RNA-seq and multidimensional mass cytometry studies have revealed strong parallels between the activities of HCW9201 and IL-12/15/18 in generated ML-NK cells. Moreover, HCW9201 stimulation improved NK cell metabolic fitness, and resulted in the DNA methylation remodeling characteristic of memory-like differentiation. NK cells primed with HCW9201 and the 12/15/18 cocktail had similar increases in ML-NK cell cytotoxicity and IFN-g production against leukemia targets. HCW9201- and 12/15/18-primed NK cells also equivalently controlled leukemia in vivo in NSG mice. Thus, HCW9201 represents a protein engineering approach that solves many problems associated with multi-signal receptor engagement on immune cells, and HCW9201-primed NK cells will be advanced as an ideal approach for clinical cGMP-grade ML-NK cell production for cancer therapy.

The figures below show that NK cells primed with HCW9201 and 12/15/18 cocktail killed leukemia cells (left) and controlled leukemia tumors in mice (right) better than NK cells primed with IL-15 alone.

 

img111359907_10.jpg 

 

HCW9206

We have used our TOBITM platform to combine cytokine IL-7, IL-15, and IL-21 receptor engagement into a single protein complex: HCW9206. Although ML-NK cells have been demonstrated to be beneficial in clinical trials, the initially evaluated NK cell products were derived from fresh prepared apheresis lymphocytes from individual matched donors. Thus, this approach has limitations in the availability of donors and the reproducibility, scalability, and costs of generating clinical-grade ML-NK cells for adoptive cell therapy. To translate this exciting therapy to many patients, we have developed methods to expand the numbers of NK cells to support a multiple dosing regimen and for multiple patients. We have extensively tested HCW9206 and demonstrated that this complex can expand ML-NK cells without the use of feeder cells, which is the current process for producing NK cells using a cancer cell line that must be removed from the final drug product.

Out-License Programs

We have internally developed over 30 immunotherapeutic molecules and plan to develop additional molecules through our TOBITM platform. Our strategy is to focus on the clinical development of our lead product candidates, HCW9218 and HCW9302, as immunotherapeutics for the treatment of age-related diseases, administered by subcutaneous injection. Our strategy is to out-license molecules and product rights not in our focus area, in particular ex vivo applications. We expect out-licensing to provide non-dilutive financing to bolster resources available to fund our core programs and possibly commercialize molecules with the potential to be developed successfully by our licensees for disease indications with large, unmet medical needs.

We established our first out-license arrangement in December 2020, when we entered into an exclusive worldwide license agreement with Wugen (the “Wugen License”) for limited rights to develop cell therapy-based treatments using two HCW internally-developed fusion protein molecules and improvements thereto, including a clinical-stage and preclinical stage fusion molecule. We believe these molecules are capable of generating highly activated ML-NK cells in a short time frame and large-scale NK cell expansion without relying on feeder cells. Two Phase 2 clinical trials were initiated in January 2021 by the School of Medicine at Washington University in St. Louis with support from Wugen, in which certain of these licensed molecules were used. One trial is using ex vivo ML-NK cells, induced by the licensed molecule, against r/r AML with donor leukocyte infusion (“DLI”) after haploidentical stem cell transplantation. The second Phase 2 clinical trial is also using ex vivo induced ML-NK cells against r/r AML. As licensor, we have limited information rights to clinical data which we are required to treat as nonpublic confidential information. As licensee, Wugen determines when and if clinical data read outs are disclosed to the public.

19

 


 

We retained manufacturing rights and other rights, including regulatory T cell-based cellular therapy and injectable rights, for licensed molecules under the terms of the Wugen License. We intend to enter into supply agreements with Wugen to provide cGMP and non-cGMP grade licensed molecules based on industry-standard terms, one agreement for development supply and one agreement for commercial supply. According to the terms of the Wugen license, Wugen will fund all future clinical development and commercialization activities for any indications utilizing the licensed molecules for cell therapy as covered by the license. We have the opportunity to receive additional payments for development and commercialization milestones as well as single-digit royalties.

Other TOBITM Discovery Programs

Our discovery efforts for new product candidates are focused on characterizing and expanding our library of fusion molecules with cytokines, chemokines, ligands, receptors, and internally-developed single-chain antibodies, including fusion domains with increased or decreased biological activity, for cancer and other age-related diseases with an emphasis on neurodegenerative, fibrotic, and autoimmune diseases. Other TOBITM discovery programs are summarized in the table below.

 

Name

Fusion Domains

Activity

Indications

HCW9206

IL-7, IL-15, IL-21

NK cell and CD8+ T cell stimulation

Injectable for cancer

HCW9207

IL-18, IL-15, IL-12, anti-CD16 scFv

NK cell stimulation

Cancer

HCW9212

IL-7, IL-15, IL-21, CD137L

NK cell and CD8+ T cell stimulation

Cancer

HCW9213

Anti-CD3, anti-CD28 scFvs

T cell/Treg stimulation

Cancer, inflammatory diseases

HCW9228

TGRßRII dimer

TGF-ß antagonist

Cancer, fibrotic diseases

 

 

 

 

Antibodies

 

 

 

 

 

 

 

HCW9106

Anti-CD26 scFv

Senescent cell inhibition and targeting

Inflammatory and age-related disease

HCW9107

Undisclosed target

Senescent cell inhibition and targeting

Inflammatory and age-related disease

HCW9108

Undisclosed target

Treg binding, activation, inhibition, and targeting

Inflammatory and age-related disease

 

Manufacturing

Our product candidates include molecules that are multi-specific fusion protein complexes, such as HCW9201, HCW9206, and HCW9218; bispecific fusion protein complexes, such as HCW9302; and an internally-developed affinity ligand used in our manufacturing processes, HCW9101. We have established internally-developed manufacturing processes for producing these fusion molecules from Chinese hamster ovary (“CHO”) cells at large scale in a cGMP-compliant setting.

On March 14, 2019, we entered into a manufacturing agreement with EirGenix, Inc. (“EirGenix”), a third-party global contract development and cGMP manufacturer of biologics, for the manufacture of the Company’s internally-developed molecules. By the end of 2019, we successfully launched cGMP production with manufacturing runs adequate to support clinical trials. During the year ended December 31, 2020, various testing and quality control procedures were conducted on the materials manufactured in 2019-2020 to ensure materials met all expected quality requirements. During the year ended December 31, 2021, we successfully completed production of four molecules, HCW9101, HCW9201, HCW9218, and HCW9302. This includes clinical grade materials we need to initiate clinical trials and toxicology studies we have planned for 2022. Manufacturing, quality control procedures, and vialing will continue for several molecules in 2022, including additional clinical and research grade materials for our licensee.

We currently rely on EirGenix and other third-party manufacturers for the cGMP production of larger quantities of our drug product candidates for our clinical trials. Our management team and other internal personnel have extensive cGMP manufacturing experience in order to ensure seamless technology transfer and to manage the manufacturing and development processes conducted by third-party manufacturers. Our agreements with third-party manufacturers include confidentiality and intellectual property provisions as well as routine quality audits. In some instances, we have reserved resources from third-party manufacturers for the development and manufacture of our product candidates for near-term clinical programs. However, we currently obtain our products from these manufactures on a per project basis and do not have long-term supply arrangements in place. Should any of these manufacturers become unavailable to us for any reason, we believe that there are a number of potential replacements available to us on commercially reasonable terms to meet our future production requirements, although we may incur some delay and cost in qualifying and re-establishing the manufacturing processes at the replacements. We mitigate this risk by maintaining an inventory of clinical material for clinical trials we expect to initiate in the next 12-24 months.

20

 


 

We do not own or operate facilities for clinical drug manufacturing, storage, distribution, or quality testing. Currently, all of our clinical manufacturing is outsourced to third-party manufacturers. We plan to use some of the net proceeds of the IPO to establish our own manufacturing facilities in the US. We have expertise in building and running cGMP manufacturing facilities for immunotherapeutics. In addition, our manufacturing process is wholly-owned and developed by us, so we will not rely on a third-party for manufacturing expertise or processes.

Intellectual Property

Overview

We strive to protect and enhance internally-developed technology, inventions, and improvements that are commercially important to the development of our business, including seeking, maintaining, and defending patent rights, for our internally-developed molecules and manufacturing processes. We also rely on trade secrets relating to our technology platform and on know-how, continuing technological innovation to develop, strengthen, and maintain our proprietary position in the field of inflammaging and the diseases it promotes that may be important for the development of our business.

As with other biotechnology and pharmaceutical companies, our ability to secure and maintain intellectual property protection for our product candidates, future products, and other internally-developed technologies will depend on our success in obtaining effective patent coverage and enforcing those patents if granted. However, we cannot guarantee that our pending patent applications, and any patent applications that we may in the future file, will result in the issuance of patents, or that any issued patents we may obtain will provide sufficient proprietary protection from competitors. Any issued patents that we obtain may be challenged, invalidated, or circumvented by third parties.

In addition to patents, we also rely on trade secrets, know-how and continuing technological innovation to develop and maintain our competitive position. We seek to protect our internally-developed technology, in part, through confidentiality agreements and invention assignment agreements with our employees, consultants, scientific advisors, contractors and potential collaboratorWe also rely on trade secrets relating to our manufacturing process and on know-how, continuing technological innovation and in-licensing opportunities to develop, strengthen, and maintain our proprietary position in the field of inflammaging that may be important for the development of our business. We additionally may rely on regulatory protection afforded through data exclusivity, market exclusivity, and patent term extensions, where available.

Internally-Developed Intellectual Property

As of December 31, 2021, we own 61 pending patent applications worldwide, including 11 pending U.S. utility patent applications, one pending provisional U.S. patent application, six pending PCT applications, four Hong Kong applications, and 39 pending non-U.S. national phase patent applications. Our policy is to file patent applications to protect technology, inventions and improvements to inventions that are commercially important to the development of our business. We seek United States and foreign patent protection for a variety of technologies, including: our internally-developed platform, specific chimeric polypeptides developed using our platform, methods of using the chimeric polypeptides both in vivo and in cellular therapy to treat various conditions, methods for treating diseases of interest, and methods for manufacturing our products. We also intend to seek patent protection or rely upon trade secret rights to protect other technologies that may be used in combination with our products in the development of novel products or methods of use. We seek protection, in part, through confidentiality and proprietary information agreements.

Our intellectual property portfolio is in its early stages and is continually evolving during prosecution of our applications. We own multiple families of patent applications that are directed to our TOBITM platform technology and our single-chain and multi-chain chimeric polypeptides and methods of use of these polypeptides alone and in combination.

Single-Chain Chimeric Polypeptides Patent Family

This family includes patent applications with claims directed to compositions of various single-chain chimeric polypeptides created using the TOBITM platform. These applications also include methods of use and manufacture thereof and methods of promoting the activation and proliferation of a NK cell or a T cell using our single-chain chimeric polypeptides. As of December 2021, this family, which includes HCW9302, includes one pending U.S. utility patent application, and 11 pending patent applications filed in Europe, Australia, Canada, Israel, Japan, New Zealand, Korea, China, Singapore, Hong Kong and Taiwan. The earliest predicted expiration date of any patent issuing from a patent application in this family is 2039.

21

 


 

Multi-Chain Chimeric Polypeptides Patent Family

This family includes patent applications with claims directed to compositions of various multi-chain chimeric polypeptides created using the TOBITM platform. These applications also include methods of use and manufacture thereof and methods of promoting the activation and proliferation of a NK cell or a T cell using our multi-chain chimeric polypeptides. As of December 2021, this family, which includes claims encompassing HCW9218, HCW9201, HCW9206, HCW9228, HCW9207, and HCW9212, includes three pending U.S. utility patent applications, and 11 pending patent applications filed in Europe, Australia, Canada, Israel, Japan, New Zealand, Korea, China, Singapore, Hong Kong and Taiwan. The earliest predicted expiration date of any patent issuing from a patent application in this family is 2039.

With respect to HCW9218, the composition is claimed in one pending U.S. utility patent application and 11 pending patent applications filed in Europe, Australia, Canada, Israel, Japan, New Zealand, Korea, China, Singapore, Hong Kong and Taiwan.

With respect to HCW9201, the composition is claimed in one pending U.S. utility patent application and 11 pending patent applications filed in Europe, Australia, Canada, Israel, Japan, New Zealand, Korea, China, Singapore, Hong Kong and Taiwan. Wugen has obtained an exclusive license to these patent applications limited to use of the licensed chimeric polypeptides in manufacturing of certain cellular therapy products.

With respect to HCW 9206, the composition is claimed in one pending U.S. utility patent application and 11 pending patent applications filed in Europe, Australia, Canada, Israel, Japan, New Zealand, Korea, China, Singapore, Hong Kong and Taiwan. Wugen has obtained an exclusive license to these patent applications limited to use of the licensed polypeptides in manufacturing of certain cellular therapy products.

Methods of Culturing and Methods of Expansion and Proliferation

These two families include patent applications with claims directed to methods of promoting the activation and proliferation of NK cells through the use of our single-chain or multi-chain chimeric polypeptides for ex vivo cell therapy use. As of December 2021, these two families, which include methods of using HCW9201 and HCW9206, includes two pending U.S. utility patent applications and 14 pending patent applications filed in Europe, Australia, Canada, Israel, Japan, South Korea, Singapore, Hong Kong and China. The earliest predicted expiration date of any patent issuing from a patent application in the first of these two families is 2039. The earliest predicted expiration date of any patent issuing from a patent application in the second of these two families is 2040. Wugen has obtained an exclusive license to these two patent families limited to use in manufacturing of certain cellular therapy products.

Treating Age Related Disorders

These four families include patent applications with claims directed to methods of killing or reducing the number of senescent cells in a subject using our single-chain or multi-chain chimeric polypeptides. As of December 2021, these four families, which include methods of using HCW9218, HCW9228 and HCW9302, include three pending U.S. utility patent applications, one pending provisional U.S. patent application, three pending PCT applications, and six pending patent applications filed in Europe, Australia, Canada, Israel, Japan, Hong Kong and China. The earliest predicted expiration date of any patent issuing from a patent application in the first of these three families is 2039. The earliest predicted expiration date of any patent issuing from a patent application in the second of these families is 2041. The earliest predicted expiration date of any patent issuing from a patent application in the third of these families is 2040. The earliest predicted expiration date of any patent issuing from a patent application in the fourth of these families is 2042.

Methods of Activating Regulatory T cells

This family includes patent applications with claims directed to methods of promoting the activation and proliferation of Regulatory T cells through the use of our single-chain or multi-chain chimeric polypeptides for ex vivo cell therapy use. As of December 2021, this family, which includes methods of using HCW9213 and HCW9302, includes one pending U.S. utility patent application and one pending PCT application. The earliest predicted expiration date of any patent issuing from a patent application in this family of applications is 2041.

22

 


 

Antibodies

This family includes patent applications with claims directed to anti-CD26 scFv antibodies. As of December 2021, this family, which includes composition claims for HCW9106, includes one pending PCT application. The earliest predicted expiration date of any patent issuing from a patent application in this family of applications is 2041.

The various methods of use of our chimeric polypeptides covered in our portfolio broadly include: ex vivo cellular therapy use; in vivo or injectable use; methods of inducing differentiation of an immune cell into a memory or memory-like immune cell (in vitro or in vivo); methods of stimulating an immune cell (in vitro or in vivo); and methods of inducing or increasing proliferation of an immune cell (in vitro or in vivo). Indications covered in the portfolio broadly include cancers, including solid and hematological cancers; age-related diseases; and infectious diseases. We are also pursuing innovative combinations of use with our chimeric polypeptides and antibodies, which include both known and internally-developed antibodies. Patents that may issue from these HCW Biologics, Inc. owned applications are generally expected to expire between the years 2039 to 2041, subject to possible patent term adjustment and/or extension.

The term of individual future patents may vary based on the countries in which they are obtained. Generally, patents issued from applications filed in the United States are effective for 20 years from the earliest effective non-provisional filing date. In certain cases, a patent term can be extended to recapture a portion of the term effectively lost as a result of the FDA regulatory review period. The Hatch-Waxman Act permits a patent term extension of up to five years beyond the expiration of a U.S. patent, though the total patent term, including any extension, must not exceed 14 years following FDA approval. A U.S. patent can only be extended once, such that, if a single patent is applicable to multiple products, it can only be extended based on one product.

The term of patents outside of the United States varies in accordance with provisions of applicable local law, but typically is also 20 years from the earliest effective national filing date. Similar patent term extension provisions are available in Europe and other foreign jurisdictions to extend the term of a patent covering an approved drug. When possible, we expect to apply for patent term extensions for future patents covering our product candidates and their methods of use.

Trademarks

We have filed five U.S. trademark applications for our corporate name, corporate logo, and the TOBITM platform. In the future, we intend to file applications for trademark registrations in connection with our Company, our product candidates, and other technologies in various jurisdictions, including the United States as the products are further developed.

Trade Secret Protection

Finally, we may rely, in some circumstances, on trade secrets to protect our technology. We seek to protect our internally-developed technology and processes, in part, by entering into confidentiality agreements with our employees, consultants, scientific advisors, and contractors. We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems.

In addition to the above, we have established expertise and development capabilities focused in the areas of preclinical research and development, manufacturing and manufacturing process development, quality control, quality assurance, regulatory affairs, and clinical trial design and implementation. We believe that our focus and expertise will help us develop products based on our internally-developed intellectual property.

Contracts and Agreements

Wugen Exclusive License Agreement

In December 2020, we entered into an exclusive worldwide license agreement with Wugen (the “Wugen License”), for rights to use certain HCW fusion protein molecules to develop, manufacture, and commercialize their cellular therapy products. The term of the agreement will expire on a product-by-product and country-by-country basis, upon the later of (i) the expiration of the last-to-expire valid patent claim or (ii) ten (10) years from the first commercial sale of such product.

23

 


 

As consideration for the Wugen License, HCW received shares of Wugen’s common stock equivalent to a 10% ownership interest in Wugen as of the effective date of the Wugen License. The upfront payment for the license fee consisted of common stock of Wugen that had a fair value of $1.6 million on the effective date of the Wugen License. We also agreed to sell Wugen non-financial assets for $2.5 million, including cGMP-grade clinical materials needed in order to begin Phase 2 clinical trials in January 2021. We may receive additional payments in the future, based upon the occurrence of certain development milestones with a value of over $200 million. We will be eligible to receive additional payments for commercialization milestones as well as single-digit royalties for commercial sales once product sales commence.

We retained all other rights and use of the licensed molecules outside of Wugen’s right to use the molecules to develop, manufacture, and commercialize cellular therapy products. Wugen’s rights are limited to use of the licensed molecules in cellular therapy products, which products are a pharmaceutical or biological product, process or therapy that contains or comprises cells (including without limitation, CIML NK cells or T cells) that have been engineered, modified, or otherwise manipulated ex vivo, but excludes regulatory T cell-based cellular therapy products. Our retained rights include use of the molecules for injectable therapy product, regulatory T cell-based cellular therapy products, and manufacturing rights to the licensed molecules. We oversee manufacturing and supply of these licensed molecules to Wugen, utilizing our internally-developed manufacturing process, under supply agreements with Wugen that have industry-standard terms. Wugen funds all future clinical development and commercialization activities for the cellular therapy treatments developed by Wugen using the licensed molecules.

Contract Research Agreements

We have certain contract research agreements with contractors that were entered into the two years ended December 31, 2021 for the (i) screening and identification of specific human antibodies to three particular proteins that influence the cellular-senescence process, (ii) hybridoma development, (iii) cell line improvement, and (iv) research to support pre-clinical studies. We own all rights to the resulting intellectual property, including the antibodies, sequences, and data. To date, we have received several sequences and hybridomas from the contractors. For certain contractors, we are obligated to pay one (1) future milestone payment upon filing and acceptance of an IND for each respective human antibody or protein from cell line, however no additional future development or financial obligations are due under these contractor research agreements.

Competition

The biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies, intense competition, and a strong emphasis on internally-developed products. We believe that our immunotherapeutic approach, internally-developed technology, expertise, scientific knowledge, track record in successfully developing drugs from bench to commercialization and intellectual property provide us with competitive advantages. We face potential competition from many different sources, including major pharmaceutical, specialty pharmaceutical and biotechnology companies, academic institutions, governmental agencies, and public and private research institutions. Any product candidates that we successfully develop and commercialize may compete with existing therapies and new therapies that may become available in the future.

Many of the companies which we are competing against, or which we may compete against in the future, have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals, and marketing approved products than we do. In addition, we face a constantly changing competitive landscape because of numerous mergers and acquisitions in the pharmaceutical and biotechnology industry, which will concentrate resources among a smaller number of large pharmaceutical companies. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements and co-development deals with large and established companies. These competitors also compete with us in establishing clinical trial sites and patient registration for clinical trials necessary to advance the clinical development of our product candidates.

Although our novel approach is unique from most other existing or investigational therapies across the disease areas where we are focusing our development, we will need to compete with currently approved therapies, and potentially those currently in development if they are approved. We are aware of several marketed and investigational products in our leading disease areas, including but not limited to the products and competitors discussed below.

24

 


 

We compete in the segments of the pharmaceutical, biotechnology, and other related markets that develop cancer therapies. There are many other companies that have commercialized or are developing cancer therapies, including large pharmaceutical and biotechnology companies, such as AstraZeneca/MedImmune, Bristol Myers Squibb, Merck, Novartis, Pfizer, and Roche/Genentech. We face significant competition from pharmaceutical and biotechnology companies that target specific tumor-associated antigens using immune cells or other cytotoxic modalities. These generally include immune cell redirecting therapeutics (e.g., T cell engagers), adoptive cellular therapies (e.g., CAR-Ts), antibody drug conjugates, targeted radiopharmaceuticals, targeted immunotoxin, and targeted cancer vaccines.

As we expand to other indications, we will focus on the treatment of fibrotic diseases, including NAFLD, or non-alcoholic fatty liver disease. NAFLD is an umbrella term that encompasses the entire spectrum of fatty liver disease, from isolated steatosis to NASH, or non-alcoholic steatohepatitis. There are currently no FDA approved therapies for the treatment of NAFLD. Instead, doctors will treat the underlying condition, such as obesity. Most of the drugs currently in development for NAFLD are focused on decreasing liver fat or improving liver inflammation as opposed to direct liver anti-fibrotic approaches. There are a number of companies developing product candidates for NAFLD including Pliant Therapeutics, Intercept, Pfizer Inc., Gilead, AbbVie, Novartis, AstraZeneca plc, Eli Lilly & Company, GlaxoSmithKline plc, Amgen, Inc., BMS, Johnson & Johnson, Merck & Co., Inc., Roche, Sanofi S.A., Takeda Pharmaceuticals, Novo Nordisk, Genfit SA, Madrigal Pharmaceuticals, Inc., Viking Therapeutics, Inc., Cirius Therapeutics, Inc., NGM Biopharmaceuticals, Akero Therapeutics, Inc. and Metacrine, Inc.

With respect to our lead internally-developed product candidate, HCW9218, we are not aware of any other competing clinical-stage companies with a first-in-class immunotherapeutic that utilizes multiple mechanisms of action, including the cytokine-based activation of immune cells and neutralization of TGF-ß immunosuppression.

With respect to our second lead product candidate, HCW9302, there is a growing momentum behind modulating Treg cells as a potential treatment for autoimmune diseases. We are not aware of other competing clinical-stage companies with a first-in-class immunotherapeutic for deactivation of inflammasomes and reduction of inflammatory cytokines they release through the activation of Treg cells.

We are aware of several other companies developing programs that utilize IL-2 for the selective expansion of Treg cells, including Amgen Inc., Nektar Therapeutics (in partnership with Eli Lilly & Company), Roche, Merck & Co., Bristol Myers Squibb, and Celgene Corporation (“Celgene”). We are also aware of other companies with research or preclinical-stage programs in this area, including Synthorx, Inc., Moderna, Inc., and Xencor, Inc. We are also aware of other companies with PD-1 agonist programs for the treatment of autoimmune diseases, including AnaptysBio, Inc., Celgene, and Eli Lilly & Company.

We could see a reduction or elimination of our commercial opportunity if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any products that we or our collaborators may develop. Our competitors also may obtain FDA or foreign regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we or our collaborators are able to enter the market. Key product features that would affect our ability to effectively compete with other therapeutics include the efficacy, safety, and convenience of our therapeutics, the ease of use and effectiveness of any complementary diagnostics and/or companion diagnostics, and price and levels of reimbursement.

Government Regulation

Government authorities in the United States, at the federal, state, and local level, and in other countries and jurisdictions, extensively regulate, among other things, the research, development, testing, manufacture, quality control, approval, packaging, storage, recordkeeping, labeling, advertising, promotion, distribution, marketing, post-approval monitoring and reporting, and import and export of pharmaceutical products. The processes for obtaining regulatory approvals in the United States and in foreign countries and jurisdictions, along with subsequent compliance with applicable statutes and regulations and other regulatory authorities, require the expenditure of substantial time and financial resources.

25

 


 

FDA Approval Process

In the United States, biological products are subject to extensive regulation by the FDA. The Federal Food, Drug, and Cosmetic Act (the “FDC Act”), and other federal and state statutes and regulations, govern, among other things, the research, development, testing, manufacture, storage, recordkeeping, approval, labeling, promotion and marketing, distribution, post-approval monitoring and reporting, sampling, and import and export of pharmaceutical products. Biological products used for the prevention, treatment, or cure of a disease or condition of a human being are subject to regulation under the FDC Act, with the exception that the section of the FDC Act which governs the approval of drugs via New Drug Applications (“NDAs”), does not apply to the approval of biologics. In contrast, biologics are approved for marketing under provisions of the Public Health Service Act (“PHSA”), via a Biologics License Application (“BLA”). However, the application process and requirements for approval of BLAs are very similar to those for NDAs. Failure to comply with applicable U.S. requirements may subject a company to a variety of administrative or judicial sanctions, such as clinical hold, FDA refusal to approve pending BLAs, warning or untitled letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, civil penalties, and criminal prosecution.

Biological product development for a new product in the United States typically involves preclinical laboratory and animal tests, the submission to the FDA of an IND, which must become effective before clinical testing may commence, and adequate and well-controlled clinical trials to establish the safety and effectiveness of the drug or biologic for each indication for which FDA approval is sought. Satisfaction of FDA pre-market approval requirements typically takes many years and the actual time required may vary substantially based upon the type, complexity, and novelty of the product or disease.

Preclinical tests include laboratory evaluation of product chemistry, formulation, and toxicity, as well as animal trials to assess the characteristics and potential safety and efficacy of the product. The conduct of the preclinical tests must comply with federal regulations and requirements, including Good Laboratory Practices. The results of preclinical testing are submitted to the FDA as part of an IND along with other information, including information about product chemistry, manufacturing and controls, and a proposed clinical trial protocol. Long-term preclinical tests, such as tests of reproductive toxicity and carcinogenicity in animals, may continue after the IND is submitted. A 30-day waiting period after the submission of each IND is required prior to the commencement of clinical testing in humans. If the FDA has neither commented on nor questioned the IND within this 30-day period, the clinical trial proposed in the IND may begin. Clinical trials involve the administration of the investigational drug or biologic to healthy volunteers or patients under the supervision of a qualified investigator. Clinical trials must be conducted: (i) in compliance with federal regulations; (ii) in compliance with Good Clinical Practice (“GCP”), an international standard meant to protect the rights and health of patients and to define the roles of clinical trial sponsors, administrators, and monitors; as well as (iii) under protocols detailing the objectives of the trial, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated. Each protocol involving testing on U.S. patients and subsequent protocol amendments must be submitted to the FDA as part of the IND.

The FDA may order the temporary or permanent discontinuation of a clinical trial at any time, or impose other sanctions, if it believes that the clinical trial either is not being conducted in accordance with FDA regulations or presents an unacceptable risk to the clinical trial patients. Imposition of a clinical hold may be full or partial. The study protocol and informed consent information for patients in clinical trials must also be submitted to an institutional review board (“IRB”), for approval. The IRB will also monitor the clinical trial until completed. An IRB may also require the clinical trial at the site to be halted, either temporarily or permanently, for failure to comply with the IRB’s requirements, or may impose other conditions. Additionally, some clinical trials are overseen by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board or committee. This group provides authorization for whether a trial may move forward at designated checkpoints based on access to certain data from the trial.

Clinical trials to support BLAs for marketing approval are typically conducted in three sequential phases. In Phase 1, the initial introduction of the drug or biologic into patients, the product is tested to assess safety, dosage tolerance, metabolism, pharmacokinetics, pharmacological actions, side effects associated with drug or biologic exposure, and to obtain early evidence of a treatment effect if possible.

Phase 2 usually involves trials in a limited patient population to determine the effectiveness of the biologic for a particular indication, determine optimal dose and regimen, and to identify common adverse effects and safety risks. If a compound demonstrates evidence of effectiveness and an acceptable safety profile in Phase 2 evaluations, Phase 3 trials are undertaken to obtain additional information about clinical effects and confirm efficacy and safety in a larger number of patients, typically at geographically dispersed clinical trial sites, to permit the FDA to evaluate the overall benefit-risk relationship of the biologic and to provide adequate information for the labeling of the product.

26

 


 

In most cases, the FDA requires two adequate and well-controlled Phase 3 clinical trials to demonstrate the safety and efficacy of the biologic. In rare instances, a single Phase 3 trial may be sufficient when either (1) the trial is a large, multicenter trial demonstrating internal consistency and a statistically very persuasive finding of a clinically meaningful effect on mortality, irreversible morbidity or prevention of a disease with a potentially serious outcome and confirmation of the result in a second trial would be practically or ethically impossible or (2) the single trial is supported by other confirmatory evidence. Approval on the basis of a single trial may be subject to a requirement for additional post-approval studies.

These phases may overlap or be combined. For example, a Phase 1/2 clinical trial may contain both a dose-escalation stage and a dose-expansion stage, the latter of which may confirm tolerability at the recommended dose for expansion in future clinical trials (as in traditional Phase 1 clinical trials) and provide insight into the anti-tumor effects of the investigational therapy in selected subpopulation(s). Typically, during the development of oncology therapies, all subjects enrolled in Phase 1 clinical trials are disease-affected patients and, as a result, considerably more information on clinical activity may be collected during such trials than during Phase 1 clinical trials for non-oncology therapies.

In addition, the manufacturer of an investigational biologic in a Phase 2 or Phase 3 clinical trial for a serious or life-threatening disease is required to make available, such as by posting on its website, its policy on evaluating and responding to requests for expanding access to such investigational drug or biologic.

After completion of the required clinical testing, a Biologics License Application (“BLA”) is prepared and submitted to the FDA. FDA approval of the BLA is required before marketing and distribution of the product may begin in the United States. The BLA must include the results of all preclinical, clinical, and other testing and a compilation of data relating to the product’s pharmacology, chemistry, manufacture, and controls. The cost of preparing and submitting a BLA is substantial. The submission of most BLAs is additionally subject to a substantial application user fee. Under an approved BLA, the applicant is also subject to an annual program fee. These fees typically increase annually. A BLA for a biologic that has been designated as an orphan drug is not subject to an application fee, unless the BLA includes an indication for other than a rare disease or condition. The FDA has 60 days from its receipt of a BLA to determine whether the application will be filed based on the FDA’s determination that it is adequately organized and sufficiently complete to permit substantive review. Once the submission is filed, the FDA begins an in-depth review. The FDA has agreed to certain performance goals to complete the review of BLAs. Most applications are classified as Standard Review products that are reviewed within ten months of the date the FDA files the BLA; applications classified as Priority Review are reviewed within six months of the date the FDA files the BLA. A BLA can be classified for Priority Review when the FDA determines the biologic has the potential to treat a serious or life-threatening condition and, if approved, would be a significant improvement in safety or effectiveness compared to available therapies. The review process for both standard and priority reviews may be extended by the FDA for three or more additional months to consider certain late-submitted information, or information intended to clarify information already provided in the BLA submission.

The FDA may also refer applications for novel biologic products, as well as biologic products that present difficult questions of safety or efficacy, to be reviewed by an advisory committee—typically a panel that includes clinicians, statisticians and other experts—for review, evaluation, and a recommendation as to whether the BLA should be approved. The FDA is not bound by the recommendation of an advisory committee, but generally follows such recommendations. Before approving a BLA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP. Additionally, the FDA will inspect the facility or the facilities at which the biologic product is manufactured. The FDA will not approve the product unless compliance with cGMP is satisfactory and the BLA contains data that provide substantial evidence that the drug is safe and effective, or the biologic is safe, pure, potent, and effective, in the respective claimed indication.

After the FDA evaluates the BLA and completes any clinical and manufacturing site inspections, it issues either an approval letter or a complete response letter. A complete response letter generally outlines the deficiencies in the BLA submission and may require substantial additional testing, or information, in order for the FDA to reconsider the application for approval. If, or when, those deficiencies have been addressed to the FDA’s satisfaction in a resubmission of the BLA, the FDA will issue an approval letter. The FDA has committed to reviewing such resubmissions in two or six months depending on the type of information included. An approval letter authorizes commercial marketing and distribution of the biologic with specific prescribing information for specific indications. As a condition of BLA approval, the FDA may require a risk evaluation and mitigation strategy (“REMS”), to help ensure that the benefits of the biologic outweigh the potential risks to patients. A REMS can include medication guides, communication plans for healthcare professionals, and elements to assure a product’s safe use (“ETASU”). An ETASU can include, but is not limited to, special training or certification for prescribing or dispensing the product, dispensing the product only under certain circumstances, special monitoring, and the use of patient-specific registries. The requirement for a REMS can materially affect the potential market and profitability of the product. Moreover, the FDA may require substantial post-approval testing and surveillance to monitor the product’s safety or efficacy.

27

 


 

Once granted, product approvals may be withdrawn if compliance with regulatory standards is not maintained or problems are identified following initial marketing. Changes to some of the conditions established in an approved BLA, including changes in indications, product labeling, manufacturing processes or facilities, require submission and FDA approval of a new BLA, or supplement to an approved BLA, before the change can be implemented. A BLA supplement for a new indication typically requires clinical data similar to that in the original application, and the FDA uses the same procedures and actions in reviewing BLA supplements as it does in reviewing original BLAs.

Disclosure of Clinical Trial Information

Sponsors of clinical trials of FDA regulated products, including biologics, are required to register and disclose certain clinical trial information on the website www.clinicaltrials.gov. Information related to the product, patient population, phase of investigation, study sites and investigators, and other aspects of the clinical trial is then made public as part of the registration. Sponsors are also obligated to discuss the results of their clinical trials after completion. Disclosure of the results of these trials can be delayed in certain circumstances for up to two years after the date of completion of the trial. Competitors may use this publicly available information to gain knowledge regarding the progress of development programs.

 

Expedited Development and Review Programs

Fast Track Designation and Priority Review

Fast track designation may be granted for a product that is intended to treat a serious or life-threatening disease or condition for which there is no effective treatment and preclinical or clinical data demonstrate the potential to address unmet medical needs for the condition. Fast track designation applies to both the product and the specific indication for which it is being studied.

The sponsor of an investigational biological product may request that FDA designate the product candidate for a specific indication as a fast track product concurrent with, or after, the submission of the IND for the product candidate. FDA must determine if the product candidate qualifies for fast track designation within 60 days of receipt of the sponsor’s request. For fast track products, sponsors may have more frequent interactions with the FDA and the FDA may initiate review of sections of a fast track product’s BLA before the application is complete. This “rolling review” is available if the FDA determines, after preliminary evaluation of clinical data submitted by the sponsor, that a fast track product may be effective. The sponsor must also provide, and the FDA must approve, a schedule for the submission of the remaining information and the sponsor must pay applicable user fees. Fast track designation may be withdrawn if FDA believes that the designation is no longer supported by data emerging in the clinical trial process.

Priority review may be granted for products that are intended to treat a serious or life-threatening condition and, if approved, would provide a significant improvement in safety and effectiveness compared to available therapies. FDA determines at the time of the filing the BLA whether the proposed product would be a significant improvement and therefore receive a priority review designation. FDA will attempt to direct additional resources to the evaluation of an application designated for priority review in an effort to facilitate the review.

Breakthrough Therapy Designation

FDA is also required to expedite the development and review of applications for approval of biologics that are intended to treat a serious or life-threatening disease or condition where preliminary clinical evidence indicates that the biologic may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints. Under the breakthrough therapy program, the sponsor of a new product candidate may request that FDA designate the product candidate for a specific indication as a breakthrough therapy concurrent with, or after, the filing of the IND for the product candidate. FDA must determine if the product candidate qualifies for breakthrough therapy designation within 60 days of receipt of the sponsor’s request. The FDA may take certain actions with respect to breakthrough therapies, including holding meetings with the sponsor throughout the development process, providing timely advice to the product sponsor regarding development and approval, involving more senior staff in the review process, assigning a cross-disciplinary project lead for the review team and taking other steps to design the clinical studies in an efficient manner.

28

 


 

Accelerated Approval

Accelerated approval may be granted for a product that is intended to treat a serious or life-threatening condition and that generally provides a meaningful therapeutic advantage to patients over existing treatments. A product eligible for accelerated approval may be approved on the basis of either a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity or prevalence of the condition and the availability or lack of alternative treatments. The accelerated approval pathway is most often used in settings in which the course of a disease is long, and an extended period of time is required to measure the intended clinical benefit of a product, even if the effect on the surrogate or intermediate clinical endpoint occurs rapidly. Thus, accelerated approval has been used extensively in the development and approval of products for treatment of a variety of cancers in which the goal of therapy is generally to improve survival or decrease morbidity and the duration of the typical disease course requires lengthy and sometimes large studies to demonstrate a clinical or survival benefit. The accelerated approval pathway is contingent on a sponsor’s agreement to conduct additional post-approval confirmatory studies to verify and describe the product’s clinical benefit. These confirmatory trials must be completed with due diligence and, in some cases, the FDA may require that the trial be designed, initiated, and/or fully enrolled prior to approval. Failure to conduct required post-approval studies, or to confirm a clinical benefit during post-marketing studies, would allow the FDA to withdraw the product from the market on an expedited basis. All promotional materials for product candidates approved under accelerated regulations are subject to prior review by the FDA.

Regenerative Medicine Advanced Therapy Designation

The Regenerative Medicine Advanced Therapy (“RMAT”) designation is an expedited program for the advancement and approval of regenerative medicine products that are intended to treat, modify, reverse, or cure a serious condition and where preliminary clinical evidence indicates the potential to address unmet medical needs for life-threatening diseases or conditions. Similar to Breakthrough Therapy designation, the RMAT allows companies developing regenerative medicine therapies to work earlier, more closely, and frequently with the FDA, and RMAT-designated products may be eligible for priority review and accelerated approval. Regenerative medicine therapies include cell therapies, therapeutic tissue engineering products, human cell and tissue products, and combination products using any such therapies or products, except for those regulated solely under section 361 of the PHSA and Title 21 of the Code of Federal Regulations Part 1271. For product candidates that have received a RMAT designation, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens.

Pediatric Information

Under the Pediatric Research Equity Act (“PREA”), BLAs or supplements to BLAs must contain data to assess the safety and effectiveness of the biological product for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the biological product is safe and effective. FDA may grant full or partial waivers, or deferrals, for submission of data. Unless otherwise required by regulation, PREA does not apply to any biological product for an indication for which orphan designation has been granted except that PREA will apply to an original BLA for a new active ingredient that is orphan-designated if the drug is a molecularly targeted cancer product intended for the treatment of an adult cancer and is directed at a molecular target that FDA determines to be substantially relevant to the growth or progression of a pediatric cancer.

Additional Controls for Biologics

To help reduce the increased risk of the introduction of adventitious agents, the PHSA emphasizes the importance of manufacturing controls for products whose attributes cannot be precisely defined. The PHSA also provides authority to the FDA to immediately suspend biologics licenses in situations where there exists a danger to public health, to prepare or procure products in the event of shortages and critical public health needs, and to authorize the creation and enforcement of regulations to prevent the introduction or spread of communicable diseases within the United States.

29

 


 

After a BLA is approved, the product may also be subject to official lot release as a condition of approval. As part of the manufacturing process, the manufacturer is required to perform certain tests on each lot of the product before it is released for distribution. If the product is subject to official release by the FDA, the manufacturer submits samples of each lot of product to the FDA together with a release protocol showing a summary of the lot manufacturing history and the results of all of the manufacturer’s tests performed on the lot. The FDA may also perform certain confirmatory tests on lots of some products, such as viral vaccines, before allowing the manufacturer to release the lots for distribution. In addition, the FDA conducts laboratory research related to the regulatory standards on the safety, purity, potency, and effectiveness of biological products. After approval of a BLA, biologics manufacturers must address any safety issues that arise, are subject to recalls or a halt in manufacturing, and are subject to periodic inspection after approval.

Post-Approval Requirements

Once a BLA is approved, a product will be subject to certain post-approval requirements. For instance, FDA closely regulates the post-approval marketing and promotion of biologics, including standards and regulations for direct-to-consumer advertising, off-label promotion, industry-sponsored scientific and educational activities, and promotional activities involving the internet. Biologics may be marketed only for the approved indications and in a manner consistent with the approved labeling.

Adverse event reporting and submission of periodic reports are required following FDA approval of a BLA. FDA also may require post-marketing testing, known as Phase 4 testing, REMS, and surveillance to monitor the effects of an approved product, or FDA may place conditions on an approval that could restrict the distribution or use of the product. In addition, quality control, biological product manufacture, packaging, and labeling procedures must continue to conform to cGMP after approval. Biologics manufacturers and certain of their subcontractors are required to register their establishments with FDA and certain state agencies. Registration with FDA subjects entities to periodic unannounced inspections by FDA, during which the Agency inspects manufacturing facilities to assess compliance with cGMPs. Accordingly, manufacturers must continue to expend time, money, and effort in the areas of production and quality control to maintain compliance with cGMPs. Regulatory authorities may withdraw product approvals or request product recalls if a company fails to comply with regulatory standards, if it encounters problems following initial marketing, or if previously unrecognized problems are subsequently discovered.

Biosimilars

The Biologics Price Competition and Innovation Act of 2009 (“BPCIA”) creates an abbreviated approval pathway for biological products shown to be highly similar to or interchangeable with an FDA-licensed reference biological product. Biosimilarity sufficient to reference a prior FDA-approved product requires that there be no differences in conditions of use, route of administration, dosage form, and strength, and no clinically meaningful differences between the biological product and the reference product in terms of safety, purity, and potency. Biosimilarity must be shown through analytical trials, animal trials, and a clinical trial or trials, unless the Secretary of Health and Human Services waives a required element. A biosimilar product may be deemed interchangeable with a previously approved product if it meets the higher hurdle of demonstrating that it can be expected to produce the same clinical results as the reference product and, for products administered multiple times, the biologic and the reference biologic may be switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic. The first biosimilar was approved in 2015, and the first interchangeable product was approved July 28, 2021. Complexities associated with the larger, and often more complex, structures of biological products, as well as the process by which such products are manufactured, pose significant hurdles to biosimilar product implementation, which is still being evaluated by the FDA.

A reference biologic is granted 12 years of exclusivity from the time of first licensure, or BLA approval, of the reference product, and no application for a biosimilar can be submitted for four years from the date of licensure of the reference product. The first biologic product submitted under the biosimilar abbreviated approval pathway that is determined to be interchangeable with the reference product has exclusivity against a finding of interchangeability for other biologics for the same condition of use for the lesser of (i) one year after first commercial marketing of the first interchangeable biosimilar, (ii) 18 months after the first interchangeable biosimilar is approved if there is no patent challenge, (iii) eighteen months after resolution of a lawsuit over the patents of the reference biologic in favor of the first interchangeable biosimilar applicant, or (iv) 42 months after the first interchangeable biosimilar’s application has been approved if a patent lawsuit is ongoing within the 42-month period.

Other Healthcare Laws

In addition to FDA restrictions on marketing of pharmaceutical products, several other types of state and federal laws have been applied to restrict certain general business and marketing practices in the pharmaceutical industry. These laws include anti-kickback, false claims, transparency and health information privacy laws, and other healthcare laws and regulations.

30

 


 

The federal Anti-Kickback Statute prohibits, among other things, knowingly and willfully offering, paying, soliciting or receiving remuneration to induce, or in return for, purchasing, leasing, ordering or arranging for the purchase, lease or order of any healthcare item or service reimbursable under Medicare, Medicaid, or other federally financed healthcare programs. The Patient Protection and Affordable Care Act as amended by the Health Care and Education Reconciliation Act, collectively, the ACA, amended the intent element of the federal Anti-Kickback Statute so that a person or entity no longer needs to have actual knowledge of the statute or specific intent to violate it in order to commit a violation. This statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers and formulary managers, among others, on the other. Although there are a number of statutory exceptions and regulatory safe harbors protecting certain common activities from prosecution or other regulatory sanctions, the exceptions and safe harbors are drawn narrowly, and practices that involve remuneration intended to induce prescribing, purchases or recommendations may be subject to scrutiny if they do not qualify for an exception or safe harbor. Additionally, the ACA amended the federal Anti-Kickback Statute such that a violation of that statute can serve as a basis for liability under the federal civil False Claims Act.

Federal civil and criminal false claims laws, including the federal civil False Claims Act, prohibit any person or entity from knowingly presenting, or causing to be presented, a false claim for payment to the federal government, or knowingly making, or causing to be made, a false statement to have a false claim paid. This includes claims made to programs where the federal government reimburses, such as Medicare and Medicaid, as well as programs where the federal government is a direct purchaser, such as when it purchases off the Federal Supply Schedule. Pharmaceutical and other healthcare companies have been prosecuted under these laws for, among other things, allegedly inflating drug prices they report to pricing services, which in turn are used by the government to set Medicare and Medicaid reimbursement rates, and for allegedly providing free product to customers with the expectation that the customers would bill federal programs for the product. In addition, certain marketing practices, including off-label promotion, may also violate false claims laws. Most states also have statutes or regulations similar to the federal Anti-Kickback Statute and civil False Claims Act, which apply to items and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the payor.

Other federal statutes pertaining to healthcare fraud and abuse include the civil monetary penalties statute, which prohibits, among other things, the offer or payment of remuneration to a Medicaid or Medicare beneficiary that the offeror or payor knows or should know is likely to influence the beneficiary to order or receive a reimbursable item or service from a particular supplier, and the additional federal criminal statutes created by the Health Insurance Portability and Accountability Act of 1996 (“HIPAA”), which prohibit, among other things, knowingly and willfully executing or attempting to execute a scheme to defraud any healthcare benefit program or obtain by means of false or fraudulent pretenses, representations or promises any money or property owned by or under the control of any healthcare benefit program in connection with the delivery of or payment for healthcare benefits, items or services.

In addition, HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, and their respective implementing regulations, including the Final Omnibus Rule published on January 25, 2013, impose obligations on certain healthcare providers, health plans, and healthcare clearinghouses, known as covered entities, as well as their business associates and their subcontractors that perform certain services involving the storage, use or disclosure of individually identifiable health information, including mandatory contractual terms, with respect to safeguarding the privacy, security, and transmission of individually identifiable health information, and require notification to affected individuals and regulatory authorities of certain breaches of security of individually identifiable health information. HITECH increased the civil and criminal penalties that may be imposed against covered entities, business associates and possibly other persons, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorney’s fees and costs associated with pursuing federal civil actions. In addition, many state laws govern the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, and often are not preempted by HIPAA.

Further, pursuant to the ACA, the Centers for Medicare & Medicaid Services (“CMS”), issued a final rule that requires certain manufacturers of prescription drugs to collect and annually report information on certain payments or transfers of value to physicians (defined to include doctors, dentists, optometrists, podiatrists, and chiropractors), physician assistants, certain types of advance practice nurses and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. The reported data is made available in searchable form on a public website on an annual basis. Failure to submit required information may result in civil monetary penalties.

31

 


 

We may also be subject to analogous state and foreign anti-kickback and false claims laws that may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers, or that apply regardless of payor. In addition, several states now require prescription drug companies to report certain expenses relating to the marketing and promotion of drug products and to report gifts and payments to individual healthcare practitioners in these states. Other states prohibit various marketing-related activities, such as the provision of certain kinds of gifts or meals.

Further, certain states require the posting of information relating to clinical studies and their outcomes. Some states require the reporting of certain drug pricing information, including information pertaining to and justifying price increases. In addition, certain states require pharmaceutical companies to implement compliance programs and/or marketing codes. Several additional states are considering similar proposals. Certain states and local jurisdictions also require the registration of pharmaceutical sales representatives. Additionally, we may also be subject to state and foreign laws governing the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.

Efforts to ensure that business arrangements with third parties comply with applicable state, federal, and foreign healthcare laws and regulations involve substantial costs. If a drug company’s operations are found to be in violation of any such requirements, it may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, the curtailment or restructuring of its operations, loss of eligibility to obtain approvals from the FDA, exclusion from participation in government contracting, healthcare reimbursement or other federal or state government healthcare programs, including Medicare and Medicaid, integrity oversight and reporting obligations, imprisonment, and reputational harm. Although effective compliance programs can mitigate the risk of investigation and prosecution for violations of these laws, these risks cannot be entirely eliminated. Any action for an alleged or suspected violation can cause a drug company to incur significant legal expenses and divert management’s attention from the operation of the business, even if such action is successfully defended.

Data Privacy and Security

Numerous state, federal and foreign laws, govern the collection, dissemination, use, access to, confidentiality, and security of personal information, including health-related information. In the United States, numerous federal and state laws and regulations, including state data breach notification laws, state health information privacy laws, and federal and state consumer protection laws and regulations, govern the collection, use, disclosure, and protection of health-related and other personal information could apply to our operations or the operations of our partners. For example, HIPAA, as amended by HITECH, and their respective implementing regulations, imposes privacy, security and breach notification obligations on certain health care providers, health plans, and health care clearinghouses, known as covered entities, as well as their business associates that perform certain services that involve creating, receiving, maintaining or transmitting individually identifiable health information for or on behalf of such covered entities. Entities that are found to be in violation of HIPAA may be subject to significant civil, criminal and administrative fines and penalties, and/or additional reporting and oversight obligations if required to enter into a resolution agreement and corrective action plan with HHS to settle allegations of HIPAA non-compliance. Further, entities that knowingly obtain, use, or disclose individually identifiable health information maintained by a HIPAA covered entity in a manner that is not authorized or permitted by HIPAA may be subject to criminal penalties.

Even when HIPAA does not apply, according to the FTC, violating consumers’ privacy rights or failing to take appropriate steps to keep consumers’ personal information secure may constitute unfair acts or practices in or affecting commerce in violation of Section 5(a) of the Federal Trade Commission Act.

In addition, certain state and non-U.S. laws, such as the GDPR govern the privacy and security of personal information, including health-related information, in certain circumstances. Failure to comply with these laws, where applicable, can result in the imposition of significant civil and/or criminal penalties and private litigation. For example, the CCPA, which went into effect on January 1, 2020, creates new data privacy obligations for covered companies and provides new privacy rights to California residents. In Europe, the GDPR went into effect in May 2018 and introduces strict requirements for processing the personal data of individuals within the EEA. Further, recent legal developments in Europe have created complexity and compliance uncertainty regarding certain transfers of personal data from the EEA. For example, on July 16, 2020, the CJEU invalidated the Privacy Shield under which personal data could be transferred from the EEA to United States entities who had self-certified under the Privacy Shield scheme. Moreover, it is uncertain whether the standard contractual clauses will also be invalidated by the European courts or legislature.

32

 


 

Companies that must comply with the GDPR face increased compliance obligations and risk, including more robust regulatory enforcement of data protection requirements and potential fines for noncompliance of up to €20 million or 4% of the annual global revenues of the noncompliant company, whichever is greater. Additionally, following the United Kingdom’s withdrawal from the European Union and the EEA, companies have to comply with the GDPR and the GDPR as incorporated into United Kingdom national law, the latter regime having the ability to separately fine up to the greater of £17.5 million or 4% of global turnover. The relationship between the United Kingdom and the European Union in relation to certain aspects of data protection law remains unclear, for example around how data can lawfully be transferred between each jurisdiction, which exposes us to further compliance risk.

Coverage and Reimbursement

Significant uncertainty exists as to the coverage and reimbursement status of any pharmaceutical or biological product for which we obtain regulatory approval. Sales of any product, if approved, depend, in part, on the extent to which such product will be covered by third-party payors, such as federal, state, and foreign government healthcare programs, commercial insurance, and managed healthcare organizations, and the level of reimbursement, if any, for such product by third-party payors. Decisions regarding whether to cover any of our product candidates, if approved, the extent of coverage and amount of reimbursement to be provided are made on a plan-by-plan basis. Further, no uniform policy for coverage and reimbursement exists in the United States, and coverage and reimbursement can differ significantly from payor to payor. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement rates, but also have their own methods and approval process apart from Medicare determinations. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our product candidates to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance.

For products administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult because of the higher prices often associated with such drugs. Additionally, separate reimbursement for the product itself or the treatment or procedure in which the product is used may not be available, which may impact physician utilization. In addition, companion diagnostic tests require coverage and reimbursement separate and apart from the coverage and reimbursement for their companion pharmaceutical or biological products. Similar challenges to obtaining coverage and reimbursement, applicable to pharmaceutical or biological products, will apply to companion diagnostics.

In addition, the U.S. government, state legislatures and foreign governments have continued implementing cost-containment programs, including price controls, restrictions on coverage and reimbursement, and requirements for substitution of generic products. Third-party payors are increasingly challenging the prices charged for medical products and services, examining the medical necessity and reviewing the cost effectiveness of pharmaceutical or biological products, medical devices, and medical services, in addition to questioning safety and efficacy. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit sales of any product that receives approval. Decreases in third-party reimbursement for any product or a decision by a third-party not to cover a product could reduce physician usage and patient demand for the product.

U.S. Healthcare Reform

Healthcare reforms that have been adopted, and that may be adopted in the future, could result in further reductions in coverage and levels of reimbursement for pharmaceutical products, increases in rebates payable under U.S. government rebate programs and additional downward pressure on pharmaceutical product prices. On September 9, 2021, the Biden administration published a wide-ranging list of policy proposals, most of which would need to be carried out by Congress, to reduce drug prices and drug payment. The Depart of Health and Human Services, or HHS, plan includes, among other reform measures, proposals to lower prescription drug prices, including by allowing Medicare to negotiate prices and disincentivizing price increases, and to support market changes that strengthen supply chains, promote biosimilars and generic drugs, and increase price transparency. Many similar proposals, including the plans to give Medicare Part D authority to negotiate drug prices, require drug manufacturers to pay rebates on drugs whose prices increase greater than the rate of inflation, and cap out-of-pocket costs, have already been included in policy statements and legislation currently being considered by Congress. It is unclear to what extent these and other statutory, regulatory, and administrative initiatives will be enacted and implemented.

33

 


 

Other Government Regulation Outside of the United States

In addition to regulations in the United States, we are subject to a variety of regulations in other jurisdictions governing, among other things, research and development, clinical trials, testing, manufacturing, safety, efficacy, quality control, labeling, packaging, storage, record keeping, distribution, reporting, export and import, advertising, marketing, and other promotional practices involving biological products as well as authorization, approval as well as post-approval monitoring and reporting of our products. Because biologically sourced raw materials are subject to unique contamination risks, their use may be restricted in some countries.

Whether or not we obtain FDA approval for a product, we must obtain the requisite approvals from regulatory authorities in foreign countries prior to the commencement of clinical trials or marketing of the product in those countries. Certain countries outside of the United States have a similar process that requires the submission of a clinical trial application (a “CTA”), much like the IND prior to the commencement of human clinical trials.

The requirements and process governing the conduct of clinical trials, including requirements to conduct additional clinical trials, product licensing, safety reporting, post-authorization requirements, marketing and promotion, interactions with healthcare professionals, pricing, and reimbursement may vary widely from country to country. No action can be taken to market any product in a country until an appropriate approval application has been approved by the regulatory authorities in that country. The current approval process varies from country to country, and the time spent in gaining approval varies from that required for FDA approval. In certain countries, the sales price of a product must also be approved. The pricing review period often begins after market approval is granted. Even if a product is approved by a regulatory authority, satisfactory prices may not be approved for such product, which would make launch of such products commercially unfeasible in such countries.

Regulation in the European Union

Drug and Biologic Development Process

The conduct of clinical trials is currently governed by the EU Clinical Trials Directive 2001/20/EC (“Clinical Trials Directive”), and will be replaced by the EU Clinical Trials Regulation (EU) No. 536/2014 (“Clinical Trials Regulation”), once the latter comes into effect. The Clinical Trials Regulation introduces a complete overhaul of the existing regulation of clinical trials for medicinal products in the EU. Currently it is not expected to come into force before December 2021.

Under the current regime, before a clinical trial can be initiated, it must be approved in each EU Member State where there is a site at which the trial is to be conducted. The approval must be obtained from two separate entities: the National Competent Authority (“NCA”), and one or more Ethics Committees. The NCA of the EU Member States in which the clinical trial will be conducted must authorize the conduct of the trial, and the independent Ethics Committee must grant a positive opinion in relation to the conduct of the clinical trial in the relevant EU Member State before the commencement of the trial. Any substantial changes to the trial protocol or other information submitted with the clinical trial applications must be submitted to or approved by the relevant NCA and Ethics Committees. Under the current regime all suspected unexpected serious adverse reactions to the investigated drug that occur during the clinical trial must be reported to the NCA and to the Ethics Committees of the EU Member State where they occur.

A more unified procedure will apply under the new Clinical Trials Regulation. A sponsor will be able to submit a single application for approval of a clinical trial through a centralized EU clinical trials portal. One national regulatory authority (the reporting EU Member State proposed by the applicant) will take the lead in validating and evaluating the application and the other regulatory authorities will have limited involvement. If an application is rejected, it may be amended and resubmitted through the EU clinical trials portal. If an approval is issued, the sponsor may start the clinical trial in all concerned Member States. However, a concerned EU Member State may in limited circumstances declare an “opt-out” from an approval and prevent the clinical trial form being conducted in such Member State. The Clinical Trials Regulation also aims to streamline and simplify the rules on safety reporting, and introduces enhanced transparency requirements such as mandatory submission of a summary of the clinical trial results to the EU Database.

Under both the current regime and the new Clinical Trials Regulation, national laws, regulations, and the applicable Good Clinical Practice and Good Laboratory Practice standards must also be respected during the conduct of the trials, including the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (“ICH”), guidelines on Good Clinical Practice (“GCP”), and the ethical principles that have their origin in the Declaration of Helsinki.

34

 


 

During the development of a medicinal product, the European Medicines Agency (“EMA”), and national regulators within the EU provide the opportunity for dialogue and guidance on the development program, usually in the form of scientific advice. A fee is incurred with each scientific advice procedure. Advice from the EMA is typically provided based on questions concerning, for example, quality (chemistry, manufacturing, and controls testing), nonclinical testing and clinical studies, and pharmacovigilance plans and risk-management programs.

Drug Marketing Authorization

In the European Union, medicinal products, including advanced therapy medicinal products (“ATMPs”), are subject to extensive pre- and post-market regulation by regulatory authorities at both the European Union and national levels. ATMPs comprise gene therapy products, somatic cell therapy products, and tissue engineered products, which are genes, cells, or tissues that have undergone substantial manipulation and that are administered to human beings in order to cure, diagnose or prevent diseases or regenerate, repair or replace a human tissue. Pursuant to the ATMP Regulation, the Committee on Advanced Therapies (“CAT”), is responsible in conjunction with the CHMP for the evaluation of ATMPs. The CHMP and CAT are also responsible for providing guidelines on ATMPs. These guidelines provide additional guidance on the factors that the EMA will consider in relation to the development and evaluation of ATMPs and include, among other things, the preclinical studies required to characterize ATMPs; the manufacturing and control information that should be submitted in a marketing authorization application; and post-approval measures required to monitor patients and evaluate the long term efficacy and potential adverse reactions of ATMPs. Although such guidelines are not legally binding, compliance with them is often necessary to gain and maintain approval for product candidates.

In the European Union and in Iceland, Norway, and Liechtenstein (together the European Economic Area, or EEA), after completion of all required clinical testing, medicinal products may only be placed on the market after a related Marketing Authorization (“MA”), has been granted. MAs can be obtained through, amongst others, a centralized procedure, which is compulsory for certain medicinal products such as ATMPs. The centralized procedure provides for the grant of a single MA by the European Commission (“EC”), that is valid for all 27 EU Member States and, after respective national implementing decisions, in the three additional EEA Member States (Iceland, Norway, and Liechtenstein). The centralized procedure is compulsory for certain medicinal products, including medicinal products derived from biotechnological processes, orphan medicinal products, ATMPs, and products with a new active substance indicated for the treatment of AIDS, cancer, neurodegenerative disorders, diabetes, autoimmune diseases, and viral diseases. It is optional for medicinal products containing a new active substance not yet authorized in the EEA before May 20, 2004, that constitute significant therapeutic, scientific or technical innovations, or for which the grant of a MA through the centralized procedure would be in the interest of public health at EU level. The timeframe for the evaluation of an application under the centralized procedure is 210 days, excluding clock stops. Typically, the overall process takes a year or more unless the application is eligible for an accelerated assessment.

All new marketing authorization applications must include a Risk Management Plan (“RMP”), describing the risk management system that the company will put in place and documenting measures to prevent or minimize the risks associated with the product. The regulatory authorities may also impose specific obligations as a condition of the MA. RMPs and Periodic Safety Update Reports (“PSURs”), are routinely available to third parties requesting access, subject to limited redactions.

Additionally, the holder of a marketing authorization for an ATMP must put in place and maintain a system to ensure that each individual product and its starting and raw materials, including all substances coming into contact with the cells or tissues it may contain, can be traced through the sourcing, manufacturing, packaging, storage, transport, and delivery to the relevant healthcare institution where the product is used.

MAs have an initial duration of five years. The authorization may subsequently be renewed for an unlimited period unless the EC or the national competent authority grants only a five-year renewal.

Data and Market Exclusivity

As in the United States, the European Union also provides opportunities for market and/or data exclusivity. For example, new Chemical Entities (“NCE”), approved in the European Union generally qualify for eight years of data exclusivity and ten years of market exclusivity. Data exclusivity is the period during which another applicant cannot rely on the MA holder’s pharmacological, toxicological, and clinical data in support of another MA for the purposes of submitting an application, obtaining marketing authorization or placing the product on the market. But after eight years, a generic or biosimilar product application may be submitted and generic companies may rely on the MA holder’s data.

35

 


 

However, even if a generic or biosimilar product is authorized it cannot be placed on the market in the European Union until the expiration of the 10-year market exclusivity period. An additional non-cumulative one-year period of marketing exclusivity is possible if during the data exclusivity period (the first eight years of the 10‑year marketing exclusivity period), the MA holder obtains an authorization for one or more new therapeutic indications that are deemed to bring a significant clinical benefit compared to existing therapies.

Products may not be granted data exclusivity since there is no guarantee that a product will be considered by the European Union’s regulatory authorities to include a NCE. Even if a compound is considered to be a NCE and the MA applicant is able to gain the prescribed period of data exclusivity, another company nevertheless could also market another version of the medicinal product if such company can complete a full marketing authorization application with their own complete database of pharmaceutical tests, preclinical studies, and clinical trials and obtain MA of its product.

Post-Approval Regulation

Similar to the United States, both MA holders and manufacturers of medicinal products are subject to comprehensive regulatory oversight by the EMA, the European Commission, and/or the competent regulatory authorities of the EU Member States. This oversight applies both before and after grant of manufacturing licenses and marketing authorizations. It includes control of compliance with EU good manufacturing practices rules, manufacturing authorizations, pharmacovigilance rules, and requirements governing advertising, promotion, sale, and distribution, recordkeeping, importing, and exporting of medicinal products.

Failure by us or by any of our third-party partners, including suppliers, manufacturers, and distributors to comply with EU laws and the related national laws of individual EU Member States governing the conduct of clinical trials, manufacturing approval, marketing authorization of medicinal products, and marketing of such products, both before and after grant of marketing authorization, statutory health insurance, bribery and anti-corruption, or other applicable regulatory requirements may result in administrative, civil, or criminal penalties.

These penalties could include delays or refusal to authorize the conduct of clinical trials or to grant marketing authorization, product withdrawals and recalls, product seizures, suspension, withdrawal or variation of the marketing authorization, total or partial suspension of production, distribution, manufacturing or clinical trials, operating restrictions, injunctions, suspension of licenses, fines, and criminal penalties.

The holder of a marketing authorization for a medicinal product must also comply with EU pharmacovigilance legislation and its related regulations and guidelines, which entail many requirements for conducting pharmacovigilance, or the assessment and monitoring of the safety of medicinal products. These pharmacovigilance rules can impose on holders of MAs the obligation to conduct a labor intensive collection of data regarding the risks and benefits of marketed medicinal products and to engage in ongoing assessments of those risks and benefits, including the possible requirement to conduct additional clinical studies or post-authorization safety studies to obtain further information on a medicine’s safety, or to measure the effectiveness of risk-management measures, which may be time consuming and expensive and could impact our profitability. MA holders must establish and maintain a pharmacovigilance system and appoint an individual qualified person for pharmacovigilance, who is responsible for oversight of that system. Key obligations include expedited reporting of suspected serious adverse reactions and submission of PSURs in relation to medicinal products for which they hold MAs. The EMA reviews PSURs for medicinal products authorized through the centralized procedure. If the EMA has concerns that the risk benefit profile of a product has varied, it can adopt an opinion advising that the existing MA for the product be suspended, withdrawn or varied. The agency can advise that the MA holder be obliged to conduct post-authorization Phase IV safety studies. If the EC agrees with the opinion, it can adopt a decision varying the existing MA. Failure by the marketing authorization holder to fulfill the obligations for which the EC’s decision provides can undermine the ongoing validity of the MA.

More generally, non-compliance with pharmacovigilance obligations can lead to the variation, suspension or withdrawal of the MA for the product or imposition of financial penalties or other enforcement measures.

Sales and Marketing Regulations

The advertising and promotion of our products is also subject to EU laws concerning promotion of medicinal products, interactions with physicians, misleading and comparative advertising and unfair commercial practices. In addition, other national legislation of individual EU Member States may apply to the advertising and promotion of medicinal products and may differ from one country to another. These laws require that promotional materials and advertising in relation to medicinal products comply with the product’s SmPC as approved by the competent regulatory authorities.

36

 


 

The SmPC is the document that provides information to physicians concerning the safe and effective use of the medicinal product. It forms an intrinsic and integral part of the marketing authorization granted for the medicinal product. Promotion of a medicinal product that does not comply with the SmPC is considered to constitute off-label promotion. All advertising and promotional activities for the product must be consistent with the approved SmPC and therefore all off-label promotion is prohibited. Direct-to-consumer advertising of prescription-only medicines is also prohibited in the European Union. Violations of the rules governing the promotion of medicinal products in the European Union could be penalized by administrative measures, fines, and imprisonment. These laws may further limit or restrict the advertising and promotion of our products to the general public and may also impose limitations on its promotional activities with healthcare professionals.

Anti-Corruption Legislation

In the EU, interactions between pharmaceutical companies and physicians are also governed by strict laws, regulations, industry self-regulation codes of conduct and physicians’ codes of professional conduct both at EU level and in the individual EU Member States. The provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of medicinal products is prohibited in the European Union. The provision of benefits or advantages to physicians is also governed by the national anti-bribery laws of the EU Member States. Violation of these laws could result in substantial fines and imprisonment.

Payments made to physicians in certain EU Member States also must be publicly disclosed. Moreover, agreements with physicians must often be the subject of prior notification and approval by the physician’s employer, his/her regulatory professional organization, and/or the competent authorities of the individual EU Member States. These requirements are provided in the national laws, industry codes, or professional codes of conduct, applicable in the individual EU Member States. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment.

Other Markets

Following the UK’s formal departure from the EU on January 31, 2020, the UK entered a transition period to last until December 31, 2020, during which time EU medicines laws will remain applicable to the UK. After the transition period however, changes may be forthcoming as the terms of the UK and EU’s future relationship are negotiated. The UK Medicines and Healthcare Products Regulatory Agency has proposed that, subject to being approved by the UK Parliament, a centralized MA will automatically convert into a UK MA. However, the draft of the “Medicines and Medical Devices Bill 2019-21” currently discussed in the UK House of Lords does not contain such a provision, but would only authorize the UK government to become active in the field of legislation concerning market authorizations in relation to human medicines.

For other countries outside of the European Union, such as countries in Eastern Europe, Latin America or Asia, the requirements governing the conduct of clinical trials, product licensing, pricing, and reimbursement vary from country to country. In all cases, again, the clinical trials must be conducted in accordance with GCP and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki.

If we fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension of clinical trials, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions, and criminal prosecution.

Human Capital Management

Our approach to human capital resource management starts with our mission to discover and develop novel immunotherapies to lengthen health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. Our industry exists in a complex regulatory environment. The unique demands of our industry, together with the challenges of running an enterprise focused on the discovery, development, manufacture and commercialization of innovative medicines, require talent that is highly educated and/or has significant industry experience. Additionally, for certain key functions, we require specific scientific expertise to oversee and conduct R&D activities and the complex manufacturing requirements for biopharmaceutical products.

37

 


 

Our human capital resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing and integrating our existing and additional employees. We recognize that attracting, motivating and retaining talent at all levels is vital to our continued success. Our employees are a significant asset and we aim to create an equitable, inclusive and empowering environment in which our employees can grow and advance their careers, with the overall goal of developing, expanding and retaining our workforce to support our current pipeline and future business goals. By focusing on employee retention and engagement, we also improve our ability to support our clinical trials, our pipeline, our platform technologies, business and operations, and also protect the long-term interests of our stockholders. Our success also depends on our ability to attract, engage and retain a diverse group of employees.

Our base pay program aims to compensate management and staff members relative to the value of the contributions of their role, which takes into account the skills, knowledge and abilities required to perform each position, as well as the experience brought to the job. We also provide annual incentive programs to reward our management team and staff members in alignment with achievement of Company-wide goals that are established annually and designed to drive aspects of our strategic priorities that support and advance our strategy across our Company. Our management team and staff members are eligible for the grant of equity awards under our long-term incentive program that are designed to align the experience of these staff with that of our stockholders. All management team and staff members also participate in a regular performance measurement process that aligns pay to performance and through which they receive performance and development feedback.

Our benefit programs are also generally broad-based, promote health and overall well-being and emphasize saving for retirement. All management team and regular staff members are eligible to participate in the same core health and welfare and retirement savings plans. Other employee benefits include medical plans, health savings plan, dental plans, vacation and sick-pay plans, employee assistance programs, life and accident insurance and short and long-term disability benefits.

Our Compensation Committee provides oversight of our compensation plans, policies and programs.

As of December 31, 2021, we had 44 full-time employees, 34 of whom were engaged in research, clinical development, manufacturing, and quality control activities, and 10 of whom were engaged in administrative activities. None of our employees are represented by labor unions or covered by collective bargaining agreements. We consider our relationship with our employees to be good.

Corporate Information

We were incorporated in Delaware on April 2, 2018. Our principal executive offices are located at 2929 N Commerce Parkway, Miramar, FL 33025. Our telephone number at that location is (954) 842-2024. References in this Annual Report on Form 10-K to “we,” “our,” “us,” “HCW Biologics,” and the “Company” refer to HCW Biologics Inc. Our corporate website address is www.hcwbiologics.com. Information contained on our website is not a part of this Annual Report on Form 10-K and the inclusion of our website address in this Annual Report on Form 10-K is an inactive textual reference only.

HCW BIOLOGICS INC. and TOBI are trademarks of HCW Biologics Inc. All other brand names or trademarks appearing in this Annual Report on Form 10-K are the property of their respective holders. Solely for convenience, the trademarks and trade names in this Annual Report on Form 10-K are referred to without the ® and ™ symbols, but such references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto.

Available Information

We make available, free of charge through our website, our annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K, and amendments to those reports, filed or furnished pursuant to Sections 13(a) or Section 15(d) of the Securities Exchange Act of 1934, as amended, as soon as reasonably practicable after they have been electronically filed with, or furnished to, the SEC.

The SEC maintains an internet site (http://www.sec.gov) that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC.

38

 


 

Item 1A Risk Factors.

Our operations and financial results are subject to various risks and uncertainties, including those described below that could adversely affect our business, financial condition, results of operations, cash flows and the trading price of our common stock. It is not possible to predict or identify all such risks; our operations could also be affected by factors, events or uncertainties that are not presently known to us or that we currently do not consider to present significant risks to our operations. Therefore, while you should carefully consider the following risks, together with all of the other information in this Annual Report on Form 10-K, including the section titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” our financial statements and the related notes thereto. You should not consider the following risks to be a complete statement of all the potential risks or uncertainties we could face.

Summary of Key Risk Factors

 

We are an early-stage biopharmaceutical company and have incurred significant losses since our inception, and we expect to incur losses for the foreseeable future. We have no products approved for commercial sale and may never achieve or maintain profitability.
Our limited operating history may make it difficult for you to evaluate the success of our business to date and to assess our future viability
We will require additional funding in order to complete development of our product candidates and commercialize our products, if approved. Additional funding may not be available on acceptable terms, or at all. If we are unable to raise capital when needed, we could be forced to delay, reduce, or eliminate our product development programs, our efforts to access manufacturing capacity and our commercialization efforts.
Raising additional capital may cause dilution to our existing stockholders, restrict our operations, or require us to relinquish rights to our technologies or product candidates.
Public health crises such as pandemics or other events could materially and adversely affect our business operations, workforce, product development activities, research and development activities, preclinical and clinical trials, toxicology studies, and financial condition.
Our TOBITM platform is based on novel technologies that are unproven and may not result in approvable or marketable products, which exposes us to unforeseen risks and makes it difficult for us to predict the time and cost of product development and potential for regulatory approval. We may not be successful in our efforts to use and expand our technology platform to develop and commercialize our product candidates, or may experience significant delays in doing so.
Our clinical trials may fail to demonstrate substantial evidence of the safety and efficacy of our product candidates or any future product candidates, which would prevent or delay or limit the scope of regulatory approval and commercialization.
Preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data becomes available and are subject to audit and verification procedures that could result in material changes in the final data.
Clinical drug development is a lengthy and expensive process with uncertain outcomes. If clinical trials of our product candidates are prolonged or delayed, we or any collaborators may be unable to obtain required regulatory approvals, and therefore be unable to commercialize our product candidates on a timely basis or at all.
Our product candidates may have serious adverse, undesirable, or unacceptable side effects or other properties that may delay or prevent marketing approval.
If we experience delays or difficulties enrolling patients in our clinical trials, our research and development efforts and business, financial condition, and results of operations could be materially adversely affected.
The development and commercialization of biopharmaceutical products is subject to extensive regulation, and the regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time-consuming, and

39

 


 

inherently unpredictable. If we are ultimately unable to obtain regulatory approval for our product candidates on a timely basis if at all, our business will be substantially harmed. We operate in highly competitive and rapidly changing industries, which may result in others discovering, developing or commercializing competing products before or more successfully than we do.
We rely on third parties to manufacture biological materials and our product candidates. The manufacture of our product candidates is complex.
We rely on patents and other intellectual property rights to protect our technology, including product candidates from our TOBITM platform, methods used to manufacture those product candidates, formulations thereof, and the methods for treating patients using those product candidates.

Risks Related to our Financial Position and Need for Additional Capital

We have incurred significant losses since our inception and we expect to incur losses for the foreseeable future. We may never achieve or maintain profitability.

Since our inception, we have devoted substantially all of our financial resources and efforts to research and development, including preclinical studies and our clinical trials, and have incurred significant operating losses. For the years ended December 31, 2020 and 2021, we reported a net loss of $5.8 million and $12.9 million, respectively. As of December 31, 2021, we had $11.7 million in cash and cash equivalents, $25.0 million in short-term investments held in U.S. Treasury bills, and $9.9 million in long-term investments held in U.S. Treasury notes. From inception to December 31, 2021, we incurred cumulative net losses of $27.9 million. To date, we have financed our operations primarily through our initial public offering, or the IPO, the sale of our redeemable preferred stock, and to a lesser extent, upfront payments received under our exclusive worldwide license with Wugen Inc. (“Wugen License”) for certain rights to two of our internally-developed molecules and proceeds from an SBA Paycheck Protection Loan (“PPP loan”) obtained through the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) which was forgiven.

Our losses have resulted principally from expenses incurred in the research and development of our product candidates and from management and administrative costs and other expenses that we have incurred while building our business infrastructure. We expect to continue to incur significant operating losses for the foreseeable future. The only revenue we have generated to date relates to our Wugen License. We have not generated any revenues from product sales. We anticipate that our expenses will increase substantially as we:

undertake our initial Phase 1b/2 clinical trial for HCW9218 in pancreatic cancer;
continue to advance the preclinical and clinical development in pursuit of immunotherapeutic treatments for other indications such as fibrotic diseases and autoimmune diseases using our lead product candidates, HCW9218 and HCW9302;
initiate preclinical studies and clinical trials for additional product candidates that we may identify in the future;
scale up our manufacturing process and capabilities to support our clinical trials of our product candidates;
expand our operational, financial, and management systems and increase personnel, including personnel to support our clinical development, manufacturing, and commercialization efforts;
continue to develop, perfect, and defend our intellectual property portfolio; and
incur additional legal, accounting, or other expenses in operating our business, including the additional costs associated with operating as a public company.

We have no products for which we have obtained marketing approval and have not generated any revenue from product sales. Even if we obtain marketing approval for, and are successful in commercializing, one or more of our product candidates, we expect to incur substantial additional research and development and other expenditures to develop and market additional product candidates or to expand the approved indications of any marketed product. We may encounter unforeseen expenses, difficulties, complications, delays, and other unknown factors that may adversely affect our business. The size of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenue.

40

 


 

To become and remain profitable, we must succeed in developing and eventually commercializing products that generate significant revenue. This will require us to be successful in a range of challenging activities, including completing preclinical testing and clinical trials of our product candidates, discovering and developing additional product candidates, obtaining regulatory approval for any product candidates that successfully complete clinical trials, accessing manufacturing capacity, establishing marketing capabilities, and ultimately selling any products for which we may obtain regulatory approval. We may never succeed in these activities and, even if we do, we may never generate revenue that is sufficient to achieve profitability.

Because of the numerous risks and uncertainties associated with pharmaceutical products and biological development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve profitability. If we are required by the FDA, or other regulatory authorities to perform studies in addition to those we currently anticipate, if there are any delays in completing our clinical trials or the development of any of our product candidates or if there are any third-party challenges to our intellectual property or we need to defend against any intellectual property-related claim, our expenses could increase and commercial revenue could be further delayed and more uncertain.

Our limited operating history may make it difficult for you to evaluate the success of our business to date and to assess our future viability.

Since our inception in 2018, we have devoted a significant portion of our resources to identifying and developing our product candidates emerging from our internally-developed immunotherapy platform technology, our other research and development efforts, building our intellectual property portfolio, raising capital, and providing general and administrative support for these operations. We have not yet demonstrated our ability to successfully complete clinical trials, obtain regulatory approvals, manufacture a commercial scale product or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful product commercialization. Additionally, we expect our financial condition and operating results to continue to fluctuate significantly from period to period due to a variety of factors, many of which are beyond our control. Consequently, any predictions you may make about our future success or viability may not be as accurate as they could be if we had a longer operating history.

We will require additional funding in order to complete development of our product candidates and commercialize our products, if approved. However, this additional financing may not be available on acceptable terms, or at all. If we are unable raise capital when needed, we could be forced to delay, reduce, or eliminate our product development programs or commercialization efforts.

Based on our current business plans, including anticipated revenues from out-license agreements, we believe that our existing cash and cash equivalents and short-term investments, will enable us to fund our operating expenses through the end of 2023. We have based this estimate on assumptions that may prove to be wrong, and we could use our capital resources sooner than we currently expect, requiring us to seek additional funds sooner than planned, through public or private equity or debt financings or other sources, such as strategic collaborations. In addition, we may seek additional capital due to favorable market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. Attempting to secure additional financing may divert our management from our day-to-day activities, which may adversely affect our ability to develop our product candidates. Our future capital requirements will depend on many factors, including:

the scope, timing, progress, costs, and results of discovery, preclinical development, laboratory testing, and clinical trials for our product candidates;
the costs, timing, and outcome of regulatory review of any of our product candidates;
the cost of manufacturing clinical supplies of our product candidates;
the costs and timing of future commercialization activities, including manufacturing, marketing, sales, and distribution, for any of our product candidates for which we receive marketing approval;
the extent to which we earn additional revenues under our licensing agreement with Wugen to develop certain cellular therapy products or enter into, maintain, and derive revenues from other licensing agreements, including agreements to out-license HCW9302 and HCW9213 and other product candidates, research and other collaborations, joint ventures and other business arrangements;
the costs and timing of preparing, filing, and prosecuting patent applications, maintaining and enforcing our intellectual property rights, and defending any intellectual property-related claims, including any claims by third parties that we are infringing upon their intellectual property rights;

41

 


 

the cost of building a sales force in anticipation of product commercialization;
the revenue, if any, received from commercial sales of our product candidates for which we receive marketing approval;
the effect of competing technological and market developments; and
the extent to which we acquire or invest in business, products, and technologies.

Our ability to raise additional funds will depend on financial, economic, and market conditions and other factors, over which we may have no or limited control. Market volatility resulting from the COVID-19 pandemic or other factors could also adversely impact our ability to access capital as and when needed. Additional funds may not be available when we need them, on terms that are acceptable to us or at all. If adequate funds are not available to us on a timely basis, we could be required to:

delay, limit, reduce, or terminate preclinical studies, clinical trials, or other research and development activities, or eliminate one or more of our development programs altogether; or
delay, limit, reduce, or terminate our efforts to access manufacturing capacity, establish sales and marketing capabilities or other activities that may be necessary to commercialize our product candidates, or reduce our flexibility in developing or maintaining our sales and marketing strategy.

Raising additional capital may cause dilution to our stockholders, restrict our operations, or require us to relinquish rights to our technology or product candidates.

Until such time, if ever, as we can generate substantial product revenues, we expect to finance our operations with our existing cash and cash equivalents and accounts receivable, equity or debt financings, and upfront and milestone and royalty payments, if any, received from future licenses or collaborations. If we raise additional capital through the sale of equity or convertible debt securities, our stockholders’ ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a holder of our common stock. In addition, the possibility of such issuance may cause the market price of our common stock to decline. Debt financing, if available, may result in increased fixed payment obligations and involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, declaring dividends, or acquiring, selling, or licensing intellectual property rights, which could adversely impact our ability to conduct our business.

If we raise additional funds through collaborations, strategic alliances or marketing, distribution, or licensing arrangements with third parties, we may have to relinquish valuable rights to our intellectual property, technology, future revenue streams, or product candidates or grant licenses on terms that may not be favorable to us. We could also be required to seek funds through arrangements with collaborators or others at an earlier stage than otherwise would be desirable. Any of these occurrences may have a material adverse effect on our business, operating results, and prospects.

Public health crises such as pandemics or similar outbreaks could materially and adversely affect our preclinical and clinical trials, business, financial condition, and results of operations.

In March 2020, the World Health Organization declared COVID-19 a global pandemic and the United States declared a national emergency with respect to COVID-19. In response to the COVID-19 pandemic, we have implemented recommended public health guidance measures, limited the number of on-site staff and operated on a staggered schedule, which has altered our operations and processes. Similar changes from normal business activities have occurred at our key vendors and partners. We have experienced delays in the development of our lead product candidates as a result of the ongoing COVID-19 pandemic as new variants spread and prolong its impacts, including delays with certain third-party vendors conducting preclinical IND-enabling studies. Additionally, the worldwide demand and rapid development of COVID-19 diagnostics, vaccines and therapeutics has limited and may continue to limit the availability of services and materials necessary for our product candidates’ manufacture and testing. While we are using our best efforts to mitigate these disruptions, we expect that our clinical development program timelines, including the timing of the IND submissions, may continue to be negatively affected by COVID-19, which could materially and adversely affect our business, financial condition, and results of operations.

As a result of the COVID-19 pandemic, or similar pandemics, and related public health guidance measures and orders, we have and may in the future experience disruptions that could materially and adversely impact our clinical trials, business, financial condition, and results of operations.

42

 


 

Potential disruptions include but are not limited to:

COVID-19-related delays or interruptions at the contract testing or manufacturing operations, our laboratories, or in the supply chain;
delays or difficulties in enrolling patients in our clinical trials;
delays or difficulties in initiating or expanding clinical trials, including delays or difficulties with clinical site initiation and recruiting clinical site investigators and clinical site staff;
patients withdrawing from our future clinical trials following enrollment as a result of contracting COVID-19 or other health conditions or being forced to quarantine;
delays in clinical sites receiving the supplies and materials needed to conduct our planned clinical trials;
interruption of key clinical trial activities, such as clinical trial site data monitoring and efficacy, safety and translational data collection, processing and analyses, due to limitations on travel imposed or recommended by federal, state, or local governments, employers, and others or interruption of clinical trial subject visits, which may impact the collection and integrity of subject data and clinical study endpoints;
diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials;
delays or disruptions in preclinical experiments and IND-enabling studies including toxicology studies due to restrictions of on-site staff and unforeseen circumstances at vendors;
interruption or delays in the operations of the FDA and comparable foreign regulatory agencies;
delays in receiving approval from local regulatory authorities to initiate our planned clinical trials;
limitations on employee or other resources that would otherwise be focused on the conduct of our clinical trials and preclinical work, including because of sickness of employees or their families, the desire of employees to avoid travel or contact with large groups of people, an increased reliance on working from home, school closures, or mass transit disruptions;
changes in regulations as part of a response to the COVID-19 pandemic which may require us to change the ways in which our clinical trials are conducted, which may result in unexpected costs, or to discontinue the clinical trials altogether;
delays in necessary interactions with regulators, ethics committees, and other important agencies and contractors due to limitations in employee resources or forced furlough of government or contractor personnel; and
refusal of the FDA to accept data from clinical trials in affected geographies outside the United States.

The extent to which the COVID-19 or outbreaks of its variants may affect our clinical trials, business, financial condition, and results of operations will depend on future developments, which are highly uncertain and cannot be predicted at this time, such as the potential spread of the vaccine/treatment-resistant disease, the duration of the outbreaks, travel restrictions, and actions to contain the outbreaks or treat their impact, such as social distancing and quarantines or lock-downs in the United States and other countries, business closures, or business disruptions and the effectiveness of actions taken in the United States and other countries to contain and treat the disease. Future developments in these and other areas present material uncertainty and risk with respect to our clinical trials, business, financial condition, and results of operations.

If we or any collaborators we work with in the future are unable to successfully develop and commercialize our product candidates, or experience significant delays in doing so, our business, financial condition, and results of operations will be materially adversely affected.

43

 


 

Our ability to generate product and royalty revenues, which we do not expect will occur for at least the next several years, if ever, will depend heavily on the successful development and eventual commercialization of our product candidates, which may never occur. We currently generate no revenue from sales of any products, and we may never be able to develop or commercialize a marketable product. Each of our product candidates and any future product candidates we develop will require significant clinical development; management of clinical, preclinical, and manufacturing activities; regulatory approval in multiple jurisdictions; establishing manufacturing supply, including commercial manufacturing supply; and require us to build a commercial organization and make substantial investment and significant marketing efforts before we generate any revenue from product sales. We are not permitted to market or promote any of our product candidates before we receive regulatory approval from the FDA or comparable foreign regulatory authorities, and we may never receive such regulatory approval for any of our product candidates.

The successful development of our product candidates will depend on several factors, including the following:

timely completion of successful clinical trials and preclinical studies for which the FDA, or any comparable foreign regulatory authority agree with the design, endpoints, or implementation;
sufficiency of our financial and other resources to complete the necessary preclinical studies and clinical trials;
receiving regulatory approvals or authorizations for conducting our planned clinical trials or future clinical trials;
initiation and successful patient enrollment in, and completion of, additional clinical trials on a timely basis;
our ability to demonstrate to the satisfaction of the FDA or any comparable foreign regulatory authority that the applicable product candidate is safe and effective as a treatment for our targeted indications or, in the case of an applicable product candidate which is regulated as a biological product, that the applicable product is safe, pure, and potent for our targeted indications;
our ability to demonstrate to the satisfaction of the FDA or any comparable foreign regulatory authority that the applicable product candidate’s risk-benefit ratio for its proposed indication is acceptable;
timely receipt of marketing approvals for our product candidates from applicable regulatory authorities;
the extent of any required post-marketing approval commitments to applicable regulatory authorities; and
establishing and scaling up, either alone or with third-party manufacturers, manufacturing capabilities of clinical supply for our clinical trials and commercial manufacturing, if any of our product candidates are approved.

If we do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully develop and commercialize our product candidates, which would materially adversely affect our business, financial condition, and results of operations.

A key element of our strategy is to enter into out-licensing arrangements for certain rights to HCW internally-developed molecules that we do not intend to develop into lead product candidates on our own or together with co-development partners. We may not be able to identify licensees, which could lower any return on our investments and increase our need for external funding.

Since we have already generated over 30 immunotherapeutic molecules, and plan to develop additional molecules, through our immunotherapy platform technology, our strategy includes funding operations in part through revenues derived from out-licensing molecules that are outside our oncological and anti-aging focus to third parties. Despite our efforts, we may be unable to enter into such licensing agreements. Supporting diligence activities conducted by potential licensors and negotiating the financial and other terms of a license agreement are long and complex processes with uncertain results, and we may fail to derive any revenues from these activities. Further, our potential licensors may develop alternative products or pursue alternative technologies either on their own or in collaboration with others, potentially resulting in our receiving no future milestone or royalty payments under any such licenses. For example, we have an exclusive worldwide license arrangement with Wugen pursuant to the development of certain cellular therapy products under which we may earn additional milestone or royalty payments, but there can be no assurance that Wugen will be successful in commercializing any products related to this license or that any such payments will ever be earned. If we fail to successfully out-license to third parties internally-developed molecules that are outside our focus areas, our revenues and return on our research and development activities would be negatively affected and we could be required to seek additional funding of our operations through the issuance of additional shares of common stock, or other equity or debt securities convertible into common stock, which could result in substantial dilution to our existing stockholders and could cause the price of our common stock to decline.

44

 


 

Our immunotherapy platform technology is based on novel technology that is unproven and may not result in approvable or marketable products, which exposes us to unforeseen risks and makes it difficult for us to predict the time and cost of product development and potential for regulatory approval.

We are developing a pipeline of product candidates using our internally-developed immunotherapy platform technology. We have not received regulatory approval for any of our product candidates. The scientific research that forms the basis of our efforts to develop product candidates with our immunotherapy platform technology is still ongoing. Further, the scientific evidence to support the feasibility of developing therapeutic treatments based on our immunotherapy platform technology is both preliminary and limited. Given the novelty of our technology, we intend to work closely with the FDA and other regulatory authorities to perform the requisite scientific analyses and evaluation of our methods to obtain regulatory approval for our product candidates. The validation process takes time and resources, may require independent third-party analyses, and may not be accepted by the FDA and other regulatory authorities. We cannot be certain that our approach will lead to the development of approvable or marketable products, alone or in combination with other therapies. Moreover, the FDA or other regulatory agencies may lack experience in evaluating the safety and efficacy of our immunotherapy platform technology, which could result in a longer than expected regulatory review process, increase our expected development costs, and delay or prevent commercialization of our product candidates. Additionally, even if our lead product candidates, such as HCW9218 and HCW9302, are approved, we will need to educate medical personnel regarding the potential efficacy and safety benefits of incorporating product candidates, such as HCW9218 and HCW9302 into existing treatment regimens, including in combination with other treatments for certain types of cancer. If we do not continue to successfully develop and begin to commercialize product candidates, we will face difficulty in obtaining product revenues in future periods, which could result in significant harm to our financial position and adversely affect our share price.

The potential long-term growth of our business depends on our efforts to leverage our immunotherapy platform technology to expand our portfolio of molecules and product candidates, which may require substantial financial resources and may ultimately be unsuccessful.

The potential long-term growth of our business depends upon our ability to utilize our internally-developed immunotherapy technology platform to build a pipeline of molecules and product candidates and either progress those product candidates through clinical development for the treatment of a variety of different types of diseases or out-license those molecules to third parties. Although our research and development efforts to date have resulted in a pipeline of product candidates directed at various cancers and aging-associated diseases, as well as other immunotherapy molecules, we may not be able to develop product candidates that are safe and effective. Research programs to identify new molecules, indications, and product candidates require substantial technical, financial, and human resources whether or not we ultimately identify any product candidates. Our research programs may initially show promise in identifying potential product candidates, yet fail to yield product candidates for clinical development for a number of reasons, including:

the research methodology used may not be successful in identifying potential product candidates; or
potential product candidates may on further study be shown to have harmful side effects or other characteristics that indicate they are unlikely to be effective drugs.

Even if we are successful in continuing to build our pipeline, the potential product candidates that we identify may not be suitable for clinical development, including as a result of being shown to have harmful side effects or other characteristics that indicate that they are unlikely to be products that will receive marketing approval and achieve market acceptance. There are a number of FDA requirements that we must satisfy before we can commence a clinical trial. If we are able to identify additional potential product candidates, satisfaction of these regulatory requirements will entail substantial time, effort, and financial resources. We may never satisfy these requirements. Any time, effort, and financial resources we expend on development of other product candidates may impair our ability to continue development and commercialization of HCW9218 for oncological and other indications, and we may never commence clinical trials of such development programs despite expending significant resources in pursuit of their development. If we do commence clinical trials of other product candidates, these product candidates may never demonstrate sufficient safety and efficacy to be approved by the FDA or other regulatory authorities. If any of these events occur, we may be forced to abandon our development efforts for such program or programs, which would harm our business.

We expect to continue to expand our capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.

As of December 31, 2021, we had 44 full-time employees. We expect to experience continued growth in the number of our employees and the scope of our operations, particularly in the areas of drug development and regulatory affairs. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational, and financial systems; expand our

45

 


 

facilities; and continue to recruit and train additional qualified personnel. Due to our limited financial resources and the limited experience of our management team in managing a public company with such anticipated growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations.

In addition, future growth imposes significant added responsibilities on members of management, including: identifying, recruiting, integrating, maintaining, and motivating additional employees; managing our internal development efforts effectively, including the clinical and FDA review process for our product candidates, while complying with our contractual obligations to contractors and other third parties; and improving our operational, financial and management controls, reporting systems, and procedures.

We currently rely on certain independent organizations, advisors, and consultants to provide certain services, including strategic, financial, business development services, as well as certain aspects of regulatory approval, clinical management, manufacturing, and preparation for a potential commercial launch. There can be no assurance that the services of independent organizations, advisors, and consultants will continue to be available to us on a timely basis when needed, or that we can find qualified replacements. In addition, if we are unable to effectively manage our outsourced activities or if the quality or accuracy of the services provided by consultants or contract manufacturing organizations is compromised for any reason, our clinical trials may be extended, delayed, or terminated, and we may not be able to obtain regulatory approval of our product candidates or otherwise advance our business. There can be no assurance that we will be able to manage our existing consultants or find other competent outside contractors and consultants on economically reasonable terms, or at all.

Our future growth and ability to compete depends on retaining our key personnel and recruiting additional qualified personnel.

Our success depends upon the continued contributions of our key management, scientific, and technical personnel, many of whom have been instrumental for us and have substantial experience with our product candidates and related technology. The loss of key managers and senior scientists could delay our research and development activities. Despite our efforts to retain valuable employees, members of our management, scientific, and development teams may terminate their employment with us on short notice. Although we have employment agreements with certain of our key employees, these employment agreements provide for at-will employment, which means that any of our employees could leave our employment at any time, with or without notice. In addition, the competition for qualified personnel in the biotechnology and pharmaceutical industries is intense, and our future success depends upon our ability to attract, retain, and motivate highly-skilled scientific, technical, and managerial employees. We face competition for personnel from other companies, universities, public and private research institutions, and other organizations. If our recruitment and retention efforts are unsuccessful in the future, it may be difficult for us to implement our business strategy, which could have a material adverse effect on our business.

Risks Related to the Development and Clinical Testing of Our Product Candidates

Our clinical trials may fail to demonstrate substantial evidence of the safety and efficacy of our product candidates or any future product candidates, which would prevent or delay or limit the scope of regulatory approval and commercialization.

To obtain the requisite regulatory approvals to market and sell any product candidates, we must demonstrate through extensive preclinical studies and clinical trials that our investigational drug products are safe and effective for use in each targeted indication. Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical development process. Most product candidates that begin clinical trials are never approved by regulatory authorities for commercialization. We may be unable to establish clinical endpoints that applicable regulatory authorities would consider clinically meaningful, and a clinical trial can fail at any stage of testing.

Further, the process of obtaining regulatory approval is expensive, often takes many years following the commencement of clinical trials, and can vary substantially based upon the type, complexity, and novelty of the product candidates involved, as well as the target indications, patient population, and regulatory agency. Prior to obtaining approval to commercialize our product candidates and any future product candidates in the United States or abroad, we, our collaborators or our potential future collaborators must demonstrate with substantial evidence from adequate and well-controlled clinical trials, and to the satisfaction of the FDA or comparable foreign regulatory authorities, that such product candidates are safe and effective for their intended uses.

Clinical trials that we conduct may not demonstrate the efficacy and safety necessary to obtain regulatory approval to market our product candidates. In some instances, there can be significant variability in safety or efficacy results between different clinical trials of the same product candidate due to numerous factors, including changes in trial procedures set forth in protocols, differences in

46

 


 

the size and type of the patient populations, changes in and adherence to the clinical trial protocols, and the rate of dropout among clinical trial participants. If the results of our clinical trials are inconclusive with respect to the efficacy of our product candidates, if we do not meet the clinical endpoints with statistical and clinically meaningful significance, or if there are safety concerns associated with our product candidates, we may be delayed in obtaining marketing approval, if at all. Additionally, any safety concerns observed in any one of our clinical trials could limit the prospects for regulatory approval of that product candidate or other product candidates in any indications.

Even if the trials are successfully completed, clinical data are often susceptible to varying interpretations and analyses, and we cannot guarantee that the FDA or comparable foreign regulatory authorities will interpret the results as we do, and more trials could be required before we submit our product candidates for approval. We cannot guarantee that the FDA or comparable foreign regulatory authorities will view our product candidates as having efficacy even if positive results are observed in clinical trials. Moreover, results acceptable to support approval in one jurisdiction may be deemed inadequate by another regulatory authority to support regulatory approval in that other jurisdiction. To the extent that the results of the trials are not satisfactory to the FDA or comparable foreign regulatory authorities for support of a marketing application, approval of our product candidates, and any future product candidates may be significantly delayed, or we may be required to expend significant additional resources, which may not be available to us, to conduct additional trials in support of potential approval of our product candidates. Even if regulatory approval is secured for a product candidate, the terms of such approval may limit the scope and use of the specific product candidate, which may also limit its commercial potential.

In the near term, we are dependent on the success of HCW9218. If we are unable to complete the clinical development of, obtain marketing approval for or successfully commercialize HCW9218, or if we experience significant delays in doing so, our business would be substantially harmed.

We do not currently have products approved for sale and are investing a significant portion of our efforts and financial resources in the development of HCW9218. Although we have other programs in preclinical development and we intend to develop additional product candidates in the coming years, it will take additional investment and time for such product candidates to reach the same stage of development as HCW9218, and there can be no assurance that they will ever do so. Our prospects are substantially dependent on our ability to develop and obtain marketing approval for, and successfully commercialize, HCW9218 in one or more disease indications.

Preliminary, topline or interim data from our clinical trials that we announce or publish from time to time may change as more patient data becomes available and are subject to audit and verification procedures that could result in material changes in the final data.

From time to time, we may publicly disclose preliminary or topline data from our preclinical studies and clinical trials, which is based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial. We also make assumptions, estimations, calculations, and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the topline results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Topline data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, topline data should be viewed with caution until the final data are available.

From time to time, we may also disclose data from planned interim analyses of our clinical trials. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Adverse differences between interim data and final data could significantly harm our business prospects. Further, disclosure of interim data by us or by our competitors could result in volatility in the price of our common stock.

Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions, or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product, and our company in general. If the interim, topline, or preliminary data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, our product candidates may be harmed, which could harm our business, operating results, prospects, or financial condition.

 

47

 


 

Results of preclinical studies of our product candidates may not be predictive of the results of future preclinical studies or clinical trials.

To obtain the requisite regulatory approvals to market and sell any of our product candidates, we or any collaborator for such candidates must demonstrate through extensive preclinical studies and clinical trials that our product candidates are safe, pure, and potent in humans. Before IND can be submitted to the FDA and become effective, which is a prerequisite for conducting clinical trials on human subjects in the United States, a product candidate must successfully progress through extensive preclinical studies, which include preclinical laboratory testing, animal studies, and formulation studies in accordance with Good Laboratory Practices.

Success in preclinical studies does not ensure that later preclinical studies or clinical trials will be successful. A number of companies in the biotechnology and pharmaceutical industries have suffered significant setbacks in clinical trials, even after positive results in earlier preclinical studies. These setbacks have been caused by, among other things, preclinical findings made while clinical trials were underway and safety or efficacy observations made in clinical trials, including previously unreported adverse events. The design of a clinical trial can determine whether its results will support approval of a product, and flaws in the design of a clinical trial may not become apparent until the clinical trial is well advanced. In addition, preclinical and clinical data are often susceptible to varying interpretations and analyses. Notwithstanding any potential promising results in earlier studies, we cannot be certain that we will not face similar setbacks. In addition, the results of our preclinical animal studies, including our non-human primate studies, may not be predictive of the results of outcomes in subsequent clinical trials on human subjects. Product candidates in clinical trials may fail to show the desired pharmacological properties or safety and efficacy traits despite having progressed through preclinical studies.

If we fail to receive positive results in preclinical studies or clinical trials of our product candidates, the development timeline and regulatory approval and commercialization prospects for our most advanced product candidates, and, correspondingly, our business and financial prospects would be negatively impacted.

All of our product candidates are in preclinical or early-stage clinical development. Clinical drug development is a lengthy and expensive process with uncertain timelines and uncertain outcomes. If clinical trials of our product candidates are prolonged or delayed, we or any collaborators may be unable to obtain required regulatory approvals, and therefore be unable to commercialize our product candidates on a timely basis or at all.

Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process. Product candidates in later stages of clinical trials may fail to produce the same results or to show the desired safety and efficacy traits despite having progressed through preclinical studies and initial clinical trials. Our future clinical trial results may not be successful.

To date, we have not completed any clinical trials required for the approval of our product candidates. We may experience delays in our clinical trials, and we do not know whether planned clinical trials will begin on time, need to be redesigned, enroll patients on time, or be completed on schedule, if at all. Clinical trials can be delayed, suspended, or terminated for a variety of reasons, including the following:

delays in or failure to obtain regulatory authorization to commence a trial;
delays in or failure to obtain institutional review board (“IRB”), approval at each site;
delays in or failure to reach agreement on acceptable terms with prospective clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different trial sites — we are currently engaged in negotiations with a sponsor for an IND for HCW9218, but these negotiations, and any other discussions with potential clinical sites may not reach an agreement;
difficulty in recruiting clinical trial investigators of appropriate competencies and experience;
delays in establishing the appropriate dosage levels in clinical trials;
delays in or failure to recruit and enroll suitable patients to participate in a trial, particularly considering study inclusion and exclusion criteria and patients’ prior lines of therapy and treatment;
the difficulty in certain countries in identifying the sub-populations that we are trying to treat in a particular trial, which may delay enrollment and reduce the power of a clinical trial to detect statistically significant results;

48

 


 

lower than anticipated retention rates of patients in clinical trials;
failure to have patients complete a trial or return for post-treatment follow-up;
clinical sites deviating from trial protocol or dropping out of a trial;
delays adding new investigators or clinical trial sites;
safety or tolerability concerns could cause us or our collaborators or governmental authorities, as applicable, to suspend or terminate a trial if it is found that the participants are being exposed to unacceptable health risks, undesirable side effects, or other unfavorable characteristics of the product candidate, or if such undesirable effects or risks are found to be caused by a chemically or mechanistically similar therapeutic or therapeutic candidate;
our third-party research contractors failing to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all;
changes in regulatory requirements, policies, and guidelines;
manufacturing sufficient quantities of a product candidate for use in clinical trials;
the quality or stability of a product candidate falling below acceptable standards;
changes in the treatment landscape for our target indications that may make our product candidates no longer relevant;
third-party actions claiming infringement by our product candidates in clinical trials outside the United States and obtaining injunctions interfering with our progress; and
business interruptions resulting from geo-political actions, including war and terrorism, natural disasters including earthquakes, typhoons, floods, and fires, or disease, including the COVID-19 pandemic.

In addition, even if the regulatory authorities agree with the design and implementation of the clinical trials set forth in an IND or similar application, we cannot guarantee that such regulatory authorities will not change their requirements in the future. These considerations also apply to new clinical trials we may submit as amendments to existing INDs.

Clinical trials must be conducted in accordance with the FDA and other applicable regulatory authorities’ legal requirements, regulations or guidelines, and are subject to oversight by these governmental agencies and Ethics Committees or IRBs at the medical institutions where the clinical trials are conducted. We could encounter delays if a clinical trial is suspended or terminated by us, by the IRBs or Ethics Committees of the institutions in which such trials are being conducted, by the Data Review Committee or Data Safety Monitoring Board for such trial or by the FDA, or other regulatory authorities. Such authorities may impose such a suspension or termination due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions, or lack of adequate funding to continue the clinical trial. If we experience delays in the completion of, or termination of, any clinical trial of our product candidates, the commercial prospects of our product candidates will be harmed, and our ability to generate product revenues from any of these product candidates will be delayed. In addition, any delays in completing our clinical trials will increase our costs, slow down our product candidate development and approval process, and jeopardize our ability to commence product sales and generate revenues. Significant clinical trial delays could also allow our competitors to bring products to market before we do or shorten any periods during which we have the exclusive right to commercialize our product candidates and impair our ability to commercialize our product candidates and may harm our business and results of operations.

In addition, clinical trials must be conducted with supplies of our product candidates produced under current good manufacturing practices, or cGMP, requirements and other regulations. Furthermore, we rely on clinical trial sites to ensure the proper and timely conduct of our clinical trials and while we have agreements governing their committed activities, we have limited influence over their actual performance. We depend on our collaborators and on medical institutions to conduct our clinical trials in compliance with good clinical practice (“GCP”) requirements. To the extent our collaborators fail to enroll participants for our clinical trials, fail to conduct the study in accordance with GCP, or are delayed for a significant time in the execution of trials, including achieving full

49

 


 

enrollment, we may be affected by increased costs, program delays, or both, which may harm our business. In addition, clinical trials that are conducted in countries outside the United States may subject us to further delays and expenses as a result of increased shipment costs, and additional regulatory requirements, as well as expose us to risks associated with clinical investigators who are unknown to the FDA, and different standards of diagnosis, screening, and medical care.

Our lead product candidate, HCW9218, has been cleared by the FDA to proceed with two initial Phase 1/1(b) clinical trials in cancer indications. If we experience delays in the commencement or completion of our clinical trials, or if we terminate a clinical trial prior to completion, the commercial prospects of HCW9218 could be harmed, and our ability to generate revenues from HCW9218 may be delayed. In addition, any delays in our clinical trials could increase our costs, slow down the development and approval process and jeopardize our ability to commence product sales and generate revenues. Any of these occurrences may harm our business, financial condition and results of operations. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates.

We may incur unexpected costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates.

We may experience numerous unforeseen events during, or as a result of, clinical trials that could delay or prevent our ability to receive marketing approval or commercialize our product candidates, including:

regulators or IRBs or independent ethics committees may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site;
we may experience delays in reaching, or fail to reach, agreement on acceptable clinical trial contracts or clinical trial protocols with prospective trial sites;
regulators may decide the design of our clinical trials is flawed, for example if our trial protocol does not evaluate treatment effects in trial subjects for a sufficient length of time;
clinical trials of our product candidates may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical trials or abandon product development programs;
preclinical testing may produce results based on which we may decide, or regulators may require us, to conduct additional preclinical studies before we proceed with certain clinical trials, limit the scope of our clinical trials, halt ongoing clinical trials or abandon product development programs;
the number of patients required for clinical trials of our product candidates may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate or participants may drop out of these clinical trials at a higher rate than we anticipate;
our third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all;
regulators, IRBs or ethics committees may require us to perform additional or unanticipated clinical trials to obtain approval or we may be subject to additional post-marketing testing requirements to maintain regulatory approval;
regulators may revise the requirements for approving our product candidates, or such requirements may not be as we anticipate;
the cost of clinical trials of our product candidates may be greater than we anticipate;
the supply or quality of our product candidates or other materials necessary to conduct clinical trials of our product candidates may be insufficient or inadequate;
new lots of our product candidates may not be approved for use in clinical trials;
our product candidates may have undesirable side effects or other unexpected characteristics, causing us or our investigators, regulators, IRBs or ethics committees to suspend or terminate the trials; and

50

 


 

regulators may withdraw their approval of a product or impose restrictions on its distribution, such as in the form of a risk evaluation and mitigation strategy (“REMS”).

We could encounter delays if a clinical trial is suspended or terminated by us, by the IRBs of the institutions in which such trials are conducted or their ethics committees, by the data review committee or data safety monitoring board for such trial or by the FDA, European Medicines Agency (“EMA”) or other foreign regulatory authorities. Such authorities may suspend or terminate a clinical trial due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA, EMA or other foreign regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, including those relating to the class of products to which our product candidates belong.

If we are required to conduct additional clinical trials or other testing of our product candidates beyond those that we currently contemplate, if we are unable to successfully complete clinical trials of our product candidates or other testing, if the results of these trials or tests are not positive or are only modestly positive or if there are safety concerns, we may:

be delayed in obtaining marketing approval for our product candidates;
not obtain marketing approval at all;
obtain approval for indications or patient populations that are not as broad as intended or desired;
obtain approval with labeling or a REMS that includes significant use or distribution restrictions or safety warnings;
be subject to additional post-marketing testing requirements; or
have the product removed from the market after obtaining marketing approval.

Our development costs will also increase if we experience delays in preclinical studies or clinical trials or in obtaining marketing approvals. We do not know whether any of our preclinical studies or clinical trials will begin as planned, will need to be restructured or will be completed on schedule, or at all. We may also determine to change the design or protocol of one or more of our clinical trials, including to add additional patients or arms, which could result in increased costs and expenses and/or delays. Significant preclinical study or clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize our product candidates or allow our competitors to bring products to market before we do and impair our ability to successfully commercialize our product candidates and may harm our business and results of operations.

We may not be able to file INDs or IND amendments to commence additional clinical trials on the timelines we expect, and even if we are able to, the FDA or a comparable foreign regulatory may not permit us to proceed.

We may not be able to file INDs for any of our product candidates on the timelines we expect, if at all. Moreover, we cannot be sure that submission of an IND will result in the FDA allowing further clinical trials to begin, or that, once begun, issues will not arise that require us to suspend or terminate clinical trials. Commencing each of these clinical trials will be subject to finalizing the trial design and selection of relevant endpoints based on discussions with the FDA and other regulatory authorities. Any guidance we receive from the FDA or other regulatory authorities is subject to change. These regulatory authorities could change their position, including, on the acceptability of our trial designs or the clinical endpoints selected, which may require us to complete additional clinical trials or impose stricter approval conditions than we currently expect. Successful completion of our clinical trials is a prerequisite to submitting a BLA to the FDA for each drug candidate and, consequently, the ultimate approval and commercial marketing of each drug candidate. There is also no assurance that, even if completed, our ongoing or any future clinical trials of drug candidates will be successful or will generate positive clinical data.

Our product candidates may have serious adverse, undesirable, or unacceptable side effects or other properties that may delay or prevent marketing approval. If such side effects are identified following approval, if any, the commercial profile of any approved label may be limited, or we may be subject to other significant negative consequences following marketing approval, if any.

Undesirable side effects that may be caused by our product candidates could cause us or regulatory authorities to interrupt, delay, or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other comparable foreign authorities.

51

 


 

Results of our clinical trials could reveal a high and unacceptable severity and prevalence of side effects. In such an event, our clinical trials could be suspended or terminated, and the FDA or comparable foreign regulatory authorities could order us to cease further development of or deny approval of our product candidates for any or all targeted indications. The drug-related side effects could affect patient recruitment or the ability of enrolled patients to complete the clinical trial or result in potential product liability claims. Any of these occurrences may harm our business, financial condition, and prospects significantly.

Further, clinical trials by their nature utilize a sample of the potential patient population. With a limited number of patients and limited duration of exposure, rare and severe side effects of our product candidates may only be uncovered with a significantly larger number of patients exposed to the product candidate.

In the event that any of our product candidates receives marketing approval and we or others later identify undesirable or unacceptable side effects caused by such products, a number of potentially significant negative consequences could result, including:

regulatory authorities may withdraw or limit approvals of such products and require us to take our approved product off the market;
regulatory authorities may require the addition of labeling statements, specific warnings, a contraindication or field alerts to physicians and pharmacies, or issue other communications containing warnings or other safety information about the product;
regulatory authorities may require a medication guide outlining the risks of such side effects for distribution to patients, or that we implement a REMS to ensure that the benefits of the product outweigh its risks;
we may be required to change the dose or the way the product is administered, conduct additional clinical trials, or change the labeling of the product;
we may be subject to limitations on how we may promote or manufacture the product;
sales of the product may decrease significantly;
we may be subject to litigation or product liability claims; and
our reputation may suffer.

Any of these events could prevent us, our collaborators, or our potential future partners from achieving or maintaining market acceptance of the affected product or could substantially increase commercialization costs and expenses, which in turn could delay or prevent us from generating significant revenue from the sale of any products.

The manufacture of our product candidates is complex. Our third-party manufacturers may encounter difficulties in production, which could delay or entirely halt their ability to supply our product candidates for clinical trials or, if approved, for commercial sale.

Our product candidates are considered to be biologics and the process of manufacturing biologics is complex and requires significant expertise and capital investment, including the development of advanced manufacturing techniques and process controls. We do not own or operate any cGMP manufacturing facilities. We rely, and expect to continue to rely, on third-party contract development and manufacturing organizations for the manufacture of our product candidates for preclinical and clinical testing. To date, we and our contract manufacturers have limited experience in the manufacturing of cGMP batches of our product candidates. Our contract manufacturers must comply with cGMP, regulations, and guidelines for the manufacturing of biologics used in clinical trials and, if approved, marketed products. To date, we and our contract manufacturers have only produced smaller cGMP batches of our product candidates and have not scaled up the manufacturing process for later-stage clinical trials and commercialization. Some of our product candidates may require the development of new processes to scale up, which could cause delays in the scale-up of manufacturing, as well as greater costs that could negatively impact the financial viability of our product candidates.

The process of manufacturing our biologic product candidates is extremely susceptible to product loss due to contamination, oxidation, equipment failure, or improper installation or operation of equipment, vendor or operator error, inconsistency in yields, variability in product characteristics, and difficulties in scaling the production process. Even minor deviations from normal manufacturing processes could result in reduced production yields, product defects, and other supply disruptions. If microbial, viral, or other contaminations are discovered in our product candidates or in the manufacturing facilities in which our product candidates are

52

 


 

made, this could lead to withdrawal of our products from the market, and such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination. Moreover, if the FDA determines that our third-party manufacturers are not in compliance with FDA laws and regulations, including those governing cGMP, the FDA may not approve our BLA until the deficiencies are corrected, or we replace the manufacturer in our BLA with a manufacturer that is in compliance.

Any adverse developments affecting manufacturing operations for our product candidates, if any are approved, may result in shipment delays, inventory shortages, lot failures, product withdrawals or recalls, or other interruptions in the supply of our products. We may also have to take inventory write-offs and incur other charges and expenses for products that fail to meet specifications as a result of defects or storage over an extended period of time, undertake costly remediation efforts, or seek more costly manufacturing alternatives. As part of our process development efforts, we also may make changes to our manufacturing processes at various points during development, for various reasons, such as controlling costs, achieving scale, decreasing processing time, increasing manufacturing success rate, or other reasons. Such changes carry the risk that they will not achieve their intended objectives, and any of these changes could cause our product candidates to perform differently and affect the results of our clinical trials or future clinical trials. In some circumstances, changes in the manufacturing process may require us to perform ex vivo comparability studies and to collect additional data from patients prior to undertaking more advanced clinical trials.

We depend on enrollment of patients in our clinical trials for our product candidates. If we experience delays or difficulties enrolling in our clinical trials, our research and development efforts and business, financial condition, and results of operations could be materially adversely affected.

Successful and timely completion of clinical trials will require that we enroll a sufficient number of patient candidates. These trials and other trials we conduct may be subject to delays for a variety of reasons, including as a result of patient enrollment taking longer than anticipated, patient withdrawal, or adverse events. For example, there were delays in commencing clinical trials of HCW9201 as a result of the ongoing pandemic. These types of developments could cause us to delay the trial or halt further development.

Our clinical trials will compete with other clinical trials that are in the same therapeutic areas as our product candidates, and this competition reduces the number and types of patients available to us, as some patients who might have opted to enroll in our trials may instead opt to enroll in a trial being conducted by one of our competitors. Moreover, enrolling patients in clinical trials for cancer therapies is challenging, as cancer patients will first receive the applicable standard of care. This may limit the number of eligible patients able to enroll in our clinical trials who have the potential to benefit from our drug candidates and could extend development timelines or increase costs for these programs. Patients who fail to respond positively to the standard of care treatment will be eligible for clinical trials of unapproved drug candidates. However, these patients may have either compromised immune function from prior administration of chemotherapy or an enhanced immune response from the prior administration of checkpoint inhibitors. Either of these prior treatment regimens may render our therapies less effective in clinical trials. Additionally, patients who have failed approved therapies will typically have more advanced cancer and a poorer long-term prognosis.

Because the number of qualified clinical investigators and clinical trial sites is limited, we expect to conduct some of our clinical trials at the same clinical trial sites that some of our competitors use, which will reduce the number of patients who are available for our clinical trials at such clinical trial sites.

Patient enrollment depends on many factors, including:

the size and nature of the patient population;
the severity of the disease under investigation;
eligibility criteria for the trial;
the proximity of patients to clinical sites;
the design of the clinical protocol;
the ability to obtain and maintain patient consents;
the ability to recruit clinical trial investigators with the appropriate competencies and experience;

53

 


 

the risk that patients enrolled in clinical trials will drop out of the trials before the administration of our product candidates or trial completion;
the availability of competing clinical trials;
the availability of new drugs approved for the indication the clinical trial is investigating; and
clinicians’ and patients’ perceptions as to the potential advantages of the drug being studied in relation to other available therapies.

These factors may make it difficult for us to enroll enough patients to complete our clinical trials in a timely and cost-effective manner. Delays in the completion of any clinical trial of our product candidates will increase our costs, slow down our product candidate development and approval process, and delay or potentially jeopardize our ability to commence product sales and generate revenue. In addition, some of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates.

We may become exposed to costly and damaging liability claims, either when testing our product candidates in the clinic or at the commercial stage, and our product liability insurance may not cover all damages from such claims.

We are exposed to potential product liability and professional indemnity risks that are inherent in the research, development, manufacturing, marketing, and use of pharmaceutical products. While we currently have no products that have been approved for commercial sale, the current and future use of product candidates by us and our partners in clinical trials, and the sale of any approved products in the future, may expose us to liability claims. These claims might be made by patients that use the product, healthcare providers, pharmaceutical companies, our partners, or others selling such products. Any claims against us, regardless of their merit, could be difficult and costly to defend and could materially adversely affect the market for our product candidates or any prospects for commercialization of our product candidates.

Although the clinical trial process is designed to identify and assess potential side effects, it is always possible that a drug, even after regulatory approval, may exhibit unforeseen side effects. If any of our product candidates were to cause adverse side effects during clinical trials or after approval of the product candidate, we may be exposed to substantial liabilities. Physicians and patients may not comply with any warnings that identify known potential adverse effects and patients who should not use our product candidates.

Even successful defense against product liability claims would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in: decreased demand for our product candidates; injury to our reputation; withdrawal of clinical trial participants; initiation of investigations by regulators; costs to defend the related litigation; a diversion of management’s time and our resources; substantial monetary awards to trial participants or patients; product recalls, withdrawals or labeling, marketing or promotional restrictions; loss of revenue; exhaustion of any available insurance and our capital resources; the inability to commercialize any product candidate; and a decline in our share price.

Although we maintain adequate product liability insurance for our product candidates, it is possible that our liabilities could exceed our insurance coverage. We intend to expand our insurance coverage to include the sale of commercial products if we obtain marketing approval for any of our product candidates. However, we may be unable to maintain insurance coverage at a reasonable cost or obtain insurance coverage that will be adequate to satisfy any liability that may arise. If a successful product liability claim or series of claims is brought against us for uninsured liabilities or in excess of insured liabilities, our assets may not be sufficient to cover such claims, and our business operations could be impaired.

Risks Related to Our Regulatory Environment

The development and commercialization of biopharmaceutical products is subject to extensive regulation, and the regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time-consuming, and inherently unpredictable. If we are ultimately unable to obtain regulatory approval for our product candidates on a timely basis if at all, our business will be substantially harmed.

The clinical development, manufacturing, labeling, packaging, storage, recordkeeping, advertising, promotion, export, import, marketing, distribution, adverse event reporting, including the submission of safety and other post-marketing information and reports, and other possible activities relating to our product candidates are subject to extensive regulation. In the United States, marketing approval of biologics requires the submission of a BLA to the FDA, and we are not permitted to market any product

54

 


 

candidate in the United States until we obtain approval from the FDA of the BLA for that product candidate. A BLA must be supported by extensive clinical and preclinical data, as well as extensive information regarding pharmacology, chemistry, manufacturing, and controls. Outside the United States, many comparable foreign regulatory authorities employ similar approval processes.

We have not previously submitted a BLA to the FDA or similar regulatory approval filings to comparable foreign authorities, for any product candidate, and we cannot be certain that any of our product candidates will receive regulatory approval. Obtaining approval of a BLA can be a lengthy, expensive, and uncertain process, and as a company we have no experience with the preparation of a BLA submission or any other application for marketing approval. In addition, the FDA has the authority to require a REMS as part of a BLA or after approval, which may impose further requirements or restrictions on the distribution or use of an approved biologic, such as limiting prescribing to certain physicians or medical centers that have undergone specialized training, limiting treatment to patients who meet certain safe-use criteria and requiring treated patients to enroll in a registry. We also would not be permitted to market our product candidates in countries outside of the United States until we receive marketing approval from applicable regulatory authorities in those countries.

Our product candidates could fail to receive regulatory approval for many reasons, including the following:

the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials;
we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that a product candidate is safe and effective for its proposed indication;
the results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval;
we may be unable to demonstrate that a product candidate’s clinical and other benefits outweigh its safety risks;
the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials;
the data collected from clinical trials of our product candidates may not be sufficient to support the submission of a BLA or other submission or to obtain regulatory approval in the United States or elsewhere, or regulatory authorities may not accept a submission due to, among other reasons, the content or formatting of the submission;
the FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and
the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval.

This lengthy approval process, as well as the unpredictability of future clinical trial results, may result in our failing to obtain regulatory approval to market any of our product candidates, which would significantly harm our business, results of operations, and prospects. The FDA and other regulatory authorities have substantial discretion in the approval process, and determining when or whether regulatory approval will be obtained for any of our product candidates. As a result, we may be required to conduct additional preclinical studies, alter our proposed clinical trial designs, or conduct additional clinical trials to satisfy the regulatory authorities in each of the jurisdictions in which we hope to conduct clinical trials and develop and market our products, if approved. Further, even if we believe the data collected from clinical trials of our product candidates are promising, such data may not be sufficient to support approval by the FDA or any other regulatory authority.

In addition, even if we were to obtain approval, regulatory authorities may approve any of our product candidates for fewer or more limited indications than we request, may not approve the price we intend to charge for our products, may grant approval contingent on the performance of costly post-marketing clinical trials, or may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. Any of the foregoing scenarios could materially harm the commercial prospects for our product candidates.

 

55

 


 

Even if our product candidates obtain regulatory approval, we will be subject to ongoing obligations and continued regulatory review, which may result in significant additional expense. Additionally, our product candidates, if approved, could be subject to labeling and other restrictions and market withdrawal and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our products.

If the FDA or a comparable foreign regulatory authority approves any of our product candidates, the manufacturing processes, labeling, packaging, distribution, import, export, adverse event reporting, storage, advertising, promotion, and recordkeeping for the product will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with cGMP and GCP for any clinical trials that we conduct post-approval, all of which may result in significant expense and limit our ability to commercialize such products. In addition, any regulatory approvals that we receive for our product candidates may also be subject to limitations on the approved indicated uses for which the product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including Phase 4 clinical trials, and surveillance to monitor the safety and efficacy of the product candidate.

Manufacturers and manufacturers’ facilities are required to comply with extensive FDA and comparable foreign regulatory authority requirements, including ensuring that quality control and manufacturing procedures conform to cGMP regulations. As such, we and our contract manufacturers will be subject to continual review and inspections to assess compliance with cGMP and adherence to commitments made in any approved marketing application. Accordingly, we and others with whom we work must continue to expend time, money, and effort in all areas of regulatory compliance, including manufacturing, production, and quality control.

If there are changes in the application of legislation or regulatory policies, or if problems are discovered with a product or our manufacture of a product, or if we or one of our distributors, licensees or co-marketers fails to comply with regulatory requirements, the regulators could take various actions. These include issuing warning letters or untitled letters, imposing fines on us, imposing restrictions on the product or its manufacture, and requiring us to recall or remove the product from the market. The regulators could also suspend or withdraw our marketing authorizations, requiring us to conduct additional clinical trials, change our product labeling, or submit additional applications for marketing authorization. If any of these events occurs, our ability to sell such product may be impaired, and we may incur substantial additional expense to comply with regulatory requirements, which could materially adversely affect our business, financial condition, and results of operations.

In addition, if we have any product candidate approved, our product labeling, advertising, and promotion will be subject to regulatory requirements and continuing regulatory review. In the United States, the FDA and the Federal Trade Commission (“FTC”), strictly regulate the promotional claims that may be made about pharmaceutical products to ensure that any claims about such products are consistent with regulatory approvals, not misleading or false in any particular, and adequately substantiated by clinical data. The promotion of a drug product in a manner that is false, misleading, unsubstantiated, or for unapproved (or off-label) uses may result in enforcement letters, inquiries and investigations, and civil and criminal sanctions by the FDA or the FTC. In particular, a product may not be promoted for uses that are not consistent with the uses approved by the FDA as reflected in the product’s approved labeling. If we receive marketing approval for a product candidate, physicians may nevertheless prescribe it to their patients in a manner that is inconsistent with the approved label. If we are found to have promoted such off-label uses, we may become subject to significant liability. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant sanctions and may result in false claims litigation under federal and state statutes, which can lead to consent decrees, civil monetary penalties, restitution, criminal fines and imprisonment, and exclusion from participation in Medicare, Medicaid, and other federal and state healthcare programs. The federal government has levied large civil and criminal fines against companies for alleged improper promotion and has enjoined several companies from engaging in off-label promotion. The FDA has also requested that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed.

If a regulatory agency discovers previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, or disagrees with the promotion, marketing or labeling of a product, such regulatory agency may impose restrictions on that product or us, including requiring withdrawal of the product from the market. If we fail to comply with applicable regulatory requirements, a regulatory agency or enforcement authority may, among other things:

issue warning or untitled letters;
issue, or require us to issue, safety-related communications, such as safety alerts, field alerts, “Dear Doctor” letters to healthcare professionals, or import alerts;

56

 


 

impose civil or criminal penalties;
suspend, limit, or withdraw regulatory approval;
suspend any of our preclinical studies and clinical trials;
refuse to approve pending applications or supplements to approved applications submitted by us;
impose restrictions on our operations, including closing our contract manufacturers’ facilities; or
seize or detain products, refuse to permit the import or export of products, or require us to conduct a product recall.

Any government investigation of alleged violations of law could require us to expend significant time and resources in response, and could generate negative publicity. Any failure to comply with ongoing regulatory requirements may significantly and adversely affect our ability to commercialize and generate revenue from our products, if approved. If regulatory sanctions are applied or if regulatory approval is withdrawn, the value of our company and our operating results will be adversely affected.

Moreover, the policies of the FDA and of other regulatory authorities may change and additional government regulations may be enacted that could prevent, limit, or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature, or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. In addition, if we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability.

Disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire, retain, or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved, or commercialized in a timely manner or at all, which could negatively impact our business.

The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, statutory, regulatory, and policy changes, the FDA’s ability to hire and retain key personnel and accept the payment of user fees, and other events that may otherwise affect the FDA’s ability to perform routine functions. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. Disruptions at the FDA and other agencies may also slow the time necessary for new biologics or modifications to licensed biologics to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, including for 35 days beginning on December 22, 2018, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities.

Separately, in response to the COVID-19 pandemic, on March 10, 2020, the FDA announced its intention to postpone most inspections of foreign manufacturing facilities, and on March 18, 2020, the FDA temporarily postponed routine surveillance inspections of domestic manufacturing facilities. Subsequently, on July 10, 2020, the FDA announced its intention to resume certain on-site inspections of domestic manufacturing facilities subject to a risk-based prioritization system. The FDA intends to use this risk-based assessment system to identify the categories of regulatory activity that can occur within a given geographic area, ranging from mission critical inspections to resumption of all regulatory activities. Regulatory authorities outside the United States may adopt similar restrictions or other policy measures in response to the COVID-19 pandemic. If a prolonged government shutdown occurs, or if global health concerns continue to prevent the FDA or other regulatory authorities from conducting their regular inspections, including product pre-approval inspections reviews, or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business.

Our research and development activities could be affected or delayed as a result of possible restrictions on animal testing.

Certain laws and regulations require us to test our product candidates on animals before initiating clinical trials involving humans. Animal testing activities have been the subject of controversy and adverse publicity. Animal rights groups and other organizations and individuals have attempted to stop animal testing activities by pressing for legislation and regulation in these areas and by disrupting these activities through protests and other means. To the extent the activities of these groups are successful, our research and development activities may be interrupted, delayed, or become more expensive.

57

 


 

Our business operations and current and future relationships with healthcare professionals, principal investigators, consultants, vendors, customers, and third-party payors in the United States and elsewhere are subject to applicable anti-kickback, fraud and abuse, false claims, physician payment transparency, and other healthcare laws and regulations, which could expose us to substantial penalties, contractual damages, reputation harm, administrative burdens, and diminished profits.

Healthcare providers, healthcare facilities and institutions, physicians, and third-party payors in the United States and elsewhere will play a primary role in the recommendation and prescription of any product candidates for which we obtain marketing approval. Our current and future arrangements with healthcare professionals, healthcare facilities and institutions, principal investigators, consultants, customers, and third-party payors may expose us to broadly applicable fraud and abuse and other healthcare laws, including, without limitation, the federal Anti-Kickback Statute and the federal False Claims Act, that may constrain the business or financial arrangements and relationships through which we research, sell, market, and distribute any product candidates for which we obtain marketing approval. In addition, we may be subject to physician payment transparency laws and regulation by the federal government and by the states and foreign jurisdictions in which we conduct our business. The applicable federal, state, and foreign healthcare laws that affect our ability to operate include, but are not limited to, the following:

the federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting, offering, receiving, or providing any remuneration (including any kickback, bribe, or certain rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, lease, order or recommendation of, any good, facility, item or service, for which payment may be made, in whole or in part, under any U.S. federal healthcare program, such as Medicare and Medicaid. The term “remuneration” has been broadly interpreted to include anything of value, including stock options. The federal Anti-Kickback Statute has also been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers and formulary managers on the other the other hand. Any arrangements with prescribers must be for bona fide services and compensated at fair market value. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;
the U.S. federal civil and criminal false claims and civil monetary penalties laws, including the civil False Claims Act, which prohibit, among other things, including through civil whistleblower or qui tam actions, individuals or entities from knowingly presenting, or causing to be presented, to the U.S. federal government, claims for payment or approval that are false or fraudulent, knowingly making, using, or causing to be made or used, a false record or statement material to a false or fraudulent claim, or from knowingly making a false statement to avoid, decrease, or conceal an obligation to pay money to the U.S. federal government. Pharmaceutical manufacturers can cause false claims to be presented to the U.S. federal government by, among other things, engaging in impermissible marketing practices, such as the off-label promotion of a product for an indication for which it has not received FDA approval. In addition, the government may assert that a claim including items and services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act;
the federal Health Insurance Portability and Accountability Act of 1996 (“HIPAA”), which imposes criminal and civil liability for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing, or covering up a material fact or making any materially false statement, in connection with the delivery of, or payment for, healthcare benefits, items, or services. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the healthcare fraud statute implemented under HIPAA or specific intent to violate it in order to have committed a violation;
the U.S. Physician Payments Sunshine Act and its implementing regulations, which requires, among other things, certain manufacturers of drugs, devices, biologics, and medical supplies that are reimbursable under Medicare, Medicaid, or the Children’s Health Insurance Program, with specific exceptions, to report annually to the Centers for Medicare and Medicaid Services (“CMS”), information related to certain payments and other transfers of value to physicians, as defined by statute, physician assistant, certain types of advance practice nurses and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members;
analogous U.S. state laws and regulations, including: state anti-kickback and false claims laws, which may apply to our business practices, including but not limited to, research, distribution, sales and marketing arrangements, and claims involving healthcare items or services reimbursed by any third-party payor, including private insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry’s voluntary compliance guidelines and the relevant compliance guidance promulgated by the U.S. federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws and regulations that require drug manufacturers to file reports relating to pricing and marketing information, which requires tracking gifts and other

58

 


 

remuneration and items of value provided to healthcare professionals and entities; and state and local laws requiring the registration of pharmaceutical sales representatives; and
similar healthcare laws and regulations in foreign jurisdictions, including reporting requirements detailing interactions with and payments to healthcare providers.

Ensuring that our internal operations and future business arrangements with third parties comply with applicable healthcare laws and regulations will involve substantial costs. It is not always possible to identify and deter employee misconduct or business noncompliance, and the precautions we take to detect and prevent inappropriate conduct may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. Efforts to ensure that our business arrangements will comply with applicable healthcare laws may involve substantial costs. We have entered into consulting and scientific advisory board arrangements with physicians and other healthcare providers, including some who could influence the use of our product candidates, if approved. Compensation under some of these arrangements includes the provision of stock or stock options in addition to cash consideration. Because of the complex and far-reaching nature of these laws, it is possible that governmental authorities could conclude that our payments to physicians may not be fair market value for bona fide services or that our business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of the laws described above or any other governmental laws and regulations that may apply to us, we may be subject to significant penalties, including civil, criminal, and administrative penalties, damages, fines, exclusion from government-funded healthcare programs, such as Medicare and Medicaid, or similar programs in other countries or jurisdictions, integrity oversight and reporting obligations to resolve allegations of noncompliance, disgorgement, individual imprisonment, contractual damages, reputational harm, diminished profits, and the curtailment or restructuring of our operations. If any of the physicians or other providers or entities with whom we expect to do business are found to not be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs and imprisonment, which could affect our ability to operate our business. Further, defending against any such actions can be costly, time-consuming, and may require significant personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired.

Our employees, independent contractors, principal investigators, consultants, commercial partners, and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.

We are exposed to the risk of employee fraud or other misconduct. We cannot ensure that our compliance controls, policies, and procedures will in every instance protect us from acts committed by our employees, agents, contractors, or collaborators that would violate the laws or regulations of the jurisdictions in which we operate, including, without limitation, employment, foreign corrupt practices, trade restrictions and sanctions, environmental, competition, and patient privacy and other privacy laws and regulations. Misconduct by employees could include failures to comply with FDA regulations, provide accurate information to the FDA, comply with manufacturing standards we may establish, comply with federal and state healthcare fraud and abuse laws and regulations, report financial information or data accurately, or disclose unauthorized activities to us. In particular, sales, marketing, and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing, and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, labeling, marketing and promotion, sales commission, customer incentive programs, and other business arrangements. Employee misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations.

If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a material and adverse effect on our business, financial condition, results of operations, and prospects, including the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, individual imprisonment, disgorgement of profits, possible exclusion from participation in Medicare, Medicaid, and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, additional reporting or oversight obligations if we become subject to a corporate integrity agreement or other agreement to resolve allegations of noncompliance with the law, and curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and pursue our strategy.

Current and future legislation may increase the difficulty and cost for us and any future collaborators to obtain marketing approval of and commercialize our product candidates and affect the prices we, or they, may obtain.

59

 


 

In the United States and other jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory changes and proposed changes to the healthcare system that could affect our future results of operations. In particular, there have been and continue to be a number of initiatives at the U.S. federal and state levels that seek to reduce healthcare costs and improve the quality of healthcare. For example, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (collectively the “ACA”), was enacted, which substantially changed the way healthcare is financed by both governmental and private payors. Among the provisions of the ACA of importance to the pharmaceutical and biotechnology industries, which includes biologics, are those which increased manufacturers’ rebate liability under the Medicaid Drug Rebate Program, imposed a significant annual fee on companies that manufacture or import branded prescription drug products, required manufacturers to provide a discount off the negotiated price of prescriptions filled by beneficiaries in the Medicare Part D coverage gap, referred to as the “donut hole,” which is now 70% of the negotiated price, required the reporting certain payments or transfers of values (described above), and provided a licensure framework for follow-on biologics.

Since its enactment, there have been judicial and Congressional challenges to certain aspects of the ACA, and there may be additional challenges and amendments to the ACA in the future. For example, the Tax Cuts and Jobs Act of 2017, repealed the tax-based shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage that is commonly referred to as the “individual mandate.” On June 17, 2021, the United States Supreme Court dismissed a challenge on procedural grounds that argued the ACA is unconstitutional in its entirety because the individual mandate was repealed by Congress. Thus, the ACA will remain in effect in its current form.

In addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted which, among other things, have reduced Medicare payments to several types of providers, including hospitals and cancer treatment centers.

These new laws or any other similar laws introduced in the future, as well as regulatory actions that may be taken by CMS, may result in additional reductions in Medicare and other healthcare funding, which could negatively affect our customers and accordingly, our financial operations. Moreover, payment methodologies may be subject to changes in healthcare legislation and regulatory initiatives. For example, in July 2021, President Biden issued an executive order pertaining to drug pricing, which expressed support for legislation allowing direct negotiation in Medicare Part D and inflationary rebates and directed various executive branch agencies to take actions to lower drug prices and promote generic competition. Several pending legislative efforts, including President Biden’s larger Build Back Better legislative agenda and draft bill text, incorporate these drug pricing reforms in addition to inflationary rebates on Part B and Part D drugs that would be payable on commercial and governmental program utilization, policies aimed at redesigning the Medicare Part D benefit and adopting drug price transparency measures. Drug manufacturers who are unwilling to negotiate with Medicare would be subject to additional excise taxes. Additionally, the plan would impose tax penalties on drug manufacturers that increase the prices of drug products faster than the rate of inflation. If elements of the recently announced prescription drug pricing plan become law, our pricing strategy and commercial prospects may be adversely affected.

Additionally, on September 9, 2021, the Biden administration published a wide-ranging list of policy proposals, most of which would need to be carried out by Congress, to reduce drug prices and drug payment. This plan includes, among other reform measures, proposals to lower prescription drug prices, including by allowing Medicare to negotiate prices and disincentivizing price increases, and to support market changes that strengthen supply chains, promote biosimilars and generic drugs, and increase price transparency. Many similar proposals, including the plans to give Medicare Part D authority to negotiate drug prices, require drug manufacturers to pay rebates on drugs whose prices increase greater than the rate of inflation, and cap out-of-pocket costs, have already been included in policy statements and legislation currently being considered by Congress. It is unclear to what extent these new proposals or any future legislation or regulations by the Biden Administration will have on our business.

Additionally, individual states in the United States have passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing and costs. Similar developments have occurred outside of the United States, including in the European Union where healthcare budgetary constraints have resulted in restrictions on the pricing and reimbursement of medicines by relevant health service providers. To obtain reimbursement or pricing approval in some European Union member states, we may be required to conduct studies that compare the cost-effectiveness of our product candidates to other therapies that are considered the local standard of care.

We cannot predict the likelihood, nature, or extent of government regulation that may arise from future legislation or administrative action in the United States or any other jurisdiction. If we or any third parties we may engage are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we or such third parties are not able to maintain regulatory compliance, our product candidates may lose any regulatory approval that may have been obtained and we may not achieve or sustain profitability.

60

 


 

Even if we are able to commercialize any product candidate, coverage and adequate reimbursement may not be available or such product candidate may become subject to unfavorable pricing regulations or third-party coverage and reimbursement policies, which would harm our business.

The regulations that govern regulatory approvals, pricing, and reimbursement for drug products vary widely from country to country. Some countries require approval of the sale price of a drug product before it can be marketed. In many countries, the pricing review period begins after marketing approval is granted. In some foreign markets, prescription drug product pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we might obtain regulatory approval for a product in a particular country, but then be subject to price regulations that delay our commercial launch of the product, possibly for lengthy time periods, and negatively impact the revenues we are able to generate from the sale of the product in that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more product candidates, even if our product candidates obtain regulatory approval.

Our ability to commercialize any products successfully also will depend in part on the extent to which coverage and adequate reimbursement for these products and related treatments will be available from third-party payors, such as government authorities, private health insurers, and other organizations. Even if we succeed in bringing one or more products to the market, these products may not be considered cost-effective, and the amount reimbursed for any products may be insufficient to allow us to sell our products on a competitive basis. Because our programs are in the early stages of development, we are unable at this time to determine their cost effectiveness or the likely level or method of coverage and reimbursement. Increasingly, the third-party payors who reimburse patients or healthcare providers are requiring that drug companies provide them with predetermined discounts from list prices, and are seeking to reduce the prices charged or the amounts reimbursed for drug products. If the price we are able to charge for any products we develop, or the coverage and reimbursement provided for such products, is inadequate in light of our development and other costs, our return on investment could be affected adversely.

There may be significant delays in obtaining reimbursement for newly-approved drug products, and coverage may be more limited than the purposes for which the drug product is approved by the FDA or similar foreign regulatory authorities. Moreover, eligibility for reimbursement does not imply that any drugs product will be reimbursed in all cases or at a rate that covers our costs, including research, development, manufacture, sale, and distribution.

Interim reimbursement levels for new drug products, if applicable, may also be insufficient to cover our costs and may not be made permanent. Reimbursement rates may be based on payments allowed for lower cost drug products that are already reimbursed, may be incorporated into existing payments for other services and may reflect budgetary constraints or imperfections in Medicare data. Net prices for drug products may be reduced by mandatory discounts or rebates required by third-party payors and by any future relaxation of laws that presently restrict imports of drug products from countries where they may be sold at lower prices than in the United States. Obtaining coverage and adequate reimbursement for our product candidates may be particularly difficult because of the higher prices often associated with drugs administered under the supervision of a physician. Similarly, because some of our product candidates will be physician-administered subcutaneous injectables, separate reimbursement for the product itself may or may not be available. Instead, the administering physician may or may not be reimbursed for providing the treatment or procedure in which our product is used.

Further, no uniform policy for coverage and reimbursement exists in the United States, and coverage and reimbursement can differ significantly from payor to payor. Third-party payors often follow Medicare coverage policy and payment limitations in setting their own reimbursement rates, but also have their own methods and approval process apart from Medicare determinations. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our product candidates to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. Decisions regarding the extent of coverage and amount of reimbursement to be provided for any product candidates that we develop will be made on a payor-by-payor basis. One payor’s determination to provide coverage for a drug does not assure that other payors will also provide coverage and adequate reimbursement for the drug. Additionally, a third-party payor’s decision to provide coverage for a therapy does not imply that an adequate reimbursement rate will be approved.

There have been, and likely will continue to be, legislative and regulatory proposals at the foreign, federal, and state levels directed at broadening the availability of healthcare and containing or lowering the cost of healthcare. We cannot predict the initiatives that may be adopted in the future, including repeal, replacement, or significant revisions to the ACA. The continuing efforts of the government, insurance companies, managed care organizations, and other payors of healthcare services to contain or reduce costs of healthcare and/or impose price controls may adversely affect:

the demand for our product candidates, if we obtain regulatory approval;

61

 


 

our ability to set a price that we believe is fair for our products;
our ability to obtain coverage and reimbursement approval for a product;
our ability to generate revenue and achieve or maintain profitability;
the level of taxes that we are required to pay; and
the availability of capital.

We face potential liability related to the privacy of health information we obtain from clinical trials sponsored by us or our collaborators, from research institutions and our collaborators, and directly from individuals.

We and our partners and vendors are subject to various federal, state, and foreign data protection laws and regulations (i.e., laws and regulations that address data privacy and security). If we fail to comply with these laws and regulations we may be subject to litigation, regulatory investigations, enforcement notices, enforcement actions, fines, and criminal or civil penalties, as well as negative publicity and a potential loss of business.

In the United States, numerous federal and state laws and regulations, including state data breach notification laws, state health information privacy laws, and federal and state consumer protection laws and regulations that govern the collection, use, disclosure, and protection of health-related and other personal information could apply to our operations or the operations of our partners. For example, most healthcare providers, including research institutions from which we or our collaborators obtain patient health information, are subject to privacy and security regulations promulgated under HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 (“HITECH”). Under HIPAA, we could potentially face substantial criminal or civil penalties if we knowingly receive individually identifiable health information from a HIPAA-covered healthcare provider or research institution that has not satisfied HIPAA’s requirements for disclosure of individually identifiable health information, or otherwise violate applicable HIPAA requirements related to the protection of such information. Even when HIPAA does not apply, failing to take appropriate steps to keep consumers’ personal information secure may constitute a violation of the Federal Trade Commission Act.

In addition, we may maintain sensitive personally identifiable information, including health information, that we receive throughout the clinical trial process, in the course of our research collaborations, and directly from individuals (or their healthcare providers) who enroll in our patient assistance programs. As such, we may be subject to state laws requiring notification of affected individuals and state regulators in the event of a breach of personal information. These state laws include the recently enacted California Consumer Privacy Act, which establishes additional data privacy rights for residents of the State of California. Similar laws have been proposed in other states and at the federal level, and if passed, such laws may have potentially conflicting requirements that would make compliance challenging.

Our clinical trial programs and research collaborations outside the United States may implicate international data protection laws, including, in Europe, the General Data Protection Regulation (“GDPR”), which became effective in 2018. The GDPR imposes stringent operational requirements for processors and controllers of personal data. Among other things, the GDPR requires detailed notices for clinical trial subjects and investigators, as well as requirements regarding the security of personal data and notification of data processing obligations or security incidents to appropriate data protection authorities or data subjects. If our privacy or data security measures fail to comply with the GDPR requirements, we may be subject to litigation, regulatory investigations, enforcement notices, and/or enforcement actions requiring us to change the way we use personal data and/or fines. In addition to statutory enforcement, a personal data breach can lead to negative publicity and a potential loss of business. Further, following the United Kingdom’s withdrawal from the E.U. effective as of December 31, 2020, we have to comply with the GDPR and the GDPR as incorporated into United Kingdom national law, which may have differing requirements. If we fail to comply with United Kingdom data protection laws we may be subject to litigation, regulatory investigations, enforcement notices, and/or enforcement actions, as well as negative publicity and a potential loss of business.

We are also subject to evolving EEA laws on data export, as we may transfer personal data from the EEA to other jurisdictions. Recent legal developments in Europe have created complexity and uncertainty regarding transfers of personal data from the EEA to the United States. For example, on July 16, 2020, the Court of Justice of the European Union (“CJEU”), invalidated the EU-US Privacy Shield Framework (“Privacy Shield”), under which personal data could be transferred from the EEA to United States entities who had self-certified under the Privacy Shield scheme. Moreover, it is uncertain whether the standard contractual clauses will also be invalidated by the European courts or legislature. As government authorities issue further guidance on personal data export mechanisms and/or start taking enforcement action, we could suffer additional costs, complaints, and/or regulatory investigations or

62

 


 

fines, and/or if we are otherwise unable to transfer personal data between and among countries and regions in which we operate, it could affect the manner in which we provide our services, the geographical location or segregation of our relevant systems and operations, and could adversely affect our financial results. These laws and regulations may apply, not only to us, but also to vendors that store or otherwise process data on our behalf, such as information technology vendors. If such a vendor misuses data we have provided to it, or fails to safeguard such data, we may be subject to litigation, regulatory investigations, enforcement notices, and/or enforcement actions, as well as negative publicity and a potential loss of business.

We are likely to be required to expend significant capital and other resources to ensure ongoing compliance with applicable privacy and data security laws. Claims that we have violated individuals’ privacy rights or breached our contractual obligations, even if we are not found liable, could be expensive and time-consuming to defend, and could result in adverse publicity that could harm our business. Moreover, even if we take all necessary action to comply with regulatory requirements, we could be subject to a hack or data breach, which could subject us to fines and penalties, as well as reputational damage.

If we or any collaborators fail to comply with applicable federal, state, or local regulatory requirements, we could be subject to a range of regulatory actions that could affect our or any collaborators’ ability to seek to commercialize our clinical candidates. Any threatened or actual government enforcement action could also generate adverse publicity and require that we devote substantial resources that could otherwise be used in other aspects of our business.

If we fail to comply with environmental, health, and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business.

We are subject to numerous environmental, health, and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment, and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals and biological and radioactive materials. Our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties. Although we maintain workers’ compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological, hazardous or radioactive materials.

In addition, we may incur substantial costs in order to comply with current or future environmental, health, and safety laws and regulations. These current or future laws and regulations may impair our research, development or commercialization efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.

Risks Related to Commercialization of Our Product Candidates

We operate in highly competitive and rapidly changing industries, which may result in others discovering, developing or commercializing competing products before or more successfully than we do.

The biotechnology and pharmaceutical industries are highly competitive and subject to significant and rapid technological change. Our success is highly dependent on our ability to discover, develop, and obtain marketing approval for new and innovative products on a cost-effective basis and to market them successfully. In doing so, we face and will continue to face intense competition from a variety of businesses, including large pharmaceutical and biotechnology companies, academic institutions, government agencies, and other public and private research organizations. These organizations may have significantly greater resources than we do and conduct similar research, seek patent protection, and establish collaborative arrangements for research, development, manufacturing, and marketing of products that compete with our product candidates. Mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated in our competitors. Competition may increase further as a result of advances in the commercial applicability of technologies and greater availability of capital for investment in these industries.

With the proliferation of new oncology drugs and therapies, we expect to face increasingly intense competition as new technologies become available. If we fail to stay at the forefront of technological change, we may be unable to compete effectively. Any product candidates that we successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future. The highly competitive nature of and rapid technological changes in the biotechnology and pharmaceutical industries could render our product candidates or our technology obsolete, less competitive or uneconomical. Our competitors may, among other things:

63

 


 

have significantly greater financial, manufacturing, marketing, drug development, technical, and human resources than we do;
develop and commercialize products that are safer, more effective, less expensive, more convenient or easier to administer, or have fewer or less severe side effects;
obtain quicker regulatory approval;
establish superior proprietary positions covering our products and technology;
implement more effective approaches to sales and marketing; or
form more advantageous strategic alliances.

Should any of these factors occur, our business, financial condition, and results of operations could be materially adversely affected.

In addition, any collaborators may decide to market and sell products that compete with the product candidates that we have agreed to license to them, and any competition by our collaborators could also have a material adverse effect on our future business, financial condition, and results of operations.

Smaller and other early stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.

If the market opportunity for any product candidate that we or our strategic partners develop is smaller than we believe, our revenue may be adversely affected and our business may suffer.

We intend to initially focus our product candidate development on treatments for various oncology indications. Our projections of addressable patient populations that may benefit from treatment with our product candidates are based on our estimates. These estimates, which have been derived from a variety of sources, including scientific literature, surveys of clinics, patient foundations, and market research, may prove to be incorrect. Further, new studies may change the estimated incidence or prevalence of these cancers. Additionally, the potentially addressable patient population for our product candidates may not ultimately be amenable to treatment with our product candidates. Our market opportunity may also be limited by future competitor treatments that enter the market. If any of our estimates prove to be inaccurate, the market opportunity for any product candidate that we or our strategic partners develop could be significantly diminished and have an adverse material impact on our business.

We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.

Because we have limited financial and managerial resources, we may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate or the third-party to whom we relinquish such rights may not take full advantage or be properly qualified to take full advantage of such valuable rights. Failure to allocate resources or capitalize on strategies in a successful manner will have an adverse impact on our business.

Failure to successfully identify, develop and commercialize additional product candidates could impair our ability to grow.

Although a substantial amount of our efforts will focus on the continued preclinical and clinical testing and potential approval of our product candidates in our current pipeline, we expect to continue to innovate and potentially expand our portfolio. Because we have limited financial and managerial resources, research programs to identify product candidates may require substantial additional technical, financial and human resources, whether or not any new potential product candidates are ultimately identified. Our success

64

 


 

may depend in part upon our ability to identify, select, and develop promising product candidates and therapeutics. We may expend resources and ultimately fail to discover and generate additional product candidates suitable for further development. All product candidates are prone to risks of failure typical of biotechnology product development, including the possibility that a product candidate may not be suitable for clinical development as a result of its harmful side effects, limited efficacy or other characteristics indicating that it is unlikely to receive approval by the FDA, the EMA, and other comparable foreign regulatory authorities and achieve market acceptance. If we do not successfully develop and commercialize new product candidates we have identified and explored, our business, prospects, financial condition, and results of operations could be adversely affected.

Even if approved, our products may not gain market acceptance, in which case we may not be able to generate product revenues, which will materially adversely affect our business, financial condition, and results of operations.

Even if the FDA or any other regulatory authority approves the marketing of any product candidates that we develop on our own or with a collaborator, physicians, healthcare providers, patients, or the medical community may not accept or use them. Additionally, the product candidates that we are developing are based on our internally-developed immunotherapy platform technology, which is a new technology. If these products do not achieve an adequate level of acceptance, we may not generate significant product revenues or any profits from operations. The degree of market acceptance of any of our product candidates will depend on a variety of factors, including:

the timing of market introduction;
the terms of any approvals and the countries in which approvals are obtained;
the number and clinical profile of competing products;
our ability to provide acceptable evidence of safety and efficacy;
the prevalence and severity of any side effects;
relative convenience and ease of administration;
cost-effectiveness;
patient diagnostics and screening infrastructure in each market;
marketing and distribution support;
adverse publicity about our product candidates;
availability of coverage, adequate reimbursement, and sufficient payment from health maintenance organizations and other insurers, both public and private, for our product candidates, or the procedures utilizing our product candidates, if approved;
the willingness of patients to pay out-of-pocket in the absence of coverage by third-party payors and government authorities; and
other potential advantages over alternative treatment methods.

If our product candidates fail to gain market acceptance, this will have a material adverse impact on our ability to generate revenues to provide a satisfactory, or any, return on our investments. Even if some products achieve market acceptance, the market may prove not to be large enough to allow us to generate significant revenues.

We currently have no marketing, sales, or distribution infrastructure and we intend to either establish a sales and marketing infrastructure or outsource this function to a third party. Either of these commercialization strategies carries substantial risks to us.

We currently have no marketing, sales, and distribution capabilities because all of our product candidates are still in clinical or preclinical development. If any of our product candidates are approved, we intend to either establish a sales and marketing

65

 


 

organization with technical expertise and supporting distribution capabilities to commercialize our product candidates in a legally compliant manner, or to outsource this function to a third party. There are risks involved if we decide to establish our own sales and marketing capabilities or enter into arrangements with third parties to perform these services. To the extent that we enter into collaboration agreements with respect to marketing, sales or distribution, our product revenue may be lower than if we directly marketed or sold any approved products. Such collaborative arrangements with partners may place the commercialization of our products outside of our control and would make us subject to a number of risks including that we may not be able to control the amount or timing of resources that our collaborative partner devotes to our products or that our collaborator’s willingness or ability to complete its obligations, and our obligations under our arrangements may be adversely affected by business combinations or significant changes in our collaborator’s business strategy.

If we are unable to enter into these arrangements on acceptable terms or at all, we may not be able to successfully commercialize any approved products. If we are not successful in commercializing any approved products, either on our own or through collaborations with one or more third parties, our future product revenue will suffer and we may incur significant additional losses, which would have a material adverse effect on our business, financial condition, and results of operations.

Our product candidates for which we intend to seek approval as biologic products may face competition sooner through an abbreviated pathway.

The ACA includes a subtitle called the Biologics Price Competition and Innovation Act of 2009 (“BPCIA”), which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA-licensed reference biological product. Under the BPCIA, an application for a highly similar or “biosimilar” product may not be submitted to the FDA until four years following the date that the reference product was first approved by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first approved. During this 12‑year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing the sponsor’s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity, and potency of their product. The law is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate impact, implementation, and meaning are subject to uncertainty.

We believe that any of our product candidates approved as a biological product under a BLA should qualify for the 12-year period of exclusivity. However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider our product candidates to be reference products for competing products, potentially creating the opportunity for competition sooner than anticipated. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. Moreover, the extent to which a biosimilar, once approved, will be substituted for any one of our reference products in a way that is similar to traditional generic substitution for non-biological products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing.

Jurisdictions in addition to the United States have established abbreviated pathways for regulatory approval of biological products that are biosimilar to earlier approved reference products. For example, the European Union has had an established regulatory pathway for biosimilars since 2004. However, biosimilars can only be authorized once the period of data exclusivity on the reference biological medicine has expired.

The increased likelihood of biosimilar competition has increased the risk of loss of innovators’ market exclusivity. Due to this risk, and uncertainties regarding patent protection, if our clinical candidates are approved for marketing, it is not possible to predict the length of market exclusivity for any particular product with certainty based solely on the expiration of the relevant patent(s) or the current forms of regulatory exclusivity. It is also not possible to predict changes in United States regulatory law that might reduce biological product regulatory exclusivity. The loss of market exclusivity for a product would likely materially and negatively affect revenues, and we may not generate adequate or sufficient revenues from them or be able to reach or sustain profitability.

Risks Related to Our Dependence on Third Parties

We rely on third-parties to manufacture our product candidates. Any failure by a third-party manufacturer to produce acceptable drug substance for us or to obtain authorization from the FDA or comparable regulatory authorities may delay or impair our ability to initiate or complete our clinical trials, obtain regulatory approvals or commercialize approved products.

We do not currently own or operate any cGMP manufacturing facilities nor do we have any in-house cGMP manufacturing capabilities. We rely on third-party contract manufacturers to produce sufficient quantities of materials required for the manufacture of our product candidates for preclinical testing and clinical trials, in compliance with applicable regulatory and quality standards, and intend to do so for the commercial manufacture of our products, if approved. If we are unable to arrange for such third-party

66

 


 

manufacturing sources, or fail to do so on commercially reasonable terms, we may not be able to successfully produce sufficient supply of product candidate or we may be delayed in doing so. Such failure or substantial delay could materially harm our business.

We rely on third parties for biological materials that are used in our discovery and development programs. These materials can be difficult to produce and occasionally have variability from the product specifications. Any disruption in the supply of these biological materials consistent with our product specifications could materially adversely affect our business. Although we have control processes and screening procedures, biological materials are susceptible to damage and contamination and may contain active pathogens. We may also have lower yields in manufacturing batches, which can increase our costs and slow our development timelines. Improper storage of these materials, by us or any third-party suppliers, may require us to destroy some of our biological raw materials or product candidates.

Reliance on third-party manufacturers entails risks to which we would not be subject if we manufactured product candidates ourselves, including reliance on the third party for regulatory compliance and quality control and assurance, volume production, the possibility of breach of the manufacturing agreement by the third party because of factors beyond our control (including a failure to synthesize and manufacture our product candidates in accordance with our product specifications), and the possibility of termination or nonrenewal of the agreement by the third party at a time that is costly or damaging to us.

In addition, the FDA and other regulatory authorities require that our product candidates be manufactured according to cGMP and similar foreign standards relating to methods, facilities, and controls used in the manufacturing, processing, and packing of the product, which are intended to ensure that biological products are safe and that they consistently meet applicable requirements and specifications.

Pharmaceutical manufacturers are required to register their facilities and list their products manufactured after beginning drug manufacturing and then annually thereafter with the FDA and certain state and foreign agencies. If the FDA or a comparable foreign regulatory authority does not approve the manufacture of our product candidates at any of our proposed contract manufacturer’s facilities, or if any contract manufacturer fails to maintain a compliance status acceptable to the FDA or a comparable foreign authority, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for, or market our product candidates, if approved. Any discovery of problems with a product, or a manufacturing or laboratory facility used by us or our strategic partners, may result in restrictions on the product or on the manufacturing or laboratory facility, including marketed product recall, suspension of manufacturing, product seizure, or a voluntary withdrawal of the drug from the market. We may have little to no control regarding the occurrence of third-party manufacturer incidents.

If we were unable to find an adequate replacement or another acceptable solution in time, our clinical trials could be delayed, or our commercial activities could be harmed. In addition, the fact that we are dependent on our collaborators, our suppliers, and other third parties for the manufacture, filling, storage, and distribution of our product candidates means that we are subject to the risk that the products may have manufacturing defects that we have limited ability to prevent or control. The sale of products containing such defects could adversely affect our business, financial condition, and results of operations. Any failure by our third-party manufacturers to comply with cGMP or failure to scale up manufacturing processes, including any failure to deliver sufficient quantities of product candidates in a timely manner, could lead to a delay in, or failure to obtain, regulatory approval of any of our product candidates.

Pharmaceutical manufacturers are also subject to extensive post-marketing oversight by the FDA and comparable regulatory authorities in the jurisdictions where the product is marketed, which include periodic unannounced and announced inspections by the FDA to assess compliance with cGMP requirements. If an FDA inspection of a manufacturer’s facilities reveals conditions that the FDA determines not to comply with applicable regulatory requirements, the FDA may issue observations through a Notice of Inspectional Observations, commonly referred to as a “Form FDA 483”. If observations in the Form FDA 483 are not addressed in a timely manner and to the FDA’s satisfaction, the FDA may issue a Warning Letter or pursue other forms of enforcement action. Any failure by one of our contract manufacturers to comply with cGMP or to provide adequate and timely corrective actions in response to deficiencies identified in a regulatory inspection could result in enforcement action that could lead to a shortage of products and harm our business, including withdrawal of approvals previously granted, seizure, injunction or other civil or criminal penalties. The failure of a manufacturer to address any concerns raised by the FDA or foreign regulators could also lead to plant shutdown or the delay or withholding of product approval by the FDA in additional indications, or by foreign regulators in any indication. Certain countries may impose additional requirements on the manufacturing of drug products or drug substances, and on manufacturers, as part of the regulatory approval process for products in such countries. The failure by our third-party manufacturers to satisfy such requirements could impact our ability to obtain or maintain approval of our products in such countries.

67

 


 

We expect to rely on third parties, including independent clinical investigators, to conduct our preclinical studies and clinical trials. If these third parties do not successfully carry out their contractual duties, comply with applicable regulatory requirements, or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our product candidates and our business could be substantially harmed.

We plan to rely upon third parties, including independent clinical investigators, to conduct our preclinical studies and clinical trials and to monitor and manage data for our preclinical and clinical programs. We will rely on these parties for execution of our preclinical studies and clinical trials, and control only certain aspects of their activities. Nevertheless, our reliance on these third parties will not relieve us of our regulatory responsibilities, and we are responsible for ensuring that each of our studies and trials is conducted in accordance with the applicable protocol, legal, regulatory, and scientific standards, including GCP requirements, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities for all of our products candidates in clinical development. Regulatory authorities enforce these GCP requirements through periodic inspections of trial sponsors, principal investigators, and trial sites. If we fail to comply with applicable GCP, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with GCP regulations. In addition, our clinical trials must be conducted with product produced under cGMP regulations. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process.

Further, these investigators are not our employees and we will not be able to control, other than by contract, the amount of resources, including time, which they devote to our product candidates and clinical trials. If independent investigators fail to devote sufficient resources to the development of our product candidates, or if their performance is substandard, it may delay or compromise the prospects for approval and commercialization of any product candidates that we develop. In addition, the use of third-party service providers may require us to disclose our proprietary information to these parties, which could increase the risk that this information will be misappropriated.

There is a limited number of third-party service providers that specialize or have the expertise required to achieve our business objectives. If any of our relationships with these third-party laboratories, or clinical investigators terminate, we may not be able to enter into arrangements with alternative laboratories, or investigators or to do so in a timely manner or on commercially reasonable terms. If laboratories, or clinical investigators do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our preclinical or clinical protocols, regulatory requirements or for other reasons, our preclinical or clinical trials may be extended, delayed, or terminated, and we may not be able to obtain regulatory approval for or successfully commercialize our product candidates. As a result, our results of operations and the commercial prospects for our product candidates would be harmed, our costs could increase, and our ability to generate revenues could be delayed. Switching or adding additional laboratories or investigators involves additional cost and requires management time and focus. In addition, there is a natural transition period when a new laboratory commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines.

In addition, clinical investigators may serve as scientific advisors or consultants to us from time to time and may receive cash or equity compensation in connection with such services. If these relationships and any related compensation result in perceived or actual conflicts of interest, or the FDA concludes that the financial relationship may have affected the interpretation of the preclinical study or clinical trial, the integrity of the data generated at the applicable preclinical study or clinical trial site may be questioned and the utility of the preclinical study or clinical trial itself may be jeopardized, which could result in the delay or rejection by the FDA. Any such delay or rejection could prevent us from commercializing our clinical-stage product candidate or any future product candidates.

We may not realize the benefits of any existing or future co-development or out-licensing arrangement, and if we fail to enter into new strategic relationships our business, financial condition, commercialization prospects, and results of operations may be materially adversely affected.

Our product development programs and the potential commercialization of our product candidates will require substantial additional cash to fund expenses. Therefore, for some of our product candidates, we may decide to enter into collaborations with pharmaceutical or biopharmaceutical companies for the development and potential commercialization of those product candidates.

We face significant competition in seeking appropriate collaborators. Collaborations are complex and time-consuming to negotiate and document. We may not be able to negotiate collaborations on acceptable terms, or at all. If our strategic collaborations do not result in the successful development and commercialization of product candidates, or if one of our collaborators terminates its

68

 


 

agreement with us, we may not receive any future research funding or milestone or royalty payments under the collaboration. In instances where we do enter into collaborations, we could be subject to the following risks, each of which may materially harm our business, commercialization prospects, and financial condition:

we may not be able to control the amount and timing of resources that is required of us to complete our development obligations or that the collaboration partner devotes to the product development or marketing programs;
the collaboration partner may experience financial difficulties;
collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials, or require a new formulation of a product candidate for clinical testing;
we may be required to relinquish important rights such as marketing, distribution, and intellectual property rights;
collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to litigation or potential liability;
collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability;
a collaborator could move forward with a competing product developed either independently or in collaboration with third parties, including our competitors;
we and our collaboration partner may disagree regarding the development plan for product candidates on which we are collaborating (for example, we may disagree with a collaboration partner regarding target indications, inclusion or exclusion criteria for a clinical trial, or the decision to seek front line therapy approval versus second, third, or fourth line therapy approval);
disputes may arise between the collaborators and us that result in the delay or termination of the research, development or commercialization of our product candidates or that result in costly litigation or arbitration that diverts management attention and resources;
business combinations or significant changes in a collaborator’s business strategy may adversely affect our willingness to complete our obligations under any arrangement; or
collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable product candidates.

If we license products or businesses, we may not be able to realize the benefit of such transactions if we are unable to successfully integrate them with our existing operations and company culture. We cannot be certain that, following a strategic transaction or license, we will achieve the results, revenue, or specific net income that justifies such transaction.

To date, we have relied on one third-party manufacturer for the cGMP production of our drug product candidates. The loss of this third-party manufacturer could negatively impact our ability to develop our product candidates and adversely affect our business.

We do not currently own any facility that may be used as our clinical-scale manufacturing and processing facility and currently rely on a single third-party vendor to manufacture supplies and process our product candidates. We have not yet caused our product candidates to be manufactured or processed on a commercial scale and may not be able to do so for any of our product candidates.

Although in the future we intend to develop our own manufacturing facility, we also intend to use third parties as part of our manufacturing process and may, in any event, never be successful in developing our own manufacturing facility.

Manufacturers of biologic products often encounter difficulties in production, particularly in scaling up or out, validating the production process, and assuring high reliability of the manufacturing process (including the absence of contamination). These

69

 


 

problems include logistics and shipping, difficulties with production costs and yields, quality control, including stability of the product, product testing, operator error, availability of qualified personnel, as well as compliance with strictly enforced federal, state and foreign regulations. Furthermore, if contaminants are discovered in our supply of our product candidates or in the manufacturing facilities, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination.

The lead time needed to establish relationships with new manufacturers can be lengthy, and we may experience delays in meeting demand in the event we must switch to a new manufacturer. The time and effort to qualify a new manufacturer could result in additional costs, diversion of resources, or reduced manufacturing yields, any of which would negatively impact our operating results. Our reliance on a single third-party manufacturer exposes us to certain risks, including the following:

we may be unable to identify replacement manufacturers on acceptable terms or at all because the number of potential manufacturers is limited and the FDA must approve the use of any manufacturers of our product candidates. This approval would require new testing and cGMP compliance inspections by the FDA. In addition, a new manufacturer would have to be educated in, or develop substantially equivalent processes for, production of our products;
initial replacement manufacturers may not be able to execute our manufacturing procedures and other logistical support requirements appropriately or timely;
under our exclusive license agreement with Wugen, we are contractually obligated to oversee the manufacturing and supply of our internally-developed fusion molecules HCW9201 and HCW9206 in the manufacture of Wugen’s cellular therapeutics, and if our single third-party manufacturer is unable to timely manufacture our product or produce the quantity and quality required to meet our and Wugen’s clinical needs, then Wugen has priority over us which could result in our financial results and the commercial prospects for our product candidates being harmed, our costs could increase and our ability to generate revenue could be delayed; and
our ability to develop our product candidates could be materially and adversely impacted if the single third-party manufacturer upon which we rely were to experience a significant business challenge, disruption or failure due to issues such as financial difficulties or bankruptcy, issues relating to other customers such as regulatory or quality compliance issues, or other financial, legal, regulatory, or reputational issues.

Moreover, to meet anticipated demand, our third-party manufacturer may need to increase manufacturing capacity, which could involve significant challenges. This may require us and our vendor to invest substantial additional funds and hire and retain the technical personnel who have the necessary experience. Neither we nor our third-party manufacturer may successfully complete any required increase to existing manufacturing capacity in a timely manner, or at all.

If we are unable to obtain sufficient raw and intermediate materials on a timely basis or if we experience other manufacturing or supply difficulties, our business may be adversely affected.

The manufacture of certain of our product candidates requires the timely delivery of sufficient amounts of raw and intermediate materials. We work closely with our suppliers to ensure the continuity of supply, but cannot guarantee these efforts will always be successful. Further, while efforts are made to diversify our sources of raw and intermediate materials, in certain instances we acquire raw and intermediate materials from a sole supplier. While we believe that alternative sources of supply exist where we rely on sole supplier relationships, there can be no assurance that we will be able to quickly establish additional or replacement sources for some materials. A reduction or interruption in supply, and an inability to develop alternative sources for such supply, could adversely affect our ability to manufacture our product candidates in a timely or cost-effective manner.

Supply sources could be interrupted from time to time and, if interrupted, there is no guarantee that supplies could be resumed within a reasonable time frame and at an acceptable cost or at all.

We rely on our manufacturers to purchase from third-party suppliers the materials necessary to produce our product candidates for our clinical trials. There are a limited number of suppliers for raw materials that we use to manufacture our drugs, and there may be a need to assess alternate suppliers to prevent a possible disruption of the manufacture of the materials necessary to produce our product candidates for our clinical trials, and if approved, ultimately for commercial sale. We do not have any control over the process or timing of the acquisition of these raw materials by our manufacturers. Moreover, we currently do not have any agreements for the commercial production of these raw materials. We cannot be sure that these suppliers will remain in business, or that they will not be purchased by one of our competitors or another company that is not interested in continuing to produce these materials for our intended purpose. In addition, the lead time needed to establish a relationship with a new supplier can be lengthy, and

70

 


 

we may experience delays in meeting demand in the event a new supplier must be used. The time and effort to qualify a new supplier could result in additional costs, diversion of resources, or reduced manufacturing yields, any of which would negatively impact our operating results. Although we will not begin a clinical trial unless we believe we have a sufficient supply of a product candidate to complete the clinical trial, any significant delay in the supply of a product candidate, or the raw material components thereof, for an ongoing clinical trial due to the need to replace a third-party manufacturer could considerably delay completion of our clinical trials, product testing, and potential regulatory approval of our product candidates. If our manufacturers or we are unable to purchase these raw materials after regulatory approval has been obtained for our product candidates, the commercial launch of our product candidates would be delayed or there would be a shortage in supply, which would impair our ability to generate revenues from the sale of our product candidates.

Risks Related to Intellectual Property and Information Technology

We expect to rely on patents and other intellectual property rights to protect our technology, including product candidates and our immunotherapy platform technology, the prosecution, enforcement, defense, and maintenance of which may be challenging and costly. Failure to protect or enforce these rights adequately could harm our ability to compete and impair our business.

Our commercial success depends in part on obtaining and maintaining patents and other forms of intellectual property rights for technology related to our product candidates, including, but not limited to, our immunotherapy platform technology, product candidates, methods used to manufacture those product candidates, formulations thereof, and the methods for treating patients using those product candidates. Given that the development of our technology and product candidates is at an early stage, our intellectual property portfolio with respect to certain aspects of our technology and product candidates is also at an early stage. We seek to protect our proprietary position by filing patent applications in the United States and abroad related to our novel platform technology and product candidates that are important to our business. The patent prosecution process is expensive and time-consuming, and we may not be able to prepare, file, and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. In addition, during the patent prosecution process, we may receive rejections. Although we would be given an opportunity to respond to those rejections, we may be unable to overcome such rejections.

The issuance, scope, validity, enforceability, and commercial value of our current or future patent rights are highly uncertain. It is possible that we will fail to identify patentable aspects of inventions made in the course of development and commercialization activities before it is too late to obtain patent protection on them. Our pending and future patent applications may not result in patents being issued which protect our technology or product candidates, in whole or in part, or which effectively prevent others from commercializing competitive technologies and product candidates. The patent examination process may require us to narrow the scope of the claims of our pending and future patent applications, which may limit the scope of patent protection that may be obtained. Further, even if we obtain patents with sufficient scope to protect our technology or product candidates in their present forms, future technical changes to our technology or product candidates may render the patent coverage inadequate.

We cannot assure you that all of the potentially relevant prior art relating to our patents and patent applications has been found. If such prior art exists, it can invalidate or narrow the scope of a patent or prevent a patent from issuing from a pending patent application. Even if patents do successfully issue and even if such patents cover our product candidates, third parties may initiate opposition, interference, re-examination, post-grant review, inter partes review, nullification, or derivation actions in court or before patent offices, or similar proceedings challenging the validity, ownership, enforceability, or scope of such patents, which may result in the patent claims being narrowed, invalidated, or held unenforceable or circumvented. Because patent applications in the United States and other jurisdictions are confidential for a period of time after filing, and some remain so until issued, we cannot be certain that we were the first to make the inventions claimed in our patents or pending patent applications, or that we were the first to file any patent applications related to such inventions. Our patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless and until a patent issues from such applications, and then only to the extent the issued claims cover the technology. Furthermore, even where we have a valid and enforceable patent, we may not be able to exclude others from practicing our invention where the other party can show that they used the invention in commerce before our filing date or the other party benefits from a compulsory license. Additionally, our competitors or other third parties may be able to evade our patent rights by developing new biologics, biosimilars, or alternative technologies or products in a non-infringing manner.

In addition, given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our intellectual property may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. Moreover, some of our owned patent applications may in the future be, co-owned with third parties. If we are unable to obtain an exclusive license to any such third-party co-owners’ interest in such patents or patent applications, such co-owners may be able to license their rights to other third parties, including our competitors, and our competitors could market competing products and technology. In addition, we may need the cooperation of any such co-owners of our owned patents in order to enforce such patents

71

 


 

against third parties, and such cooperation may not be provided to us or our licensors. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations and prospects.

The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment, and other provisions during the patent application process. There are situations in which noncompliance can result in abandonment or lapse of a patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, competitors might be able to enter the market earlier than would otherwise have been the case. The standards applied by the USPTO, foreign patent offices, and patent courts or other authorities in granting patents and ruling on claim scope and validity are not always applied uniformly or predictably. Patent positions of life sciences companies can be uncertain and involve complex factual, scientific, and legal questions. Changes in either the patent laws or their interpretation in any jurisdiction that we seek patent protection may diminish our ability to protect our inventions, maintain and enforce our intellectual property rights; and, more generally, may affect the value of our intellectual property, including the narrowing of the scope of our patents and any that we may license.

Failure to protect or to obtain, maintain or extend adequate patent and other intellectual property rights could materially adversely affect our ability to develop and market our product candidates.

We may become involved in lawsuits to protect or enforce our issued patents relating to one or more of our product candidates or our internally-developed platform, which could ultimately render our patents invalid or unenforceable and adversely affect our competitive position. Intellectual property litigation or other legal proceedings could cause us to spend substantial resources and distract our personnel from their normal responsibilities.

Competitors may infringe our patents or other intellectual property that relate to our immunotherapy platform technology and product candidates, their respective methods of use, manufacture, and formulations thereof. To protect our competitive position and counter infringement or unauthorized use, we may from time to time need to resort to litigation to enforce or defend any patents or other intellectual property rights owned or licensed by us by filing infringement claims. As enforcement of intellectual property rights is difficult, unpredictable, time-consuming, and expensive, we may fail in enforcing our rights, in which case our competitors may be permitted to use our technology without being required to pay us any license fees. In addition, litigation involving our patents carries the risk that one or more of our patents will be held invalid (in whole or in part, on a claim-by-claim basis) or held unenforceable. Such an adverse court ruling could allow third parties to commercialize our product candidates or methods, or our immunotherapy platform technology, and then compete directly with us, without payment to us.

Even if resolved in our favor, such litigation and other legal proceedings may cause us to incur significant expenses and would be likely to divert significant resources from our core business, including distracting our technical and management personnel from their normal responsibilities, and may impact our reputation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments, and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce our resources available for development activities. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their substantially greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace.

If we were to initiate legal proceedings against a third party to enforce a patent related to one of our product candidates, the defendant could counterclaim that our patent is invalid and/or unenforceable. In patent litigation in the United States or in certain jurisdictions in Europe, defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, for example, novelty, non-obviousness, written description or enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. Third parties may also raise similar invalidity and/or unenforceability claims before administrative bodies in the United States or abroad, even outside the context of litigation through opposition, interference, re-examination, post-grant review, inter partes review, nullification, or derivation actions or proceedings. The outcome following legal assertions of invalidity and unenforceability during patent litigation or administrative proceedings is unpredictable. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on one or more of our technologies, product candidates, methods or certain aspects of our immunotherapy platform technology. Such a loss of patent protection could have a material adverse impact on our business.

72

 


 

There is also a risk that, even if the validity of our patents is upheld, the court will construe our patent’s claims narrowly or decide that we do not have the right to stop the other party from using the invention at issue on the grounds that our patent claims do not cover our own products or the other party’s products. Even if we establish infringement, the court may decide not to grant an injunction against further infringing activity and instead award only monetary damages, which may or may not be an adequate remedy. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during litigation. Patents and other intellectual property rights also will not protect our technology if competitors design around our protected technology without infringing our patents or other intellectual property rights.

We may fail to identify relevant third-party patents or may incorrectly interpret the relevance, scope, or expiration of a third-party patent which might adversely affect our ability to develop our immunotherapy platform technology and product candidates.

We cannot guarantee that our operations and activities do not, or will not in the future, infringe existing or future patents. We also cannot guarantee that any of our patent searches or analyses, including the identification of relevant patents, the scope of patent claims or the expiration of relevant patents, are complete or thorough, nor can we be certain that we have identified each and every third-party patent and pending application in the United States and abroad that is relevant to our immunotherapy platform technology or necessary for the commercialization of our product candidates in any jurisdiction.

Numerous U.S. and foreign patents and pending patent applications exist in our market that are owned by third parties. Our competitors in both the United States and abroad, many of which have substantially greater resources and have made substantial investments in patent portfolios and competing technologies, may have applied for or obtained or may in the future apply for and obtain, patents that will prevent, limit, or otherwise interfere with our ability to make, use, and sell our product candidates or any products, if approved. We do not always conduct independent reviews of pending patent applications of and patents issued to third parties. Patent applications in the United States and elsewhere are typically published approximately 18 months after the earliest filing for which priority is claimed, with such earliest filing date being commonly referred to as the priority date. Certain U.S. applications that will not be filed outside the United States can remain confidential until patents are issued. In addition, patent applications in the United States and elsewhere can be pending for many years before issuance, and unintentionally abandoned patents or applications can be revived. Furthermore, pending patent applications that have been published can, subject to certain limitations, be later amended in a manner that could cover our technology, our product candidates, or the use thereof. As such, there may be applications of third parties now pending or recently revived patents of which we are unaware. These applications may later result in issued patents, or the revival of previously abandoned patents, that will prevent, limit, or otherwise interfere with our ability to make, use, or sell our product candidates or any products, if approved.

The scope of a patent claim is determined by an interpretation of law and, among other considerations, the written disclosure in a patent and the patent’s prosecution history. The claim scope sought in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted or further altered even after patent issuance, including through interferences, post-grant proceedings, opposition proceedings, or other intellectual property proceedings to address issues or errors that may render claims of the issued patent either wholly or partially invalid or unenforceable. Our interpretation of the relevance or the scope of a patent or a pending application may be incorrect, which may negatively impact our ability to market our product candidates. We may incorrectly determine that our product candidates are not covered by a third-party patent or may incorrectly predict whether a third party’s pending application will issue with claims of relevant scope. Our determination of the expiration date of any patent in the United States or abroad that we consider relevant may be incorrect, which may negatively impact our ability to develop and market our product candidates. We cannot provide any assurances that third-party patents do not exist which might be enforced against our current technology, including our immunotherapy platform technology, product candidates and their respective methods of use, manufacture, and formulations thereof, and could result in either an injunction prohibiting our manufacture or future sales, or, with respect to our future sales, an obligation on our part to pay royalties and/or other forms of compensation to third parties, which could be significant.

Intellectual property rights of third parties could adversely affect our ability to develop or commercialize our product candidates, such that we could be required to litigate or obtain licenses from third parties in order to develop or market our product candidates.

Our commercial success depends, in part, on our ability to develop, manufacture, market, and sell our product candidates or any products, if approved without infringing, or otherwise violating the intellectual property and other proprietary rights of third parties. Our competitive position may suffer if patents issued to third parties or other third-party intellectual property rights cover our methods or product candidates or elements thereof, our manufacture or uses relevant to our development plans, our product candidates or other attributes of our product candidates, or our immunotherapy platform technology. In such cases, we may not be in a position to develop or commercialize product candidates unless we successfully pursue litigation to nullify or invalidate the third-party

73

 


 

intellectual property right concerned, which can be expensive and time-consuming, or have to enter into a license agreement with the intellectual property right holder, if available on commercially reasonable terms at all.

There is a substantial amount of intellectual property litigation in the biotechnology and pharmaceutical industries, and we may become party to, or threatened with, litigation or other adversarial proceedings regarding intellectual property rights with respect to our product candidates. Parties making claims against us may seek and obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize our product candidates. If we are sued for patent infringement, we would need to demonstrate that our product candidates or platform technology either do not infringe the patent claims of a relevant patent or that the patent claims are invalid or unenforceable, and we may not be able to do this. Proving invalidity may be difficult. For example, in the United States, proving invalidity in court requires a showing of clear and convincing evidence to overcome the presumption of validity enjoyed by issued patents. We may not have sufficient resources to bring these actions to a successful conclusion. If we are unable to successfully settle future claims on terms acceptable to us, we may be required to engage or continue costly, unpredictable, and time-consuming litigation and may be prevented from or experience substantial delays in marketing our product candidates.

Our involvement in litigation, and in any interferences, post-grant proceedings, opposition proceedings, or other intellectual property proceedings inside and outside of the United States may divert management from focusing on business operations, and even if we are successful in these proceedings, we may incur substantial costs and the time and attention of our management and scientific personnel could be diverted in pursuing these proceedings, which could have a material adverse effect on our business and operations. In addition, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation.

Any current and potential intellectual property litigation also could force us to do one or more of the following:

stop marketing, selling, incorporating, manufacturing, or using our product candidates or any products, if approved, in the United States and/or other jurisdictions that use the subject intellectual property;
obtain from a third party asserting its intellectual property rights, a license to sell or use the relevant technology, including the obligation to pay royalties, which license may not be available on reasonable terms, or at all, or may be non-exclusive thereby giving our competitors access to the same technologies licensed to us;
redesign those products or processes that use any allegedly infringing or misappropriated technology, which may result in significant cost or delay to us, or which redesign could be impossible or technically infeasible; or
pay damages, including the possibility of treble damages and attorneys’ fees in a patent case if a court finds us to have willfully infringed certain intellectual property rights.

We may need to obtain licenses of third-party technology that may not be available to us or are available only on commercially unreasonable terms, and which may cause us to operate our business in a more costly or otherwise adverse manner that was not anticipated.

We own and are pursuing rights to the intellectual property, including patent applications relating to our immunotherapy platform technology and our product candidates. In the future, we may be required to license technologies relating to our therapeutic research programs from additional third parties to further develop or commercialize our platform technology and product candidates. The fusion components of our product candidates may have also been the subject of research by companies that could have filed patent applications on their specific construct and therapeutic methods. There can be no assurance any such patents will not be asserted against us or that we will not need to seek licenses from such third parties. We may not be able to secure such licenses on acceptable terms, if at all, and any such litigation would be costly and time-consuming.

Should we be required to obtain licenses to any third-party technology, including any such patents required to manufacture, use, or sell our product candidates or any products, if approved, the growth of our business will likely depend in part on our ability to acquire, in-license, maintain, or use these proprietary rights. The inability to obtain any third-party license required to develop or commercialize any of our product candidates could cause us to abandon any related efforts, which could seriously harm our business and operations.

In addition, our product candidates may require specific formulations to work effectively and efficiently and the rights to these formulations may be held by others. We may be unable to acquire or in-license any compositions, methods of use, processes, or other third-party intellectual property rights from third parties that we identify as necessary for our product candidates. The licensing

74

 


 

and acquisition of third-party intellectual property rights is a competitive area, and a number of more established companies are also pursuing strategies to license or acquire third-party intellectual property rights that we may consider attractive. These established companies may have a competitive advantage over us due to their size, cash resources, and greater clinical development and commercialization capabilities.

In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment. Even if we are able to obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. If we are unable to successfully obtain a license to third-party intellectual property rights necessary for the development of a product candidate or program, we may have to abandon development of that product candidate or program and our business and financial condition could suffer.

If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.

Our registered or unregistered trademarks or trade names may be challenged, infringed, circumvented, or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition by potential collaborators, partners, or customers in our markets of interest. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected. If other entities use trademarks similar to ours in different jurisdictions, or have senior rights to ours, it could interfere with our use of our current trademarks throughout the world.

During trademark registration proceedings, we may receive rejections. Although we would be given an opportunity to respond to those rejections, we may be unable to overcome such rejections. In addition, in both the USPTO and comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks, which may not survive such proceedings. If we are unable to establish name recognition based on our trademarks and trade names, we may not be able to compete effectively and our business may be adversely affected.

We may license our trademarks and trade names to third parties, such as distributors. Though these license agreements may provide guidelines for how our trademarks and trade names may be used, a breach of these agreements or misuse of our trademarks and tradenames by our licensees may jeopardize our rights in or diminish the goodwill associated with our trademarks and trade names.

Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time.

Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional or PCT filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired for a product, we may be open to competition from competitive medications, including biosimilar medications. In addition, although upon issuance in the United States a patent’s life can be increased based on certain delays caused by the USPTO, this increase can be reduced or eliminated based on certain delays caused by the patent applicant during patent prosecution. If we do not have sufficient patent life to protect our product candidates and any products, if approved, our business and results of operations will be adversely affected. Given the amount of time required for the development, testing, and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.

If we do not obtain protection under the Hatch-Waxman Amendments and similar non-U.S. legislation for extending the term of patents covering each of our product candidates, our business may be materially harmed.

Depending upon the timing, duration, and conditions of FDA marketing approval of our product candidates, one or more of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Amendments, and similar legislation in the European Union. The Hatch-Waxman Amendments permit a patent term extension of up to five years for a patent covering an approved product as compensation for effective patent term lost during product development and the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval, and only claims covering such approved drug product, a method for using it or a method for manufacturing it may be extended.

75

 


 

However, we may not receive an extension if we fail to apply within applicable deadlines, fail to apply prior to expiration of relevant patents, or otherwise fail to satisfy applicable requirements. Moreover, the length of the extension could be less than we request. If we are unable to obtain patent term extension or the term of any such extension is less than we request, the period during which we can enforce our patent rights for that product will be shortened and our competitors may obtain approval to market competing products sooner. As a result, our revenue from applicable products could be reduced, possibly materially.

We expect there may be only limited geographical protection with respect to certain patents and may not be able to protect our intellectual property rights throughout the world.

Patents are of national or regional effect. While we will endeavor to try to protect our technology, products, and product candidates with intellectual property rights such as patents throughout the world, as appropriate, the process of obtaining patents is time-consuming, expensive, and sometimes unpredictable in other countries. We may not be able to file, prosecute, maintain, enforce, or license all necessary or desirable patent rights at a commercially reasonable cost or in a timely manner. In addition, we may not pursue or obtain patent protection in all markets. As such, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions.

International applications under the Patent Cooperation Treaty (“PCT”), are usually filed within 12 months after the priority filing. Based on the PCT filing, national and regional patent applications may be filed in additional jurisdictions where we believe our product candidates may be marketed. We have not, and will not, file for patent protection in all national and regional jurisdictions where such protection may be available. Filing, prosecuting, and defending patents on all of our research programs and product candidates in all countries throughout the world would be prohibitively expensive, and, therefore, the scope and strength of our intellectual property rights will vary from jurisdiction to jurisdiction. In addition, we may decide to abandon national and regional patent applications before grant. Finally, the grant proceeding of each national/regional patent is an independent proceeding which may lead to situations in which applications might in some jurisdictions be refused by the relevant patent offices, while granted by others. Further, the standards applied by the USPTO and foreign patent offices in granting patents are not always applied uniformly or predictably. It is common that depending on the country, the scope of patent protection may vary for the same product candidate and/or technology. As such, we do not know the degree of future protection that we will have on our technology and product candidates in different jurisdictions.

Competitors may use our or our collaboration partners’ technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we or our collaboration partners have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our product candidates, and our or our collaboration partners’ patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.

The laws of some jurisdictions, particularly certain developing countries, do not protect intellectual property rights, particularly those relating to pharmaceuticals or biologics, to the same extent as laws in the United States, and many companies have encountered significant difficulties in protecting and defending such rights in such jurisdictions. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. If we encounter difficulties in protecting, or are otherwise precluded from effectively protecting, the intellectual property rights important for our business in such jurisdictions, the value of these rights may be diminished, and we may face additional competition from others in those jurisdictions.

Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain significant commercial advantage from the intellectual property that we develop or license.

Some countries, including China and India, have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, some countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we are forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired and our business and results of operations may be adversely affected.

We may become subject to claims challenging the inventorship or ownership of our patents and other intellectual property.

76

 


 

We generally enter into confidentiality and intellectual property assignment agreements with our employees, consultants, and contractors. These agreements generally provide that inventions conceived by the party in the course of rendering services to us will be our exclusive property. However, those agreements may not be honored and may not effectively assign intellectual property rights to us. Moreover, there may be some circumstances, where we are unable to negotiate for such ownership rights. Disputes regarding ownership or inventorship of intellectual property can also arise in other contexts, such as collaborations and sponsored research. If we are subject to a dispute challenging our rights in or to patents or other intellectual property, such a dispute could be expensive and time consuming. If we were unsuccessful, we could lose valuable rights in intellectual property that we regard as our own. In addition, interferences, post-grant proceedings, opposition proceedings, derivation proceedings, or other intellectual property proceedings provoked by third parties or brought by us or declared by the USPTO may be necessary to determine the priority of inventions with respect to our patents or patent applications.

The failure to name the proper inventors on a patent application can result in the patents issuing thereon being unenforceable. Inventorship disputes may arise from conflicting views regarding the contributions of different individuals named as inventors, the effects of foreign laws where foreign nationals are involved in the development of the subject matter of the patent, conflicting obligations of third parties involved in developing our product candidates or as a result of questions regarding co-ownership of potential joint inventions. Litigation may be necessary to resolve these and other claims challenging inventorship and/or ownership. Alternatively, or additionally, we may enter into agreements to clarify the scope of our rights in such intellectual property. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.

Intellectual property rights do not necessarily address all potential threats to our competitive advantage.

The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business, or permit us to maintain our competitive advantage. Moreover, if a third party has intellectual property rights that cover the practice of our technology, we may not be able to fully exercise or extract value from our intellectual property rights. The following examples are illustrative:

others may be able to make product candidates similar to our product candidates but that are not covered by the claims of the patents that we own or have exclusively licensed;
the patents of third parties may have an adverse effect on our business;
we or any future strategic partners might not have been the first to conceive or reduce to practice the inventions covered by the issued patent or pending patent application that we own or have exclusively licensed;
we or any future strategic partners might not have been the first to file patent applications covering certain of our inventions;
others may independently develop similar or alternative technologies or duplicate any of our technology without infringing, misappropriating, or otherwise violating our intellectual property rights;
it is possible that our pending patent applications will not lead to issued patents;
issued patents that we own or have exclusively licensed may not provide us with any competitive advantage, or may be held invalid or unenforceable, as a result of legal challenges by our competitors;
we cannot predict the degree and range of protection any issued patents will afford us against competitors, whether or not others will obtain patents claiming aspects similar to those covered by our patents and patent applications, or whether we will need to initiate litigation or administrative proceedings which may be costly whether we win or lose;
our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;
third parties performing manufacturing or testing for us using our product candidates or technologies could use the intellectual property of others without obtaining a proper license; and

77

 


 

we may not develop additional technologies that are patentable.

Should any of these events occur, they could significantly harm our business, results of operations, and prospects.

Composition of matter patents for biological and pharmaceutical products such as our product candidates are generally considered to be the strongest form of intellectual property protection for those types of products, as such patents provide protection without regard to any method of use. We cannot be certain that the claims in our pending patent applications covering composition of matter of our product candidates will be considered patentable by the USPTO or by patent offices in foreign countries, or that the claims in any of our issued patents will be considered valid and enforceable by courts in the United States or foreign countries. Method of use patents protect the use of a product for the specified method. This type of patent does not prevent a competitor from making and marketing a product that is identical to our product for an indication that is outside the scope of the patented method. Moreover, even if competitors do not actively promote their product for our targeted indications, physicians may prescribe these products “off-label.” Although off-label prescriptions may infringe or contribute to the infringement of method of use patents, the practice is common and such infringement is difficult to prevent or prosecute.

Changes in patent laws or patent jurisprudence could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.

As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involve both technological complexity and legal complexity. Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. Therefore, obtaining and enforcing biopharmaceutical patents is costly, time-consuming, and inherently uncertain.

In September 2011, the America Invents Act (the “AIA”), was enacted in the United States, resulting in significant changes to the U.S. patent system. An important change introduced by the AIA was a transition to a “first-to-file” system for deciding which party should be granted a patent when two or more patent applications are filed by different parties claiming the same invention, which went into effect on March 16, 2013. Therefore, a third party that now files a patent application in the USPTO before we do could be awarded a patent covering an invention of ours even if we created the invention before it was created by the third party. While we are cognizant of the time from invention to filing of a patent application, circumstances could prevent us from promptly filing patent applications for our inventions.

Among some of the other changes introduced by the AIA were changes that limit where a patentee may file a patent infringement suit and providing opportunities for third parties to challenge any issued patent in the USPTO. This applies to all of our U.S. patents. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in U.S. federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. The AIA and its continued implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications, and the patent applications of our collaborators, and the enforcement or defense of our issued patents.

Depending on decisions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. For example, in the case, Assoc. for Molecular Pathology v. Myriad Genetics, Inc., the U.S. Supreme Court held that certain claims to DNA molecules are not patentable. While we do not believe that any of the patents owned by us will be found invalid based on this decision, we cannot predict how future decisions by the courts, the U.S. Congress or the USPTO may impact the value of our patents. Similarly, there is complexity and uncertainty related to European patent laws. For example, European patent laws are stringent in the type of amendments that are allowed during prosecution, and the complexity and uncertainty of European patent laws have also increased in recent years. These limitations and requirements could adversely affect our ability to obtain new patents in the future that may be important for our business.

We may rely on trade secret and proprietary know-how, which can be difficult to trace and enforce and, if we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.

In addition to seeking patents for some of our technology and product candidates, we may rely on trade secrets and/or confidential know-how to protect our technology, especially where patent protection is believed to be of limited value, to maintain our competitive position with respect to our research programs and product candidates. Elements of our product candidates, including

78

 


 

processes for their preparation and manufacture, may involve proprietary know-how, information, or technology that is not covered by patents, and thus for these aspects we may consider trade secrets and know-how to be our primary intellectual property. Any disclosure, either intentional or unintentional, by our employees or by other third parties of our trade secrets or proprietary information could enable competitors to duplicate or surpass our technological achievements, thus adversely eroding our competitive position in our market.

Trade secrets and/or confidential know-how can be difficult to protect or maintain as confidential. To protect this type of information against disclosure or appropriation by competitors, we generally require our employees, consultants, contractors, collaborators, advisors, and other third parties to enter into confidentiality agreements with us. Despite these efforts, any of these parties may unintentionally or willfully breach the agreements and disclose our confidential information, and confidentiality agreements may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. Monitoring unauthorized uses and disclosures is difficult, and we do not know whether the steps we have taken to protect our internally-developed technology will be effective. Enforcing a claim that a third party obtained illegally and is using trade secrets and/or confidential know-how is also expensive, time-consuming, and unpredictable.

The enforceability of confidentiality agreements may vary from jurisdiction to jurisdiction. The laws of some foreign countries do not protect proprietary rights to the same extent or in the same manner as the laws of the United States. As a result, we may encounter significant problems in protecting and defending our intellectual property both in the United States and abroad. Furthermore, if a competitor lawfully obtained or independently developed any of our trade secrets, we would have no right to prevent such competitor from using that technology or information to compete with us, which could harm our competitive position. Additionally, if the steps taken to maintain our trade secrets are deemed inadequate, we may have insufficient recourse against third parties for misappropriating the trade secret. In addition, some courts inside and outside the United States are less willing or are unwilling to protect trade secrets or other proprietary information.

Trade secrets can over time be disseminated within the biopharmaceutical industry through independent development, the publication of journal articles, and the movement of personnel skilled in the art from company to company or academic to industry scientific positions. Though our agreements with third parties typically restrict the ability of our employees, consultants, contractors, collaborators, advisors, and other third parties to publish data potentially relating to our trade secrets, our agreements may contain certain limited publication rights. Because from time to time we expect to rely on third parties in the development, manufacture, and distribution of our product candidates and provision of our services, we must, at times, share trade secrets with them. Despite employing the contractual and other security precautions described above, the need to share trade secrets increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third party, we would have no right to prevent them from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor or other third party, our competitive position would be harmed.

In addition, our competitors may independently develop substantially equivalent trade secrets, proprietary information, or know-how and may even apply for patent protection in respect of the same. If successful in obtaining such patent protection, our competitors could limit our use of our trade secrets and/or confidential know-how. Under certain circumstances and to make it more likely that we have our freedom to operate, we may also decide to publish some know-how to make it difficult for others to obtain patent rights covering such know-how, at the risk of potentially exposing our trade secrets to our competitors.

We may be subject to third-party claims asserting that our employees, consultants, contractors, collaborators, or advisors have misappropriated or wrongfully used or disseminated their intellectual property, or claiming ownership of what we regard as our own intellectual property.

Many of our employees, including our senior management, were previously employed at universities or at other biopharmaceutical companies, including our competitors or potential competitors. Some of these employees executed proprietary rights, non-disclosure, and non-competition agreements in connection with such previous employment. Similarly, we work with consultants, contractors, collaborators, advisors, or other third parties who have worked with, and do currently work with, other companies, including our competitors or potential competitors, and have executed proprietary rights, non-disclosure, and non-competition agreements in connection with such other companies. Although we try to ensure that our employees, consultants, contractors, collaborators, advisors, or other third parties do not use or disclose the proprietary information or know-how of others in their work for us, we may be subject to claims that we or these employees or individuals that we work with have used or disclosed confidential information or intellectual property of others, including trade secrets or other proprietary information, or that we caused an individual to breach the terms of his or her non-competition or non-solicitation agreement with a current or former employer or competitor.

79

 


 

Litigation may be necessary to defend against these claims and, even if we are successful, could result in substantial costs and could be a distraction to management, our employees, and our routine business. If we fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel or sustain damages. Such intellectual property rights could be awarded to a third party, and we could be required to obtain a license from such third party to develop or commercialize our technology or product candidates. Such a license may not be available on commercially reasonable terms or at all. Moreover, any such litigation or the threat thereof may adversely affect our reputation and our ability to form strategic alliances or sublicense our rights to collaborators, engage with scientific advisors or hire employees or consultants, each of which would have an adverse effect on our business, results of operations, and financial condition.

Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment, and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for noncompliance with these requirements.

Periodic maintenance and annuity fees on any issued patent are due to be paid to the USPTO and foreign governmental patent agencies in several stages over the lifetime of the patent. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment, and other similar provisions during the patent application process. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Noncompliance events that could result in abandonment or lapse of a patent or patent application include failure to respond to official actions within prescribed time limits, non-payment of fees, and failure to properly legalize and submit formal documents within prescribed time limits. If we fail to maintain the patents and patent applications covering our product candidates or if we otherwise allow our patents or patent applications to be abandoned or lapse, our competitors might be able to enter the market, which would have an adverse effect on our business.

Our information technology systems, or those used by other contractors or consultants, may fail or suffer security breaches, which could adversely affect our business.

We collect and maintain information in digital form that is necessary to conduct our business, and we are dependent on our information technology systems and those of third parties to operate our business. In the ordinary course of our business, we collect, store, and transmit large amounts of confidential information, including intellectual property, proprietary business information, and personal information, and data to comply with cGMP and data integrity requirements. It is critical that we do so in a secure manner to maintain data security and data integrity of such information. We have established physical, electronic, and organizational measures to safeguard and secure our systems to prevent a data compromise. We have also outsourced elements of our information technology infrastructure, and as a result a number of third-party vendors may or could have access to our confidential information. Despite the implementation of security measures, our information technology systems and data and those of our contractors and consultants are vulnerable to compromise or damage from computer hacking, malicious software, fraudulent activity, employee misconduct, human error, telecommunication and electrical failures, natural disasters, or other cybersecurity attacks or accidents. Future acquisitions could expose us to additional cybersecurity risks and vulnerabilities from any newly acquired information technology infrastructure. Cybersecurity attacks are constantly increasing in sophistication and are made by groups and individuals with a wide range of motives (including industrial espionage) and expertise, including by organized criminal groups, “hacktivists,” nation states, and others. Our systems may be subject to attacks and could be targeted by foreign actors for purposes of economic espionage. Due to the nature of some of such attacks, there is a risk that an attack may remain undetected for a period of time. While we continue to make investments to improve the protection of data and information technology, there can be no assurance that our efforts will prevent service interruptions or security breaches.

Any cybersecurity incident could adversely affect our business, by leading to, for example, the loss of trade secrets or other intellectual property, demands for ransom or other forms of blackmail, or the unauthorized disclosure of personal or other sensitive information of our employees, clinical trial patients, customers, and others. Although to our knowledge we have not experienced any material cybersecurity incident to date, if such an event were to occur, it could seriously harm our development programs and our business operations. We could be subject to regulatory actions taken by governmental authorities, litigation under laws that protect the privacy of personal information, or other forms of legal proceedings, which could result in significant liabilities or penalties. Further, a cybersecurity incident may disrupt our business or damage our reputation, which could have a material adverse effect on our business, prospects, operating results, share price, stockholder value, and financial condition. We could also incur substantial remediation costs, including the costs of investigating the incident, repairing or replacing damaged systems, restoring normal business operations, implementing increased cybersecurity protections, and paying increased insurance premiums.

80

 


 

Risks Related to Ownership of Our Common Stock

Our stock price may be volatile or may decline regardless of our operating performance, resulting in substantial losses for investors.

The market price of our common stock may be highly volatile and may fluctuate substantially as a result of a variety of factors, some of which are related in complex ways. The market price of our common stock may fluctuate significantly in response to numerous factors, many of which are beyond our control, including the factors described in this “Risk Factors” section and elsewhere in this Annual Report on Form 10-K.

In addition, the stock market in general, and the Nasdaq Stock Market, or Nasdaq, and biopharmaceutical companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Additionally, the trading prices for pharmaceutical, biopharmaceutical and biotechnology companies have been highly volatile as a result of the COVID-19 pandemic. Also, broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance.

We could be subject to securities class action litigation.

In the past, securities class action litigation has often been instituted against companies following periods of volatility in the market price of a company’s securities. This type of litigation, if instituted, could result in substantial costs and a diversion of management’s attention and resources, which would harm our business, operating results, or financial condition. Additionally, the dramatic increase in the cost of directors’ and officers’ liability insurance may cause us to opt for lower overall policy limits or to forgo insurance that we may otherwise rely on to cover significant defense costs, settlements, and damages awarded to plaintiffs.

Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval.

As of December 31, 2021, our executive officers, directors, holders of 5% or more of our capital stock and their respective affiliates beneficially owned approximately 50% of our outstanding voting stock (excluding any stock options exercisable within 60 days of such date held by such persons). Therefore, these stockholders have the ability to influence us through this ownership position. These stockholders may be able to determine all matters requiring stockholder approval. For example, these stockholders may be able to control elections of directors, amendments of our organizational documents, or approval of any merger, sale of assets, or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our common stock that you may feel are in your best interest as one of our stockholders.

Future sales of our common stock in the public market could cause our common stock price to fall.

Sales of a substantial number of shares of our common stock in the public market, or the perception that these sales might occur, could depress the market price of our common stock and could impair our ability to raise capital through the sale of additional equity securities.

In addition, in the future, we may issue additional shares of common stock, or other equity or debt securities convertible into common stock, in connection with a financing, acquisition, employee arrangement, or otherwise. Any such issuance could result in substantial dilution to our existing stockholders and could cause the price of our common stock to decline.

If we engage in future acquisitions or strategic partnerships, this may increase our capital requirements, dilute our stockholders, cause us to incur debt or assume contingent liabilities, and subject us to other risks.

We may evaluate various acquisitions and strategic partnerships, including licensing or acquiring complementary products, intellectual property rights, technologies, or businesses. Any potential acquisition or strategic partnership may entail numerous risks, including:

increased operating expenses and cash requirements;
the assumption of additional indebtedness or contingent liabilities;
assimilation of operations, intellectual property and products of an acquired company, including difficulties associated with integrating new personnel;

81

 


 

our inability to achieve desired efficiencies, synergies or other anticipated benefits from such acquisitions or strategic partnerships;
the diversion of our management’s attention from our existing product programs and initiatives in pursuing such a strategic merger or acquisition;
retention of key employees, the loss of key personnel, and uncertainties in our ability to maintain key business relationships;
risks and uncertainties associated with the other party to such a transaction, including the prospects of that party and their existing products or product candidates and regulatory approvals; and
our inability to generate revenue from acquired technology and/or products sufficient to meet our objectives in undertaking the acquisition or even to offset the associated acquisition and maintenance costs.

In addition, if we undertake acquisitions, we may issue dilutive securities, assume or incur debt obligations, incur large one-time expenses and acquire intangible assets that could result in significant future amortization expense. Moreover, we may not be able to locate suitable acquisition opportunities and this inability could impair our ability to grow or obtain access to technology or products that may be important to the development of our business.

If securities or industry analysts either do not publish research about us or publish inaccurate or unfavorable research about us, our business or our market, or if they change their recommendations regarding our common stock adversely, the trading price or trading volume of our common stock could decline.

The trading market for our common stock depends in part upon the research and reports that securities or industry analysts may publish about us, our business, our market, or our competitors. If one or more of these analysts initiate research with an unfavorable rating or downgrade our common stock, provide a more favorable recommendation about our competitors or publish inaccurate or unfavorable research about our business, our common stock price would likely decline. If any analyst who may cover us were to cease coverage of us or fail to regularly publish reports on us, we could lose visibility in the financial markets, which in turn could cause the trading price or trading volume of our common stock to decline.

We are an emerging growth company, and any decision on our part to comply only with certain reduced reporting and disclosure requirements applicable to emerging growth companies could make our common stock less attractive to investors.

We are an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, and, for as long as we continue to be an emerging growth company, we may choose to take advantage of exemptions from various reporting requirements applicable to other public companies but not to emerging growth companies, including:

not being required to have our independent registered public accounting firm audit our internal control over financial reporting under Section 404 of the Sarbanes-Oxley Act;
reduced disclosure obligations regarding executive compensation in our periodic reports and annual reports on Form 10-K; and
exemptions from the requirements of holding non-binding advisory votes on executive compensation and stockholder approval of any golden parachute payments not previously approved.

We will remain an emerging growth company until the earlier of:

the last day of the fiscal year in which we have more than $1.07 billion in annual revenue;
the date we qualify as a “large accelerated filer,” with at least $700 million of equity securities held by non-affiliates;
the date on which we have issued, in any three-year period, more than $1.0 billion in non-convertible debt securities; or
December 31, 2026.

82

 


 

We cannot predict if investors will find our common stock less attractive if we choose to rely on any of the exemptions afforded to emerging growth companies. If some investors find our common stock less attractive because we rely on any of these exemptions, there may be a less active trading market for our common stock and the market price of our common stock may be more volatile.

Under the JOBS Act, emerging growth companies can also delay adopting new or revised accounting standards until such time as those standards apply to private companies. We elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that we (i) are no longer an emerging growth company or (ii) affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, these audited financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.

If we fail to maintain proper and effective internal controls over financial reporting our ability to produce accurate and timely financial statements could be impaired.

Pursuant to Section 404 of the Sarbanes-Oxley Act, our management will be required to report upon the effectiveness of our internal control over financial reporting beginning with the annual report for our fiscal year ending December 31, 2022. When we lose our status as an “emerging growth company” and a “smaller reporting company,” and become an “accelerated filer” or a “large accelerated filer,” our independent registered public accounting firm will be required to attest to the effectiveness of our internal control over financial reporting. The rules governing the standards that must be met for management to assess our internal control over financial reporting are complex and require significant documentation, testing and possible remediation. To comply with the requirements of being a reporting company under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), we have implemented and will continue to implement additional financial and management controls, reporting systems and procedures and we have hired and intend to continue to hire additional accounting and finance staff.

We cannot assure you that there will not be material weaknesses or significant deficiencies in our internal control over financial reporting in the future. Any failure to maintain internal control over financial reporting could severely inhibit our ability to accurately report our financial condition, results of operations, or cash flows. If we are unable to conclude that our internal control over financial reporting is effective, or if our independent registered public accounting firm determines we have a material weakness or significant deficiency in our internal control over financial reporting, investors may lose confidence in the accuracy and completeness of our financial reports, the market price of our common stock could decline, and we could be subject to sanctions or investigations by Nasdaq, the SEC, or other regulatory authorities. Failure to remedy any material weakness in our internal control over financial reporting, or to implement or maintain other effective control systems required of public companies, could also restrict our future access to the capital markets.

Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.

We are subject to the periodic reporting requirements of the Exchange Act. We have designed our disclosure controls and procedures to reasonably assure that information we must disclose in reports we file or submit under the Exchange Act is accumulated and communicated to management, and recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. For example, our directors or executive officers could inadvertently fail to disclose a new relationship or arrangement causing us to fail to make a required related party transaction disclosure. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected.

We do not currently intend to pay dividends on our common stock and, consequently, our stockholders’ ability to achieve a return on their investment will depend on appreciation of the value of our common stock.

We have never declared or paid cash dividends on our common stock. We currently intend to retain all available funds and any future earnings to support operations and to finance the growth and development of our business. We do not intend to declare or pay any cash dividends on our capital stock in the foreseeable future. As a result, any investment return on our common stock will depend upon increases in the value for our common stock, which is not certain.

83

 


 

Provisions in our amended and restated certificate of incorporation and our amended and restated bylaws and Delaware law might discourage, delay or prevent a change in control of our company or changes in our management and, therefore, depress the market price of our common stock.

Our amended and restated certificate of incorporation and our amended and restated bylaws contain provisions that could depress the market price of our common stock by acting to discourage, delay, or prevent a change in control of our company or changes in our management that the stockholders of our company may deem advantageous. These provisions, among other things:

establish a staggered Board divided into three classes serving staggered three-year terms, such that not all members of the Board will be elected at one time;
authorize our Board to issue new series of redeemable preferred stock without stockholder approval and create, subject to applicable law, a series of redeemable preferred stock with preferential rights to dividends or our assets upon liquidation, or with superior voting rights to our existing common stock;
eliminate the ability of our stockholders to call special meetings of stockholders;
eliminate the ability of our stockholders to fill vacancies on our Board;
establish advance notice requirements for nominations for election to our Board or for proposing matters that can be acted upon by stockholders at our annual stockholder meetings;
permit our Board to establish the number of directors;
provide that our Board is expressly authorized to make, alter or repeal our amended bylaws;
provide that stockholders can remove directors only for cause and only upon the approval of not less than 66 2/3 of all outstanding shares of our voting stock;
require the approval of not less than 66 2/3 of all outstanding shares of our voting stock to amend our bylaws and specific provisions of our certificate of incorporation; and
limit the jurisdictions in which certain stockholder litigation may be brought.

As a Delaware corporation, we are subject to the anti-takeover provisions of Section 203 of the Delaware General Corporation Law, which prohibits a Delaware corporation from engaging in a business combination specified in the statute with an interested stockholder (as defined in the statute) for a period of three years after the date of the transaction in which the person first becomes an interested stockholder, unless the business combination is approved in advance by a majority of the independent directors or by the holders of at least two-thirds of the outstanding disinterested shares. The application of Section 203 of the Delaware General Corporation Law could also have the effect of delaying or preventing a change of control of our company.

Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware will be the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.

Our amended and restated certificate of incorporation, provides that, unless we consent in writing to the selection of an alternative forum, the sole and exclusive forum, to the fullest extent permitted by law, for (1) any derivative action or proceeding brought on our behalf, (2) any action asserting a breach of a fiduciary duty owed by any director, officer or other employee to us or our stockholders, (3) any action asserting a claim against us or any director, officer, or other employee arising pursuant to the Delaware General Corporation Law, (4) any action to interpret, apply, enforce, or determine the validity of our amended and restated certificate of incorporation or amended and restated bylaws, or (5) any other action asserting a claim that is governed by the internal affairs doctrine, shall be the Court of Chancery of the State of Delaware (or another state court or the federal court located within the State of Delaware if the Court of Chancery does not have or declines to accept jurisdiction), in all cases subject to the court’s having jurisdiction over indispensable parties named as defendants. In addition, our amended and restated certificate of incorporation provides that the federal district courts of the United States is the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act of 1933, as amended (the "Securities Act") but that the forum selection provision will not apply to claims brought to enforce a duty or liability created by the Exchange Act. Although we believe these provisions benefit us by

84

 


 

providing increased consistency in the application of Delaware law for the specified types of actions and proceedings, the provisions may have the effect of discouraging lawsuits against us or our directors and officers. These provisions may limit an investor’s ability to bring a claim in a judicial forum that it finds favorable for disputes with our company, including by increasing the cost of such lawsuits, which may discourage such claims. Alternatively, if a court were to find the choice of forum provision contained in our amended and restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could harm our business, financial condition, and operating results. For example, under the Securities Act, federal courts have concurrent jurisdiction over all suits brought to enforce any duty or liability created by the Securities Act, and investors cannot waive compliance with the federal securities laws and the rules and regulations thereunder. Any person or entity purchasing or otherwise acquiring any interest in our shares of capital stock shall be deemed to have notice of and consented to this exclusive forum provision, but will not be deemed to have waived our compliance with the federal securities laws and the rules and regulations thereunder.

Our ability to use our net operating loss carryforwards and other tax attributes may be limited.

As of December 31, 2020, and 2021, we had available federal net operating loss (“NOL”) carryforwards of $14.8 million and $26.1 million, respectively. We also had available state NOLs carryforwards of approximately $15.2 million and $26.8 million, as of December 31, 2020 and 2021, respectively. As of December 31, 2021, we also had federal tax credits of $218,015, which may be used to offset future tax liabilities. The federal and state NOLs will carryforward indefinitely and be available to offset up to 100% of taxable income for taxable years before 2021 and 80% of taxable years staring after 2020.

Use of our NOL carryforwards and tax credit carryforwards depends on many factors, including having current or future taxable income, which cannot be assured. Our U.S. NOL and tax credit carryforwards could expire unused and be unavailable to offset future taxable income or income tax liabilities because of their limited duration or because of restrictions under U.S. tax law. In addition, for taxable years beginning after December 31, 2020, the deductibility of federal NOLs generated in taxable years beginning after December 31, 2017 is limited to 80% of our taxable income in such year (after taking into account utilization of NOLs generated in taxable years beginning before January 1, 2018), where taxable income is determined without regard to such NOL deduction itself. In addition, under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended (the “Code”), and certain corresponding provisions of state law, a corporation that undergoes an “ownership change” is subject to limitations on its ability to utilize its pre-change NOL and tax credit carryforwards to offset future taxable income or taxes. For these purposes, an ownership change generally occurs where the aggregate stock ownership of one or more stockholders (or groups of stockholders), each of whom owns at least 5% of a corporation’s stock, increases by more than 50 percentage points over its lowest ownership percentage within a specified testing period. We believe we may have experienced ownership changes in the past, and we believe it is likely that we will experience an additional ownership change in the future as a result of this offering or subsequent shifts in our stock ownership, some of which are outside our control. If finalized, Treasury Regulations currently proposed under Section 382 of the Code may further limit our ability to utilize our pre-change NOL and tax credit carryforwards if we undergo an additional ownership changes in the future.

If we earn taxable income in the future, we expect that our ability to use existing NOL and tax credit carryforwards to offset such taxable income will be materially limited as a result of such ownership changes.

The application of such limitations may cause U.S. federal income taxes (and possibly state income taxes) to be paid by us earlier than they otherwise would be paid if such limitations were not in effect and could cause such NOLs and tax credit carryforwards to expire unused, in each case reducing or eliminating the benefit of such NOLs and tax credit carryforwards.

To the extent we are not able to offset our future taxable income with our NOLs or offset future taxes with our tax credit carryforwards, this would adversely affect our operating results and cash flows. These same risks can arise in the context of state income and franchise tax given many states conform to federal law and rely on federal authority for determining state NOLs.

Changes in tax laws or in their implementation or interpretation may adversely affect our business and financial condition.

Recent changes in tax law may adversely affect our business or financial condition. On December 22, 2017, the U.S. government enacted the Tax Cuts and Jobs Act (“TCJA”), which significantly reformed the Code. The TCJA, among other things, contains significant changes to corporate taxation, including reducing the corporate tax rate from a top marginal rate of 35% to a flat rate of 21%, limiting the tax deduction for net interest expense to 30% of adjusted taxable income (except for certain small businesses), limiting the deduction for net operating losses, or NOLs, arising in taxable years beginning after December 31, 2017 to 80% of current year taxable income and elimination of NOL carrybacks for losses arising in taxable years ending after December 31, 2017 (though any such NOLs may be carried forward indefinitely), imposing a one-time taxation of offshore earnings at reduced rates regardless of whether they are repatriated, eliminating U.S. tax on foreign earnings (subject to certain important exceptions), allowing

85

 


 

immediate deductions for certain new investments instead of deductions for depreciation expense over time, and modifying or repealing many business deductions and credits.

As part of Congress’ response to the COVID-19 pandemic, the Families First Coronavirus Response Act (“FFCR Act”), was enacted on March 18, 2020, and the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”), was enacted on March 27, 2020. Both contain numerous tax provisions. The CARES Act did not have any material effect to the Company.

We urge prospective investors in our common stock to consult with their legal and tax advisors with respect to any recently enacted tax legislation, or proposed changes in law, and the potential tax consequences of investing in or holding our common stock.

Item 1B Unresolved Staff Comments.

None.

Item 2 Properties.

Our corporate headquarters are located in Miramar, Florida. We currently occupy approximately 12,250 square feet of space under a lease that expired on February 28, 2022. Effective March 1, 2022, we entered into a new lease for the same location with a term that will expire on February 28, 2024. We use these facilities for research and development laboratories and facilities for manufacturing research-grade materials, as well as offices for all the Company’s employees, including clinical development, research, development, quality control, quality assurance, regulatory affairs, and administration.

We are actively seeking an appropriate new location in the Miramar area that has approximately 40,000 – 60,000 square feet of space for our employee offices, laboratories, and manufacturing facilities. We continue to plan to move to our new location by the end of 2023.

Item 3 Legal Proceedings.

From time to time, we may become involved in legal proceedings arising in the ordinary course of business. We are not currently a party to any litigation or legal proceedings that, in the opinion of our management, are likely to have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources, negative publicity and reputational harm and other factors.

Item 4 Mine Safety Disclosures.

Not applicable.

PART II


Item 5 Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.

Market Information and Holders of our Common Stock

Our common stock is traded on The Nasdaq Global Select Market under the symbol “HCWB”. As of March 22, 2022, 35,779,489 shares of the Company’s common stock were issued and outstanding and were owned by approximately 3,900 holders of record. The actual number of stockholders is greater than this number of record holders and includes stockholders who are beneficial owners but whose shares are held in street name by brokers and other nominees.

Dividend Policy

We have never declared or paid any cash dividends on our common stock or any other securities. We anticipate that we will retain all available funds and any future earnings, if any, for use in the operation of our business and do not anticipate paying cash dividends in the foreseeable future. In addition, future debt instruments may materially restrict our ability to pay dividends on our common stock. Payment of future cash dividends, if any, will be at the discretion of the board of directors after taking into account various factors, including our financial condition, operating results, current and anticipated cash needs, the requirements of current or then-existing debt instruments and other factors the board of directors deems relevant.

86

 


 

Recent Sales of Unregistered Securities

From January 1, 2021 through July 21, 2021 (the date of the filing of our registration statement on Form S-8), we issued and sold to our employees, consultants and other service providers an aggregate of 162,189 unregistered shares of common stock upon the exercise of stock options under our 2019 Equity Incentive Plan, as amended, at a weighted average exercise price of $0.14. The securities issued in these transactions were exempt from the registration requirements of the Securities Act in reliance upon Rule 701 promulgated under the Securities Act. The foregoing transactions did not involve any underwriters, underwriting discounts or commissions, or any public offering.

Use of Proceeds from Initial Public Offering of Company’s Stock

On July 19, 2021, our registration statement on Form S-1 (File No. 333-256510) related to our IPO was declared effective by the SEC. On July 22, 2021, we completed the IPO pursuant to which we issued and sold 7,000,000 shares of common stock at $8.00 per share and received gross proceeds of $56.0 million, which resulted in net proceeds to us of $49.2 million, after deducting underwriting discounts and commissions and offering expenses paid by us. None of the expenses associated with the IPO were paid to directors, officers, persons owning ten percent or more of any class of equity securities or to their affiliates. EF Hutton Division of Benchmark Investments, LLC acted as sole book-running manager and Revere Securities LLC acted as co-manager for the offering.

There has been no material change in the planned use of proceeds from our IPO from that described in the final prospectus dated July 19, 2021 and filed with the SEC.

Item 6 [Reserved].

87

 


 

Item 7 Management’s Discussion and Analysis of Financial Condition and Results of Operations.

You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and related notes thereto included elsewhere in this Annual Report on Form 10-K. This discussion contains forward-looking statements that involve risk and uncertainties, such as statements of our plans, objectives, expectations, and intentions, that are based on the beliefs of our management. Our actual results could differ materially from those discussed in these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in the “Risk Factors” section of this Annual Report on Form 10-K.

Overview

We are a biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. We believe age-related, chronic, low-grade inflammation, or “inflammaging,” is a significant contributing factor to several diseases and conditions, such as cancer, cardiovascular disease, diabetes, neurodegenerative diseases, and autoimmune diseases. The induction and retention of low-grade inflammation in an aging human body is mainly the result of the accumulation of non-proliferative senescent cells and persistent activation of protein complexes, known as inflammasomes, in innate immune cells. These two elements share common mechanisms in promoting secretion of proinflammatory proteins and in many cases interact to drive inflammaging. Our novel approach is to treat both of these elements. We believe our approach has the potential to fundamentally change the treatment of age-related diseases.

Our gateway indication for clinical development is oncology. Advances in immuno-stimulatory and anti-immunosuppressive therapeutics have revolutionized cancer treatment, and our internally-developed, lead product candidate, HCW9218, is designed with both of these functionalities. We believe the bifunctionality of HCW9218 will allow it to be effective against solid tumor cancers because it simultaneously provides immunostimulation of natural killer (“NK”) cells and effector T cells to enhance the cytotoxicity of immune cells against tumor targets, while reducing immunosuppression associated with solid tumors by capturing and neutralizing TGF-β. The FDA has permitted two clinical trials in difficult-to-treat cancer indications to proceed. These include a Company-sponsored trial to evaluate HCW9218 in advanced pancreatic cancer, and an Investigator-sponsored trial by Masonic Cancer Center at University of Minnesota to evaluate HCW9218 in other solid tumors. We expect both trials to initiate in the first half of 2022.

Our internally-developed, lead product candidate, HCW9302, an IL-2-based fusion molecule that expands Treg cells in vivo and ex vivo as an injectable or cell-based strategy, is designed to reduce inflammation through deactivation of inflammasomes. Preclinical studies have demonstrated the ability of HCW9302 to reduce inflammation, allowing for the potential to treat a wide variety of autoimmune and age-related diseases. We expect to complete IND-enabling activities for an autoimmune indication by the end of 2022. Upon completion of IND-enabling activities, we intend to submit an IND for a Phase 1b clinical trial to evaluate HCW9302 in alopecia areata.

Since commencing operations in 2018, we have devoted substantially all of our efforts and financial resources to building our research and development capabilities, and establishing our corporate infrastructure. To date, we have not generated any product revenue and we have never been profitable. We have incurred significant operating losses since the commencement of our operations. As of December 31, 2021, we had an accumulated deficit of $30.6 million. Our cumulative net losses for the years ended December 31, 2020 and 2021 were $15.1 million and $27.9 million, respectively. Our net losses for years ended December 31, 2020 and 2021 were $5.8 million and $12.9 million, respectively. We do not expect to generate product revenue unless and until we obtain marketing approval for and commercialize a drug candidate, and we cannot assure you that we will ever generate significant revenue or profits from product sales.

To date, we have financed our operations primarily with proceeds of $29.4 million from the sale and issuance of redeemable preferred stock, $49.2 million in net proceeds from our IPO, and to a lesser extent, the proceeds of upfront payments from an out-license agreement. As of December 31, 2021, we had cash and cash equivalents of $11.7 million, short-term investments in U.S. government-backed securities of $25.0 million, and long-term investments in U.S. government-backed securities of $9.9 million.

We expect to continue to incur significant expenses and operating losses for the foreseeable future, as we continue our clinical development activities, particularly if and as we:

Advance the development of our lead product candidate, HCW9218, and clinical trials for oncology, and if approved by the FDA, commercialization;
Advance preclinical development of other indications for HCW9218, including fibrotic indications, especially those resulting in NAFLD and liver cancer;

88

 


 

Advance the preclinical development of our second lead product candidate, HCW9302, for autoimmune diseases and pro-inflammatory diseases, such as coronary artery disease;
Establish our own domestic manufacturing capability;
Maintain, expand, and protect our intellectual property portfolio;
Scale up our clinical and regulatory capabilities; and
Expand operational and management information systems as well as investor relations, legal, accounting, and audit services required to operate as a public company.

As a result of these anticipated expenditures, we will need substantial additional financing to support our continuing operations and pursuit of our clinical development strategy. Until such time as we can generate significant revenues from sales of an approved drug or drugs, if ever, we expect to finance our operations through a combination of equity offerings or other financings, collaborations, strategic alliances, co-development deals, and out-licensing arrangements. We may be unable to raise additional funds or enter into such other agreements when needed on favorable terms or at all. If we fail to raise capital or enter into such agreements as, and when, needed, we may need to significantly delay, scale back, or discontinue the development and commercialization of one or more of our product candidates which may have a negative impact on our financial condition.

We believe that our existing cash and cash equivalents, will be sufficient to fund our operating expenses through the end of 2023. We have based this estimate on assumptions that may prove to be wrong, we could utilize our available capital resources sooner than we expect. See the section entitled “Liquidity and Capital Resources.” Our future viability beyond 2023 is dependent on our ability to raise additional capital to finance our operations and fund capital expenditure requirements. Because of the numerous risks and uncertainties associated with our programs, we are unable to estimate the amounts of increased capital outlays and operating expenses associated with completing the preclinical and clinical development of our product candidates.

Recent Developments

The Company achieved several milestones in the past year:

Initial Public Offering. On July 19, 2021, the Company’s S-1 registration statement for an Initial Public Offering ("IPO") was declared effective. On July 22, 2021, the Company closed its IPO resulting in net proceeds of approximately $49.2 million, after deducting underwriting discounts and commissions and estimated offering expenses paid by the Company.
FDA clearance for Company-sponsored Phase 1b clinical trial in cancer. On October 28, 2021, the Company announced that we were cleared by the FDA to proceed to evaluate our lead drug candidate, HCW9218, in a first-in-human Phase 1b clinical trial in patients with advanced pancreatic cancer. We expect to initiate this multi-center trial in the first half of 2022.
FDA clearance for Investigator-sponsored Phase 1 clinical trial in cancer. On January 24, 2022, the Company announced that the Masonic Cancer Center, University of Minnesota was cleared by the FDA to proceed to evaluate our lead drug candidate, HCW9218, in a Phase 1 clinical trial in patients with advanced solid tumors with progressive disease after prior chemotherapies. We expect to initiate this single-center trial in the first half of 2022.
Three publications in peer-reviewed journals. We are successfully executing our strategy to publish pivotal scientific papers to establish our leadership in oncology and other age-related diseases in the scientific and clinical communities. Thus far, three papers have been published:
o
An article in Cancer Immunology Research describing our platform: Becker-Hapak MK, et al. A Fusion Protein Complex Combines IL-12, IL-15, and IL-18 Signaling to Induce Memory-like NK Cells for Cancer Immunotherapy. September 9, 2021.
o
An article in Molecular Therapy on the characterization of our lead molecules, HCW9218: Liu B et al., Bifunctional TGF-ß Trap/IL-15 Protein Complex Elicits Potent NK Cell and CD8 + T Cell Immunity Against Solid Tumors. October 6, 2021.

89

 


 

o
An article in Molecular Therapy which discusses HCW9218 and its ability to augment anti-tumor activity and reduce side effects of chemotherapy regimens: Chaturvedi, P et al., Immunotherapeutic HCW9218 Augments Anti-tumor Activity of Chemotherapy via NK Cell Mediated Reduction of Therapy Induced Senescent Cells, January 17, 2022.

Trends and Uncertainties – COVID-19 Pandemic

There created significant uncertainty around the breadth and duration of business disruptions related to COVID-19, as well as its impact on the U.S. and international economies and, as such, we are unable to determine if it will have a material impact on our operations. The COVID-19 pandemic continues to impact U.S. and international markets and supply chains through the spread of COVID-19 variants.

The COVID-19 pandemic continues to present a substantial public health and economic challenge around the world. The global COVID-19 pandemic continues to evolve, and we will continue to monitor the COVID-19 situation closely. The extent of the impact of the COVID-19 pandemic on our business, operations and development timelines and plans remains uncertain, and will depend on certain developments, including the duration and spread of the pandemic and its impact on our development activities, third-party manufacturers, and other third parties with whom we do business, as well as its impact on regulatory authorities and our key scientific and management personnel. See "Risk Factors-- Public health crises such as pandemics or similar outbreaks could materially and adversely affect our preclinical and clinical trials, business, financial condition, and results of operations."

For additional information on the various risks posed by the COVID-19 pandemic, please read section titled “Risk Factors” set forth in Part I, Item 1A of this Annual Report on Form 10-K and in our other filings with the Securities and Exchange Commission (the “SEC”).

Components of Results of Operation

Revenues

To date, we have not generated any revenue from product sales and do not expect to generate revenue from product sales for the foreseeable future. Until that occurs, our sole source of revenue will be derived from out-licenses, collaborative agreements, and co-development deals.

On June 18, 2021, we entered into a master services agreement with Wugen related to a development supply agreement, under which the Company will sell cGMP and non-cGMP grade licensed molecules to Wugen for clinical development. As of December 31, 2021, we had not finalized any statements of work for orders placed under the master services agreement. Thus, as of December 31, 2021, a contract does not exist between Wugen and the Company on which to base revenue recognition for the sale of material to Wugen. Revenues will be deferred until such time as a contact exists. In future periods, we intend to enter into an agreement with Wugen for commercial supply of licensed molecules when commercialization commences. In addition, under the terms of the Wugen License, we may be eligible to receive additional cash payments that will be recognized as revenue, including development and commercialization milestones and single-digit royalties based on annual net sales of licensed products.

Operating Expenses

Our operating expenses are reported as research and development expenses and general and administrative expenses.

Research and Development

Our research and development expenses consist primarily of costs incurred for the development of our product candidates, which include:

Employee-related expenses, including salaries, benefits, and stock-based compensation expense.
Expenses related to manufacturing and materials, consisting primarily of expenses incurred in connection with third-party contract manufacturing organizations (“CMO”), that produce cGMP materials for clinical trials on our behalf.
Expenses associated with preclinical activities, including research and development and other IND-enabling activities.
Expenses incurred in connection with clinical trials.

90

 


 

Other expenses, such as facilities-related expenses, direct depreciation costs for capitalized laboratory equipment, and an allocation for overhead.

We expense research and development costs as they are incurred. Costs for contract manufacturing are recognized based on an evaluation of the progress to completion of specific tasks using information provided to us by our vendors. Payments for these activities are based on the terms of the agreement, and the pattern of payments for goods and services will change depending on the material. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses and recognized as expenses as the related goods are delivered or the services are performed.

We expect research and development expenses to increase substantially for the foreseeable future as we continue the development of our product candidates. We cannot reasonably determine the nature, timing, and costs of the efforts that will be necessary to complete the development of, and obtain regulatory approval for, any of our product candidates. Product candidates in later stages of development generally have higher development costs than those in earlier stages. We expect our research and development expenses will increase substantially for the foreseeable future as we continue to invest in research and development activities related to developing our lead product candidates, advance into later stages of development, begin to conduct larger clinical trials, expand our product pipeline, continue to maintain, expand, protect, and enforce our intellectual property portfolio, and establish our own manufacturing capabilities. In particular, we expect our research and development expenses will increase substantially as we progress to Phase 2 and Phase 2/3 clinical trials for our lead product candidates, primarily due to the increased size and duration of later-stage clinical trials.

The duration, costs, and timing of the clinical development of our product candidates are highly uncertain and will depend on a variety of factors, including, but not limited to:

Number and scope of preclinical and IND-enabling studies;
Successful and timely patient enrollment in, and completion of, clinical trials;
Per subject trial costs;
Number of trials required for regulatory approval;
Number of sites included in the trials;
Number of subjects needed for each trial;
Cost and timing of manufacturing of cGMP materials for clinical trials;
Receipt of regulatory approvals from applicable regulatory authorities;
Establishing commercial manufacturing capabilities; and
Costs to maintain, defend, and enforce our intellectual property rights.

A change in the outcome of any of these variables with respect to the development of any of our product candidates could significantly change the costs and timing associated with the development of that product candidate.

General and Administrative Expenses

General and administrative expenses consist primarily of employee-related expenses, including salaries, related benefits, and stock-based compensation expense, for employees in the executive, legal, finance and accounting, human resources, and other administrative functions. General and administrative expenses also include third-party costs such as insurance costs, fees for professional services, such as legal, auditing and tax services, facilities administrative costs, and other expenses.

91

 


 

We expect that our general and administrative expenses will increase in the foreseeable future as the size of our business grows to support additional research and development activities. We anticipate increased expenses relating to our operations as a public company, including increased costs for the hiring of additional personnel, and for payment to outside consultants, including lawyers and accountants, to comply with additional regulations, corporate governance, internal control and similar requirements applicable to public companies, as well as increased costs for insurance.

Interest and Other Income, Net

Interest and other income, net consists of interest earned on our cash, cash equivalents, unrealized gains and losses related to our investments in U.S. government-backed securities, and other income related to non-operating activities, offset by miscellaneous non-operating expenses.

Results of Operations

The following table summarizes our results of operations for the years ended December 31, 2020 and 2021:

 

 

Years Ended
December 31,

 

 

 

 

 

 

 

 

2020

 

2021

 

 

$ Change

 

 

% Change

 

Revenues

$

4,099,750

 

$

 

 

$

(4,099,750

)

 

*

 

Operating Expenses:

 

 

 

 

 

 

 

 

 

 

Research and development

 

7,255,227

 

 

8,173,624

 

 

 

918,397

 

 

 

11

%

General and administrative

 

2,669,048

 

 

5,194,210

 

 

 

2,525,162

 

 

 

49

%

Total operating expenses

 

9,924,275

 

 

13,367,834

 

 

 

3,443,559

 

 

 

26

%

Loss from operations

 

(5,824,525

)

 

(13,367,834

)

 

 

(7,543,309

)

 

 

56

%

Interest and other income, net

 

22,324

 

 

505,366

 

 

 

483,042

 

 

*

 

Net loss

$

(5,802,201

)

$

(12,862,468

)

 

$

(7,060,267

)

 

 

55

%

 

* - not meaningful

Revenue

In the year ended December 31, 2020, the Company recognized $4.1 million of revenue, as a result of entering into the Wugen License. No revenues were recognized in the year ended December 31, 2021.

On December 24, 2020, we entered into the Wugen License. We assessed the Wugen License and determined this was a transaction with a customer and should be accounted for under Topic 606. The three performance obligations that had been satisfied as of the effective date of the Wugen License were: (1) exclusive worldwide license, (2) vials of HCW9201, and (3) R&D know-how.

This is the first time we have entered into an out-license arrangement and the first time the Company has established prices for its goods and services. Accordingly, the standalone selling price of the various performance obligations is uncertain, and we determined that an observable standalone selling price was not available for the identified performance obligations under the Wugen License. Where a standalone selling price is not directly observable, then we estimate the standalone selling price considering marketing conditions, entity-specific factors, and information about the customer that is reasonably available. The process for determining a standalone selling price involves significant judgment and includes consideration of multiple factors, including assumptions related to the market opportunity and the time needed to commercialize a product candidate pursuant to the relevant license, estimated direct expenses, and other costs.

The estimated transaction price for performance obligations that were satisfied as of December 31, 2020 was $4.1 million. First, we determined a standalone selling price of $2.5 million for the vials of HCW9201 and the R&D know-how. The prices were determined based on costs for developing the know-how and costs incurred in producing the vials. The standalone selling price for the license was then determined using the residual approach and was priced at $1.6 million.

As of December 31, 2020, we recorded $2.5 million in Accounts receivable, net for the nonrefundable payments related to the sale of non-financial assets to Wugen that were due after the reporting period. The Company records amounts as accounts receivable when the right to consideration is deemed unconditional.

92

 


 

On June 18, 2021, the Company entered into a master services agreement with Wugen related to supply of licensed molecules for use in research and clinical development. As of December 31, 2021, the Company has not finalized any statements of work, which will specify the performance obligations required to be completed by the Company for supplies ordered by Wugen. Thus, a contract did not exist as of December 31, 2021. Revenues will be deferred until a contract exists. The standalone selling price for materials purchased during the year ended December 31, 2021 was determined using industry-standard “cost plus” terms which is the pricing set forth in the Wugen License. Deferred revenue represents amounts billed, or yet to be billed to the Company’s customer, where payment has been received for which the related revenues have not been recognized because one or more of the revenue recognition criteria have not been met.

Because a contract did not exist as of December 31, 2021, we deferred revenue recognition. As of December 31, 2021, we recognized $1.8 million of deferred revenue, included within Accrued liabilities and other current liabilities on the accompanying balance sheet. The Company’s policy is to recognize deferred revenue only to the extent product release occurred after meeting specification required, product is shipped, and cash payment is received.

Research and Development Expenses

The following table summarizes our research and development expenses for the years ended December 31, 2020 and 2021:

 

 

Year Ended
December 31,

 

 

 

 

 

 

 

 

2020

 

 

2021

 

 

$ Change

 

 

% Change

 

Salaries, benefits and related expenses

$

2,726,046

 

 

$

2,825,303

 

 

$

99,257

 

 

 

4

%

Manufacturing and materials

 

2,560,350

 

 

 

2,483,687

 

 

 

(76,663

)

 

 

-3

%

Preclinical expenses

 

1,188,018

 

 

 

2,007,264

 

 

 

819,246

 

 

 

69

%

Clinical trials

 

234,498

 

 

 

249,204

 

 

 

14,706

 

 

 

6

%

Other expenses

 

546,315

 

 

 

608,166

 

 

 

61,851

 

 

 

11

%

Total research and development expenses

$

7,255,227

 

 

$

8,173,624

 

 

$

918,397

 

 

 

13

%

 

Research and development expenses increased by $918,397, or 13%, from $7.3 million for the year ended December 31, 2020 to $8.2 million for the year ended December 31, 2021. The increase was primarily attributable to an increase in preclinical expenses and salaries, benefits and related expenses.

Salaries, benefits and related expenses increased $99,257, or 4%, from $2.7 million for the year ended December 31, 2020 to $2.8 million for the year ended December 31, 2021. The increase is primarily attributable to an increase in salaries, performance bonuses, and benefits of $313,745 and an increase in payroll taxes of $25,624, offset by a reimbursement of $240,000 for certain expenses incurred as required under the terms of the Wugen License.

Manufacturing and materials expenses decreased $76,663, or 3%, from $2.6 million for the year ended December 31, 2020 to $2.5 million for the year ended December 31, 2021. During the year ended December 31, 2020, various testing and quality control procedures were conducted on the materials manufactured in 2019 and 2020 to ensure materials met all expected quality requirements. Beginning in May 2020, we launched manufacturing for three additional molecules as well as larger cGMP production runs of the internally-developed affinity ligand used in our manufacturing process. During the year ended December 31, 2021, the Company completed necessary procedures to release clinical materials for HCW9218. Additionally, the Company conducted several manufacturing activities for HCW9302, including initiating the master cell bank characterization, effecting a technology transfer to our contract manufacturer, performing a 200-liter cGMP production run, as well as other testing procedures.

Expenses associated with preclinical activities increased by $819,246, or 69%, from $1.2 million for the year ended December 31, 2020 to $2.0 million for the year ended December 31, 2021. The increase is due primarily to an increase in expenses for the toxicology studies for HCW9218 required to prepare for submission of our IND to evaluate HCW9218 in a pancreatic cancer trial, and toxicology studies for HCW9302, which is a multi-dose nonhuman primate toxicology study that began in the second half of 2021 and is expected to be completed in the second half of 2022. Upon completion of IND-enabling activities, we intend to submit an IND for a Phase 1b clinical trial to evaluate HCW9302 in alopecia areata.

Expenses associated with clinical trials including professional fees related to regulatory filings, increased by $14,706, or 6%, from $234,498 for the year ended December 31, 2020 to $249,204 for the year ended December 31, 2021. The Company expects to initiate two clinical trials for cancer indications in the first half of 2022. One of these trials is a Phase 1b, Company-sponsored study to evaluate HCW9218 in advanced pancreatic cancer. The other is a Phase 1 clinical trial sponsored by the Masonic Cancer Center at University of Minnesota to evaluate HCW9218 in solid tumors, such as breast, ovarian, prostate, and colorectal cancers. As we

93

 


 

advance our product candidates through clinical development, we expect our clinical trial expenses to increase significantly, as we conduct larger, later-stage clinical trials and expand the number of indications we advance in clinical development.

Other expenses consist primarily of direct depreciation costs for laboratory equipment, an allocation for rent expense, repairs and maintenance, as well as general office furniture and supplies. The increase from the year ended December 31, 2020 to the year ended December 31, 2021 is primarily attributable to an increase in repairs and maintenance, office equipment, and rent expense, offset by a decrease in depreciation expense.

General and Administrative Expenses

The following table summarizes our general and administrative expense for the years ended December 31, 2020 and 2021:

 

 

 

Year Ended
December 31,

 

 

 

 

 

 

 

 

 

2020

 

 

2021

 

 

$ Change

 

 

% Change

 

Salaries, benefits and related expenses

 

$

1,492,382

 

 

$

2,341,807

 

 

$

849,425

 

 

 

57

%

Professional services

 

 

447,093

 

 

 

1,263,270

 

 

 

816,177

 

 

 

183

%

Facilities and office expenses

 

 

243,241

 

 

 

308,741

 

 

 

65,500

 

 

 

27

%

Depreciation

 

 

233,039

 

 

 

218,466

 

 

 

(14,573

)

 

 

-6

%

Rent expense

 

 

100,972

 

 

 

100,457

 

 

 

(515

)

 

 

-1

%

Other expenses

 

 

152,321

 

 

 

961,469

 

 

 

809,148

 

 

 

531

%

Total general and administrative expenses

 

$

2,669,048

 

 

$

5,194,210

 

 

$

2,525,162

 

 

 

95

%

 

General and administrative expenses increased by $2.5 million, or 95%, from $2.7 million for the year ended December 31, 2020 to $5.2 million for the year ended December 31, 2021. The increase is attributable primarily to an increase in salaries, benefits and related expenses, professional services fees, and other expenses.

Salaries, benefits and related expenses increased $849,425, or 57%, from $1.5 million for the year ended December 31, 2020 to $2.3 million for the year ended December 31, 2021. The increase is attributable primarily to an increase of $367,750 for performance-based bonuses paid upon the successful completion of the Wugen License and the IPO and an increase of $323,453 in stock-based compensation expense. Professional services increased primarily due to legal services required for patent filings and advisories fees paid for investor relations services. Other expenses increase is primarily due to an increase in insurance premiums.

We expect to incur increasing general and administrative expenses as a result of operating as a public company, including expenses for SEC reporting, investor relations, additional insurance requirements, and other administrative expenses. We expect to increase our administrative function to support the growth in our business and public company reporting requirements.

Interest and Other Income, Net

For the years ended December 31, 2020 and 2021, other income (expense), net increased by $483,042 primarily due to the forgiveness of the SBA Paycheck Protection Loan and accrued interest.

Liquidity and Capital Resources

Sources of Liquidity

Since inception, we have funded our operations primarily from the issuance of redeemable preferred stock and our IPO. From our inception in 2018 to July 19, 2021, the effective date of our IPO, we raised net proceeds of approximately $85.4 million, including $49.2 million of net proceeds from the IPO.

Based on our existing business plan, we believe that our existing cash, cash equivalents and investments will be sufficient to fund our anticipated operating expenses through the end of 2023.

We have based our projections of operation expenses and capital expenditure requirements on assumptions that may prove to be incorrect, and we may use all of our available capital sooner than we expect. Because of the numerous risks and uncertainties associated with the clinical development and commercialization of immunotherapeutics, we are unable to estimate the exact amount of capital requirements to pursue these activities. Our funding requirements will depend on many factors, including, but not limited to:

94

 


 

Timing, progress, costs, and results of our ongoing preclinical studies and clinical trials of our immunotherapeutic products;
Impact of COVID-19 on the timing and progress of our clinical trials and our ability to identify and enroll patients;
Costs, timing, and outcome of regulatory review of our product candidates;
Number of trials required for regulatory approval;
Whether we enter into any collaboration or co-development agreements and the terms of such agreements;
Effect of competing technology and market developments;
Cost of maintaining, expanding, and enforcing our intellectual property rights; and
Costs and timing of future commercialization activities, including product manufacturing, marketing, sales, and distribution, for any of our product candidates for which we receive regulatory approval.

A change in the outcome of any of these or other factors with respect to the clinical development and commercialization of our product candidates could significantly change the costs and timing associated with the development of that product candidate. Further, our operating plan may change, and we may need additional funds to meet operational needs and capital requirements for clinical trials and other research and development expenditures.

If we raise additional funds by issuing equity securities, our stockholders will experience dilution. Any future debt financing into which we enter may impose upon us additional covenants that restrict our operations, including limitations on our ability to incur liens or additional debt, pay dividends, repurchase our common stock, make certain investments and engage in certain merger, consolidation or asset sale transactions. Any debt financing or additional equity that we raise may contain terms that are not favorable to us or our stockholders. If we are unable to raise additional funds when needed, we may be required to delay, reduce, or terminate some or all of our development programs and clinical trials. We may also be required to sell or license to others rights to our drug candidates in certain territories or indications that we would prefer to develop and commercialize ourselves.

Summary of Statements of Cash Flows

The following table summarizes our cash flows for the years ended December 31, 2020 and 2021:

 

 

 

Years Ended
December 31,

 

 

 

2020

 

 

2021

 

Cash used in operating activities

 

$

(10,431,326

)

 

$

(11,041,749

)

Cash used in investing activities

 

 

(186,682

)

 

 

(34,952,883

)

Cash provided by financing activities

 

 

11,718,008

 

 

 

49,269,475

 

Net increase in cash and cash equivalents

 

$

1,100,000

 

 

$

3,274,843

 

 

Operating Activities

Net cash used in operating activities was $10.4 million for the year ended December 31, 2020 and $11.0 million for the year ended December 31, 2021.

Cash used in operating activities for the year ended December 31, 2020 consisted primarily of net loss for the period of $5.8 million and an increase in Accounts receivable of $2.5 million pursuant to the Wugen License, partially offset by $595,911 of depreciation and amortization.

Cash used in operating activities for the year ended December 31, 2021 consisted primarily of net loss for the period of $12.9 million, a gain on extinguishment of debt of $567,311, and an increase in Prepaid expenses and other assets of $2.8 million, primarily offset by an decrease of $2.4 million in Accounts receivable, an increase of $1.9 million in Accounts payable and other liabilities, and $595,765 of depreciation and amortization.

95

 


 

Investing Activities

For the year ended December 31, 2020, the cash used in investing activities reflects the purchase of laboratory equipment and general office equipment.

For the year ended December 31, 2021, cash used in investing activities reflects the purchase of U.S. government-backed securities with the proceeds of our IPO and the purchase of laboratory equipment and general office equipment. As of December 31, 2021, we held $34.9 million in U.S. government-backed securities.

Financing Activities

For the year ended December 31, 2020, cash provided by financing activities was $11.7 million, consisting of an increase of $11.1 million from proceeds from the issuance of Series C redeemable preferred stock and an increase of $563,590 from proceeds from an SBA Paycheck Protection Loan.

For the year ended December 31, 2021, cash provided by financing activities was $49.3 million, consisting primarily of net proceeds of $49.2 million from our IPO.

Contractual Obligations and Commitments

 

As of December 31, 2021, we had $36,000 of obligations for the two months remaining in the lease terms for a non-cancellable operating lease agreement and a short-term sublease agreement related to our facilities in Miramar, Florida. On February 25, 2022, HCW Biologics was assigned all rights, title, and interest in the primary lease which underlies the sublease. Effective March 1, 2022, we entered into a lease extension for our current location for a period of two years. Total contractual obligations under the lease extension are $339,300, all of which are due by February 29, 2024.

 

The Company has commitments with a third-party manufacturing organization to supply us with clinical grade materials. As of December 31, 2021, we are under contract for obligations of $2.5 million that we expect to pay during the two years ending December 31, 2023.

 

In the normal course of business, we enter into contracts for non-clinical studies, preclinical testing, and other services and products. These contracts generally provide for termination following a certain period after notice and therefore we believe that our non-cancellable obligations under these agreements are not material.

Critical Accounting Policies, Significant Judgements and Use of Estimates

The financial statements are prepared in conformity with accounting principles generally accepted in the United States (“U.S. GAAP”), which requires the use of estimates, judgments and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses in the periods presented. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgements about the carrying value of assets and liabilities that are not readily apparent from other sources. We believe the accounting estimates employed are appropriate and the resulting balances are reasonable; however, due to the inherent uncertainties in developing estimates, actual results could differ from the original estimates, requiring adjustments to these balances in future periods. Refer to Note 1 to our financial statements for our significant accounting policies related to our critical accounting estimates.

We believe that the accounting policies discussed below are critical to understanding our historical and future performance, as these policies relate to the more significant areas involving management’s judgements and estimates.

96

 


 

Revenue Recognition

For the year ended December 31, 2020, we adopted provisions of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 606, Revenue from Contracts with Customers (“Topic 606”). Under Topic 606, we recognize revenue when our customer obtains control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. To determine the appropriate amount of revenue to be recognized for arrangements determined to be within the scope of Topic 606, we perform the following five steps: (i) identification of the contract(s) with the customer, (ii) identification of the promised goods or services in the contract and determination of whether the promised goods or services are performance obligations, (iii) measurement of the transaction price, (iv) allocation of the transaction price to the performance obligations, and (v) recognition of revenue when (or as) we satisfy each performance obligation. We only apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to our customer. Refer to Note 1 to our financial statements for our significant accounting policies related to revenue recognition.

Fair Value Measurements

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. FASB ASC Topic 820, Fair Value Measurements and Disclosures, establishes a fair value hierarchy for those instruments measured at fair value that distinguishes between fair value measurements based on market data (observable inputs), and those based on our own assumptions (unobservable inputs). This hierarchy maximizes the use of observable inputs and minimizes the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows:

Level 1: Observable inputs such as quoted prices in active markets;
Level 2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and
Level 3: Unobservable inputs in which there is little or no market data, which require a reporting entity to develop its own assumptions.

Fair Value

Under the Wugen License, we received shares of common stock of Wugen on the effective date of the Wugen License. We estimated that the fair value of the stock was $1.6 million. As the common stock of Wugen is not currently publicly traded, the fair value was determined based on inputs other than a public market price. We relied primarily on the most recent third-party financing completed by Wugen. In addition, we considered the results of a third-party valuation assessment. Since our ownership interest in Wugen is less than 20% and we do not have significant influence over the operations of Wugen, we account for these securities as a cost method investment. We will carry this investment at cost less impairment, adjusted for observable price changes in orderly transactions for an identical or similar investment of the same investee. We assess the investment each reporting period to determine if an impairment has occurred. In the event that a public market becomes available for the common stock of Wugen in the future and the shares become freely tradeable, we will recognize changes in fair value according to the market price in other income in the statements of operations.

Stock-based Compensation

As described in Note 1 and Note 10 to our audited financial statements which appear elsewhere in this Annual Report on Form 10-K, we maintain a stock-based compensation plan as a long-term incentive for employees, non-employees, and directors. The plan allows for grants of incentive stock options, non-qualified stock options, and other forms of equity awards. We have granted options with service-based and performance-based vesting conditions.

We measure our stock-based awards granted to employees and directors based on the estimated fair value of the option on the date of grant (grant date fair value) and recognize compensation expense over the vesting period. Compensation expense is recorded as either research and development or general and administrative expenses in the statements of operations based on the function to which the related services are provided. Forfeitures are accounted for as they occur. We estimate grant date fair value using the Black-Scholes option-pricing model.

97

 


 

For stock option grants with service-based vesting, stock-based compensation expense represents the portion of the grant date fair value of employee stock option grants recognized over the requisite service period of the awards on a straight-line basis, net of estimated forfeitures. For options that vest upon the achievement of performance milestones, the Company estimates fair value at the date of grant and compensation expense is recognized using the accelerated attribution method when it is determined that the performance criteria is probable of being met.

In determining the fair value of the stock-based awards, we use the Black-Scholes option-pricing model and assumptions discussed below. Each of these inputs is subjective and its determination generally requires significant judgment. These assumptions include, but are not limited to:

 

Fair Value of Common Stock—Prior to our initial public offering, the estimated fair value of our common stock was determined by our board of directors as of the date of each option grant, with input from management, considering our most recently available third-party valuation of our common stock as well as our board of directors’ assessment of additional objective and subjective factors that it believed were relevant and which may have changed from the date of the most recent third-party valuation to the date of the grant. Since the completion of our initial public offering on July 19, 2021, the fair value of each share of common stock underlying stock option grants is based the quoted market price on the primary stock exchange on which our common stock is traded on the day the stock award or option is granted.
Expected term—The expected term of stock options is determined using the “simplified” method, whereby the expected life equals the arithmetic average of the vesting term and the original contractual term of the option due to the Company’s lack of sufficient historical data.
Expected volatility—Since there is no trading history for our common stock, the expected volatility was estimated based on the historical equity volatility for comparable publicly traded biotechnology companies. The comparable companies were chosen based on their similar size, stage in the life cycle or area of specialty.
Risk-free interest rate—The risk-free interest rate is based on the U.S. Treasury Bond in effect at the time of grant for periods corresponding with the expected term of the exit event.
Dividend yield—The expected dividend yield is 0% because the Company has not historically paid, and does not expect, for the foreseeable future, to pay a dividend on its common stock.

Determination of the Fair Value of Our Common Stock

Until July 19, 2021 when our IPO was effective, there was no public market for our common stock historically. Prior to this offering, our board of directors considered various objective and subjective factors to determine the fair value of our common stock as of each grant date, which may be as a date later than the most recent third-party valuation date, including:

results of third-party valuations performed in accordance with the guidance outlined in the American Institute of Certified Public Accountants’ Accounting Practice Aid entitled, Valuation of Privately-Held-Company Equity Securities Issued as Compensation;
the prices at which we sold shares of redeemable preferred stock and the superior rights and preferences of the redeemable preferred stock relative to our common stock at the time of each grant;
the progress of our research and development programs, including the status of preclinical and planned clinical trials for our product candidates;
our stage of development and commercialization and our business strategy;
external market conditions affecting the biotechnology industry, and trends within the biotechnology industry;
our financial position, including cash on hand, and our historical and forecasted performance and operating results;
the lack of an active public market for our common stock and our redeemable preferred stock;
the likelihood of achieving a liquidity event, such as an IPO, or a sale of our company considering prevailing market conditions; and
the analysis of IPOs and the market performance of similar companies in the biopharmaceutical industry.

98

 


 

For financial reporting purposes, it is our policy to perform a contemporaneous valuation when a material number of stock awards or options are granted. As a private company, we relied primarily on the evidence of third-party financings to support valuation of common stock. The assumptions underlying these valuations represent management’s best estimates, which involve inherent uncertainties and the application of management judgment. As a result, if factors or expected outcomes change, and we use significantly different assumptions or estimates, our stock-based compensation expense could be materially different.

Now that we have completed our IPO, our board of directors determines the fair value of each share of underlying common stock based on its closing price as reported on the date of grant according to the quoted market price on the primary stock exchange on which our common stock is traded.

Income Taxes

We recognize deferred income taxes for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis and operating loss and tax credit carryforwards. In evaluating our valuation allowance, we consider all available positive and negative evidence, including scheduled reversals of deferred tax liabilities, projected future taxable income, tax planning strategies, and recent financial performance. Due to our lack of earnings history and uncertainties surrounding our ability to generate future taxable income, the net deferred tax assets have been fully offset by a valuation allowance.

As of December 31, 2020 and 2021, we had available federal net operating loss (“NOL”) carryforwards of $14.8 million and $26.1 million, respectively. We also had available state NOLs carryforwards of approximately $15.2 million and $26.8 million, as of December 31, 2020 and 2021, respectively. The federal and state NOLs will carryforward indefinitely. Federal NOLs are available to offset up to 100% of taxable income for tax years before 2021, and state NOLs are available to offset 80% of taxable income for tax years starting after 2020.

Under Sections 382 and 383 of the Code, substantial changes in our ownership may limit the amount of NOL and research and development credit carryforwards that could be used annually in the future to offset taxable income. The tax benefits related to future utilization of federal and state NOL carryforwards, credit carryforwards, and other deferred tax assets may be limited or lost if cumulative changes in ownership exceeds 50% within any three-year period. We have not completed a Section 382/383 analysis under the Code regarding the limitation of NOL and credit carryforwards. If a change in ownership were to have occurred, the annual limitation may result in the expiration of NOL carryforwards and credits before utilization.

We record unrecognized tax benefits as liabilities or reduce the underlying tax attribute, as applicable, and adjust them when our judgment changes as a result of the evaluation of new information not previously available. Because of the complexity of some of these uncertainties, the ultimate resolution may result in a payment that is materially different from our current estimate of the unrecognized tax benefit liabilities. These differences will be reflected as increases or decreases to income tax expense in the period in which new information is available.

Recent Accounting Pronouncements

See Note 1 to our audited annual financial statements appearing elsewhere in this Annual Report on Form 10-K for more information about recent accounting pronouncements.

 

99

 


 

Emerging Growth Company and Smaller Reporting Status

As an emerging growth company, or EGC, under the JOBS Act, we may delay the adoption of certain accounting standards until such time as those standards apply to private companies. Other exemptions and reduced reporting requirements under the JOBS Act for EGCs include presentation of only two years of audited financial statements in a registration statement for an initial public offering, or IPO, an exemption from the requirement to provide an auditor’s report on internal controls over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act of 2002, an exemption from any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation, and less extensive disclosure about our executive compensation arrangements.

We may remain classified as an EGC until the end of the fiscal year until December 31, 2026, although if the market value of our common stock that is held by non-affiliates exceeds $700 million as of any June 30 before that time or if we have annual gross revenues of $1.07 billion or more in any fiscal year, we would cease to be an emerging growth company as of December 31 of the applicable year. We also would cease to be an EGC if we issue more than $1 billion of non-convertible debt over a three-year period.

We are also a “smaller reporting company,” as defined in Rule 12b-2 under the Exchange Act. Similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations, such as an ability to provide simplified executive compensation information and only two years of audited financial statements in an annual report on Form 10-K, with correspondingly reduced “Management’s Discussion and Analysis of Financial Condition and Results of Operations” disclosure.

 

Item 7A Quantitative and Qualitative Disclosures About Market Risk.

We are a smaller reporting company, as defined by Rule 12b-2 under the Exchange Act and are not required to provide the information under this item.

100

 


 

Item 8 Financial Statements and Supplementary Data.

HCW Biologics Inc.

Index to Financial Statements

 

Years ended December 31, 2020 and 2021

 

Audited Financial Statements

 

Page

Report of Independent Registered Public Accounting Firm (PCAOB ID Number 248)

 

102

Balance Sheets

 

103

Statements of Operations

 

104

Statement of Changes in Redeemable Preferred Stock and Stockholders’ (Deficit) Equity

 

105

Statements of Cash Flows

 

106

 

101


 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

Board of Directors and Shareholders

HCW Biologics Inc.

 

Opinion on the financial statements

 

We have audited the accompanying balance sheets of HCW Biologics Inc. (the “Company”) as of December 31, 2021 and 2020, and the related statements of operations, changes in redeemable preferred stock and stockholders’ (deficit) equity, and cash flows for the years then ended, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2021 and 2020, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2021, in conformity with accounting principles generally accepted in the United States of America.

 

Basis for opinion

 

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

 

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

 

/s/ GRANT THORNTON LLP

 

We have served as the Company’s auditor since 2019.

 

Miami, FL

March 29, 2022

 

 

 

 

 

 

 

102


 

HCW Biologics Inc.

Balance Sheets

 

 

 

December 31,

 

 

 

2020

 

 

2021

 

ASSETS

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

Cash and cash equivalents

 

$

8,455,834

 

 

$

11,730,677

 

Short-term investments

 

 

 

 

 

24,983,520

 

Accounts receivable, net

 

 

2,500,000

 

 

 

133,000

 

Prepaid expenses

 

 

538,306

 

 

 

2,196,557

 

Other current assets

 

 

654,528

 

 

 

1,436,617

 

Total current assets

 

 

12,148,668

 

 

 

40,480,371

 

Investments

 

 

1,599,750

 

 

 

11,522,050

 

Property and equipment, net

 

 

1,615,426

 

 

 

1,119,090

 

Other assets

 

 

34,242

 

 

 

393,318

 

Total assets

 

$

15,398,086

 

 

$

53,514,829

 

LIABILITIES, REDEEMABLE PREFERRED STOCK AND STOCKHOLDERS’
   (DEFICIT) EQUITY

 

 

 

 

 

 

Liabilities

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

Accounts payable

 

$

155,343

 

 

$

223,664

 

Accrued liabilities and other current liabilities

 

 

845,741

 

 

 

2,097,925

 

Total current liabilities

 

 

1,001,084

 

 

 

2,321,589

 

Commitments and contingencies (Note 14)

 

 

 

 

 

 

Redeemable preferred stock:

 

 

 

 

 

 

Series A, $0.0001 par value; 14,738,948 shares authorized and 6,316,691
   shares issued at December 31, 2020;
nil shares authorized or issued at
   December 31, 2021

 

 

6,140,792

 

 

 

 

Series B, $0.0001 par value; 28,029,449 shares authorized and 12,012,617
   shares issued at December 31, 2020;
nil shares authorized or issued at
   December 31, 2021

 

 

13,680,306

 

 

 

 

Series C, $0.0001 par value; 18,181,818 shares authorized and 5,439,112
   shares issued at December 31, 2020;
nil shares authorized or issued at
   December 31, 2021

 

 

11,294,301

 

 

 

 

Total redeemable preferred stock

 

 

31,115,399

 

 

 

 

Stockholders’ (deficit) equity:

 

 

 

 

 

 

Common stock:

 

 

 

 

 

 

Class B convertible, $0.0001 par value; 10,000,000 shares authorized and
   
4,285,714 shares issued at December 31, 2020; nil shares authorized or issued at
  December 31, 2021

 

 

429

 

 

 

 

Common, $0.0001 par value; 74,950,215 shares authorized and 507,680
   shares issued at December 31, 2020;
250,000,000 shares authorized
   and
35,768,264 shares issued at December 31, 2021

 

 

51

 

 

 

3,577

 

Additional paid-in capital

 

 

 

 

 

81,827,006

 

Accumulated deficit

 

 

(16,718,877

)

 

 

(30,637,343

)

Total stockholders’ (deficit) equity

 

 

(16,718,397

)

 

 

51,193,240

 

Total liabilities, redeemable preferred stock and stockholders’ (deficit) equity

 

$

15,398,086

 

 

$

53,514,829

 

 

The accompanying notes are an integral part of these financial statements.

 

103


 

HCW Biologics Inc.

Statements of Operations

 

 

 

Years Ended
December 31,

 

 

 

2020

 

 

2021

 

Revenues:

 

 

 

 

 

 

 Revenues

 

$

4,099,750

 

 

$

 

Total revenues

 

 

4,099,750

 

 

 

 

 

 

 

 

 

 

 

Operating expenses:

 

 

 

 

 

 

Research and development

 

 

7,255,227

 

 

 

8,173,624

 

General and administrative

 

 

2,669,048

 

 

 

5,194,210

 

Total operating expenses

 

 

9,924,275

 

 

 

13,367,834

 

Loss from operations

 

 

(5,824,525

)

 

 

(13,367,834

)

Interest and other income, net

 

 

22,324

 

 

 

505,366

 

Net loss

 

$

(5,802,201

)

 

$

(12,862,468

)

Less: cumulative preferred dividends earned in the period, net of forfeitures

 

 

(1,271,675

)

 

 

 

Net loss available for distribution to common stockholders

 

$

(7,073,876

)

 

$

(12,862,468

)

Net loss per share, basic and diluted

 

$

(1.49

)

 

$

(0.69

)

Weighted average shares outstanding, basic and diluted

 

 

4,739,285

 

 

 

18,770,935

 

 

The accompanying notes are an integral part of these financial statements.

104


 

HCW Biologics Inc.

Statements of Changes in Redeemable Preferred Stock and Stockholders’ (Deficit) Equity

 

 

Redeemable Preferred Stock

 

 

 

Stockholders’ Deficit

 

 

Series A

 

Series B

 

Series C

 

 

 

Common Stock

 

Additional
Paid-In

 

Accumulated

 

Total
Stockholders’

 

 

Shares

 

Amount

 

Shares

 

Amount

 

Shares

 

Amount

 

 

 

Shares

 

Amount

 

Capital

 

Deficit

 

(Deficit) Equity

 

Balance, December 31, 2019

 

6,316,691

 

$

5,792,302

 

 

12,012,617

 

$

12,883,859

 

 

 

$

 

 

 

 

4,717,542

 

$

472

 

$

 

$

(9,676,766

)

$

(9,676,294

)

Issuance of Class A
   Common Stock upon
   exercise of stock
   options

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

75,851

 

 

8

 

 

9,895

 

 

 

 

9,903

 

Issuance of Series C
   Redeemable Preferred
   Stock, net of issuance
   costs

 

 

 

 

 

 

 

 

 

5,439,112

 

 

11,144,520

 

 

 

 

 

 

 

 

 

 

 

 

 

Stock-based compensation

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

21,871

 

 

 

 

21,871

 

6% cumulative dividends
   on redeemable
   preferred stock

 

 

 

348,490

 

 

 

 

776,804

 

 

 

 

146,381

 

 

 

 

 

 

 

 

(31,766

)

 

(1,239,910

)

 

(1,271,676

)

Accretion of issuance costs

 

 

 

 

 

 

 

19,643

 

 

 

 

3,400

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(5,802,201

)

 

(5,802,201

)

Balance, December 31, 2020

 

6,316,691

 

$

6,140,792

 

 

12,012,617

 

$

13,680,306

 

 

5,439,112

 

$

11,294,301

 

 

 

 

4,793,393

 

$

480

 

$

 

$

(16,718,877

)

$

(16,718,397

)

Issuance of Class A
   Common Stock upon
   exercise of stock
   options

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

206,455

 

 

20

 

 

29,517

 

 

 

 

29,537

 

6% cumulative dividends
   on redeemable
   preferred stock

 

 

 

193,050

 

 

 

 

430,319

 

 

 

 

336,651

 

 

 

 

 

 

 

 

(33,053

)

 

(926,966

)

 

(960,019

)

Accretion of issuance costs

 

 

 

 

 

 

 

7,858

 

 

 

 

20,398

 

 

 

 

 

 

 

 

 

 

 

 

 

Issuance of common
    stock upon initial
    public offering, net of
    issuance cost

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

7,000,000

 

 

700

 

 

49,239,247

 

 

 

 

49,239,947

 

Conversion of Series A
    Redeemable Preferred
    Stock, with forfeited
    cumulative dividends

 

(6,316,691

)

 

(6,333,842

)

 

 

 

 

 

 

 

 

 

 

 

6,316,691

 

 

632

 

 

6,353,474

 

 

(20,265

)

 

6,333,841

 

Conversion of Series B
    Redeemable Preferred
    Stock, with forfeited
    cumulative dividends

 

 

 

 

 

(12,012,617

)

 

(14,118,483

)

 

 

 

 

 

 

 

12,012,613

 

 

1,201

 

 

14,170,312

 

 

(53,030

)

 

14,118,483

 

Conversion of Series C
    Redeemable Preferred
    Stock, with forfeited
    cumulative dividends

 

 

 

 

 

 

 

 

 

(5,439,112

)

 

(11,651,350

)

 

 

 

5,439,112

 

 

544

 

 

11,706,534

 

 

(55,737

)

 

11,651,341

 

Stock-based compensation

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

360,975

 

 

 

 

360,975

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(12,862,468

)

 

(12,862,468

)

Balance, December 31, 2021

 

 

$

 

 

 

$

 

 

 

$

 

 

 

 

35,768,264

 

$

3,577

 

$

81,827,006

 

$

(30,637,343

)

$

51,193,240

 

 

The accompanying notes are an integral part of these financial statements.

105


 

HCW Biologics Inc.

Statements of Cash Flows

 

 

 

Years Ended December 31,

 

 

 

2020

 

 

2021

 

Cash flows from operating activities:

 

 

 

 

 

 

Net loss

 

$

(5,802,201

)

 

$

(12,862,468

)

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

 

 

 

Depreciation and amortization

 

 

572,868

 

 

 

543,598

 

Stock-based compensation

 

 

21,875

 

 

 

360,975

 

Gain on extinguishment of debt

 

 

 

 

 

(567,311

)

Unrealized gain (loss) on investments, net

 

 

 

 

 

65,832

 

Accretion of issuance costs

 

 

23,043

 

 

 

28,256

 

Changes in operating assets and liabilities:

 

 

 

 

 

 

Accounts receivable

 

 

(2,500,000

)

 

 

2,367,000

 

Prepaid expenses and other assets

 

 

(2,118,264

)

 

 

(2,799,415

)

Accounts payable and other liabilities

 

 

(628,647

)

 

 

1,887,816

 

Net cash used in operating activities

 

 

(10,431,326

)

 

 

(10,975,717

)

Cash flows from investing activities:

 

 

 

 

 

 

Purchases of property and equipment

 

 

(186,682

)

 

 

(47,263

)

Purchases of short-term investments

 

 

 

 

 

(24,987,277

)

Purchases of long-term investments

 

 

 

 

 

(9,984,375

)

Net cash used in investing activities

 

 

(186,682

)

 

 

(35,018,915

)

Cash flows from financing activities:

 

 

 

 

 

 

Proceeds from PPP loan

 

 

563,590

 

 

 

 

Proceeds from the sale of Series C Preferred Stock

 

 

11,144,520

 

 

 

 

Proceeds from initial public offering

 

 

 

 

 

56,000,000

 

Issuance costs of initial public offering

 

 

 

 

 

(6,760,053

)

Proceeds from issuance of common stock

 

 

9,898

 

 

 

29,528

 

Net cash provided by financing activities

 

 

11,718,008

 

 

 

49,269,475

 

Net changes in cash and cash equivalents

 

 

1,100,000

 

 

 

3,274,843

 

Cash and cash equivalents at the beginning of the period

 

 

7,355,834

 

 

 

8,455,834

 

Cash and cash equivalents at the end of the period

 

$

8,455,834

 

 

$

11,730,677

 

Non-cash operating, investing and financing activities:

 

 

 

 

 

 

In-kind payment for license fee

 

$

1,599,750

 

 

$

 

Cumulative dividends earned, accrued and forfeited in the reporting period

 

$

1,271,676

 

 

$

 

Forfeiture of cumulative dividends, upon conversion of Preferred Stock

 

$

 

 

$

2,822,081

 

PPP loan forgiveness

 

$

 

 

$

567,311

 

 

The accompanying notes are an integral part of these financial statements.

 

106


 

HCW Biologics Inc.

Notes to the Financial Statements

December 31, 2020 and 2021

1. Organization and Summary of Significant Accounting Policies

Organization

HCW Biologics Inc. (the “Company”) is a biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The Company believes age-related low-grade chronic inflammation, or “inflammaging,” is a significant contributing factor to several chronic diseases and conditions, such as cancer, cardiovascular disease, diabetes, neurodegenerative diseases, and autoimmune diseases. The Company is located in Miramar, Florida and was incorporated in the state of Delaware in April 2018.

Reverse Stock Split

In June 2021, the Company’s board of directors and stockholders approved an amendment to the Company’s certificate of incorporation to effect a 3-for-7 reverse stock split for all issued and outstanding common stock, redeemable preferred stock, and stock options, that was effective on June 25, 2021 (the “Reverse Stock Split”). The number of authorized shares and the par values of the common stock and redeemable preferred stock were not adjusted as a result of the Reverse Stock Split. The accompanying financial statements and notes to the financial statements give retroactive effect to the Reverse Stock Split for all periods presented.

Liquidity

On December 24, 2020, the Company entered into the Exclusive Worldwide License Agreement with Wugen Inc. (“Wugen License”). As a result of this transaction, as of December 31, 2020 and 2021, the Company holds a minority interest in Wugen Inc. (“Wugen”) carried at $1.6 million, the fair value on the effective date of the Wugen License. The underlying shares of common stock are not currently traded on any public market and thus have limited marketability. These shares were subject to an anti-dilution provision based on the terms of a subsequent financing. During the year ended December 31, 2021, the Company received additional shares in Wugen under the terms of the anti-dilution provision for no additional consideration. The Company deemed the additional shares to be a similar instrument to those shares already held. During the year ended December 31, 2021, the Company received cash payments of $2.5 million for amounts due under the terms of the Wugen License.

As of December 31, 2021, the Company had not generated any revenue from sales of its immunotherapeutic products. In the course of its development activities, the Company has sustained operating losses and expects to continue to incur operating losses for the foreseeable future. Since inception, substantially all the Company’s activities have consisted of research, development, establishing large-scale cGMP production for clinical trials, and raising capital.

On July 19, 2021, the Company’s registration statement on Form S-1 for its initial public offering (“IPO”) was declared effective by the Securities and Exchange Commission (the “SEC”). On July 22, 2021, the Company closed its IPO with the sale of 7,000,000 shares of common stock, at a public offering price of $8.00 per share, resulting in net proceeds of approximately $49.2 million, after deducting underwriting discounts and commissions and estimated offering expenses paid by the Company. The IPO met the provisions for mandatory conversion of all shares of redeemable preferred stock according to the designations for these securities. As a result of the conversion, the Company issued 23,768,416 shares of common stock to the former holders of redeemable preferred stock. In addition, as a result of conditions for mandatory conversion, the Company was relieved of its obligation to pay $2.8 million in cumulative dividends that were accrued and unpaid on the conversion date.

As of December 31, 2021, the Company had cash and cash equivalents of $11.7 million, short-term investments of $25.0 million held in U.S. government-backed securities, and long-term investments of $9.9 million held in U.S. government-backed securities. Since inception to December 31, 2021, the Company incurred cumulative net losses of $27.9 million. Management expects to incur additional losses in the future to conduct product research and development and recognizes the need to raise additional capital to fully implement its business plan. The Company intends to raise capital through the issuance of additional equity financing, sale of investment, and/or third-party collaboration funding. However, if such financing is not available at adequate levels, the Company will need to reevaluate its operating plan and may be required to delay the development of some of its products. The Company expects its cash and cash equivalents and current and long-term investments in government-backed securities as of December 31, 2021 will be sufficient to fund operating expenses and capital expenditure requirements for a period of at least one year from the issuance date of the financial statements.

107


 

Summary of Significant Accounting Policies

Basis of Presentation

The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”).

Segment Reporting

The Company has one operating segment. The Company’s chief operating decision maker, its Chief Executive Officer, reviews financial information on an aggregate basis for allocating capital and evaluating performance.

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts in the financial statements and accompanying notes. Management must apply significant judgment in this process. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ from estimates.

Cash and Cash Equivalents

Cash and cash equivalents consist of demand deposits at financial institutions, money market funds, and highly liquid investments with original maturities of three months or less.

Fair Value Measurements

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 820, Fair Value Measurement (“Topic 820”), establishes a fair value hierarchy for those instruments measured at fair value that distinguishes between fair value measurements based on market data (observable inputs) and those based on the Company’s own assumptions (unobservable inputs). This hierarchy maximizes the use of observable inputs and minimizes the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows:

Level 1: Observable inputs such as quoted prices in active markets;

Level 2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and

Level 3: Unobservable inputs in which there is little or no market data, which require a reporting entity to develop its own assumptions.

Fair value measurements are classified based on the lowest level of input that is significant to the measurement. The Company’s assessment of the significance of a particular input to the fair value measurement requires judgment, which may affect the valuation of the assets and liabilities and their placement within the fair value hierarchy levels. The determination of the fair values, as disclosed in Note 3, takes into account the market for the Company’s financial assets and liabilities, the associated credit risk, and other factors as required. The Company considers active markets as those in which transactions for the assets or liabilities occur in sufficient frequency and volume to provide pricing information on an ongoing basis.

Concentration of Credit Risk and Other Risks and Uncertainties

Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash, cash equivalents, accounts receivable, and investments. The Company’s cash and cash equivalents are deposited in accounts with financial institutions that management believes are of high credit quality. Such deposits may, at times, exceed federally insured limits. The Company has not experienced any losses on its deposits of cash and cash equivalents.

108


 

Currently all of the Company's revenues are derived from the Wugen License. For the year ended December 31, 2020, the Company recognized revenues of $4.1 million, $1.6 million of which was consideration received in the form of shares of Wugen common stock. These shares have limited marketability, and there was no public market on which to trade these shares as of December 31, 2021. As of December 31, 2021, the Company received cash payments of $1.8 million for the sale of research and clinical-grade material, which are currently recognized as deferred revenue on the accompanying balance sheet since the criteria for revenue recognition have not been met.

The Company is highly dependent on a third-party manufacturer to supply drug products for its research and development activities of its programs, including clinical and non-clinical studies. These programs could be adversely affected by a significant interruption in the supply of such drug products. The Company has no off-balance sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts or other hedging arrangements.

Property and Equipment, Net

Property and equipment is stated at cost less accumulated depreciation. Depreciation expense is calculated using the straight-line method over the estimated useful lives of the assets, which range from 3 to 7 years. Leasehold improvements are amortized on a straight-line method over the shorter of the useful life of the leasehold improvement or the term of the lease. Upon retirement or sale of the assets, the cost and related accumulated depreciation and amortization are removed from the accompanying balance sheets and the resulting gain or loss is recorded to the statements of operations. Repairs and maintenance are expensed as incurred.

Impairment of Long-Lived Assets

Long-lived assets are reviewed for indications of possible impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. Recoverability is measured by comparison of the carrying amounts to the future undiscounted cash flows attributable to these assets. An impairment loss is recognized to the extent an asset group is not recoverable, and the carrying amount exceeds the projected discounted future cash flows arising from these assets. Impairment losses, if any, are recognized in earnings. There were no impairment losses for any of the periods presented.

Redeemable Preferred Stock

The Company applied the relevant accounting standards to distinguish liabilities from equity when we assessed the classification and measurement of preferred stock. Preferred Stock subject to mandatory redemptions was considered a liability and measured at fair value. Conditionally redeemable preferred stock issued by the Company was considered mezzanine or temporary equity and presented outside of the equity section of the accompanying balance sheet as of December 31, 2020.

Cumulative Dividends on Preferred Stock

The Company’s Preferred Stock earned a 6% cumulative dividend that compounded annually, whether or not declared by the Board of Directors. The Company considered cumulative dividends a legal obligation that should be recognized and accrued until such time as the dividends were declared and paid or liquidation occurred.

If Preferred Stock was classified as other than equity, this obligation was presented within Redeemable preferred stock. If Preferred Stock was included within equity, this obligation was treated as a long-term liability and presented within other liabilities in the accompanying balance sheet. As of December 31, 2020, all of the Company’s Preferred Stock was classified as other than equity, or mezzanine equity. Holders of Preferred Stock earned cumulative dividends beginning on June 7, 2019, with the original issuance of Series B Preferred Stock. During the year ended December 31, 2020, Series A Preferred Stock earned $348,490 in cumulative dividends; Series B Preferred Stock earned $776,804 in cumulative dividends; and Series C Preferred Stock earned $146,381 in cumulative dividends. Upon the IPO, all of the Company’s preferred stock converted to common stock. At that time, Series A Preferred Stock forfeited $753,307 of cumulative dividends; Series B Preferred Stock forfeited $1,550,403 of cumulative dividends; and Series C Preferred Stock forfeited $518,371 of cumulative dividends. No dividends were declared as of the conversion date.

109


 

Collaborative Arrangements

When the Company enters into collaboration arrangements, it assesses whether the arrangements fall within the scope of FASB issued ASC 808, Collaborative Arrangements, based on whether the arrangements involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. If the payments from the collaboration partner to the Company represent consideration from a customer, such as license fees and contract research and development activities, the Company accounts for those payments within the scope of FASB issued ASC 606, Revenue from Contracts with Customers (“Topic 606”). However, if the Company concludes that the payments are not from a customer, for certain activities and associated payments, such as for certain collaborative research, development, manufacturing, and commercial activities, these payments are presented as a reduction of research and development expense or general and administrative expense, based on where the Company presents the underlying expense.

Revenue Recognition

The Company recognizes revenue when its customer or collaborator obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services.

To determine revenue recognition for arrangements that are within the scope of Topic 606, it performs the following five steps:

i.
identify the contract(s) with a customer;
ii.
identify the performance obligations in the contract;
iii.
determine the transaction price;
iv.
allocate the transaction price to the performance obligations within the contract; and
v.
recognize revenue when (or as) the entity satisfies a performance obligation.

 

At contract inception, once the contract is determined to be within the scope of Topic 606 and it is probable of collection, the Company assesses the goods or services promised within the contract to determine whether each promised good or service is a performance obligation. The promised goods or services in the Company’s arrangements may consist of a license, or options to license, the Company’s intellectual property and research, development, and manufacturing services. The Company may provide options to additional items in such arrangements, which are accounted for as separate contracts when the customer elects to exercise such options, unless the option provides a material right to the customer. Performance obligations are promises in a contract to transfer a distinct good or service to the customer that (i) the customer can benefit from on its own or together with other readily available resources, and (ii) is separately identifiable from other promises in the contract. Goods or services that are not individually distinct performance obligations are combined with other promised goods or services until such combined group of promises meet the requirements of a performance obligation.

The Company determines the transaction price based on the amount of consideration the Company expects to receive for transferring the promised goods or services in the contract. Consideration may be fixed, variable, or a combination of both. At contract inception for arrangements that include variable consideration, the Company estimates the probability and extent of consideration it expects to receive under the contract utilizing either the most likely amount method or expected amount method, whichever best estimates the amount expected to be received. The Company then considers any constraints on the variable consideration and includes in the transaction price variable consideration to the extent it is deemed probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved.

The Company then allocates the transaction price to each performance obligation based on the relative standalone selling price and recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) control is transferred to the customer and the performance obligation is satisfied. For performance obligations which consist of licenses and other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.

110


 

The Company records amounts as accounts receivable when the right to consideration is deemed unconditional. When consideration is received, or such consideration is unconditionally due, from a customer prior to transferring goods or services to the customer under the terms of a contract, a contract liability is recorded as deferred revenue.

Deferred Revenue

Deferred revenue represents amounts billed, or in certain cases, yet to be billed to the Company’s customer for which the related revenues have not been recognized because one or more of the revenue recognition criteria have not been met. The current portion of deferred revenue represents the amount to be recognized within one year from the balance sheet date based on the estimated performance period of the underlying performance obligations. As December 31, 2021, current deferred revenue includes amounts of $1.8 million allocated to the development supply agreement performance obligation under the Wugen License that is included within Accrued liabilities and other current liabilities.

Investments

The Company holds a minority interest in Wugen. The underlying shares of common stock are not traded on any public market and thus have limited marketability. The Company does not have significant influence over the operating and financial policies of Wugen. As a result, the Company has accounted for this investment using the measurement alternative whereby the investment is recorded at cost less impairment, adjusted for observable price changes in orderly transactions for an identical or similar investment of the same investee. No impairment was recognized during the years ended December 31, 2020 and 2021.

The Company invests net proceeds of its IPO in bills and notes issued by the U.S. Treasury which are classified as trading securities. As of December 31, 2021, the Company holds, $25.0 million in U.S. Treasury bills included in Short-term investments and $9.9 million in U.S. Treasury notes included in Investments in the accompanying balance sheet.

Research and Development Expenses

Research and development costs are expensed as incurred and include salaries, benefits, and other operating costs such as outside services, supplies and allocated overhead expenses. The Company may perform research and development for its own proprietary drug candidates and technology development or for certain third parties under collaborative arrangements. For its proprietary drug candidates and its internal technology development programs, the Company invests its own funds without reimbursement from a third party. Where the Company performs research and development activities under a clinical joint development collaboration, it records the partner’s share of collaboration expenses as a reduction to research and development expense when reimbursement amounts are due under the agreement.

The Company records an accrued expense for the estimated costs of its contract manufacturing activities performed by third parties. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to vendors. Payments under the contracts include upfront payments and milestone payments, which depend on factors such as the achievement of the completion of certain stages of the manufacturing process. For purposes of recognizing expense, the Company assesses whether the production process is sufficiently defined to be considered the delivery of a good, as evidenced by predictive or contractually required yields in the production process, or the delivery of a service, where processes and yields are developing and less certain. If the Company considers the process to be the delivery of a good, the Company recognizes the expense when the drug product is delivered, or otherwise bears risk of loss. If the Company considers the process to be the delivery of a service, the expense is recognized based on its best estimates of the contract manufacturer’s progress towards completion of the stages in the contracts. The Company recognizes and amortizes upfront payments and accrues for liabilities based on the specific terms of each arrangement. Arrangements may provide upfront payments for certain stages of the arrangement and milestone payments for the completion of certain stages, and, accordingly, may result in advance payments for services that have not been completed or goods not delivered and liabilities for stages where the contract manufacturer is entitled to a milestone payment.

Advance payments for goods or services that will be used or rendered for future research and development activities are capitalized as prepaid expenses and recognized as expense as the related goods are delivered or the related services are performed. The Company bases its estimates on the best information available at the time. However, additional information may become available to the Company which may allow it to make a more accurate estimate in future periods. In this event, the Company may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain. Such increases or decreases in cost are generally considered to be changes in estimates and will be reflected in research and development expenses in the period identified.

111


 

Patent Costs

Costs related to filing and pursuing patent applications are recorded as general and administrative expenses in the accompanying statements of operations, and expensed as incurred since recoverability of such expenditures is uncertain.

Stock-based Compensation

The Company measures its stock-based awards granted to employees and directors based on the estimated fair value of the option on the date of grant (grant date fair value) and recognizes compensation expense over the vesting period. Compensation expense is recorded as either research and development or general and administrative expenses in the accompanying statements of operations based on the function to which the related services are provided. Forfeitures are accounted for as they occur. The Company has granted options with service-based and performance-based vesting conditions.

The Company uses the Black-Scholes option pricing model for the respective grant to determine the grant date fair value. The Black-Scholes option pricing model requires the input of highly subjective assumptions. These variables include, but are not limited to, its stock price volatility over the term of the awards and actual and projected employee stock option exercise behaviors. Management will continue to assess the assumptions and methodologies used to calculate the estimated grant date fair value of stock-based compensation. Circumstances may change and additional data may become available over time, which could result in changes to these assumptions and methodologies and materially impact the Company’s grant date fair value determination.

For stock option grants with service-based vesting, stock-based compensation expense represents the portion of the grant date fair value of employee stock option grants recognized over the requisite service period of the awards on a straight-line basis, net of estimated forfeitures. For options that vest upon the achievement of performance milestones, the Company estimates fair value at the date of grant and compensation expense is recognized using the accelerated attribution method when it is determined that the performance criteria is probable of being met.

Deferred Offering Costs

The Company defers offering costs consisting of legal, accounting and other fees and costs directly attributable to its IPO. The deferred offering costs will be offset against the proceeds received upon the completion of the IPO. Deferred offering costs will be recorded under other non-current assets on the accompanying balance sheets. In the event the IPO is terminated, all of the deferred offering costs will be expensed within the Company’s statements of operations. As of December 31, 2020, there were no deferred offering costs recorded on the accompanying balance sheets. As of December 31, 2021, deferred offering costs related to underwriting discounts and commissions and offering expenses of $6.8 million were offset against IPO proceeds upon the consummation of the IPO.

Income Taxes

The Company accounts for income taxes using an asset and liability approach in accordance with applicable guidance prescribed by FASB issued ASC 740, Income Taxes (“Topic 740”). Topic 740 requires that the deferred tax consequences of temporary differences between the amounts recorded in the financial statements and the amounts included in the federal and state income tax returns to be recognized in the balance sheet.

The Company makes judgments regarding the realizability of its deferred tax assets. The balance sheet carrying value of its deferred tax assets is based on whether the Company believes it is more likely than not that the Company will generate sufficient future taxable income to realize these deferred tax assets after consideration of all available evidence. The Company regularly reviews its deferred tax assets for recoverability considering historical profitability, projected future taxable income, the expected timing of the reversals of existing temporary differences and tax planning strategies. In assessing the need for a valuation allowance, the Company considers both positive and negative evidence related to the likelihood of realization of the deferred tax assets. The weight given to the positive and negative evidence is commensurate with the extent to which the evidence may be objectively verified. As such, it is generally difficult for positive evidence regarding projected future taxable income exclusive of reversing taxable temporary differences to outweigh objective negative evidence of recent financial reporting losses. Generally, cumulative loss in recent years is a significant piece of negative evidence that is difficult to overcome in determining that a valuation allowance is not needed.

112


 

The Company’s tax positions may be subject to income tax audits. The Company recognizes the tax benefit of an uncertain tax position only if it is more likely than not that the position is sustainable upon examination by the taxing authority, based on the technical merits. The tax benefit recognized is measured as the largest amount of benefit which is more likely than not to be realized upon settlement with the taxing authority. The Company recognizes interest accrued and penalties related to unrecognized tax benefits in its tax provision. The Company evaluates uncertain tax positions on a regular basis. The evaluations are based on a number of factors, including changes in facts and circumstances, changes in tax law, correspondence with tax authorities during the course of the audit, and effective settlement of audit issues. The provision for income taxes includes the effects of any accruals that the Company believes are appropriate, as well as the related net interest and penalties.

Tax Credit Receivable

The Company is eligible for research and development credits for its research and development activities, in accordance with Internal Revenue Code (“I.R.C.”) § 41(c). The credits are generally available to offset income tax liabilities. The Company has applied approximately $250,000 of research and development credits to offset its federal payroll tax expenses for both years ended December 31, 2020 and 2021, due to its small business status. As of December 31, 2020 and 2021, the current portion of outstanding payroll tax receivables is recorded in Other current assets in the accompanying balance sheets and the noncurrent portion is recorded in Other noncurrent assets.

Net Loss Per Share

Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period, without consideration of potential dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the sum of the weighted average number of common shares plus the potential dilutive effects of potential dilutive securities outstanding during the period. Potential dilutive securities are excluded from diluted earnings or loss per share if the effect of such inclusion is anti-dilutive. The Company’s potentially dilutive securities, which include convertible redeemable preferred stock and outstanding stock options under the 2019 Equity Incentive Plan (“2019 Plan”) and the 2021 Equity Incentive Plan (“2021 Plan”), have been excluded from the computation of diluted net loss per share as they would be anti-dilutive to the net loss per share. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company’s net loss position.

Recently Issued Accounting Pronouncements

In June 2016, FASB issued Accounting Standards Update (“ASU”) No. 2016-13, Financial Instruments—Credit Losses: Measurement of Credit Losses on Financial Instruments, as clarified in subsequent amendments to the initial guidance (collectively, “Topic 326”). Topic 326 requires measurement and recognition of expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecast. The Company adopted Topic 326 using a modified retrospective approach which requires a cumulative effect adjustment as of the beginning of the reporting period in which the guidance is adopted. Topic 326 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019, with early adoption permitted. The Company adopted Topic 326 effective January 1, 2020. The adoption did not have a material impact on our financial statements.

In February 2016, the FASB issued ASU No. 2016-02, Leases (“Topic 842”), which requires an entity to recognize assets and liabilities arising from a lease for both financing and operating leases. The ASU will also require new qualitative and quantitative disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. Topic 842 is effective for the Company in the fiscal years beginning after December 15, 2021, with early adoption permitted. The Company will adopt Topic 842 for the fiscal year ended December 31, 2022. The Company plans to use a practical expedient provided by FASB, and it will not recast comparative periods to reflect the impact of the new lease standard. Effective March 1, 2022, the Company entered into a non-cancelable operating lease for its current location with a two-year term. This is the only lease in scope of Topic 842. The Company expects accounting for the new lease under Topic 842 will materially affect the reported amount of total assets and total liabilities within the balance sheet, but it does not expect a material impact to the statement of operations.

113


 

2. Property and Equipment, Net

Property and equipment, net consists of the following:

 

 

 

At December 31,

 

 

 

2020

 

 

2021

 

Laboratory equipment

 

$

1,924,596

 

 

$

1,949,318

 

Office equipment

 

 

152,003

 

 

 

175,245

 

Furniture and fixtures

 

 

292,866

 

 

 

292,165

 

Leasehold improvements

 

 

349,976

 

 

 

349,976

 

 

 

$

2,719,441

 

 

$

2,766,704

 

Less: Accumulated depreciation and amortization

 

 

(1,104,015

)

 

 

(1,647,614

)

Property and equipment, net

 

$

1,615,426

 

 

$

1,119,090

 

 

Depreciation and amortization expense for the year ended December 31, 2020 was $572,867 of which $362,892 is included in research and development expenses. Depreciation and amortization expense for the year ended December 31, 2021 was $543,598, of which $353,388 is included in research and development expenses.

3. Fair Value of Financial Instruments

The carrying amount of the Company’s financial instruments, including cash and cash equivalents, accounts receivable, prepaid expenses and other current assets, U.S. government backed securities with maturity dates up to one year, accounts payable and accrued liabilities, approximate fair value due to their short-term maturities.

 

Money market funds included in cash and cash equivalents and U.S. government backed securities are measured at fair value based on quoted prices in active markets, which are considered Level 1 inputs. No transfers between levels occurred during the periods presented. The following table presents the Company’s assets which were measured at fair value at December 31, 2020 and 2021:

 

 

 

At December 31, 2020

 

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

 

Assets:

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

6,752,266

 

 

$

 

 

$

 

 

$

6,752,266

 

Investment in Wugen

 

 

 

 

 

 

 

 

1,599,750

 

 

 

 

Total

 

$

6,752,266

 

 

$

 

 

$

1,599,750

 

 

$

6,752,266

 

 

 

 

At December 31, 2021

 

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

 

Assets:

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

9,506,499

 

 

$

 

 

$

 

 

$

9,506,499

 

Treasury bills

 

 

24,983,520

 

 

 

 

 

 

 

 

 

24,983,520

 

Treasury notes

 

 

9,922,300

 

 

 

 

 

 

 

 

 

9,922,300

 

Total

 

$

44,412,319

 

 

$

 

 

$

 

 

$

44,412,319

 

 

4. Investments

As of December 31, 2020, Investments consisted of a balance of $1.6 million. In December 2020, the Company entered into the Wugen License for limited rights to develop, manufacture and commercialize cellular therapy products based on two of the Company’s fusion protein molecules. As part of the consideration received for the Wugen License, the Company received shares of Wugen common stock, which were recognized at $1.6 million, the fair value of the securities as of December 24, 2020, the effective date for the Wugen License. Initial recognition was at fair value based on level 3 inputs, since there was no public market on which to trade these shares at the time they were received. The fair value was determined based primarily on the pricing and terms of a third-party financing completed by Wugen in 2020. So long as there continues to be no public market for these securities, the Company will classify this asset as a cost method investment, recorded at cost less impairment adjusted for observable market changes.

114


 

As of December 31, 2021, Investments had a balance of $11.5 million in the accompanying balance sheet, consisting of $1.6 million for the investment in Wugen, which the Company continues to carry at cost since no public market exists for these securities, and no impairment adjusted was necessary. In addition, Investments include $9.9 million in U.S. Treasury notes as of December 31, 2021. These securities are classified as trading securities.

5. Related Party Transactions

As of December 31, 2020, related parties held capital stock in the Company. The Company's Founder and Chief Executive Officer, Hing C. Wong, PhD., held all Class B Common Stock and Series A Preferred Stock issued by the Company. In addition, Dr. Wong purchased shares of Series B Preferred Stock and Series C Preferred Stock on the same terms and conditions for third-party investors. All shares of Preferred Shares held by Dr. Wong earned cumulative dividends.

During the year ended December 31, 2021, all shares purchased by Dr. Wong prior to the IPO were converted to common stock, and the Company was relieved of its obligation to pay cumulative dividends on Preferred Shares that were accrued and unpaid as of the conversion date. Dr. Wong purchased additional shares of the Company's common stock in the IPO and in the open market post IPO, in compliance with SEC regulations and the Company's insider trading policies.

6. Accrued Liabilities and Other Current Liabilities

In May 2020, the Company received an SBA Paycheck Protection Loan (“PPP loan”) in the principal amount of $563,590. As of December 31, 2020, the Company had $845,741 of Accrued liabilities and other current liabilities, primarily consisting of the PPP loan of $567,311, including principal and accrued but unpaid interest, and accrued liabilities of $273,907.

As of December 31, 2021, the Company had a balance of $2.1 million in Accrued liabilities and other current liabilities, consisting of $1.8 million related to deferred revenue, $48,750 related to manufacturing materials, $51,000 related to legal fees, and $50,000 for other expenses. On January 8, 2021, the Company received full loan forgiveness of $567,311 for obligations related to the PPP loan. The Company accounted for the PPP loan as debt, and the loan forgiveness was accounted for as a debt extinguishment. The amount of loan and interest forgiven is recognized as a gain upon debt extinguishment and is reported within Interest and other income, net in the accompanying statement of operations for the year ended December 31, 2021.

7. License Agreement

On December 24, 2020, the Company entered into the Wugen License transferring rights to Wugen to develop, manufacture, and commercialize certain cellular therapy products based on two of the Company’s fusion protein molecules. The term of the agreement will expire on a product-by-product and country-by-country basis, upon the later of (i) ten (10) years from the first commercial sale of the product or (ii) the expiration of the last-to-expire valid patent claim of such product.

The Company retained regulatory T cell-based cellular therapy, injectable rights, and manufacturing rights, not granted to Wugen under the terms of the Wugen License. The Company and Wugen will enter into two supply agreements under industry-standard terms, under which the Company will provide cGMP and non-cGMP grade materials, including a development supply agreement and a commercial supply agreement.

According to the terms of the agreement, Wugen will fund all future clinical development and commercialization activities for cellular therapy treatments for any indications utilizing the licensed fusion protein molecules covered by the Wugen License. In January 2021, two Phase 2 clinical trials related to treatment for relapsed / refractory acute myeloid leukemia based on one of the licensed molecules were initiated by the School of Medicine at Washington University in St. Louis and supported by Wugen.

The Company concluded that Wugen is a customer and the Wugen License is a functional license under the provisions of Topic 606. The Company identified the following performance obligations at the inception of the agreement:

Provide Wugen with exclusive worldwide license rights for certain fusion proteins.
Sell vials of HCW9201 clinical grade product available immediately.
Transfer R&D know-how.
Supply of cGMP and non-cGMP grade materials for development.

115


 

Supply of cGMP grade materials for commercialization.

 

For the year ended December 31, 2020 the Company recognized $4.1 million for performance obligations satisfied in the period. This is the first time the Company has entered into an out-license arrangement and the first time the Company has established prices for its goods and services. Accordingly, the standalone selling price of the various performance obligations is uncertain, and the Company determined that an observable standalone selling price is not available for the identified performance obligations under the Wugen License. Where a standalone selling price is not directly observable, then the Company estimates the standalone selling price considering marketing conditions, entity-specific factors, and information about the customer that is reasonably available. The process for determining a standalone selling price involves significant judgment and includes consideration of multiple factors, including assumptions related to the market opportunity and the time needed to commercialize a product candidate pursuant to the relevant license, estimated direct expenses and other costs.

The Company first determined the standalone selling price of $2.5 million for the vials of HCW9201 and the R&D know-how. The price was determined based on the cost of developing the know-how and the costs incurred in producing the vials. The standalone selling price for the license was determined using the residual approach and was priced at $1.6 million.

As of December 31, 2020, the Company and Wugen had not finalized the development supply agreement. Therefore, there was no contract for purchase of materials during Wugen's development phase. The Company will defer recognition of revenues and costs for supply of materials during development until a contract is in place. The commercial supply agreement will be entered into in the future, pursuant to the terms of the Wugen License.

For the year ended December 31, 2021, the Company entered into a master services agreement with Wugen related to the development supply agreement to provide cGMP and non-cGMP grade licensed material based on industry-standard terms. However, as of December 31, 2021, the Company and Wugen have not finalized any statements of work under the master services agreement, thus no contract exists. Until such time that the Company enters statements of work for Wugen orders related to licensed material for clinical development, the Company will defer recognition of revenues.

The Wugen License includes milestone payments and royalties. The Company uses judgment to determine whether milestones or other variable consideration should be included in the transaction price. For revenue-based royalties, including milestone payments based on the level of sales, the Company will include royalties in the transaction price at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty is allocated has been satisfied (or partially satisfied). As part of management’s evaluation of the transaction price, the Company considers numerous factors, including whether the achievement of the milestones is outside of our control, contingent upon the efforts of others or subject to scientific risks of success. If the Company concludes it is probable that a significant revenue reversal would not occur, the associated milestone payment is included in the transaction price. Milestone payments that are not within our control, such as regulatory approvals, are generally not considered probable until those milestones are achieved. The Company reevaluates the transaction price, including estimated variable consideration included in the transaction price and all constrained amounts, in each reporting period and as uncertain events are resolved or other changes in circumstances occur.

8. Redeemable Preferred Stock

In a series of closings which took place in 2020, the Company completed the private placement of Series C Preferred Stock. The terms of the redeemable preferred stock provided for an adjustment to the conversion price upon the occurrence of certain transactions or events, such as stock splits, split-up, certain dividends, or distributions. Cumulative dividends accrued whether or not declared by the Board of Directors. Giving effect to the Reverse Stock Split, a total of 5,439,112 shares of Series C Preferred Stock were issued at $2.05 per share, for $11.2 million, net of offering costs. The Company’s Series C Preferred Stock was convertible into shares of Class A common stock and earned cumulative dividends at a rate of 6% per annum and compound annually until converted or redeemed.

On July 22, 2021, the Company closed on its IPO, and the requirements for mandatory conversion were met. All outstanding shares of Series A, Series B, and Series C Preferred Stock converted into an equal number of shares of common stock. As a result, the rights, preferences, and terms ascribed to these shares are no longer applicable. Cumulative dividends of $2.8 million accrued as of the conversion date were forfeited and such forfeiture was recognized through Additional paid-in capital.

At December 31, 2021, the Company has 10,000,000 shares of preferred stock authorized and no shares issued.

116


 

9. Net Loss Per Share

The following table summarizes the computation of the basic and diluted net loss per share:

 

 

 

Years Ended December 31,

 

 

 

2020

 

 

2021

 

Numerator:

 

 

 

 

 

 

Net loss

 

$

(5,802,201

)

 

$

(12,862,468

)

Less: cumulative preferred dividends earned in the
   period, net of forfeitures

 

 

(1,271,675

)

 

 

 

Net loss available for distribution to common stock
   holders

 

$

(7,073,876

)

 

$

(12,862,468

)

Denominator:

 

 

 

 

 

 

Weighted-average common shares outstanding

 

 

4,739,285

 

 

 

18,770,935

 

Net loss per share, basic and diluted

 

$

(1.49

)

 

$

(0.69

)

 

The following table summarizes the outstanding potentially dilutive securities that have been excluded in the calculation of diluted net loss per share because their inclusion would be anti-dilutive:

 

 

 

As of December 31,

 

 

 

2020

 

 

2021

 

Redeemable Preferred Stock

 

 

23,768,416

 

 

 

 

Common stock options

 

 

742,114

 

 

 

1,770,739

 

Potentially diluted securities

 

 

24,510,530

 

 

 

1,770,739

 

 

10. Stock-based Compensation

On June 21, 2021, the 2021 Plan was adopted by the Company’s board of directors and approved by the Company’s stockholders. As of the adoption date, the 2019 Plan was terminated. No terms were changed for grants previously awarded under the 2019 Plan, and the Company concluded a modification did not occur. Under the 2019 Plan, the Company primarily granted employees incentive stock options, which had a maximum term of ten years from the date of the grant. Generally, the incentive stock options granted under the 2019 Plan have a four year, service-based vesting period. All of the options granted under the 2019 Plan had an exercise price equal to the fair value of a share of common stock on the date of the grant, according to Company policy.

The 2021 Plan permits the grant of incentive stock options, nonstatutory stock options, stock appreciation rights, restricted stock, restricted stock units, and stock bonus awards. The 2021 Plan initially reserved 3,444,343 shares of Common Stock, including the transfer of remaining shares reserved under the 2019 Plan. In addition, the number of shares reserved for issuance under the 2021 Plan will increase automatically on the first day of each fiscal year beginning with the 2022 fiscal year.

Under the 2021 Plan, the term of each stock option must be stated in the stock award agreement. In the case of an incentive stock option, the term will be ten years from the date of grant, or such shorter term as may be provided in the stock award agreement. Moreover, in the case of an incentive stock option granted to a participant who owns stock representing more than 10% of the total combined voting power of all classes of our stock or the stock of any of our affiliates, the term of the incentive stock option will be five years from the date of grant or such shorter term as may be provided in the stock award agreement. Under the 2021 Plan, the Company continues to have a policy to grant options with an exercise price equal to the fair value of a share of common stock, as determined by the closing price on NASDAQ on the grant date.

117


 

The following summarizes the Company’s stock option activity for the year ended December 31, 2021:

 

 

Shares

 

 

Weighted

 

Weighted Average

 

 

 

 

Issuable

 

 

Average

 

Remaining

 

Aggregate

 

 

under

 

 

Exercise

 

Contract

 

Intrinsic

 

 

Options

 

 

Price

 

Term

 

Value

 

Outstanding at December 31, 2019

 

 

586,662

 

 

0.13

 

9.6 years

 

$

5,500

 

Granted

 

 

263,976

 

 

0.20

 

 

 

 

 

Exercised

 

 

(75,851

)

 

0.13

 

 

 

 

 

Forfeited or cancelled

 

 

(32,740

)

 

0.12

 

 

 

 

 

Outstanding at December 31, 2020

 

 

742,047

 

 

0.16

 

9.1 years

 

$

39,078

 

Exercisable at December 31, 2020

 

 

88,531

 

 

0.15

 

9.0 years

 

$

5,413

 

 

 

 

 

 

 

 

 

 

 

 

Outstanding at December 31, 2020

 

 

742,047

 

 

0.16

 

9.1 years

 

$

39,078

 

Granted

 

 

1,249,287

 

 

4.16

 

 

 

 

 

Exercised

 

 

(206,455

)

 

0.13

 

 

 

 

 

Forfeited or cancelled

 

 

(14,140

)

 

0.19

 

 

 

 

 

Outstanding at December 31, 2021

 

 

1,770,739

 

 

2.96

 

9.0 years

 

$

1,124,215

 

Exercisable at December 31, 2021

 

 

41,084

 

 

0.17

 

7.9 years

 

$

87,522

 

The aggregate intrinsic value is calculated based on the difference between the exercise price of the underlying stock options and the fair value of the Company’s common stock for stock options as of the reporting date. The intrinsic value of stock options exercised during the years ended December 31, 2020 and 2021 was $6,032 and $447,115, respectively. The weighted-average fair value of options granted during the years ended December 31, 2020 and 2021 was $0.20 and $4.16 per share, respectively.

For stock option grants with service-based vesting, stock-based compensation expense represents the portion of the grant date fair value of employee stock option grants recognized over the requisite service period of the awards on a straight-line basis, net of estimated forfeitures. For options that vest upon the achievement of performance milestones, the Company estimates fair value at the date of grant and compensation expense is recognized using the accelerated attribution method when it is determined that the performance criteria is probable of being met.

In determining the grant date fair value of the stock-based awards, the Company uses the Black-Scholes option-pricing model and assumptions discussed below. Each of these inputs is subjective and its determination generally requires significant judgment.

Fair Value of Common Stock—Prior to our initial public offering, the estimated fair value of our common stock was determined by our board of directors as of the date of each option grant, with input from management, considering our most recently available third-party valuation of our common stock as well as our board of directors’ assessment of additional objective and subjective factors that it believed were relevant and which may have changed from the date of the most recent third-party valuation to the date of the grant. Since the completion of our initial public offering on July 19, 2021, the fair value of each share of common stock underlying stock option grants is based the quoted market price on the primary stock exchange on which our common stock is traded on the day the stock award or option is granted.

Expected term—The expected term of stock options is determined using the “simplified” method, whereby the expected life equals the arithmetic average of the vesting term and the original contractual term of the option due to the Company’s lack of sufficient historical data.

Expected volatility—We have limited information on the income volatility of our stock as shares of our common stock were not actively traded on any public markets prior to July 19, 2021. The expected volatility was derived from the historical stock volatilities of comparable peer public companies within our industry.

Risk-free interest rate—The risk-free interest rate is based on the U.S. Treasury Bond in effect at the time of grant for periods corresponding with the expected term.

Dividend yield—The expected dividend yield is 0% because the Company has not historically paid, and does not expect, for the foreseeable future, to pay a dividend on its common stock.

118


 

For the years ended December 31, 2020 and 2021, the fair value of employee and director stock option awards was estimated at the date of grant using a Black-Scholes option-pricing model with the following assumptions:

 

 

 

Years Ended December 31,

 

 

2020

 

2021

Expected term (years)

 

6.25

 

6.24

Expected volatility

 

87.30%

 

83.18%

Risk-free interest rate

 

0.50%

 

1.02%

Dividend yield

 

 

Fair value underlying common stock

 

$0.18

 

$2.95

For the year ended December 31, 2020, for options with service-based vesting conditions, the Company recognized $9,590 of employee stock-based compensation expense in research and development expenses and $12,285 of employee stock-based compensation in general and administrative expenses in the accompanying statements of operations. For the year ended December 31, 2021, for options with service-based vesting conditions, the Company recognized $25,239 of employee stock-based compensation expense in research and development expenses and $335,736 of employee stock-based compensation in general and administrative expenses in the accompanying statements of operations.

As of December 31, 2020, the Company had an aggregate of $103,045 of unrecognized employee stock-based compensation cost for options with service-based vesting, which is expected to be recognized over a weighted average vesting period of 5.12 years.

As of December 31, 2020 and 2021, there was no unrecognized employee stock-based compensation cost for options with performance-based vesting conditions, as no performance-based options were unvested. For the years ended December 31, 2020 and 2021, the Company recognized an aggregate of $6,750 and nil of employee stock-based compensation cost, respectively, for options with performance-based vesting conditions which vested immediately upon achieving the performance target, respectively.

11. Employee Benefit Plan

The Company offers a defined contribution savings plan (the “Benefit Plan”) under Section 401 of the Internal Revenue Code for all eligible employees. The Benefit Plan allows for discretionary contributions which are limited to the maximum allowable for federal tax purposes. The total expense related to the discretionary payments made by the Company to the Benefit Plan for the years ended December 31, 2020 and 2021 was $146,400 and $173,400, respectively.

12. Collaborative Arrangements

In March 2020, the Company entered into two collaborative arrangements relating to IND-enabling activities which continued in 2021. Pursuant to these agreements, the Company supplied materials for the studies and reimbursed the collaboration partner costs in connection with the projects. In turn, the partner will provide written reports and a body of scientific data for the results of the projects.

13. Income Taxes

The Company did not have a provision for income taxes (current or deferred tax expense) for tax years ended December 31, 2020 and 2021.

The following table summarizes the differences between the statutory federal income tax rate and the Company's effective income tax rate (percent data):

 

Rate Reconciliation

 

2020

 

 

 

 

 

2021

 

 

 

 

Net Loss Before Taxes

 

$

(5,802,201

)

 

 

 

 

$

(12,862,468

)

 

 

 

Benefit at statutory rate

 

 

(1,218,462

)

 

 

21.00

%

 

 

(2,701,118

)

 

 

21.00

%

State tax benefit net of federal benefit

 

 

(264,152

)

 

 

4.55

%

 

 

(590,728

)

 

 

4.59

%

Permanent book/tax differences

 

 

10,161

 

 

 

(0.18

%)

 

 

(85,678

)

 

 

0.67

%

Other adjustments

 

 

(34,591

)

 

 

0.60

%

 

 

2,093

 

 

 

(0.02

%)

R&D credit carryforward

 

 

(46,608

)

 

 

0.80

%

 

 

(85,000

)

 

 

0.66

%

Change in valuation allowance

 

 

1,555,740

 

 

 

(26.81

%)

 

 

3,460,431

 

 

 

(26.90

%)

Other

 

 

(2,088

)

 

 

0.04

%

 

 

 

 

 

0.00

%

Income tax expense/(benefit)

 

$

 

 

 

0.00

%

 

$

 

 

 

0.00

%

 

119


 

 

The tax effects of temporary differences that give rise to significant portions of the deferred tax assets and deferred tax liabilities at December 31, 2020 and 2021 are presented below:

 

 

 

2020

 

 

2021

 

Deferred tax assets:

 

 

 

 

 

 

Federal net operating loss carryforward

 

$

3,102,649

 

 

$

5,479,664

 

State net operating loss carryforward

 

 

658,595

 

 

 

1,164,970

 

Accrued expenses

 

 

24,585

 

 

 

12,356

 

Stock-based compensation

 

 

2,821

 

 

 

84,612

 

Deferred rent

 

 

2,089

 

 

 

307

 

R&D credit

 

 

133,015

 

 

 

218,015

 

Unrealized gain/loss

 

 

 

 

 

16,708

 

Deferred revenue

 

 

 

 

 

397,464

 

Net deferred tax assets

 

 

3,923,754

 

 

 

7,374,096

 

Deferred tax liabilities:

 

 

 

 

 

 

Depreciable assets

 

 

(10,054

)

 

 

35

 

Net deferred tax liabilities

 

 

(10,054

)

 

 

35

 

Less: valuation allowance

 

 

(3,913,700

)

 

 

(7,374,131

)

Net deferred tax asset (after valuation allowance)

 

$

 

 

$

 

 

A valuation allowance is recorded to reduce the deferred tax asset if, based on the weight of the evidence, it is more likely than not that some portion or all of the deferred tax asset will not be realized. As of December 31, 2021, after consideration of all the evidence, both positive and negative, management has determined that a valuation allowance of $7.4 million is necessary to reduce the deferred tax asset to the amount that will more likely than not be realized. During the year ended December 31, 2021, the valuation allowance increased by $3.5 million.

On March 27, 2020, the Coronavirus Aid, Relief and Economic Security (“CARES”) Act was enacted and signed into law. Certain provisions of the CARES Act could impact the 2019 income tax provision computations of the Company and will be reflected in the period of enactment (tax year 2020). The CARES Act, among other things, contains modifications on the limitation of business interest expense under Section 163(j), allow for net operating loss ("NOL") carryovers and carrybacks to offset 100% of taxable income for taxable years before 2021, and includes a technical correction to the TCJA with respect to Qualified Improvement Property ("QIP") where such property has a 15-year recovery period for purposes of the general depreciation system of Section 168(a). The Company is currently evaluating the impact of the CARES Act, and aside from the 15-year QIP technical correction, it believes that none of other modifications or tax law changes will result in any material benefit or apply.

As of December 31, 2020 and 2021, the Company had available federal NOL carryforwards of $14.8 million and $26.1 million. The Company also has available state NOLs carryforwards of approximately $15.2 million and $26.8 million, as of December 31, 2020 and 2021, respectively. The federal and state NOLs will carry forward indefinitely and be available to offset up to 100% of taxable income for taxable years before 2021 and 80% of taxable years staring after 2020. In addition, the Company had federal research and development credits carryforwards of $133,015 and $218,015, as of December 31, 2020 and 2021, respectively, to reduce future federal income taxes, if any. These carryforwards expire from 2038 through 2041 and are subject to review and possible adjustment.

Under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, (the Code), substantial changes in the Company’s ownership may limit the amount of net operating loss and research and development credit carryforwards that could be used annually in the future to offset taxable income. A formal Section 382 study has not been completed to determine if an ownership change has occurred and if its net operating losses are subject to an annual limitation. Such annual limitations could affect the utilization of NOL and tax credit carryforwards in the future.

14. Commitments and Contingencies

Leases

The Company leases its operating facilities in Miramar, Florida under non-cancelable operating lease agreements and a short-term sublease agreement for additional office space. Rent expense is recognized for leases with increasing annual rents on a straight-line basis over the term of the lease. The amount of rent expense in excess of cash payments is classified as deferred rent. Lease incentives received are deferred and amortized over the term of the lease.

120


 

The future minimum payments for the lease and sublease agreements at December 31, 2021 are as follows:

 

2022 (remaining 2 months)

 

$

36,000

 

 

For the year ended December 31, 2020 and 2021, rental expense, including common area maintenance costs, recognized by the Company was $183,943 and $208,348, of which $82,971 and $100,457, respectively, are included in Research and development, in the accompanying statements of operations.

Contractual Commitments

During the year ended December 31, 2021, the Company entered into several agreements with a third-party global contract development and manufacturer of biologics for the manufacture of the Company’s proprietary molecules for use in clinical trials. At December 31, 2020, the future minimum payments under such agreements were $3.9 million. At December 31, 2021, future payment obligations under such agreements were $2.5 million of which approximately $181,600 was paid in January 2022.

Legal

Management has no knowledge of any pending or unasserted claims against the Company.

Other

In March 2020, the World Health Organization declared the outbreak of a novel coronavirus (COVID-19) as a pandemic, which continues to spread throughout the United States and the world. The spread of COVID-19 has caused significant volatility in the U.S. and international markets. There is significant uncertainty around the breadth and duration of business disruptions related to COVID-19, as well as its impact on the U.S. and international economies and, as such, the Company is unable to determine if it will have a material impact to its operations.

15. Subsequent Events

Subsequent events have been evaluated through the date the financial statements were issued. As of such date, there were no material subsequent events identified that required recognition or disclosure other than as disclosed below or in the footnotes herein.

Effective March 1, 2022, the Company entered into a non-cancelable operating lease agreement for its current location with a two-year term and future minimum payments of $339,300.

121


 

Item 9 Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.

None.

Item 9A Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

Our disclosure controls and procedures are designed to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act, is recorded, communicated to our management to allow timely decisions regarding required disclosure, summarized and reported within the time periods specified in the SEC's rules and forms.

Under the supervision and with the participation of our management, including the Chief Executive Officer and Chief Financial Officer, we have evaluated the effectiveness of our disclosure controls and procedures as required under Rules 13a-15(e) and 15d-15(e) under the Exchange Act as of December 31, 2021. Based on that evaluation, the Chief Executive Officer and Chief Financial Officer have concluded that these disclosure controls and procedures are effective as of December 31, 2021.

Management's Report on Internal Control over Financial Reporting

This Annual Report on Form 10-K does not include a report of management’s assessment regarding internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) or an attestation report of our registered public accounting firm due to a transition period established by the rules of the SEC for newly public companies. Additionally, for as long as we remain an “emerging growth company” as defined in Section 2(a) of the Securities Act, as modified by the JOBS Act, we intend to take advantage of the exemption permitting us not to comply with the requirement that our independent registered public accounting firm provide an attestation on the effectiveness of our internal control over financial reporting.

Attestation Report of the Independent Registered Public Accounting Firm

This Annual Report on Form 10-K does not include an attestation repot of our independent registered public accounting firm (PCAOB ID Number 248) due to an exemption provided by the JOBS Act for "emerging growth companies."

Changes in Internal Control over Financial Reporting

There have been no changes in our internal control over financial reporting during the quarter ended December 31, 2021 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Item 9B Other Information.

None.

Item 9C Disclosure Regarding Foreign Jurisdictions That Prevent Inspections.

Not applicable.

122

 

 


 

PART III

Item 10 Directors, Executive Officers and Corporate Governance.

The information required by this item is included under the captions "Board of Directors and Corporate Governance," "Proposal One: Election of Directors," "Executive Officers" and "Delinquent Section 16(a) Reports" included in our definitive Proxy Statement for the 2022 Annual Meeting of Stockholders to be filed with the SEC within 120 days after the end of the year ended December 31, 2021, and is incorporated herein by reference.

 

Item 11 Executive Compensation.

The information required by this item is included under the captions “Board of Directors and Corporate Governance” and "Executive Compensation" in our definitive Proxy Statement for the 2022 Annual Meeting of Stockholders to be filed with the SEC within 120 days after the end of the year ended December 31, 2021, and is incorporated herein by reference.

Item 12 Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.

The information required by this item is included under the captions "Equity Compensation Plan Information" and “Security Ownership of Certain Beneficial Owners and Management” in our definitive Proxy Statement for the 2022 Annual Meeting of Stockholders to be filed with the SEC within 120 days after the end of the year ended December 31, 2021, and is incorporated herein by reference.

Item 13 Certain Relationships and Related Transactions, and Director Independence.

The information required by this item is included under the captions "Board of Directors and Corporate Governance" and “Certain Relationships and Related Party Transactions” in our definitive Proxy Statement for the 2022 Annual Meeting of Stockholders to be filed with the SEC within 120 days after the end of the year ended December 31, 2021, and is incorporated herein by reference.

Item 14 Principal Accounting Fees and Services.

The information required by this item is included under the caption “Proposal Two: Ratification of Appointment of Independent Registered Public Accounting Firm” in our definitive Proxy Statement for the 2022 Annual Meeting of Stockholders to be filed with the SEC within 120 days after the end of the year ended December 31, 2021, and is incorporated herein by reference.

123

 

 


 

PART IV

Item 15 Exhibits, Financial Statement Schedules.

(a)(1) Financial Statements

The information concerning HCW Biologics’ audited financial statements and the Report of Independent Registered Public Accounting Firm required by this Item 15(a)(1) is incorporated by reference herein to the section of this Annual Report on Form 10-K in Part II, Item 8, titled "Financial Statements and Supplementary Data."

(a)(2) Financial Statement Schedules

All financial statement schedules have been omitted as the information is not required under the related instructions or is not applicable or because the information required is already included in the condensed financial statements or the notes to those condensed financial statements.

(a)(3) Exhibits

We have filed, or incorporated into this Annual Report on Form 10-K by reference, the exhibits listed on the accompanying Exhibit Index immediately preceding the signature page of this Annual Report on Form 10-K.

124

 

 


 

Exhibit Index

 

 

 

 

 

Incorporated by reference

 

Filed or

furnished

herewith

Exhibit No.

 

Exhibit title

 

Form

 

File No.

 

Exhibit No.

 

Filing date

 

 

  3.1

 

Amended and Restated Certificate of Incorporation

 

8-K

 

001-40591

 

3.1

 

07/26/2021

 

 

  3.2

 

Amended and Restated Bylaws

 

8-K

 

001-40591

 

3.2

 

07/26/2021

 

 

  4.1

 

Specimen Stock Certificate

 

S-1/A

 

333-256510

 

4.1

 

07/09/2021

 

 

  4.2

 

Description of Securities

 

 

 

 

 

 

 

 

 

X

10.1

 

Form of Indemnification Agreement between HCW Biologics Inc. and each of its officers and directors.

 

S-1/A

 

333-256510

 

10.1

 

07/09/2021

 

 

10.2+

 

2019 Equity Incentive Plan, as amended, and forms of agreement thereunder.

 

S-1

 

333-256510

 

10.2

 

07/09/2021

 

 

10.3+

 

First Amendment to 2019 Equity Incentive Plan.

 

S-1

 

333-256510

 

10.3

 

07/09/2021

 

 

10.4+

 

2021 Equity Incentive Plan and forms of agreement thereunder

 

S-1

 

333-256510

 

10.4

 

07/09/2021

 

 

10.5+

 

Employment Agreement, dated July 6, 2021, between Peter Rhode and the Registrant.

 

S-1

 

333-256510

 

10.6

 

07/09/2021

 

 

10.6+

 

Employment Agreement, dated October 9, 2019, between Rebecca Byam and the Registrant.

 

S-1

 

333-256510

 

10.7

 

07/09/2021

 

 

10.7+

 

Non-Employee Director Compensation Policy.

 

S-1

 

333-256510

 

10.8

 

07/09/2021

 

 

10.8+

 

Employment Agreement, dated June 18, 2021, between Dr. Hing C. Wong and the Registrant.

 

S-1

 

333-256510

 

10.13

 

07/09/2021

 

 

10.9+

 

Executive Incentive Bonus Plan.

 

S-1

 

333-256510

 

10.11

 

07/09/2021

 

 

10.10†

 

Exclusive License Agreement, dated December 24, 2020, between the Registrant and Wugen, Inc.

 

S-1

 

333-256510

 

10.10

 

07/09/2021

 

 

10.11†

 

Master Services Agreement, dated March 14, 2019, between the Registrant and EirGenix, Inc.

 

S-1

 

333-256510

 

10.12

 

07/09/2021

 

 

23.1

 

Consent of Independent Registered Public Accounting Firm

 

 

 

 

 

 

 

 

 

X

24.1

 

Power of Attorney (incorporated by reference to the signature page of this Annual Report on Form 10-K)

 

 

 

 

 

 

 

 

 

X

31.1

 

Certification of Chief Executive Officer pursuant to Rules 13a-14(a) and Rule 15d-14(a) of the Exchange Act

 

 

 

 

 

 

 

 

 

X

31.2

 

Certification of Chief Financial Officer pursuant to Rules 13a-14(a) and Rule 15d-14(a) of the Exchange Act

 

 

 

 

 

 

 

 

 

X

32.1*

 

Certification of Chief Executive Officer pursuant to Rule 13a-14(b) of the Exchange Act and 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

 

 

 

 

 

 

 

 

 

X

32.2*

 

Certification of Chief Executive Officer pursuant to Rule 13a-14(b) of the Exchange Act and 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

 

 

 

 

 

 

 

 

 

X

101.INS

 

Inline XBRL Instance Document

 

 

 

 

 

 

 

 

 

X

101.SCH

 

Inline XBRL Taxonomy Extension Schema Document

 

 

 

 

 

 

 

 

 

X

101.CAL

 

Inline XBRL Taxonomy Extension Calculation Linkbase Document

 

 

 

 

 

 

 

 

 

X

101.DEF

 

Inline XBRL Taxonomy Extension Definition Linkbase Document

 

 

 

 

 

 

 

 

 

X

101.LAB

 

Inline XBRL Taxonomy Extension Label Linkbase Document

 

 

 

 

 

 

 

 

 

X

101.PRE

 

Inline XBRL Taxonomy Extension Presentation Linkbase Document

 

 

 

 

 

 

 

 

 

X

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

 

 

 

 

 

X

 

 

 

125

 

 


 

* Furnished and not filed.

+ Indicates a management contract or compensatory plan or arrangement.

† The schedules to this Exhibit have been omitted in accordance with Regulation S-K Item 601(b)(2). The Registrant agrees to furnish supplementally a copy of any omitted schedule to the Securities and Exchange Commission upon its request.

Item 16 Form 10-K Summary

None.

126

 

 


 

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

 

HCW Biologics Inc.

 

 

 

 

Date: March 29, 2022

 

By:

/s/ Hing C. Wong, Ph.D.

 

 

 

Hing C. Wong, Ph.D.

 

 

 

Founder and Chief Executive Officer

 

POWER OF ATTORNEY

 

Each person whose signature appears below constitutes and appoints Hing C. Wong and Rebecca Byam, , and each of them, as his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his substitutes, may lawfully do or cause to be done by virtue thereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.

 

Name

 

Title

 

Date

 

 

 

 

 

/s/ Hing C. Wong, Ph.D.

 

Founder, Chief Executive Officer

 

March 29, 2022

Hing C. Wong, Ph.D.

 

 (Principal Executive Officer)

 

 

 

 

 

 

 

/s/ Rebecca Byam

 

 Chief Financial Officer

 

 March 29, 2022

Rebecca Byam

 

 (Principal Financial and Accounting Officer)

 

 

 

 

 

 

 

/s/ Scott T. Garrett

 

 Chairperson of the Board of Directors

 

 March 29, 2022

Scott T. Garrett

 

 

 

 

 

 

 

 

 

/s/ Lisa M. Giles

 

 Director

 

 March 29, 2022

Lisa M. Giles

 

 

 

 

 

 

 

 

 

/s/ Rick S. Greene

 

 Director

 

 March 29, 2022

Rick S. Greene

 

 

 

 

 

 

 

 

 

/s/ Gary M. Winer

 

 Director

 

 March 29, 2022

Gary M. Winer

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

127

 

 


EX-4.2 2 hcwb-ex4_2.htm EX-4.2 EX-4.2

 

Exhibit 4.2

DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934

The following description summarizes the most important terms of our securities registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), certain securities convertible into such registered securities, and some of the provisions of our restated certificate of incorporation, restated bylaws, and relevant provisions of Delaware General Corporate Law (the “DGCL”). The descriptions herein are qualified in their entirety by our restated certificate of incorporation and restated bylaws, each of which have been previously filed with the Securities and Exchange Commission and are incorporated by reference as an exhibit to the Annual Report on Form 10-K of which this Exhibit 4.2 is a part, as well as the relevant provisions of Delaware General Corporate Law.

General

Our authorized capital stock consists of 250,000,000 shares of common stock, par value $0.0001 per share, and 10,000,000 shares of redeemable preferred stock, par value $0.0001 per share.

Common Stock

Voting Rights

Each holder of common stock is entitled to one vote for each share on all matters submitted to a vote of the stockholders, including the election of directors. Our certificate of incorporation and bylaws to be in effect upon the completion of this offering do not provide for cumulative voting rights. Because of this, the holders of a plurality of the shares of common stock entitled to vote in any election of directors can elect all of the directors standing for election, if they should so choose. With respect to matters other than the election of directors, at any meeting of the stockholders at which a quorum is present or represented, the affirmative vote of a majority of the voting power of the shares present in person or represented by proxy at such meeting and entitled to vote on the subject matter shall be the act of the stockholders, except as otherwise required by law. The holders of a majority of the stock issued and outstanding and entitled to vote, present in person or represented by proxy, shall constitute a quorum for the transaction of business at all meetings of the stockholders.

Dividends

Subject to preferences that may be applicable to any then outstanding redeemable preferred stock, holders of common stock are entitled to receive dividends, if any, as may be declared from time to time by the board of directors out of legally available funds.

Liquidation

In the event of our liquidation, dissolution or winding up, holders of common stock will be entitled to share ratably in the net assets legally available for distribution to stockholders after the payment of all of our debts and other liabilities and the satisfaction of any liquidation preference granted to the holders of any then outstanding shares of redeemable preferred stock.

 


 

Rights and Preferences

Holders of common stock have no preemptive, conversion, subscription or other rights, and there are no redemption or sinking fund provisions applicable to the common stock. The rights, preferences and privileges of the holders of common stock are subject to, and may be adversely affected by, the rights of the holders of shares of any series of redeemable preferred stock that we may designate in the future.

Fully Paid and Nonassessable

All of our outstanding shares of common stock are, and the shares of common stock to be issued pursuant to this offering, when paid for, will be fully paid and nonassessable.

Preferred Stock

Our board of directors has the authority, without further action by the stockholders, to issue up to 10,000,000 shares of redeemable preferred stock in one or more series and to fix the rights, preferences, privileges and restrictions thereof. These rights, preferences, and privileges could include dividend rights, conversion rights, voting rights, redemption rights, liquidation preferences, sinking fund terms and the number of shares constituting any series or the designation of such series, any or all of which may be greater than the rights of common stock. The issuance of redeemable preferred stock could adversely affect the voting power of holders of common stock and the likelihood that such holders will receive dividend payments and payments upon liquidation. In addition, the issuance of redeemable preferred stock could have the effect of delaying, deferring or preventing change in our control or other corporate action. We have no present plan to issue any shares of redeemable preferred stock.

Anti-Takeover Effects of Delaware Law and Our Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws

Certain provisions of our restated certificate of incorporation, restated bylaws and Delaware law, which are summarized below, are expected to discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed, in part, to encourage persons seeking to acquire control of us to negotiate first with our board of directors. We believe that the benefits of increased protection of our potential ability to negotiate more favorable terms with an unfriendly or unsolicited acquirer outweigh the disadvantages of discouraging a proposal to acquire us.

Undesignated Preferred Stock

As discussed above, our board of directors has the ability to issue preferred stock with voting or other rights or preferences that could impede the success of any attempt to change control of us. These and other provisions may have the effect of deterring hostile takeovers or delaying changes in control or management of our company.

Limits on Ability of Stockholders to Act by Written Consent or Call a Special Meeting

Our amended and restated certificate of incorporation provides that our stockholders may not act by written consent, which may lengthen the amount of time required to take stockholder actions. As a result, a holder controlling a majority of our capital stock would not be able to amend our bylaws or remove directors without holding a meeting of our stockholders called in accordance with our bylaws.

 

 


 

In addition, our amended and restated bylaws provides that special meetings of the stockholders may be called only by the chairperson of the board, the Chief Executive Officer or our board of directors. Stockholders may not call a special meeting, which may delay the ability of our stockholders to force consideration of a proposal or for holders controlling a majority of our capital stock to take any action, including the removal of directors.

Requirements for Advance Notification of Stockholder Nominations and Proposals

Our amended and restated bylaws establishes advance notice procedures with respect to stockholder proposals and the nomination of candidates for election as directors, other than nominations made by or at the direction of our board of directors or a committee of our board of directors. These provisions may have the effect of precluding the conduct of certain business at a meeting if the proper procedures are not followed. These provisions may also discourage or deter a potential acquirer from conducting a solicitation of proxies to elect the acquirer’s own slate of directors or otherwise attempting to obtain control of our company.

Board Classification

Our board of directors is divided into three classes, one class of which is elected each year by our stockholders. The directors in each class will serve three-year terms. A third party may be discouraged from making a tender offer or otherwise attempting to obtain control of us as it is more difficult and time-consuming for stockholders to replace a majority of the directors on a classified board.

No Cumulative Voting

Our amended and restated certificate of incorporation and amended and restated bylaws do not permit cumulative voting in the election of directors. Cumulative voting allows a stockholder to vote a portion or all of its shares for one or more candidates for seats on the board of directors. Without cumulative voting, a minority stockholder may not be able to gain as many seats on our board of directors as the stockholder would be able to gain if cumulative voting were permitted. The absence of cumulative voting makes it more difficult for a minority stockholder to gain a seat on our board of directors to influence our board’s decision regarding a takeover.

Amendment of Charter and Bylaws Provisions

The amendment of the above provisions of our amended and restated certificate of incorporation will require approval by holders of at least two-thirds of our outstanding capital stock entitled to vote generally in the election of directors. The amendment of our bylaws will require approval by the holders of at least two-thirds of our outstanding capital stock entitled to vote generally in the election of directors.

Choice of Forum

Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware will be the exclusive forum for the following types of actions or proceedings under Delaware statutory or common law: (1) any derivative action or proceeding brought on our behalf; (2) any action asserting a claim of breach of a fiduciary duty or other wrongdoing by any of our directors, officers, or employees to us or our stockholders; (3) any action asserting a claim against us or our stockholders arising pursuant to any provision of the General Corporation Law of the State of Delaware or our certificate of incorporation or bylaws; (4) any action to interpret, apply, enforce, or determine the validity of our certificate of incorporation or bylaws; (5) any action as to which the Delaware General Corporation Law confers jurisdiction to the Court of Chancery of the State of Delaware; or (6) any action asserting a claim governed by the internal affairs doctrine. The provisions would not apply to suits brought to

 


 

enforce a duty or liability created by the Securities Act of 1933, as amended (the “Securities Act”), the Exchange Act, or any other claim for which the U.S. federal courts have exclusive jurisdiction. Furthermore, Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all such Securities Act actions. Accordingly, both state and federal courts have jurisdiction to entertain such claims. To prevent having to litigate claims in multiple jurisdictions and the threat of inconsistent or contrary rulings by different courts, among other considerations, our amended and restated certificate of incorporation provides that the federal district courts of the United States of America will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act.

While the Delaware courts have determined that such choice of forum provisions are facially valid, a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions. In such instance, we would expect to vigorously assert the validity and enforceability of the exclusive forum provisions of our amended and restated certificate of incorporation. This may require significant additional costs associated with resolving such action in other jurisdictions and there can be no assurance that the provisions will be enforced by a court in those other jurisdictions.

Delaware Anti-Takeover Statute

We are subject to the provisions of Section 203 of the DGCL regulating corporate takeovers. In general, Section 203 prohibits a publicly held Delaware corporation from engaging, under certain circumstances, in a business combination with an interested stockholder for a period of three years following the date the person became an interested stockholder unless:

prior to the date of the transaction, our board of directors approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder;
upon completion of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, calculated as provided under Section 203; or
at or subsequent to the date of the transaction, the business combination is approved by our board of directors and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least two-thirds of the outstanding voting stock which is not owned by the interested stockholder.

Generally, a business combination includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to the interested stockholder. An interested stockholder is a person who, together with affiliates and associates, owns or, within three years prior to the determination of interested stockholder status, did own 15% or more of a corporation’s outstanding voting stock. We expect the existence of this provision to have an anti-takeover effect with respect to transactions our board of directors does not approve in advance. We anticipate that Section 203 may also discourage attempts that might result in a premium over the market price for the shares of common stock held by stockholders.

The provisions of Delaware law and the provisions of our amended and restated certificate of incorporation and amended and restated bylaws could have the effect of discouraging others from attempting hostile takeovers and, as a consequence, they might also inhibit temporary fluctuations in the market price of our common stock that often result from actual or rumored hostile takeover attempts. These provisions might also have the effect of preventing

 


 

changes in our management. It is possible that these provisions could make it more difficult to accomplish transactions that stockholders might otherwise deem to be in their best interests.

Transfer Agent and Registrar

The transfer agent and registrar for our common stock is American Stock Transfer & Trust Company LLC. The transfer agent and registrar’s address is 6201 15th Avenue, Brooklyn, NY 11219, and its telephone number is (718) 921-8124.

Listing

Our common stock is listed on the Nasdaq Global Market under the trading symbol “HCWB”.

 


EX-23.1 3 hcwb-ex23_1.htm EX-23.1 EX-23.1

Exhibit 23.1

 

 

 

 

 

 

 

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

We have issued our report dated March 29, 2022 with respect to the financial statements included in the Annual Report of HCW Biologics Inc. on Form 10-K for the year ended December 31, 2021. We consent to the incorporation by reference of said report in the Registration Statement of HCW Biologics Inc. on Form S-8 (File No. 333-258067).

/s/ GRANT THORNTON LLP

 

Miami, Florida

March 29, 2022

 


EX-31.1 4 hcwb-ex31_1.htm EX-31.1 EX-31.1

 

Exhibit 31.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO

RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Hing C. Wong, certify that:

1.
I have reviewed this Annual Report on Form 10-K of HCW Biologics Inc.;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:
(a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(c)
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.
The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent functions):
(a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

/s/ Hing C. Wong

 

Hing C. Wong

Founder and Chief Executive Officer

Date: March 29, 2022

 


EX-31.2 5 hcwb-ex31_2.htm EX-31.2 EX-31.2

 

Exhibit 31.2

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO

RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Rebecca Byam, certify that:

1.
I have reviewed this Annual Report on Form 10-K of HCW Biologics Inc.;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:
(a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(c)
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.
The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent functions):
(a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

/s/ Rebecca Byam

 

Rebecca Byam

Chief Financial Officer

Date: March 29, 2022

 


EX-32.1 6 hcwb-ex32_1.htm EX-32.1 EX-32.1

 

Exhibit 32.1

CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

Pursuant to 18 U.S.C. Section 1350, I, Hing C. Wong, hereby certify that, to the best of my knowledge, HCW Biologics Inc.’s Annual Report on Form 10-K for the period ended December 31, 2021 (the “Report”), as filed with the Securities and Exchange Commission on the date hereof, fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, as amended, and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of HCW Biologics Inc.

 

 

Date: March 29, 2022

 

By:

/s/ Hing C. Wong

 

 

 

Hing C. Wong

 

 

 

Founder and Chief Executive Officer

 

 


EX-32.2 7 hcwb-ex32_2.htm EX-32.2 EX-32.2

 

Exhibit 32.2

CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

Pursuant to 18 U.S.C. Section 1350, I, Rebecca Byam, hereby certify that, to the best of my knowledge, HCW Biologics Inc.’s Annual Report on Form 10-K for the period ended December 31, 2021 (the “Report”), as filed with the Securities and Exchange Commission on the date hereof, fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, as amended, and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of HCW Biologics Inc.

 

 

Date: March 29, 2022

 

By:

/s/ Rebecca Byam

 

 

 

Rebecca Byam

 

 

 

Chief Financial Officer

 

 


GRAPHIC 8 img111359907_0.jpg GRAPHIC begin 644 img111359907_0.jpg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�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end GRAPHIC 9 img111359907_1.jpg GRAPHIC begin 644 img111359907_1.jpg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end GRAPHIC 10 img111359907_2.jpg GRAPHIC begin 644 img111359907_2.jpg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end GRAPHIC 11 img111359907_3.jpg GRAPHIC begin 644 img111359907_3.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_X1#R17AI9@ 34T *@ @ ! $[ ( M - (2H=I 0 ! (6)R= $ : 0T.H< < @, /@ M &UL;G,Z9&,](FAT=' Z M+R]P=7)L+F]R9R]D8R]E;&5M96YT#IX;7!M971A/@T*(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" * M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" \/WAP86-K970@ M96YD/2=W)S\^_]L 0P '!04&!00'!@4&" <'" H1"PH)"0H5#Q ,$1@5&AD8 M%1@7&QXG(1L=)1T7&"(N(B4H*2LL*QH@+S,O*C(G*BLJ_]L 0P$'" @*"0H4 M"PL4*AP8'"HJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ M*BHJ*BHJ*BHJ*BHJ_\ $0@ P0(B P$B (1 0,1 ?_$ !\ $% 0$! 0$! M ! @,$!08'" D*"__$ +40 (! P,"! ,%!00$ !?0$" P $ M$042(3%!!A-180'EZ@X2%AH>( MB8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R;GZ.GJ\?+S]/7V]_CY^O_$ !\! ,! 0$! 0$! 0$ ! M @,$!08'" D*"__$ +41 (! @0$ P0'!00$ $"=P ! @,1! 4A,08205$' M87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)BH*#A(6&AXB)BI*3E)66 MEYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7F MY^CIZO+S]/7V]_CY^O_: P# 0 "$0,1 #\ ^D:*** "BBB@ HHHH **** " MBF2RQP0O+/(L<:*6=W; 4#J23T%9W_"3:#_T&]._\"X_\: -2BLO_A)M!_Z# M>G?^!G?^!G?\ @7'_ (T :E%9?_"3:#_T M&]._\"X_\:/^$FT'_H-Z=_X%Q_XT :E%9?\ PDV@_P#0;T[_ ,"X_P#&C_A) MM!_Z#>G?^!G?\ @7'_ (T :E%9?_"3:#_T M&]._\"X_\:/^$FT'_H-Z=_X%Q_XT :E%9?\ PDV@_P#0;T[_ ,"X_P#&C_A) MM!_Z#>G?^!P)5G4 @ M'@FG:'K4.O:>M[:Q2) X!C9V0[P1G.%8X^AP>: -*BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@#E_B;_R2GQ3_P!@FY_]%-7P)7W]\1XGG^%_B:*, N^EW"KDXY,;5\&R M:5=1$AT7@9^\*ER2T;'9LIT4$$=1BBJ$%%%% !1110 XZ4NX^M)10 4444 M%%%% !0#@Y%%% "EBWWB3]32444 %%%% !1110 4444 %%%% !5JRTVYOI%$ M,9V$\R$84?C6KX>\-'6[6>X'F%;=OG5%_AQUS78Z/I$=["UO"P18QA5 ^5/J M?>N6KB%#W8[FU*C*HTD,8A>*4(WT)(Q7''&33LU<]"M MEZA&Z?R/"I(98<>;$\>>FY2,U]D?LU_\D8M/^ON?_P!#KYA\9O! QL6W"=)- MRH6#%%/]XCC.,5]/?LU_\D8L_P#K[G_]#KTJL4445H2%%%% M'/WNBZE>^)TO9[BUDL;=<6L#(V87*D-(1T9N<#/ &?4FJ"^!5OK&^MM8G6%+ MN*"$KI&ZT $))#94Y#$M@XXP .:Z^B@#S+X86/\ 8WC[QYHL%W>W%G8SV0MQ M>7+SLFZ#>W+'N2:]-KSSP/\ \E?^)/\ U\:?_P"DU>AT %%%% !145S=0V=N M\]S((XDZL:99WUO?PF6UDWJK;6!4J5/H0>0:GGCSTG!-O)9RANJ>6N?\:^GOB$2OPU\1D= M1IEQC_OV:^*&E$@22(&.7C>1W/K7+67O(ZJ%7D331W+:3I\V?/TZW<[=IPH& M:S)/ >CW"2/$)(7)^4!LA?;%4K7Q')%:-!>[Y,#"-&.0:GA\5KL=)X?,9,,F M"$+ =1]>_O6?-IH$VGL)_P ()IS_ +L*RG',@+'GZ9XJA/\ #E@6,5T/92>O M\JW;3Q-;W/RHIC8G&'QR/4GVK3:[$:KN=<-T.[KZ4*4EU'R1;LM3SF[\%WUL MN[^ 'DD?X553PKJ,@9D$81?XW?8/UKU,07#1K(UOF,]#D9_*F?9HI"1=VY=, M\QNO%#KR7F=:R^3>NB/)[W0K^QA6:6'?"V<21G0FWF !,,@!Z?*> M:#;S#K%)_P!\FO9;G2K4VX8_.2><()+>/*C (+#C\Z7UN_053 MRIOEDSQO[/,3@129_P!TU8BTB_F7 *D5/UJ?8(X-R MM;4\K;0-03<'B"R*<&,L,_6FKH6HLV%MRQ] P/\ 6O6Y;:%Y<3PHQ4;>@/ZT MY5AC7]W%&G^Z@%/ZS/L9O#)/4\C3P_J^5FE48,2V/3-.%L"JNQ8+Z@4UB)Q M6YO'!PF]-CR>;P5J]O\ ZZ)5'J,D?F!2VO@G5+MCL,*(O5Y&('\J]76.9>4D M(I/WH='DRVWD COZT_K50(8*FY>\W8PO".EWOAO2[F"=UW33!PT>2" ,=P*W M[3"1SO*J1(P),A7;@]34K73>6J(&W9[CI6;J=[JKQR6RV0CB;@2-\Y/Y<"N6 M3.>@JEK/BVTM?#\DT$3)<@[46 M1.A]>*\YU<:\ERXO_/R&P2A.W]*QV9R<.6SZ$UV4\*G9MGG5LQJ2;25A9YY+ MF=YIW:221BS,QR237V1^S7_R1BS_ .ON?_T.OCB"WFNI-EO$\KXSM1(76RLWDM?M6&: MZ8L)AND.%8#:67L>PS0 [P/_ ,E?^)/_ %\:?_Z35Z'7EOPLOKW4OB+\0;O5 M-+DTF[DN+'S+*659&BQ;X&67@Y !X]:]2H **** *NHV:7UF8GD:(JPD21<9 M1E.0>>.HIFF62VL GRXA@# X'7&3P.37,U^_3Y>F_W_UW MU.E/]R_>Z[?=_7;0TJ***Z3F"BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** .7^)G'PJ\4X_Z!-S_P"BVKX&\QQT=OSK M[Y^)O_)*?%/_ &";G_T4U?)?P?\ #NF>)&\5V^K"R3R="FE@NKW_ %=K)N0" M4D"?!6FRS MOINKZG=ZC;QW<%H)#<-'(VTRDL,* H QGK7+_!KP_8W_ ,7/[)UZTM;V&&"Z M#QW*[HMZ(<$^P(J7"+Z%*36QS4?C*^3)^T3;B.IP?TZ5.OBR]E:,_P!HS+Z[ MGQ^8KL]?T33_ !/XDT?1K6+PULD6:623P3:2W$N !\KJ[ ?0Y ')-;6C?"#P M]H7C"2V\0375_;3^'9M4MHVB0-"R@AMX60J67J,$J3U/'.;HP9K]8J]9,Y&# MQ7;_ &/RKJ:VFD"X68RR9EQ>(M!N,?9YT^7^( M@_+FI9=3LK62)A/'*LA/0\8(ZTMI\#_[;6:\^W2VAU&^O8[(6]H/LMN(9'0> MH).]R\B+B4JX5MQW'&UAA0! M@@DG!J5A$E9,*F.G4=VC;_M?3#(%-U&OH'X_*FMKVDS 1"X&,]=P'\S7CU%' MU5=S-XJ3W1[-;:IITY\M=1AR@_C=0337U*!2JI=QYD.T!9@TVM<.BHRY17."?6FR7%O%L$CI&9ON;V&,>H->1'6= M0,>QKJ0\YW$Y/YTUM8U!HU1KR8JHPJEN!4+"RO>YT/,5K:![.Z11H")XVQC) M##%02WMG'&7ENXRP(&U6'3IFO'AJM^J[5NY57G@-CK55G9VR[%CZDU2PLNK, M/KB3;C'<]EN->TN-?FF+E1C]V.GY\5DWGCC2K96$:R2':>%*YSTKR_-%7'"Q M6[,7B9O8ZZ'QQ(ZA;M'7RUX\D ^:<]'ST7'I5[_A91%I'$+(Y ^8EN"?I7!T M5H\/3?0B.(JP^%G>1?$R1.)+(.OH&Q^M74^)]GPK:=<$=!^\7C]*\VHJ7AJ3 MZ%K&5DK+K;7 ZR+Y]2VUS-:3B:VD:.1>C"HEA(\MEN73QM2$M=NQ[5=V$=_:&= M(\=0SC@D?UK O?!-K?,)49):^;K3QQHESAT445Z!R MF#XJ-N;2&/4+V_L[-R?->S)3=Z*\J\Q@^N5SZ^O+_#?;?S7%U86U_I4$17,# M7LUS!,&!X/G*-LBX&2A(Y')K0^)6F2W^GV4GVZ[L[>"1S,]O#+*J@C =EB=7 M)7G!^91DY'<6?"^LZ!-ZIR?3O0!UA5 M2P)4$CH<4H '08HHH \\\#_\E?\ B3_U\:?_ .DU>AUYYX'_ .2O_$G_ *^- M/_\ 2:O0Z "BB@].* "BLEVU]$9O^);A03_RTJ&QN]>OM/@NXUTY5GC60*WF M9&1FN?ZPK\O*[^AT>P=K\R^\W**;%YGE)YVWS,#=LZ9[XIU=!SA1110 5F:Q MJTNFO:16UDUY/=R&-(UD5,84L22?85IU1U/1[35UA%X),POOC:*5HV4X(ZJ0 M>A-5&U]3.HIN'N;_ ->HW1M3;5;.262V:UDBF>%XF<-AE.#R.#6A533=,MM) MM#;V:N$+M(=[EV+,QN/-0MB-B"=O(P>!SS7Z$D!@0PR#U!J+[-!_SQC_ .^!0!\(Z+\2 M]>T&RT&ULH[0QZ#=2W5IYD1)+R AMW/(YXZ5VW@KXLZ+HVFZ7/KIO+F_TN[N M+F& :=%($\TEBD,Q<&-6)YRK'KC%?7'V:#_GC'_WP*/LT'_/&/\ [X% 'PM9 M_%/7M/DT%K2&S"Z!%/%6H^# M]6DO]+2"1IK=[:>&YCWQS1.,,C#(.#QT(KH_^%P^(AJ]C?K9:4@LM/DTV.V2 MU(A:V?K&5#=!T&"#QSFON#[-!_SQC_[X%'V:#_GC'_WP* /@?PGXYU+P9KM[ MJFDV=@[7L$EO+;W,!DA\MV!*A<]. .2>*UKOXO>([G5-&NH;;2[_M%I8 M65F(;<2=V* \G\:^XOLT'_/&/_O@4?9H/^>,?_? H ^&8/BOX@AM'ADM=,N7 M6>XGM9[BS$DEDTY)D\HDX ))."#BLC4O&.HZMX.TSPY?6]I);Z6S&UN/)(G1 M6)+)NS@J2<],\#FOOW[-!_SQC_[X%'V:#_GC'_WP* /SAP?2C!]*_1[[-!_S MQC_[X%'V:#_GC'_WP* /SAP?2C!]*_1[[-!_SQC_ .^!1]F@_P">,?\ WP* M/SAP?2C!]*_1[[-!_P \8_\ O@4?9H/^>,?_ 'P* /SAP?2C!]*_1[[-!_SQ MC_[X%'V:#_GC'_WP* /SAP?2C!]*_1[[-!_SQC_[X%'V:#_GC'_WP* /SAP? M2C!]*_1[[-!_SQC_ .^!1]F@_P">,?\ WP* /SAP?2C!]*_1[[-!_P \8_\ MO@4?9H/^>,?_ 'P* /SAP?2C!]*_1[[-!_SQC_[X%'V:#_GC'_WP* /@;P1M M&M9D4ENN\;K+KCK"[#]W'B.7@Y.>A([5]F"WA7I%&/HHI?(B_YY)_W MR*Y9X?FJ>T3U.F.(<:3I6T9^>T/AG4'G"2((TSRY;(Q[5]C_ +79\+;5>>+ MB8<_[]>A>1%_SR3_ +Y%.50HPH 'H!6RC+FYFSGNK"T445H(R/%.L3:%X=GO M[:.&25&C1?/Y )"KNR<#H*Q/ ?BW4O$LVH0ZM'IJ2V@3*V,CL8W) M=6CD# ;6!3IZ$'O6OXO>]3PO<_V9.(+EVC16\Q8V8,Z@HKL"%=@2JDC )%9' MP\MO$D%G,WB6&YME,42)%>7$<\K2*&#R%DR,,-G4DY!/&<4 ;5[XA2R\26>D MO9W!%U#)*;K $:;!G;ZECZ#I4&A>*[35]);4+B6ULX@J,5:XYC#C*[]P7:3^ MM:%[I,=[JEE>O+(CV:RA G&=Z[3^6*S?^$-L+V"[B\1M_;BW4<44BWD2%2D1 M+("H !.YB2?4]J .9\ 7$-U\6/B/-:S1SQ/<6&V2)PRM_HW8CBO1Z\Q^&>EV M&B_$SXB:=I%I#96<-Q8>7! NU$S;Y.![DD_C7IU $=S.MK:RW$F2D2%VP.< M9KEU^(NE.JE;342'^Z1;CYOISS70:Q_R [[_ *]I/_037(:';+=>$]-W/)&T M2;XY(VPR')Z?A7EXNM7C54*3MI?;S1Z6%HT94G.JKZI;^3+S_$#3)(7"66I' M(*Y^S]#^=5M*\I#I#VVG)?[BV6/DO MO<$Y8[B.IYYJOI=SC0Y;#4([Y49=B*8'9E7:,\XZ9S@5YCQ=?VB]]7L^FGIO MY'HK"T/9OW':_?7UV-L?$723G%IJ!VC)_P!'' ]>M='IU_%JFFP7ML&$4R[E M#C!Q[UR,EM(FE7]U/<&:6:T*9\OR\*%.!M]>:W/!W_(FZ9_UP'\Z]'!UZ\ZO M)5=]+[>?JSAQ5&A&ESTE;5+?R]$;=%%%>L>4%%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% '-_$"U:^\$7MLMFEX)6B5XW@:8*AD7<_EJ07VC+8!&=MTG_H)KEO#'_(KZ?_ -Y? M/[G+8JZI_P @B\_ZX/\ ^@FK_@[_ )$W3/\ K@/YU0U3_D#WG_7!_P#T$U?\ M'?\ (FZ9_P!Y7++L=9_PN+XA?]#;J/_?P?X4?\+B^(7_0VZC_ -_!_A7("SN6.!;RG_@! MJ9=(OV&1:R?B,4.45NP49/9'4_\ "XOB%_T-NH_]_!_A1_PN+XA?]#;J/_?P M?X5R[:-J"L0ULP(]Q33I5Z/^7=OS%+GAW#EEV.J_X7%\0O\ H;=1_P"_@_PH M_P"%Q?$+_H;=1_[^#_"N6&DWS'"VS$^G%*-'OR<"U*]10A3^\,@X]\XKES\8 MOB$"1_PENHGW$@_PIOBF*4?:D0?ZL*IP.PQFN,JL,W*/,V36LG:QVO\ PN+X MA?\ 0VZC_P!_!_A7UQ\'=6O]<^$FAZEJ]U)>7D\'/^N4O_HYZZ4[JYD]#T*BBBF(PO&=Y M#8>$;VYNI)HHHPI9X+P6KCY@.)20%_/VKC_AQXETV36+ZV_MK*W1C6SL[S6D MO9MX#%]H4G:""O&23@FNL\<^0?"%RMP+EBTD*PK:HCR-,95$8"O\AR^W(;@C M.:Y[X:7!U"\U*]U""]^WS1P/YMU#;Q*\?[P+L6(GH0X))ST':@#7\1:3K864'E:M') M%#)<(6\YCM&XG:0-PR"0.3BO0Z* /+/A6=8;XB?$$^)4LDU3[18^>M@SF$?Z M/\NTO\WW<9SWS7J=>>>!_P#DK_Q)_P"OC3__ $FKT.@"GK'_ " [[_KVD_\ M037+>&/^17T__KE_4UU.L?\ (#OO^O:3_P!!-H_ MX7^:/4P_^[2_Q+\F:-Q<16L#33MM1>O&23V '_S^1?N< MGF-U3_D#WG_7!_\ T$U?\'?\B;IG_7 ?SJAJG_('O/\ K@__ *":O^#O^1-T MS_K@/YUIA_\ >_\ MU_FB:W^Z_\ ;R_)FW3)IHK>%I;B1(HU^\[L% ^I-/KE M_B1_R3O5O^N:_P#H:U[,8\TDCQ:U3V=.4^R;+6J^+O#-G#Y&I:I;%+A64JI, M@8="#MSCK7'^*8/!;>'8[[3;VSM9-K-!Y2[FE)0@*5ZK]3C!K.O-$M5;3/[- MTN%YWLO,>-;:-@XPN20Q'.3^M46T>"^\.6O]G:'<"=48_:#:Q_OB01S\W'/? MMBNZ%.,;--GSV(Q-6KS1E!/33?RZ_P##'0VL'A6W\,Q3V4FFZE"X&QP5!XW'MTKA]-TFSM;3R[OP MO-=S%BS2&TB'7L!NZ"K7B/0-(@\+ZC-#I5I%*ELS*RP@%3CM4RC&3LV:T:M6 MG'GC%*RU6JZ/R_4]/5@ZAD(92,@@Y!%+5/2/^0)8_P#7O'_Z"*N5Q/1GOQ=T MF%%%%(H**** "BBB@ HHHH **** "BBB@ HHHH **** ./\ BS;B[^%.O0-C M#VXZ_P"^M?*]IX8\R!6EGV,S;I$SN^G?%?5'Q9F,'PIUZ41B0K;CY#T/SK7R MQ#KU@X GMI(>P"'(%>=BW-27*=^%C!Q?,R^WAQ1$!'&;E@1+: \\%1S],,?D*[> M&2W^V(DJ8C!R14EVUD]SMMHU4A!C[/G,N+28?[/\F>/ M(V9+!<_3%8PT1Y;N6*W$P51E6D %=3)$XL1(MP%3_GF>/PJE;WL=P,QRJQ'! M4-R*RA4DKLZ<7&*Y8\MM"A'I$B1C?,@/?:,U-'I2;LR2E@/1:TD7S 6"+@'! M.15G[0/+(CCB.>K!N:ASD8JBXJ\D8\NEP,PW$NS '(/^%-_LZUE98VXV\#G] M*T5E$9WIM!%33?8Q:@@'SVY/7@_RQ2YY7-(TXU+M:6,V&RMHI0R0Q J>"YG&I*&B&QZ;8J' M=XR9"W /(Q2RZ99O%\T"C<:7<7+=:(SX M]%T]"Q*,Y((YQQ^E-&B60_YZ$?[^*T#&Q.1R/8T[RW)&1Q]*.>7"[&0''DJ?\ =846W@C38;@-.$F3'*[F_P :Z@1D?>%* MD461DC\*KZS5M;F8O8QYM8HS=-T'3["11%;!EW9)(K8BL%EF.V 8QU48(%$] MY9V40:5RI_AQU-6[*\1H4GADS',N02.:Y:DYOWF>A2HP=HW,RXL[1Y&\Z!9# MGJ>"3[US=UX2T];H30Q1C(S@@\M].E='=W%W!=&5K9);7=A]HR<>N:IWVH6L M$Q1&:51T95XK:E.(M2&H:D3$P,2=,=">YK[+^!'_)$/#G_ %RE_P#1SU]'04E3 M7,?/5+<[L>A4445L9G%?$B\ODL;33]-A-V]WYC2V@L4N?,C0!BQWR(!M)'P!$CB2^G$@A51@ M!<*,#'UZ"@#:HIDSF*%Y C.54L%4%!R6+9;(R.X/ H RO _\ R5_XD_\ 7QI__I-7H=>7?"[6M.\0_$?X MA:KHMTEY8W%Q8F*= 0&Q;[3U /!!'X5ZC0!3UC_D!WW_ %[2?^@FN6\,?\BO MI_\ UR_J:ZG6/^0'??\ 7M)_Z":Y;PQ_R*^G_P#7+^IKR<3_ +U'_"_S1ZF' M_P!VE_B7Y,U:***0BKJG_('O/^N#_P#H)J_X._Y$W3/^N _G5#5/^0/>?]<' M_P#035_P=_R)NF?]C_ ",=-+AOK/3YWEN( M98K5$5X)2AP54D''T%4]7:+1;/2K2.]GLK3S6C>2,[GV[21S@]_:MG3_ /D% MVG_7O'_Z"*@U.RN;J6SFLI8HI;64N/-0LK94KC@^]=*EK9['E2I^Y>*UT_0Q MH_.UGPNXB:34E6_^7S&"M+$L@X)X[5%=63V?A7Q&WV'[!#-#F*#>&QA,$\'U MKH-*LYK*UD6YD2266=YF:-2%RQS@ U7\4_\ (HZK_P!>K_RJE+WK+:YFZ/[O MGENE^C^?XG9Z1_R!+'_KWC_]!%7*IZ1_R!+'_KWC_P#015RN%[GOT_@04444 MBPHHHH **** "BBB@ HHHH **** "BBB@ HHHH X;XSR"'X-^(G() MEX'^^ MM?%_]MPCI%)^8K[,^-__ "17Q)_U[K_Z,6OD3PWX'F\1^"O$>N6L\K3Z+]GV M6<5N9&N/-?:>0TD4I/%5XPVAI"HZ9D.<4J^++]"V MUFPPP0TA/%='KGP@URQ\/:7K.C13:K9WFDIJ5P\<:K]G!Y9<;B6"C!) [U1^ M&_@6#QWJ>IP7FIR:=!IU@][))%:FX9E4@%0@()//;)H]A3[#]M4[F2WBF[;^ M'Z98DBJ[:[,S[V3+>N\YKH]7^'@DUR'3/!-S?:Y)]F:XN#=:>UCY"@XR?,;& MW_:) [5-I7P@\27UKXB>]A&GSZ% LLEO,R[I2W*@')+IT".-ZCH&8FFIK[Q]+=?KN-;O@'P1IWBRRUV_P!:UM]'LM&MTGEE M2T-P6#-M^Z&!KVO[6Q/F!X5)>-HBPP>/7U]*/ M8T^P.M4>[.3/C*Y-KY/V:/'=MQR:SYM?NWR(MD0_V5R?S-7$\#>)9/#;>((] M(N&TL*7^T8'* X+[<[MH/&[&/>K_ (W^'>I>!;'1;C4I8I?[5M%N,1LI\IC_ M ,L^"-QE"[B-O7&#UK6\*^!Y?%/A;Q)JMM/()M$BAD2UB@ M,C7!DX/7/2FOKE^Z@>:JX&,K&!G]* M[>T^#U_>V_A7;>_99]=ANI[E;N QBPB@;#.Q)R1CGH.H^M!^'OA&\U#2HM"^ M(%O?QWNH)83*]DT,T1EU)4N-$O9K9++R>;A(75)) =W&-W3!Z M=>:MS_!>TTZ^OTU?Q(]O;6#V5K-)'8^8XNKA0P3;O'RJ&&6SWX%/DAV%SR74 M\[C\1ZA$VY9%W>NVFMX@U)F)-QU.> *[K1_A'!=^+-0\,:MX@^RZS;WK6L5M M;63SAE"[O/=LJ$BY'/)&>E-\.?"$:UI]BUUKT5K>:Q=7-KI,4<'FQW#0 [F: M0,-BDC (!]:7LJ?9%>TGM*=6"QJUTS+']P'M^57XO&]^(U28MA3N!1SU M_&MOP_\ #;3O$6FR067B0-X@CLIKV33Q9-Y4(BZQR2DC#GV4CWKSZI="D]XE M*M47VF=;%X^O8I0X\P@=BPQ_*IX_B)=>8?-CW*3W53C]!7%T5F\)1?V2EB:R M5E([O_A86TY$:MZCR\#^=26_C1[^Y6.)88G(.-Y*C]:X"@$JP(X(.0:AX*E; M1%?6JM[MGI5I%<:Q_I#N&!.&N3V,J^U>?4H2C-1FM#LI5$X.2 M=F=GX=UNQGMY+:[DBAFB8J1)(!_^NL3QL\4MB_V26$@*ZJ4=>I'M7GT'B7[- M=;XK9<="S %B/H1BKVL>*[34HWC^S*"8RH>.,(,D>E*.!G"JI+8N>.YZ3@V< MG7W#\"/^2(>'/^N4O_HYZ^'J^X?@1_R1#PY_URE_]'/7O'C'H5%%% !1110 MV2-9HGCD&4=2K#.,@UGZ;H-EIGG&/S9WF"*\ES(96*I]UIK2HH \ M[\"JJ?%WXD*BA5%QI^ HP!_HU>B5YYX'_P"2O_$G_KXT_P#])J]#H IZQ_R M[[_KVD_]!-&/^17T_P#ZY?U- M>3B?]ZC_ (7^:/4P_P#NTO\ $OR9JT444A%75/\ D#WG_7!__035_P '?\B; MIG_7 ?SJAJG_ "![S_K@_P#Z":O^#O\ D3=,_P"N _G1A_\ >_\ MU_FBJW^ MZ_\ ;R_)FW7,?$C_ ))WJW_7-?\ T-:Z>N8^)'_).]6_ZYK_ .AK7MTOXD?4 M\'%_[O4]'^14T_\ Y!=I_P!>\?\ Z"*L57T__D%VG_7O'_Z"*L5L]SAC\*"L MKQ3_ ,BCJO\ UZO_ "K5K*\4_P#(HZK_ ->K_P JD?\@2Q_ MZ]X__015RJ>D?\@2Q_Z]X_\ T$5YZU/X$%%%%(L**** "BBB@ HHHH * M*** "BBB@ HHHH **** ."^-_P#R17Q)_P!>Z_\ HQ:^5_ _CU?"'@'Q98V5 MY>66LZD;7[#/;#&W9(2^6S\N5)'OFOM77=#T_P 2Z'=:1K,)GLKI0LT8>M/AI_T )/_ .G M_P#BZ /F[PGX[LKO6;^]^(]U0?;EM7W9R8G8!AR<9Z&NKUWX MH^%-%M,TG^TGT'0HKUI;J>%?.N)YXV7(0' 4%O M7O[5[7_PSQ\-/^@!)_X'3_\ Q='_ SQ\-/^@!)_X'3_ /Q= 'B3?%S0W\%0 M!4:WUBWT%M&\A-.B8R=5W?:&)(C*DDIMSGH:X[Q_XDT;Q-H/A-M.FN%OM+TB M'3;JWE@ 4&,'YU?/()/3'%?3W_#/'PT_Z $G_@=/_P#%T?\ #//PSY_XD+\= M?].G_P#BZ /G.Z^.'B>Z^'">&7NG\\R,DMWLBQ):F/8(=NSC'7=G-4_A_P". MX_!OA'Q;;P7=W9ZMJ4$"6$UL,%&1R6RV?EX.*^F!^SS\,R 1H+D'H?MT_P#\ M71_PSQ\-/^@!)_X'3_\ Q= 'AL'QCLGM_"$FNF^UBXM+._L=:,I^>2*X; *. M3R0H'7'3%_$/1+S[) M<+H"Z?<1:I!Y(!>:?ER%!^;YE3G/K7+Z%\3-//C;Q+K.I:WK&E+J=^ES$MK; M17$/AI_P! "3_P.G_^+H_X9X^&G_0 D_\ M Z?_ .+H \%T_P"(/AF^^(U[XVU*^US1]0.IBX%O9QI)%=6B@8@;D$,=H!)R MN#TJ[H/Q6\,Q?V7?ZC;75E<>'M2O[VPL;6%6CN$N=S+&6R/+VL<9P>!7MG_# M//PS! .@OD]!]NG_ /BZ7_AGCX:?] "3_P #I_\ XN@#P>R\9>%++X:7&E:5 MK%UI6MZPKR:U>?V9YKSELGR$;S!LCY(/'/XFO(:^UO\ AGCX:?\ 0 D_\#I_ M_BZ1OV>OADJDMH3@#J3?3_\ Q= 'Q517VM_PSS\,_P#H OST_P!.G_\ BZ/^ M&>/AI_T )/\ P.G_ /BZ /BFBOM-_P!G[X7Q8\W1"F>F[4)A_P"STI_9[^&( M95.AL"WW1]OGY^GST ?%=:USKKW6E_9)(0#@*&5N <]*^P/^&>/AI_T )/_ M .G_P#BZ0?L\_#,D@:"^1U_TZ?C_P ?J90C)IOH-2:V/BJBOM;_ (9X^&G_ M $ )/_ Z?_XNC_AGCX:?] "3_P #I_\ XNJ$?%-?'/^N4O_HYZ MK)^SW\-(W##P^Q(.<->SD?EOKOM&T>QT#2+?2])@%O9VX*Q1 D[023U/N32U MN!=HHHI@%%%% 2 ,G@"JFGZK8ZJDCZ==17*QMM?8[L>&KU[2SM(9UBCNMOD[M[;#\I#; MMHSS@9P.E %/P/\ \E?^)/\ U\:?_P"DU>AUY98_"[QGINL:GJME\3'CO-5: M-KR0Z% ?,,:[$X+8&%XXQ6C_ ,(;\1?^BIM_X3]M_C0!VVL?\@.^_P"O:3_T M$URWAC_D5]/_ .N7]36?-X'^(5Q!)#+\4F:.12C#_A'[<9!&#WJK:_#;QQ96 ML=M;?$YTBC&U%_L* X'UW5PUL/.=95%M9K\4=E*O&%%TWO=/\&=?17(W/@7Q M];VLLP^)[MY:%L?V#;\X&?6J/AOPMX_U_P +:7K#?$IK?\ 7!__ $$U?\'?\B;IG_7 ?SKCI?AWX[GA M>*7XGN4D4JP_L&#D'@_Q4^R\ ^/M/LHK2T^*+)#$NU%.@6YP/J312P\X5_:/ M:UOQ'4Q$94/9K>]_P9Z37,?$C_DG>K?]\?_H(JQ7-Q_#?QQ%$DX$!T2!?,VC.W.3C/TK1U%:5CN:RO%/_(HZK_UZO\ RK(T MSP/X[U'2+.]/Q+>,W,"3%/["@.WG_ /"&_$7_ **FW_A/VW^-8O5G=%6BD>A45Q>C>%_&]EK% MOIR.>>/2NTI%!1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 $>9/:0LL,&^=W** KE4' X!//8'(]1HH \F@U[Q0+/2I M-5N=2M+R:XM((H_L@6.=6E*2>9E?E;IU(Q\N.IJP^N^*+B*R4?;TMEM+1=0F M:W>)HYMDWF;2(F.2XC#%5(''0$FO3I88IU43QI(%8.H=0<,#D$9[@\YI] '! MZ!J'B$^)+%-7>[N//@42QI T*6_[K)9U9-K L.H<$%MNW J&:ZU!-6OVEEN[ M>%M5ECO9[.+?-'$L"FW4#!(4YSD#J? M@C.>I*U0U?6?%\?B2]328[UDW7,8B-L7"*J91U^4+DX)7YF+$X..E>G44 >9 M7PU_5H=2LK6[U=M,^PWAM)C'Y7& MJVNEAB;>>"T)DFD"0[5?]V201OZCDYR>!7I-% ''^([[6+/Q59G3FN;F%HU5 M;.&-E&\L069BA1EP1D%E*A<@G.*P--U/Q/(EN-5GOX;%S'_:$T4+M+!*4D+* MN8AA=XC!"A@O][!->GT4 >5RMX@LM3OY-+.J3--/)*TD]MN=8S!;@.H*@!N) M,*.I7!':K$]YXG>2\>QN=5:SM+:>>Q9KIVMZUU=1!7DCG>-HXD/F$+'L9 0VT]59E(7/&>>;>/7=IT4 >?\ BFWUJ]\4-J^GV+20 M^'A&T +LCS,3NG\M0I#YBP@Y')(K-M==UZ\A\_3;W4[F%[F=-1=K7_CUB6Z" M*8?DY81;^FX\9(R,5ZE3(88K>/RX(TB3);:B@#).2<#U))_&@#RT17-SXF%U MK0/V<6C16MQ?:0UR98Q.^PD #:VW!Y )&"17>1Z9!A4&?O=>:V:* .'U-?$%QXNE2&]U&WL3J$-N%@C78(&MF9V!*G_ ): M#=G@\=ZR=/U'Q%*\+:V^IV5K+%&9[BUL_P![YOV>/ P$)P6WYX/( X'%>G44 M <1X:O\ Q'<>*9$U/SA#FX\Z*2-MJ*' A*_(%4E.3AFSDYQBNWHHH **** " MBBB@ HHHH **** "BBB@ K$\6:Y)X>T:._CC>4?:X(G2.)I'*/(JMM5>2V#Q MBMNJM_I\&I111W(8K%/'.NUL?.C!E_4"@#@M7^(=[)#J)T>"XM!!+8Q(;S2Y M3*#,[AR(3M9^%&,>]68=5\47D6C6EGJEM#<7S7+O/=Z-)"52,* ODM("#DDY M)Y&.*ZJZ\/6%YJ#7LZR&9I()"0Y S"S,G'U()+26:\O[.:T+^ M5-8W!A?# !@2.H.!^5 #/"FK7FJZ;<+JJ0B^L;N2SN&MP1'(R'[Z@Y(!!!P2 M<'(R:W*HZ/H]GH.F1V&G1LD*%F)=R[NS$EF9CDLQ)))-7J "LCQ9JLVA^$M3 MU2U56EM+=I5#*6!('H.3]*U)IH[>"2:=UCBC4N[LZDEHDMYH4MKY2^6[L?+>3+YV@ Y '-;% MW<>#_$S7DK:Q9W/DVYL[@P7BD1I(ZG!P>,LJ@'\*M^(H-%UNWFM+[56M)-+= M+N62VNO*EM?E;:Q(^Z"N[KUYH 9X8U;4I[K5M*UYK:6]TN5 UQ:1LD1,;C4&GO?.GW8 +R%CD8 [ #'2I[;7O#%OI=WK=MJU@MC M-/NN+L7*F,R;53ELX!PJC'TH W:*S9_$>BVTUE%<:M91O?@&T5KA09P>A3GY MLY&,=%71TW<\C;"4_[:UZI10!Y59^ M'M5MO&4SV>EW\VG:>;Z<6U[%;QQ7!F!_=)*,M('9B2:X M_AW4[FQ76%O3:744/VMLVSQ$A%(4K&2@4?>QN/. 3ZQ10!Y"=+O(=-TO1+[P MK>)!-&);VXM;5)G2/[0\D=J&W )MW?,PSCHO/(]>HHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** + "BBB@ HHHH _]D! end GRAPHIC 12 img111359907_4.jpg GRAPHIC begin 644 img111359907_4.jpg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img111359907_5.jpg GRAPHIC begin 644 img111359907_5.jpg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end GRAPHIC 14 img111359907_6.jpg GRAPHIC begin 644 img111359907_6.jpg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ⅅ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end GRAPHIC 15 img111359907_7.jpg GRAPHIC begin 644 img111359907_7.jpg M_]C_X 02D9)1@ ! @ 0 ! #_VP!# @&!@<&!0@'!P<)"0@*#!0-# L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#W^BBB@"O? M7L&FV,UY .2:S'\5Z6FJ6FGEY/.N45U.SA0P+#=Z< _3OB MM6[MQ=V4]LS%5FC:,L.H!&*Q&\)VYOX;@7#"-%C$D?EKF1HU*JV[&1P>@H < MOBZP>W\U;>]9B1MB$!WNI4L' _N[03G^O%:T>HVIYR!7._$;P1X<_X0?6-2DTN&;4+ M33"D5U)DR#8F%.?48% 'I ((!!R#WHK/T+_D7M,_Z](O_0!4;^)-$CUE='?5 M;-=2;I:F8>8?PH U***QXO$^FSZW+I,+323Q2&*1UA8QI)MW;"^, XYH V** MR[OQ%I5I#%,UY'(DEREJ#"1)B1SA0<=.:D@UO3IXHW^UQ1&3[J2N%8_,5Z$^ MHH T**A%W;&[-H+B(W(7<8=XW@>N.N*FH **** "BBB@ HHHH **** "BD8[ M5)P3@9P*PK?Q7;7.I&P73M56=0A??9L BL6"L3V!VM^5 &]1110 4444 %%% M% !1110 4444 %%%% !1110 5R_Q(_Y)KXC_ .P?-_Z":ZBN7^)'_)-?$?\ MV#YO_030!;AT]]5\$6MBEY<6;3642BXMVVR1_*.5/K7@]W\"?%K^-S(E^)+% MKD2_VF\_[T+G.XCKO_K7T+H7_(O:;_UZ1?\ H JNWB?3%E,9DDR&V_<.*QK8 MBE1M[225^Y<*9$1]\-CD<8'>O0 XEW/I]S%9'4& MTT71*E?.#;1D Y"EN ?<5L0M9WDFBA3?=:;,_[\-DP,WF$ Y M&T#MQ57_ (5CK9TF>!HK,SG2S;1$N/ED^UF7(../E/7UKT"P\47-_K>HZ4-& MF2;3U4S,9D(RZED YYR!^%,\-^-['Q3>M;:?;7(,,(>[:1-HMI-Q7R6_V^"< M>G/>@#'L_!FH0^.&U.-7_Z\+3_T.>MRL.S_ .1XU?\ Z\+3_P!#GH W M**** "BBB@ HHHH **** "BBB@ HHHH **** "N7^)'_ "37Q'_V#YO_ $$U MU%$;[S25DAV; MN,LEBIT%[KW%M+6.SMD@BW;%Z;CDUQ-IX'U)(VL+F\M#IK:P^J-L1O-;]YY MBISP.<9/M7>5REMX\L[BXP=.OXK0WSZ>MVZIY9G5BNWABP!(P"0!TKLC%12C M'9&+;;NRW::%=V/B#Q%JT,\+/J20^0C*<1M'&5^;U!//%9OA+P;?^%M2EN/[ M5^UQW\9EU%95.9+O.3*GH"#MV^@6K5MXQDN;K5+9?#^J"73%S<+F$G)3>JKB M0[B1T_6I_#_C/2_$S7+:;YTEK;Q))+=,H$:LPR8\YSO4?>&.,U0CH:*YW6?% MUOI.G6FHQ65SJ%C=-&L<]H\94EV"I]YP3DD3R!F0AB ,LHR,\F@#HJ*YV;QEIMOKKZ9(DX6.5;>2ZVCRDF9-XC)SG) M7G.,=LYJ3P_XLLO$3LMO#<0DPKH'G0L2%D7!/!(/!P?:@#>HHHH **** M "BBB@!DKM'"[JA=E4D*.K'TKYG\+?%7Q;>_%=!*@E2^G2TFLEC'R1JS8P>H M*[F.?K7M'Q'\43Z!H<5EI8\S7-5D^R6$0Z[CP7^B@Y^N*H^ O!VG^%-:NK-( M8Y;R+3K5YKIER[RN\^]LGD9P/P H ]!HHHH **** "BBB@ HHHH **** "BL M_6-:L=#LOM-_<+"A)"L59AG!/(4$X !R:R=.ANM:MEO(_$MX&#$,D%LD* ^A M21"_ZB@#H+N[M["TEN[N9(8(E+O(YP% ZU2;7]-2ZM[9K@A[A5:,[&VG<"5R MV,#(!Z^E+]AO+G2+JRO[B&:25'C69(MO!& 2N3R/:J#:%>R7]D9+N&2PM851 M8"A!#A2I?K@GTSTY]: )QXLT4VS7 NR4#A.(V).02"!C)& 3GI@5G?$*6.X^ M%_B":%U>.33971U.0P*9!%.3PSJ4:+(NJ1&ZB588W-O\OE!2N",_>.WI0!W&GVD=_X1LK65 MG5);*-6*-M8#8.A[5P5U\/=:.KO/;S+]F#X3?B:%_R+VF_P#7 MK%_Z *KOXHT=+HVS7@$P?84V-G=G&.E:TZDX_"IKC+/P5JZQOIMU-8C3&UE]4,D;N96'F>8L>TJ .<9.3]*[ M^N7M_'>F7%R$%M?) ;U[ 7+Q 1&=25VYSD9(P"1@FLV[ZLZ(Q459;#H]#U6Q MOO$]_83VGVG4S&UIYN[;&RQA,O@>O/%9?A_X?'1[*^T:ZN4OM&O$69UDR)5N MB,2,,#&UN&]CQTK3C\:P23:I$-(U3?IB;KD>2I(^7> ,-R2.F*LZ-XPT?7EO M)M/G,EI:1J\MT1B(;EW8W>H'7TI#,RY\!V]MX2LM"T9EA2WNK>9GF))<1NI) M./XB%],54\2> [_Q)J>L7DFK_9EGM$M;...-6"A3ORY921^\P?E(. .:Z=_$ M-@NL66F*[22WML]U"Z#*-&FW)S_P(8K,M_'>FWMG9SV%K?WDEU UPD$$(,BQ MJQ4LP) '(('/- &;/X(O=0\366IWKVD:1/!/]'M[R6T2.[N9XROR01;BP,7FDKSR% M3!/U H ZJBN>?QCIR7-B@BNVMKTQ+#>"+]R6E&4&[/4X[#C(S4#^/]!$>KR) M-++'I4D<4[1QDAI';:JI_>.[CTSWH ZBBL[1=9M==L6NK594"2O#)'*NUXY$ M.&4CU!K1H *BN+B&TMI;FXD6.&)"\CLM #/ MM+XS\57GC_4$86HW6NBPN/N1 D-)CU8Y_7V MKJK*W8>.-5_TB8XL;0\MU^>?BMNVMH-+TV.VM(5CM[:()'&O "J.!7":=XFU M-_%DUW)HJ)#>1P6V1=J2FQI#NQCG_6#CVKFKUZ%)I596;V-:=.I--P5ST2BB MBNDR"BBB@ HHHH **** "BBB@"K=Z?;7S0M.FXPOO3GU&"#Z@@]*Y*'7VM=3 MU2V@FTBR:.[82)?7+>;(>,/@= 1C ]!7;UY_!'T\&ZO\ 9WTNY-JMBVMMJCS*Y+LGF^8J!<#! MS@$YZ9KT"N;M_&^E7%P(PETD;7C6*SO"1&TZDC9N[$D8&>":DDB&BZQ8WOBF M^T^2U^U:D8FL_-)VHRQA,OQV/.*RM#^'CZ9H6I>&;J[-SHUU'OCD#%)HYF4B M3I@%2?F&?7'-;2>,[-Y-23[!J6[34WW0^S\I\NX <\DCG JSI/BO2-<-TVGW M/G06L:22W&,1#2.V>: ,'_A7MO#J^A^22VFZ=836S*\[B1G;8 <@ M]/E.1G'/2J_AOP=K/A6VT^:T:SN;J+3S8SQ2.RKQ*SHZM@G^,@C%=<^O6":O M9Z9YC/<7EN]S"4&5:--N3G_@0K.@\<:3>6MI-9)>7374+7"0P0%I!&K%2S#L M,@@>O:@#(U7P->:UXPTO5[V>W-JEH8M0@CR!+( X1E![ R-U/85E:?\ #G4[ M'PK#9R/:W&J"YFD:Y\]XV1'3REVL!S\@4$$<\XYYKI]0^(.@:7:7US=RW$:6 M2V[S PMNQ-]P@=3T.?3!J2Z\=:+;7DMINN)IXRN4AA+E@8_-)&.H"8)^HH P MX?!NK0Z]H*S-#=Z)HEM%%:PF8H?.50IF=<'<0,X&:L:QX+O;^;Q*;>2V2+4_ MLGEQL" RQ8YVJB_WCNXX[T 3>$-%N-!T1K.X,0+7$LR1Q M$LL2.Q8)N/+8SU/6J-U9:@WB^&S37M1CMYK66X,:^7A2KH =N<88UNZ/K%I MKEDUU:&0*DKPR)(A5XY$.&5@>A!JC/\ \CY8_P#8-G_]&14 +XM\2VOA'PS= MZO=_,(5Q%'WED/"J/J?ZUB?#;PU=:3I5QK.L_-KVLO\ :;QB.4!^[&/0*.W^ M%8B?\7)^))?[_AKPU+A>ZW5YZ^X7_/6O4J *]]/';6,TTIPBH'3)-' M--*T;J$F" =B3@'\OUK6O#_:NKI8KS;6V))\?Q-V6K<4Y_M"1OL\X1T103&0 M,@M_B*\>M2I8K$1G45XQ=EYOJ_D[+UN=L)2I4VH[O7_(T****]@X@HHHH ** M** "BBB@ HHHH 1V"(SL<*HR:\^M]*6XOM3U 0Z9J,-S-E3 PK*% MP-N,?SKT*N0OM6\*-J]Q%<:>LTUJDDLLXM-R#8RAQN[E2ZYH Z6PO;6^M]]I M-'+&AV%HVW+D#H#W^M6JCA$0@3R @BP"@08&/:I* "N7^)'_ "37Q'_V#YO_ M $$UU%:.W\,Z?+,ZI&MI$69C@#Y!51O%^D+ MJ:V?V@$$?ZX'Y ?3-6](ABN/#&GPS1K)$]I$&1QD$;!U%5&\(:.VIK>?9E"A M<>0 /+)]<5C5]MI[.WS$[]#:@GBN8A+!(LD;=&4Y!K@+3P?K)M7TNX6V2S;7 M&U-[A926,?F^8J!<<,2 "<\UT^&.(QW<:R= ^'UQIF@ZIX8N[L3Z3=Q^9%<)\DJ3.I$N0.",_,/R-8UE MKU[9_#-KQM4O)-5U&^DT^":65I#&?/9 RKZJ@)X_NTI\0ZO=^%M/*7UW,;"6 MZM-1DM6"3RR1(?*?#8.T_*Y^O/%,#?'@!(-8T+RI'?3M.T^:V8M,PD9VV 'C MM\IXZ56\,^$=<\*P:=/;K:75Q'IQL9X7E9 ")7=&5L'(^<@C'YUD6_B/Q*=5 MT6[NWN<7KZ>J1Q;?)"2QDRB1OH*RM-^'FKV/A>&"9H;C5Q2:\K^(WQ4M(/%$^D:'(PU 6[Z:UXY"Q0/)(FYL] M?E"GGU^E>Z=*^;]&\ Z5X]^*>JZ@?,@T,W,LL*)S]I,;('Y[*6;^E 'NWA/P M[9^%?#-EI%E\T<*9>3O*YY9S[DU=U2^&GV+S ;I#\L:_WF/2KBJ$4*HP , 5 MBP_\3?6VG/-I9G;'Z-)W/X5RXJI*,5"'Q2T7ZOY(UI13?-+9?U;YES2+$V-D M%D.Z>0^9*WJQJ_116U*G&E!0CLB)R*-7ORL:@B[<9"@=A325C.3D MI)(U****1H%%%% !7EE]/X>EU35[N\AU&Q,,EU"(UN-EO?D%3(NG7,BQ6LTC2>4J(6,F,[0!U_"O-+VX6XT]E\^\DLKN ZA<6O]G6KA82 M<>!B@#TJSD66R@D1-BO&K!!_"".E0RZK80ZA'827<2W<@RL1 M;D]U'PU<7OB>+4UN(UA4)D?-N&T.,8^ MZ<[^IZKQ(DJW-@;F)%@C'DL$,80ID\Y#D7_H K0K/T+_ M )%[3/\ KUB_] %:% !1110!2BT?385MUBL;=!;R-+"%C \MVSN8>A.3S[FH M[GP_H]XTC7.EVDQDE$SF2%3N<# 8\=<<9]*T:* *9TG3CJ*ZB;&V^VJNQ;CR MAO"^F>M7*** "BBB@ HHHH X[XFZ_+H/@RX%H206Z M6UOS=7)\N,>GJ?PJW8V<=A91VT?1!R?4]S69I2MJ-]+JT@(0_N[93V7N?QK; MKDPW[V;Q#V>D?3O\]_2QM5]Q*FOGZ_\ "BBBNTP"BBB@ HHK*UOQ!9:% K7 M!:2>3B&WCY>0^@']::3;LB9SC"/-)V1>O+RWT^UDNKJ58H8QEF8UR?@?Q/'K M5SJ<# )(9VGB7N4/'YC _.I+;P_>^(9UU#Q-Q$.8--4_)'[OZM5GPSHFF6ES M?7-O911S17./I6MH1BT]6<7-6J5836D==]W_ )'34445B=X4444 M,EB2:%XI%#(ZE64]P>#7,6?A72)[*ZMH+ZZFB)6TE(FY6.+($&0.%&3GN<\F MNJKS#4'@BO==U"&06GV:[(EM#JMQ#)<,,?,%5@%W?P@ YXH ].551%1 %51@ M =A2U' VZWC;:RY4':_WAQW]ZDH *Y?XD?\ )-?$?_8/F_\ 03745R_Q(_Y) MKXC_ .P?-_Z": -C0O\ D7M,_P"O2+_T 5H5GZ%_R+VF?]>D7_H K0H **** M "BBB@ HHHH **** "LGQ/KD'AKPSJ&L7!&RUA+@?WFZ*OXD@?C6M7FOCTGQ M3XTT#P3&=UL'_M+4P#_RR0_*I_WF_I0!J_"[0Y](\'175\,ZGJDC7]VQZEY. M0/P&*@U77;JYGFA*HBC=%E2=# M?G]],C2NH? 4Y&!^M>)FZK5G&A0E9]?1Z([L&X0O4J+T.GMXTBMXXXU"HJ@ M#M4E(!@ #H*6O:BK))'$W=W"B@\BLN&";^U9HC?7+1QQQN%)7DDMG/'3@520 M6-2BFR2)#&TDKJB*,LS' KS_6/&8U:X:PTR[^R60.V:]"DN_M&O]:J$'+8Q MJ55"RW;V2W?]=S>UCQ,Z79TG1(1>ZHW! /[N#W<_TJ31/#*6%PVHZA,;[59/ MOW#]$]D'85EZ.US96GV;P]H+QQMRUU>MM,A_O'N:T?["U6_YU769 AZPV@\M M?IGJ:MV2LM/S)AAY2ESUGKT71?\ !\RYK>M6VGV,VV^MXKK:?+#G=\WH0.:Y MWP/J&K7]Y=F8PBUWM+)A""9&QP/RKI;'P[I6GD-!9Q^9_P ]'^=OS-/TF*.+ M[;Y:*N;IR<#J>*GF2BTC=QB]>J-&BBBLP"BBB@ K@/[2NKW7-3:2XE5K2[:& M)K;2?/55&,#S,'+>OH>*[^O/M=LY]'?5=2M=3MH4,AN)(!>R1ECQG@' ; Z MD7_H K0K/T+_D7M,_Z](O_ M $ 5H4 %%%% !1110 4444 %%%% $=Q/%:VTMQ,X2*)"[L>BJ!DG\J\\^%T, MFK/K/CB\4K+K,Y%L'_@MHSM0?C@G\*F^*]_<3:/9>%=/?%_X@N!:@CJD/61O MICCZ$UO/;1V]K9^&-+'EPPPK'(P_Y9Q*,8^IK&O65*'-:[V2[OL73ASRL36H M.M:G]M!(8E"H@P *DJ*&'4(^ M_K)ZM^?^2V152I=^[HEL%%%4=4U:TTBV\ZY?D\)&O+.?0"NE*^B,DKEJXEB@ MMY))Y!'$JDL[' ^M>/"]GMM9N;B'4Y%@A(=))Y&_>+D[0%ZM]*W]2U2YU2_ M2&XMVN[K.8-*A;Y8_P#:G;M]/Y5G:1I.J-XVCOK_ /L^=U*M(GF#"@Y V#U& MW@5UTHAT4J2A=WNWN_ZZ>04445!J,D M\SRV\HJ'Q\N[I5*PMKVWEE,TD#)(YD.Q2""<>_M6A13N.X4444A!1110!5U. M62'2;R6(D2I [(0,X(4XKE=)BO+[2=/O;KPO83W4UO%+)-(Z!GE-:6-'1'=59SA03@L?;UI]('8"K E3GJ@Z%_R+VF?]>D7_H K0K/T+_D M7M-_Z]8O_0!6A0 4444 %%%% !1110 445Y1\5/']YX2\RUL=;L3=W"%4LOL MI:6(%,^AKT;2 M;!K.W9YCONICOF?W]/H*Y3X<>&UTOP[IRN 8[>/*?[I[=[+X?U?SZ>7J;S_=Q]FM^O^7]=0K/?4;A;P6XTZ9F(+!A(F"H(&>ON*OL MRHA=V"J!DDG %>,ZYJ$C^*YH],N[FZ\QB(O+8Y))!P/QKTJ5/G=CDJU52CS2 MV/2-?\46VD*T,>V6[QG86PL8]7/;Z5R6FV6K^)[LW<HH=%>*^-U_:$S,P4,IBB (4D@< M+Q]XUK=*KK?6CN$6Z@+$X $@S6+F^KW-52@DDE9+Y%BBBBD:!1110 4444 % M%%% !1110 4444 %%%% !7+_ !(_Y)KXC_[!\W_H)KJ*Y?XD?\DU\1_]@^;_ M -!- &QH7_(O:9_UZ1?^@"M"L_0O^1>TS_KTB_\ 0!6A0 4444 %%%% !111 M0 R::*V@DGFD6.*-2SNQP% Y))KY)\6:?_PG?CN^UC3KB*#3[VZ,4,MS)@L$ M49<#^[QQ^5>N^*]4N_B1XE;P7H4K+H]JX.KWJ'B0@_ZI3Z>O_P!;GO;3PSX9 MT^TAM!INFD0H$'F0H6X'?(S7/4K (!FIM3U:STBV,]W*%'\*CEF/H!6'K_B^PT*W-M9B.29%VA5X MCB'8))!Z ?PK792I-13F]/S.:K649+K25MFGVMW?O_ -,8 MB%_,TWS_ !1?_P"JMK33HSWE;S'_ "'%J(WEI^0JK:^%]"37) MQL22-8D*1,^5!)8'_P!!'YUE4E6;C:*6O43;.C74[!SA;VW/TE7_ !IZWMJ_ MW;F$X]'%9[>%]#<8.F0?E3#X2T$_\PV(?3(_K6MZW9?>_P#(K4UEGA;[LJ'Z M,*<)$/1U_.L1O!V@M_RXJ/HQ_P :8?!FB?PV\B#T65A_6CFK?RK[_P#@!J;D M@66)E$A3(^\AP165HLL=U)=/'J$MP(IFCVEP1CC';Z\U6;P7I)!"FZ0$=%N& MQ^55_"OAQ-*N[RX,[.ZR-"H' VCN1W-9MU74C>.GJ+6YU5%%%=104444 %%% M% !1110 5R_Q(_Y)KXC_ .P?-_Z":ZBN7^)'_)-?$?\ V#YO_030!L:%_P B M]IG_ %Z1?^@"M"L_0O\ D7M,_P"O2+_T 5H4 %%%% !1110 5YQ\0O%=]+?0 M^"O"[;M$],B@LHOM6N7[>386B\EG/&X MC^Z/_K5S?A^"P^'&FS7>K3_VAXIU$^;=OG+;C_#GL!42YI/DAN_P\QWC%<\W M9(Z_PSX>TKP%X92UC=(T0;IYWZR/W)KSCQ;K=K?Z_)<6D0VL "6&"V!C-;D> MD^)?&]PMS?N;&PZJ&&#C_97^IK9/PSTL%-KY"\G>K$OQW(8?IBMZ7LZ"MJ_3 M_AU:TJ*@M/GY_,Y MW_A&KJY_Y".MWDP/5(B(U_2LW_A&=-AUJ*5=/O7MT4[E92RL^1@\G)'6NTHK M.6&IOI^OYFG*AJ(D:!40*HZ # IU%%=!0=:KK86:.'6UA#@Y#!!FK%%)I/< MHHHI@%%%% #)8DFB:.1=R,,$>M5[;3+*TE\R"!8WYY!-6Z*3BF[M %%%%, H MHHH **** "BBB@!DDL<*;Y9%1>FYC@5S7Q(_Y)KXC_[!\W_H)JWXFTZ6_@M] MMA%J"1NV^VE*@'*D!OFXR"?U..:XWQYHOBR/P+J$=OK5JNGPZ5Y>:5HOQ!.CV)B\7:;'&;>/:C:3 MDJ-HP#\]6_[$^(G_ $..F?\ @H_^SH [BBN'_L3XB?\ 0XZ9_P""C_[.C^Q/ MB)_T..F?^"C_ .SH [BO./B!\7]-\":M%I;Z?/>W;1B5PCA%13TY.92.ZD'[JQBR1LCSU;U/^.:]4T/P M1IVDR?:KDF^OR=S3S\X/L/Z]:QK'P;XKT*RBTSP_XEL+/2X%VP0RZ;YC+W)+ M;QDDDG\:L?V)\1/^AQTS_P %'_V=5"3Y-K7W_P"#_5C"5"+GS3?-;;LO1?KN M=Q17#_V)\1/^AQTS_P %'_V=']B?$3_H<=,_\%'_ -G3-3N**X?^Q/B)_P!# MCIG_ (*/_LZQM3?XBZ=XAT32AXET^4:H\RF==*PL/EIOY^;G/3J* /4:*X?^ MQ/B)_P!#CIG_ (*/_LZ/[$^(G_0XZ9_X*/\ [.@#N**X?^Q/B)_T..F?^"C_ M .SH_L3XB?\ 0XZ9_P""C_[.@#N**X?^Q/B)_P!#CIG_ (*/_LZQ].?XBZAX MEUO1SXET^(:9Y&)VTGY9O,0MQ\W;&.IH ]0HKA_[$^(G_0XZ9_X*/_LZ/[$^ M(G_0XZ9_X*/_ +.@#N**X?\ L3XB?]#CIG_@H_\ LZ/[$^(G_0XZ9_X*/_LZ M .XHKA_[$^(G_0XZ9_X*/_LZQ_#K?$77[>^E/B73[7[+?36>'TK._P ML;Q\ MPX/6@#U"BN'_ +$^(G_0XZ9_X*/_ +.C^Q/B)_T..F?^"C_[.@#N**X?^Q/B M)_T..F?^"C_[.NKTF'4+?2X(M4NXKN]4'S9XHO*5^3C"Y..,#KVH NT444 % M%%% !6)XEU6^TVUMH],MEN+Z[F\F)7&5!",Y)^91T0CJ.M;=5[VQM=2M6MKV MWCG@;&8Y%R#B@"+2+UM1TBUO'"J\L89@N< ]P,^]7:;'&D,:QQHJ(HPJJ, # MTIU !1110 5S7B7Q'-HE]:0IY*QR(TC&6-G,A#*/+7:?E)W9R M&:-9(G&UD89##T(JL-)T]=2_M(64 O=FSS]@WX],T 7**** "BBB@ HHHH * M*** "BBB@ HHHH **** "O-[%[N'P,/$0U*]^WQW+$^9.S)(//*;"AXP1QQ@ MYQ7I%8=KX0T.SEC>&S($J:CIBW^DV9DMF>%':.+S9(LH6D.S M(+%3M4KUZGM6R/"6CPWB7]O8H+R%WFMV=W*Q2,#DA(-W@[^UA>6?F[<>;Y-N,YXKE9];UK6KZ+2EOGM?)U.**246S0O-&\1D *ELKR"/?BN[;0=,;1O[ M(-HGV'&/*R?7.W@T\789"SL%0_,,#CEN:Z_P_JFIZO?7[72Q6]O; MNL2VX7,@8HK'.M1MQ>7[06VGQ74<373N4 M4D@?FQ_.LF+P5X>A\S9IR@/'Y1!D<@)O#[0">!N4' ]* ,.\\4:WI,MV]VUG M-;V-_!;.(HF#RK*%]_E*EO?.*@O?&>LZ?H4&J2)92#4+&2[MHE!_6UK%-"[1+$K>;$!( OS9Y)&< M],'I756_A/2H_LLLL'F7,,<2-('91(8P I90<-C'<&E?PCH4AN=]@I6Y5UE0 MNVS#_>PN<+GN1B@#%@US5;C7IM%M'@CG,\Q-Q,K,H2-8^ N>I:0<9P #5!/& MFM7=O>7D"64<-C:0SRQE6;S':21&56SPN$R#UKK)O"^CSPF.2T)S(9=ZR.K[ MBNTG<#GD \\U(OAS2$MYK=+&)8IH([=T7(!C3)5?PW'\Z --6W(&]1FEI MH '0<4M !1110 4444 )FC-%% !FC-%% !FC-%% !FC-%% !FC-%% !FC-%% M !FC-%% !FC-%% !FC-%% !FC-%% !FC-%% !FC-%% !FC-%% !FC-%% !FC 0-%% !FC-%% !FC-%% '_V0$! end GRAPHIC 16 img111359907_8.jpg GRAPHIC begin 644 img111359907_8.jpg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img111359907_9.jpg GRAPHIC begin 644 img111359907_9.jpg M_]C_X 02D9)1@ ! @ 0 ! #_VP!# @&!@<&!0@'!P<)"0@*#!0-# L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#W^BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **YCQSXXTSP)H1U&__>RNVRWM48!Y MF[XST ')/;ZD"M7P_JZZ_P"'M/U=(3"M[;I.(RV2H89QGO0!I4444 %%>1>* MOCS8>&/$]_HO]B3W1M'$;3+,'H21^%8__ TM8?\ 0M7/_@4O_P 3 M0![K14-G<"[LH+D+M$T:R;IV:7=A=P7=M)G9-!()$;!P<,.#@@C\* +%%%% !167J/B70='N%M]4UO3;& M=EWB.ZNTB8KR,X8@XX//M5/_ (3OP?\ ]#7H?_@QA_\ BJ .@HJ&UN[:^M8[ MJTN(KBWE&Z.6%PZ./4$<$5-0 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %87C'5 M-5T;PI>WVB:>=0U./8MO;;6;>S.JY(7D@!B3TX'4=:W:* /EKXB>#?%*^&9/ M&/C/4=^IRW$<,-E&05@1@3@XX&,=%^I))KW_ .'7_)-_#?\ V#H?_0!7(?M" M?\DT'_7_ !?R:NO^'7_)-_#?_8.A_P#0!0!TU(S!5+,0% R2>U+574K/^T=+ MO+(3/!]I@>'S8\;DW*1N&>XSF@#PCX2:SHT.H>+_ !CX@O+6U@OKW9"]RP&2 M6:1E4'DG#)P*]2N ^!U.T@''X5P6A?L[^';%Y6 MUB_NM4!.NTDEO?('M7.?$WX267@[1_^$K\)W%W:26$B/)%YI8J" MP =&^\""1G)/'ICD ^A0 !@# %%<]X%\0/XI\$:3K,H437,'[W:,#S%)5\#L M-RFOEWQIXT\56OCKQ#;V_B7688(M3N4CCCOY55%$K -@ #C% 'V'17Q!_P MG?C#_H:]<_\ !C-_\57J?P#\2Z]K/CJ]M]4UO4KZ!=,D=8[JZ>50WFQ#(#$C M."1GW- 'T91110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5>_OK; M3-/N+^\E$5K;QM++(03M4#).!S5BJ]]8VVIV$]C>1"6VN$,X2PL+4+OMF4,-@08RP(^^[=JZ;_AG'P? M_P!!+7/^_P##_P#&JXS1/"WQ3'BKQ%-I5@-&FU.9I)[VZ*C8K.S;48;LYSR5 M!Q@*+;QCX5LM:MT\OSUQ)%G/ER X9<]^ M1P>XP:\^\;_'/_A#?%][H/\ PCGVS[+Y?[_[;Y>["OCI_PF'BZPT'_A'/LGVLO^_P#MWF;=J,_W?+&? MNXZ]Z /8**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBN%\=?%70/ R-!,_VW5,?+90,-P]"Y_@'YGVH [JBOFZX M\1_&+X@,6T?3[O3=/?[GV=1;J5['S7(+!?C+X6<3:9?74ZI_#;WXD3_ +]R$9_(UO:!\<]8T2^3 M2_'^BS6[=/M20-%(/=HSU'NN/8&@#WJBJFF:I8ZSI\5_IMU%=6LHRDL39!_^ MO[5;H *\X^(7Q?TOP-=C38K5]1U4J&,".$6('IO;!Y(Y _+(KT>ODC2/$^D MV_QAU'Q)XD\R2&&:::*,1[V:3.$4#IP#QD@# H ]+\._'];G7HM+\1Z&VE^: MP03"0GRR>FY64$ YZ_I7K>N:Y8>'=$N=7U"79:6Z;V(Y)] /4DX KQ23QO\ M#+XG^);.+Q%I-[;7('DV\TTFR-@3D*S(V1R3C/')YK2_:'N39>"M)TZ LL$M MSR-Q.0B\ D\G[WZ4 9RMLB8R$JS_W&! *GTZY]JX/X,J/ M$'QCU35[N-9'6.>X!;!*R,X&?R+?G5K]H>W73O%^BZO:XCNGAR64/_P##1W@__H&ZY_WXA_\ CM>C>%/$UEXP\.V^MZ?%<16T MY<*MPH5QM8J<@$CJ/6@#:HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH *R_$>O6?ACP_>ZS?DBWM8]Y"XRYZ!1GN20!]:U*\R^/<-Q M+\+KEH,[(KF%YL?W-V/_ $(K0!Y9<_&CXB^)[^1?#=HUNBG(@L;+[2X';<65 ML_4 4O\ PF7QS_Y]=<_\$2__ !FO8_@Y8V%G\+]'>P2,?:8S-.ZXR\NXALGN M1C;[;<=J[R@#Y@_X3+XY_P#/KKG_ ((E_P#C->O_ EU3Q=JOAZ]F\8QW:7J MW96(75F+=O+V*>%"KD9)YQ7H%% !1110 4444 %%%% !1110!Y5^T)_R30?] M?\7\FKK_ (=?\DW\-_\ 8.A_] %7O$GAC2O%NE?V;K-NT]KY@EV+(R?,,X.5 M(/UFT_QQ<-8ZI#*R^N:]2\1?#CPEXJN?M6K:-%+='K/&S1.W^\4( MW<<>%?"&/!6DZ-)L\ MZV@ EV=/,)+/CU&XGGO70444 >0?M'?\D\L/^PK'_P"BI:\^_9Q_Y*'?_P#8 M*D_]&Q5Z#^T=_P D\L/^PK'_ .BI:\^_9Q_Y*'?_ /8*D_\ 1L5 'U!1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!P/QK_P"21:[](/\ MT?'3/@C_ ,DBT3ZW'_H^2MKXA^'+SQ;X%U+0["2".ZNA'L>=B$&V17.2 3T4 M]J;\.O#=YX1\"Z=H=_+!)=6QEWO;L2AW2,XP2 >C#M0!U-,ED\J%Y-C/M4MM M7J<=A[USGCW1M'"@\C<@)YJWX0TW5-(\*6%AK M5[]MU&%")[CS6DWG<3G:[+KOA M#6#I%]*Q=XBS(N\\DJZ-O%37L,+<1QSRSNR]P' MDQLS[ T =+^S[8SVGPU,TQ;9=WLLT0/90%3C\48_C5[Q3\%?#GB[Q'=:Y?WN MJQW5SLWI;RQA!M0(, QD]%'>O0+*RMM.L8+*SA6&V@01Q1H,!5 P *GH \,\ M1_ +PKH_A?5M3M]0UEIK.RFN(UDFB*ED0L <1@XR/6O,?@I_R5W0OK/_ .B) M*^H_''_)/_$G_8+NO_135\N?!3_DKNA?6?\ ]$24 ?8-%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &?KEO?W>B7EM MI=RMK?2Q%(9V_P"6;'^+\*Y+PA\)] \,.+ZZ3^UM98[Y;^[&X[SU*JN]HH **** &3316T$D\\J10QJ7DD=@JHH&223T '>L9SX7\;:=+;^;I>M6B MG#K'(DZH?J"=I_6E\9_\B-X@_P"P;<_^BFKRG]FO_D!:W_U\I_Z#0!V7AGX: M#P7XI>]T#4YX]&N$87&FS,64/_"RG].>?:_$/X/:;XXO!J=O=MIVJ@!7F6/>LH'3<, M@Y'3(- 'GG[1>DZ1876ASV5K;6]Y,LHF$*A2R#;M) ^K#/M[5;^+]O?W?P?\ M(ZA>!_M$2QBXR.0[Q#.?Q4UK:#^S]%%K$>H>)MU>L MZYH&G^(=#N-'U"'?9SIL*KP5QT*GL1VH Y/P/KMF/@M8:B9T,-EIA24_W3&F M"#[Y%>;_ +.%K))K.OWX!$(2.,''!)+']!C\ZLS?LYWRRR6UIXM*:;(^XQO; MMGVRH?:Q''/'X5Z]X.\'Z;X)T&/2M-5BN=\LS_>E<]6/Y?D* /!O@NX\/_&# M4](O)521XYK<;N"TBN#@?@&_*K?[1%P-0\7Z)I%MB2Y6#&T'G<[X4?H/SKN_ M'WP5LO%NL'6]-U%]+U-B#(0F^.1AT; (*MTY'ITSS5;P5\#K?0-?37-Q-OB4QD*K_WV))+'TZ8]Z /1[S23J'A2XT6;BR:V,NW.WOHCX&_\ ))=)_P!^?_T<]>5?M(?\CQIG_8-7_P!&25ZK\#?^22Z3 M_OS_ /HYZ /1:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "N=\>:G;:-X&U>_O-/34+:.#$MH[[!*K$*03@XZ^E=%4%Y9VNH6DEI> MVT-S;2##PS1AT8=>5/!H ^3O!_Q>U'P3/X'[31P,^$03WQJ7_VJO2]F_#?Q]_P ML+1+K4?[,^P>1Z8[5!H-E\+_$Z,VBZ5X9O"HRR1V,( M=1ZE"H8#ZBNMTW1],T:!X-+TZTL8G;>T=K L2LV,9(4#)P!0!=HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** /(/VCO\ DGEA_P!A6/\ ]%2UY]^S MC_R4._\ ^P5)_P"C8J]!_:._Y)Y8?]A6/_T5+7GW[./_ "4._P#^P5)_Z-BH M ^H**** "BBB@ KS7QO\9-,\#^(3H]WI=W"O%MOXU\.1ZS:VTMO$\CQB.4@M\IQVKH:\R^ G_)+;7_ M *^9O_0J]-H \M\7_&[2O"'BB\T*YTF\GFM=FZ2-U"MN17&,^S5V_A#Q+!XO M\+V>NVT$D$-UOVQR$%EVNR'./=:^6_C;_P E>UW_ +=__1$=>_\ P2_Y)#H? M_;Q_Z/DH [V66.")Y99%CC0%F=S@*!U)/85Y#XF_:%T#2;B2VT6RFU>1#M,P M?RH<^S$$M^6#V-EC(Z'\C[?44 ?9 MOB;7%\-^'+[67MI+E+2/S'BC(#%/XD?"Y9;D 27]I):7:CC$F"CD8Z _>'L17R+ MIMU-H'B2SNY(V6;3[Q)63N&C<$C\Q0!]W5YOXX^,>E>!_$ T>XTZZNYA"LK- M"R@+NS@<]\ '\:]&CD26))$8,C@,I'<&OBGQ]JK>)/B)K-["#+Y]XT4(09+J MOR)CZA10!]*^ OBYI7CW69]+M;"YM)XH#./.92'4, 0,=_F%>AU\9_"?6?[# M^)FB7!EZ1J\>J^';/67C-K#@XKXCMXKKQ+XFBA9Q]KU.\"EL?QR/C/YM7O/[07B2;1]$TOPKI[F&* MY0O<;3@F),*J?0G)/^Z/6@#=US]H'PEI=V]M91WFIE#@RVZ!8\^S,03]0,>] M6/#?QV\):_>I97!N=+G/?##X0R>/+&?5+R_:RTZ.4 MPIY<>YY6 !.,\ #(YYR%[C1[Z5I+K2 MBJQNQY:%L[1[[2I'TVUR?[1NN7\FHZ?H<23+IT,?VB5PIV22DD 9_P!D?^AT M =/J/[1?A:UN6BLK#4;U%./."+&K>X#'/Y@5O^$?C+X5\77J6$+/#L>MZIJ#?'OQ3-K'CAM&CE;[#I:A @/RM*PRS?49"_@?6@#T*Y_:/\-1W!2WTG5)H M@<>80B9'J!N_GBNX\&_$GPYXY5DTNY>.\1=SV=PNR55Z9 R0P]P3C(SC->,> M#/@(?$?A+_5Y+.>\C\VVB2$.%4_=9N>XV;@OUZ"OCBUM]6\<>+DA$GVC5-3N.9)6P-S')) M] !SQT X% 'OB_M)>'C-AM%U019^\#&6_+=_6O1?"7CSP]XVMWDT:]\R6( R MV\B[)8\^JGJ/<9'O7DMY^S7&FCL;/Q \FIJF0)8 L3MZ<$E1[\_2O&?#FMWW M@_Q7:ZE"9(I[.<":,'!90<.A^HR* /N2BCM10 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 8/CC_ ))_XD_[!=U_Z*:OESX*?\E=T+ZS_P#HB2OJ/QQ_R3_Q)_V" M[K_T4U?+GP4_Y*[H7UG_ /1$E 'V#1110 4444 %07%]:6A47-U!"6Y DD"Y M_.IZ^=/VE?\ D,:#_P!>\G_H0H ^A;>\MKL,;:YAF"_>\MPV/KBFW%_9VKA+ MB[@A+_ +-W_(FZK_V$#_Z+2O:* "BBB@ HHKRO MXR_$JX\%V$&F:2RKJUZA<2D ^1'G&[!ZDG(';@T >G3W5O:J&N+B*$'H9'"Y M_.G0W$%RF^":.5/[R,&'Z5\166D^*/'&HS36MMJ&KW7668[I"/\ ><\#VR:8 MZ>)/ ^M@,+[1]1C 8?_ E\?OX[\-R->A%U2R81 MW(08#@_=<#MG!_$&O0* "D9@JEF("@9)/04M>.?'SQNVBZ#'XM 'K<%_9W3E+>[@F8#)$<@8@?A3)=4T^&1HY;ZUC=>"KS*" M/PS7EO[/_A8:3X.DUN9"+K5'RN1R(D)"_F=Q]P17B/Q;_P"2I:]_U\#_ -!% M 'U]_;.E_P#02L_^_P"O^-21:C8W#;8;VWD;T252?T-?&&F?#OQ=K.G0ZAIV MA7-Q:3 F.5-N&&<=S[56UGP5XF\/0?:-6T.]M8,X,SQ$H#[L.!0!]PT5\H?" MSXJZGX9UJVTW4[N6ZT6X=8F69RWV;)P'4GH!W'3&>]?5X.1D=* "BBB@ HHH MH **** *DFJZ=#(T7<7EO$^,[9)54_D35FOG?XT M>!?$_B+QW]MTC1KB[MOLL:>9'C&1G(Y- 'T)#/#QKNZ "BBB@!KND:,[LJHHRS,< #WJ M*WO;2[+"VNH9BO41R!L?E4DT,=Q!)#,BO%(I1T89# C!!KY*M[R\^$'Q=N(U M9_L<,^R5,Y\ZV;D'ZX(/U% 'UQ145O<17=M%<0.LD,J!T=3D,",@BI: "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HK%\6V^I7?A+5+?1VE74I( M&6W,4OEL'[8;(P??(KYZ_P"$-^.?_/UKG_@]7_X]0!]/T5\P?\(;\<_^?K7/ M_!ZO_P >H_X0WXY_\_6N?^#U?_CU 'T)XS_Y$;Q!_P!@VY_]%-7E/[-?_("U MO_KY3_T&N-F\#_&ZY@D@GEUF6&12DD;ZXC*ZD8((,O(([5Z=\$/!^O>$-)U2 M#7;#[))/.KQKYR2;@%Q_ QQ0!ZK1110 4444 %%%% !1110 4444 %%%% 'S M+^TA_P CQIG_ _P#1DE>J_ W_ ))+I/\ OS_^CGKRK]I#_D>-,_[!J_\ MHR2O5?@;_P DETG_ 'Y__1ST >BT444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %8/C/Q+%X1\):AK MKR_X_1RO\+YFCSMCNX6D_P!W)'\RM 'E_@WX<:Y\6;N?Q1XCU26*RED91+MW M23$'D1@\*@.1GIQ@#KCT8?L[^#!!Y9N=7+X_UOVA-W_H&/TKJ?A5=6MW\,- M:T*E$M1$X':1>'S_ ,"!/XUV- 'S%XW^$NK?#@1>*/#6J3SV]HX=GP%FMNP8 MXX9>QX'7D$9->Z_#WQ6/&?@NQUAU5+E@8[E%Z+*O#8] >H'H14WCVYM+3X?^ M();XJ+?[!,C G&XLA4*/$(=&NM*N[B5)9)#)$ZA2&.>]=9_PTGH?_0!U#_OXG^-)8/%_C;4-=MH)((;KR]LV20 ,VZ-7.<>[5]-?!+_DD.A_]O'_ */DH ^8O'UY M+?\ Q!\07$I)8ZA,HSV57*J/P KZY^'U@NF_#SP]:J@0BPB=U']]E#-_P"/ M$U\B>.[66R\?^(()5(9=0G(SW! M&]:ATG6-52TNY8A*@=&*[22!E@"%^Z>N* -^TL[6P@$%G;0V\()(CAC"+GZ" MOCKXKZ3_ &-\3M59%SZ9!Q7SO^TCI/D>)-(U=0=MU;- V!QNC;.?KB0?E0!Z7I/B[R/@)#XA\ MP&:WTHQAB>LR#RAGZN!^=> ?!_1?[;^)VD1LFZ&V:7 M)X8^(VL6<)\LV]X98"O&U6Q(GY!A7TC\0/$\8?M':+]E\4:9K"+A+VV,3X'\<9ZG_@+J/PKF=9\7"_^!^@:"92;BWU M&57&>2B+N7/M^^ '^[[4 'P0TC^U?BCIS,H:.R22ZD?N9=/$2G_ &DD;:3D9"OC&#_ +)Z'\#VH Y']GK6K*Z\#2:2LJB]L[EV>(M\ MQ1L$,!Z9)'U%9/[2.KV7]BZ3HXG1K[[3]I:(')6,*RY/IDMQZX/I7CFH^"?& M'AC4]DVCZC#/&?DGMHV93[JZ<=/>EU#P1XEM?#MQXFUJUGM(/-6-3>!A-.[$ M]%/. 3DXSQC- ';_LYW4D7CZ^MP3YDW<[6-T6:%G;]Y! M(A!QN&,]00>OY9(!],^$?#L/A/PII^AP/Y@M8MK28QO.+OQAX5F@U.7SM1TZ0122D_-(C E&;WX8>^W M/>OF+Q1&T/BW68FQN2^G4X]0YH ^U_#T,=MX:TN")0L<=I$B*.P" 5\K?'& MW$'Q8U9E/$J0R8QT_=*/Z9_&OJW12#H.G$'(-M'R/]T5\J_'659/BQJ2J>8X MH%;V/EJ?Y$4 >\_",QZM\'M%CO88YXFBEA>.10RLJRNH!!X(P!716G@OPQI^ MHQ:A9>']-M;N$DQRV]LD97((.-H'8FN>^"J-'\(]"#J02)VP?0SR$?H:Z+Q7 MXLTKP;HDFJ:M,4C7Y8XTP7F?LJCN?T'4T +XM\4:?X/\.W.L:C( D0Q''_%+ M(?NHON?T&3T%?(/A71+OQUX[M;+86:\N3-=,HP$CSND;VXSCW('>M36=;\4_ M&'QA';PPO(68_9;*-OW5M'W)/Y98]?R%?1OPV^'%CX!T@J"MQJMPH^U76.O^ MPOHH_7J>P !W%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!@^./^2?\ B3_L M%W7_ **:OESX*?\ )7="^L__ *(DKZC\4?$/X,R>._$9U@>(/LA\E(E@:T\P #/\6\>I/2K7_"^_ G_/Y>?^ M K5Z-97<6H6%O>0$F&XC65"1@[6&1Q^- '-_#SP8G@7PI'I'FQSS^:\LTZ)M M\QB>#CV4*/PKS/\ :5DLO[-T*)MIOO-E9/41X&?PSM_(UZ;X[\>Z5X#T8WE\ MPENI 1;6:-AYF_HH[MV]S@'Y:E;Q-\6O&[/'$UQ>W! &?*M8AZGG:@_4GN3 MR >G_LTV3$K=F8;R1^ *_G7T!6#X.\+6?@WPS:Z-9_,(ANEE( MP99#]YC]3^0P.U;U !7QAXVU>;QQ\2[R:&3>MS=BUM>>) M+QM.\+:O?+G=;64TPQZJA/\ 2OD#X96JWWQ-\/QLI8?;%EP/5,N/_0: /L?2 M["'2M)L]/MEVP6T*0H/15 _E7Q_\6_^2I:]_P!? _\ 017V77QI\6_^2I:] M_P!? _\ 010!])_!_P#Y)5H7_7)O_0VKJ]8-@NBWIU4Q#3_(?[1YN-OEX^;. M?:OC33/B)XNT;3H=/T[7;FWM(01'$FW"C.>X]ZJZQXT\2^((3!JNN7UU 3DP MO*=A/^Z./TH PWQO;'3/%?4OQ2\W<2@3KM:Y(Y"A3SMSC)Z$<#V[/\ :4&-%T ?]-Y? M_05H YQ?V@=<'@^X63[.VO37!2&1(0$@B"K\Y!R&8DG Z<'/H8_AC\2?'6M^ M/=/TN;5C>6URY,Z3PJ0J %F(( *G P.<9(X-8GP7\#V/C/Q1<-JJ&6PL(A(\ M(8CS'8X4''.."?P%?1-GX)\*>$KZX\1:;I4=G/%:NKF)B%*##'Y2< _+U% ' M.?$[XOVO@>3^R].ACO=990S([?N[<$<%\.#G(XSXD_Q6^)&MW,CVNJ M79V_,8K.V7:@_!T M[PQHMOI>F6Z0P1* <#EV[LQ[D^M 'S?X:^/OBG2;Q4US9JMINPX>-8Y4'^RR M@ _0@_45])Z!KVG^)M%M]6TN;S;6=*\:_:&\'V"Z7;^*;2W6 M*\$ZP73(,>:I!VLWN",9Z\^PK*_9OUV6/5]5T!W)@EA^UQJ>BNI"MCZAE_[Y MH \X^)W_ "4SQ#_U^R?SKZQ\ ?\ ).O#7_8+MO\ T6M?)WQ._P"2F>(?^OV3 M^=?0M[K,F@_LZ6M_"Q69=$MHHV4X(9T1 1[C=G\* .0^(WQYN;/4KC2/"8B' MDDQRZA(N_+#@B-3Q@?WCG/88Y/GB_%+XDV\:ZB=8OO(8\226R&)CZ#_!9U72C$+G[2D?[U-PP0<\?A7R?J$L&C>+[F;1;@2065\SV<_\ US;^ M5 'S+IOQW\:76MV=I(]AY4MRD;8MN<%@#WKT+]HHY^'%D?\ J)Q?^BY:^<=$ M_P"1HT[_ *_8O_0Q7T=^T3_R3BR_["<7_HN6@#A?V;_^1QU3_KQ_]G6NU^*_ MQDD\*WR:+X>-O-J*'-U+(N](1V0#/+>OI]3QX3X/\:7W@LZG/IJ+]LO+;[/' M,Q_U.6!+ =SQQ^?;!7P/H=MXP\<66FZKJ#01W3M![,W/)_4\4 > MY?"SQ=\0/'5ZUY?26=OHD#8DE6UPTS?W$)./J>W\J7Q8^*OB7P=XR_LO2FM! M;?9TD_>P[CDYSSGVKVG3M.M-)T^"PL8$@M8$"1QH,!0*^7_V@O\ DI/_ &YQ M?UH ]X^%_B74/%O@6TU?4S$;J6216\I-JX5R!Q]!7D?C7XU>+M!\::MI5D]D M+:UN6CCWV^3@'NB^ M*/CIKNJ/#IO@Z)@XB4S72VV^21\#=L0@A5Z\D9^E<;9_&/Q_I=_OEUB2[A4J<=01@$?@0:^@OA!X=LM"^'>ES00*+F_@6ZGFVCQKR#]I+1%CU#1]VE8=,J=R_B=S?E6G^S5,QTG M783C8L\;CZE2#_(5N?M#6RS?#F&4G#0W\;#CJ"KC'ZC\J )_@+XA?6?A^ME. MVZ;3)3;@GJ8\;D_(';_P&O4J^3MEMXY,?[K$?^S5]'4 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !114%YYOV&X\C/G>6VS'][' M'ZT >4^,OCWI'AS5)M,TS3WU2X@8I-)YOE1*PZ@'!+8/L![URW_#3%U_T*T/ M_@:?_B*K? CPCHGB"[UK4=9M(+^:WD6-(+A0ZKG)+%3P-,_[!J_^C)*] M5^!O_))=)_WY_P#T<]>5?M(?\CQIG_8-7_T9)7JOP-_Y)+I/^_/_ .CGH ]% MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *SM=T6T M\1:%>Z1?*6MKN(QOCJOHP]P<$>X%1:MXHT'09T@U;6+*QED7>B7$RH67.,C/ M:K=QJMA::6=3N+R"*P""0W#N FTXP<],'(_.@#YC23Q[\#=5N8XHOM&D2R9W MO&7MINP;@Y1\<8R#QW %;P_:7OO*P?#-OYF/O?:VQ^6W^M>Q-\0_!3*5;Q1H MY4\$&Z3G]:S3XC^&!E\TZAX8,F<[\PYS]: /$+K6/B!\;+Z+3X;81:6LF6$* M,EM'_M2.<[B >F?H*^D/"OART\)^&K+1;+)BMDP7(P9&)RS'ZDD_I6>GQ"\$ MQH$C\3:.B#@*MT@ _6MG2=6'_85C_\ 14M> M??LX_P#)0[__ +!4G_HV*O0?VCO^2>6'_85C_P#14M>??LX_\E#O_P#L%2?^ MC8J /J"BBB@ HHHH *^4OV@?^2G/_P!>@#2^ G_ "2VU_Z^9O\ T*O3:Y3X=^$IO!/A*+19[J.Z M=)7D\R-2H.XYZ&NKH ^0/C;_ ,E>UW_MW_\ 1$=>_P#P2_Y)#H?_ &\?^CY* MY7QY\#[_ ,8>--0UV'6K:VCNO+Q$\+,5VQJG4'_9S7H_@/PU+X/\%Z?H4URE MS):^9F5%*AMTC/T/^]B@#QG]H#P)/'J*^+["$O;S*L=\$&3&XX5S[$8'L0/6 MN;^%WQ?D\#6[Z5J5K+>:2[F1?*(\R!CUV@D @^F1SSFOJJ:&*X@DAGC26*12 MKHZAE8'@@@]17C_B7]GC0=4N7N=$OYM)=SDPE/.B_P" @D%?S(]!0!8U+]H; MPC;6#2V$%_>W17Y(#$(QG'\3$\#W ;Z5\[Z]K>J^-_%4M_J6C,?R+#^=>G>"/A/X=\$2"[MTDO-2QC M[7C,ZI]LMVB5V&0C$? M*V/8X/X4 ?"]?7WP5T;^Q_A?IF] DUZ6O),=]Y^4_P#? 2O,_P#AFK5/^ABL M_P#P';_&OH:QM(M/L+:R@7;#;Q+$@]%4 #]!0!YK\?-%_M/X;27B*3+IUQ'. M-HR=I.QA]/F!/^[7RC7WAKFEQ:YH.H:5,<1WEN\!;^[N4C/X9S7@/_#-6J?] M#%9_^ [?XT >E?!+1_[(^%VG,RA9;UGNY,=]QPI_[X5*C^+OCK7? >EZ=?:1 M:64T5Q,T,SW2NVQMN5 "L.N&Z^E=YI5A'I6D66G0X\JU@2!,>BJ /Y56\1>' M]/\ %&AW.D:I%YEK.N#@X92.0RGL0>: /)_AW\=;753=V_C"ZM;"XW!K>5(V M6)EQRI/.#D9Y/.:Y+XX_$G2_%4=EH>AS_:;2VE,\]P%(5I,%5"YZ@ MD].1B MF:O^SIXEMKMAI5]87MJ3\C2.8I /<8(_(UJ>%_V<[UKR.?Q/J,"6RD,;:S8L M\GL7( 7\,_AUH U?V(9T*K>,MO;9'54)+L/4%B!]5-<_\ '35/ M%6@^-A]FUS4[;2[R!9((X+EXT! "NN%(SR W_ J^C+*RMM-L8+*SA2"V@01Q M1H,!5 P!6-XP\':5XVT1M,U2,X!W0S)P\+_WE/\ ,=#0!YQ\+OC#H3^%;72_ M$6IBTU*S3RS+<;MLZ _*V[GYL8!RO?)] :LZG^SKXIMKEET^^TZ]M\_*[.T3X]U(('X$UL>%_P!G M.\-Y'/XGU*!;96RUK9DLT@]"Y V_@#]10!M_LX:+/9^'-6UB566._G2.($<, ML0;+#VRY'_ 37D_QBT1]$^)VK*4VQ7C_ &R(_P!X2\@R;:[1OGSQ?KC^,/&VH MZM#!)_IL_P"YBQE]HPJ# S\V .G>NZNOV>/&,-R4@GTR>+/RR"=EX]2"O'X9 MKT/XAZ!9P^#_ EC M;7LJQQ:;8K]HE/0;5R[?3.37R5\0/'%[X[\1R7\Y>.SCREG;$\11_P MQX)/ M] *^L_'&@7?BCP??Z+97B6@K9VOA^_DO90&N[LNFZ5_Z*.<#^I)/6?\ #2>A_P#0!U#_ M +^)_C7/_P##-6J?]#%9_P#@.W^-'_#-6J?]#%9_^ [?XT ?14,@FA20# =0 MV/K3ZC@C,-O'&3DHH7/T%24 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &#XX_Y) M_P")/^P7=?\ HIJ^7/@I_P E=T+ZS_\ HB2OJ/QQ_P D_P#$G_8+NO\ T4U? M+GP4_P"2NZ%]9_\ T1)0!]@T444 %%%% !7SI^TK_P AC0?^O>3_ -"%?1=? M/W[16F7]_J^AM9V5S6(J)HRF>&Z9%%B5X ZY]J\I\,_P#"9?\ "5Z/Y_\ ;WD_;H?,\SSMNW>,YSQC%?8PZ4 ? M.7_#-6J?]#%9_P#@.W^->L>)/%%G\,O 5H]ZRW%S! EM;PJ<&>15 _!>,D]A M[XKM:^7/C?)KGB#X@36\.G7\MCI\:PP%('9"2 SL,#&FW]AJ&OF\LKFV#Q0;3-$R;L%^F17OU &-XNM MY+OP7KMM$ 9)M/N(USZF-@*^2_A3,+;XI: [8_X^2G/^TK+_ %K[,90RE6 ( M(P0>]?%6H6TG@;XF-&ZLO]EZDLB]RR*X93^*X/XT ?:U?&GQ;_Y*EKW_ %\# M_P!!%?9$4BS0I*C!D=0RD="#7R-\5-$U:Y^)FN36^EWLL33Y5X[=V4_*.A H M ]Z^$FEZ?/\ "_0Y);&VDD:)LL\*DGYV[XKNH;"SMCF"T@B/7*1A?Y"N3^$T M$UM\,-$AN(I(I5B8,DBE6'SMU!KM* "O#/VE?^0-H/\ UWE_]!6OX99Y2PAC+D?*O7 H R/V9@/.\3''.VU_]JU[OJMH;_2+VS'6> M"2(<_P!Y2/ZUXE^SCIU]82^)/MEE<6V\6VWSHF3=CSHKWB@#X6T.[&B M^+=-O+E61;*^BEE4J<@)("1CKVK[E@FCN;>.>%U>*10Z.IR&!Y!%?/GQ>^#V MH/JUQXC\-6K745RQDNK.(9='[L@ZL">2!R"?3IP.@_%'QKX,M6TF"[(AA^5; M:\AW&'V&>1].GM0![1^T-J\-GX$@TW>OVB]NEPF>=B DM^>T?C7 _LY:=)/X MTU'4 /W-K9>6Q]&=AM_1&KBH;+QE\5?$1N-EQJ5TY"/<,NV*%?0G&U ,YP/R M)-?4OP_\$6G@3PU'IL+B:Y<^9=3XQYDA';T Z 4 ?*_Q._Y*9XA_Z_9/YU[O MXCL9+_\ 9FM8XAEX](LYL>RB-C^@->,?$G0]7N/B/K\T&EWTL3WCE72W=@1G ML0*^GO!UDLOPUT.QO8#M?2H89H9%P<&(!E(_,4 ?)7@+P]8>*O&%GHNH7%) Y]<5[;_ ,,V:'_T'M0_[]I_A7EWCWX9Z[X$UE[NSBN)M+63 MS;:^@!S%@Y X/N.?>@ M#M+?X1?#FZF,$/Q!B:8';Y?VB -GZ'FNL^--@NE_!FSL$F:=;66WB$K N%4 MC)QQS7F'PM^%&I>*-8M]2U:SEMM$@<2,9TVFYQR%4'JI[GIC('/3Z'^('AAO M%W@C4-&A94GD0- 6.!O4@@'V.,?C0!X#^SO(L?Q'N%8X+Z;*J_7?&?Z&OI;6 M[N.PT'4+N5U1(;:21F;H,*37Q2I\0>!?$B2;;G2]6M&)4NF".HS@C# C/J#7 MH=GJ_P 2OC%Y>D><8M)+ 74\4/E0@#NY_B/^R#UQQW !YIH1SXFTT^MY%_Z& M*^C_ -HG_DG%E_V$XO\ T7+7@VF^&M7M/%EFG]EWYBBOD'F&V< @..>E?0'Q M_LKJ^^'MG%:6TUQ(-1C8I%&7('ER?QYXE734G$%M$OFW,O\ M2H"!A1W)SCT'7VI?'?A:[^'WC>2SADE6.-UN+&X)^8IG*G/J",'W%>B?L]:7 MJ%AXNU-[RPNK=&LL!IH60$[UXY%>B?&CP2?%G@][JTB+ZGIN9H0HRTB?QI[\ M#(]QCO0!N_#KQC%XV\(6NI J+M/W5U&/X)1U_ \$>QKP']H+_DI/_;G%_6E^ M#NJZYX/\8)%=Z9J*:7J&(;C=;.%1L_)(>.Q.#[$GM5OX\:3J5]\1/.M-/N[B M+[)&-\4+,,\]P* /5?@3_P DJT__ *ZS?^C&KYV^)_\ R4SQ#_U^O_.OH[X( MVMQ9_#"PANH)8)1+-E)4*L/WC=C7@'Q)T/5[CXCZ]-!I=[+$]XY5TMW8$9[$ M"@#Z@^'_ /R3KPU_V#+?_P!%K7DW[3/^I\,_[US_ "BKUSP)%)#\/_#L4J-' M(FFVZLCC!4B-<@CM7EG[1VG7M_#X<^QV=Q<[&N=WDQ,^W/E8S@<=#0!%^S3_ M ,>'B#_KK#_)JZ/]H.1(_AH%8X+WT2KQU.US_(&L3]G33[VPLM=%Y9W%L7DB M*B:)DSPW3(J#]I/5 FGZ)I*D$R227#\\@* J_GEORH Q?V;+9G\1ZU=#.V*U M1#_P)B?_ &4U](UX[^SMHALO!EYJTB /J%R0C#J8X_E'_CV^O8J "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHJ&[$ILIQ!_KC&VS_ 'L]9Y)2RZE:R1YM6?/(7!!/.3QC!S@X)%:R?M+W@0"3P MQ S]RMX0#^&PU#\"?!VAZW>:W>:U8PWMS:R+$EO"21CD<8->\? M\(MX>_Z 6F?^ D?^% 'A_P#PTQ=?]"M#_P"!I_\ B*]*^&7Q$D^(5A?7,FFI M8_991&%68R;LC.>@Q73?\(OX?_Z 6F?^ D?^%7++3;#3E9;&RMK57.6$$2H" M?? H M4444 %%%% !1110 4444 %%%% !1110!\R_M(?\CQIG_8-7_T9)7JO MP-_Y)+I/^_/_ .CGKRK]I#_D>-,_[!J_^C)*]5^!O_))=)_WY_\ T<] 'HM% M%% !1110 4444 %>.>(KCQ?H]U+-RALX_"O8Z\ \3ZO M+K6O7-R[$H&*1*?X4'05U857D^QXV)_PE6O_P#08O?^_P : MU-'O/&&MR,MAJ-U,4P67[6JG'KAF!(KE*NZ3J4^DZI;WMNQ#QN"0/XAW'XBN MZ4%;1*Y\_2KRYU[23MY,^B$R$7=UP,TZF12":%)%Z.H8?C3Z\<^X6P4444#" MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** /.OB'\)[;X@ZK:7T^K2V9MX/)")"'W?,3G)(]:Z+6/"<> MK^ W\+-=O%&UK';?: @)PFWG&>^WUH\:>+X/!.AC5[NPN[NU$BQR&V"DQYZ, M"?CQIF@>$+'3-8MM7OK^#S/ M-N-ROOW2,P^9FR< @<^E=!_PTCX9_P"@1J__ 'S'_P#%T 4/^&:;#_H9;G_P M%7_XJO1OAYX$@\ :/=:=!?O>K/<>>7>,(5.U1C )]/UKRWQ=\?\ 2M8\*ZAI MNE:=J<%Y>IRK$YQ72_L[PW2> KVXN-^RYU&22-G.2_R(K-[\@C MZ@T >N4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'D'[1W_)/+#_ M +"L?_HJ6O/OV4<"VO- MHZ,/N.?J/ER?1?6OH2J>JZ79ZWI5SIFH0B:TN4,QH XOX->)E\ M2?#NQ#N6NK ?8Y\G)RH&T^^5*_CFO0*Y;PE\/M"\$RW+Z*ES%]I"B59)BZG& M<'![\G\ZZF@ HHHH **** "BBB@ J"XL;2Z(-Q:P3$=#)&&Q^=3T4 -1$C0( MBJJCH%& *=110 4444 %51IMBLPF6RMA*#G>(EW9^N*M44 %%%% $-Q:6UVH M6YMXI@.0)$#8_.I$1(T"(JJH& JC %.HH **** "BBB@ HHHH **** "BBB@ M KY,^(=[QKD_"_P ,?"_A#4Y-1TJTD%VZ&/S)I2^T$Y.,],T =!H>D6^@Z'9:5:C$ M%I"L2^IP,9/N>M:%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 45F^(+Z]TWP_?7NG6AN[R"(O%;A2QD([8')_"O+-+_:$TL7'V3Q)HE_I-TI MP^T>8J_4$*P^F#0!YAK/Q$NO#_Q,U+6/#=DFG3&5XKN!I#+#O! MZYYY-=7#^TM?K&!-X9MG?NR73*#^!4_SKU?1M1^'GBE]^F?V%>32?,4,$8E. M>Y1@&_,5N?\ "+^'_P#H!:9_X"1_X4 >'_\ #3%U_P!"M#_X&G_XBO2OAE\1 M)/B%87US)IJ6/V641A5F,F[(SGH,5TW_ B_A_\ Z 6F?^ D?^%7++3;#3E9 M;&RMK57.6$$2H"?? H M4444 %%%% !1110 4444 %%%% !1110!\R_M(?\ M(\:9_P!@U?\ T9)7JOP-_P"22Z3_ +\__HYZ\J_:0_Y'C3/^P:O_ *,DKU7X M&_\ ))=)_P!^?_T<] 'HM%%% &+>^+="T^[DM;K4$BGC.&0HQQ^0J#_A.?#7 M_05C_P"^'_PJIJOP]TG6-2FO[BXO5EE.6$;H%'TRIKSOQ;XEW<\C%8K&4$YN,>6_G_F>G_P#"<^&O^@K'_P!\ M/_A6Y;7$5W;17,#AX95#HP[@]#7%+\+-#9 3=:CR,_ZQ/_B*TM8\0:=X+T:W MLE9IYXXA'!"6&X@# +$=!6R[1T M1!]YSZ 5\_7$BRW,DB*55F)"DYP,U;U;6+W6[YKN]E+N>@_A0>@'85);^'M9 MNX%GM]+NY(G&5=8C@CVKNHTE26KU9\_CL7+&S2A'1;=S,I5QO7<2%SSCK6M_ MPBNO_P#0'O?^_)JO>:'JNGP^=>:?Z\-WWF1YDM7/[Z'/##U'H:]NT[5+/ M5-/2^M9E:!AG=G&WU!],5YE:BZ;\CZW 8Z&)A;:2W12V.F>M>HUR_Q#\3OX0\#ZEK$(!N8T"6X89'F, M0JDCN!G/X4 >[3DY_>,5Y#8^[MZ5N?\*N^' M'_0$L/\ O^W_ ,57A'AOX9>+_B=!)XAN-0C$4KLJW-]*S/*0>=H / .1V'I6 M5X6^&>H>*/%.K^'HM0M+:^TQG$@EW$/L?8Q7 [''YB@#Z-7X:_#BV83'1=- M7G,DI*_B"V*ZS2;C29+4VVCS6;6UH1#Y=HRE(2 "%PO"\$<>]?'WC/X:>(_ MHCEU2"*6TE.U;JVV<&OH_X/>%(_"W@P>3JD6HQ:C(+Q)8H MRBA610!R<]O;TQQ0!Z#1110 4444 %%%% !1110 4444 %%%% !1110 4444 M >0?M'?\D\L/^PK'_P"BI:\^_9Q_Y*'?_P#8*D_]&Q5Z#^T=_P D\L/^PK'_ M .BI:\^_9Q_Y*'?_ /8*D_\ 1L5 'U!1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 8/CC_DG_B3_ +!=U_Z* M:OESX*?\E=T+ZS_^B)*^H_''_)/_ !)_V"[K_P!%-7RY\%/^2NZ%]9__ $1) M0!]@T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %4-4T32M;@\C5-.M;V/LMQ$KX^F1Q5^B@#RK7/@#X1U-FETXW>D MS1)OCSZ[6R?P!%8/_ A'Q:\'<^'?$RZO:)TM[A^<>@63( ^C"M;4?VA/ M#FFZE MQ_ FO.9?VC/"LT;1RZ)JDD;##*Z1$'ZC?3/#WQK^'.G7$J6FB7FCBX8-*\=K M&(R?4A&)S]%H ]LHJEI6KZ?KFG1:AI=W%=6DHRDL9R#ZCV(]#TJ[0 4444 % M%%% !1110 4444 %%%% 'S+^TA_R/&F?]@U?_1DE>J_ W_DDND_[\_\ Z.>O M*OVD/^1XTS_L&K_Z,DKU7X&_\DETG_?G_P#1ST >BT444 17-S!9V[W%S*D4 M*#+.YP!7C7C77K'6/$EO=V3M)#"BJ6*XR0Q/&?K5CXCZ]+?:VVFHY%K:G!4' MAG[D_3I7%5Z&'HL:S\2["'2U&D%IKMUQ^\0@1> MYSU/L*\MN;FXOKI[BXE>:>0Y9F.234->L^ _!UG;V=OK%T5N+B50\2X^6('^ M;>_:K:AAXW,(RQ&95%%O1?HZU%\OWH[5N_N_^'Y^E>FJH50J@ M #@ =J6BN"I4E4=V?2X;"T\-#E@O^"%17-M!>6TEM(^,/!\_AVY,\ :33Y#\C]T/]UO\ 'O6;H7B&[T225(G+6TZE)HCR"",9 M'N*][N;:&\MI+>XB66&0;61AD$5XQXQ\'3>'K@W%N&DT^0_*_4QG^ZW^->A1 MK*HN2>Y\UC\!/#2]O0V_+_@&KIGPXM-9L4O;/Q 'BD_Z=.5/H?GX-<]IGAK^ MTO%,NB_:_+\MG7SO+SG;_LY_K4&@>)=0\.7#R6;*R.,/%("4;T. >M)I_B*[ MT[7WUB..)IW9F96!V_-U[YK7EJJ^OH<;J822@^6SO[V^WWG?Z;\,/[/U.VO/ M[8\SR)%?9]FQNP>F=]>@USOA?Q?9^)8F55\B[C&7A8YX]5/<5T5>?5E-NT]S MZ?!T\/"'-A]GZ_J%%%%9'6%%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !7EG[0*.WPQ&X_%OA'4=$D?8;F+$;G^"12&0_0,!GVS0!1^&7D_P#"LO#OD8V?88\X_O8^ M;_Q[->66#G1/VJ[N *%BOPRD],[X!)_Z&N*H?"WQ/XM\(>,;/X?:I9 6TDS@ M1SJ0T(^9BT;#AE.&/<'/!K0^.&EZGX?\8Z-X]TR)F2#8DS 95)$;*[L?PL#M M_#'<4 >O>-])@USP1K.GW"*RR6DA4M_"ZC0F&:260%(E88;81RQP2 2! MC.>V*]!^!WANY\/?#N)KV)XKC4)VNS&_!52 J@_4*&_X%0!Z31110 4444 % M%%% !1110 4444 %%%% !1110 4444 >0?M'?\D\L/\ L*Q_^BI:\^_9Q_Y* M'?\ _8*D_P#1L5>@_M'?\D\L/^PK'_Z*EKS[]G'_ )*'?_\ 8*D_]&Q4 ?4% M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110!@^./\ DG_B3_L%W7_HIJ^7/@I_R5W0OK/_ .B)*^H_''_)/_$G M_8+NO_135\N?!3_DKNA?6?\ ]$24 ?8-%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !2.RHC.Q 51DD]A2U%@6TNTB GS+AB2>2V<$]3QQD M>M>MVWP:\ VT(C'A^.3U:6>1B?S;^5>0?#[QFWPG\5:OX<\202)://EY(UW& M)QT;'=67'3VKW"W^)O@BZA66/Q/IJJ>TDPC;\FP: //_ !U\!M"?1+F]\,QR MV5[;QF06YE:2.8 9(^8D@^G./YUG_#7P9X*^(?@AS>Z(EKJ=JYMYY[:5T;=@ M$.!DC.".H(R#Q70>.?C?X;T[1;JUT*\&HZE+&8XS"I$<1(QN+$8./09K&^%= M[;?#GX87'B7Q$988=2N@T"(FYW&WY<#WVL1VQB@"M\(_MG@SXHZYX(FG:6U( M:6,GC++C#8[$J1GZ"O?:^?/A1G MR6'BR\+@[)V\Y&/<-_\ 7R/PKFZ^@/$/ARR\1V7D70*R+S%*OWD/]1[5XUXA M\-S^']7CL))XY3* R.N1P20,^G3WKTZ%92BHO<^2S+ 3HU'46L6_S,55+L%4 M$L3@ =Z^@O#ED^G>'K&UE&)(X5#CT/<5S?A;X>V^D3QWU_*MUO:+2V/B2PFA;!\Y5/NI."/R-?00 MY%?/.@SVMKKUE/>[A;QRJSE>HQT/TSBOH.*6.:))8G#QN RLIR"*X,8O>1]' MD3_=S5^H^BBBN,]T**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "N1^)?BV;P5X)NM6M8TDN]Z0P+(,KO8]3] "?PK MKJY+XF6&C:AX U./7998;&-5D,T*[GB8,-K =^3T]": *_PV\37OCCPI;ZYJ MVFVD$PE=86B);=CY68 \ISN&,FNQN+>"[MY+>YACF@D4J\A!X(KY3\ M#_%R]^'J3Z/%%#K.CB4O"X*1R" <@$>PKJJ\2_P"&D]#_ .@#J'_? MQ/\ &O0? /CNT\?Z1@_M'?\D\L/\ L*Q_^BI:\^_9Q_Y*'?\ _8*D_P#1L5 'U!11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 8/CC_DG_ (D_[!=U_P"BFKY<^"G_ "5W0OK/_P"B)*^H_''_ "3_ M ,2?]@NZ_P#135\N?!3_ )*[H7UG_P#1$E 'V#1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444V1UBC:1SM1068G ML!0!S?BWP'X<\96P76K)6DC7Y+F-MDL8]F[CV.1[5Y?3^,/C7XPO+>PE9;&)B4AEE*06\>2%+ 9RQQUP2?H.-E?V;? M$6T;M:TL'N!YA_\ 9: /0?#GP4\#Z#=)=W,[:I.ARHNY5\M3Z[!@'_@6:[/Q M/X3T7QOI<.G:BSO:P3"4);R[?F ( ..V":\,_P"&;?$'_0;TS\I/_B:]2^%/ MP^O_ !IVH6U]>6URUS*)%,&[ &.<@4 =AH/A[2O#.F)IVCV4=K;+SM3DL? M5B>2?JO,H(_ FO+/B%=VUSXKL9;>XBEC6) 6C<, M!\Y[BNCUWXE][H[M-:TH1K_ ,3.SZ#_ );K_C5Z.1)8UDC=71AE64Y! M'J#7FW_"I/\ J-_^2G_V=>@:79?V;I5I8^9YGV>)8]^W&[ QG':L:D8)>Z[G M?AJF(FVJT.5>MRW11161UA1110 445#=+(UG.L)(E,;!"#CYL<4";LB#4M)L M-8M_(O[9)X^V[JOT(Y%>/Z-H-C?^-[G2IE?[*K2JH5L$8ZM>0J8[EB295N5#'/7G-=U)*":YT?/XN(-!N?#VIO:7 RO6*3'#KZUU7@#QA]AE32+^3_1G.(9&/\ JV/8^Q_2HY_! M_C+5I(HM3E:2(-]Z6X5]F>^,UQVHZ???#_QA]MC32-0D_TE!B"1C_K .Q]Q^M>@UYM2#A*S M/JL-B(8BFJD HHHJ#<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH *JZCIUGJUA-8W]NEQ:S#$D4@RK#.>?Q%6JR/%'B"V\ M+>&K_6[L;HK2+<$!P78\*H/NQ _&@# O?A]\.]-MFN;_ $31[6!?O2SX11]2 M3BLO2]#^$6MZA]@TNST*\NMI;RX/F.!U/%>4Z#X-\6?&N]E\0:WJOV73UD9( MG9"P'()2&/( 4=,YZCN>.TMY8UD< %N%.2!]: /6H M? 'PZN+ZXLH=$T>2[MMOGP+@O'D C>+!XT\%V6KLJKI)Z4 245\\_%GXQKJ-I-H7A.>1K<$"[U&+Q?#^62?X>>'I9I&DD?3X69W.2QV#DD]: .DHHIDTL<$,DTKA(X MU+.QZ #DF@!]%?.:ZAXW^-/B*_&B:I)I'AZT?8I$CQJ06'_85C_\ 14M>??LX_P#)0[__ +!4 MG_HV*O0?VCO^2>6'_85C_P#14M>??LX_\E#O_P#L%2?^C8J /J"BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **\ M^U/XG_V=JMW9#2/,^SS-%O\ M.W=M.,XV'%5?^%M_P#4$_\ )O\ ^PK98>H] M;'!+-,)%M.?X/_(]+HKA= ^(W]N:U;Z=_97D><6'F?:-V,*3TVCT]:[JHG"4 M':1TT,13KQYJ;N@HHHJ#8**** "BBB@ HHHH **** "BBB@ HK!\8>+=.\%^ M'Y]5U%Q\H(AAW8::3LB_U/89--\$>)_^$R\(66O?8_L?VKS/W'F^9MVR,GWL M#.=N>G>@#H**** "BO/O'OQY5\J^+]%^)FL^+9M0_LK57>VF=;2Z@ MMA&ZID[<.@!(QTR>_O5N+4_CG#&L:1ZX5'0O:(Q_,J2: /I^BOF/^V/CK_SR MUG_P!C_^(KU?X2W?C2ZTW4#XS6[6=9E$'VF%8SMQSC &>: /1:*** "BBB@ MHHHH **** "BBB@ HHHH ^9?VD/^1XTS_L&K_P"C)*]5^!O_ "272?\ ?G_] M'/7E7[2'_(\:9_V#5_\ 1DE>J_ W_DDND_[\_P#Z.>@#T6BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ KEO&?A2/Q#8^; JKJ$(_=MTWC^Z?Z5U-%5&3B M[HSK4H5H.$UHSYM(GL[K!WQ3PO\ 1E8'^=>S^"O%B>(+'R+AE74(1\Z]-X_O M#^M9?Q!\(K>P2:Q8H!CQL58?B*]!J. M(A?J?,1E5RS$6>L7^*_S/I*BOGVW\3:Y:S"6+5;O<.<-*6!^H/!KU;P9XP7Q M'"]O9D[_ ,=V[/O7FGA?_DZ'7?\ 0O$I8JK>KQ28/!XRI'7T.1_9\X8$]#P=X3L=$A<2- F990,>9(QRS?3)X]L4 ;]%%% !1110 4444 %8WBOPW:^ M+O#=UH=[--%;71CWO"0' 5U?C((_AQTK9HH \1^,'A;1?"?PB6QT6QCMHOM\ M)=AR\APW+,>2?\BO2/AU_P DW\-_]@Z'_P! %(I(SAOL$JY_WEVG^==17-_$&SDO\ MX>>(+:%2TC6$I51U8A2<#ZXH Y;X"6L5O\++26-0&N;F:20@=2&V?R45=^-E MFMW\)]8. 7A\J5">Q$BY_0FL[X ZA#=_#**V0_O+.ZEBD'N3O'Z/^E6_CEJ" M6/PJU*-I DEW)%!'S]X[PQ'_ 'RK4 :'PANS>_"G0)6))6!HN?\ 8D9/_9:P M=6^/GA71M9OM+N-/UEI[*XDMY&CAB*ED8J2,R XR/05T7PHL3I_PM\/PE=I: MV\['_71C)G_Q[->3>)?@'XJUGQ5J^J6^H:,L%[>S7$:R32A@KN6 .(R,X/J: M ,_XL_%G0?'GA6UTO2[34H9XKU+AFNHT52H1UP-KL-?A-KW@/1H=4U2[TV:"6X6W5;61V8,59LG84 M\+)1FF[]CW6BO"O^$Z\2?]!-_P#OA?\ "N[^'.NZEK0U+^T+HS^5Y>S*@8SN MST'L*J>&E"/,V98?-:5>HJ<4[O\ KN=U1117.>F%%%% !1110!\^^)O^1IU; M_K[E_P#0C656KXF_Y&G5O^ON7_T(UE5[4/A1\%6_B2]6=)X"_P"1UT[ZO_Z MU>YUX9X"_P"1UT[ZO_Z U>YUP8SXUZ'TF1_[O+U_1!1117(>R%%%% !1110 M4444 %%%% !6?KMW>V.@7]UIMM]JOH8'>W@VD^8X'RK@@R3QD\<^K_!'_DD6B?6X_P#1 M\E/^-?\ R2+7?I!_Z/CIGP1_Y)%HGUN/_1\E 'H-,EE2"%Y9#A$4LQ] .:?5 M/5E+:-?*H))MY ._P IH \-^">D1>+?$^O^,]8A2YN/M&(!*-X1VRS$9]!M M ]!FN^^+WA/3_$/@/4KN6VC^W:? UU!F^,)(XO!.O22KNC73K@LN,Y'EMD4 1?LZ1NGP\O&;[KZE(R<]O+C'\P:\>^-W_)7=;^ MEO\ ^B(Z /J#QQ_R3_Q)_P!@NZ_]%-7RY\%/^2NZ%]9__1$E<#7??!3_ )*[ MH7UG_P#1$E 'V#1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%<)KWQ'_L36KC3O[*\[R2!YGVC;G(!Z;3ZUG?\ M"W/^H'_Y-_\ V%3SQ.Z.6XJ<5*,='YK_ #/3**\S_P"%N?\ 4#_\F_\ ["NO M\*^(_P#A)M,DO/LOV;9*8]GF;\X .3:3 D^H1Q M%H(G^Z[#D*>1U^M<9X2^+^A:_-_9VJ!M$UE&V26EX=@+]PK''?L<'VKT.N,\ M;_#'P_XYB\R]A-OJ"C"7L PX]F'1A]?P(H [,$$9!R**^;[GP/\ %KP$Y'AS M5;J_T]!\@MI0X4#IF&3.#_N@U4'Q1^+MBHANM,N&D'>?265C^ 'Z4 ?3=9F MM^(=(\.69N]8U&WLX>QE?!8^BCJQ]A7SU'XC^-WBIS#:6^HVT;=TLUME&?21 MP#_X]71^'/@+=W]ZNI^.]7EO9C@M;1S,Y;V>4\_@OYT =EX4^),_CGQ0]OH> MDS#0+56$^HW VEY/X54=O7UQC('?T.JVGZ?9Z58Q65A;16UK"NV.*)<*HJS0 M 4444 %%%% !1110 4444 %%%% 'S+^TA_R/&F?]@U?_ $9)7JOP-_Y)+I/^ M_/\ ^CGKRK]I#_D>-,_[!J_^C)*]5^!O_))=)_WY_P#T<] 'HM%%% !1110 M4444 %%%% !1110 4444 %%%% !1110!@>-I)(O!VHO$2&V 9'H6 /Z5X/7T MA>6L5]9S6LPS%*A1A[&O"?$7AJ]\/7S131LUN3^ZG ^5A_0^U=V$FK./4^=S MNC-RC56UK&+71^ Y)(_&5@(R?F+*P]1M-F>*-?A\+^&KW6IX7FBM$#M'&0&;+ <9^M<'\9_AO>^-K"SOM'V-J M5B&7R78*)HVYP"> P(XR0.37CVNVGQ9L?"MS:ZV-4&BQ($F$TBNH4$8R[_ /1KM%D'RNR'(Y!^Z?SJ!OAIX):7S#X7 MTS=G.! /RZ5\[>%/^%L_P#"-6G_ C/]I?V/\_V?R=FS[[;L9Y^]NK9_P"+ M[?\ 48_\AT ?1^G:5IVD6WV;3;"VLH,Y\NWB6-<^N !5NOF7_B^W_48_\AUZ MY\)_^$O_ .$?O?\ A,OM7V[[4?)^T;<^7L7ICMG- '?4444 %%%% !1110 4 M444 >=?&K0M4\1> Q8Z19R7=U]LC?RX\9V@-D\_45TW@BRN=-\"Z%97D+0W, M%C%'+&W56"@$&M^B@#B_B/J/C'3=-LG\&V*W=T\Q$ZM&'VIC@\D=ZZG36N9] M'LVOXPMU);H;A". Y4;ACZYJW10!\_7_ ,._'7P\\476J?#\_:=-N3DVP925 M7.0CHY^8#)PPYQZ9.6V_@/XA_$GQ!:W'CMC9:1;-N\G*+D=U1$.03C!9N<'C M.,5]!T4 ,BBCAB2*)%2-%"JJC 4#@ 4^BB@#R#]H[_DGEA_V%8__ $5+7GW[ M./\ R4.__P"P5)_Z-BKT']H[_DGEA_V%8_\ T5+7GW[./_)0[_\ [!4G_HV* M@#Z@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BN5\0>/=*T.0VZ9O+H<-'$PPA_P!INWTYKS[5_B'KFI2$6\OV&'LD M'WOQ;K^6*WAAYSU//Q&9X>@[-W?9'LEU?6EBF^[NH8$_O2R!1^M85WX\\.6B MG.HK*W]V%"V?QQC]:\0GN)[J4RW$TDTAZO(Q8G\33%5G8*H+,>@ R371'!Q^ MTSRJF>5&_P!W%+UU_P CUN;XJ:.G$-G>R'W55'_H1K.G^++QH1W_ #,_ MKV85/A3^4?\ @&NWQ6U8@[;&R'ID.?ZU7E^*.O2+A8K&,^J1-_5C2+\,-?;& M7LESZRGC\EJTOPIU4D;K^S [XW'^E'^SKL'_ J2[_D4/^%E>(O^>MO_ -^1 M44OQ%\2R?=O(XO\ <@3^H-;'_"I[[_H)V_\ WPU2Q?":<_Z[5XT_W("W\V%' M/AUV^X/8YF]+O[_^"<]_PL'Q1_T$_P#R7B_^)H_X6#XH_P"@G_Y+Q?\ Q-=- M_P *D_ZC?_DI_P#9T?\ "I/^HW_Y*?\ V='M,/Y?<'U7,^[_ / O^"(+JWDMY]2D>*52CJ47D'@CI M6%7IMY\+(8-/GE@OKB>X2-F2,1@;V X'XUQW_"&^(O\ H$W'Y"M*=2D_AT.7 M$87%IKVJ;_$PZT=+UW4]%\W^SKMH/-QOVJ#G&<=1[FK?_"&^(O\ H$W'Y"MW MP[\.KK41<'5A<6.S;Y?R@[\YS^6!^=5.I3MJS.CA<2YI0BT_N_$Q_P#A.?$O M_05D_P"^$_PH_P"$Y\2_]!63_OA/\*[3_A4]C_T$[C_OA:/^%3V/_03N/^^% MK'VM#M^!W_4LR[O_ ,"_X)Q?_"<^)?\ H*R?]\)_A1_PG/B7_H*R?]\)_A7: M?\*GL?\ H)W'_?"T?\*GL?\ H)W'_?"T>UH=OP#ZEF7=_P#@7_!.+_X3GQ+_ M -!63_OA/\*/^$Y\2_\ 05D_[X3_ KM/^%3V/\ T$[C_OA:/^%3V/\ T$[C M_OA:/:T.WX!]2S+N_P#P+_@GG:[WX=6UIK M-K?/J&GV$[1NH0M:1C (/HM3_P#"I['_ *"=Q_WPM=)X8\+P^&(;B.&YDG$S M!B74#&/I45:U-PM'(M(GTK5;?[193[?,BWLF[:P8#1H>AZ=XS[=S%CRQ)/))ZT ,U[Q!I?AC2GU/6+K M[-9HP5I/+9\$G X4$_I4ND:M8>(-)@U+39A<65PI,(%^"WQ#UK0M:@F&D7CB2&9 6VH"VQP.X(.#CG([XK;^)? MQDT36/#,V@>%9)M0N]1Q TBP.@12>0 P!9F^Z !W//0'U_7?#&B>)K9;?6M, MM[V-<[/,7YDSUVL.1^!K+T+X;>#_ U=B[TK0K>&Y4Y6:1FE=#T^4N25_#% M#/AIX:E\)^ =,TNY&+H(99Q_==R6*_AG'X5UM%% &#XX_P"2?^)/^P7=?^BF MKY<^"G_)7="^L_\ Z(DKZC\D6MM$UON$SV M\2HK$XXX'.,?K71>/_&DEFTFC:?OCF(Q/,000#V7_&O*R$ MJ*U:HW;HCV3P=%X:UO0[<+IE@]U!&J3K);(7W =3QSGUKKK2RM+"(Q6=K#;Q MD[BD,80$^N!7SUI6JW>C:A'>6O0^(M)2]BC:-@=DB, M/NL.N#W%5"2>AR9GA*E)\Z;<7^!KT445H>0%%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110!\R_M(?\CQIG_8-7_T9)7JOP-_Y)+I/^_/_ .CGKRK]I#_D>-,_[!J_ M^C)*]5^!O_))=)_WY_\ T<] 'HM%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4V2*.:-HY45T;@JPR#^%.HH Y[6O!^E:GI<]M!8VMM.PW1RQ0JA M#=LD#I7B%W:SV%Y+;3H8YHF*L#V(KZ0K@?B-X7^VVIUBTCS<0K^^4#[Z#O\ M4?R^E=>&K6?++9GBYK@5.'M::U7XHO\ @/Q0-;TW[)LB]F_QKKZ M^==)U.XT?4H;ZV;$D9SCLP[@^QKWS2-4M]9TR&^MFRDB\CNI[@_2IQ-+D?,M MF:95C?;T_9S^)?BB]1117,>L%%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% &)K7B_P]X=N([?6-7M;*:1-Z),V"RYQD?B*9XF70M5\'77] MLW*KHEQ"K2S!RHV$@@Y[9XKG?'WPIT_Q_JEK?7FHW5J]O#Y*K"JD$;B\8_#CPQH5MH^F>)+)+ M.WW>6KSEB-S%CR?=C6I_PM#P/_T,^G_]_*\__P"&;-#_ .@]J'_?M/\ "C_A MFS0_^@]J'_?M/\* /0/^%H>!_P#H9]/_ ._E;>B^(-)\16TESH]_!>PQOY;O M"V0&P#C\B*\D_P"&;-#_ .@]J'_?M/\ "O0? /@2T\ :1@_M'?\D\L/\ L*Q_^BI: M\^_9Q_Y*'?\ _8*D_P#1L5 'U!1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !17'ZA\1]'T[4+BREM[YI()#&Q2-""1P<9856/Q4T/' M%IJ/_?M/_BZU5&H^AR/'X9.SFCK]0U&TTJS>[O9EBA3JQ[GT [GVKR+Q'\0= M2U=I(+)FL[(\ (<2./\ :;M]!^M8WB'Q#>>(M0:XN7(B!(BA!^6,?X^II_AS MPS?>([SR[==D"G][.P^5!_4^U=E.A&FN:9X6+S"KBI^RP][?B_\ @?TS'CC> M:18XT9W8X55&23["NTTCX9ZM>E)+]TLH3R0?FDQ]!P/Q/X5Z+H/A32_#T8-K M#ON",-<2Q/\ ._O/HO2;F2]T M:QNI<>9-;I(^T8&2H)Q^=7*S?#W_ "+6E?\ 7I%_Z *TJ\F6[/M:;;@F^P44 M44BPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#!\)+9P0L%Y$ M,R0ENW]X>W\J5U>QLJ%1TW52]U'245PWB'XDV&FLUOIBK>W X+Y_=*?K_%^' MYUYSK'BO6=-Y)_Y8Q_(GY#K^.:EU$CMP^55ZVLO=7G_ )'LVI>*]#TK M(NM1A#C_ )9QG>WY+G'XUS=U\5M)CW"VLKN9AT+;4!_4G]*\CK3M/#NLWRAK M;2[N1#T<1$*?Q/%9^TD]CTXY3AJ:O4=_G8Z^?XLW[$_9],MH_3S'9_Y8K/D^ M)WB%VROV2,?W5BX_4FH[;X;>(YP"\$$&?^>LP_\ 9[C3@S% H)]N3Q[TGS+?IA:?_PJ_P /_P!^]_[^C_XFJY)'G_VG M@UT_ \I_MK5?^@G>_P#?]O\ &C^VM5_Z"=[_ -_V_P :]6_X5?X?_OWO_?T? M_$T?\*O\/_W[W_OZ/_B:.20?VI@^WX'E/]M:K_T$[W_O^W^-']M:K_T$[W_O M^W^->K?\*O\ #_\ ?O?^_H_^)H_X5?X?_OWO_?T?_$T]2U8]"E64TN6+2?H:WA#PA/XCNO-EW16$9_>2=V/ M]U??^5>V6EI!8VL=K:Q+%#&-JHO0"O-=(^)5AI>D6EB-,F_<1*A*,H!(')_$ M\UV_AKQ#%XET^2\A@>%4D,>UR"> #GCZUK#E6Q\_F?UF;YJD;16QLT445H>0 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5X1XU^/EQ!J[Z5X/L MH;HHYC-W*ID$C?\ 3-5(R/>_ ML^>'M/@\(OKWE1R:A=3.AE(!:-%.-H/;.,^^: .2TO\ : \3Z5J*P^)]&AE@ M."RI$T$R@]QDX/TP,^M>]^'O$>E^*=)BU/2+I9[=^N/O(W=6'8CTI/$/AG2/ M%.F/8:Q91W,+#Y21\T9_O*W4'Z5\\/#K_P !?&RRKOO- O&P2!Q,@[>TBY_R M#0!]%>(KZ;3/#&K7]OM\^ULYIH]PR-RH2,CZBN%^#?CG6?'&EZE<:PT!>WF5 M$\F/8,%<\\UT6L:U8>(?A=K&J:9<+/:7&E7#(Z_]&9I)1()+;SLXRB.\>?]\*5_6NOMKF"\MH[FVFCF@E M4,DD;!E8'H01UKP?PK\&O#^K?"E-1N(Y7UF[M6N8K@2L!&2"44*#@CIG()Z] M*G_9RUVXDM=7\/SN6BM66: $_=W$A@/09 /XF@#UOQ#XO\/^%(DDUO5(+,/R MB-EG8>H506/Y5%X=\;^&O%F\:)JT-VZ#+1X9' ]=K ''OBOG[0K*#XL?&S4# MK$DDMA&)95B5R,Q(P54!'0?,.GOZTGQ$T&W^%'Q&TC5/#HEM[1@LXB\PMC#8 M= 6R2"/4GK0!]145 +N%;#[9+*D< C\UY'8*JKC)))Z #O6-_P )WX/_ .AK MT/\ \&,/_P 50!X+^TA_R/&F?]@U?_1DE>J_ W_DDND_[\__ *.>O'?C]J^F M:SXQTZ?2]1M+Z%-/5&DM9UE56\QS@E2><$<>]>Q? W_DDND_[\__ *.>@#T6 MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D(# @@$'@@TM M% 'BGCKPR="U3S[=#]AN"63'1&[K_A2^!/$YT/4_LUP_^@W) ;/1&[-_C_\ M6KUO6=*M]:TN:QN1\D@X;NK=B*\#U33;C2-2FL;E=LD38]B.Q'L:]&C-5HGU%=Y7 M#.#A+E9]#AZ\:]-5(]0HHHJ#<**** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH \B^+?Q3USP%KEA8Z7:Z=-%<6WG.;J-V(.XCC:Z\<5Y[_P -'>,/ M^@;H?_?B;_X[7T_10!\P?\-'>,/^@;H?_?B;_P".T?\ #1WC#_H&Z'_WXF_^ M.UZSXS^,_AOPA=26"^;J6HQG#P6Q 6,^CN> ?89([UP/_#3,WF9_X12/9GI] MO.O\ PE\@_M'?\D\L/^PK'_P"BI:\^_9Q_Y*'?_P#8 M*D_]&Q4 ?4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 ?/_BG_ )&O5?\ KZD_]"-9%:_BG_D:]5_Z^I/_ $(UD5[,/A1\%7_BR]6: M7A_3%UG7;2P>0QI,^&8=0 ,G'OQ7OME96VG6<=K:1+%#&,*JC_.3[UXEX%_Y M'/3O]YO_ $$U[K7%C&^9(^AR.$?92G;6]@HHHKC/<"BBB@ KS?XJ6UQ<-I9A M@ED $N=B$X^[Z5Z115TY\DE(Y\506(I.DW:Y\X_V=??\^5Q_WZ;_ H_LZ^_ MY\KC_OTW^%?1U%=7UQ]CR/["C_/^'_!,[0%9/#FF(ZE66TB!!&"#L%:-%%<; M=W<]V$>6*CV"BBBD4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 8/CC_DG M_B3_ +!=U_Z*:OESX*?\E=T+ZS_^B)*^H_''_)/_ !)_V"[K_P!%-7RY\%/^ M2NZ%]9__ $1)0!]@T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %9FN:Y9Z!IS7=V_LD8/S.WH*TZP_%6B MZ=K&C2C4&6$0J72X[Q'U^GJ.])WMH:T5!U$JFWD>+:]KUYX@U%KJZ?CI'&/N MHOH*S%9E.58C(QP:& #$ Y /!]:?;V\UU<)!!&TDLAVJBC))KFW/MHQC"-EH MD.M;2XO;E+>UA>:9SA409)KT'1?A9+(J3:Q=>5GDP08+?BW0?AGZUTO@SP;% MX?MQ+.Y^9>IA)['_9]#^!]_9*;)&DL;1R(KHP*LK#((/8U,HJ2.K"8 MN>&GS1VZH^:*[3P3X*?6Y5O[]633D/ Z&8CL/;U/^1TI^&%F?$7V@38TO[_V M?G=N_NY_N^_7M[UWL420Q)%$BI&@"JJC ]!41IZZGKXS-HN'+0W?7M_P18X MTAB6*-%2- %55& .PIU%%:GSP4444 %%%% &3=^&-$O[I[FZTZ"69_O.P.3 M4'_"&^'/^@1;_D?\:W:*5D:JO52LI/[V87_"&^'/^@1;_D?\:TM/TRRTJ!H+ M&V2")FW%4Z$^OZ5;HHLA2K5)*TI-_,****9F%%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110!3U73HM7TB\TV(QX>_LIF\2KIQL%/)OPFP M'_@7>@!/"^OQ^*/#=EK,5O);QW2;UCD() SCM2^)_#6G>+-!N-(U.+?!,.&' MWHV'1E/8C_ZW0UQ:_&+X<:%;1Z?8ZA^X@ 1([6UD**!V!P!CZ4Z+X[^ I'PV MHW,0_O/:28_0&@#QC47\7?!^75?#LX^T:/J<$L2,X/E2!E*[T/\ "XR,C_ZQ MKO\ ]FO_ ) 6M_\ 7RG_ *#7I=KK7@[X@:?)90W>G:O RY>V?!8#L2C?,/KB MIO"_@O0_!L=U%HEL]O%F61S96K0R2;MI^12$5NGWCGJ?:OJ.6))X7BD& MY'4JPSC(/!K@S\$_AXQ)/A_D\G_3;C_XY0!X@WB[0O\ A?B^)1??\2<7)?[1 MY+_=\LKG;MW=?:NS^/NI6FN^"O#NK:;+Y]C-.[)+M*Y!48X8 CH>U<\WPO'_ M N<:N-V.=U>P^,_AO9:[\/!X9TI%M!:%9+ M$.[,J,N>"22<$$COUSVH N^!ID/PHT23.%32HPQ^D8S_ "KR#]G-2?%&O.!\ MHA4$_5C6?9W'QO3/;BO5O@]\/ M[CP/X>G?4@@U2^8/,J'=Y:C[J9[D9)/;)_&@#R_X ,;?XE:M:RJRRFTDX]-L MBY'ZU=_:4D4ZMH<>?G$#L1[%O_K&I_%G@;Q?X)^(,WB[P;9M?03NTIBC3S"A M;ED9!@E<]-OM5;2?"'C;XF^.[37_ !?ISZ;8VI3*20F'*J^ZGTR2&./(&7:(@#)X')[U\O?\*2^(?_0O?^3MO_\ M'*^O@ H '0<"EH ^&?$GA36_"-]%9:[9?9+B6/S43S4DRN2,Y0D=0:^H?@;_ M ,DETG_?G_\ 1SUY5^TA_P CQIG_ _P#1DE>J_ W_ ))+I/\ OS_^CGH M]%HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *X[Q] MX8_MG3?MMLF;VV4G ',B=Q]1U%=C150FX2YD95Z,:U-TY[,^;[.[GT^]BNK= MRDT+;E/O7O7AW7(/$&D17D6 _P!V5,_<;N*\W^(?A?\ LR]_M2T3%I<-\Z@< M1O\ X&LCP?XD?P]JZN[$VDV%G7V[-]17?5BJT.:.Y\WA*T\!B'1J?"_Z3/=: M*;'(DT2R1L&1P"K Y!%.KSCZD**** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH *XWXI>)9_"OP^U+4+1MEXP6"!LX*NYQN'N!DCW%=E7F_P =--FU M#X77KPHSM:31W#*HR=H."?H V?PH XSX0?"/2]0T.#Q-XDM_MLMWE[:VD.45 M,X#N/XB>3@\8([]/81X.\,+!Y \.:0(<8\O[#'M_+;7+?!KQ/8Z_\/\ 3[2& M5!>Z;$MM<09^9=O"MCT( Y]:_P"'K5+"ZLHVGF@C M_P!5+&HRV%_A( R,<'!&.^*'B:R\,^ ]4DN94%Q=6[VUM$3\TCNI7@>@SD^PKF/V>=-GLOAW-= M3*56]OI)8O= JIG_ +Z5ORH ]9HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** /(/VCO\ DGEA_P!A6/\ ]%2UY]^SC_R4._\ ^P5)_P"C8J]!_:._ MY)Y8?]A6/_T5+7GW[./_ "4._P#^P5)_Z-BH ^H**** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ K-U_5X]#T2YOWP3&N(U/\ $YX _/\ 2M*O M)OB?K7VG4XM)B?\ =6PWR@=Y"./R'\S6M&GSS2./'8GZO0<^NR]3A9YI+FXD MGFG^$? &GS:*EWK5J99[CYT0R,GEIV^Z1R>OY5Q?@W0_[= M\100.N;>+][-[J.WXG _.O> ,# KJQ55QM&)X^48.-6]:JKKI?\ $PK#P;H& MF7L=Y9V'ESQDE'\Z1L<8Z%B.];M%%<+DY;L^AA3A35H))>04444BPHHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,'QQ_ MR3_Q)_V"[K_T4U?+GP4_Y*[H7UG_ /1$E?4?CC_DG_B3_L%W7_HIJ^7/@I_R M5W0OK/\ ^B)* /L&BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ KRKXD^*#<7!T2TD_6/1%[L:]?\(>"X/#D9GN"D]^W!D'W4'HN?YTG M@3PR-"TD3W"8OKD!I,]47LO^/O764X0MJS/,H0Z3I5WJ-P2(;6%YGQUPH)/ M\J^:M&\-^(_CEXAN]9U._-II4$FQ6QN"=#Y<:Y';&2?4=:^@?'%A-J?@;6[. MW4M-+9R!%'5B!D#\<8KS?]GWQ-ILOA>3PZ\T<.I6TSN(F.&E1CGM %^R_9Z\&6R8N)=3NV[F2<*/P"J*GG^ '@:6(HD6H0L?XX[HDC_OH$?I7J M-% 'SGXO^!EYX5M'U_PEJUU*]D/-,,F%F4#JR.N 2!VP. >O2O4OA1XTF\:^ M#8[N\Q]OMI#;W) P&8 $-CW!!^N:VO&?B73?"OAF\U#4ID5?+9(HB?FFJ_ W_DDND_[\_P#Z.>@#T6BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH K7]C!J5C-9W*;X95VL/Z M_6O!-?T6?0=6ELIQD*S/,S/!?6*?-'XE^/DY^$?$ZV]/\ M@&_1117(>V%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5'<00W-M+!< M1I)!*A21'&592,$$>F*DKSCXYSWL'PLO_L>\+)+$D[(2"(BW/X$[0?8T >=^ M)/@EXF\.:R^K> [V5XMQ,<,=QY-Q"#_"&) 9?QS['J<_[=\=5_T;9K/IG[/& M?_']OZYKTSX#70N_ATLDFHW%YGT ?-NA_!? MQCXMUA-1\;WTT%N#\_G7'G7#KG.U<$A!UZGCTKZ*L;&VTVP@L;.%8;:WC$<4 M:CA5 P!5BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /(/VCO M^2>6'_85C_\ 14M>??LX_P#)0[__ +!4G_HV*O0?VCO^2>6'_85C_P#14M>? M?LX_\E#O_P#L%2?^C8J /J"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH IZKJ$6DZ73^ K@?#VDMK>NVM@,A9'S(?1!RWZ"O0PT M5"#FSYC-JLJV(5"'3\V>H_#?1O[.\/\ VR5<3WIW\]0@^[_4_B*[.FQQI%&L M<:A40!54= !VIU<,Y.Q/4_@,_I2;LKETJ;J34([ ML\O\=:[_ &WXAD$3YM;;]U%CH<=6_$_IBKOPY\/_ -J:U]NGCW6MGAN>C2=A M^'7\JXP!G<*H+,QP .I->_>%=%&A>'[>T('FD;YCZN>OY=/PK&"YI79]+CZB MPF&5*&[T_P V;5%%%;GRX4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %>*^/?@0FKZE+K'A>[BL;MV\Q[67*QE^NY&'*GOC!&?2O:J\B\@^ _CGIOBG4!INJV8TN[8$Q/YN^* M3 R1D@;3U]?K7%:]\5_&_C'Q!/IW@6WN([.%BJFV@#R./[SL00@...GU- $V MC? GQ1KVHI>>-=:=8QC8[N%4)'?9(HZ^QR/IUKZ)T36K+Q#H MUKJNG2B6UN4#HW<>H/H0>"* -"BBB@ HHHH **** "BBB@ HHHH **** /F7 M]I#_ )'C3/\ L&K_ .C)*]5^!O\ R272?]^?_P!'/7E7[2'_ "/&F?\ 8-7_ M -&25ZK\#?\ DDND_P"_/_Z.>@#T6BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** /+OB1X7\J0ZW9Q_(YQ6B/RS1C^)?\:][G@BNK>2"9 \4BE64]"#7A/BOP]+X= MUA[?EK=_GA<]U]/J*[\/44X^SD?-YGA94*BQ-+3]'_P3W2TNH;VTBN;=P\4J MAE8=P:FKR?X<^*/L=R-'NW_<3-F!B?N/Z?0_S^M>L5R5:;IRL>U@\5'$TE-; M]?4****S.H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L#QM)?Q>#-4;3-/B MU"\,.V.TEA\U)LD J4_B&">*WZ* /D"T\,?$G2]4FO\ 1M UC29)3DI8I(B M>F"22/8DUT2ZM\=54*(M:P/6R0G_ -!KU/Q=\;O"_A>[DL83+JE[&2KI:D;( MV'4,YXS],X[XKAO^&F9O,S_PBB;/[OV\Y_/R_P"E &-_;'QU_P">6L_^ ,?_ M ,17KWPGNO%]UX?O7\9+=+>BZ(B^TPK&WE[%Z <9S5+PC\;_"_BB[CL9C+I M=[(0L:76-DC'H%<<9^N,]!FO2Z "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH \@_:._Y)Y8?]A6/_T5+7GW[./_ "4._P#^P5)_Z-BKT']H[_DG MEA_V%8__ $5+7GW[./\ R4.__P"P5)_Z-BH ^H**** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "@D $DX HKG/'.JG2O"MTZ-MEG_<1_5NO_CN:J,>9 MI(SJU%2@YO9'D7B?5?[:\17EZ#F-GVQ?[@X'Z#/XUVWPJTG"7>K2+R?W$1/I MP6/\OR->:(C22*B*6=B .YKZ$T'3%T?0[2P7&8HP'([L>6/YDUWXF2A34$? M-Y53=?$NM+IK\V:-%%%>LWUW'86%Q=RG]W#&SM^ S7SK> M74E[>SW4IS),Y=C[DYK.H]+'M9-0YJCJOI^;.E^'NC_VIXFCE=-YGOM'"_U/XUV5."LCES.O[7$.VRT"BBBK M//"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#$\8ZE+H_@S6-0@)$ MT%I(T9'9MO!_ XKRKX#^"=(G\-MXDU"S@O+VYF=8C-&&$*J<< \9)SSZ<5[# MKFEIK>@W^ER-M2[MWA+?W=P(S^'6OG'P'\1+OX4:C?\ A;Q)83O:13DXC \R M%O4 X#*1@]?<9S0!V'QW\"Z4OAG_ (273[2&TO;611,T*!!*C'&2!_$#CG_Z MU=E\']'L])^&NDM:Q@27D0N9WQR[MSS]!@?05UMO+9:]H\$[0+-:7<2RB.>, M'*D9&5-6+2SMK"UCM;.WAM[>,82*% B*/8#@4 9?BW0[/Q'X6U#3+Y%:*6%B MK-_ X&58>A!KS3]G2]FD\*ZI82.6CM;P^7GL&4$C\\G\:ROB7\;D$6H>&M L MKA;HL]K/=3879_"PC4$DD\C)QCTKM?@QX1NO"G@A?MZ,E[?R?:9(V',8( 53 M[X )]R: /1:*** "BBB@ HHHH **** "BBB@ HHHH ^9?VD/^1XTS_L&K_Z, MDKU7X&_\DETG_?G_ /1SUY5^TA_R/&F?]@U?_1DE>J_ W_DDND_[\_\ Z.>@ M#T6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "L7Q1X?B\1:.]LV!.GS0N?X6_P-;5%.+<7=$5*<:D7"6S/FZ>":RNW MAE5HYHFVL#P5(KV;P-XG&O:6(9W'VZW 60?WQV:L?XC^%_M$)UJSC_>QC%PJ MC[R]F_"O.]%U:XT35(;ZW/S(?F7/#KW!KT9)8BG=;GR].4\MQ7++X7^*[_(^ MAZ*IZ7J5OJVG0WMLVZ*5W+G +J<[23TR,KGMF@#S_P"$_P 'M$;P MY9Z_XAMDO[J]C$T,$F?*BC/*Y7^(D<\\<@8XR?5O^$0\,^3Y/_".Z1Y6,;/L M4>W'TVUYM\*OBCI<>B6WA;Q'<)I>JZ:OV53M+J M5B\7FI>V[1XSO$JD8^N: /(/BG\'-#F\.7NM>'K)+"_LXVG>&'(BF11EAM[, M "1CKT/7(Z3X*^*+GQ/\/H6O7:2[L)39R2. MD^&;[2M,OH+[5;R)K<+;N'6$,,,S,. 0"<#KG'&*O?!GP^?"?@..+4)8XKV] MF:ZEB9QF,$!54^^%!/H210!Z3142W,#L%2>-F/0!P34M !1110 4444 %%%% M !1110 4444 %%%% !1110!Y!^T=_P D\L/^PK'_ .BI:\^_9Q_Y*'?_ /8* MD_\ 1L5>@_M'?\D\L/\ L*Q_^BI:\^_9Q_Y*'?\ _8*D_P#1L5 'U!1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 5Y5\5-3\W4K334/RP(97_ -YN MGY ?K7JM?/GB/4?[5\0WUZ#E))3L/^R.%_0"NK"1O._8\?.JW)04%]I_E_2- M+P%IO]I>++79I!$A/\ =7D_J?TK MT*IQ,N:I;L:911]GADWO+4****YSU HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH P?''_ "3_ ,2?]@NZ M_P#135\N?!3_ )*[H7UG_P#1$E?4?CC_ ))_XD_[!=U_Z*:OESX*?\E=T+ZS M_P#HB2@#[!HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@#AOB?JOV30([!&Q)=O\W^XO)_7'ZUY3IME)J6IVUE'G M=/($SZ9/)_ 5T7Q$U+[?XKFC5LQVJB%?J.6_4G\JT/A=I8N=;GU!URMJF$_W MVX_D#^=8/WI6/J]K_-[?H>L6T$=K;16\2[8XD"*/0 8%2T45N?+- MWU84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7)^.="\&:G MIOVCQ?%9)#&-J7,\GE.OLK@@_A^E=)?WL.FZ=&=4^..O7GB+7[V:UT:"4Q000G)]=J9X QELKVDA_]!!K.O\ ]GOP=<6316DE_:W& M/EF$V_GW4C!'TQ7GWA/X=>&IO%FH^"/%$-S#K$&7MKRVGVB=,9'RD$ X((XZ M?3D ]<\+Z#\.M3UNY\1:%]AU#4II6GDF\XR-&S$DD(3\G7T!KOJ^;_%GP:U? MP)$_B7PEK%Q*ME^]=3\DT:CDG(X<>HP..QKU_P"&7C/_ (3?P=!J,RJM[$Q@ MNE7IY@QR/8@@X[9H [&BBB@ HHHH **** "BBB@ HHHH **** /F7]I#_D>- M,_[!J_\ HR2O5?@;_P DETG_ 'Y__1SUY5^TA_R/&F?]@U?_ $9)7JOP-_Y) M+I/^_/\ ^CGH ]%HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH 1E5T*.H96&"",@BO$/&WAEO#^K%X5/V*X):( M_P!WU7\*]PK-UW1[?7=)FL9P!N&4?'*-V-;4*OLY>1PX_!K$TK+XEL>6> /$ MYT?4?L-T^+*Y8#)Z1OV/T/0U[*#D9%?.6HZ?<:7?S65RA66)MI'K[CVKU7X> M^*/[4L?[-NY,W=NOR,3S(G^(KHQ-*Z]I$\W*<8XOZM4^7^1W%%%%<)] %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !15*[U?3+"01WFHVEN[=%FG5"?P)JW')'-&LD3JZ,,AE.0?QH =1110 M 45%<7,%I$9;F>.&,=7D<*!^)J"SU;3=08K9:A:7)'40S*^/R- %RBBB@ HJ MI>ZII^F[/MU]:VN_[OGS*F[Z9/-6@0RAE(((R".] "T444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 5@>-] G\4>#=2T6VFCAFNXPBR2 M9VKA@><<]JWZ* /FK_AFWQ!_T&],_*3_ .)H_P"&;?$'_0;TS\I/_B:^E:* M/FK_ (9M\0?]!O3/RD_^)H_X9M\0?]!O3/RD_P#B:^E:* /"_ OP.UGPIXTT MW6[G5;":&U=F:.(/N.49>,C'>O=*** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@#R#]H[_DGEA_V%8__14M>??LX_\ )0[_ /[!4G_HV*O0?VCO^2>6 M'_85C_\ 14M>??LX_P#)0[__ +!4G_HV*@#Z@HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH Q?%FI?V5X8OKD-B3RS''_O-P/RSG\*\"KT_P"*^H[8 M;'3%/WB9Y![#A?\ V;\JXKPGIO\ :OBBQMBN8Q())/\ =7D_GC'XUZ.&7)3< MF?+9K-U\6J4>EE\V>T>&]._LGP[8V97#I$"X_P!H\M^I-:M%%>>W=W9]/""A M%16R"BBBD4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% &#XX_Y)_XD_[!=U_Z*:OESX*?\E=T+ZS_ /HB M2OJ/QQ_R3_Q)_P!@NZ_]%-7RY\%/^2NZ%]9__1$E 'V#1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %5[^[2PT^XNY/N M0QM(?? S5BN,^)FI?8_#/V56Q)=R!/\ @(Y/]/SI-V5S;#TO:U8P[L\>N9WN MKF6>0Y>1R['U).:]H^'6F_8/"D,C+B2Z8S'Z'A?T /XUXU86CW^H6]I']^:1 M8Q[9.*^C+:!+6UB@C&$C0(H] !BLJ:UN>[G-7EIQI+K^A+1116Q\X%%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110!SOCRVFO/ .O06X8RM92[ M0O4X4G ^N*\\_9[\26-SX5E\/F1(]0M)7D\L\&2-CGL+H M'AV_U9X#.MI$93$&V[@.V<&OD37;K0;S73K/A"\N=(F=]XM+@^4T3GJ8I5)4 M+R?O%<>] 'V?7SK?:W!XB_:7TV327$L=M((#+&9J>I3QW.L3)L_=CY($[A2 M>23W/'3 [D@';^*M..%86 5V ,C8.$ [DUY?\ LY0RCPUK M%R598);W]WGH<*,D?F!^%'CCX-ZOXV^(EQJLFJ0VVDR+& "6>1=J*"%7H,D' MG/?H:]6\/Z#I_AG1;;2=,A\JU@7"CJ6/=B>Y)YH TZ*** "BBB@ HHHH *** M* "BBB@ HHHH ^9?VD/^1XTS_L&K_P"C)*]5^!O_ "272?\ ?G_]'/7E7[2' M_(\:9_V#5_\ 1DE>J_ W_DDND_[\_P#Z.>@#T6BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH XGX@^%_[ M5L/[1M4S>6Z_, .9$_Q%>3V%]<:9?PWELY2:)MP/]#[5]'5XY\0/"_\ 9&H? M;[5,65PW( XC?N/H>U=N&JW_ ''>"_$K>']6 E8_8IR%F']WT;\/Y5[>CK(BNC!E89!'<5A7I>SEY M'HY?C%B:5W\2W'4445B=X4444 %%%% !1110 4444 %%%-D3S(G0'!92,^E M'BGQ%\2ZQ%\8O#VA17\L6F-)#(]O&=H=BW\1')^AXKVVOD+Q7X N](^)%CX> MEU@W$UZZ%;HQD>7N/'&XDX^M?2G@#PG<>#?#@TNYU(ZA)YK2><4*]>V"3_.@ M#J:*** "BBB@ HHHH **YGQWX6N/&'AE])MM0-A(TJOYX4MC&>, CU]:\I_X M9ZUG_H=G_P# =_\ XY0![Y17@?\ PSUK/_0[/_X#O_\ '*]3\ >$KCP9X<_L MNYU(ZA)YK2><4*\'M@D_SH ZFO,/C/XZO?"^C6NF:.SKJVI-LC>/!:-.F0/4 MDX'XUZ?7SI\5=9L['XX:3=:JK-8Z=#'(54;B< N !Z[L4 :&A_L\KJ&GB^\2 MZW=_VC<#S'2 [">?F9LECZ]*B\*Z/XK^%OQ(@T5/MNI>';P@-)' YB4-T8X MR$8'@\_TJ:3Q]\6O$R'4O#7AL6VE'YH2T2LTB^N7(W?\!%;/P\^,-[K&O_\ M",^*]/6QU4DK'($,89A_ R-RIQ^!]NX![#574KZ+2]+N[^;/E6T+RL!U(4$_ MTJU2.BR(4=0RL,%2,@B@#YE\/>%]<^-^N7NMZUJLMOI<$I2-5&['?9&I.% & M,GG\36KXM^ [>'-)EUOPQK5V;FQ4S,DI"OA1DLCKC! Y_K7OECIEAI:2)I]E M;VB2/O=8(@@9O4@#K7"_%OQ[8^$O#%S8B4/JM_"T4$"GE588+GT YQ[_ (T M/^#WC.Y\8^#!+?OYE_9R>1/)C'F8 (;ZD$9]Z]!KS;X)^%;GPUX'$E\A2ZU" M3[2R,.4! "@^^ #^->DT >!?M+?ZK0/]Z7_V6O:XM1LM/TFS>]O+>V0Q( TT MJH#\H]37BG[2W^JT#_>E_P#9:FTCX+WOC.QAUSQEKMX+VXC!C@@ Q"F/E7+9 M'3L * /CI?"XM_.WM<&/;\Q&,;3Z5P__#3%U_T*T/\ MX&G_ .(H ^AJ*^>?^&F+K_H5H?\ P-/_ ,11_P -,77_ $*T/_@:?_B* /H: MBOGG_AIBZ_Z%:'_P-/\ \17J'PS\>R?$'0[O49-/6R,%R8-BR^9N^56SG _O M4 =M1110 4444 %%%% !574=1L](TZXU"_N$M[2W0O+*_10/\]*M5XG^T+J- MW-;>'_#-FV#J5R6D&[&XJ55 ?;+D_P# 10 Z]_:1T*&]:.TT6_N+<-CSF=8R MP]0O/'U(_"O1?!OCK1/'.FO=Z1,V^(A9[>4;9(B>F1Z'G!&0<'N#4^A>#M#\ M/Z##I%KI]LT"1A)"\*DS'&"S\U 'D?BKX\V'ACQ/?Z+_8D]T;1Q&TRW 4,< M GC!Z$D?A6/_ ,-+6'_0M7/_ (%+_P#$U3^$FLZ-#J'B_P 8^(+RUM8+Z]V0 MO$/$DQ@TC4M.NIP"WDK@/@=3M(!Q^% &_9W N M[*"Y"[1-&LFW.<9&<5-0 , 8 HH \@_:._Y)Y8?]A6/_P!%2UY]^SC_ ,E# MO_\ L%2?^C8J]!_:._Y)Y8?]A6/_ -%2UY]^SC_R4.__ .P5)_Z-BH ^H*** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH ***JZE>+IVF75Z_W8(FDQZX&<4) M7T$VHJ[/%O'>H?VAXNO6#92 B!?;;P?_ ![-=%\*-/W75_J++PBB%#[GD_R' MYUYY+(\TKRR'<[L68GN37MW@'3_[/\(VFYC7?)2Y4?+9: MGB,:ZKZ79TU%%%>I)X KC+ MSXP^ +&261@JHHY))/ ]: )**KV-_9ZG9I>6%W!=VLF=DUO()$;!P<, M.#@@C\*L4 %%%% !1110 452U+5],T:!9]4U&TL87;8LEU.L2LW7 +$<\&F: M9KVCZWYO]DZM8W_DX\S[+<)+LSG&=I.,X/Y&@#0HHJ*YN;>RMI+FZGB@@B4M M)+*X54 ZDD\ 4 2T5E:=XGT#5[DVVF:YIE[.%+F*VNXY&VCJ<*2<$;O67022KB.WB)QYDK?='T')/L#0!TM%?.6C>"?B3\1+ M!?$=]XIEL8[D&2VB::1W<]<>NW\/_%WBCPKXZ'@/QI.]R9A_HES M(Y]45D>%]*N=#\,Z?IEW=F[N+: M(1R3G/[P^O/-:] &#XX_Y)_XD_[!=U_Z*:OESX*?\E=T+ZS_ /HB2OJ/QQ_R M3_Q)_P!@NZ_]%-7RY\%/^2NZ%]9__1$E 'V#1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %>/?%'4/M/B**S4_+:Q $? M[3P$A5+$@ #))[5\[:W?G4];O;TGB65F7V&>!^59U'I8]C)J7-6<^R M_,Z/X::=]L\4"X892TC,G_ CP/YD_A7L]<'\+-/\C0[B^88:YEPI]57C^9:N M\IP5HF&:5?:8E^6@44459YP4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% $-U:V]]:RVMW!'/;RJ5DBD4,K#T(/6O/]7^!W@;5=[1Z=+82M_' M9S,N/HK94?@*]&IDLL<$32S2)'&HRSNP ]R: / ]0_9SN[2<7/ASQ,8YDYC M%RA1E/\ UT3_ .)J%8?CCX,/R&36;2,=-RW0;\\2UZ'X@^-/@K0=R+J1U*X7 M_EE8+Y@/_ \A/UKSB\^.OB_Q+=-9>$/#PC8G *QM@#2L?VA M+S39EM?%GA6XM9@/F:WRC9_ZYR8_]"KU7PCXVT7QM8RW>C32NL+!)4EB*,A( MS@]C^!->+I\-OBGX["GQ5KC65HQR89Y=WXB*/"_F0:]:^'_P^LOA_ID]K:WD M]V]PXDEDE 49 Q\H'0?4F@#L**** "BBB@ HHHH **** "BBB@ HHHH ^9?V MD/\ D>-,_P"P:O\ Z,DKU7X&_P#))=)_WY__ $<]>5?M(?\ (\:9_P!@U?\ MT9)7JOP-_P"22Z3_ +\__HYZ /1:*** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JIJ6G6^JZ?-97*[HI5 MP?4'L1[BK=%"=M4*45)6>Q\\ZWI%QH>JS6-P.4/RMV=>Q%>@_#?Q1Y\0T2\D M_>(,V[$_>7^[^'\OI6YXW\,C7]*,L"C[=;@M&?[X[K_A7BT,TUE=)+$S1S1- ME2.JD5Z46J].SW/EJD9Y;BN:/PO\NWR/I*BL/PMX@B\0Z.EP"%N$^69/[K?X M&MRO.E%Q=F?3TZD:D5..S"BBBD6%%%% !1110 4444 %%%% 'SY\2/\ DX'P M[]8/_0J]YU'4+;2=-N-0O9/+MK=#)(^TG 'L.37BGQG\/>)(_&ND>*M"TN2^ M6UC7(BB,A5U8GYE7G!!'->A> M?U7QEX*O%;?,MY>_9K=O6&/@?U'X5Z'=7=O8VLMU=S1P6\2EI) M)&PJ@=R: /"]1T"_^"_B'1KS0]6O+K0KZY%M<6=TX."2.> !GG(( /'O7O*L M&0,.A&:\666Z^,7CJSNK>&2+PEHDV]9GR/M4H.>!Z<#Z >]>U # Z4 &7?PE$)=5\U0JD(?EYS][CTKRG^U?CY_P! U/\ OW;?_%5[Y10!X'_: MOQ\_Z!J?]^[;_P"*KU/P!/XJN/#F_P 7PB+4_-8;0$'R=ON<5U-% !7SA\7M M.MS\:]%;41FRN_L^_/=$C%K(D6J6A+6[O]UP> MJ$_R/^- '>1(D<2)$ L:@!0O0#M7@?QN@M[?XD>%;NT"KJ,CQ[PO#,!( I/\ MOPJM8^._BYX5MO[&O?"\^HR0CRXIY+.60GT^>,[7'3W]36IX'\!>*?$OC1/& M?CI6B:$[K>UD&&)'W?D_@4>AYS^H![E&28U+?>P,TZN.^(GB?7/"VCV]UH6C MG5+B2;8\0B=]JXZX3FIY?$6J+\-/[>;395U5K$2_8XX69EE8 !=GWN">GM0! MSGQ+^+$'A%AH^CQ"^U^;"K$/F6$GH6 ZL>R_Y.-X!^%-[=:N/%_CJ5KO5I&\ MV.UE.X1GL7[9'91P/Y>7>%;_ ,7>&-?N=:EJ4[%A/=VO\ BO3KR?7M%.ERPRA(T,4D>]< MY^?WKMJ / OVEO\ 5:!_O2_^RU[II_\ R#+7_KBG\A7B_P"T/I&IZK'H8T[3 MKN\\LR[_ +/ TFW.WKM!Q7M-@I73K96!#") 0>W H \+^*/_ "73PI](O_1A MKWRO#_B3I&I7?QH\,7EMIUW-:Q"+S)HX69$^<]6 P*]PH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@#.U#3M&O)4?4K.PGD5<*;F)&('MN M'2JG]A^%?^@5HW_@/%_A7"?%7X5:GX_UNQOK'4+2V2WMO)99PV2=Q.1@'UK@ M?^&;?$'_ $&],_*3_P")H ]Y_L/PK_T"M&_\!XO\*/[#\*_] K1O_ >+_"O! MO^&;?$'_ $&],_*3_P")H_X9M\0?]!O3/RD_^)H ]Y_L/PK_ - K1O\ P'B_ MPK1T^TTZSA9--M[6"(MEEMD55)]3M[U\Z_\ #-OB#_H-Z9^4G_Q->L_"KP+> M^ = O-/OKNWN9)[HSJT&[ &U5P<@<_+0!WE%%% !1110 4444 %>&?&?Y?B? MX#=N%^T)R>G^N2O!XX5_?J;5F(X)3[0W?Z!N/\ &NGT+XZ^#K[0H[K5+XZ?>J@\ M^V:%W.[_ &2JD,"?_KXKCO!UQ/\ $_XWR>+8[66'1]*CQ$9!SPI"*?\ :)9G MP.F,?4 ^@*JZE9_VCI=Y9"9X/M,#P^;'CWAGUJ_C MLXIGV1LZL=S8SC@&G:I->WOA>YN- F3[9+:F2RD9.OK0!YEH7[ M._AVQ>5M8O[K5 7)BC'[A%7CKM));WR![5SGQ-^$EEX.T?\ X2OPG<7=I)82 M(\D7FEBH+ !T;[P()&F.=OP'\G?-9OQ4^*FF>*=%_X1/PF9M1N=0E2.26.-E& P(100"Q) ]L9ZYH ] M;\"^('\4^"-)UF4*)KF#][M&!YBDJ^!V&Y37R[XT\:>*K7QUXAM[?Q+K,,$6 MIW*1QQW\JJBB5@ &P !QBOJ/P1H#>&/!6DZ-)L\ZV@ EV=/,)+/CU&XGGO7 M04 ?"FI>)=>UFW6WU36]2OH%<.L=U=/*H;!&0&)&<$C/N:]+_9Q_Y*'?_P#8 M*D_]&Q5Z#^T=_P D\L/^PK'_ .BI:\^_9Q_Y*'?_ /8*D_\ 1L5 'U!1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !7&?$S4/LGA@6JG#W?F=7V>%EYZ??_P#C+"T>_U& MVLX_OSRK&/;)QFOHR&)(((X8QM2-0JCT &!7C7PVL/M?BQ)B,I:QM*?J?E'\ M\_A7M%:8R5Y*)R9)2Y:4JG=_D%%%%(?\ KS>NMKDOB?\ M\DR\0_\ 7F] 'AGPD^%6A^/?#U[J&J7>HPRP71A46LB*I78K<[D;G)->@?\ M#./@_P#Z"6N?]_X?_C5F_P#"[?AY_P!##_Y)7'_QN@#&LOV>_"=C?6]W%J&M&2"595#318)4Y&?W M?3BO5;B>*UMI;B>18X8D+R.W15 R2?PKD]$^*7@SQ'J\&E:5K/VB^GW>7%]E MF3=M4L>60 < GDU4^,E_+I_PJUN2$X>5$@S_ ++NJM_XZ2/QH \@EN->^//C MB:SM[F2R\.V3;\$96-,X5BO\4C8.,].>PY]1LO@3X"M;58I],GO) ,&::[D# M'WPA4?I6?^SWIB6?P[DO=O[R^NW M#;VZ@AMI5\U"^6@RQ%=!>6=MJ%G+:7D$<]M,I22*1TMPR^$--U32/"EA8:U>_;=1A0B>X\UI-YW$YW, 3P1UH VZ\Y^,7 MCV;P3X7C33W"ZKJ#-';N1GRU &]\>HR /?S& 55,Q,A.>GR@?E0!9\*_ ,:YIB:OXOU74!?W@\TQ0NN]<\C>[ALMZ MC'%8&NZ+JOP)\8Z?J>E7\MUI-X<.CC!D52-T;@<$X.5;].#75ZE\;_$.JW!O"4^H6D#[3=26TLV_WV1XV_B<^PZ5?\$_'(:KK::%XJTU=*OW81I*NY4,G M]UE;E#Z9)_"@#U^WGCNK:*XB;='*@=#Z@C(J2BB@"KJ.I66DV,E[J-W#:VL8 MR\LSA5'XFOF[XK?%N7Q=:3Z/X#[ M3QOHD>DWUQ-#;BX29S#C??%CPSH_A7X-W5AHUC':P_:(2Q4 M9:0[NK,>6/UH Z+X(_\ )(M$^MQ_Z/DKT&O/O@C_ ,DBT3ZW'_H^2O0: "BB MOEKXA7.L6O[0M\V@9_M60Q06Y R0TELD>1Z$!B<]NO:@#Z0O/$^@:==BTOM< MTRUN2<"&>[C1_P#ODG-::.DB*Z,K(PR&4Y!%>)6G[..F2Z9OU;7;^35I 6DE MAV^4'/)X8%F^NX9Z\5A>!-3UKX6_$Q?!&L7/G:7>2!(B2=@+_P"KD0'IN/RD M>I/I0!T_[2'_ ")&F?\ 81'_ *+>N(^#EQ-X1^)EKI=S(1;ZUIT4B$C"EGC6 M5#^&67ZFNW_:0_Y$C3/^PB/_ $6]<9\0K";2/"OPV\9V8Q-;6%I [9_B1%DC M_P#9_P A0!],5Y1\?M=?3_ \.D6Y8W.K7 B"+]XHI#-@#KSL&/\ :KTW3;^# M5=+M-0MFW074*31MZJP!'\Z\8UP_\)O^T9INECY[#0(Q-*.V]<.3_P!]M&I_ MW?S .7^"6G/H_P 9=5TR1MSV=O*"4@O& MC;';>F1_Z!0![)8VT=E86]K"H6*&)8T & !@5XC\=E73_&O@G5U&)5G(W+U MQ')&P_\ 0C^=>TZ5?PZII%GJ%NP:&Y@29".X8 C^=>*_&UUU;XB^"M"BS)*) M0S(.PDD1?Y(?PH ]U'(%+0. *;)(D4;R2,%1 68GL!0!\M^&?%^N0?$'Q5JO MA_P_-JNKW\SI#F-BMO&9"3O Y[(.2.G6ND?XN_$3PE?0OXP\-*+"1@"P@:(_ M1'R5)P"<']*]MT37M%\0QS7.C7UM>*C!)7A.<'' /X5G_$*&QG^'NOKJ*JUN M+&5_F X8*2A&?XMP&/?% &KHFM6/B'1;75M-F$MI_M/_"MG\[_ %7V MZ7R/]S"Y_P#'MU5_&_P,_P"$R\7WNO?\)']C^U>7^X^Q>9MVHJ?>\P9SMST[ MT 9?B/X^^%=8\+ZMIEOI^LK->64UO&TD,04,Z%03B0G&3Z5YC\%/^2NZ%]9_ M_1$E=EKG[._]C>']2U7_ (2GSOL5K+<>5_9^W?L0MC/FG&<8S@UQOP4_Y*[H M7UG_ /1$E 'V#1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 87C'4/[-\*7\P.':/RD^K@65GC#1Q*&_WNI_7-:5%%;GS4Y.4G)]0HHHH)"BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH P?&VI7>C^"M8U&QE\JZM[9GB?:&V ML.AP>#^-?*EA2-)8VCD171AA ME89!'N*X/Q!\&O!7B#2+RB?I(@*'\J /H:BO M,/#_ ,>/!VLE8KR:?2IR<;;M,H3[.N0![MBO1[*_L]2MEN;&[@NH&Y66"0.I M_$<4 6**** "BBB@ HHHH **** "BBB@ HHHH ^9?VD/^1XTS_L&K_Z,DKU7 MX&_\DETG_?G_ /1SUY5^TA_R/&F?]@U?_1DE>J_ W_DDND_[\_\ Z.>@#T6B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "O*?B/X7^R7!UFSC_IX1X6\02^'=82Y!)MW^2=!W7U^ MHKW>WN(KJWCN('#Q2*&5AT(->#>)M F\/:Q):ODPGYH7/\2_XUU?PX\4>1*- M%O)/W;G-NS'[K=U_'M77B*:G'VD3Q,LQ4L/5>&JZ?H_^">IT445P'TH4444 M%%%% !1110 4444 %%%% 'E'QS_Y!GAW_L*Q_P Q78^-]9&@?#_5-1WE'CM" ML9'4.PVKC\3FMN^TO3]46-=0L+6[6)P\8N(5D",.XR#@^].O=/LM1MOLU]9V M]U;Y!\J>)77(Z'!&* ,#X>:*= \!Z392*%F$(DF_ZZ-\S?J37C7BCQ[HGCGQ MG-INO:])I?A2P?B*&*1FOF!YR4!P.._0=.>:^C-J[-FT;<8VXXQ6"? OA%F+ M-X5T,DG))T^+G_QV@#E],^+/PRTZTM].TW6(X((P(XHH[&=0/_(=>C*P=%=3 ME6&0:P5\#>$58,OA71 P.01I\60?^^:W@ H X % "T444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !5>^OK;3+"XOKR98;:WC:661NBJ!DFK%>9?'J]EM/A M=>,/'G MP_\ B/>:MY<[^'[N9!#!,V^WD544$*1GRV.">QSR017MOAS7K/Q/X?LM9L"3 M;W4>\!L90]"IQW!!!^E9_C_3K75/A_KUM>!/*^PRR!G'",BEE;\" ?PK@_V< M[F67P#?0NQ*0ZBXCSV!C0D?GD_C0![!1110 4444 %%%% !2,JNA1U#*PP01 MD$4M% '!WGP9\ WUV;F30$C9CED@GDB0_P# 58 ?ABNOTG1].T+3TL-+LH;2 MU3D10KM&>Y/J?<\U=HH P?%/@[1/&5I!;:W:M<10.9(PLK)AB,?PD=JV+2UB ML;*"T@4K#!&L4:DYPJC &?H*FHH Y7Q%\./"7BJY^U:MHT4MT>L\;-$[?[Q0 MC=QQSFG^&_AYX5\)S&?1](AAN#D>>[-)(,]<,Q) ^F*Z>B@ HHHH \@_:._Y M)Y8?]A6/_P!%2UY]^SC_ ,E#O_\ L%2?^C8J]!_:._Y)Y8?]A6/_ -%2UY]^ MSC_R4.__ .P5)_Z-BH ^H**** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^? M/$=__:?B*_O SVK\%)>O^7ZGJ_PJL/*TJ\OV7#3RB-2?[JC_%C^5>@5D>%]/_LOPU86 MA&'6(,X_VF^8_J36O7+5ES3;/8P=+V6'A#R"BBBLSI"N2^)__),O$/\ UYO7 M6UR7Q/\ ^29>(?\ KS>@#Q_X)?#[POXN\,:A>:[I?VNXBO#$C_:)8\+L4XPC M =2:]-_X4E\//^A>_P#)VX_^.5YE\$OB#X7\(^&-0L]=U3[)<2WAE1/L\LF5 MV*,Y12.H->F_\+M^'G_0P_\ DE:?L_7\=W\-%ME;+V=W+ M&P],D./_ $*O5*^8O#VKZC\#/'M[I>KV\TVC79^^@^^@)V2IV) ."/?V%>Z6 M?Q*\%7UH+F+Q/I:(1G;/<+$X_P" O@_I0!T5[>6^GV-Q>W<@BMK>-I99#T55 M&2?R%4-"\3:)XGMFN-%U*WO8TQO\IN4STW*>1WZBO%?BU\7++6M,?PMX5DDO M'NV$=Q"_!45O=IMU&[;[1=#KL8@ M)GV 'XYH YOQ-XK\;:E\4[OPGX-O+*#['9I--]JB!7/RDG=M)Z2(*N:?8?&9 M=3M6O]6T)[(3(;A8T&XQY&X#]WUQFN0T5/B%-\0_%VH>']%CADO;DHM_J<31 MI'"K,%" _>) 3D _=ZE>=1:M\;+O M2UU^&RTE('3S4TQH\2%.HX)SG';<#[9XJ7XW+]O\0> =(<*]K?:F1(KV\=^'!J,<)M[J)_)NKH(.1^7:NKKQ_P"& M41T[XN?$#3XR! TZSA > 2S$8_[[KV"@#RWXB?&3_A ?$<>D?V#]NWVZS^;] ML\K&2PQC8W]WKGO7(_\ #37_ %*/_E2_^U5] 44 ?/\ _P --?\ 4H_^5+_[ M57LOA#Q#_P )7X4L-<^R_9?M:%_)\S?LPQ'WL#/3TK;HH *^8OCKIQNOBYI] MLSE!>VUNH;&=H,C)G]*^G:\>^/7@R\UO1[/7]+B>2[TS<)4B!+M$2#N&.?E( MS]"3VH ]5TG2K+1-+MM-T^W2"UMT"1QJ.@_J3U)[UXQ^T?H-D=#TS7UB5+U; MH6CNHP9$9&89]<%./]XUI>$/CYX3GUP* />O!FH3: MKX)T._N3NGN+&&21O5B@R?SKA@W&.RTZU";B"=L<:XSQR>!6? MX9\;^'?&)NAH.H_:_LNSSOW,D>W=G;]]1G.T]/2@#H*\S^/7_)+;O_KXA_\ M0J],KS/X]?\ )+;O_KXA_P#0J +?P1_Y)%HGUN/_ $?)7H->??!'_DD6B?6X M_P#1\E>@T %>"+%#)^UK-YN,JBL@)ZM]C7^F3^%>]U\M?$/5;_0_VA;W5=,A M::ZM'@E$2@G>HMD+@X[;=V?:@#ZEKY\^.X5/B/X4EM\?;=J8[<";Y.?J6KMK M7X]>!IM,6YGO+FWN-N6M&MG9P?0,!M/YBO/_ RM_P#%_P",">)YK1X-%TMT M*;N@"'=''GNQ8[B.PSZC(!U'[1__ "(^E_\ 807_ -%O6KJ>@_\ "1_L[V-F MJ%IX]%MKB$*,G?'$K #Z@$?C65^TA_R)&F?]A$?^BWKT3P& ?AWX:!&1_95M M_P"BEH X3X,^+H?^%37#WDA)T(2B7<>?+ ,B_A@E1_NU3^ .GSWL.O\ BZ^7 M-UJ=V5#8X(!+.1[%FQ_P&O)/$LM]X#\0>,/"EJFVUU%UC 4D$1AQ)'CU^5BI M'O7U'X'T$>&O!.D:3L"R06Z^*O^NE]_P"C MQ7T-7SS\-?\ DXSQ5_UTOO\ T>*^AJ "BBB@ K%\6>&K3Q=X9O-%O"5CN%^6 M0#F-QRK#Z$#COR*VJ* /G;3=)^,W@&%]&TFW6_T\,?(==DJ+GNNXAE^AX]JZ M;X;_ UUZ/Q1)XS\;S>;JYSY,+.KLA(QN8K\HP. HX'M@5['10!S7CJ\\16/ MAB6?PM:BYU02($C*!LKGYN"1VJUX2N-8O?"MC-XAMQ#JDB'[3%M .X\8Y[8 MK;HH \!U3X<>./ /B6ZU?X>S>?8W1R]J"F4&2=K(_# =B/FY/N36O/#GQ=^) M#QZ?X@*:7I(8&0,$1..^Q26<^@)QD=J^AZ* ,SP]H5EX9T"ST?3T*VUK'L7/ M5CU+'W)))]S6G110!@^./^2?^)/^P7=?^BFKY<^"G_)7="^L_P#Z(DKZC\HC3('T.* /<=7^(GA#0BZW_ (AL4D3[T4&((Y M(M.TR]U(D8_>!8HV_$Y/_CM1:)^SCH=KL?6=6O+YQR8X5$,9]C]YOR(KT;1/ MA_X3\/;6TS0;**5>DSQ^9(/^!MD_K0!\X:G:ZU\1Y?-T'X;6MBDGS+-,_P"P:O\ Z,DKU7X&_P#) M)=)_WY__ $<]>5?M(?\ (\:9_P!@U?\ T9)7JOP-_P"22Z3_ +\__HYZ /1: M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** ,'Q9X=C\1:0\( %S'EX'/9O3Z&O"Y$FL[ID< M-%/$^".A5@:^DJ\W^)'A?>AUNSC^9>+E5'4=F_QKKPM6SY'L>)F^"YX^WANM M_3_@'1>"O$J^(-)"RL!>P +*O][T;\:Z:OGK0=9GT'5HKZ YVG#IV=>XKWS3 M[^#4["&\MG#12KN!_I48BER2NMF;Y9C?K%/EE\2_'S+-%%%7R28Y%'(P2<'T..,GU.!-+ECE\NY M.=K95<8XSV->G>.?#?P[\2ZW;Z=KDT$.O7)$<1MI-MR ;.QNTV7L[-=7*?W7;'RGW"A0?<&N*^&MO\*= M-\0-9Z7+*^NPRM'')JN-Y8$C]V0 F?3'S8KVN@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** /(/VCO^2>6'_85C_P#14M>??LX_\E#O_P#L%2?^ MC8J]!_:._P"2>6'_ &%8_P#T5+7GW[./_)0[_P#[!4G_ *-BH ^H**** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH X'XJ7WE:-9V*G#3S%R/]E1_BP_*O.?#M MA_:?B*PLR,K),N\?[(Y;] :W_B7??:O%1MP?EM8ECQ[GYC_,?E4_PML?/\03 MWC#*VT. ?1F.!^@:O2A^[H7/E<1_M.8\G2]ONW_4]>HHHKS3ZH**** "JFJ: M99ZSIEQINH0^=:7*&.6/<5W*>V001^!JW10!Y_\ \*2^'G_0O?\ D[@44 >?\ _"DOAY_T+W_D[U.HH R]>\.:/XGL#9:UI\-Y!U42#E#ZJPY4^X(KSJZ_9W\&7$QDBN-7ME/_ M "SBN$*C_OI&/ZUZS10!R'A;X8^%/"%P+K3--#7@&!%_ "NOHH MH YOPCXXT?QK%>-I9G62SD$<\-PFR1">A*Y/'!'U!KA_VA;RT7P-::3R0?3DFCPU\'X]/\11^(?$NNW?B'5(2# UR"$B(Y!P68D@Y(Y &>F0#0 M!A?&*WETFR\!Z[.'V:1>QK/MYP3Y;?\ M(U[-%/#-;)<1RH\+H'613E2I&0< M^F*I:[H>G^)-%N=)U.'SK2X7#KG!'<$'L0>0:\I/P/UE+5M)M_B!J4>A,<&S M,;'Y.Z\.%(_#'?% $OPCE.M_$'QUXBA):QFNA#!)G(D 9B,?\!"G_@0KV*L; MPOX8TWPAH,&CZ7&RV\7)9SEY&/5F/%GA+'U.PKD_6MG0O#&B>&;=H-%TRVLD?[YB3YG M_P!YCR?Q-:U% $5U;0WMI-:W";X9HVCD7)&5(P1D<]#6)X9\$>'?!QNCH.G? M9/M6SSOWTDF[;G;]]CC&X]/6N@HH *S->\/:7XGTI],UBU^TV;L&:/S&3)!R M.5(/ZUIT4 9^B:'IWAS2(-*TFW^SV4&[RXM[/MW,6/+$D\DGK6A110 5\\WO M_)VB?]=(_P#TC%?0U>>3?"[SOBTOCO\ MC&&5OL7V7TA$7W]_MG[OM[T :5[ M\*? VHZB;^Y\.VQN"=S%&>-6/J45@I_*NIL;"STRSCL["UAMK:,82*% BK] M*L44 8WB3PIHGBZQBLMA-:-A8VVF:=;6%G'Y5K M:Q+#"FXMM10 !DY)X ZU8HH YK5_A_X7U[7H-;U/2EN-1@V;)C-(OW#E'-'\1W?B"PT[R=4NS(9Y_/D;>7;>!70T44 M%%%% !1110 4444 %%%% !1110 4444 8/CC_DG_ (D_[!=U_P"BFKY<^"G_ M "5W0OK/_P"B)*^H_''_ "3_ ,2?]@NZ_P#135\N?!3_ )*[H7UG_P#1$E ' MV#1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5 MS_C:_&G^$KZ0'#R)Y*^Y;@_IFN@KS3XL:CA+#35/4F=Q^B_^S5,G9'7@:7M< M1&/G^1YDJEF"J"6)P .]?1>CV0T[1K.S'_+&%4/N0.37B'@[3_[2\5V$)&46 M3S7^B\_S 'XU[Y44EU/2SNK[T:?S"BBD)"J22 !R2>U:GA"T52_MG2_^@E9_ M]_U_QH_MG2_^@E9_]_U_QH NT52_MG2_^@E9_P#?]?\ &KBL&4,I!4C((/!H M 6BBN=U#Q[X2TNX:WO?$6FQ3*<-']H4LI]P.GXT =%169I'B/1=>5FTC5K.^ MVC+"WF5ROU .1^-:= !1110 4444 %%%% !1110 4444 %%%% !114+7=LEP MMNUQ$L[?=C+@,?H.M $U%%-=UC0N[!5')9C@"@!U%0V]W;78)MKB*8+U,;AL M?E4U !1110 4444 %%%59=3L()3'-?6T501^!- %JBFHZR(KHP9&&0R MG((IU !14%Q>VMIM^TW,,.[[OF2!<_G3X9X;F,202QRQGHR,&'YB@"2BBB@ MHHHH **** "O&_B#\=[3P]>S:5X>MXK^]B.V6XE)\F-NX '+G\0/K7:?%#79 MO#OPZU:^MF*7!C$,3 X*ER%R#Z@$G\*\\^!7P]TU]$3Q9JELMS>7#L+59ERL M2J<;@#_$2#SZ8QWR >M^%-7DU_PII>JS($FNK9)9$ P%8CD#\:N:O/<6VC7T M]G"\UU' [0Q(,EW"G:!]3BKE% 'S;H'QQ\5>&]573_&=A+/"#A_-@\FYC'KC M ##V(R?6OH;2]4LM:TRWU'3[A)[2= \>"=.\;^'IK*Z@3[6B M$VEQM&^)^V#Z'C([_E7F/[.>L7(CUKP_<,Q2V=9HE8GY2-,_[!J_^C)*]5^!O_))=)_WY_P#T<] 'HM%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !39(TEC:.10R."K*>A![4ZB@#POQEX;?P]J["-2;.8 MEH6]!W7ZBM3X>^*/[+O_ .S;I_\ 1+AOD)/$;_X&O3/$.B0:_I$ME-@,1NB? M^XW8UX)?64^G7LMI<(4FB8JP->C2FJT.66Y\MBZ,\!B%6I?"_P"FCZ/HKR'3 M_B=J5E8Q6TMI#<-&NWS78@L/>K/_ MB^_Z!EO\ ]]M7,\+4['JK-\*U=O\ M!GJM%>5?\+8OO^@9;_\ ?;5Z)H6I/J^BVM_)&L;3)N*J<@5$Z,X*\CIP^.HX MB3C3=V:-%%%9'6%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !7)_$KQ/+X0\!ZCJMMC[6%$5OGM(YV@^^,EL>U=97FGQX ML);WX77R^;?6LC6MQ(1@N5 *L?(+/P[X!U>XNI41Y[:2W MMT;K)*ZD* ._J?8&N0_9XT^:T^'D]U*N%O+Z22+W555,_P#?2L/PH ];HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** /(/VCO^2>6'_85C_\ 14M> M??LX_P#)0[__ +!4G_HV*O0?VCO^2>6'_85C_P#14M>??LX_\E#O_P#L%2?^ MC8J /J"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *1F"J68@ #))[4M87C'4?[, M\*7\P.'>/RD^K/@$G Y-?0^AV']F:%966,-%"JM_O8Y_7- M=^*?+!11\WDT'4Q$JKZ?F_Z9H4445YY].%%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 8/C MC_DG_B3_ +!=U_Z*:OESX*?\E=T+ZS_^B)*^H_''_)/_ !)_V"[K_P!%-7RY M\%/^2NZ%]9__ $1)0!]@T444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %>%^/+_ .W^+[TALI"1"OMM&#^N:]MO;E;*QN+I_NPQ MM(?H!FOG&>9[BXDF1BS'U)-957I8]S)*5YRJ=M#T/X3V&ZZO]08?<584/ MUY/\EKU*N4^'5A]B\(P.1A[EVF;\3@?H!75U<%:)P9A4]IB9/Y?<%4]6_P"0 M-??]>\G_ *":N53U;_D#7W_7O)_Z":HXCY1^%GP[LOB#?ZK#>7UQ:BT5&4PJ M#NW%NN?I7IO_ S9H?\ T'M0_P"_:?X5R'P'\2Z+XR69(A&9FQ MN(+YQ^8KV_\ X6AX'_Z&?3_^_E 'G_\ PS9H?_0>U#_OVG^%>S65JME8V]JK M%EAC6,,>IP,5SUM\1_!MY=PVMMXBL)9YG6..-9.68G ^I-:/BK4)-*\(ZQJ M$6?-M[.61,?W@A(_7% 'A_C[QEK_ ,0/&I\#^$9VCLE8Q32(2HF8??9V'(C' M3CK[Y '4:-^SQX7M+11JMS>W]T1\[+)Y2 _[( S^9-8'[-NE*QUW674&0E+: M,XY7JS<^^5_*O?J /GGQS\&Y?!MFWBCP9J-[&]C^]DA9_P!XBCJR, ,@=P>V M>>U>F_"OQT?'/A1;FYV+J-JWDW2KP"V.' [ C].12K*>A!X M(K,T/POH?AJ*2/1=+MK(2X\PQ)\SXSCI[F@#6HHHH **** "BBB@ H MKA/B3I?CC4H]-'@O4%LVC,GVK=($W [=G4'T;\ZX#_A%_CG_ -#%%_X$K_\ M$4 >]45X+_PB_P <_P#H8HO_ )7_P"(KTKX=:?XMT[0[F+QC>K=W[7):)U< M/B/:N!D =PU '8444C,%4LQ 4#))[4 8_BKQ+8^$O#MUK%^V(H5^5!UD<_=4 M>Y/YU=U>2R_&KXDK M8PEQX2T5]TK@X6X;/_LV,#T4$\$UDRQ1P?M3011(J1I,JJJC %OP!0!]%W$ M\5K;2W$SA(HD+NQZ!0,DU\SV\'B/X\>+[W?J#V.A6C95,%DB4D[0%!PSG!)) M/Z8%?34D:2QM'(BNC@JRL,@@]016=:Z9HWANTNY['3[6PAP9I_L\*Q@X')(& M.<"@#PCQ1\%+_P %:5+XC\+:_=-<6*>;(A'ER;!RQ5E/8-O!D=Y>;?M]O(;>Y*C 9@ 0V/<$'ZYK@/'7QQTO6-%N= \-6UQ<76H)]F,\ MX$4:*_RG&3DG!QS@#.W4AN)]C;E4D !0>^ !^.: M.[HHKG_'4LD/@/7I8G9)$L92K*<$':>0: -\D $DX ZDU#!>6MT6%O

H
MCD#8_*OEGP-I_C#XEZ>?#2:K-;Z);R&:\NI&9RS'[JG)RW3A<@#DGM70^*/@
M=J7A'3FU_P *ZU$]]^0=3LG\FX; 'F<9#X'3(Z^X-><.J
MO^U>BL 59V!!Z$?930!WOP-UXZS\.;:WD?=/ISM:N.X4"_C%K_ (0F5Z
M5ITUS\%?''BN\!:ZU6XC <_Q*LZ$D?5F8?A7JGP(_P"25V/_ %VF_P#1C4 >
ME4444 %%%% !1110!POQBTV74_A?J\<*EI(56< =PK M^F3^%97P'UNWU/X<
MV]BCK]IT^1XI4[@%BRG'I@_F#7ILD:31/'(H='!5E89!!Z@U\V^*/!'BKX5>
M(Y?$7@YIY=*Y/ ^M>&_L[037FL^)-8=2(WV(&'0L2S$?AQ^=)9P
M6WV?2 ^2(U*6R<]7$;+P5X:M](LSO*_/-,1@RR'JQ_I[
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MQ4>JD]/ITKVBWGCNK>.>%@\I]3@\;3Q,?=T:Z$E%%%9':
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !4-W:6]_9SV=U$LUO/&T!KR>>V8
M_*()Q%.B]=K D!QTZ9SZ52_X2GXYHWV;[/KF?NY_L=#U_P!OROUS7T]10!\U
M:7\)O'GCO5HKWQI?7-M:*>3#^N:Z<+&]2_8
M\K.*O)AN5?:=B+P?IW]I^*K" KF-9/-?_=7G]< ?C7O=>8_"C3\RW^I,OW0(
M$/U^9OY+7IU&*E>=NPLFH\F'YOYF%%%%G4_H,?C7BUO ]UO?\ "A/ G_/G>?\ @4U>8? ?Q+HOAS4]=?6=2M[)9DB$
M9F;&X@OG'YBO;_\ A:'@?_H9]/\ ^_E &1I_P2\%Z9J5KJ%M:W8N+69)HBUR
MQ 92&&1WY%=/XUMI+SP-KUO"I:62PF"*.YV' K/_ .%H>!_^AGT__OY72V=Y
M:ZG8Q7=I,D]K.@>.1>5=3T(]J /$_P!FR]1M(US3\_O8KA)B,=F7;_[(:]TK
MYCD>\^"'Q9EG:WDDT*]W;=H^_ 3G"G.-Z''7]-P->^Z-XW\,Z]:+JV=XT?WTAF5F3Z@'-;T/1?#%C8WNHZCYA,5T#VQMP0Z@?Q=3VK&
M_P"$A^.?_0F:'_W^7_Y(K!\6Z]??\-!+)I6B2ZQ?:98B&W@1MH#,N2['LH\P
MCG'/>MF7XH^.O"EU#-XY\(P6VE32!/M%D^XQ9]<.X)]OES0!ZM)J(T[0FU'5
MF2V$%OYMR1R$P,MCKG]:\G@^)WQ"\3K+J/@_P9!+HTQ!!&01CT)[6O'C
M%_9/[32FW78NIZ<6E /!P.N/K&*]AH XKX@_$BR^'J:>UY8W%U]M,@7R64;=
MFW.<_P"]7#_\-)Z'_P! '4/^_B?XU[/<6=K=[?M-M#-M^[YB!L?3-0?V-I?_
M $#;/_OPO^% 'C__  TGH?\ T =0_P"_B?XUZ'X"\* ):\<
M^.?CF32[*'PGI\RPW>IJ/M,SG:L<#';C/OSD]@#ZU['7'>*OACX:\9:HFHZQ
M!<27"1"(&.3MZ_7BO5/^%">!/^?.\_\  IJ\=G\$
M:)'\=T\)K%+_ &290I3S3NQY6[[W7K0!]/Z/KFE^(+,WFDWT-Y;ABADB.1N'
M4?K5J5(+R":WD"2Q.ICE0G(((Y!_ USNG>!=*T/PAJ'AW1S-;6]VDHWM(69&
M==NX'VX->%_#'QF?A=XEU3PUXHCEMK627YY-A/DR#C<0!DJPQR,] >AS0![/
MKWPH\':YI(-9\$7\[31V0=
MX 3D1E'VN ?0D@X^M=AXD^-GA#1M+DFL=1CU.]*GR;>W!(8]MS8PH_7VKE/@
M+X=U&>^U7QIJD95M0RD#,,&0,VYV^A(&/H: /&+X#Y7BCQ/# Q>WVI\WKAGV_
MH333_P G8Q_]=#_Z2FNM^ WA&YT'PQ<:M?Q-%=ZHZNJ.,,L2YVY^N2?H17)'
M_D[&/_KH?_24T 6?C3 _A;XB^'/&5LK*K,JSE!U,9&7?Q"\;^$--NT)M=!MH>-=#3PY^SK=:2@ -O:VZO
MCNYE0L?Q))J]\"/^25V/_7:;_P!&-5[XS?\ ))->_P!R+_TOZ!>Z3-*\4=W$8F= "5![C->2?\,V:'_T'M0_[]I_A
M0!T6I:U\']7E:;4)_#MQ,WWI6C7>?JV,U7M;SX*V<@DA_P"$:#@Y!>)7P?;<
M#BO/_'WP2TOPAX.O=;MM6O)Y;E^,?!=EKESJUY;R
MW#2 QQ(I4;79>_TH ]E3XF^!8T5(_$FFJBC 57P *V]%\2:-XCBEET?48+U(
MFVNT+9"GT->3?\,V:'_T'M0_[]I_A7>> /A[9_#^SN[:SO9[I;F02,9E ((&
M.,4 =C1110 445\TZQK7BKXK_$JZ\.:7J68G'!Z9
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M44 %%%% !1110!4U2^33-*NKY\8@B9\'N0.!^)XKYUD=I9&D(>*=0_M/Q-?W0
M.5:4JA_V5X'Z 5WOPHT_98WVH,.9'$2D^BC)_G^E>5DY.:]]\(:?_9GA6PMR
M,.8_,!/^?.
M\_\  IJ] TG2[71-)M=,LE9;:UC6*(,V2% P,GO5VB@#-UWP_I/B736T_6+&
M*[MF.=L@Y4^JD3R.:\MO?VTU/4[9"<^661P/894'\\U[)10!YG
MX;^!GA#P_=QWDL=QJ=Q&=R?;&!13Z[% !_X%FO3  !@# %%% &-I_BO1-4UZ
M^T.SOA)J5C_Q\0&-U**X;
MS3[>0.+2Q7:)/J0B >F<$X)P1F@#%URPNIOV7=-:16#0"*<@\G87(7\,,*]G
M\+:A%JOA32K^%PR3VL;@_51^M6KC2;&ZT:32);9#820F P@8&S&,#'3BO)(/
MAA\0O# ET_P?XS@BT>1V98KM/GB!/1?D89]QMR><#- $YE_M;]II1 V]=,TX
MK*0. 2.F?K(*]AKBOA[\/8?!%M=S3WKZCJ]\^^[O) 06Y)P,DG'))).23GT
M[6@ HHHH **** "BBB@ KE'^'?A^3QH/%C0S_P!K!MX?SCMSMV_=Z=*ZNB@
MKG_$O@?PYXO1!K>EQ7+IPDH)211Z;E(./;I7044 >?Z;\%? FFW2W T@IU% !7.^/O^2?>(/^O";_ - -
M=%69XBTM];\-ZEI<-"H **N.?]VNWH .EG0UU-% $<\,=Q!)!*H:.12C*>X(P17,>%/AUX=\&7ES=:/;2I-<*$=
MI)2_ .<#/2NKHH S=?T*Q\2Z)DZ4DB6D;,RJ[ECECD\GW-:]% !1110 4444 %%%% !139)$BC:21U1%&2S'
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M)VY)/6R_,!ZD9!_ T =5X%C0?"K
M0U !5M*CR#SG,8S7C_[.A(\5:\H/'D+Q_P "-,\._&ZPT?X8C0KBRNFU>WMV
MMH&15\HC!"LQR",<9&."00,C/K3/%6L_\+G^)FE66BVMR+&-%B)D
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MV!.%8\F'_P"M[5Z_%+'/$DL3J\;C*LIR"*\!U_P_>>'K\VUTN4/,"19(G&Y74Y!%2UP'TB=]4%%%% !1110 4444 %%%% !1110 4444 %
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHJ&[NH;*TFNIVVPQ(7<@9P![5S3_ !%\.+&S+=2,P!(41-S[=*J,)2V1E4KT
MJ6DY)>IP/Q&U+[=XKDA5LQVB"(>F>K?J^97A5_
M=T;(^8P36)Q_/+NW_D=U1117FGU@4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 8/C
MC_DG_B3_ +!=U_Z*:OESX*?\E=T+ZS_^B)*^H_''_)/_ !)_V"[K_P!%-7RY
M\%/^2NZ%]9__ $1)0!]@T444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 5Y]\4]42'2[;3$<>;._F.H/(0=,_4_RK?\5^*[;PU9?PRWL@
M_B>(HKN]C+1%3'O'_+,G
M^+'?T_&O=HI8YXDEB=7C^*\)_P"&:M4_Z&*S_P# =O\ &OHVB@#YR_X9JU3_ *&*
MS_\  =O\:/\ AFK5/^ABL_\ P';_ !KZ-HH ^"-8X8U"
M(B# 4#H *DHH P[CP;X8N[_[=<>'M+ENB=QE>T0L3ZDXY/O6VJA5"J % P !
MP*6B@"GJ6D:;K-M]GU.PM;V'.1'<1+( ?4 CK4>E:#I&A1O'I.EV=BKG+BVA
M6/@#T6BBB@ HHHH *
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !7!:_\ !WP;X@U W\NGM:73/O=[1@@D.T4 %1M/"C[
M'EC5O[I8 U)7S+\7O^2ZZ9_VZ?\ H= 'MWC/X=>'_'-N!JENR7:#$5Y 0LJ#
MTSC##V(/4XQ47P[\!1_#_2;S3XM0:]CN+DSJS1;"@VJNT\G/W>O'7I78T4 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Y!^T=_R3RP_P"PK'_Z
M*EKS[]G'_DH=_P#]@J3_ -&Q5Z#^T=_R3RP_["L?_HJ6O/OVX_/\F>D4445Y9]B%%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M &#XX_Y)_P")/^P7=?\ HIJ^7/@I_P E=T+ZS_\ HB2OJ/QQ_P D_P#$G_8+
MNO\ T4U?+GP4_P"2NZ%]9_\ T1)0!]@T444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110!Y9\1?")F&/>(?)#X5
M^(44459Y@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%(2%!)( '))[4 +17RYJWB/QS\5O&-Y9>&KB\CT^!CY<4$Q@C2/.
M TAR,D]>IR)OCW7[['&W=PWTS^1H ^OZ0.I8
MJ&!8=1GD5\?>*_"_Q#\)6WG:Q-J'V-CL\^*\:2,GT.#Q^(%>W_ WPQ>Z%X7N
M+Z[O+6Y75'6XB:"0O\NW^(D#G/UH ]3HHHH **** "BBB@ HHHH **** "BB
MB@#YE_:0_P"1XTS_ +!J_P#HR2O5?@;_ ,DETG_?G_\ 1SUY5^TA_P CQIG_
M _P#1DE>J_ W_ ))+I/\ OS_^CGH ]%HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@"M?V%MJ=G):7<2RPR#!4_S'H:\5\6>$KGPY
M=;UW2V,A_=RXZ?[+>_\ .OJ6FL6,=Y9RB2)Q^*GT([&O'O
M%_@Z?P]<&> -+I[GY7QRG^RW^/>L[PYXDO/#E\)H#OA8XEA)X1[]15#1]8L]N
M+::2&:.T9DDC8JRGU!'(KC/V?=3O]4\'ZG+J%]P>#(>OY#C\ZR?!6AG7/$4,;KFV@_
M?3>A Z#\3@?3->E0C[.GS,^4S&H\5BU2ATT_S.STGX9Z9-I-K+?R78NI(P\B
MHX 4GG&,=NE=3H'AFP\-QSI8F9O/(+F5@3QG'0#U-;-%<,JLY:-GT-'!T*+3
MA'5=0HHHK,Z@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH P?''_)/_$G_ &"[K_T4
MU?+GP4_Y*[H7UG_]$25]1^./^2?^)/\ L%W7_HIJ^7/@I_R5W0OK/_Z(DH ^
MP:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "JVH(\FFW4'?LXO;?V9K\8*_:Q=*7'&=F/E]^
MH:H_BV3HWQ?\':VAV!VCB=NV!)AO_'7K&\7>"O&GP_\ &-WXA\%K=26-TY?%
MK&)#'DY*/'@Y4'H<'CT-=Q\9O!FH>*?!EE>V<33ZIIO[PQQCYI%8#?M ZD$
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M'SE:W"$ 9(P*Y7_AI'PS_P! C5_^^8__ (N@#V:BO&?^&D?#/_0(U?\
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M)-*X2.-2SL>@ Y)I](I(SAOL$JY_WEVG^= 'C:ZAXW^-/B*_&
MB:I)I'AZT?8I$CQJ0]M9!);W$:RQ..C*PR#^1J>N)^$-V;WX4Z
M!*Q)*P-%S_L2,G_LM8.K?'SPKHVLWVEW&GZRT]E<26\C1PQ%2R,5)&9 <9'H
M* *G[1W_ "3RP_["L?\ Z*EKS[]G'_DH=_\ ]@J3_P!&Q5+\6?BSH/CSPK:Z
M7I=IJ4,\5ZEPS74:*I4(ZX&UV.MJ-/VDK=#AQ^+6&HM]7M_7DI)Y)KVGP!HG]D>'(Y9$VW-YB63/4+_"/RY^I->:^"] .O:_''(A-I!^\G
M/8@=%_$_IFO=1P,"NC%U/L(\O)<,VW7EZ+]6%%%%<)]$%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %(2 "20
M.I-+7F/QV\1W&A?#YK>T#/$>H1V%O?R6US*P6)+N+RP['H W(R>P)YK
MS+X>:#!\5_'>N^*?$437%E#(%@MG)VDDG:IP>BJ!QWSWYKJ?BM\*?#K^#;W5
MM&TV#3[ZPC,_^C+L21%^\&4<=,D'KQ0![%17%?"CQ%/XF^'>FWMTY>[C#6\S
MDY+,AP"?#^,?$#>(-=DF0
MG[+%^[@'^R._U/6N]^)'B5;'3SI%M)_I5P/WI4_GY#G\J
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M -&25ZK\#?\ DDND_P"_/_Z.>@#T6BBB@ HHHH **** "BBB@ HHHH ****
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M9AM7.<<$=S61_P *B\!?]"W;?]]R?_%5VU% '$_\*B\!?]"W;?\ ?Z%9P6T*[Y)7DD 4>I^:M;
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M?G[U"#F[(RK5H48.WU/\OJ*\IMK>:[
MN8[>",R2RL%11U)--FFEN)WFFD:261BSNQR6)ZDUZM\/O"!TZ)=7OX\7;)N3NSZJG"-.*A%:(****184444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 5X7^TL?^)/H _P"F\W_H
M*U[I7E?Q]T*;5OA\+RW1GDTVX6=PH)/ED%6X'ID$GL : /4D "* ,#%>&_M
MY&O>"FA_X^/M$N,#XI?&W0;#17^T:9I3+)+.%^5@KAY&'^R<*@/KZ@B
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MU)C?-<6<N^9;7,30S)]D@&Y&!##(
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MQ)8_"7XF7UQX6NH+ZVO,_P!H:9@J(7!S@.!C().,9QD@BNDC_:4T?9Y0BV[2$!F.268@Y/MSCKG->V?\
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MD=U:RM%/&&>)LJPX*FN]J&(C=;GSD)U\LKT@]5_P *ZRO/G!P=F?34:T*T%.#N@HHHJ34*
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MO=)'3M*N[T)YA@A:39G&[ SC->=_\+9E_Z!*?
M]_C_ (5I"E.>L4UG>"?4K6.5#AD:0 @^]1_P#"4:%_T%K3_OZ*KDEV,W6IK1R7WFM1
M6;;^(-'NIT@@U*UDEW<-OYF=GF.%W8ZX_,5;KS3XMD;=(&>YX7]N5?Y4?2D4L<\*30NL
MD;J&5U.0P/0@U'=WEM86[7%W/'#$O5W; KQY/B+J]MI5O86<=O L,2Q"7;N?
M@8SSQ^EZE-YU[=2W$G8R,3CZ>E9QPDF]7H=57.Z<8^XKO\#O?$?Q-:
M59+71$9%/!NI!\Q_W5[?4_D*\Z9GED+,6=W.22$3ZG_)KU;PQX"LM"9;JZ9;N^'(8CY(S_LCU]S^E;N5.@K+<\^%+%9C/FEM
MWZ+T,;P5X!,+1:IK,>)!AH;9A]WT9_?V_/TKTBBBO/J5)3=V?28;#4\/#D@O
M^"%%%%0= 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %-DC26-HY$5XW!5E89# ]013J* /*-6_9]\'ZC
M?/KG+0V\JF,?0,I(_/'M79>#_  'H/@>R>#1[=A)+CSKB9MTLN.F3
MP,>P 'M72T4 8/C'PI:>-/#TFC7T\\$$CJY> C=E3D=015CPSH%OX7\.V>BV
MLLLL%JI5'EQN())YP .]:U% ''^,_AGX<\7_XFCF77_ .)H_P"%@^%_^@I_Y+R__$T7
M_P")H_X6#X7_ .@I_P"2\O\ \31S+N'U3$?R/[F=-17,_P#"P?"__04_\EY?
M_B:/^%@^%_\ H*?^2\O_ ,31S+N'U3$?R/[F=-17,_\ "P?"_P#T%/\ R7E_
M^)H_X6#X7_Z"G_DO+_\ $T7_XFC_A8
M/A?_ *"G_DO+_P#$TQWQRBJZ//]KM_74]UHKF!\0O"^/^0GC_ +=Y?_B:7_A8
M/A?_ *"G_DO+_P#$U?,NYP?5,1_(_N9TU%-Z;MHS^IJC/\ %L\BWT%K7PW8[5Q)=R#]]-CK[#T%>;/\1=06\FN[
M73M.M[B8 /*(V+D#ISG'Z5DWOB_Q!J&1/JDX4]5B/EC\EQ6<7&)ZN)H8K%)1
M=HQZ]3VS4]?TK1U)O[Z*)O[F22..,G\.W@_:5TIHE-QX>O4D[K'
M.K@?B0/Y5WNJ>"OA[;W(FU32='AFNI<*UP0IED8]!D\DD]J+OX=_#ZPM);N\
MT#2H+>)=TDLBA54>I)- '#?\-)Z'_P! '4/^_B?XUWG@#XA6?Q L[NYL[*>U
M6VD$;"9@221GC%<59ZC\#+[418Q6^E+(6VJ\ML\<9/\ OL /S->HZ)X-,_[!J_^C)*]5^!O_))
M=)_WY_\ T<] 'HM%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !7!^-? JZF'U+2T"W@YDB'27W'^U_.N\H
MJX3<'=&.(P\*\.2:/FU'GL[D.C/#/$V01PRD5Z_X,\;1:W&ME?,L>H*.#T$H
M]1[^U-\9^"(]91[_ $]5COU&67H)O_K^]>1$3V=S@AX9XF^C*PKO]S$1\SYK
M]_EE;O%_<_\ @GTE17#>"_'*:JJ:=J3JE\!A)#P)O\&KH_$MY?6&@W%SIT9>
MZ3&Q0F_//I7#*G*,N5GT5/%4ZE+VT=5^)K45Y(WC+QJBEFLG50,DFR8 "H;?
MQ[XMN]WV:)9MOWO+M2V/KBM?JL^Z.3^UZ%[6E]Q[#17!^$O$'B74M;^SZK:O
M';>4S;C;%.>,O&O#GBFO4****@W"BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** //_ !]\5M/\
M :I:V-YIUU=/<0^
M6'_85C_]%2UY]^SC_P E#O\ _L%2?^C8J]!_:._Y)Y8?]A6/_P!%2UY]^SC_
M ,E#O_\ L%2?^C8J /J"BBB@ HHHH R_$O\ R*^J_P#7K)_Z":^?*^@_$O\
MR*^J_P#7K)_Z":^?*]#!_"SYK/?XD/0*T](\0ZIH0F&FW7D>=CS/W:MG&
M!]36973>$O"/_"4B\/V[[+]GV?\ ++?NW;O]H8^[73-Q4;RV/)P\:LZBC1^+
MUL'_  L'Q1_T$_\ R7B_^)H_X6#XH_Z"?_DO%_\ $UTW_"I/^HW_ .2G_P!G
M1_PJ3_J-_P#DI_\ 9US^TP_E]QZ7U7,^[_\  O\ @G,_\+!\4?\ 03_\EXO_
M (FC_A8/BC_H)_\ DO%_\373?\*D_P"HW_Y*?_9T?\*D_P"HW_Y*?_9T>TP_
ME]P?5+_XFC_A8/BC_ *"?_DO%_P#$UTW_
M  J3_J-_^2G_ -G1_P *D_ZC?_DI_P#9T>TP_E]P?57D^H
M7DMW=2>9/*VYVP!D_0<5!5[6=._LG6+JP\WS?(?9OV[=WX9.*HUU*UM#R9J2
MDU+?J36EW/8W4=U;2&.:,[D<#H:V_P#A.?$O_05D_P"^$_PK-T73AJVLVM@T
MAC$[["X&3_ +\#_P"*JPOP
MHTP+\VH79/J H_I6?MJ"_P"&.KZCF,MV_P#P+_@GGS>*=?8$'6+WGTF8?UJJ
MVLZHX(;4KQ@>H,['^M>FCX4Z3D;KZ]([@%!_[+5E?AAH"XR]XV/64<_DM'UB
MBMOR#^S,=+=_B>12W=S.NV6XED'H[DU#7MC3-C],55U3X9
MZ1=K$+!FL"I.\C=+OSC'WFXQ_6FL53O8F638JU[IOU/'J*]/_P"%2Q?]!A__
M  ''_P 51_PJ6+_H,/\ ^ X_^*JOK-+N8_V3B_Y?Q7^9SFC_  ]UG5K:*ZS!
M;6\JAD:5\EE/0@#/ZXKM-)^&6DV>U[^22^E'8_(GY#G\S76Z=9C3M,M;(.7$
M$2Q[B,;L#&:M5QSQ$Y;/0][#Y7AZ:3E&[\_ZL16]M!:0K#;PQPQ+]U(U"@?@
M*EHHKG/222T04444#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@#!\.O($FDZ3+^]^[/
M.I^[ZJI]?4UW>JVDM_I=Q:P7+VTLJ%5E3JM> :MI5YHVH26=[&4E4]>S#U![
MBLZC:6AZV4X>E5FY3>JZ?J4262UMK9\O.O5C_=
M'KGOVQ6*5W8^CK58TH.8?
MVY_T[_'_ (!\S45],T4>R\P_MS_IW^/_  #YFHKM_B)K^HW6JR:9+$]M:0M\
ML9_Y:^CGU'I7$5DU9V/:H5)5*:G)6OYW"BK.GW]UIE[%=V
M_P"A7]QJ>C6UY=6K6TTBY:,_S'L>M5&/,?_ &Y_T[_'_@'S-17TS11[+S#^W/\ IW^/_ /F:BOIFBCV7F']N?\ 3O\
M'_@'S-17JOCGP,+L2:MI,7[_ .]/ H_UG^TOO[=_KUSO W@4W9CU75HL6X^:
M&W8?ZS_:8?W?;O\ 3K'([V/0CF5%T?;-_+K?L>=T5],@8&!THJ_9>9Y_]N?]
M._Q_X!\TQ0RSMMBB>0^B*34W]FWW_/E8GGCZ0_'_ (!\
MXKI>H.P5;&Y)/80M_A4@T35B<#2[W_P'?_"OHJBCV7F+^VY_R?B?/J>%=?<#
M&CWO/K"P_G5Z#P!XFGP1II0'O)*B_IG->Z44_9(SEG5;I%?B>.P?"W79"/-F
MLHAWS(Q/Z+6W9?":W4 W^IRN>ZP(%Q^)S_*O1Z*:IQ.>>:XJ76WHCG]-\%>'
M],(:+3TED'\<_P"\/Z\#\!70  # & ***I)(X9U)U'>;N%%%%,@**** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M3V/O_.MCQ=X.M_$5N9H0L6H(/DD[/[-_C7B]W:7&GW!_%5KX#LQ[=^M9
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M JQ_\!T_PJQ;65I9!A:VL, ;[PBC"Y^N*GHHNV"A%.Z04444B@HHHH ****
M.%UCX;1:MJ]S?_VF\1G?>4\D-CCUR*H_\*EB_P"@P_\ X#C_ .*KTBBMEB*B
M5DSAEEN%DW)PU?F_\SA='^&T6DZO;7XU-Y3 ^\)Y(7/XYKNJ**B:E=ZW);:
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MC(]Z]Q^!OAF'0_!S7UOJD5_'J3"8&.,J(R!@J-,_P"P:O\ Z,DKU7X&_P#))=)_WY__
M $<]>5?M(?\ (\:9_P!@U?\ T9)7JOP-_P"22Z3_ +\__HYZ /1:*** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH *XGXDZ982Z"VH31XNXB%CD7J%=TR@2(/4CM^6:TI2Y9IG-C*?M*$XVOH>"T4K*58JP((."#VI*]@^&.\^&.
MK2P:Q)IK.3!.A<+Z./\ ZW\J];KR/X8Z3+<:S)J+(1!;H5#$=6/I^'\Z]2?#_P[\0?&7B[2_&FH73FUM[A9!/>N5$D><.L2 < C(X 7F@#Z
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MHHHH **** "BBB@ HHHH **** "BBB@#!\NPC X^H-1?&1AH_Q
M3\&ZX&V#*M&\6W'B;P-)*5N',C16TOERPL>6') 9
M2>WX8XS7>,_!=JMIB75]/_>1AN#*" '7K@$X!_#'>@#O]0MK?4=*N
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M+:/=&?+;C(!EA?=@GME2H_ ^E>\Z'K=AXBT:VU73)UFM;A-RL.H]01V(/!%
M&A1110!C^*]&MO$/A74]*NT#17%NRY(^ZP&58>X(!'TKQO\ 9HOI6@\0Z>QS
M"C03(/1F#JWYA5_*O3/B9XNMO!_@J^NGE O)XV@LX\_,TC @''HO4_3U(K@_
MV<-$EM/#NK:S*I5;Z=(HLCJL8.2/8LY'_ : /;**** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@#R#]H[_DGEA_V%8__14M>-_";P5IOCSQ5=:7JD]W
M#!%9/<*UJZJQ8.BX.Y6&,.>WI7LG[1W_ "3RP_["L?\ Z*EKS[]G'_DH=_\
M]@J3_P!&Q4 >@?\ #./@_P#Z"6N?]_X?_C5'_#./@_\ Z"6N?]_X?_C5>P44
M >/_ /#./@__ *"6N?\ ?^'_ .-4?\,X^#_^@EKG_?\ A_\ C5>P44 >/_\
M#./@_P#Z"6N?]_X?_C5'_#./@_\ Z"6N?]_X?_C5>P44 >/_ /#./@__ *"6
MN?\ ?^'_ .-4?\,X^#_^@EKG_?\ A_\ C5>P44 >/_\ #./@_P#Z"6N?]_X?
M_C5'_#./@_\ Z"6N?]_X?_C5>P44 >/_ /#./@__ *"6N?\ ?^'_ .-4?\,X
M^#_^@EKG_?\ A_\ C5>P44 >/_\ #./@_P#Z"6N?]_X?_C5'_#./@_\ Z"6N
M?]_X?_C5>P44 >/_ /#./@__ *"6N?\ ?^'_ .-4?\,X^#_^@EKG_?\ A_\
MC5>P44 >/_\ #./@_P#Z"6N?]_X?_C5'_#./@_\ Z"6N?]_X?_C5>P44 ?%'
MQ$\-V?A'QWJ6AV$D\EK;>5L>=@7.Z)'.2 !U8]J]C\-? /PKK/A72-4N-0UE
M9[VRAN)%CFB"AG0,0,QDXR?4UQGQ@\)^)-3^*6LWEAX?U6[M9/(V3064DB-B
M&,'# 8.""/PKZ+\%P36O@3P];W$4D,\6FVR21R*59&$2@@@\@@]J /._^&[NI/)V0P1F1VQ-&3A1R> 3^% 'R_\
M._#EGXM\=Z;H=_)/':W7F[W@8!QMB=Q@D$=5':O=_P#AG'P?_P!!+7/^_P##
M_P#&J\W^$'A/Q)IGQ2T:\O\ P_JMI:Q^=OFGLI(T7,,@&6(P.2!^-?5% 'C_
M /PSCX/_ .@EKG_?^'_XU1_PSCX/_P"@EKG_ '_A_P#C5>P44 >/_P##./@_
M_H):Y_W_ (?_ (U1_P ,X^#_ /H):Y_W_A_^-5[!10!X_P#\,X^#_P#H):Y_
MW_A_^-4?\,X^#_\ H):Y_P!_X?\ XU7L%% 'C_\ PSCX/_Z"6N?]_P"'_P"-
M4?\ #./@_P#Z"6N?]_X?_C5>P44 >/\ _#./@_\ Z"6N?]_X?_C5'_#./@__
M *"6N?\ ?^'_ .-5[!10!X__ ,,X^#_^@EKG_?\ A_\ C5'_  SCX/\ ^@EK
MG_?^'_XU7L%% 'C_ /PSCX/_ .@EKG_?^'_XU1_PSCX/_P"@EKG_ '_A_P#C
M5>P44 >/_P##./@__H):Y_W_ (?_ (U1_P ,X^#_ /H):Y_W_A_^-5[!10!X
M_P#\,X^#_P#H):Y_W_A_^-5XY\6?!.F^ _%-KIFESWM?8=?.GQ]\-:]K/CFQN-+T34KZ!=-1&DM;5Y5#>;*<$J",X(X]Q0
M_P"'7P5\-^+O NG:Y?WNJQW5SYN]()8P@VR,@P#&3T4=ZZC_ (9Q\'_]!+7/
M^_\ #_\ &JZ?X/V%YIGPMT>SO[2>TNHS/OAGC,;KF9R,J>1D$'\:[F@#Q_\
MX9Q\'_\ 02US_O\ P_\ QJC_ (9Q\'_]!+7/^_\ #_\ &J]@HH \?_X9Q\'_
M /02US_O_#_\:H_X9Q\'_P#02US_ +_P_P#QJO8** /'_P#AG'P?_P!!+7/^
M_P##_P#&J/\ AG'P?_T$M<_[_P /_P :KV"B@#Q__AG'P?\ ]!+7/^_\/_QJ
MC_AG'P?_ -!+7/\ O_#_ /&J]@HH \?_ .&SLIKB-9)HBI9$+ '$8.,CUKQ+P-_P E \-_
M]A6U_P#1JU]B^,H)KKP/X@M[>)YIY=-N$CCC4LSL8V   Y))[5\K>#?!?BJU
M\<>'[BX\,ZS#!%J5N\DDEA*JHHD4DDE<  =Z /L2BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH P?''_)/_$G_8+NO_135\/5]P^./^2?^)/^P7=?
M^BFKY<^"G_)7="^L_P#Z(DH X&BOO^B@#X HK[_HH ^ **^_Z* /@"BOO^B@
M#X HK[_HH ^ **^_Z* /@"BOO^B@#X HK[_HH ^ **^_Z* /@"BO8OVC_P#D
M?M._[!:?^C9:[O\ 9P_Y$'4?^PH__HJ*@#YBHK[_ ** /@"BOO\ HH ^ **^
M_P"B@#X HK[_ ** /@"BOO\ HH ^ **^_P"B@#X HK[_ ** /@"BOO\ HH ^
M **^_P"B@#X HI\O^N?_ 'C7WS%_J4_W10!\!T5]_P!% 'P!17W_ $4 ? %%
M??\ 10!\ 45]_P!% 'P!17W_ $4 ? %%??\ 10!\ 45]_P!% 'P!17W_ $4
M? %%??\ 7D?[1?\ R3JT_P"PG%_Z+DH ^7**]<_9T_Y*-=_]@R7_ -&1U]1T
M ? %%??]% 'P!17W_10!\ 45]_T4 ? %%??]% 'P!17W_10!\ 45]_T4 ? %
M%??]% 'P!17W_10!\ 45]_U\B?''_DK>K_[D'_HE* /=_@=_R232/]^?_P!'
M/7HE>=_ [_DDFD?[\_\ Z.>O1* "BBB@ HHHH **** "BBB@ HHHH **** *
M&MZO;Z#HEYJMTDKP6D9E=8@"Q ] 2!G\:\N_X:.\'_\ 0-US_OQ#_P#':]6U
M+3K35]-N-/OHO-M;A#'+'N*[E/;(((_"N"N_@_\ #&P@,]YI$-M".LDVH3HH
M_$R8H QO^&CO!_\ T#=<_P"_$/\ \=H_X:.\'_\ 0-US_OQ#_P#':O:=\,_A
M#J[E-,MM/O6'5;;5I9"/^^936E_PI+X>?]"]_P"3MQ_\/]*\?6EU-,_[!J_^C)*]5^!O_))=)_WY_P#T<] 'HM%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %97B.UU"\T.>#3)6BNVQL=9"A'//(Z5JT4T[.Y,X*<7%]3RA_"OCR1&
M1]3G9&&&5K]B"/0\U!:>!O&%AN^QW'V;?][R;LIGZXKUZBM_K,^R/->4T6[\
MTOO.&\*:)XJL-9\[6+Z::U\MAM>[:0;N,<$_6NYHHK*&B<='4^H_7D'@U\\S>%_B7
M\([^:;0I)[O3&;"V39!#'$O\ =10H_2@#YOT+X4^-/B!K4>L>-[JZM;4X+?:#B=U_
MNI'TC'U QZ&OHO3M/M-)TZWT^Q@6"UMT$<4:]%459HH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@#R#]H[_DGEA_V%8_\ T5+7GW[./_)0[_\
M[!4G_HV*O0?VCO\ DGEA_P!A6/\ ]%2UY]^SC_R4._\ ^P5)_P"C8J /J"BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHI"0H))  Y)- "T5RWA?Q_HG
MC#5M5T_2#/+_ &:RK)<%5\J7)(!0@DD?*>2![9KJ: "BN \4_&/PCX3OWL+F
MXGO+R,XEALHPYC/H22%S[9R*O>#_ (G>&?&TS6VEW4D=XJ[S:W*;)".Y')#8
M[X)Q0!V-%%>>?$7XHV/A*QN;/3"M_KP0D6\0WBW&,F27'W0 AT
M5D^%]0GU;PEHVI76W[1=V,$\NT8&YXU8X'89-:U !1110 4444 %%%% !111
M0 4444 %%%<]XQ\9Z3X'T8:EJS2%&<1QPP@&20GKM!(' Y//]* .AHJO87D>
MHZ=:WT*LL5S$DR!QA@& (SCOS4>J:K8:+ITVH:E=16MI",R2RM@#L/J2> .I
MH N45Y2W[0O@I;[[.$U1HLX^TBV7R_K@MN_\=KTC1]9T[Q!I<.IZ5=QW5G,,
MI(GZ@@\@CN#R* +U%XW?9;5-\@';/("_B10!V5%<%X4^,'A/Q=?I86EQ<6E[)_JX+V,(9#Z @E2?
M;.:[V@ HKSV;7/&?B3Q%J5EX:BLM+TS3I/(>]U&!W:YE'7RUX&T>O?@CK@7O
M!?BW4M4UC6/#GB"UMX=;TDH97M23#,CC*LN>1QC(/J/<  [2BBB@ HHHH **
M** "BBB@ HHHH **** "BLKQ'XAT_P +:%,:G8-^E 'JM%9/A[Q+I'BK2
MUU'1KU+JW)VL1D,C?W6!Y!Y[UK4 %%>9?$[XES^%KJTTK18UFU!I(VNI&3;Y'E8RJKC&YO[N7?#KX._\(!XCEU?^WOM_F6K
M6_E?8_*QEE;.=[?W>F.]>HT44 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 5Y#XY^!W_"9^+;S7?\ A(OL?V@1CR/L7F;=J*OWO,&<[<]*]>HH
M YWP-X6_X0SPE9Z%]L^V?9S(?/\ *\O=N\O9[T0V4#\R2Y,=NK=$C4=3@?U)]?H?XC,R?#G7RIP?L3C\Q7!_LW@?\(-
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'D'[1W_)/+#_
M +"L?_HJ6O/OV6(4W8QG#2"O7?'^O2>&/ >L:O"<3008B;&<2.0BG\&85Y/\ L]_\
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M>!/^2>>&O^P5:_\ HI:Z"L7P?:3V'@G0;.ZB:*XM].MXI8VZHZQJ"#]"*VJ
M"BBB@ HHHH **** "BBB@ HHHH YSQOXDN?"OAJ74K+37U*Z\Q(HK9"+O&4ZQ7%S<"WM]/4?ZE"K-T!PO3IR3GDYKZRKQK
M]I#_ )$G2_\ L(C_ -%O0!Z?X6_Y%'1?^O&#_P! %>0?&J>[\2^._#/@6WF:
M*"X*S3D="78J"?7:JL?^!5Z_X6_Y%'1?^O&#_P! %>0Z_P#\G2Z'_P!>Z_\
MHJ2@#T5/A;X(32!IO_".6#1;-AE:(&8\=?,^]GWS7FOPH\_P5\6?$'@9IWDL
MF!E@WGGMPP)R[>9#OE
M;&"[G=RQQ_3I0!Z9:6L5C906D Q%!&L:#T51@?RJ:H+&XDNK"VN)K:2VEEB5
MW@D(W1$C)4XXR.E3T %%%% !1110 4444 %%%% !1110!Y#XUU[QWXE\27W@
M_P ):<;.TA(CN]6  / P?;'KGQ$_
MY)QXC_[!TW_H!KEO@'_R2ZV_Z^9O_0J .=^-'PXT:P\,-XFT&QBTV]T^2,R"
MS7RU="P .U< ,&(.1VSGMCT[P)KK^)? ^D:O*RM-<6X\XKT,B_*__CP-4?BI
MY?\ PJ_Q!YN-OV4X^N1C]<5E? W?_P *ETG=G&^?;]/.?^N: .TUJWU6YTUX
MM&OH;*\)&)YH?-51W^7(R?QKSKX?"X\.?$#6M \1*+GQ#?Q"^&JJ^5NX02H7
M;@>7M]!D<'L!G1^W>.?"FO:DDVEW'B;1;F8S6KMH/AV_U5+5KI[6$R+ K8,A[+G!ZGV-:E% '
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M6?2]-@$-I;1,D:9)P/('4GJ2>Y)P.>.]8MM\8?&OA75[>#QYX?
M$5C.<>=' 8W7U*G)5L=QU]ZN_LZZ='-I^N>()LR7L]W]G,K? W,3$9*-'\V1Z< CZ$T ==;7,-Y:PW5O(LL$R"2-U
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MG_7])_):B_:(U&2U\ VUI&Q47=ZJR8[JJL$O$UN!%.
M9MLL@XR(W0C^*9-0G\33Q"2>]-ZWF6\A&=J;6VX4G ZCBO45.Y ?49KR_Q+
MXFU;QMJ-SX1\$N$B0^7J>LG_ %<"]TC(^\YYZ?IU !H?!_7-0UKPA.FHW37K
MV%[)9Q7C')N(U *N3WZXSSG')S7H-9/AKP]8^%= M='T]2(+=<;F^](W4LWN
M3DUK4 %%%% !1110 4444 %%%% !1110 5XYXZ^,PT[Q7I_A_P -203R?:4C
MO;AEWH,L!L7GDC)R>W3UKK_B+X9\0^*[&STS1=8&EVKNWVZ3)W-'@8  Y/?C
M(![UXI\0? VD^!?$/@^QTP2.\LP>>>4Y>5O,49/8#T _^O0!]/*1QGT1/N+]*\&\,PIXG_:4U
MV]NE,B:6)!$&/"NA6)>/IN/UH K3_%'XJ^'HDU37?#$8TPL-^^U>,*#VW DH
M>WS U[1X3\46'C#P];:QIQ812@AHW^]&XX*GW!_QK5N[6"^LYK2YB66"9#'(
MC#(92,$&O$O@#)+IVL>*_#SOF.UN%=!T^;+(QQ]%6@#T3QEX9U?Q5>Z;8IJ(
MM/#ZLSZBD,K)/#)IH9M0N?)O=*%RTJ
M/#WE*L25*C)S[<=\^H7'B/2;3Q#::#/=^7J=W&98(3&V)%&8V5B>>.HYZ^Q ![)138V+1JQ&"
M0#3J "BBB@ HHHH **** "BBB@ HHHH H:SK.G^']*GU/4[E+>TA7+.QZ^@
M[D]A7G/PR^)NH>/?%NM0O%'#ID"![6/9\X!)'S'/)P*35?A1J'C#QG+;>! D4>41!T4"1@!0![]7A
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MK>D6^O:)>:5=/*D%W&8G:(@, ?0D$9_"O+O^&2[[CN)Z*I(_&O
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M6B7&EW#.L5S;-;R,A 8*RE21D$9Y]*\L_P"&/?^%@ZY:ZE_9OV#R+80>7Y_F[L,S9SM7'WNF.U=7X&^./_  A?A*TT+_A'
M?MGV=I#Y_P!M\O=N[FAGM!.S73JS!B[
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M5'_#./@__H):Y_W_ (?_ (U0!S__  TU_P!2C_Y4O_M5'_#37_4H_P#E2_\
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MQ N-6CU6XO819I$T?V5T7.XMG.Y6_NB@#L_^&FO^I1_\J7_VJC_AIK_J4?\
MRI?_ &JN@_X9Q\'_ /02US_O_#_\:H_X9Q\'_P#02US_ +_P_P#QJ@#G_P#A
MIK_J4?\ RI?_ &JC_AIK_J4?_*E_]JKH/^&317%MYS&Z=68
M'<1QM5>.* /IKP)XL_X3;PI;ZY]B^Q><[IY/F^9C:Q7[V!Z>E=)7FWP(_P"2
M4Z?_ -=I_P#T8:])H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH ***IZMJMCH>EW&IZE<);V=NF^65L\#Z#DG
ML .2: +E%>*77[26A1WACMM$OYK8''FLZ(Q]PO/ZD5Z5X0\::-XWTHW^D3LP
M0A9H)!MDA8]F']1D'!YXH Z&BBB@ HKQ[Q)\?M.\/^(]0T@:)-=&SF:%IDN
MH9EX;C;V.1^%9?\ PTM8?]"U<_\ @4O_ ,30![K13(9/-ACDQC>H;'ID4^@#
MR#]H[_DGEA_V%8__ $5+7GW[./\ R4.__P"P5)_Z-BKT']H[_DGEA_V%8_\
MT5+7GW[./_)0[_\ [!4G_HV*@#Z@HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** / _P!GO_D8_%_^]%_Z')7K'Q T%_$W@+6=)A4M--!NB4'&Z1"'
M0?BRBJO@WX=:1X(O=2N],N;Z634"IE%RZ,%P6(V[5']X]B>*?@WX1\5W\E_"9CEZ39Z?#
M_JK6!($P,<*H4?RJU110 4444 %%%% !1110 4444 %%%% !1110 5XU^TA_
MR).E_P#81'_HMZ]EKF?&W@;3/'FEP:?JD]W##!-YZFU=58MM(YW*W&": -#P
MM_R*.B_]>,'_ * *\@^-4-SX:\>>&/',$3R00,L,X7IE&+8]BRLX_P" U[;8
M6<>G:=:V,+,T5M$D*%SEB%  SCOQ4>JZ58:WILVG:G:QW5I,,212#(/?XU^+/B#QRT#QV
M2@Q0;QSN8*JC/3(C7G']X>M=&W[/7@IK[[0'U18LY^S"Y7R_IDKN_P#'J]'T
M;1=.\/Z7#IFE6J6MG",)&F?Q))Y)/6\ENQ'8.I4_SKPGX
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M  [^E 'E7[0.EWD%OH/BJQ7U^((GG\
M-ZI#&,O)9RJH]24(%>*:?_R=9>?[C?\ I.*]\(!&#R* /&_V<9$/@G5(<_.N
MILQ'L8XP/Y&O0?B!.MM\//$4CD '3ITY]60J/U->(R7.M_ KQSJ$L>G->>'-
M1?&4T?[=]MVRO)YOE>7]XYQC>(?^P?-_Z :Z2N;^('_)//$/\
MV#YO_0#0!Q?[/7_).)/^OZ3^2UG_ +2$3'P?I4H'R+?;2?E 'N&OZ7=:SX9N],L]0.GSW,/E"Z$>\Q@XW8&1SC(ZC&F:YIEG+'KOB'^VIV
MDW)-]B2VV+@?+M0D'G)S[UM444 %%%% !1110 4444 %%%% !1110 5X-\=O
M^1X\'?\ 70?^C%KWFO!OCM_R/'@[_KH/_1BT >\)]Q?I7A?PX_T7]H'QG;S?
M+)*UQ(@/<><#_)A7NB?<7Z5X3\4M'USP9X^M_B'H%LT\+*!>(JEE0A=IW@=%
M91U[$?3(![O7A7P387WQ%\;:A&08FFR".0=TCD<_A5'5OVA;K5M'.GZ#H$\.
MK72^6',GF^63UV*!ECZ9Q]#TKO\ X.^";GP=X28ZBFS4[^3SYTR"8QC"IGU
MY/N30!O^+?!EIXK2TF-S/8:E8OYEI?6QQ)$>X]P>XK%M?AS?WNJ6=]XM\57.
MOBQD\VVMC:I;0JXZ,RJ3N(]37?T4 %%%% !1110 4444 %%%% !1110 4444
M %>"_!7_ )*=XQ_WV_\ 1C5[U7@OP5_Y*=XQ_P!]O_1C4 >F?%&)YOAEKZ(,
MM]F+?@""?T%8_P "Y4?X3Z6BG+1R3JP]#YK'^1%=]?V4.I:=JL"#_.OG'0_$^N_ W6K[0M8TR2\TB:8R0R+\F[MOC8Y!! &5['TYR >J_&V
M=8?A1JZ,1F8Q(N?7S%/]#5WX2P-;_"[048\M;[^G9B3_ %KQ_7?%6N?''5K/
MP]HNF26>DQ3"6>5SOV]M[G&!@$X7N3^7T5IMA!I>F6NGVR[8+:)8HU]%48'\
MJ +5*K"]T+2_M=O%9")W^T11X;>YQA
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MP^L]+U>V^S7D1&&.[!//(XP#0!T5>(?'Z\NM0OO#'A*UFV+J%QND'JQ94CS[ LQQ]/
M2MK_ (:$\$_W=3_\!A_\57._%1P_QI\ 3\B-I;4@GC_EX!_K0!ZYI7A'0M'T
M*/1[;3+4VBQB-U>)6\WCDOD?,3WS7CFBV4?P]_:,_LC3P8M*U:$[8+T'85Z]H?B?PEXED:/1]0TZ[E4;C$F X'KM(!Q[XK
M@=!_9W\-6'F-K%Y=:HY)V ?N$5>W"DDGWSCVKE_B;\*[;P)I\7B[PE=W5HUE
M,AEB:0L8]Q"JR-UZD @YSGVP0#Z)HK$\'ZXWB3P?I6L.JK)=6ZO(J] _1L>V
M0:^5_&GC3Q5:^.O$-O;^)=9A@BU.Y2..._E5442L   V  .,4 >R?M'?\D\L
M/^PK'_Z*EKS[]G'_ )*'?_\ 8*D_]&Q5YIJ7B77M9MUM]4UO4KZ!7#K'=73R
MJ&P1D!B1G!(S[FO2_P!G'_DH=_\ ]@J3_P!&Q4 ?4%%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %9'B?Q%9^%/#EYK5\28;9,[%ZNQ.%4>Y) K
M7KQ7]I&]>+PII%DI(6>\,C8[[$('_H= 	^)_C-X[1]8\/1+9Z82PA5%A56
MP<8!D^9CVS]W(/2NI^&OQ0UB_P#$/=7^*U_X9\%Z@8ULX%9H\1!?NJ6;+CU<#\*A
M_LKX^?\ 023_ +^6W_Q-F^'O''BSQ)<6D]_?:A,8[&&+Y=R-(S$%C
MG ^6,=">G%=MH_[1EG)J2VNOZ#/IL1(!FCE,NS/=D*@X^F3[4 >N>'$U./PY
MIR:T^_4UMT%TV0M &CXX_Y)_XD_[!=U_Z*:OE
MSX*?\E=T+ZS_ /HB2O:O%7Q@\":EX/UNPM-=\RYN;">&%/LDXW.T;!1DI@-)4*2(KHPP589!ID%K;VJE;
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M %OJ14]% !3)H8KB,QS1)(AZJZ@@_@:?10!'#!#;QB.")(D'144*/R%2444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4UW2.-I'8*B@EF)P !WIU<+\8M2ETSX7ZO) Q6295@W#T
M9@&_,9'XT FO
M=Z4\BR1$+/;S "2,GIG'!![$5P7P#\.::W@">^N+&":6^G=)&EC#;D7Y=O/;
MKQ[UQWPN_P"*<^/&JZ+:DBU,ES;; BC_'BN*_9_\ ^2:I_P!?4O\ .N#^/-Q+JOQ%T/0V
M9OLXCC4*/[TCX)'X8_*@#IK#]H_0)[]8KS2+ZUMF;'GAEDVCU*CG\LU[':74
M%]:175K*DL$R!XY$.0RGD$5Y?\7_  KI,7PDF:WL+>%M,6)H#&@4H-P4@$=C
MNZ>U3_ 749;[X:PQ2LS?99Y(5)_NYR!^&<4 >GT444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 5P7CCXM>'_  -:B5#&VM\?(#TWL
M3@9].3[5WM>6I\&;>3XCR>*]1U4:A%).T_V*:UX!/W1N+$$#L,=A0!0T/]H?
MPYJ5]';:C876FK(VT3LPDC7_ 'B,$#WP:];EN[>"S>\EF1+9$,C2D_*% R3G
MTQ7S]^T6-&6ZT>UM((!JWS&3R5 ;RSC:&Q[YP*Z'Q_"RTF]O+=&V^?O6/=[J#DD?7%>C>#_ !GI
M'C;2/[0TF5L*=LL,@Q)$WHP_J.*X;X)>&-+D^&"2W>GP2R:BTGGF1 Q==Q4#
MGM@5P_P3DDT7XLZQHL;?Z.\%-&EU75KCR;:/C@99V/15'110N70VT@4[O4Y!!_^O0!YRG[26AM>A'T/4%M2<>;
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M.C^)M,C;S=&F^::/\
M=?!E]H:7FH7K6%XJ S6;0N[!O12JX89Z'TZXKC?A^]S\2/C1>>-C;RP:7IZE
M( _KLV(I/K@LY /!([$5Z%=?!?P!=WC7+Z"J,QRR0W$L:'Z*K #\,5V.EZ58
M:+I\=AIEG#:6L?W(H5"J/4_7WH J:_XHT7PO;PSZU?QV<4S[(V=6.YL9QP#3
M=&YD-]):^=9.5!#G&Y1@^HXY]:B\4^#M$\96D%MK=JUQ% YDC
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M_%U#\<6U._\ AUX3U+5;<6]Z6(NHMA79(T8)&#T^Z:^@JY?XA>$E\:^#;S2
MZI(?'170JHX"AE!5U'&,
M?G6SX"\,^)_&WC]/'?B^U>UAM1_HEO)&4W$9VA5/(1&=5/C#P9;7]
M[8_9A?PN);8L3M!)4C) [>U $NC^&?#>D7,UWHVDZ?:S2G#R6T2J?H,=!["L
M/XK>'],UOX?ZO+?01F:SM9+BWG(^>-T!8 'T.,$>]>36H\;_  1U>^MK32WU
M;P_<2&1&",RGT;
M(_B-JFJZ3H_VBRG$/ER_:H4W;8D4\,X(Y!'2O=/"7ARW\)>%['1+9MZ6T>&D
M(P7WN94<#J"3NY_!A7GG@#_B9
M_M&:I>6Q#Q"XNY]P.1M+$9_\>%:$O$Z0Z?<_*P:XD@@_##X80> ;6>>XN5N]5N@!+,H(1%'\*YYZ]3WH ]"HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\_P#C7_R2G5_^V?\
MZ&M>@5ROQ%\.WOBOP/?Z/I[0K$]1\&>#UTK4V@:X$SR9@.2!2?$GX/-4%KIFN^)X6T>V
M/R(MS+-M'^PC*!G'')XKWC0]&L_#^BVNE6"%+:VC"(".O$?BF_UF2[TO=<3%TS<."JY^4?Y:/X3W?#BV\,:_LN";007!1
MRP)]02.H."#CM0!A? ^]CN/A9I_S*# \J.,_=PYZ_A@UYE\'R=2^->K7\"DP
M;)W+>FYQC^OY5?E^"'CG1I+NS\->)XDTNZ.'5KB2 L/]M54@\<9!YKTKX9_#
M:W^'^F3![@7>I71!N)PN% '15'7 YY/7/;I0!W=%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %Z#X)6 ZU--&;C/E".%GW8Z\CC\Z
MZ:N6\>>![#QYH)T^[0&R0FX'('MWQ[UC_\*3^(
M9M?[$;Q1;_V)N_U?VJ8IC_KGMQ^&<>]>R>!O!.G^!= 73;)FE=COGG88,K^N
M.P]!0!XE\"Y?L'Q.UC3[C"3212#:W7*OR/UJ3]HA_MOC'1--@PTQMP.O1F<@
M C\OSKJO'/P8OM1\3-XE\):JFGZB[^8\.30!TU%%5-4U-*NM1N=_D6L32R;!D[5&3@4 6Z*Y;P;X_T
M7QTET^CBY M2HD\^,)USC')]*ZF@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HK/M]M7: "BN:\8^.=(\#6EM9]FNHQ)'YBX;!]10!?HJ&ZNK>QM9+JZFC@@B7
M<\DC!54>I)KRO7/V@_"FF7#0:?!>:FR\&2)0D9^A;D_EB@#UJBO%=/\ VD=!
MFG5+_1K^UC)QYD;K+CW(X/Y9KU?0O$.E>)M,34-'O8[JV;CK=RM&$=808SOQ@YSTYYXKLP00".AH 6BJ>K:I;
M:+I-UJ5XQ6VMHS)(5&3@>GO7'^%OB[X8\7:TFDZ:;Q;ET+KY\(53CJ,Y/- '
M>445SOC#QMI'@C3X;S5VF\N:3RT6%-S$XSTR.* .BHK.T+6;;Q!HMKJMFDJV
MUT@DC$J[6*GH<9-IF>ZC.'AM$,I4^A(^4'VSF@#N:*X7
MP]\7_!GB2[2TMM3-O=.<)%=QF+4+B^9,_ZT6IV_P"/Z4 >GT5E:#XET;Q/8_;-
M%U"&\AZ,4.&0^C*>5/L16K0 45ROBGXB^&/!SB'5]25;DC(MXE,DF/<#I^.*
MP])^.'@?5;M+;[?-9N[;5-W"44G_ 'AD#\2* /1J*:CK(BNC!E89# Y!%5=4
MU;3]$L'OM3O(;2U3[TDK;1]/<^U %RBO,+CX^^!H)_+2XOIU_P">D5J=O_CQ
M!_2NJ\,>/O#/B_NUL$CW&10!TM%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M6%XE\9>'_"-LLVMZE%;%QF.+EI'_ -U!DGZXQ69\2?'$7@3PI+J "27TQ\FS
MB?D-(1U./X0.3^ [UX#X$^'^L_%C6;O7-?;=,=B 'N8
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MXM[>XN88IKEBD$;N TC 9(4=^ 35BOESPUJ%YJ/[24@ [4 ?4=<7J_Q3\+Z'XH;P[>W%PNHJ\<918"RY<*5Y^C"NTKB]7^%G
MA?7/%#>(KVWN&U%GCD+K.57*!0O'T44 =I1110 4444 %%%% !1110 4444
M%%%% 'GFI?&OP9I.J7>G75U=+J2:=H
MT\\ES'"9V$D)0; RJ>3[L*^<_P"Q[37_ (^7^E7ZLUK#W^RM70_$[_DF7B'_KS>OC^TT>
M6\T#4M4C)*V$D"R+_LR;QG\"JC_@5 'W4CK(BNC!E89!'0BG5POP@\0#Q#\-
MM+E=]UQ:+]CFYR0T? S[E=I_&NZH ANKF&RLYKNX<1P01M)(YZ*JC)/Y"O./
M^%]^!/\ G\O/_ 5JE^..OG1/AM=PQOMGU%UM$QUVGE_PVJ1_P*OE[6]#DT6'
M23,3YE]8I>%?[H=GVX^JA3^- 'W*)T-MY_.S9OZ=L9KS8_'OP(#_ ,?EY_X"
MM7HEJ@DTR%&^ZT*@_E7BWQ ^#WA#P_X%U;5M/MKI+NVB#QLUPS '.=$\;0W4NBRS2+;,JR>9$4P3G&,_2NDKPG]FG_D&>(/^NT/_ *"U>[4
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%?*VL?%/Q=X3^)/
MB$6>J27-HFHSH+.])FA"J[!0H)R@&?X2O09R!BO0/#'[1.B7L4,'B.RGTZY/
M#W$"F6#A<[L#YUR<@* V..>N #VFBJ6F:QIFM6[7&EZC:7T*ML:2VF615; .
M"5)P<$<>]7: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@#E_B/\ \DYU_P#Z\WKS7]FO_D!ZW_U\I_Z#
M7I7Q'_Y)SK__ %YO7@OP=^).@^!M-U*WU<79>XF5T\B(., 8YY% 'U%7/>//
M^1!U_P#Z\)O_ $$UQ?\ PT)X)_NZG_X##_XJLCQ1\<_"&K^%=5TZV74?/NK6
M2*/?;@#],RHI9B H&22> *\%_9I_X]=?\
M]^+^357^,7B?6/$GC.V\ Z%,Z1ED2<*VT32,,X8CG8H/(^O7 H ]6O/B?X)L
M+@V\_B6P\P'!$;F0 ^Y4$5NZ3KNDZ];&XTG4;6]B'#-!*'VGT..A^M>;Z-^S
M]X1L]-2+5!%?WDWG-&H;OM5>@^N:\Y\:^#]4^#7B&S\1>&K^8Z=))M D
M/*GJ8Y,8#*1G'^(!H ^FY98X(GEFD2.-!N9W. H]23TJ"RU*PU%6:QO;:Z5#
MAC!*K@'WP:Y/5];A\2?![4-8@4JEWI4DFT]5)0Y!^AXK@OV:_P#D":W_ -?*
M?^@T >YU2MM8TR]N6MK74;2>=02T44ZLP ZY .:NU\U?!/\ Y+-K'_7M)GR
M5_WL?=_'%>+?M&RR6_BC0IHF*R1VQ=6'8AR0:Z+PM\#-$U+PK%>^(I;RXUB_
MC\Z2<3$&%FYP!T)'1)XFL2_3,;%U_P"^E!'ZUX]\9"_ANQ\-> K*[>#2TMU>:5N!*=Q7<^.N
M,%L>]=YI?P'\"C2H?-BN;UW0-]I-TPW9'4!<#'X4 >BZ5K>E:[;?:-*U&UO8
M1P6@E#X/H<=#]:OU\WCP%XF^'7Q4LV\*6^HW^G/L=Y A*F(G#I(PPN1@D?@<
M5]'J25!(P2.E "U5O=2L=.17OKVWM5(?M)_P#(OZ)_U\2?
M^@B@#U?6/%>@>'X(Y]5U>TM4E&Z/?(,R#U4#DCZ5!HGC?PQXCF\C2=;L[J?!
M(A63$A ZD*<$_E7D/@'X4+XTTV'Q/XTN;FY-S&!:VJOL B PI)'.,= ,<54^
M)GP;M?#&E-XD\)S74'V,AYH#(69!G >-OO#!ZY)]<\4 ?1%5[V_M--M7NKZZ
MAMK=/O2S.$4?4FN+^%7C1O%W@:.]OI!]LM"8;ISW*C.X_48->-O_ &Q\I/MQ]J%R2^?7'W?T
MKS70+S6O@S\3$T"]NFN-'O)%! ^XZ,<+* ?NL#U^AZ\4 ?31(4$D@ B^((
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M !X>'/\ KK:?RKPWXP_$O0?'&E:=:Z0MWYEO,[N9X@@P0 ,''U"YH \B^)GB#4OB)\1(/!&CS%;&&?RFQG#R#[[MZA>
M)+%[35-+MID88#^6 Z>ZL.0:^??#\&L_"
MKXPMH]LEU=Z?/(J2)&A;?"WW7('=<\GV-?3M&!G..: /G_\ :/TAEET77H58
M-AK=W7C;@[E_'D_E7M/A;5%UKPKI>HH#+#4H8\MI\WEG'9&&/R!4?G0![(CB1%
M=3E6 (KYW^/]X^L>,]"\-P,-RA?PDE8 ?H%KV#X;ZW_PD'P_TB_9MTI@$.Z&G_"9_M(WE\5W6]A([@]05C&Q?Z'\* .[^*FNR>!/AA;V&EN8+
MB94LXF0X,:!?F(]\\'F06\I/EHAZ,1_$3UY
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M#CI7DGCSXUOX4UF^TBQT![N:U"@W+S8B4D \@#MGID4 <%9V#[>]>^^,-?7PQX2U+6& +6T)* ]"YX7]2*\,^%<
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M/P&*MT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 ?+_[1.KR7GCJUTS=^YL+12%]'D.YC^("?E7T!X'T2
M/P[X)T?2T15:&V0RX'61AN<_BQ-?,7QPC=/BYK+,,"18&7GJ/)0?S!KZ[C96
MC5DQM(!&/2@!U%%% '&W/PM\(WWB>?Q#>::9[^:193NF8(K@ 9"@@=L\YYKL
MJ*R/%6J/HGA+6-4C_P!;:V_W=QV_0XJ
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M MT(+W%M?-(J'/&\9Z?48YKU[X-?$JZ\;Z?C:O:PWVC7UI<('AFMY(W4CJI4@U\S_ +.S,OQ(N0#@-ILH/N-\9_I0
M!]1DA5+,0 !DD]J^;_''QGU_7]>?0O!1DBM_-,,Z/3*\?*N>F.>^>P
M]?\ BMJTFB_#'7+J%BLK0"!"IP1YC!"0?4!B?PKS']F[P_;NNK>(945YT=;2
M D?\MM6/FG\=V,_C6C\/?B]KV@^(
MD\-^-))Y8#*(#-=#$]L^<#>3RRYZD\\YSVKZ/K@/&'PA\/\ C7Q#'K&HS7D,
MJQ+&Z6S*HEP3@L2IYP<<=@* .YO+NWL+*>\NYEAMH(S)+(YP%4#))_"OFO7_
M (I>,_B%XA;1_!:7=K:G/EQVORS2*/XWD_@'T( S@DUZ#\>]3?1_AI%IT#MF
M]N([9B6^8QJ"Q^O*J#]:XKX1?$'P3X(\+/%?R3IJUU,SW+I;EOE!PBAAV YQ
MZL: ,Z7X:?%ZR@-]%?WCS@9*0:JWF^_\0!_ UO\ PV^,NK0Z]'X9\:!R[R>1
M'=31^7+#)T"2C R"<#. 0>N>H[/_ (7WX$_Y_+S_ ,!6KQ7XQ^)O#/B[7K+5
M?#[2-,T)BNR\)CR5(V'GJ<$C/L* /K>OG3Q]\2-?\-_&F:T&K72:):W-H\MK
M&%(,7EQM(HR.^6[]Z]M\$ZI+K7@?1-1G),\]G&TI/=]H#'\2#7S/\7;4WWQP
MU*S#;3/-:Q;O3=#$,_K0!OO??%7XLR27NE>?I^C%F6)8KC[/%@'&"W#2'L3R
M,@\#I6!JC?$[X7WT,]YJ%_#%(V(Y#<^?;RGK@@DC/L0#UQ7U=8V5OIUA;V5I
M$L5O;QK%$BCA548 KB_C+:17?PIUOS5R8DCE0]U82+R/U'T)H N_#;QJOCOP
MC%J;QI%>1.8+J-,[1( #E<]B"#WQG&3BO._C;_PG?V^Z_L?[9_PC?]G?Z9Y>
MWR^K;\YY^[BD_9I=CH^OQD_*+B(@>Y5L_P A7IWQ$_Y)QXC_ .P=-_Z : /E
M;P'_ ,)QYU]_PA7VOS-J?:?LVWISMSN_X%7TTEWKEA\&[F\U*6:+7+?1YY9)
M'QO298V(/ID$"O+OV:/^/[Q'_P!<[?\ G)7L_CK_ ))[XE_[!5U_Z*:@#YNT
M'XL^.;NQO=%MKRZU#5]2DBBM)-H+0J-^_;C&&.4Y/  )XZUN:9X(^+NB:_I=
MT^H:@$N;E$N)8[[SQ$I/S&122" "3T(X]<5!^SEIL=SXTU"_D"DVEF0@/4,[
M 9'X!A^-?3= '$_$SX@0_#_P\ERL27&HW3&.T@K8LS*'6X^RP?0*"-V.F<'W->Y>.OAEHWC^6VFU*YOH);9"D
M1MY% P3DY#*?;TZ5T%C#I?A;0[+3?M,%M:VD*Q(9I%3(48R<]SC)- 'S5JO@
MOXL>$;=M3%YJ+PPC?)+9Z@S[ .Y7.2.N>",9S7HGP7^*FH>*KJ70->99KZ.(
MRP704*95! *L!QN&)-/?'!2WD\]OIA,FOGSX/W
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M9;7S;V*_WHY>FC[5!)CE0/OCZ%<_B
M>U ':Z)K5CXAT6UU;39A+:7*;T;N.Q!]"#D$=B#7C'QU\9^(O#/B/3+?1M6G
MLX9;0NZ1XPS;R,\CTJ?]FW5Y;C0=9TB1B4M)TFC!/02 @@?BF?QKFOVDO^1L
MT?\ Z\3_ .C&H EO_&'Q#^*5]+:>#HKNTTB B-IHI!"7/'+RY')Z[%/0]#UK
MG==T'XH_#V--6N=1U!+<, UQ;WK2HI[!QGIV^88YQ7T7\.M(@T3X>Z':0(JY
MM(Y9"O\ %(X#,?S)K3\26D-_X7U:TN%W0S6X\I$L>/YFO
MIZ@ HHHH ^4M%_Y.5E_[#UU_Z')7U;7REHO_ ":", @H0I?MGD9K*GU;XE?%[4;B;0?M-EHT;E46.
M?R(E'8,P(+MTSUQZ"J'QDL)-5^-9TZ(XDNOLL"'&<%@JC^=?3>CZ39Z%H]II
M=A"(K6VC$<:CT'<^I/4GN30!\N:A/\4?A7>PW%Y?7R6[OM1GG^T6TIZE2"2
M3SZ-UQZU]!_#SQW:>/?#@OXD$-W"WEW=OG/EOC.1_LGJ#]1V-;?B'0[3Q)X?
MO=(O8U>"ZB*'(^Z?X6'N#@CZ5\Y_L_:C/IOQ$N])=BJ7=LZ/'G_EI&<@_@-X
M_&@#W/XG?\DR\0_]>;UX5\%="3Q+H/C?1G"YNK.)$+#(63+E#^#!3^%>Z_$[
M_DF7B'_KS>O)/V:/^/\ \1_]2,-U5Y20H_! P_*
ML/\ :(_Y*-;_ /8.C_\ 0WH ^GK'_CPM_P#KDO\ *N2^+?\ R2O7_P#K@O\
MZ&M=;8_\>%O_ -[5X3^S3_R#/$'_7:'_P!!:O=J "BBB@ HHHH ***YCXAWFN:?X%U*Z\-K
M.VKIY?V<00"9SF10V$(.?E+=O>@#IZ*^8/\ A,OCG_SZZY_X(E_^,T?\)E\<
M_P#GUUS_ ,$2_P#QF@#Z?HKY@_X3+XY_\^NN?^")?_C-'_"9?'/_ )]=<_\
M!$O_ ,9H ^GZ*^8/^$R^.?\ SZZY_P"")?\ XS1_PF7QS_Y]=<_\$2__ !F@
M#Z?HKY@_X3+XY_\ /KKG_@B7_P",T?\ "9?'/_GUUS_P1+_\9H ^GZ*^8/\
MA,OCG_SZZY_X(E_^,T?\)E\<_P#GUUS_ ,$2_P#QF@#Z?HKY@_X3+XY_\^NN
M?^")?_C-'_"9?'/_ )]=<_\ !$O_ ,9H ^GZ*^8/^$R^.?\ SZZY_P"")?\
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M@_X3+XY_\^NN?^")?_C-'_"9?'/_ )]=<_\ !$O_ ,9H ^GZ*^8/^$R^.?\
MSZZY_P"")?\ XS1_PF7QS_Y]=<_\$2__ !F@#Z?HKY@_X3+XY_\ /KKG_@B7
M_P",T?\ "9?'/_GUUS_P1+_\9H ^GZ*^8/\ A,OCG_SZZY_X(E_^,T?\)E\<
M_P#GUUS_ ,$2_P#QF@#Z?HKY@_X3+XY_\^NN?^")?_C-'_"9?'/_ )]=<_\
M!$O_ ,9H ^GZ*^8/^$R^.?\ SZZY_P"")?\ XS1_PF7QS_Y]=<_\$2__ !F@
M#Z?HKY@_X3+XY_\ /KKG_@B7_P",T?\ "9?'/_GUUS_P1+_\9H ^GZ*^8/\
MA,OCG_SZZY_X(E_^,T?\)E\<_P#GUUS_ ,$2_P#QF@#Z?HKY@_X3+XY_\^NN
M?^")?_C-'_"9?'/_ )]=<_\ !$O_ ,9H ^GZ*^8/^$R^.?\ SZZY_P"")?\
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M@_X3+XY_\^NN?^")?_C-'_"9?'/_ )]=<_\ !$O_ ,9H ^GZ*^8/^$R^.?\
MSZZY_P"")?\ XS1_PF7QS_Y]=<_\$2__ !F@#@OB!_R4;Q+_ -A.X_\ 1C5S
ME7=8GU"YUJ^GU82#49)W>Z$D?EL)"3NRN!M.<\8&*I4 7-.U74='N3Y ^E2T %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110!R_Q'_P"2;UY!\ O#.
MA:]H^KR:MI%G?/'<*J-<0JY4;>@S7K_Q'_Y)SK__ %YO7FO[-?\ R ];_P"O
ME/\ T&@#TS_A77@O_H5M(_\  1/\*P_&?@/PE9^"M:N;;PWI<,\5E*\C8Q^'Z5M?LT_\>NO_ ._%_)JH_%W0]5\'?$&U\>Z5&S6[R(\C
M 9$<@&"K>@8=_9?'D0GX87'FXW"YB,>?[W/\ 3-2:-\
M:BVG7 7,EO/"Y*GV*@AOPY]J\O\ B1XZF^*FKV'ACPK:SSVBR[PS(097Z;B.
MJJH)Y/J&[A]6U><>7;10
MPN%5VX!)(&?H,DGCCK7F_P !;>XM/BOJ%O=QF.YCL9EE0]582)D4 7?VD_\
MD8=&_P"O1O\ T,U]$V8"V, 4  1K@#Z5\[?M)_\ (PZ-_P!>C?\ H9KZ*M/^
M/.#_ *YK_*@#COB/\-[+X@Z;"CW!M+^V),%P%W  ]589&1Q^'\_&&^'WQ:\#
MOG1+JYGMDR1_9]UN0_6)L9_[Y-=Q\:/$7C3PIJFF:GI%[(FB';YL:1KCS0V2
MK-C.&&._K6]HWQP\$ZEI\-M-+1Y"RRFW,$\?^T4QAA[ #^E?1$,T=Q!'-$P:.10RL.X-?,GQ8\6Z=\3
M/$.C:1X6MY;R:)FC6X\HJ92^. "-VU<$Y..I^M?2&BV!TO0[&P9BYMX$B+'O
M@ 4 7J\0_:3_ .1?T3_KXD_]!%>WUXA^TG_R+^B?]?$G_H(H ]?T%(X_#^GI
M" (Q;H%QTQM%4_&80^!]>$F-O]GS]?7RVQ^M>4_#7XQZ9IVA6VA>+6ETZ[M(
MU2&>6)RLL>/E)P"0<8Y/!ZYYQ57XI?&+3=8T:3PWX5>6]FO2(Y;A(V48S]Q
M0"Q)XZ8QZYX ,[X*M<+\//&YCSM%M(8\#)W^4W_UJO\ [-6S_BH2=OG9AW>N
M/FQ^N:[_ .%'@I_"G@-+*_BQ>7Q,UW&3G:6&-OX* #[YKQVPO-1^!WQ+NDO;
M::?2+O(RN/WL6 4T_[6-:+$C(@6WD\S/IC;^N<>]>16?]I?&KXK0ZE]D>'1[-UR6&1'$IR%
M)Z;F/;W/I0![?XP\#V'CSPI!I]Y(T,T:K)!<(N3&VWT[@]Q7B4OPM^*/@J9I
M/#U]+/ K$@Z?=E,C_:C8C/T^:O1/C;JGB[P]HUEJ/AR^EMK!"8[L11*Q0\;6
M)() [=AT]:F\,?'/PEJ>DP'5[XZ;J 0":*6-RI8=2K*""/K@^U 'GVE_&[QI
MX6OX[+Q?I37$8(#^= ;><#/4+A867D\!$!&XY[]N!U[>T>%="NM$^'%EH\_
M-W%8^6Z@Y 'AS_KK*\'_:7_X\/#G_ %UN/Y)0!V/@3P+X3OO .@W=WXXF
ML8GDEDME+.Q49)..370_\*Z\%_\ 0K:1_P" B?X4GPY_Y)MX;_[!T/\ Z"*Z
M>@#Y[^/GAC0M!T/29=)TBRL9))W5VMX50L,#@XKU'X9IZIGT
MRN*X3]I+_D7M%_Z^9/\ T$5Z#\+_ /DF?A__ *\T_E0!XI\"IVTKXGZII=RO
MERRPR)ANNY&Z?J?RKZ8KYS^+7AK4_!7CJW\=Z)&?L\DPED*KD1R_Q!O9AGGW
M->F^$_C!X4\2V$;SZE;Z9>X DMKR01X;_98\,/3'/L* ._KFM>\?>&?#&K0:
M9K.IK:7,\?F)OC8KMR1RP! Z'KBJNO\ Q.\(>'K.2>XUNTN)5'RV]K*LLC'L
M,*3CZG KPOPUI^J_&+XHMKM["T6F6\JR2D] 'TU=00ZEI
MLUN^'@N86C;W5AC^1KP?X$W3Z#XM\3>'+QQ&8LR;.RE&(8_D5KZ 50JA0, #
M %?,?Q0EE\$?%K4-0ME(CU2Q?[O!_>(58_\ ?0S0!M?"96\6?_%$JL8X2
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MX#MG(S78?%R677O@A9ZB1AB]OJD']6KS_P 3:QJ'QN\>6>GZ+:S1Z9;?
M*&P]A7T#K/A6VU3P-<>&EPL+VH@C/92H&T_F!0!@_!:[6[^%N
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MP3_=U/\ \!A_\50!ZK15'1]5MM0Q"\"2,D\GW5AC_=->T_#;Q#'XF\ :3?J
MX:985@N .JRH-K9],XS]"*L>.?"%KXW\+7.CW+"-VQ);S;<]*]1^(%M->?#37X
MBO[XZ=*Q5.?F5=Q _*O'O@G\,;V?58/%VNP-%;PGS+*&92'ED[2D'HHZCU.#
MT'/T1)&DL;1R*&1P592."#U% 'SU^S1=QIJ'B*R)'FRQ02J,_P *%P?_ $-:
M^AZ^3-:TK7/@K\18]1LHV>R+L;61\^7/">L;$=P.#[@'TKUC3OVAO"-S8B6^
MAO[.Y ^:'RA("Q6'PQ\0RRD /:-",]V?"#]6%>7_ +,]
MLX'B2[*D(?L\:GL2/,)_+*_G7)_$/XF:A\3KRUT'0].N([$S Q0?>FN9.@+
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M::YJ'V62Y4O&?*=Q@''.T''XUQK?M">#!8&=4U(S[PZ 'I/[0LD6I> =#U2SD$MI)=JR2
M*.&5XV*GZ$#]:R_A7\+_  ;XQ\"6VIWT-Q)?K+)#<&.X90&#$@8'3Y"GYUZY
MXP\'6OB?P-<^'$VP+Y2BU;'$3IC9^'&#[$U\W>"?&NM?"+Q)>Z;J>GRM;.X6
M[LW.UE(X$D9/&!/^?.\_\"FIA^!'@!9%C-O=!V&54WC9
M/T%02_M"^"TL?/C34Y)B.+?[. V?0G=M_4UXSJNI^(?C/\08!9VS1YQ'!$K$
MI:1 \NSUTNQ5EM;6,1Q!FW$ >_>OF#XF?\G"3_
M /7Y9?\ HN*OJ+2]/CTK2;33X6=X[6%(59SEF"C&2>Y.*^7?B9_R<)/_ -?E
ME_Z+BH ^K:XKXN?\DJU__K@O_H:UVM<5\7/^25:__P!<%_\ 0UH \^_9I_Y!
M?B'_ *[P_P#H+5ZA\1/^2<>(_P#L'3?^@&O+_P!FG_D%^(?^N\/_ *"U>J^.
M[:6[\ >(8(%+ROI\X50.6.P\#WH \:_9H_X_O$?_ %SM_P"S^.O\ DGOB
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M.*_CI-X@B.@^"-,O'O+W,(N)% D&>/W:*3SC/S$C'IW' _"RW
MFT#XVZ79:BGE7%O_)H ^NZ^4_!O_)QW_<5O/Y2U]65\A)J
M\?@SXZW>IZE#*T5IJMPTBQCYBK%P&&<9X8'WH ^O:^4OB9_R<)/_ -?EE_Z+
MBKZ*\(^.-$\;074VBRRR);,J2>9&4P2,C@_2OG7XF?\ )PD__7Y9?^BXJ /H
M?XAVSW?PY\0PQ@LYL)6  Y.U2V/TKQW]FB[C34?$5D2/-EB@E49[(7!_]#%?
M0SQI+$THKY.UO2M<^"WQ%CU&QC9[(NQM9'SLGA/6-B.X'!]P
M#Z4 ?6=1]<5YA\0_B;J'Q.N[70-#TZXCL3,#'!]Z:YDZ L!P ,GC)]2?0
MZO\ 9GMG'_"1W94A#]GC5NQ/[PG\LK^=9/[27_(V:/\ ]>)_]&-7L7PO\%GP
M/X-AT^P  ]R">]>._M)?\ (V:/_P!>)_\ 1C4 >_\
MA;_D4=%_Z\8/_0!5G6/^0)?_ /7M)_Z":K>%O^11T7_KQ@_] %6=8_Y E_\
M]>TG_H)H ^;/VNO_0Y*^K: /F3X
ME7,=E^T3I]U,P6*&ZL9').  "A/\J^FZ^3?CI&TOQ9NXT&7>&!5'J2@KN_!W
MQYM].L5T?QE:W<5_9Y@>YC3=O*\?.N&=#N-9U2%X;_4@H2&1<-%$,D9'8L3DC
MT"]\T =A\3O^29>(?^O-Z\D_9H_X_P#Q'_UR@_F]>M_$[_DF7B'_ *\WKR3]
MFC_C_P#$?_7*#^;T :W[1_A_[1HVE^((D^>UE-M,0/X'Y4GV!!'_  .FZWX^
M,_[.%M=^=F^O8UTM\\DL,JY./5%)_P"!#Z5ZGXWT >)_!6K:1M#23VY\K/\
MST7YD_\ '@*^.M(BU'7+G3/"T3N(IK_*1@=))-B,Q'L$'TP: /IKX%^'_P"Q
M/AQ;W,B;;C4I&NFSUVGA/PV@'_@5>2_M$?\ )1K?_L'1_P#H;U]/V=K#8V4%
MG;H$@@C6*-1T55& /R%?,'[1'_)1K?\ [!T?_H;T ?3UC_QX6_\ UR7^5O_P#7!?\ T-:ZVQ_X\+?_ *Y+_*N2^+?_ "2O7_\ K@O_ *&M 'GO
M[-/_ "#/$'_7:'_T%J]VKPG]FG_D&>(/^NT/_H+5[M0 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110!\1_$#_DHWB7_ +"=Q_Z,:NA^#;>>#0[5[>.=@\@:5GR0,?Q$UOT4 %5M0L+?5-.N;"
M[0O;W$;12*&(RI&",CI5FB@#G?"W@?0?!B7*Z':/;BX(,FZ9GSCI]XG'6MZ>
M"&Z@>"XB26&0;7CD4,K#T(/45)10!P-Y\%_ -[S###,@)=OJYRQ_$ULT4 %&:
MX'_+=&:.0_5E()_'-=-10!ROA[X;^$O"UP+G2M&ACN1TGD9I77Z%R'M$\277B"PLWCU*Z#B64S.P;
MXE@39&5G=,#.?X2*Z9$$:*BC"J,#Z4ZB@"&ZM+:^M9+6[@BN+>0;7BE0,K#T
M(/!KAKKX*> +J9I3H7E,QR1%"_#GA4'^Q=(M[1V&&
MD +2$>A=B6Q^-;U%% !7B'[2?_(OZ)_U\2?^@BO;ZX7XF_#V3X@Z=8VL>I)8
MFVD9RS0^9NR ,=1Z4 16/@/PSXN\%Z$^M:5%<3)8Q!9E+1R ;1QN4@D>QXK6
M\._#GPGX5G^T:3HT,5SVGD9I7'T+D[?PQ6UHFG'2-#L=.:02FU@2(N!C=M&,
MX[5?H *H:MHNF:]9&SU6P@O+FV<%I;)]V*% JC\!5NB@!DL4<\3Q31K)&XVLCC(8>
MA!ZUPU_\&O 6H7#3R:"D3L44 ^'_A7PM()='T:W
M@GQCSVS))SU^9B2/PKI:** .*UGX2^"=>U![^]T5!35NBB@#!
M\4>#=$\96T%OK=JUQ% Q>,+*R8)Z_=(K1TG2K31-*MM-L(S':VR".)"Q8A1T
MY/)J[10!'<6\-W;R6]S#'-#(I5XY%#*P/8@]17F>L? /P5JDS36\=[IK,5:VT8CB3).%'3D\FKE%% '(^(/AEX4\4:Q
M_:NK::9[O"J7$SJ"%Z9 .#76(BQQJBC"J  /04ZB@ KDM?\ AEX/\379N]3T
M6)[ICEIHG:)F_P![81N_'-=;10!R_A[X=>$_"TXN-)T:"*X'2>0M*X^C,21^
M&*ZBBB@"KJ&FV.K63V>HVD%W;/\ >BF0.I_ UQ$GP2^'\MP93H97)R46ZF5?
MR#L_LFD:?;V4.DP73J,+*:9R[L;N7DGJ?O5Z!10!YS_PHOP!_T")O
M_ R7_P"*H_X47X _Z!$W_@9+_P#%5Z-10!4TO3;71M+M=-L8S':VL8BB0L6P
MHX R>35NBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_GG]:[C1M!TKP[8BRTBP@L[<*H5BUO2K
M>\VC".XPZ#T5QAA^!K:HH \U7X$> EEWG3KEES]PW6$2\N?5F/+'W)-:E% !6!?>"?#.I:N=6O=%M)]0+*YN'3+Y4 *<
M^P _*M^B@ JKJ.G6>K6$UC?VZ7%K,,212#*L,YY_*K5% &5HGAK1?#B3)HVF
MV]DLQ!D$*XW$=,_G6K110!P&K?!?P-J]_+>RZ4T$TK%I/LTS1JQ]=H.!^ %=
M1I?AC2-'\-#P[:6@&E>7)&8)'+@JY)8$DDD' I
M9O,73)XAG.Q+N3;^I)_6O2** ,#PYX)\.>$T(T328+5V&&EY>1AZ%V);'MG%
M$_@CPQ[
M5=OVB*1HW(]#M.&_'.*ZRB@#FO"7@/0/!"W0T2VDB-UL\YI)FIP,;C
MTJ:^\$^&=2UZ+:3Z@65C<.F7RH 4Y]@!^5;]% !534M+L-8L7LM2LX+N
MU?[T4Z!U/H<'O[U;HH \XG^!?@*>8R+ID\()R4CNI-OZDUU'ASP3X;\)H1HN
MDP6KL,-+R\C#T+L2V/;.*WZ* "L76O"'A[Q%<1W&L:3:WLL:;$>9*W@01PQ($1%Z*H& !3I(TFB>*10R.I5E/<'J*=10!AZ-X-\.
M>'KQ[O2-'M;.X>,QM)"F"5)!(^F0/RK-K[QIJ^L:^?9O9/$B_;&EQ(70@X/LK;?&;_DM+?\ ;M_Z"M>_^)OAQX5\7S+<
MZOI:/= 8^T1.T;D>Y4C=^.:\V^(OPI\2^)OB.VN:^%?@[PS=+=V&CHUTIRL]P[2LI]5W$A3[@ UV5%% %>^L;74[&:R
MO8$GMIEV21.,AAZ&L_1/"N@^&WF?1M+MK)I@!(85QN SC/YFMBB@ KG[/P-X
M7T_5EU6TT.RAOE=G6=(\,&."_#?B"]%YJVC6EY9"!
M]<5\RW'P:^)MU$\,^H1RQ/\ >234693]0: .H_9I_P"09X@_Z[0_^@M7NU>7
M_!GP'K7@:RU:+65MPUU)&T?DR;^%!!SQ[UZA0 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
%44 ?_]D!

end



GRAPHIC
18
img111359907_10.jpg
GRAPHIC

begin 644 img111359907_10.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1       $     #A"
M24T$&@     #-0    8              =,   6)          $
M                 0             %B0   =,
M 0                         0     0       &YU;&P    "    !F)O
M=6YD'1)D%L:6=N96YU;0    ]%4VQI8V5(;W)Z
M06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E
M7!E96YU;0   !%%4VQI
M8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M"FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M  MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
M #A"24T$$0       0$ .$))3004       $     SA"24T$#      ,GP
M  $   "@    -0   >   &-@   ,@P 8  '_V/_M  Q!9&]B95]#30 "_^X
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M(\%2T? S)&+A7U5F9VAI:FML;6YO8G-T=79W>'EZ>WQ__:
M  P# 0 "$0,1 #\ []F3=U#J74.FVL8,/&%46,'ASSM(--S]KJV[:G>^ICF>S]'_-U_HOT:!T2M@ZOUHML8XNM
M9N:QQ+FF+/YQKJV>D[^2VR__ $G_  2(WI>/T_(Z>VE]KAZ[A^D>7#^CWC5N
MC'.]GTW>_P#ZVDIV$E3S64ORL0/M=5;N?Z.U^TD["7>S:YMNU@_.4HZA4=',
MR6?RAZ;_ /.;-3O\RI DC<&NXU4->K:257I^:,NAKGM].\ &VDR'-GC1VWVN
M5I($$ C8JVW0M=E>NX/96*=-C@\EYY^DS8UO
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M     /_A04YH='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O #P_>'!A8VME
M="!B96=I;CTB[[N_(B!I9#TB5S5-,$UP0V5H:4AZDY48WIK8SED(C\^
M"CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z;65T82\B('@Z>&UP=&L]
M(D%D;V)E(%A-4"!#;W)E(#4N,RUC,#$Q(#8V+C$T-38V,2P@,C Q,B\P,B\P
M-BTQ-#HU-CHR-R @(" @(" @(CX*(" @/')D9CI21$8@>&UL;G,Z&UL;G,Z>&UP34T](FAT=' Z+R]N&%P+S$N,"]M
M;2\B"B @(" @(" @(" @('AM;&YS.G-T179T/2)H='1P.B\O;G,N861O8F4N
M8V]M+WAA<"\Q+C O&UP+F1I9#I$.3=",D$R-S(S031%0C$Q03)$.44T1$8U-3)#,39!,3PO>&UP
M34TZ1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.DEN&UP
M+FEI9#I$0C=",D$R-S(S031%0C$Q03)$.44T1$8U-3)#,39!,3PO>&UP34TZ
M26YS=&%N8V5)1#X*(" @(" @(" @/'AM<$U-.D]R:6=I;F%L1&]C=6UE;G1)
M1#Y&-S5&03A$0T$P,#$R1#)$-S(S.45%04,U-SDQ13,R-CPO>&UP34TZ3W)I
M9VEN86Q$;V-U;65N=$E$/@H@(" @(" @(" \>&UP34TZ2&ES=&]R>3X*(" @
M(" @(" @(" @/')D9CI397$^"B @(" @(" @(" @(" @(#QR9&8Z;&D@7!E/2)297-O
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M7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA
M8W1I;VX^9&5R:79E9#PO7!E/2)297-O
M=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^8V]N=F5R
M=&5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IP
M87)A;65T97)S/F9R;VT@87!P;&EC871I;VXO=FYD+F%D;V)E+G!H;W1O7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA
M8W1I;VX^9&5R:79E9#PO&UP34TZ1&5R:79E
M9$9R;VT@&UP34TZ1&5R:79E9$9R;VT^"B @(" @(#PO&UP
M.DUE=&%D871A1&%T93X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(#PO
M'!A8VME="!E;F0](G'Q!R,R)#-"4C0U4W-T%B4F1&)RHK*S_]H
M# ,!  (1 Q$ /P#]_'")PBU<]E0F]!^X=]%*=9=V&:L>ZJU=V"&JV2:1E55"
MV]"@[!@:I8JHR#*5M0CK9-G*BYK4LML5XG+&1P,^/$@ (,.=?'E\.]/VX\/C
MGX[:W8/M'I[8E';L^D='3-(WW?VN
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M<9QYQG&,X^7*BUQ]N;[4Q^\='Z\&;J-:\W&?*TPZ%BS]M+U[K:LT
M$3L88]<#IZIJ,A!>U[5LR'$EZIJ%(+Q+B])F2WBHH37!XBU6%9!G7\=8^_QP
MNYLMA[26[6/;(;9ED-,(K=3L&2;M)>L;B2AJW0:Y;R X2-
M!1J\^"D.!Q*@FQXI3!VY2]?:R)CKSX_NH0'WBYN[HTW#(7Z_(V/,'=3T4B@Y
MLUE: 7'5-EIU@?W[;S=.1/37K9+@2FC\FQ6TX,FEJ<4KM&9CDA3YL=&+NNOW
M4P/GC/=W#ECP'/U)F,3UV[ UG;E,N+-R?M=3K-GVH>^',[BV"@M$%GKQN&RB
MZ^JN/BY57NV+L"NVO:U,5:)D&!JQG7T9VGQYS28,=@JIZU!ONPW_ &KM+3=V
MU?)UO<]74_5]XFX1;Q%R$& 6U2.QQ87,(@,A#G(\V#+UF:^T(TF)A.&I5O-M.NO1.NNOVLMPB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")P
MB<(G"*GW>^S;PIW62[V;KS.M O9(@Q0)"2M)H=>VC;1%,C
M#+L5#T!ZR%(=:3*BD"KT-,86^B>N/Y(J+^STVYWNV+N^R+V[9-I['ZV30M\3
M5[?N'K;1>N5FC30#>H5U$AFO5\HBT#Y]C*V7:H9RO6<"E4L)2!MN8=#H*1QL
MLATTTSQZUUQIP[\+=3PB<(J.][/W,=:_Y\747_B\$X17BX1.$3A$X1.$3A$X
M1.$3A$X1.$3A%$.PY.[8Y"/^QC7=9F1F8"US';Q;++7YB"'KSA+$:,#JE@8D
M1,LI0O+K\F*O#N5(PC"<8B;!WT*!#DC9E%U$V0;N)UB D_9C-9G_ &.B;A*,P8=:J]FA3@C#F'V0!*=)
MB%" U#+TU#ZEIG2=M<8MGV3L925%4]GLD;GF$,?F=W /[0^[[H.^T>\"!D-X
M+D=G*K^I,M-.;O;K&'BX3-C-545-'.:7?QF&&EHZF&2%@R()9)HI9@]'.> QD Z9.- /D-,KZ2,XUX\\<,JH?6G:NQ P':='DUZWW';R
M=U7$@ K&QUW^GC'J,[!KCT>8.V";IEAKS8V*Q\8^,&Q'W&Y,A,B)'2P_[[TW
MKRZX_%#^.O7KDH5WE2]I_?3=4$]M/> ^D3=[ZLM,(IG7.TMI ?N^[H?8CRM>
M!06D2VOC(:B#KLNK,K)AGI>)UK%!X5O<)6"S/ELNNOW33KOX_GZK:#I$QON B*@4*>&9=>D1\
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M2+A/J+O(8:0[)'[RT4=IJ9FMN%KJ&4S'-]FJ#.SWO>[)T> #[G^1))+>.  #R766N>ZU$+GW6WT
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MU&Q4M@62;8RF1G&1KG0D#Z]=Q!71^RDKN:WIK843.HZ]I[+
M^RWY'V'7.H-KZ;12?FL5YO)5^AVZ\7N=9GU>CX3[V1B42(MN,D1B%AT:X^\'
M#H?+.GEIY*GCQX]=PU6T9UUIAIQYYQ#++2%..NN+2AMIM"
M#&*]FS ,'\K]U@)DP/\ M;WGH][[O[.^(^+]?N_"_3[KU>C.%>/3GSS']JIN
MV]F[>'MSG$/:M[4X!',9;RK"TJQC2W/:.P6::.GNU[M%KGEB,T45QN-)1/DB#BPO:
MVHE8XMW@1D-()! 6WMNSU_O,:D,+6AS'C0T/]2-B*\/,6U%D88ZNIH^SGN=OIY9'T]2^F$D
M,PCW<>.WY6\\I#:<>I6,<[9I#AD$$'@00X$'4$$:$$'3PUU
M7$^>GF",8XZ'7OX@*BKW=&U+U0!W+&T"7'U16P;Y0[J*M5_K0BZ5\I3]]$="
MC:U6:Z$B6IB];+M9H>Z6&TV*5#!4I2H&Q=YYAZ"S+_2N/ID8[L9^FODLHG=Q
MH8VZTZLR=86Q0"Y&-_0(5_CRX#M:9B:%CWY4[T-JPV5)'+4_KD_)$AQ<&9"@
M@'!9M%A
MO-0K5?U;#V&D@>!;"UIJ LT<*$C](J@T6D=]W)OWYK]C'74@(>7X(?/R.,<_
M'/+^%A53]HR'M%JZUUI>L\@7^PE&UG2*)D@,P>:A#Y;B4-S9 F?"(HC9
M=S$EQW_0Z@B_.%TNJ%&HO=[215U75"VE:EVQLG5P<*U4_M"48DSG.I=AW8SV
M4J'H3;BY3;:GIK+K
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M/E!9D8.SECJ,R?>[6 K71C8[U.VA-AURF2;A90(*LPK*K5^MPFSSARMWF-%U5MT5ID5<;27!TG T7;K$9"B;.=6.'5-T[]OUUXL37('>K8TBV#K[3*C>
M1$8I#$W.L +6,AFQ[PDU$'V(5$,0HQ<5(\OC"C$:8TT0'OY]]"EI>C._Y1I7
M"+*.$3A$X1.$3A$X1.$3A$X18'<"-J@20:*_. 1621>*)D), R)5S"Y3,EY$
MAER%8@J&TM_#^A3"VW5+RM*\/-XQZ5^\+8W=IV@?[L3GMW' >\".(+'9&">8
M\U@UDE5&8/9WP-$E1'$\3122'#P[.Z62QAIR&X)#AQ'=C.&<.X:;P^I"GL(3
MAU;2%-MKE;A%:A@#M6R]JD*NQ?K$@&-ZMUCLZ5
M^'^_6229$=*,,'B
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M?MD_3!]%MAX53A%J3N.GNQKO<^=L>F$XC0/!9F4%58AE_K=%2=D:LU$+ZG]0?2=E
M[*(")S%2,C;.]I>(W,FQ'[I;4"0,:9_J75K7?K5:RD_3W0.@=2NDBB<9&O;1
MQ,-5&R2G+VMJ'R QXE:#V+R"]6D)]D+]K##F-V:)M@L6S_X]XU=,:V53DM-X
M_/FS6TL!; "BX\+5EN:+<WANJ4Z'V6T7LA,-%4V37),V;A.(X@C*R"..+SG"J&#MUKFM.A(6NJH*BAJ'4=?355OK&:24E?33T55&=='T]3'%*W@<$LP0,M)!!
M,X-O-N^?1G*L8QC/GQGQG&?GCTY^BOU^//CSC]/.G#P[5N2--0--?'PY]R\U
MT,RX50<3:"D+&#@F'\M88%2RL&,1?R^O"&,,PWGT2',O+SA+6$MYRXK.$H\Y
MSC',>2MHXI6025,,]D4C=U[8Y'-+H\@D@L<"
M':C59M%<:ZWS1S453-!)'+',T1R.:QTD;FN89(P=R0>Z 0]K@6^Z002%%.L.
MN>H=0(*LTFK8B,&G8STUDJ1(V-&7XJ7$M/1\'))#X-STN*2ZJ-EI3Z4M8>]Y
M[EKT^_&AQW
MI4EYF+%C-./R)#ZT,QX[+*=R"#P\
MO1<6< =:Y_)5/C?5C5^#E/L$'9M\IK^M+#MO:(6'!.TB:&'G-V7ZP7VZW.0,
MNE/LT.).^TCUA!@+/%1!)5ZK$C8 648C%S?QU5!^/\# ^AP5E4;3.C5U;4D&
M)89/V#I&K&DU Q O&8LE(2W4;1:]G6(=3*V'AV-\1'+TNUV*6:B8A$*[DLX_
M#A62.:&1X4%#[(KLIF15.LQ\26D--^KUN,-+D1T.
M.H3E#:Y#*5Y3EU&,D7T\(G")PBP#:M!C;3UM>=<3)K(V+=JP8K;Q"17ZS;(\
M-)6&[%Q)D5BYB#U3L##*G,+>#V(,2$$&TJBSHCS#BT\)Y>'7P6IFA>SZWQ2;
MN*57;![.+5[]>=<^RMV:9Z# *GV09;D1I$*8L&@EL8QKVHGI8R5)C.FV UA&
M^AUU6:JJ)(7%03.G//GRZ\5M*V#N37.FOV.A.P;6@>7V/<:SK:DPWF7)IJTV
MNP$QH.&EJ"-C>I,=$XG"<-%'S*\&APV'Y9BPQW08UF240J+@G77!86CM+J5R[TZA-3;&\4NHBGE1Y9J
MI'G*F+>V&+-&:&"LMI3#4&KUCMH^O%G0P8C*:ENNMCXDA,:6?KC![6(4:W#Y,542>HF[,KZH
M0@@1D?"*AMJ)3T07I4M+#*EH:;<<]VG#GG*590SEO@-KOZ=[-[:0PT]V@EB$
M<[JITE ^.DJ)9]TL9--(V%QF<&.>,2>YEY)U8W'<['?U%VHV&J)JFR5469J9
MU*8JZ(UE-'&][)'.@@D>V.&;>C:!,P!^[OL_Q>[,HTBCUVA X *O#F(K$&#!
M'KEICPT$"2!D5N)'EEI<2-%^/GK;1ZGI3K>%N.K<7G&,KSYZJSV>WV.BIK?;
MJ9D,-/3Q4X>&,;+*R!FXQ]0^-C!+,0,OD(!:VHK[A423S5$
MTU0X/DD>R-\[S(]L(D>_LXMXX:QNC6@ : *'=N];@&V7]@E$; V%KXUL?75,
MU6:/4(D%'DX=4IUSL=P^$%.E 1?$5^QJM1JOV%Y2'5OUZ6J/ P.F8^.SMEKN
MNNY== ZJT=C5^P=7$[)82T+8]+$:X,&VH%)K4\53JZ$DA*Y6ZT'IM2KM0 #
M,8@5DC!T&MMQ6)94@]EE27\(23/Y&NGC]M5Z+=U3I][V*/OUQOVR+## VB)<
MJI1B12O.U&J'6#-/-$U"7DUENU/BS4JE"V9@ Q9BH6'%G&F!, U\*3AP^
M'X'#DOJO_5FE7PT:LZ;5<:O;B6S >V1MA!YJD]ZN6D+J1W2/F #MU6LU8(C"
M5 F%8,R%9 1M+1 FZ7'+@$88Q^$3KK"FO6E#K6J=>4+5].;E,U/7E/K5&J[,
MZ8Z1FM@*F$A@P[_Y>FR4#1\=+\IW.5ON84ZKYJ\8)]UG'")PB<(G"+Q]6
M/5Z?GYQ^K_7_ "<(O+A$X1.$3A%A5O\ _'J?_P XB/\ [>?SUBXR?^5)]%@U
MG_RW_KJ?[K->>2SDX1.$6K7VGG6SLSV!J&O9'46/6:KO2DOW%ZH;TG;UN&E[
M/J==B:9].OI
MR4C^SFZ^7SKEI@O3]EZ>U5JR\E+5FPVHUK/S+_>=K52M
MW5VV&24)^/\ 9Q*;:$CQ$,;'CG%M)Q&8*<_#'7CUZ[ ^%4X14=[V?N8ZU_SX
MNHO_ !>"<(>!Z^BO%PB<(H1<3;/V9HP7%W)XK+U4F6E=?P'K&&,X\X^?,$M:00X;P(+2':@@\00="#
MP((U&G!;\9&OCG08P>_3F.]5[V%U]2W#5>:B#WI+ROEAX
ML-7%D@#^<8S\\'PY-.<)QC&$XQSA;W_3?92\R/JOT]MLN3\YN-G9'15,A.[I
M4Q1L]EKF9:W,=9!.,# QDYZJEVRO45*RWW!]-M!:HVAK+9M# RY4L3 "-VEE
MF!J[?H2&F@J*?!W=-!B!?V -O:I5A[7=O/EA*,Y4B/5+,W63<="/*D-_<.[(
MM6HS><8QY=;%1]7EK5["GV%O&_V$EQV)K93EK"^:_;/.E=C.Z7!UXMT
M9()PV*\!H)(:UK2#56[=B>P]>[%ZS$/RIQ<:-CY?("R6J,U8_/ /O_$W/[2"
MX?-22)& )$+D0I]**21L[,-E0AE4E@/M EIV.=/;J^R/M
M==+%+VTM4'T\C7LE=#24IF9+;JJ:-SFAL3G/)8M'>-D-K+6UMR@BI;W8(HS*
M^]66>"OMQ@9404LG:S0%U13U/;54#_9:NFHYFP.[65C"=U;D:W8@UK#CS]=*
M0#00K$:FC28V2W*AS(SV,Y0ZR\TK*5)\XRE6/&%(6E3;F$N(6G']&4E93UT,
M=32RQ5%/-&)(IXGA[)&DD M U TP0=0[+3[S2%J@YK@',=O-<-YKAJ"//)&0
M52H%C6^2=;WE(&V
M5B^;PCPS>W%O;4BZ;0QL;+5=MVNA:_MZH/WI=X @R89KD#):6Y.#D9'?JK5=C:I8+UUUWM2*O#R5M%PTYLRK5
MX>EV+$R0.GZ69%"8:7YCS4.-F7/EL,X=EOM1F. =."V2UQ7?JKOUO<58O)V1:>QFOZYK?03%PHU@C:7!R;W$I%T
MVC-.ZS'CH4"B5DLJK$;33=JQ&[B^P*/D:=% _>)M^J-BVB=
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M#&>1U)(.<#AC(Y<&4BAWJSMS3NRG),F(Y+Q)B:QV76+[,$-);=94T
M\88KRA[,C*U-1GWVI#K3R&LMJ*===='B((HR.D0OLX&<=79ADDK\+]D32#K77AS
MZ.5DX7J=4*<&[%-5 R90<['#K*_;Y9](F:%M7.QW6S6")2$.SZC.
ML)F94I .20DNN%54+JMIND:-[N=O*;057-823H/IZ==5>MF;(VL9^T)MK[6Q
M'\-67:5KN-C8@>Y@1O/,^.>N?)X_;"V8Y^
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M;(@X@N#!G SF"1K&-E FNW9:[5"O/T]E1@6)DT.,*#;'S>TW9W&*^,LR6B+E?Q2GIJVHCC"&7%+
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MSJ$MYC>Z\K4K*,K_ #N>X>3 ]N ?[D6#@9 W9,@'&=<#/?C"UKX(Q_V>0"0#NG&3WDJ3T_3'\GZ>>"V2YX1.$3A%A5O\8=JF
M<_HN0?\ ^V(9_P"7/6+C)X0OTYZC'6GCP6#6Z>R>-=3Y_P#R_"S7GDLY.$3A
M%J3]K72[\2U73-B5<\X"KFNB9%%GS![*]L=!'2Q*Z$*Q6:77:R#ZGUFU6O:M
MCL5CD,! M:GBWY3!.?%;!,//$IV$0]:XX_7KO1>/L>SDD_H2[SYMGDV&5+O
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M/>QI+"LJ2K_X4N,O,NI<8E1GT-R(DEIV/(::>:<;3STT$U/*^">-TTAT;FDM>TMQ86PST5&24!B+$96S(M$0@AF$_A<61 (A[H&:&RH>JR:9LU-"R!C8WU[)&L9-VP=%+#
M=J=D#V/=(^%\, #7O+IV3X#1V=CVTK+%;)+;2TE*\25#J@S5%+:9VN+F!CF2
M1U-HJ9:ACPR)KFU%2]I;&QL8@W01"AT+M[J::FW&NL$]H:A(RW9UP#16VVST
M+"U>F18'QL1M$-D['9\.3+$);C#+/ZH='9+TYK2Z2:P54YD%NNG+XXE&5Y>@$H>7$HEPY&$.LYSA64^Z6VM7UF
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M7_ZS+"?_ -X4_P#Z2J__ *TJS3&<83C.<^,8QC.?'JQY\>?
MK^CSG'^W'&>OVX_!3(Z^OEXJ.K=M_6%$=:B6R\5T*2DYRB"%D$&EV D[\\)8
M%5^/[XT3D.9QE+3$"!)><5CPVA6>>T--/4;Q@A?(&!QZU+5'$JQA>'7,V)N3?_=*3G'NUP==D$+5G
M"5K:_.6GW]CCCUJ*V",Y(,4+7U,PQ_\ 4QS:<:\S(Z:SJ_%4NHP
M_)KU"''G&8K4=QQ2S?WF)ST2+:9%-*4P+#3Z[7*_+;DR%D&\+RE.-C;J^U4'
MM374$E8V> L;).8VN#BUH+=QN^UK21_D"3@#.\/+614[Z:EI2"]SVDAH5^X#$B.PPS(?X;V&Z#)  X#[N1?M.$6N
M?O=<*Z:MG6SJW?H5.':S[(W*TN7:_7"[V?7DZL?L/"A>P:J/U1;*F8KA,+O
MC;F0UAH)+[P0/LR)3K$1CQR,J.Q'P11Q[)H#0Z#0.R&GJ"!KOV9I;LJ>UO\
MLEU78UUVL&VR,%:YUM,II9RXWTL;,I/4.B$*QJ>S5D>3>J]8-4:4.K3 T;A
MJ"3QU^/CQYGU5X^S^HBF]=&W?6(,LV%-F\UHH&G/$BX6*LM3K7V7:=RM*6$#;M ;+D]A-ZV002[V=8)#.HK 1UN[JP0@OMP0EB(+A#-:"
M[DB,"]>%!L3+K,>;4VWF>\0QZ\+)P!YZ'P_CSY>>JVN<(G"**7*/9W-BM77%
MJ$8&M"7Z_P#8BJO*S-R)D3(Q)Q/VU]Z PM8:.I-S;7^U1!@IW4QIQ38<8G/
M;(<3=L?>WF#7L]TC.6<,1%<=>VC45E)[6TH+68%F)"RFU-,1E-1X]M4K'B3<
MJ!AU2(@C8S"$I5,&85%$7EI/N""HIW$4LK.CJXZR&.DKW^_$WLZ6N?ESX68
M9!.=2^F9@]GH7Q$G!+9;M88\-%8>$E;:]X]G3W)K
M?>EA:&0W!K2Q_9SN$IGF@;"JNR*R,M-.)-%0LY*F,.I0]&E0)\9:F)P@H/DM
MMRQ9@9*;#AS'<6
MN&0X$8*Z&W7&CNE)!6T,K9::8'=(!8^-[7%CX98SA\4\3VO9+"]K71N:0>\Y
MUSP6P3A%Z7V$OH]"LYQCYX^F,_7Z^<*QE.?I^G&?U(R<<2FHP02T@Y!&,@CNR"/D>_B 15&R:"*4*TS=J=>9(^LV:H>)+E9)'.9:;J&$N!C8UKG4%62<-EI]V%SR'2Q'?F,FRKKG/N^[9MFOK$A$&U5V4I*,X4_#PXXB<*D^OUC3HUR4*),*;=CR8R_=(P\?\ %[=3&7##F!VKF^\,A2\G/G&,_C^'_KGG0+\KGA$X1.$3
MA$X1.$3A$X1.$3A$X1.$7BKSZ<^/K\O']/"+\WO6/9UMI/M'R-/O.F.MSEHV
MCOKL%7PW84AU.[.4/L79*>W+OMR#U"/N@OU]J>I+8NM5H/##9--7IX68I0*,
MIHO8G68I$A.?#XX[]?KQ\5=.\^G/U\^BOTB0V2KEM;KA
MOP1T[JEK.TDDW6M#&O\ \L9)+M[W<8SAPQD8/ U^W%JH]JX]G_9KG5W&.ADQ
M'14AG[2>9\,K:=@+V:]C%)(Z8N%,P-&93EVY+;MJ[!VQ"45W7-2UJ*D)0G)C
M95B59K(PES&<>O%&H+^0ZE-Y]*O0[M"*[G&?SFFUIRWG [.@BQVT\]07'&Y2
MQ%C0>(#II2"&G@7MC.Z=<$!;P5>TE:?]);*2TPD9$]VJ34U8)&F[;K:7PY&0
M??NK#D;NYS7FSI U9&\YV?M[8EO;>\.. ZW-1JJKHSG_ #F6HU$6/M,
MYS'.70VEQO.&I"GT>KU4U<<8+:2BIJ8ZQP!T/;5TH>"=X$'"D>H:IUY06G6Z;4*
M_7,R?7F7(%"8,6?-ROQ^=/)H9^TISN,X]67Y>$M343X[>>
M67' 2/+FM TPUARQH\&M'#O6SHK3;+:"*"AI:7>U>Z&%@DE=K[\TQ!FE?J$8\>?.?Q\?/QCY8Q]=Z
M[%K"I]=CQK:V@Z_V7!OVW7%4":@L@VD3AEHNNP[Y7]=TYIZ9L-M=3 H:/6J&
MIX^3RC V-E];'O)"VF'2=VN%$/LR>SNO>RVE;"]J_0E0ZXTW6=F"U03K>E62
MB6 -"CV?7M,VE&E)CZW&P*M7I;D&^0V"U?;6\8%FXQ.'8&!Q>/)A-$ZZ_9;(
M>$3A%1WO9^YCK7_/BZB_\7@G"'@VM"CIRW\;'<6KX.
MN[&A1_&!5F2WB.9;9:"V5MV+F)/&[""HAEB;25IZ.3N-JJ[?637W9]@-5+[UVM+GB*EO4;0 Z5I<"*:[PL!--5M
MPVI&*>J!:6R-EC66SJKLZMILE*7VNC>0T.[*I@E:8JJBJ6-':TU= \E]-41@MWXWAN01(W>8
M]KC)>,XSC&=X
MZ&&;12,LE?*3J)M>LX4NF[(K^,,E1BT^I?V680A;7VU6IBE+1-$2E+:REQQ;
M&$*<>0_R&U&RE/?V1U---/:[Y2$.MUYH\1U--(P.W6RO&#-2NR1)"_>:/\96.CJ*9W]VFFBD]XTF
M)]J=X4F[4_5.VR56UI;GB\.ODK)-K:S%6L V2B:F->(TQ5@ X'P)4]L;!>PS
M#D#$9D3Y$A\-)@2 J/DLVW>V]JN]OV?VC=2VNJ;4P4LEV9;_ &FVW"E?/*'W
M24FHA-'C_2QXBB?3EIJ)7&'LO9CU4T6R-30ON-!BFJ9)'1S6.YU\M'54E2(^
MUWK34"GJ*>]6N^0\M;27,N-JRII
MSU)3G*V\XSE/I5YPI/S\YPK&<><9\Y_H6*1KXV.WVORQA,C1B-Y+026')&#G
M(&<[I!X$+B2,%PW=P@D%N2=WN&3KPX9\=.*^S_K^CGJB<(G")PB<(G")PB<(
MG")PB<(H=["[C$=>=%[%$#H?4NO;5?YX04MAHD88K(B44^RX+TK*8S$D
M@N.F(T_(S[EA3V'G<*0A2-[&67%&SCDS>T[K0>TV->4
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M\+;5C*>\
MG09W=&-)&^\M XK776Y16NC?52,?,_?CAIZ:$!TU553NW(*:%N=7RO.,GW8P
M'O>0UCL89J?3\&L2'[[<8(8[N6RH?F6^ZHB(>D,O$\1%.U6NSI3?Q\.G5]B
M.$!!^%,^]C#FR4YM96=/?=]ZJL?*!3POD90P@,IX"XAI:PNQ+)&W#7SO)+GR
MNWGEQ+>8////OY^JW^!C&-.Y>6
M,8Q\L8QC'T\8QX^7X<<\\^_GZJKGA$X1.$3A$X1.$6M#VJ\PI4NJMLV9!V5;
MJ)%JTJG )D49>==:[HSSE\VIK>O0[=L:V;"U)N2.&!T)[*BKI ;42DF.+EF\
M-C)4YP=-%NO7'T_*>GQ^FG?UA1[['I];VC=H+5MC56W%2=QEROSZ+;3+
MEQ8$63.G26(<*&P]*ERY3J&(T6-';4](D2'W5):988:0MUUUQ26VVTJ6M6$X
MSGA%3*#WXT(6KE.N 5RZF:M;L6F>^=A5*:W"IE2J.TW=-$[[>VR#L*;7J@]>
MF7(L*9F)*)N"69]@D"8P8*>FBR+X>]><9J_6O.,^"<(KQ\(
MG")PB<(O%2<+3E.?IGQ_JSY_Y<:\L9\1GY:?MQ0ZJM6SM4GQUESMW2RX(G9;
M<5F/9:].=7#J6VP<'&<8W:=I" -_=#@06@'E[K9ZF.K=?+"Z.&\!
MK?:J61VY1WR!FOLU;C2.I R*2X &2)Q$4Q?2O>P=54NQA2\62O5VLT\%%>F.
M$(%I#6^Y3Z[>Z2: (&.6((:J,>FF&53(T5$X14$[:]:*CN^ZT X:A['-F7#>%!/.[V
M>E80 12U-0Z66T3;K>T=%4._1YIBYL4E!O%COH3;W9]HXH*3:_WTPW:AV V)]VI0VI#??J8ZO&6WBN%',RKMMPIB2&U-!71$PU<1(W7&-V_'('12LC>QS1)7.C6E3A$X1.
M$3A$X1.$3A$X1.$4?;8U=2MVZTO6HMCBWC5"V16"].MXB.2(AWR( [$<@DH;
M)41*@E![C\9U:$2Q\R-+85G#C#[;B4JP1:5="4'V0E*[D5NC:BOFX;9V>J>W
M[7+' SVV>X.S:NG<06C7"BVFP%I-V.V#51FS":35KA4G[(4FS9$:)6IP2,0P
ML-B/':=>A_":]?+X_OYK?7PBZ@K7P9QX-(,AQA5^NEVSX%XC!C3'0IQJ#.&M
M%Q3DAMQ4 DV.*$H*)L7+0LB^J>-'E($X62@Q)XTG#DCR,"9
M':DPYT&8RN-+ARXSJ5,R(LF.XXP^PZA3;K2UMK2I*LXR187G4VKLVFN7A6N*
M*JZ4\*W6ZG;55,$JRUFOLL38K(4"=5 R4$BV(I(E&9@093$5J.2(LMM(;GRT
MO$4@\)@=WA\.Y4AUIC&/:"]M?'R__+7TR^7C_P#FG;KDYX\.O7SYY43
MA$X1.$3A$X1.$3A$X1.$7S2I3<-ER0^I*&64*=>=6M+:&VF\94XXM:\X2A#:
M,96M6<^$IQG.?&,9SB@%Q  R2< #4DG@ .\G0>*_+G!H+G$-:T$NYB;2ON6$S,':4&OM?Y*5 FH=B'-KK0I.
M,9F6UO*QE0<\F,_Y25@!CHGN#7Q4
M)=(!FM=FSB4^GZ>/'C&/&,>,?+S^O./T_H\?^6O75=>)/>5Y<(G")PB<(NA+
M606$=89(+EH7)5Z&/<#"DU+CF?.<-I7!A248<5C&
MLAIWM9+V@+B "V*5XR<8&\UA;DDXXX',C7 G&,\_ GB<:XSA=XA:7$(<3ZO2
MM.%)]25(5X5CSCU(7A*T*^?S2I.%)S\LXQG&<@591Q.'/=9C8APHL'XZT^V
MG=JL/>%GGA[6ULRM;7C]5"SX1,*Q3S(^98K+5G+1\!8&9XNT'2&*_"*8!O W6B>@
MZTZ^?-81W(ZP:6J=RT#O '7#L;91OO9U@FDC,C8NRR0IZ38=N"$%EM4XI<)M
M*B)?2ZO##4.O1V8'G&1S<3*$YP3]_GUIS^*VP\(G")PB<(G"+Q4E*O\ .3A7
MRSCYXQGY9^N/GR8!X@'3'#D>(\O!%K4[%=>0MW[,Z[VE6;K>:%L&OB7FOM<+
M3[(?J^"@F7'54XY64-BQ668!7!4H.LT**=A)G"F\M2'H6??OO=-;KK)3VRHH
MIJ>"II7/(W'O8R7:6XW&V76"
MG+.VAI*NHI=^)Q=1&5[ Q@BDWWPU+1,UKH202S?:!.C*#O8&QK6X
M$GD0@-C:F.S-77R9\TMM52U34,?9Y>4E'KQ4+(F =0O*T#U&H[2IR];+;P^-
M]3;Y#50-(+HG;HK(=V,SMQ(ZRR7VE>G"7$JRK.<)SC.
M>G%=4"-.65%CS&'8TF.S)CO-N-/1Y#2'6'FG4Y0X
MVZTXE2%MK1G*5I6G*5)SE*L9QGQS\R,;(QS'M;(Q[7,?&\!S'M<""UP((+2#
M@@C!&0="GAR.0>' \_D1Z:2E-R8D&&^K*\N42Q1B5 F+<6H?#J9%?VVCY7?OZ?O9.R[;+3S6NY4
MQ!B9#)V?9MT+XX)M\-?2.W=;76QU%O>]SRQM(Z1TQWMFVCN%EBEH>QI[Q8*@
MAU5LYT8%3;WL;[1:KD!HROHWQR;N8Y"^)SXW=_J?M%$(RU5':[&*=:
MX4IH6^2G,2!(API(SC$0>>A$7WIE*.S\X7F".*2IH,SC'O:I9SK.<)1Z6'^H
M0;4?I6UL3+5<(I&4K;DXFFMM5,_(B;41U+HY+;5S[KG,@G$E/,6R.HJJ:,8;
MMY]G:&\T\MTV+FJ*Z&)CYKAL[5M#]H;.(V;]0\LA'97.WQ:[M=0@ED>'55-3
M#=?.1H/#.-=..B]N,XS],^?'/UUUZ(N>$3A$X1.$3A
M$X1.$6*7F=2>:_.!I2U:ZL7M/JC6@=$JH+-%WGO&,\F@]H=UW.M
M$K@@COH^^8/T6?U?B4!ZQ56R;8W"]%JP_=PL%3BVPK8*7(-+$"!3#APZ[^N:
MO7VZ\@OTU<*)PB<(G")PBI%K3]\%[;?A^ULZ9?[Z=NO'_/DYYQRX\N/#Z)UU
MU]5=WE1.$3A$X1.$3A$X1.$3A%QG/C'GSX^>/]><8_U_3A%6G9;\C;=KSI$*
M^\W5H#$0INHO%6YC. %)?'T9$AM7N'[.&DIV-
M.UM+ ZN>&NF<3%1Q/;O-+P#VE1(UWN[D QN-(/:2EK2 W><.6NIDO-8+#3OW
M:*,,FOT[2"YU,\;T-J9C)$E<<.JB<;E"UW$U$95C84./!B18D9AF.Q%89CL,
MLM-LM,M,MI;;:::;2E#3;:4X2AM"<)0G&$IQC&,>?CM(][=WV;VGN[PWO>(#?=SG4D ::DA?K7CAV-==
MTXTU.N,+V<_?%$X1.$3A%&>P!K,R34UNRB;&5VP9%SB 9,#4J9=CS5.84V.G
M1FU.>$8RE]:?>H3Y0E:4*4G.@O-.V5]O/;5D+C<:5A]GJZ^!KVN<\EKV4\T<
M3F$-)<)&.CPWWUETT[X6RAK*9X0W2..=3QDAI.$-
MI1A2E83C"<96M;B\X3C&,>I;F5+6KY>@]8S<
MC7<770,1.D04VG:>UMLZ[UQK^B/L'Z_BMB;H!V?4+55MDTS8A&0]3K74)3@5
MP@&FR84,M!)3H,^'#Z^'-!]^6O1\/FHT]C!;R=PZVVV6?MVHK99(FR9<>PKT
M)L[5-ZTT%*2*Z G/!==573E*I%3U178WQ/OH],EQC]GE./N62QVLZ0,*DXO7
M7%/#KK5;@>$3A%1WO9^YCK7_ #XNHO\ Q>"<*'@?)7BX53A$X1.$3A$X1>KW
M6,*RK&?3Y5ZL^,8\*_'&)XYY>G#AR[\<^
M&.@M%2KMT"3ZW:@XP^!*1W(Q$27@1B$"6ROQ^:]&E(<:5Z,X]:%>GUH(RT@EKAH6G0C0@A8]71TM?3R4E;3PU=+
M,"V:GJ(VRQ2,/_%S7 @8."UPPYA [+&&N=9JB0
M/N=%&"2/TFNE=FKCC&,4-PE[0-:&4U1EVXIPUSMJE;2&/D*F4P^\/?Q".@Y[
M3PJS5@IA.,N"+-72#<C+D1UMO+P:FEGI'[D["W(RQX
M(='(TXP^.1N6O:+?>(GR4,X>^%YBJJ9[715=',/\H*RED#
M9J>9O-DK&Y&K21JI*QGSCS^/T_D_1G_3]>8ZV:YX1,_/&CJ;M6,
METPRL;8XL9Z(+M@QB+]K0H[V,^]'S&I;,D<> R5?^_5VP0R(25\G%0T2D-26
M^;ONS-MOL);61M$P88HJH10R/B8X>\Q\4[)(*B!YQVE+412T[B&O;$V0;ZK'
M2P3Q5=)--15M.YKZ>LI97P5$3VN#FD21EN\-YH)8\.8[ R,@$:Q]V[*W-U-1
M6:B6-/RJ_.,,. 5#99*2/E5H;,@N&_L*0Y8X5@!/8BJ9AR*C8';&.%K)-RJG
M9XD5"QP_X1M)/M3L(^@MS+G/^D2UC9(*>"IJ3N4+'@5C+=5&7VB.-\19"^VW
M&2<4SY(WT%4R)QCA[&;;&R5T4D^U%N@I[_(PQF\T%L@GIKT]QTEKK:XL@I+A
M2.(J7UM$Z!M2UO9U--/(]U0=E6H]WZZV2)#M5ZQ9=-O@AQ%84_'D@+1(@/Q&
M7(Y; 4NXN=+@2T+]\T2AR"D%U*_*",CYKS]JV=VRL%\9!2T=:6W!L$;G6VO;
M[#="S=&[,VDG<'3PR-R]E13/F@S%YMU-!=9Z5DUIKF]I2WBWN
M95VJ?(#G,;4TY>RFF8"TRT54(*N#>:V6"-QPIP:M]WK]J8_8^ZPPA&[.]C+41UN*N73G]JD*K%_MNSKU2"!77X
MPV1[$5H;9*U(CVE,/#+9Y>@\SY K]#
MG*BZLX;#UD*7LEB*0 =?KXL@;.&BLMF +$!Q41V<3*$ITE;<>' @0F'Y/>?AO*CRF6Y+*
ME-J<8>0IMQ.,^4K3G&>$76V#:VL:HFWKL^P:97TZ_% CEYR8L@@?]T ]HD$(
ME:(V3$J6UD-$L,L23BA'I^&$E9$&2Q!R^ZTI."+J!^\]/&#%) AMD5$T3V0"
M;LU%:#&(I>/9P$AB;)A%A4\A$V!95P0\J6C!C @O@7B9D21Q&(=.NOB
MJ[ZT_?!NVOR__37TR^?_ -:=NOE_LY.?'D-/B<'/JBN]RHG")PB<(G")PB<(
MG")PBB';.QY-*"1H-?@,F;];9Z:WK^O//+:03L#[;KZYI!2&U.1Z[7H#,@_8
MYS6%JC"(3Z&<+G2(3#^130-GD/:$M@B;VL[P0#V8RVNE6TADA:K:6]$@W8)S3><7.YK]V>W-MM&V'M3
M43RO?55M6\8DJZVI/:5-0\9.X'O.(HP=V&G;% P".)JDGF,?3R6U4?S 89-[
M@DOLD9F=D&3E*F? 1<2U26IXAII_,GW67LO-M+4TA[U>\2UG+:580I6,Z.6F
MI_UR"4P1&0VZKF[0,Q(9(JNWEKBX'!(R[&1D9XD:+8MGG%KFC$TNY[9 S<#S
MN[CZ:LWF;O  [HR,X)&H6?X^F/Y,\ZE(DO#:1$,[1+L/KBOQ-?1&C Z%)1GTJ8*VR2_ IHEYO.<>^C3
M[ Q,1C/G$5>?"<\^[:6A>]\%N;+>:ECG,=%:VB>-C@2"V:L>8J&!PQ[S9:EI
M&0 '9&?(S,R0S,A'$,P<>;LAH^)R>[.BIMVBU5VEW-/UR6KQZO:PA#+ F+'K
MXR\G%S8DZ8MMR)8RY. '@0IQ*"W'=80.'HE-P/4[B&0(8F2%-?/MLK1M=?IK
M-4TU12VB-E25D\C_R*.FFFC;'(!'$Z1H)=&)'G)&+4T5?6.
M88)&0-IVNFF:7O:XQMW3O9:P[V"6@-. =[_(<1LB%L2HHV!&G2LSID>'&8ES
M_&3C?(+L9.,Z$\5G_/QX97W\]T3A%1KVCM[)ZWZB[%M06W'Z(:;,ZW
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M:L^^ 66$1@HPI;T'$";ANS=DC(8YN9(7'B'QD
M!IRXZ\=#=;!2W"5E;#)-;;O$P1T]VH=UM3&S.1%/&\.IZRE)TDIZN.6/=<=P
M,=[[:3[D[47+1EPUY2=\'[%2G29I#4R]ZO&UR?1K32LP2T1VPOC+8"-V*IV<
M787ZZX=KL649ALA%OR11">MYII.^HK,RYQ551:XV2LC:"*6J?+[7#,=71AT0
M[*:'<:1"_P!QSY'-#AO;[5P%_P!KZW9VNM%OVCJZRVF:HW9+A9X:":VU]"R&
MI::IT=93U%90U$=4ZE%52QR2M$>\^G?(TM*V7 S8HV.@E1)>&8&$(;?3C&,8\8YB1CXGO9(TQO8XM1$=?BQ'QMFK;T6(3CQW8)5A;LAJ7&=;SZ&GHS3O.9VCV=I]H8J>&ICI7
MLIJAE0PU%*Z&\8\1M@58I :\>96R<)QE2>>]JV\V/TFC-\M$.08ZJ8R/9& <"
M"^,IW5<>78#67RCEP  Z\,:1CHQ==E;YEM^MLFR]RD)+KWL]$ZML\LI.3)7[
M//DC?0QD9+WVBJ[)FG9VYQR%9/6G8[66RE0(D U@*;(LJ=@@+$["AS2:6L8P
M\\ G194P':HJ%><*EUHJ5CM^,X=4TK'HYV5@V]L%]?#3"=]LN,S Z.VW,,@F
MGR0,T4[7245P&2,FAK*K VT3&Z8-8
MP-966UQ) [.Y4E(\N.&AP()GC#[.<9SAU&<8SZ?/C&//Z\_+'Z_ES
MMO+O7GA:5>,I5C.,_3QGSY^7GY?Z/GP'-.,$$$
M9!!R".\$:(O+E1.$3A%PKZ9\8QGY?3.?&/\ 5_U_)PB_,IUSU+2%^U1./5"X
M;.M)FF[KV!L38^J4=6/N=:=,&9Q/M5*K%JW?V.,W1H$?HE\_;!WES5ZJ@ *W
M+9E)C:OA36(@.G&93SKRT^6G6JN=,#'B>.=<_CR/Q"_39PHHHWI3GMA:>V51
MF0&;7FV4T\ =K";D6UXJPQR<%R+*"MW@$Q)+U9TG&<>AM&H#.7X3CR7<.,IP
MIYLBIA6NKF[;*+J\@QLNWZQ#U+;]HN5;UX94 G( ]YU\#P'P^Y/GDFN^FT:=%UCL&_39U+VC2+#OFY@QE6CT
M$Q&J<_=.R=HWRNP95A+4LJ8*S=5P=F21PR ,-QJ+-,Q9+\P&=$O>[E!^?F4)
MS\AZ#'V6%]5:%====W.W@&^;KOF^C3N@^GI%NZ[$ :MKAV- D6OM:RP!:@:B
MU_K>KK'07HTB6Q)? /%W'B$E$HE(C-0F(LY]=9&/FGPQZ_;G
MQL3H;^/,&VW.0U$.VEOPEZ PR#K3F?4 =#)&[
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M+L&6&-;:1=KL*2TEQ5DVM8*]%DQ\+3Y3AJG5X[-FJTK(G$8!8W&#BK.H]S6=4>7LB-
M3;G*;?\ >YBW6\6,S5H^?5A6/02![VW"[UU?2Q-!R&Q6JWVFS4T]V(&K!:;;:H7NX@,?)>+J6LSH"^B+^9#N"F)BF[?Q'8@M[#H]:&LM
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MQ*4R/=)]]AM2U-8=RE'KPVIQ*%J1ZO5Z\=S> ) ?NXWP#_ )9U
M. 5]G/5?E.$58.S6Q-GTH&($Z_ZDV?MB,MJ#0RWUX'==0U,>%&(CQ$--GHNV
M[+7QYZ">3+EQ?@X""&&TPW\3VFVGV/>$4*]!Z]NL0OL@7VGHPEUJIMLV^"*Z
M/T=+M&NK$-H5!'ZBUS7C; &'JLT:IE='G=B"+A97A8U4-;Y O+*2XRI4YU]T
MBN7M+7T+:VO+?K@F>M-8&W,++ $CE)+X 6J"/GIPU-^Q368TS(V5)BY=B*E(
MC..ML2'ORV\V15]D=*]8$15/#F;!>RD&I 6*4Y&:G5>LC[5K6%80=I%:
MOM02D5&KUZ31 YBOCW!HP2(#$&ASA4"\5? 6 ^+)DZ^OI_*A_NUJC5P=SKK?
M!.MJ"+O,[O/U3?FW,=3J["MDQ\GMT.DD_*L<8'\N
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M?O>UL1)X!M8UNX._,[(M="]P&
M\[S-SVAM6EVM0NU,W _4K#&34, &KJFSS2OGP2=315%6<>\(6-=NLEW7^X];
M[0C29%(M@DV[ ,8SYBE1\1_&?HC*?SN8
MM315=&YK:F!\6^-Z)SAF.9F<;\,K=Z.5F=-^-[FGD=0MU;KU:[LQS[=60U/9
MZ31L=N3TYYMJ:>7LZB!XR,MEB:=1C(()DQ"\+QY3G&<>MF#GKCXCP7EPJO%:$N)RE6,9QGZXSCSC/ZLX_3CD(S\N0.? Y!&/@
MBK5LCJIJW869TUD>JFGYZO?23-6:BQV9\I.?+)OVP5@OL4HGIF4T\N=Z:FAA[.1Y<'MDJ*:1CH)I \!QGW65.<
MED[",KY-M1%MSL%0QLHMI):BTU$[X8?:FBLDI)#%)N""6M-37=F
MT;CF1U=;5PMD:0UC0&-'0U>VEK,;:V_[(6ZY7!K@)*^U3R6.*MWB"_\ 4;53
MQ347:NU(J;8VWN(TD8XASW;&^OEXD;+T]0;W*C3X4FQA?CGHI*0F7+;7B7*C
M9]4I$$8B2RO+/O8TE$%E#\9QEQ&%)4EQ?VS9.O?=]G[5*Y-M2VK:*IE.VE;4#M&4["XMB8XG=;EV7'#0-
MHVZ:C>M)4T%K[:*V)Y;=%DV2:IA4?7#T,/0RAMX4RV.N.O)?JKY5$X1.$3A$X14AUI^^#=M?YM?3/_
M 'T[=#B_0A2O'G./ICSX\Y\_3SXS\\
M_H^7_GR$X&<9\N/P'/R15AL"E[SV$NFLMY&]4-!AC<6_[+Y2 '%KF\K4_P#Q!,Y\9PC"<9\?+'CY)SG&/G]/KC&/.<_3'
M-83@9(SPSC \SEQ  '$DD8"ZHG&3\M?3@2?3)4:W/;=0I#V!Q"1))V)V,Y,B
MU0"S@I9),1O*DYG+'MK1@:*3E.<.FS+PT)%QA2I9%A./.>;O.U=ILI[":22K
MN+FE\5JM[#4W"1@XRNA&XVFIFCWI*RK?3T<;,O=/@:[RU[/7*Z1OJFLBHK9"
M[=J;OM*FK;O&4PH/ ;3GRW,%ZA'VHU!>2G"+(XA6<)XHW':/:J1T3&
MRT=M)&:.QUNX^6-V=YMQVJEGKF-.175B5C'ZZ/,X5",RH\W"L_:=D=,02)-$D@^["9?E93C
M2T/]*IZ?:J&\;]OI+:USYW1VZIKXZL2NA=#V(J'/;4.?*UY$]4V=LDK=X%H+
MW9YFY7+:*\7 UERO-54,DB-/+ V66&'V0>]%210Q.9%3T\$K(Y(X*<0TS-P"
M.GC)R=EU3H-/H\-4*IUT0 9>7AV7D;"98?G/^?*I)"7G"YA"4OYY7*FR)$E:
MLY4MY2O*L_8Z"V45NC[*CIHJ=KB7O,; V21YQETKR7/E>9SE>+&
M,B:&1M:QK6AH '(=Y.23G4DDDG4E9CS8K]IPB<(G")PB<(G"*CO=#L\=ZSPJ
M2;"3*80;*MVJ78:4?";%U:S UQ)=
M.!H9[8%#:5@A+)Q[]/G^>/U.-%A'LXV-Y0J#L&!V V'LVWWV';1[$VN[3HEF
MJ)VH.M XK,Q^*6-V"X5^UP;?.;?/XD:PN%CU<$?4X%J:P@GQSY>>/MS
M /WV,\(G"*CO>S]S'6O^?%U%_P"+P3A#P../)7BX1.$3A$X1.$3A$X1.$3A$
MX1.$3A%ZELM.9\K1A6<>?GGSY^>/3GZ9_3CY10:8\
M-1G7![QG.OCW:*)=B:-UGLIV,3L-;;:LX["?LBZU^60K%X#Y1YRC RW5V2.L
M$9I&?SOA/CU07<_FO1G4JRE6935U52-8&N
M)P1DYTMSV>M%V>R:KI *J,YBKZ622CN$)P0.SK:9T50&ZZQE[HB<%['8&* =
MJ2O;S002J-ZKVH6V(')V1J'[DY6:TK8(^'F0/5Z")F&(P*L %32E09Q>0$&&
M@Z)#A&9,(-Y7-&]'9666X35!N$#*0MA+FF-[A3E^@#61.>'M=X!Q:= -,KYS
MMC-MOLW34(LEQEO$$U6UKVU%)"ZZ0MTQ')/3QF*HI7@%KZF6"*HA<0][Y6G>
M;; !NS:PX&(7/_TR<$\,E=A#?
M[Q!!":W96]/=N1ASZ&HM-Q:XG +W$5M'-GBYP%*,'@WN[?':.B0D_P#M;6=P
M4'&;#(1&@;KUFF:K.$?9A&XA I7"U>,)3D28EP2.%*5GT^G,
M?SE7RQCS\N1]KN,;2]U#5;@."\0O>P>;V-+?FO:FVMV9JBUL-_M)>\9;&^M@
M@F=S.(9WQR' U.&Y',+.+F7U4_5)1^^3Z+-I@U"2,DG9GP4VO1$HSEIN8N21
M4Z/:SC+^6D/^K"O+V6T*SESTJU\MN;6EM//0BJ)<=V&6F[<[P&3NQN8X[P .
M<#.%M9Z^WPTLE7/64D='"T/EJ9)X6T\37.#&NDE>[LV-*[3GHOTG")PBXSCSC./QX0^'7\K\^E2TGVMT?[2:LWK;E_;
M'ZKW?V$.QJE>J="CP=<6K7P^:B<0&TH*YU
MW8L ,@6MEO9;2Z'77#TNG+/#TX?+TXCNU_09PHG")PB<(G"*D.M/WP7MK_-K
MZ9?+_P"M.W7^S_GR<_@//GU^>17>Y43A$X1.$3SCZ>?G^'"+C.<8^N<8_ESX
MX&O#7R4) XD#S3U)QGQG.,9^7R\X\_/Z?T_HY,C74:<=>'GW<"JH*V]>3L%(
MC76OWVE;+V"N9"!RE,?&Q:<"@X9Q9M@&(^,+2J!6H\EAD;'?Q[@Q;"  ([EM
MB=(>CYM)#$X/J:@'V6G 0Z101$XRZ1W^1;DLCWG'&,K0WJNJ8A36V
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MXVXPW$XQCB!6;>[7@&CHW[&V-V?[]:YS=H:N(M#HR(HV[MO9)EIE$!-2UAHZN+#W2-1^K]% IR]:US-@3W)*2$E-BQG *21\Y5B;+KZ77HY^:TK&%,%[
MG)M=A9SGQ@SG&$I3T%HV$L]L!=*Q]PE?+V\SZDY943#425,;W/DK7,/O1R7.
MHKYVNGLEN];+6NB ;!"6MIJ"DC!RR"AMM,(J"DA9INQP0
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MQ_7CZ?L*>/GY^7Z^.>1H>&1H?7BH1G3\??*Z Q[3GH!86/ES]-EFCP(Y98\'(=')*P@\]6
M%N,\_>U^2QYJ.DJ<>TTM/4X! ]H@AFP",'':,=C(T..]5+WGV8]D%6$8QGTM(;;2AO&NJ:B
M6KJ)ZF9P=)/(9';K6M:TD8W6AH&GGDGF25U5MMU-:J&DMU&'MIJ*!M/"V21T
MC@QISO.>\ESWDYSDX .&@# &F6BNU6YDM=60T$(#0=[#BP9LK42^&X-]"M$WZ=LJJT&
MR:FT!2PDFUS*'-S9Q?7- K-A6W$!WDW[N+]H+BN/K:<>86IIM:"<,^/>3
MW]:@>T"Z
M4C^[?9B\3NS>H8E/M&@^J8"NV21;838.=?HG7P5NORF7L__ .-WHS^O S^_RHNO+>TY
MZ,1!DZ6 [&:XO96+&=D1:I1[#!/6DPMI&5?"B!33S:I4A7CSGUNM,LM8
M:9:<6F8EY\C@T$Y(#6-SO2/)PQ@+CH"M==KI1V2VU
MEUKWF.CHHNUF>UN\[!U*3(Q*!'@I>2<%OQ5^AYF:S7H9N+A/CTNLR&93K#S*T+2O&592G(GIIJ.:H
MIZ_V>@EIY"QXK*REIFO;H631.GEB+H96N#XRYK) #N2QQRM?&W06O;FP7>BC
MK*)]PFWF[TE-!:KC5U,#@<%DK:*FJ8P\<3N2/: 0CQC/RSS!]LH QSS70O:T>\ZEAKZYF?
M^ELE#1U#'N\&N/ YPLP[2!S=ZFL6TE4PD!LC;/-21N<2, /N+J(#374 $ D9
MPH1*^W-ZJ(?7%"-N./X\8;78[95PT9><^?'K?#2;4EOTY_S\*^F,^<>^&WRJY=G2;.W1KCK@X=<8;?$<>+Q^7ZK?97M[#96LCC(UJ+A<+=!&T
M_P#26TD]?+O:Z@,R!C/(+%L^V9UT35Z8!S1%>0K&+/2 %HR#)'%42N+<:G#@1J.07[?;]JIPQAO-OIGR>Z!0VDF3?SDAD
MU=<:N(9X NIR"-=S)TKAU3[/"*Y>-MG=S=O:-JM%[=@J)WFV2ZR0LB
MK?77)E *BL@!W)8'5-2^,DEH;,3*X=A$WV!K(F/;%(0UK=AM#[8^RXU_/D'Q
MW:721BXSLI<)7FU[&C6>XD7LI]+JW3Q=V1*BMN?_ +09\!"1C&$-1FF\81C<
M6?92RV61U334C9KC-EU1=:U[JRYU#R '.EK9]^=V]C5K7,8.(8"3GZ#45=55
M&,U,\LPB&(8RX-A@:="VGA8&PP-()TAC8",-/N@-$V(]IAT 2A*?VW>C,^E*
M4^?OP,QY\8QCSX]?R_DYT8T 'AX_K\IS[/G#^(N>X.A_B/#AZA>W\I
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MG")PBB^ZZ6U9L6S5&XW:E"+%9:)*:F5L$0Y >K;D1NX1;8.V RJE
M$ZM)K+4@?+9ERYLAB/#>RDGPZX_/E_&;C5PZQ9@0H_%A%QTU[>
M+IU?EG ]9'2B"W%R3%D/RL0PX$*-BMOD3!::Y[UY,(?%D/,P(L\G(2R.'S94
MCZMJW83JWV"V+=;-7<:$"[[F_9037-IN05VM['KM0I]BM]YLM=A3HV
MO*O2UI%R)1LVS@>^DB\X\_%@CB$R,4XX\>'/R\^_3X9XJS-(W-4-AVNX5.L1
M;9)?I!0L$,'Y=/L0VG2# $JL&:%A+;/'QP9V<++L3!\Q@7+DY:DP)[>1U4L<(H:M6_=8TS8H35U@,$XUK.)J^49C5FRD:\&7>C12M4-BUV
MP>)DUFI2;U90I2NTZ/8BHYVQ'(BA0Q#\U^*R^159[+$=+[ WQUT9L.Q+%6C_
M %(W.6W850+UO;;149Y?/6W;D1>O++>1D!5$5,+C8-3]O<-:IJUY*B2^L=N:CW&[*E4RPQ(-GA:%WJ$L,
M[[HDCT0()MUS(%%%"R+4:2IZ%(;
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M+;Q3+;W8,ZWKVF@8K$^82*FU*CRFB>&!WI5$$UZ=D7)(%23L8*Q.DAQ.2,DM)+7;N_&\-DCL?7'4=B?MA;KZFLUG:9Q<:4RV5OI(2[%-%)$C"OL9T\2)5TE)M
M,"MY^R !_,X)[N(0A3H$2Q4T</'A/TSYQ\U?+/]/,GQ7L !H%S[I'S_-_SL^<_//S
MS_3\O]'(1G0\.BJ-#D 9&O <>]/=H\XSZ<>4X\)S\_.,9^OC/GY?^OX\8TQR
M\RI@9SC7AII\N"P':6S:+I?7]HV?LN .  \O+&O?IWH?AH.L8[]3XXYE7EY43A$X1
M?"4(Q@XT@6F^_P#@QD*40E_"Q)4^5\-#87(?^&@P69,Z:_[IM?N8D.._*DN>
MEF.RZ\M"%$6O,KNS0P"Z7WNS>36Q->?L0ZNC:'N&OKM2I86Q1HURLE7V=5RD
M4!A,DL0(6./-$(%1XCBVX\9\@T=;$D@IJ,-)_/7EY<_38UCYXQG\>$3A$X1.
M$6O;L-N#2ARVTQK84G:5'7UNV3,WQ7R#^O"S0;:I'7 ^;J<]5Z9)EL8D6#,4
M[NRNP6W(L6(V9(3A[]C
MRWJBD/A%QZ<>%" >(!\USPJG")PB<(G")PBB_;$,0XT$#=307-@BUU#Q")@O/C"_>(9=,8"_:+0&3,;G#QQIV
M2("3$*(^+F$5?'>M=F?T)7=,.C=$D(E;E@K"D/=*5:ME4JQ6D5>YEN(D;3#M
MEH6>,D#SCS1V9:IY>98<; ?G6F;DLVXL=(G[=:YX^OBG,_+K'?T.4ZZ%U:YI
M745)UBZ:9/.5,;(B+(0QJPPI"IA.<5R,KP1V>5-IL!.+=+#47PCH
M>NDVAL!UW%AM)B0J.^;<'LDZ.>_T&/(*X?"*H.T>MEGONV%6\;=@(JBV4AUZ
M-7^LSZR0GV246ZS;2)[5=DP
MR?O\_P ]=UZ_6,_'V82*R*7:211O8,/KLUHANDL%6+N
M,1(T20G#*YL(U49@UTS--!5,(*LRW@QJLE<\/#QY>G'C\EB)7H3>;;JQ=/NQ
M[15FOYV9LARZ;5MFK#5WMI,OL^MU  6VO7B<^TA7JAM$$U4H,.M,@FH=/$5\
M;5:^%%!!M3%L8*<_#KQ/7,K:! BYA0H,>?'"+ZN$5*-,]8;QJ6XQCZK[5SP>G58]K760M%5*"R
M S7MTVFQL:TN6PDJQ$F3ULBPQP"MU^6/'AA:5!)!HG"D.'7!PHG776JS#0FB
M;MK2^;7V+>[G5;&>VA"HL$K%H]1*4X&3*TA-G8?V*:&%;3:\IO-P'GQ@@XR'
MDP ,(34*]%@Q'5MO2%$_?[?#3R5I^$49;IUK%W)J39.J9A-X+'V'2K%45&8\
M=,M\2LX+DP&";<1;K"):H#[S4OX5;[*9.&:PYEQ)%'VFM37RBS-A&KW9
M*;:C>W[S.V#?<5^M%00:$5@T'6.LJD*JP\H>/R$BXU7UPS,/O&)LN5/.D''H
M"1\!M$1)#KZ8]55W'0,E]Q>O5&79]7RG]/T+7M&([%(:K=E[4%(U_> MYP7U
M'<4V>/(I$FPOB,"I\25,.XSC&"+BIZQ>K.W=N;-459DQ]FB=:#6!"(BVGA*Z#"L\5]
MYZ7E]:)>":K"EQM*&&,Q_AUX6I[+N,H(I=X1.$3A%A>QZHN^:]O5(:EMCW;A
M3K-5VB#S"I+4!VP!9PEN:Y'2XTM]$558SA$X1.$75FVS#P8NU7I(^&?<&3VPXWG9%#AT$S<[_6;G%L,53XRO1G*M41%+>JD2F467*J5=>A0)
M$C+SS\4ZZZ]%M,AQUQ8D6*Y)D3%QHS#"YDK+.94M3+26U29.8[,>/F0_E.77
MLL1V&.?OYJS?6S3,G0^L&J#)*!IV:'7B+D"R$8U]L;067(K;38PIDO8(493CP<"IJ,@S
M/PQ!5/A8=]^DF,E:][1[=C3=0(S+20J*#FA\;:N.O@&R:8:(62P7$.&ZET3L
MI4BM;I<>NM+D6"Y&;S$U\BO2RL*,"6PHV:,Q66248>3'=Y<._P"_=^RO'8>Z
M%IUMTC!]L=F:P .VRZ-ZX31M3ZXV3 N(LR7WA=ZU2M-UYS:"@@X M1B5=*P_
M;+&)&%:^%:=*O@9%JAPH4DJ4[^M>L7J5%83VIE^*EK;7M%B7C6UYVEK2EU/982PD7)]AJ>R>F][[9#;
M:+J#E91+=(>[J$6HQ:V]-9ER,E%3WWXR=:W#U4H.K
M]!ZR(UCMU&/YHDS=.S-E:CV-3B-/U=,VK:QFS==P]&W1=9G11$"0)@P	,E
M]NIQ$,P@S:77FR=_A\_+K'Q7;&_:I=3JYKZO;**%+^NN677)':(O R@&2I21
M5Q78"E]9I:F@\'+Q&047M.^U^#$$Q8[\Z8)=D$X[2_/6=[HV[<=@$
M=:M:;FZ;M W9]>L0VEB]D+DVNLD$QO),$]>.--=<\OV*^UGVAI1WJ]WH[%9U9!3(Z<%;T.A
MU3[W/^YOZ:=I/7NW4/2C/W=]==S/>O+@):&AIC$=H:B>E3RY*HK,//P^*

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end EX-101.DEF 19 hcwb-20211231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.CAL 20 hcwb-20211231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.PRE 21 hcwb-20211231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT EX-101.SCH 22 hcwb-20211231.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 100000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 100010 - Statement - Balance Sheets link:presentationLink link:calculationLink link:definitionLink 100020 - Statement - Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 100030 - Statement - Statements of Operations link:presentationLink link:calculationLink link:definitionLink 100040 - Statement - Statement of Changes in Redeemable Preferred Stock and Stockholders' (Deficit) Equity link:presentationLink link:calculationLink link:definitionLink 100050 - Statement - Statement of Cash Flows link:presentationLink link:calculationLink link:definitionLink 100060 - Disclosure - Organization and Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 100070 - Disclosure - Property and Equipment, Net link:presentationLink link:calculationLink link:definitionLink 100080 - Disclosure - Fair Value of Financial Instruments link:presentationLink link:calculationLink link:definitionLink 100090 - Disclosure - Investments link:presentationLink link:calculationLink link:definitionLink 100100 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 100110 - Disclosure - Accrued Liabilities and Other Current Liabilities link:presentationLink link:calculationLink link:definitionLink 100120 - Disclosure - License Agreement link:presentationLink link:calculationLink link:definitionLink 100130 - Disclosure - Redeemable Preferred Stock link:presentationLink link:calculationLink link:definitionLink 100140 - Disclosure - Net Loss Per Share link:presentationLink link:calculationLink link:definitionLink 100150 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 100160 - Disclosure - Employee Benefit Plan link:presentationLink link:calculationLink link:definitionLink 100170 - Disclosure - Collaborative Arrangements link:presentationLink link:calculationLink link:definitionLink 100180 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 100190 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 100200 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 100210 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 100220 - Disclosure - Property and Equipment, Net (Tables) link:presentationLink link:calculationLink link:definitionLink 100230 - Disclosure - Fair Value of Financial Instruments (Tables) link:presentationLink link:calculationLink link:definitionLink 100240 - Disclosure - Net Loss Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 100250 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 100260 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 100270 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 100280 - Disclosure - Organization and Summary of Significant Accounting Policies - Additional information (Details) link:presentationLink link:calculationLink link:definitionLink 100290 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 100300 - Disclosure - Property and Equipment, Net - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 100310 - Disclosure - Fair Value of Financial Instruments - Summary of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail) link:presentationLink link:calculationLink link:definitionLink 100320 - Disclosure - Investments - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 100330 - Disclosure - Accrued Liabilities and Other Current Liabilities - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 100340 - Disclosure - License Agreement - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 100350 - Disclosure - Redeemable Preferred Stock - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 100360 - Disclosure - Net Loss Per Share - Summary of Basic and Diluted Net Income (Loss) Per Common Share (Detail) link:presentationLink link:calculationLink link:definitionLink 100370 - Disclosure - Net Loss Per Share - Summary of Outstanding Potentially Dilutive Securities (Detail) link:presentationLink link:calculationLink link:definitionLink 100380 - Disclosure - Stock-Based Compensation - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 100390 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activities (Details) link:presentationLink link:calculationLink link:definitionLink 100400 - Disclosure - Stock-Based Compensation - Summary of Assumptions Used in Black-Scholes Model (Details) link:presentationLink link:calculationLink link:definitionLink 100410 - Disclosure - Employee Benefit Plan - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 100420 - Disclosure - Income Taxes - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 100430 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details) link:presentationLink link:calculationLink link:definitionLink 100440 - Disclosure - Income Taxes - Components of Net Deferred Taxes (Detail) link:presentationLink link:calculationLink link:definitionLink 100450 - Disclosure - Commitments and Contingencies - Summary of the Future Minimum Payments for the Lease and Sublease Agreements (Detail) link:presentationLink link:calculationLink link:definitionLink 100460 - Disclosure - Commitments and Contingencies - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 100470 - Disclosure - Subsequent Events - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 23 hcwb-20211231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum Expected volatility, Maximum Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 Incentive stock option period Segment Reporting Policy Policy [Text Block] Segment Reporting Temporary Equity Shares Authorized Temporary Equity, Shares Authorized Operating Leases, Rent Expense, Total Lease And Rental Expense Operating leases, rent expense Auditor Location Auditor Location Deferred Revenue Deferred Revenue, Total Operating Expenses [Abstract] Operating expenses: Investments, Fair Value Disclosure, Total Investments Fair Value Disclosure Investment (Note 4) Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation By Asset Class [Domain] Asset Class Loss from operations Operating Income Loss Loss from operations Federal and state NOL taxable income offset percentage Federal and State NOL Taxable Income Offset Percentage Federal and State NOL taxable income offset percentage. Disclosure of Cumulative Dividends on Preferred Stock Cumulative Dividends On Preferred Stock Policy Policy [Text Block] Cumulative Dividends on Preferred Stock Entity Emerging Growth Company Entity Emerging Growth Company Investment Policy [Text Block] Investments Effective Income Tax Rate Reconciliation Permanent Differences Effective Income Tax Rate Reconciliation Permanent Differences Permanent book/tax differences Income Tax Disclosure [Abstract] Increase (Decrease) in Prepaid Expense and Other Assets, Total Increase Decrease In Prepaid Deferred Expense And Other Assets Prepaid expenses and other assets Payments to Acquire Property, Plant, and Equipment, Total Payments To Acquire Property Plant And Equipment Purchases of property and equipment Common Stock, Value, Issued, Ending Balance Common Stock, Value, Issued, Beginning Balance Common Stock, Value, Issued, Total Common Stock Value Common Stock, Value, Issued Entity Address State Or Province Entity Address, State or Province Denominator Denominator [Abstract] Denominator: Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Risk-free interest rate Stockholders Equity Reverse Stock Split Stockholders' Equity, Reverse Stock Split Receivables, Net, Current, Total Receivables Net Current Accounts receivable, net Inventory, Raw Materials and Supplies, Gross, Total Inventory Raw Materials And Supplies Manufacturing materials Liabilities [Abstract] Liabilities Stockholders Equity Note Redeemable Preferred Stock Issue Policy Redeemable Preferred Stock Class Of Stock [Domain] Class of Stock Convertible Preferred Stock Shares Issued Upon Conversion Common stock issued to holder of redeemable preferred stock Temporary Equity Accretion To Redemption Value Redeemable Preferred Stock , Accretion of issuance costs , Value Weighted Average Number Of Share Outstanding Basic And Diluted Weighted average shares outstanding, basic and diluted Defined Contribution Plan, Employer Discretionary Contribution Amount Defined Contribution Plan Employer Discretionary Contribution Amount General And Administrative Expense [Member] General and Administrative Expense Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 Weighted average remaining contracted terms (in years) exercisable Series B Preferred Stock [Member] Series B Preferred Stock Short-term Debt, Total Short Term Borrowings Short-term debt Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table] City Area Code City Area Code Contractual Obligation, Total Contractual Obligation Contractual obligation Sba paycheck protection loan. Sba Paycheck Protection Loan [Member] SBA Paycheck Protection Loan [Member] Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block] Summary of Assumptions Used in Black-Scholes Model Net deferred tax assets Deferred Tax Assets, Gross Temporary Equity Par Or Stated Value Per Share Temporary Equity, Par or Stated Value Per Share Revenues [Abstract] Revenues: Accounts Payable and Accrued Liabilities, Current, Total Accounts Payable And Accrued Liabilities Current Accounts payable and accrued liabilities, current Weighted average exercise price, options forfeited or cancelled Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price Commitments and contingencies (Note 14) Commitments And Contingencies Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block] Summary of Outstanding Potentially Dilutive Securities Income Tax Reconciliation Tax Credits Research R&D credit payroll Stock Issued During Period Shares New Issues Issuance of common stock upon initial public offering, net of issuance cost, Shares Reconciliation of Effective Income Tax Rate [Table] Reconciliation Of Effective Income Tax Rate [Table] Reconciliation Of Effective Income Tax Rate [Table] Basis Of Accounting Policy Policy [Text Block] Basis of Presentation Accretion of issuance costs Amortization of Debt Issuance Costs and Discounts Amortization of Debt Issuance Costs and Discounts, Total Issuance of Series C Redeemable Preferred Stock, net of issuance costs value Stock Issued During Period, Value, Other Stock Issued During Period Value Conversion Of Convertible Securities Conversion of Redeemable Preferred Stock, with forfeited cumulative dividends, Value Income Statement [Abstract] Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] U S Government Backed Securities. U S Government Backed Securities [Member] U S Government Backed Securities Net Cash Provided By Used In Investing Activities Net cash used in investing activities Tax Credit Carryforward [Axis] Tax Credit Carryforward Temporary Equity [Abstract] Redeemable preferred stock: Tax Credit Carryforward Name [Domain] Tax Credit Carryforward, Name General and Administrative Expense, Total General And Administrative Expense General and administrative Property, Plant and Equipment, Net, Ending Balance Property, Plant and Equipment, Net, Beginning Balance Property Plant And Equipment Net Property and equipment, net Property and equipment, net Common Stock, Shares, Issued, Total Common Stock Shares Issued Common Stock, Shares, Issued Proceeds from Issuance of preferred stock, Proceeds From Issuance Of Preferred Stock [Member] Proceeds From Issuance Of Preferred Stock Net deferred tax liabilities Deferred Tax Liabilities, Gross Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Option Granted Weighted Average Remaining Contractual Terms. Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Option Granted Weighted Average Remaining Contractual Terms Weighted average remaining contracted terms (in years) granted Security Exchange Name Security Exchange Name Range [Member] Statistical Measurement Furniture And Fixtures [Member] Furniture and fixtures Net Income Loss Available To Common Stockholders Basic Net loss available for distribution to common stockholders Redeemable Noncontrolling Interest Equity Preferred Carrying Amount Total redeemable preferred stock Disclosure License Agreement Details [Line Items] Disclosure - License Agreement - (Details) [Line Items] Subsequent Event Type [Domain] Subsequent Event Type Document Period End Date Document Period End Date Series C Preferred Stock [Member] Series C Preferred Stock Income Statement Location [Axis] Income Statement Location Investment Type Categorization [Member] Investments Common Stock Shares Authorized Common Stock, Shares Authorized Cumulative Dividends Cumulative Dividends Use Of Estimates Use of Estimates Deferred Tax Assets, Deferred Income, Total Deferred revenue Deferred Tax Assets, Deferred Income Cash And Cash Equivalents Period Increase Decrease Net changes in cash and cash equivalents Statement Class Of Stock [Axis] Class of Stock License agreement. License Agreement [Abstract] Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount Potentially diluted securities Conversion Of Stock By Unique Description [Axis] Stock Conversion Description Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost Stock option compensation Percentage of Cumulative Dividends Percentage of Cumulative Dividends Percentage of cumulative dividends Accounts Payable And Accrued Liabilities Disclosure [Text Block] Accrued Liabilities and Other Current Liabilities Income tax expense/(benefit) Effective Income Tax Rate Continuing Operations Income tax expense/(benefit) Schedule Of Fair Value Assets And Liabilities Measured On Recurring Basis Table [Text Block] Summary of assets and liabilities that are measured at fair value on a recurring basis Entity Address Address Line2 Entity Address, Address Line Two Taxable income utilization percentage under CARES Act Taxable income utilization percentage under CARES Act Taxable income utilization percentage under CARES Act. Current Fiscal Year End Date Current Fiscal Year End Date License agreement text block. License Agreement [Text Block] License Agreement Schedule Of Property Subject To Or Available For Operating Lease [Text Block] Summary of the future minimum payments for the lease and sublease agreements Series B redeemable preferred stock member. Series B Redeemable Preferred Stock [Member] Series B Redeemable preferred stock [Member] Security Owned And Sold Not Yet Purchased At Fair Value [Axis] Security Owned and Sold, Not yet Purchased, at Fair Value Income Tax Examination [Line Items] Property, Plant and Equipment [Member] Property, Plant and Equipment [Member] Amount considered for performance obligations. Amount Considered For Performance Obligations Amount Considered For Performance Obligations Assets [Abstract] ASSETS Leaseholds And Leasehold Improvements [Member] Leasehold improvements Wugen license. Wugen License [Member] Wugen License Stock Issued During Period Shares Conversion Of Convertible Securities Conversion of Redeemable Preferred Stock, with forfeited cumulative dividends, Shares Valuation allowance available to reduce deferred tax asset Valuation Allowance Available To Reduce Deferred Tax Asset Valuation allowance available to reduce deferred tax asset. Assets Fair Value Disclosure [Abstract] Assets: Accounts Payable, Current, Total Accounts Payable Current Accounts payable Common Stock Par Or Stated Value Per Share Common Stock, Par or Stated Value Per Share Issuance of Series C Redeemable Preferred Stock net of issuance costs share Stock Issued During Period, Shares, Other Effective Income Tax Rate Reconciliation Tax Credits Research R&D credit payroll State [Member] State and Local Jurisdiction [Member] Shares Outstanding Ending balance (in shares) Beginning balance (in shares) Revenue Recognition Deferred Revenue Deferred Revenue Investments [Member] Research And Development Expense Policy Research and Development Expenses Operating Leased Assets [Line Items] Operating Leased Assets [Line Items] Net Loss Before Taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Total Document Type Document Type Federal [Member] Domestic Tax Authority [Member] Accounts Payable And Other Accrued Liabilities Current Accrued liabilities and other current liabilities Assets Current Total current assets Treasury notes member. Treasury Notes [Member] Treasury notes [Member] Accounts Payable And Accrued Liabilities [Member] Accounts Payable and Accrued Liabilities [Member] Share Based Compensation Option And Incentive Plans Policy Stock-based Compensation Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 Weighted average remaining contracted terms (in years) outstanding, beginning of period Income Tax Expense (Benefit), Total Income Tax Expense Benefit Income tax expense/(benefit) Other Assets Current Other current assets Earnings Per Share, Basic and Diluted, Total Earnings Per Share Basic And Diluted Net loss per share, basic and diluted Operating Leases Future Minimum Payments Due [Abstract] Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis] Antidilutive Securities Payments To Acquire Longterm Investments Purchases of long-term investments PPP loan forgiveness Debt Instrument Decrease Forgiveness Debt instrument, decrease, forgiveness Issuance Costs of Initial Public Offering. Issuance Costs Of Initial Public Offering Issuance costs of initial public offering Plan Name [Axis] Plan Name Less: Accumulated depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total Accumulated Depreciation Depletion And Amortization Property Plant And Equipment Less: Accumulated depreciation and amortization Income Tax Reconciliation Tax Credits Other Other Number of options, forfeited or cancelled Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table] Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table] Conversion Of Stock Name [Domain] Conversion of Stock, Name Revenue Recognition Policy [Text Block] Revenue Recognition Operating Expenses Total operating expenses Deferred Tax Assets Gross [Abstract] Deferred tax assets: I P O [Member] IPO Share based compensation arrangement by share based payment award options outstanding weighted average remaining contractual term 3. Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Remaining Contractual Term3 Weighted average remaining contracted terms (in years) outstanding, ending of period Preferred Stock [Member] Preferred Stock [Member] Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price Weighted average exercise price outstanding, end of period Weighted average exercise price outstanding, beginning of period Net Cash Provided By Used In Operating Activities [Abstract] Cash flows from operating activities: Earnings Per Share [Abstract] Net Income Loss Net loss Net loss Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block] Schedule of Effective Income Tax Rate Reconciliation Share Based Compensation Shares Authorized Under Stock Option Plans Percentage of Exercise Price Range. Share Based Compensation Shares Authorized Under Stock Option Plans Percentage Of Exercise Price Range Exercise Price for incentive stock Concentration Risk Credit Risk Concentration of Credit Risk and Other Risks and Uncertainties Research and Development Expense [Member] Research And Development Expense [Member] Document Fiscal Period Focus Document Fiscal Period Focus Accounting Policies [Abstract] Entity Address Address Line1 Entity Address, Address Line One Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value Intrinsic value exercised Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number Number of options outstanding, ending of period Number of options outstanding, beginning of period Liabilities Current Total current liabilities Commitments Disclosure [Text Block] Commitments and Contingencies Payables and accruals. Payables And Accruals [Table] Payables And Accruals [Table] Entity Address Postal Zip Code Entity Address, Postal Zip Code Title Of Individual [Axis] Title of Individual Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum Risk-free interest rate, Maximum Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value Aggregate intrinsic value outstanding, end of period Aggregate intrinsic value outstanding, beginning of period Subsequent Event [Table] Revenues, Total Revenues Total revenues Proceeds From Issuance Initial Public Offering Proceeds from initial public offering Residual Approach [Member] Residual approach member. Residual Approach [Member] Disclosure of tax credit receivable. Tax Credit Receivable Policy Policy [Text Block] Tax Credit Receivable Income Tax Reconciliation State And Local Income Taxes State tax benefit net of federal benefit Series A redeemable preferred stock member. Series A Redeemable Preferred Stock [Member] Series A Redeemable preferred stock [Member] Net Cash Provided By Used In Operating Activities Net cash used in operating activities Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Option Forfeited or Cancelled Weighted Average Remaining Contractual Terms. Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Option Forfeited Or Cancelled Weighted Average Remaining Contractual Terms Weighted average remaining contracted terms (in years) forfeited or cancelled License agreement description. License Agreement Description License Agreement Description Statement Equity Components [Axis] Equity Components Proceeds from Issuance of Long-term Debt, Total Proceeds From Issuance Of Long Term Debt Proceeds from PPP loan Assets Current [Abstract] Current assets: Entity Registrant Name Entity Registrant Name Series A Preferred Stock [Member] Series A Preferred Stock Entity Interactive Data Current Entity Interactive Data Current Entity Address City Or Town Entity Address, City or Town Term of agreements renewal periods Term Of Agreements Renewal Period Term Of Agreements Renewal Period Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum Expected volatility, Minimum Effective Income Tax Rate Reconciliation, Tax Credit, Percent, Total Effective Income Tax Rate Reconciliation Tax Credits R&D credit carryforward Unrealized Gain/Loss Deferred Tax Asset Unrealized Gain Loss Deferred tax asset unrealized gain (loss). Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 Expected term (years) Trading Symbol Trading Symbol Related Party Transactions Disclosure [Text Block] Related Party Transactions Net Cash Provided By Used In Investing Activities [Abstract] Cash flows from investing activities: Other noncurrent assets within property and equipment Property, Plant and Equipment, Other, Net Property, Plant and Equipment, Other, Net, Total Cumulative dividends on redeemable preferred stock , Value Preferred Stock Amount Of Preferred Dividends In Arrears Cumulative dividends on redeemable preferred stock , Value Short Term Investments [Member] Short-term Investments Local Phone Number Local Phone Number Stockholders Equity Ending balance , Value Beginning balance , Value Total stockholders’ (deficit) equity Subsequent Event Type [Axis] Subsequent Event Type Conversion of series B redeemable preferred stock member. Conversion Of Series B Redeemable Preferred Stock [Member] Conversion Of Series B Redeemable Preferred Stock [Member] Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance Change in valuation allowance Unrealized gain (loss) on investments, net Unrealized gain (loss) on investments, net Unrealized Gain (Loss) on Investments Unrealized Gain (Loss) on Investments, Total Preferred Stock, Shares Issued, Total Preferred Stock Shares Issued Preferred stock, shares issued Assets Fair Value Disclosure Assets Two thousand twenty one plan member. Two Thousand Twenty One Plan [Member] 2021 Plan [Member] Investments Investment [Text Block] Common Class A [Member] Common Class A Range [Axis] Statistical Measurement Entity Small Business Entity Small Business Consideration received on fair value of securities. Consideration Received On Fair Value Of Securities Consideration received on fair value of securities Deferred Tax Assets, Tax Credit Carryforwards, Total Deferred Tax Assets Tax Credit Carryforwards R&D credit Organization Consolidation And Presentation Of Financial Statements [Abstract] Share Price Share Price Fair Value Measurements Fair Value Hierarchy [Domain] Fair Value Hierarchy and NAV Short Term Debt Type [Domain] Short-term Debt, Type APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value Stock-based compensation , Value Cumulative losses to conduct product research and development in future. Cumulative Losses To Conduct Product Research And Development In Future Research and development Schedule Of Deferred Tax Assets And Liabilities Table [Text Block] Schedule of Deferred Tax Assets and Liabilities Impairment Or Disposal Of Long Lived Assets Policy [Text Block] Impairment of Long-Lived Assets Research Member Research [Member] Deferred revenue, Current Deferred Revenue, Current, Total Deferred Revenue Current Property Plant And Equipment Useful Life Property, Plant and Equipment, Useful Life Business Acquisition [Axis] Balance Sheet Location [Axis] Balance Sheet Location Fair Value Measurement Policy Policy [Text Block] Fair Value Measurements Additional Paid in Capital, Ending Balance Additional Paid in Capital, Beginning Balance Additional Paid in Capital, Total Additional Paid In Capital Additional paid-in capital Reconciliation of Effective Income Tax Rate [Line Items] Reconciliation Of Effective Income Tax Rate [Line Items] Reconciliation Of Effective Income Tax Rate [Line Items] Net Investment Income [Line Items] Deferred Charges Policy [Text Block] Deferred Offering Costs Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price Weighted average exercise price, options granted Sale Of Stock Name Of Transaction [Domain] Sale of Stock Income Tax Reconciliation Other Adjustments Other adjustments Temporary Equity Shares Issued Temporary Equity, Shares Issued Equity [Abstract] Selling price. Selling Price Selling Price Agreement. Agreement [Domain] Agreement Plan Name [Domain] Plan Name Class Of Stock [Line Items] Class Of Stock [Line Items] federal payroll taxes Federal Payroll Taxes Federal Payroll Taxes Income Tax Authority [Axis] Depreciation, Total Depreciation Depreciation and amortization expense Prepaid Expense, Current, Total Prepaid Expense Current Prepaid expenses Increase in valuation allowance Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount Effective Income Tax Rate Reconciliation State And Local Income Taxes State tax benefit net of federal benefit Schedule Of Operating Leased Assets [Table] Schedule Of Operating Leased Assets [Table] Stock Issued During Period Value New Issues Issuance of common stock upon initial public offering, net of issuance cost, Value Deferred offering costs reclassified to stockholders equity Deferred Offering Costs Reclassified To Stockholders Equity Deferred offering costs reclassified to stockholders equity. Accrued expenses, current Accrued expenses current. Accrued Expenses Current Accrued expenses current Stock-based compensation Share-based Payment Arrangement, Noncash Expense Share-based Payment Arrangement, Noncash Expense, Total Effective Income Tax Rate Reconciliation, Tax Credit, Amount, Total Income Tax Reconciliation Tax Credits R&D credit carryforward Schedule Of Share Based Compensation Stock Options Activity Table [Text Block] Summary of Stock Option Activities Security Owned And Sold Not Yet Purchased Fair Value Security Name [Domain] Security Owned and Sold, Not yet Purchased Fair Value, Security Name Other General Expense Other expense Payables and accruals. Payables And Accruals [Line Items] Payables And Accruals [Line Items] Property Plant And Equipment Type [Domain] Long-Lived Tangible Asset Related Party Transactions [Abstract] Income Tax Examination [Table] Deferred offering costs Deferred Offering Costs Effective Income Tax Rate Reconciliation Other Adjustments Other adjustments Interest and Other Income, Total Interest And Other Income Interest and other income, net Disclosure of Patent costs. Patent Costs Policy Policy [Text Block] Patent Costs Accrued expenses current. Accrued Expenses Current [Member] Accrued Expenses Current [Member] Accrued expenses current. Accrued Expenses Current [Domain] Accrued Expenses Current Proceeds From Issuance Of Preferred Stock And Preference Stock Proceeds from the sale of Series C Preferred Stock License agreement table. License Agreement [Table] License Agreement [Table] Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number Number of options exercisable, end of period Net cash provided by financing activities Net Cash Provided By Used In Financing Activities Commitments And Contingencies Disclosure [Abstract] Assets Total assets Fair Value Inputs Level2 [Member] Level 2 [Member] Employee Benefits And Share Based Compensation Employee Benefits and Share-based Compensation Stock Issued During Period Shares Stock Options Exercised Issuance of Class A Common Stock upon exercise of stock options , Shares Number of options exercised Statement [Line Items] Statement [Line Items] Liabilities And Stockholders Equity Total liabilities, redeemable preferred stock and stockholders’ (deficit) equity Document Quarterly Report Document Quarterly Report Deferred tax assets operating loss carryforwards federal state and local. Deferred Tax Assets Operating Loss Carryforwards Federal State And Local Federal net operating loss carryforward Balance Sheet Location [Domain] Balance Sheet Location Property Plant And Equipment [Abstract] Statement Of Cash Flows [Abstract] Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price Fair value underlying common stock Additional Paid-in Capital [Member] Investment Income [Table] Income tax reconciliation permanent differences. Income Tax Reconciliation Permanent Differences Permanent book/tax differences Security12b Title Title of 12(b) Security Net operating loss carryforwards Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration Series of Individually Immaterial Business Acquisitions [Member] Series of Individually Immaterial Business Acquisitions [Member] Fair Value Inputs Level3 [Member] Level 3 [Member] Entity Well Known Seasoned Issuer Entity Well-known Seasoned Issuer Treasury bills member. Treasury Bills [Member] Treasury bills [Member] Fair Value By Fair Value Hierarchy Level [Axis] Fair Value Hierarchy and NAV 6% cumulative dividends on redeemable preferred stock , Value Dividends, Preferred Stock Dividends, Preferred Stock, Total Increase (Decrease) in Accounts Payable and Accrued Liabilities, Total Increase Decrease In Accounts Payable And Accrued Liabilities Accounts payable and other liabilities Schedule of Property and Equipment, Net Property Plant And Equipment [Text Block] Fair Value Inputs Level1 [Member] Level 1 [Member] Net deferred tax asset (after valuation allowance) Deferred Tax Assets, Net Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance Change in valuation allowance Forfeiture of cumulative dividends, upon conversion. Forfeiture Of Cumulative Dividends Forfeiture of cumulative dividends, upon conversion of Preferred Stock Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross Number of options granted Entity Current Reporting Status Entity Current Reporting Status Collaborative Arrangement Disclosure [Text Block] Collaborative Arrangements Investment Type [Axis] Investment Type Noncash Investing And Financing Items [Abstract] Non-cash operating, investing and financing activities: Entity Voluntary Filers Entity Voluntary Filers Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum Risk-free interest rate, Minimum Deferred Tax Assets Operating Loss Carryforwards State And Local State net operating loss carryforward Money Market Funds [Member] Money Market Funds [Member] Future minimum payments Operating Leases, Future Minimum Payments Due, Future Minimum Sublease Rentals Documents Incorporated by Reference Documents Incorporated By Reference [Text Block] Earnings Per Share Policy [Text Block] Net Loss Per Share Compensation And Retirement Disclosure [Abstract] In-kind payment for license fee In-kind payment for license fee. In Kind Payment For License Fee Auditor Firm Id Auditor Firm ID Income Statement Location [Domain] Income Statement Location Investments [Abstract] Consideration received in shares of common stock Consideration Received In Shares Of Common Stock. Consideration received in shares of common stock. Business Acquisition Percentage Of Voting Interests Acquired Voting Power percentage Auditor Name Auditor Name Office Equipment [Member] Office Equipment Preferred Stock Shares Authorized Preferred stock, shares authorized Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price Weighted average exercise price, options exercisable Other Research And Development Expense Research and development expense Minimum [Member] Minimum Stock Issued During Period Value Stock Options Exercised Issuance of Class A Common Stock upon exercise of stock options , Value Cumulative dividends earned and accrued in the reporting period. Cumulative Dividends Earned And Accrued In The Reporting Period Cumulative dividends earned, accrued and forfeited in the reporting period Redeemable preferred stock. Redeemable Preferred Stocks [Member] Redeemable Preferred Stocks Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Granted, Number of Shares Document Annual Report Document Annual Report Deferred Tax Assets, Valuation Allowance, Total Deferred Tax Assets Valuation Allowance Less: valuation allowance Project [Member] Project Net Cash Provided By Used In Financing Activities [Abstract] Cash flows from financing activities: Entity Filer Category Entity Filer Category Income Tax Policy [Text Block] Income Taxes Carryforwards expiration term Operating Loss Carryforwards, Expiration Term Operating loss carryforwards, expiration term. Document Fiscal Year Focus Document Fiscal Year Focus Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table] Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table] Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value Weighted average fair value of options granted Retained Earnings (Accumulated Deficit), Ending Balance Retained Earnings (Accumulated Deficit), Beginning Balance Retained Earnings (Accumulated Deficit), Total Retained Earnings Accumulated Deficit Accumulated deficit Income Tax Disclosure [Text Block] Income Taxes Entity Ex Transition Period Entity Ex Transition Period Fair Value Disclosures [Abstract] Redeemable preferred stock. Redeemable Preferred Stock [Text Block] Redeemable Preferred Stock Property Plant And Equipment Disclosure [Text Block] Property and Equipment, Net U S Treasury Notes Securities [Member] US Treasury Notes Securities Maximum [Member] Maximum Entity Central Index Key Entity Central Index Key Revenue recognized Revenue From Contract With Customer Including Assessed Tax Revenues Business Acquisition, Acquiree [Domain] Payables And Accruals [Abstract] Series C redeemable preferred stock member. Series C Redeemable Preferred Stock [Member] Series C Redeemable preferred stock [Member] Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate Benefit at statutory rate Cash And Cash Equivalents Policy [Text Block] Cash and Cash Equivalents Entity Tax Identification Number Entity Tax Identification Number Equity Component [Domain] Equity Component Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Expected volatility Gain (Loss) on Extinguishment of Debt, Total Gains Losses On Extinguishment Of Debt Gain on extinguishment of debt Property Plant And Equipment Policy [Text Block] Property and Equipment, Net Income Tax Authority [Domain] Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 Unrecognized compensation, weighted average amortization period Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Unvested Options Grants In Period. Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Unvested Options Grants In Period Granted, Number of shares unvested Deferred Tax Liabilities [Abstract] Deferred tax liabilities: Common stock abstract. Common Stock [Abstract] Common stock: Increase Decrease In Accounts Receivable Accounts receivable Subsequent Events [Abstract] Subsequent Event [Line Items] Statement [Table] Statement [Table] Capitalized Costs Of Unproved Properties Excluded From Amortization By Property Or Project [Axis] Project Entity File Number Entity File Number Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Option Exercised Weighted Average Remaining Contractual Terms Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Option Exercised Weighted Average Remaining Contractual Terms Weighted average remaining contracted terms (in years) exercised Retained Earnings [Member] Adjustments Noncash Items To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Two thousand nineteen plan member Two Thousand Nineteen Plan [Member] 2019 Plan [Member] Liabilities Current [Abstract] Current liabilities: Disclosure Of Compensation Related Costs Share Based Payments [Text Block] Stock-Based Compensation Deferred tax liability depreciable assets. Deferred Tax Liability Depreciable Assets Depreciable assets Subsequent Event [Member] Subsequent Event [Member] Common Stock [Member] Common Stock [Member] Property, Plant and Equipment, Gross, Ending Balance Property, Plant and Equipment, Gross, Beginning Balance Property, Plant and Equipment, Gross, Total Property Plant And Equipment Gross Property, plant and equipment, gross Business Description And Accounting Policies [Text Block] Organization and Summary of Significant Accounting Policies Entity Public Float Entity Public Float Cover [Abstract] Fair Value By Asset Class [Axis] Asset Class Federal research and development credits carryforwards Deferred Tax Assets, Tax Credit Carryforwards, Research Statement Of Stockholders Equity [Abstract] Schedule Of Property Plant And Equipment [Table] Schedule Of Property Plant And Equipment [Table] Common Stock Options. Common Stock Options [Member] Common Stock Options Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] Property Plant And Equipment By Type [Axis] Long-Lived Tangible Asset Document Transition Report Document Transition Report Short Term Debt Type [Axis] Short-term Debt, Type Preferred Stock Dividends and Other Adjustments, Total Preferred Stock Dividends And Other Adjustments Less: cumulative preferred dividends earned in the period, net of forfeitures 6% cumulative dividends on redeemable preferred stock , Value Research and Development Expense, Total Research And Development Expense Research and development Numerator. Numerator [Abstract] Numerator: Operating Leases Future Minimum Payments Remainder Of Fiscal Year 2022 (remaining 3 months) Conversion of series A redeemable preferred stock member. Conversion Of Series A Redeemable Preferred Stock [Member] Conversion Of Series A Redeemable Preferred Stock [Member] US Treasury Bill Securities US Treasury Bill Securities [Member] Statement Of Financial Position [Abstract] Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate Dividend yield Depreciation, Depletion and Amortization, Total Depreciation Depletion And Amortization Depreciation and amortization Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities Accrued expenses Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate Benefit at statutory rate Stockholders Equity [Abstract] Stockholders’ (deficit) equity: Conversion of series C redeemable preferred stock member. Conversion Of Series C Redeemable Preferred Stock [Member] Conversion Of Series C Redeemable Preferred Stock [Member] Long-term Investments, Total Long Term Investments Investments Schedule Of Earnings Per Share Basic And Diluted Table [Text Block] Summary of Basic and Diluted Net Income (Loss) Per Common Share Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price Weighted average exercise price, options exercised Payments To Acquire Short Term Investments Purchases of short-term investments Increase Decrease In Operating Capital [Abstract] Changes in operating assets and liabilities: Entity Common Stock Shares Outstanding Entity Common Stock, Shares Outstanding Common Stock Capital Shares Reserved For Future Issuance Common stock reserved Deferred Rent Asset Net Current Deferred rent Entity Shell Company Entity Shell Company Class B convertible common stock member. Class B Convertible Common Stock [Member] Class B Convertible Common Stock [Member] Liabilities And Stockholders Equity [Abstract] LIABILITIES, REDEEMABLE PREFERRED STOCK AND STOCKHOLDERS’ (DEFICIT) EQUITY Pension And Other Postretirement Benefits Disclosure [Text Block] Employee Benefit Plans Icfr Auditor Attestation Flag ICFR Auditor Attestation Flag Entity Incorporation State Country Code Entity Incorporation, State or Country Code Agreement. Agreement [Axis] Agreement Earnings Per Share [Text Block] Net Loss Per Share Amendment Flag Amendment Flag Collaborative Arrangement Accounting Policy Collaborative Arrangements Schedule Of Stock By Class [Table] Schedule Of Stock By Class [Table] Accrued expenses current. Accrued Expenses Current [Axis] Accrued Expenses Current Short-term investments Short-term Investments, Total Short Term Investments Cash and Cash Equivalents, at Carrying Value, Total Cash And Cash Equivalents At Carrying Value Cash and cash equivalents at the end of the period Cash and cash equivalents at the beginning of the period Cash and cash equivalents New Accounting Pronouncements Policy Policy [Text Block] Recently Issued Accounting Pronouncements Title Of Individual With Relationship To Entity [Domain] Title of Individual Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options Unrecognized employee stock based compensation Laboratory equipment. Laboratory Equipment [Member] Laboratory equipment Income tax provisions under CARES Act Income Tax Provision under CARES Act Description Income tax provision under CARES Act description. Subsequent Events [Text Block] Subsequent Events Effective Income Tax Rate Reconciliation Tax Credits Other Other Legal Fees Legal fees Antidilutive Securities Name [Domain] Antidilutive Securities, Name Property Plant And Equipment [Line Items] Property Plant And Equipment [Line Items] Other assets Other Assets, Noncurrent Other Assets, Noncurrent, Total Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 Aggregate intrinsic value options exercisable Subsidiary Sale Of Stock [Axis] Sale of Stock Fair Value Disclosures [Text Block] Fair Value of Financial Instruments Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options Unrecognized employee stock based compensation cost Proceeds From Issuance Of Common Stock Proceeds from issuance of common stock XML 24 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Document and Entity Information - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2021
Mar. 22, 2022
Jul. 22, 2021
Cover [Abstract]      
Document Type 10-K    
Amendment Flag false    
Document Annual Report true    
Document Transition Report false    
Document Period End Date Dec. 31, 2021    
Document Fiscal Year Focus 2021    
Document Fiscal Period Focus FY    
Entity Registrant Name HCW Biologics Inc.    
Entity Central Index Key 0001828673    
Current Fiscal Year End Date --12-31    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 82-5024477    
Entity Address, Address Line One 2929 N    
Entity Address, Address Line Two Commerce Parkway    
Entity Address, City or Town Miramar    
Entity Address, State or Province FL    
Entity Address, Postal Zip Code 33025    
City Area Code 954    
Local Phone Number 842–2024    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company true    
Entity Ex Transition Period true    
Entity Shell Company false    
Title of 12(b) Security Common Stock    
Trading Symbol HCWB    
Security Exchange Name NASDAQ    
Entity Common Stock, Shares Outstanding   35,779,489  
Entity File Number 001-40591    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
ICFR Auditor Attestation Flag false    
Entity Public Float     $ 91.4
Auditor Firm ID 248    
Auditor Name GRANT THORNTON LLP    
Auditor Location Miami, FL    
Documents Incorporated by Reference

Part III incorporates by reference certain information from the registrant’s definitive proxy statement (the “Proxy Statement”) relating to its 2022 Annual Meeting of Stockholders. The Proxy Statement will be filed with the United States Securities and Exchange Commission within 120 days after the end of the fiscal year to which this report relates.

   

XML 25 R2.htm IDEA: XBRL DOCUMENT v3.22.1
Balance Sheets - USD ($)
Dec. 31, 2021
Dec. 31, 2020
Current assets:    
Cash and cash equivalents $ 11,730,677 $ 8,455,834
Short-term investments 24,983,520
Accounts receivable, net 133,000 2,500,000
Prepaid expenses 2,196,557 538,306
Other current assets 1,436,617 654,528
Total current assets 40,480,371 12,148,668
Investments 11,522,050 1,599,750
Property and equipment, net 1,119,090 1,615,426
Other assets 393,318 34,242
Total assets 53,514,829 15,398,086
Current liabilities:    
Accounts payable 223,664 155,343
Accrued liabilities and other current liabilities 2,097,925 845,741
Total current liabilities 2,321,589 1,001,084
Commitments and contingencies (Note 14)
Redeemable preferred stock:    
Total redeemable preferred stock 31,115,399
Common stock:    
Additional paid-in capital 81,827,006 0
Accumulated deficit (30,637,343) (16,718,877)
Total stockholders’ (deficit) equity 51,193,240 (16,718,397)
Total liabilities, redeemable preferred stock and stockholders’ (deficit) equity 53,514,829 15,398,086
Series A Redeemable preferred stock [Member]    
Redeemable preferred stock:    
Total redeemable preferred stock 6,140,792
Series B Redeemable preferred stock [Member]    
Redeemable preferred stock:    
Total redeemable preferred stock 13,680,306
Series C Redeemable preferred stock [Member]    
Redeemable preferred stock:    
Total redeemable preferred stock 11,294,301
Class B Convertible Common Stock [Member]    
Common stock:    
Common Stock, Value, Issued 0 429
Common Stock [Member]    
Common stock:    
Common Stock, Value, Issued $ 3,577
XML 26 R3.htm IDEA: XBRL DOCUMENT v3.22.1
Balance Sheets (Parenthetical) - $ / shares
Dec. 31, 2021
Dec. 31, 2020
Common Stock, Shares, Issued   4,285,714
Series A Redeemable preferred stock [Member]    
Temporary Equity, Par or Stated Value Per Share $ 0.0001 $ 0.0001
Temporary Equity, Shares Authorized 0 14,738,948
Temporary Equity, Shares Issued 0 6,316,691
Series B Redeemable preferred stock [Member]    
Temporary Equity, Par or Stated Value Per Share $ 0.0001 $ 0.0001
Temporary Equity, Shares Authorized 0 28,029,449
Temporary Equity, Shares Issued 0 12,012,617
Series C Redeemable preferred stock [Member]    
Temporary Equity, Par or Stated Value Per Share $ 0.0001 $ 0.0001
Temporary Equity, Shares Authorized 0 18,181,818
Temporary Equity, Shares Issued 0 5,439,112
Class B Convertible Common Stock [Member]    
Common Stock, Par or Stated Value Per Share $ 0.0001 $ 0.0001
Common Stock, Shares Authorized 0 10,000,000
Common Stock, Shares, Issued 0  
Common Stock [Member]    
Common Stock, Par or Stated Value Per Share $ 0.0001 $ 0.0001
Common Stock, Shares Authorized 250,000,000 74,950,215
Common Stock, Shares, Issued 35,768,264 507,680
XML 27 R4.htm IDEA: XBRL DOCUMENT v3.22.1
Statements of Operations - USD ($)
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Revenues:    
Revenues $ 4,099,750
Revenues, Total 4,099,750
Operating expenses:    
Research and development 8,173,624 7,255,227
General and administrative 5,194,210 2,669,048
Total operating expenses 13,367,834 9,924,275
Loss from operations (13,367,834) (5,824,525)
Interest and other income, net 505,366 22,324
Net loss (12,862,468) (5,802,201)
Less: cumulative preferred dividends earned in the period, net of forfeitures 0 (1,271,675)
Net loss available for distribution to common stockholders $ (12,862,468) $ (7,073,876)
Net loss per share, basic and diluted $ (0.69) $ (1.49)
Weighted average shares outstanding, basic and diluted 18,770,935 4,739,285
XML 28 R5.htm IDEA: XBRL DOCUMENT v3.22.1
Statement of Changes in Redeemable Preferred Stock and Stockholders' (Deficit) Equity - USD ($)
Total
Common Stock [Member]
Preferred Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Series A Redeemable preferred stock [Member]
Series A Redeemable preferred stock [Member]
Conversion Of Series A Redeemable Preferred Stock [Member]
Series A Redeemable preferred stock [Member]
Common Stock [Member]
Series A Redeemable preferred stock [Member]
Preferred Stock [Member]
Series A Redeemable preferred stock [Member]
Additional Paid-in Capital [Member]
Series A Redeemable preferred stock [Member]
Retained Earnings [Member]
Series B Redeemable preferred stock [Member]
Series B Redeemable preferred stock [Member]
Conversion Of Series B Redeemable Preferred Stock [Member]
Series B Redeemable preferred stock [Member]
Common Stock [Member]
Series B Redeemable preferred stock [Member]
Preferred Stock [Member]
Series B Redeemable preferred stock [Member]
Additional Paid-in Capital [Member]
Series B Redeemable preferred stock [Member]
Retained Earnings [Member]
Series C Redeemable preferred stock [Member]
Series C Redeemable preferred stock [Member]
Conversion Of Series C Redeemable Preferred Stock [Member]
Series C Redeemable preferred stock [Member]
Common Stock [Member]
Series C Redeemable preferred stock [Member]
Preferred Stock [Member]
Series C Redeemable preferred stock [Member]
Additional Paid-in Capital [Member]
Series C Redeemable preferred stock [Member]
Retained Earnings [Member]
Beginning balance , Value at Dec. 31, 2019 $ (9,676,294) $ 472     $ (9,676,766)       $ 5,792,302           $ 12,883,859                
Beginning balance (in shares) at Dec. 31, 2019   4,717,542 0     6,316,691           12,012,617                      
Issuance of Class A Common Stock upon exercise of stock options , Value $ 9,903 $ 8   $ 9,895                                      
Issuance of Class A Common Stock upon exercise of stock options , Shares 75,851 75,851                                          
Issuance of Series C Redeemable Preferred Stock net of issuance costs share                                   5,439,112          
Issuance of Series C Redeemable Preferred Stock, net of issuance costs value                                   $ 11,144,520          
6% cumulative dividends on redeemable preferred stock , Value $ (1,271,676)     (31,766) (1,239,910)                                    
Cumulative dividends on redeemable preferred stock , Value           $ 348,490           $ 776,804           146,381          
Redeemable Preferred Stock , Accretion of issuance costs , Value                       $ 19,643           $ 3,400          
Stock-based compensation , Value 21,871     21,871                                      
Net loss (5,802,201)       (5,802,201)                                    
Ending balance , Value at Dec. 31, 2020 (16,718,397) $ 480     (16,718,877)       $ 6,140,792           $ 13,680,306           $ 11,294,301    
Ending balance (in shares) at Dec. 31, 2020   4,793,393       6,316,691           12,012,617           5,439,112          
Issuance of Class A Common Stock upon exercise of stock options , Value $ 29,537 $ 20   29,517                                      
Issuance of Class A Common Stock upon exercise of stock options , Shares 206,455 206,455                                          
6% cumulative dividends on redeemable preferred stock , Value $ (960,019)     (33,053) (926,966)                                    
Cumulative dividends on redeemable preferred stock , Value           $ 193,050           $ 430,319           $ 336,651          
Redeemable Preferred Stock , Accretion of issuance costs , Value                       7,858           20,398          
Issuance of common stock upon initial public offering, net of issuance cost, Value 49,239,947 $ 700   49,239,247                                      
Issuance of common stock upon initial public offering, net of issuance cost, Shares   7,000,000                                          
Conversion of Redeemable Preferred Stock, with forfeited cumulative dividends, Value           $ (6,333,842) $ 6,333,841 $ 632   $ 6,353,474 $ (20,265) $ (14,118,483) $ 14,118,483 $ 1,201   $ 14,170,312 $ (53,030) $ (11,651,350) $ 11,651,341 $ 544   $ 11,706,534 $ (55,737)
Conversion of Redeemable Preferred Stock, with forfeited cumulative dividends, Shares           (6,316,691)   6,316,691       (12,012,617)   12,012,613       (5,439,112)   5,439,112      
Stock-based compensation , Value 360,975     360,975                                      
Net loss (12,862,468)       (12,862,468)                                    
Ending balance , Value at Dec. 31, 2021 $ 51,193,240 $ 3,577   $ 81,827,006 $ (30,637,343)                                    
Ending balance (in shares) at Dec. 31, 2021   35,768,264                                          
XML 29 R6.htm IDEA: XBRL DOCUMENT v3.22.1
Statement of Cash Flows - USD ($)
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Cash flows from operating activities:    
Net loss $ (12,862,468) $ (5,802,201)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 543,598 572,868
Stock-based compensation 360,975 21,875
Gain on extinguishment of debt (567,311) 0
Unrealized gain (loss) on investments, net 65,832 0
Accretion of issuance costs 28,256 23,043
Changes in operating assets and liabilities:    
Accounts receivable 2,367,000 (2,500,000)
Prepaid expenses and other assets (2,799,415) (2,118,264)
Accounts payable and other liabilities 1,887,816 (628,647)
Net cash used in operating activities (10,975,717) (10,431,326)
Cash flows from investing activities:    
Purchases of property and equipment (47,263) (186,682)
Purchases of short-term investments (24,987,277) 0
Purchases of long-term investments (9,984,375) 0
Net cash used in investing activities (35,018,915) (186,682)
Cash flows from financing activities:    
Proceeds from PPP loan 0 563,590
Proceeds from the sale of Series C Preferred Stock 0 11,144,520
Proceeds from initial public offering 56,000,000 0
Issuance costs of initial public offering (6,760,053) 0
Proceeds from issuance of common stock 29,528 9,898
Net cash provided by financing activities 49,269,475 11,718,008
Net changes in cash and cash equivalents 3,274,843 1,100,000
Cash and cash equivalents at the beginning of the period 8,455,834 7,355,834
Cash and cash equivalents at the end of the period 11,730,677 8,455,834
Non-cash operating, investing and financing activities:    
In-kind payment for license fee 0 1,599,750
Cumulative dividends earned, accrued and forfeited in the reporting period 0 1,271,676
Forfeiture of cumulative dividends, upon conversion of Preferred Stock 2,822,081 0
PPP loan forgiveness $ 567,311
XML 30 R7.htm IDEA: XBRL DOCUMENT v3.22.1
Organization and Summary of Significant Accounting Policies
12 Months Ended
Dec. 31, 2021
Organization Consolidation And Presentation Of Financial Statements [Abstract]  
Organization and Summary of Significant Accounting Policies

1. Organization and Summary of Significant Accounting Policies

Organization

HCW Biologics Inc. (the “Company”) is a biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The Company believes age-related low-grade chronic inflammation, or “inflammaging,” is a significant contributing factor to several chronic diseases and conditions, such as cancer, cardiovascular disease, diabetes, neurodegenerative diseases, and autoimmune diseases. The Company is located in Miramar, Florida and was incorporated in the state of Delaware in April 2018.

Reverse Stock Split

In June 2021, the Company’s board of directors and stockholders approved an amendment to the Company’s certificate of incorporation to effect a 3-for-7 reverse stock split for all issued and outstanding common stock, redeemable preferred stock, and stock options, that was effective on June 25, 2021 (the “Reverse Stock Split”). The number of authorized shares and the par values of the common stock and redeemable preferred stock were not adjusted as a result of the Reverse Stock Split. The accompanying financial statements and notes to the financial statements give retroactive effect to the Reverse Stock Split for all periods presented.

Liquidity

On December 24, 2020, the Company entered into the Exclusive Worldwide License Agreement with Wugen Inc. (“Wugen License”). As a result of this transaction, as of December 31, 2020 and 2021, the Company holds a minority interest in Wugen Inc. (“Wugen”) carried at $1.6 million, the fair value on the effective date of the Wugen License. The underlying shares of common stock are not currently traded on any public market and thus have limited marketability. These shares were subject to an anti-dilution provision based on the terms of a subsequent financing. During the year ended December 31, 2021, the Company received additional shares in Wugen under the terms of the anti-dilution provision for no additional consideration. The Company deemed the additional shares to be a similar instrument to those shares already held. During the year ended December 31, 2021, the Company received cash payments of $2.5 million for amounts due under the terms of the Wugen License.

As of December 31, 2021, the Company had not generated any revenue from sales of its immunotherapeutic products. In the course of its development activities, the Company has sustained operating losses and expects to continue to incur operating losses for the foreseeable future. Since inception, substantially all the Company’s activities have consisted of research, development, establishing large-scale cGMP production for clinical trials, and raising capital.

On July 19, 2021, the Company’s registration statement on Form S-1 for its initial public offering (“IPO”) was declared effective by the Securities and Exchange Commission (the “SEC”). On July 22, 2021, the Company closed its IPO with the sale of 7,000,000 shares of common stock, at a public offering price of $8.00 per share, resulting in net proceeds of approximately $49.2 million, after deducting underwriting discounts and commissions and estimated offering expenses paid by the Company. The IPO met the provisions for mandatory conversion of all shares of redeemable preferred stock according to the designations for these securities. As a result of the conversion, the Company issued 23,768,416 shares of common stock to the former holders of redeemable preferred stock. In addition, as a result of conditions for mandatory conversion, the Company was relieved of its obligation to pay $2.8 million in cumulative dividends that were accrued and unpaid on the conversion date.

As of December 31, 2021, the Company had cash and cash equivalents of $11.7 million, short-term investments of $25.0 million held in U.S. government-backed securities, and long-term investments of $9.9 million held in U.S. government-backed securities. Since inception to December 31, 2021, the Company incurred cumulative net losses of $27.9 million. Management expects to incur additional losses in the future to conduct product research and development and recognizes the need to raise additional capital to fully implement its business plan. The Company intends to raise capital through the issuance of additional equity financing, sale of investment, and/or third-party collaboration funding. However, if such financing is not available at adequate levels, the Company will need to reevaluate its operating plan and may be required to delay the development of some of its products. The Company expects its cash and cash equivalents and current and long-term investments in government-backed securities as of December 31, 2021 will be sufficient to fund operating expenses and capital expenditure requirements for a period of at least one year from the issuance date of the financial statements.

Summary of Significant Accounting Policies

Basis of Presentation

The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”).

Segment Reporting

The Company has one operating segment. The Company’s chief operating decision maker, its Chief Executive Officer, reviews financial information on an aggregate basis for allocating capital and evaluating performance.

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts in the financial statements and accompanying notes. Management must apply significant judgment in this process. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ from estimates.

Cash and Cash Equivalents

Cash and cash equivalents consist of demand deposits at financial institutions, money market funds, and highly liquid investments with original maturities of three months or less.

Fair Value Measurements

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 820, Fair Value Measurement (“Topic 820”), establishes a fair value hierarchy for those instruments measured at fair value that distinguishes between fair value measurements based on market data (observable inputs) and those based on the Company’s own assumptions (unobservable inputs). This hierarchy maximizes the use of observable inputs and minimizes the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows:

Level 1: Observable inputs such as quoted prices in active markets;

Level 2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and

Level 3: Unobservable inputs in which there is little or no market data, which require a reporting entity to develop its own assumptions.

Fair value measurements are classified based on the lowest level of input that is significant to the measurement. The Company’s assessment of the significance of a particular input to the fair value measurement requires judgment, which may affect the valuation of the assets and liabilities and their placement within the fair value hierarchy levels. The determination of the fair values, as disclosed in Note 3, takes into account the market for the Company’s financial assets and liabilities, the associated credit risk, and other factors as required. The Company considers active markets as those in which transactions for the assets or liabilities occur in sufficient frequency and volume to provide pricing information on an ongoing basis.

Concentration of Credit Risk and Other Risks and Uncertainties

Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash, cash equivalents, accounts receivable, and investments. The Company’s cash and cash equivalents are deposited in accounts with financial institutions that management believes are of high credit quality. Such deposits may, at times, exceed federally insured limits. The Company has not experienced any losses on its deposits of cash and cash equivalents.

Currently all of the Company's revenues are derived from the Wugen License. For the year ended December 31, 2020, the Company recognized revenues of $4.1 million, $1.6 million of which was consideration received in the form of shares of Wugen common stock. These shares have limited marketability, and there was no public market on which to trade these shares as of December 31, 2021. As of December 31, 2021, the Company received cash payments of $1.8 million for the sale of research and clinical-grade material, which are currently recognized as deferred revenue on the accompanying balance sheet since the criteria for revenue recognition have not been met.

The Company is highly dependent on a third-party manufacturer to supply drug products for its research and development activities of its programs, including clinical and non-clinical studies. These programs could be adversely affected by a significant interruption in the supply of such drug products. The Company has no off-balance sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts or other hedging arrangements.

Property and Equipment, Net

Property and equipment is stated at cost less accumulated depreciation. Depreciation expense is calculated using the straight-line method over the estimated useful lives of the assets, which range from 3 to 7 years. Leasehold improvements are amortized on a straight-line method over the shorter of the useful life of the leasehold improvement or the term of the lease. Upon retirement or sale of the assets, the cost and related accumulated depreciation and amortization are removed from the accompanying balance sheets and the resulting gain or loss is recorded to the statements of operations. Repairs and maintenance are expensed as incurred.

Impairment of Long-Lived Assets

Long-lived assets are reviewed for indications of possible impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. Recoverability is measured by comparison of the carrying amounts to the future undiscounted cash flows attributable to these assets. An impairment loss is recognized to the extent an asset group is not recoverable, and the carrying amount exceeds the projected discounted future cash flows arising from these assets. Impairment losses, if any, are recognized in earnings. There were no impairment losses for any of the periods presented.

Redeemable Preferred Stock

The Company applied the relevant accounting standards to distinguish liabilities from equity when we assessed the classification and measurement of preferred stock. Preferred Stock subject to mandatory redemptions was considered a liability and measured at fair value. Conditionally redeemable preferred stock issued by the Company was considered mezzanine or temporary equity and presented outside of the equity section of the accompanying balance sheet as of December 31, 2020.

Cumulative Dividends on Preferred Stock

The Company’s Preferred Stock earned a 6% cumulative dividend that compounded annually, whether or not declared by the Board of Directors. The Company considered cumulative dividends a legal obligation that should be recognized and accrued until such time as the dividends were declared and paid or liquidation occurred.

If Preferred Stock was classified as other than equity, this obligation was presented within Redeemable preferred stock. If Preferred Stock was included within equity, this obligation was treated as a long-term liability and presented within other liabilities in the accompanying balance sheet. As of December 31, 2020, all of the Company’s Preferred Stock was classified as other than equity, or mezzanine equity. Holders of Preferred Stock earned cumulative dividends beginning on June 7, 2019, with the original issuance of Series B Preferred Stock. During the year ended December 31, 2020, Series A Preferred Stock earned $348,490 in cumulative dividends; Series B Preferred Stock earned $776,804 in cumulative dividends; and Series C Preferred Stock earned $146,381 in cumulative dividends. Upon the IPO, all of the Company’s preferred stock converted to common stock. At that time, Series A Preferred Stock forfeited $753,307 of cumulative dividends; Series B Preferred Stock forfeited $1,550,403 of cumulative dividends; and Series C Preferred Stock forfeited $518,371 of cumulative dividends. No dividends were declared as of the conversion date.

Collaborative Arrangements

When the Company enters into collaboration arrangements, it assesses whether the arrangements fall within the scope of FASB issued ASC 808, Collaborative Arrangements, based on whether the arrangements involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. If the payments from the collaboration partner to the Company represent consideration from a customer, such as license fees and contract research and development activities, the Company accounts for those payments within the scope of FASB issued ASC 606, Revenue from Contracts with Customers (“Topic 606”). However, if the Company concludes that the payments are not from a customer, for certain activities and associated payments, such as for certain collaborative research, development, manufacturing, and commercial activities, these payments are presented as a reduction of research and development expense or general and administrative expense, based on where the Company presents the underlying expense.

Revenue Recognition

The Company recognizes revenue when its customer or collaborator obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services.

To determine revenue recognition for arrangements that are within the scope of Topic 606, it performs the following five steps:

i.
identify the contract(s) with a customer;
ii.
identify the performance obligations in the contract;
iii.
determine the transaction price;
iv.
allocate the transaction price to the performance obligations within the contract; and
v.
recognize revenue when (or as) the entity satisfies a performance obligation.

 

At contract inception, once the contract is determined to be within the scope of Topic 606 and it is probable of collection, the Company assesses the goods or services promised within the contract to determine whether each promised good or service is a performance obligation. The promised goods or services in the Company’s arrangements may consist of a license, or options to license, the Company’s intellectual property and research, development, and manufacturing services. The Company may provide options to additional items in such arrangements, which are accounted for as separate contracts when the customer elects to exercise such options, unless the option provides a material right to the customer. Performance obligations are promises in a contract to transfer a distinct good or service to the customer that (i) the customer can benefit from on its own or together with other readily available resources, and (ii) is separately identifiable from other promises in the contract. Goods or services that are not individually distinct performance obligations are combined with other promised goods or services until such combined group of promises meet the requirements of a performance obligation.

The Company determines the transaction price based on the amount of consideration the Company expects to receive for transferring the promised goods or services in the contract. Consideration may be fixed, variable, or a combination of both. At contract inception for arrangements that include variable consideration, the Company estimates the probability and extent of consideration it expects to receive under the contract utilizing either the most likely amount method or expected amount method, whichever best estimates the amount expected to be received. The Company then considers any constraints on the variable consideration and includes in the transaction price variable consideration to the extent it is deemed probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved.

The Company then allocates the transaction price to each performance obligation based on the relative standalone selling price and recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) control is transferred to the customer and the performance obligation is satisfied. For performance obligations which consist of licenses and other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.

The Company records amounts as accounts receivable when the right to consideration is deemed unconditional. When consideration is received, or such consideration is unconditionally due, from a customer prior to transferring goods or services to the customer under the terms of a contract, a contract liability is recorded as deferred revenue.

Deferred Revenue

Deferred revenue represents amounts billed, or in certain cases, yet to be billed to the Company’s customer for which the related revenues have not been recognized because one or more of the revenue recognition criteria have not been met. The current portion of deferred revenue represents the amount to be recognized within one year from the balance sheet date based on the estimated performance period of the underlying performance obligations. As December 31, 2021, current deferred revenue includes amounts of $1.8 million allocated to the development supply agreement performance obligation under the Wugen License that is included within Accrued liabilities and other current liabilities.

Investments

The Company holds a minority interest in Wugen. The underlying shares of common stock are not traded on any public market and thus have limited marketability. The Company does not have significant influence over the operating and financial policies of Wugen. As a result, the Company has accounted for this investment using the measurement alternative whereby the investment is recorded at cost less impairment, adjusted for observable price changes in orderly transactions for an identical or similar investment of the same investee. No impairment was recognized during the years ended December 31, 2020 and 2021.

The Company invests net proceeds of its IPO in bills and notes issued by the U.S. Treasury which are classified as trading securities. As of December 31, 2021, the Company holds, $25.0 million in U.S. Treasury bills included in Short-term investments and $9.9 million in U.S. Treasury notes included in Investments in the accompanying balance sheet.

Research and Development Expenses

Research and development costs are expensed as incurred and include salaries, benefits, and other operating costs such as outside services, supplies and allocated overhead expenses. The Company may perform research and development for its own proprietary drug candidates and technology development or for certain third parties under collaborative arrangements. For its proprietary drug candidates and its internal technology development programs, the Company invests its own funds without reimbursement from a third party. Where the Company performs research and development activities under a clinical joint development collaboration, it records the partner’s share of collaboration expenses as a reduction to research and development expense when reimbursement amounts are due under the agreement.

The Company records an accrued expense for the estimated costs of its contract manufacturing activities performed by third parties. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to vendors. Payments under the contracts include upfront payments and milestone payments, which depend on factors such as the achievement of the completion of certain stages of the manufacturing process. For purposes of recognizing expense, the Company assesses whether the production process is sufficiently defined to be considered the delivery of a good, as evidenced by predictive or contractually required yields in the production process, or the delivery of a service, where processes and yields are developing and less certain. If the Company considers the process to be the delivery of a good, the Company recognizes the expense when the drug product is delivered, or otherwise bears risk of loss. If the Company considers the process to be the delivery of a service, the expense is recognized based on its best estimates of the contract manufacturer’s progress towards completion of the stages in the contracts. The Company recognizes and amortizes upfront payments and accrues for liabilities based on the specific terms of each arrangement. Arrangements may provide upfront payments for certain stages of the arrangement and milestone payments for the completion of certain stages, and, accordingly, may result in advance payments for services that have not been completed or goods not delivered and liabilities for stages where the contract manufacturer is entitled to a milestone payment.

Advance payments for goods or services that will be used or rendered for future research and development activities are capitalized as prepaid expenses and recognized as expense as the related goods are delivered or the related services are performed. The Company bases its estimates on the best information available at the time. However, additional information may become available to the Company which may allow it to make a more accurate estimate in future periods. In this event, the Company may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain. Such increases or decreases in cost are generally considered to be changes in estimates and will be reflected in research and development expenses in the period identified.

Patent Costs

Costs related to filing and pursuing patent applications are recorded as general and administrative expenses in the accompanying statements of operations, and expensed as incurred since recoverability of such expenditures is uncertain.

Stock-based Compensation

The Company measures its stock-based awards granted to employees and directors based on the estimated fair value of the option on the date of grant (grant date fair value) and recognizes compensation expense over the vesting period. Compensation expense is recorded as either research and development or general and administrative expenses in the accompanying statements of operations based on the function to which the related services are provided. Forfeitures are accounted for as they occur. The Company has granted options with service-based and performance-based vesting conditions.

The Company uses the Black-Scholes option pricing model for the respective grant to determine the grant date fair value. The Black-Scholes option pricing model requires the input of highly subjective assumptions. These variables include, but are not limited to, its stock price volatility over the term of the awards and actual and projected employee stock option exercise behaviors. Management will continue to assess the assumptions and methodologies used to calculate the estimated grant date fair value of stock-based compensation. Circumstances may change and additional data may become available over time, which could result in changes to these assumptions and methodologies and materially impact the Company’s grant date fair value determination.

For stock option grants with service-based vesting, stock-based compensation expense represents the portion of the grant date fair value of employee stock option grants recognized over the requisite service period of the awards on a straight-line basis, net of estimated forfeitures. For options that vest upon the achievement of performance milestones, the Company estimates fair value at the date of grant and compensation expense is recognized using the accelerated attribution method when it is determined that the performance criteria is probable of being met.

Deferred Offering Costs

The Company defers offering costs consisting of legal, accounting and other fees and costs directly attributable to its IPO. The deferred offering costs will be offset against the proceeds received upon the completion of the IPO. Deferred offering costs will be recorded under other non-current assets on the accompanying balance sheets. In the event the IPO is terminated, all of the deferred offering costs will be expensed within the Company’s statements of operations. As of December 31, 2020, there were no deferred offering costs recorded on the accompanying balance sheets. As of December 31, 2021, deferred offering costs related to underwriting discounts and commissions and offering expenses of $6.8 million were offset against IPO proceeds upon the consummation of the IPO.

Income Taxes

The Company accounts for income taxes using an asset and liability approach in accordance with applicable guidance prescribed by FASB issued ASC 740, Income Taxes (“Topic 740”). Topic 740 requires that the deferred tax consequences of temporary differences between the amounts recorded in the financial statements and the amounts included in the federal and state income tax returns to be recognized in the balance sheet.

The Company makes judgments regarding the realizability of its deferred tax assets. The balance sheet carrying value of its deferred tax assets is based on whether the Company believes it is more likely than not that the Company will generate sufficient future taxable income to realize these deferred tax assets after consideration of all available evidence. The Company regularly reviews its deferred tax assets for recoverability considering historical profitability, projected future taxable income, the expected timing of the reversals of existing temporary differences and tax planning strategies. In assessing the need for a valuation allowance, the Company considers both positive and negative evidence related to the likelihood of realization of the deferred tax assets. The weight given to the positive and negative evidence is commensurate with the extent to which the evidence may be objectively verified. As such, it is generally difficult for positive evidence regarding projected future taxable income exclusive of reversing taxable temporary differences to outweigh objective negative evidence of recent financial reporting losses. Generally, cumulative loss in recent years is a significant piece of negative evidence that is difficult to overcome in determining that a valuation allowance is not needed.

The Company’s tax positions may be subject to income tax audits. The Company recognizes the tax benefit of an uncertain tax position only if it is more likely than not that the position is sustainable upon examination by the taxing authority, based on the technical merits. The tax benefit recognized is measured as the largest amount of benefit which is more likely than not to be realized upon settlement with the taxing authority. The Company recognizes interest accrued and penalties related to unrecognized tax benefits in its tax provision. The Company evaluates uncertain tax positions on a regular basis. The evaluations are based on a number of factors, including changes in facts and circumstances, changes in tax law, correspondence with tax authorities during the course of the audit, and effective settlement of audit issues. The provision for income taxes includes the effects of any accruals that the Company believes are appropriate, as well as the related net interest and penalties.

Tax Credit Receivable

The Company is eligible for research and development credits for its research and development activities, in accordance with Internal Revenue Code (“I.R.C.”) § 41(c). The credits are generally available to offset income tax liabilities. The Company has applied approximately $250,000 of research and development credits to offset its federal payroll tax expenses for both years ended December 31, 2020 and 2021, due to its small business status. As of December 31, 2020 and 2021, the current portion of outstanding payroll tax receivables is recorded in Other current assets in the accompanying balance sheets and the noncurrent portion is recorded in Other noncurrent assets.

Net Loss Per Share

Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period, without consideration of potential dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the sum of the weighted average number of common shares plus the potential dilutive effects of potential dilutive securities outstanding during the period. Potential dilutive securities are excluded from diluted earnings or loss per share if the effect of such inclusion is anti-dilutive. The Company’s potentially dilutive securities, which include convertible redeemable preferred stock and outstanding stock options under the 2019 Equity Incentive Plan (“2019 Plan”) and the 2021 Equity Incentive Plan (“2021 Plan”), have been excluded from the computation of diluted net loss per share as they would be anti-dilutive to the net loss per share. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company’s net loss position.

Recently Issued Accounting Pronouncements

In June 2016, FASB issued Accounting Standards Update (“ASU”) No. 2016-13, Financial Instruments—Credit Losses: Measurement of Credit Losses on Financial Instruments, as clarified in subsequent amendments to the initial guidance (collectively, “Topic 326”). Topic 326 requires measurement and recognition of expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecast. The Company adopted Topic 326 using a modified retrospective approach which requires a cumulative effect adjustment as of the beginning of the reporting period in which the guidance is adopted. Topic 326 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019, with early adoption permitted. The Company adopted Topic 326 effective January 1, 2020. The adoption did not have a material impact on our financial statements.

In February 2016, the FASB issued ASU No. 2016-02, Leases (“Topic 842”), which requires an entity to recognize assets and liabilities arising from a lease for both financing and operating leases. The ASU will also require new qualitative and quantitative disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. Topic 842 is effective for the Company in the fiscal years beginning after December 15, 2021, with early adoption permitted. The Company will adopt Topic 842 for the fiscal year ended December 31, 2022. The Company plans to use a practical expedient provided by FASB, and it will not recast comparative periods to reflect the impact of the new lease standard. Effective March 1, 2022, the Company entered into a non-cancelable operating lease for its current location with a two-year term. This is the only lease in scope of Topic 842. The Company expects accounting for the new lease under Topic 842 will materially affect the reported amount of total assets and total liabilities within the balance sheet, but it does not expect a material impact to the statement of operations
XML 31 R8.htm IDEA: XBRL DOCUMENT v3.22.1
Property and Equipment, Net
12 Months Ended
Dec. 31, 2021
Property Plant And Equipment [Abstract]  
Property and Equipment, Net

2. Property and Equipment, Net

Property and equipment, net consists of the following:

 

 

 

At December 31,

 

 

 

2020

 

 

2021

 

Laboratory equipment

 

$

1,924,596

 

 

$

1,949,318

 

Office equipment

 

 

152,003

 

 

 

175,245

 

Furniture and fixtures

 

 

292,866

 

 

 

292,165

 

Leasehold improvements

 

 

349,976

 

 

 

349,976

 

 

 

$

2,719,441

 

 

$

2,766,704

 

Less: Accumulated depreciation and amortization

 

 

(1,104,015

)

 

 

(1,647,614

)

Property and equipment, net

 

$

1,615,426

 

 

$

1,119,090

 

 

Depreciation and amortization expense for the year ended December 31, 2020 was $572,867 of which $362,892 is included in research and development expenses. Depreciation and amortization expense for the year ended December 31, 2021 was $543,598, of which $353,388 is included in research and development expenses.

XML 32 R9.htm IDEA: XBRL DOCUMENT v3.22.1
Fair Value of Financial Instruments
12 Months Ended
Dec. 31, 2021
Fair Value Disclosures [Abstract]  
Fair Value of Financial Instruments

3. Fair Value of Financial Instruments

The carrying amount of the Company’s financial instruments, including cash and cash equivalents, accounts receivable, prepaid expenses and other current assets, U.S. government backed securities with maturity dates up to one year, accounts payable and accrued liabilities, approximate fair value due to their short-term maturities.

 

Money market funds included in cash and cash equivalents and U.S. government backed securities are measured at fair value based on quoted prices in active markets, which are considered Level 1 inputs. No transfers between levels occurred during the periods presented. The following table presents the Company’s assets which were measured at fair value at December 31, 2020 and 2021:

 

 

 

At December 31, 2020

 

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

 

Assets:

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

6,752,266

 

 

$

 

 

$

 

 

$

6,752,266

 

Investment in Wugen

 

 

 

 

 

 

 

 

1,599,750

 

 

 

 

Total

 

$

6,752,266

 

 

$

 

 

$

1,599,750

 

 

$

6,752,266

 

 

 

 

At December 31, 2021

 

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

 

Assets:

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

9,506,499

 

 

$

 

 

$

 

 

$

9,506,499

 

Treasury bills

 

 

24,983,520

 

 

 

 

 

 

 

 

 

24,983,520

 

Treasury notes

 

 

9,922,300

 

 

 

 

 

 

 

 

 

9,922,300

 

Total

 

$

44,412,319

 

 

$

 

 

$

 

 

$

44,412,319

 

XML 33 R10.htm IDEA: XBRL DOCUMENT v3.22.1
Investments
12 Months Ended
Dec. 31, 2021
Investments [Abstract]  
Investments

4. Investments

As of December 31, 2020, Investments consisted of a balance of $1.6 million. In December 2020, the Company entered into the Wugen License for limited rights to develop, manufacture and commercialize cellular therapy products based on two of the Company’s fusion protein molecules. As part of the consideration received for the Wugen License, the Company received shares of Wugen common stock, which were recognized at $1.6 million, the fair value of the securities as of December 24, 2020, the effective date for the Wugen License. Initial recognition was at fair value based on level 3 inputs, since there was no public market on which to trade these shares at the time they were received. The fair value was determined based primarily on the pricing and terms of a third-party financing completed by Wugen in 2020. So long as there continues to be no public market for these securities, the Company will classify this asset as a cost method investment, recorded at cost less impairment adjusted for observable market changes.

As of December 31, 2021, Investments had a balance of $11.5 million in the accompanying balance sheet, consisting of $1.6 million for the investment in Wugen, which the Company continues to carry at cost since no public market exists for these securities, and no impairment adjusted was necessary. In addition, Investments include $9.9 million in U.S. Treasury notes as of December 31, 2021. These securities are classified as trading securities.

XML 34 R11.htm IDEA: XBRL DOCUMENT v3.22.1
Related Party Transactions
12 Months Ended
Dec. 31, 2021
Related Party Transactions [Abstract]  
Related Party Transactions

5. Related Party Transactions

As of December 31, 2020, related parties held capital stock in the Company. The Company's Founder and Chief Executive Officer, Hing C. Wong, PhD., held all Class B Common Stock and Series A Preferred Stock issued by the Company. In addition, Dr. Wong purchased shares of Series B Preferred Stock and Series C Preferred Stock on the same terms and conditions for third-party investors. All shares of Preferred Shares held by Dr. Wong earned cumulative dividends.

During the year ended December 31, 2021, all shares purchased by Dr. Wong prior to the IPO were converted to common stock, and the Company was relieved of its obligation to pay cumulative dividends on Preferred Shares that were accrued and unpaid as of the conversion date. Dr. Wong purchased additional shares of the Company's common stock in the IPO and in the open market post IPO, in compliance with SEC regulations and the Company's insider trading policies.

XML 35 R12.htm IDEA: XBRL DOCUMENT v3.22.1
Accrued Liabilities and Other Current Liabilities
12 Months Ended
Dec. 31, 2021
Payables And Accruals [Abstract]  
Accrued Liabilities and Other Current Liabilities

6. Accrued Liabilities and Other Current Liabilities

In May 2020, the Company received an SBA Paycheck Protection Loan (“PPP loan”) in the principal amount of $563,590. As of December 31, 2020, the Company had $845,741 of Accrued liabilities and other current liabilities, primarily consisting of the PPP loan of $567,311, including principal and accrued but unpaid interest, and accrued liabilities of $273,907.

As of December 31, 2021, the Company had a balance of $2.1 million in Accrued liabilities and other current liabilities, consisting of $1.8 million related to deferred revenue, $48,750 related to manufacturing materials, $51,000 related to legal fees, and $50,000 for other expenses. On January 8, 2021, the Company received full loan forgiveness of $567,311 for obligations related to the PPP loan. The Company accounted for the PPP loan as debt, and the loan forgiveness was accounted for as a debt extinguishment. The amount of loan and interest forgiven is recognized as a gain upon debt extinguishment and is reported within Interest and other income, net in the accompanying statement of operations for the year ended December 31, 2021.

XML 36 R13.htm IDEA: XBRL DOCUMENT v3.22.1
License Agreement
12 Months Ended
Dec. 31, 2021
License Agreement [Abstract]  
License Agreement

7. License Agreement

On December 24, 2020, the Company entered into the Wugen License transferring rights to Wugen to develop, manufacture, and commercialize certain cellular therapy products based on two of the Company’s fusion protein molecules. The term of the agreement will expire on a product-by-product and country-by-country basis, upon the later of (i) ten (10) years from the first commercial sale of the product or (ii) the expiration of the last-to-expire valid patent claim of such product.

The Company retained regulatory T cell-based cellular therapy, injectable rights, and manufacturing rights, not granted to Wugen under the terms of the Wugen License. The Company and Wugen will enter into two supply agreements under industry-standard terms, under which the Company will provide cGMP and non-cGMP grade materials, including a development supply agreement and a commercial supply agreement.

According to the terms of the agreement, Wugen will fund all future clinical development and commercialization activities for cellular therapy treatments for any indications utilizing the licensed fusion protein molecules covered by the Wugen License. In January 2021, two Phase 2 clinical trials related to treatment for relapsed / refractory acute myeloid leukemia based on one of the licensed molecules were initiated by the School of Medicine at Washington University in St. Louis and supported by Wugen.

The Company concluded that Wugen is a customer and the Wugen License is a functional license under the provisions of Topic 606. The Company identified the following performance obligations at the inception of the agreement:

Provide Wugen with exclusive worldwide license rights for certain fusion proteins.
Sell vials of HCW9201 clinical grade product available immediately.
Transfer R&D know-how.
Supply of cGMP and non-cGMP grade materials for development.
Supply of cGMP grade materials for commercialization.

 

For the year ended December 31, 2020 the Company recognized $4.1 million for performance obligations satisfied in the period. This is the first time the Company has entered into an out-license arrangement and the first time the Company has established prices for its goods and services. Accordingly, the standalone selling price of the various performance obligations is uncertain, and the Company determined that an observable standalone selling price is not available for the identified performance obligations under the Wugen License. Where a standalone selling price is not directly observable, then the Company estimates the standalone selling price considering marketing conditions, entity-specific factors, and information about the customer that is reasonably available. The process for determining a standalone selling price involves significant judgment and includes consideration of multiple factors, including assumptions related to the market opportunity and the time needed to commercialize a product candidate pursuant to the relevant license, estimated direct expenses and other costs.

The Company first determined the standalone selling price of $2.5 million for the vials of HCW9201 and the R&D know-how. The price was determined based on the cost of developing the know-how and the costs incurred in producing the vials. The standalone selling price for the license was determined using the residual approach and was priced at $1.6 million.

As of December 31, 2020, the Company and Wugen had not finalized the development supply agreement. Therefore, there was no contract for purchase of materials during Wugen's development phase. The Company will defer recognition of revenues and costs for supply of materials during development until a contract is in place. The commercial supply agreement will be entered into in the future, pursuant to the terms of the Wugen License.

For the year ended December 31, 2021, the Company entered into a master services agreement with Wugen related to the development supply agreement to provide cGMP and non-cGMP grade licensed material based on industry-standard terms. However, as of December 31, 2021, the Company and Wugen have not finalized any statements of work under the master services agreement, thus no contract exists. Until such time that the Company enters statements of work for Wugen orders related to licensed material for clinical development, the Company will defer recognition of revenues.

The Wugen License includes milestone payments and royalties. The Company uses judgment to determine whether milestones or other variable consideration should be included in the transaction price. For revenue-based royalties, including milestone payments based on the level of sales, the Company will include royalties in the transaction price at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty is allocated has been satisfied (or partially satisfied). As part of management’s evaluation of the transaction price, the Company considers numerous factors, including whether the achievement of the milestones is outside of our control, contingent upon the efforts of others or subject to scientific risks of success. If the Company concludes it is probable that a significant revenue reversal would not occur, the associated milestone payment is included in the transaction price. Milestone payments that are not within our control, such as regulatory approvals, are generally not considered probable until those milestones are achieved. The Company reevaluates the transaction price, including estimated variable consideration included in the transaction price and all constrained amounts, in each reporting period and as uncertain events are resolved or other changes in circumstances occur.

XML 37 R14.htm IDEA: XBRL DOCUMENT v3.22.1
Redeemable Preferred Stock
12 Months Ended
Dec. 31, 2021
Equity [Abstract]  
Redeemable Preferred Stock

8. Redeemable Preferred Stock

In a series of closings which took place in 2020, the Company completed the private placement of Series C Preferred Stock. The terms of the redeemable preferred stock provided for an adjustment to the conversion price upon the occurrence of certain transactions or events, such as stock splits, split-up, certain dividends, or distributions. Cumulative dividends accrued whether or not declared by the Board of Directors. Giving effect to the Reverse Stock Split, a total of 5,439,112 shares of Series C Preferred Stock were issued at $2.05 per share, for $11.2 million, net of offering costs. The Company’s Series C Preferred Stock was convertible into shares of Class A common stock and earned cumulative dividends at a rate of 6% per annum and compound annually until converted or redeemed.

On July 22, 2021, the Company closed on its IPO, and the requirements for mandatory conversion were met. All outstanding shares of Series A, Series B, and Series C Preferred Stock converted into an equal number of shares of common stock. As a result, the rights, preferences, and terms ascribed to these shares are no longer applicable. Cumulative dividends of $2.8 million accrued as of the conversion date were forfeited and such forfeiture was recognized through Additional paid-in capital.

At December 31, 2021, the Company has 10,000,000 shares of preferred stock authorized and no shares issued.
XML 38 R15.htm IDEA: XBRL DOCUMENT v3.22.1
Net Loss Per Share
12 Months Ended
Dec. 31, 2021
Earnings Per Share [Abstract]  
Net Loss Per Share

9. Net Loss Per Share

The following table summarizes the computation of the basic and diluted net loss per share:

 

 

 

Years Ended December 31,

 

 

 

2020

 

 

2021

 

Numerator:

 

 

 

 

 

 

Net loss

 

$

(5,802,201

)

 

$

(12,862,468

)

Less: cumulative preferred dividends earned in the
   period, net of forfeitures

 

 

(1,271,675

)

 

 

 

Net loss available for distribution to common stock
   holders

 

$

(7,073,876

)

 

$

(12,862,468

)

Denominator:

 

 

 

 

 

 

Weighted-average common shares outstanding

 

 

4,739,285

 

 

 

18,770,935

 

Net loss per share, basic and diluted

 

$

(1.49

)

 

$

(0.69

)

 

The following table summarizes the outstanding potentially dilutive securities that have been excluded in the calculation of diluted net loss per share because their inclusion would be anti-dilutive:

 

 

 

As of December 31,

 

 

 

2020

 

 

2021

 

Redeemable Preferred Stock

 

 

23,768,416

 

 

 

 

Common stock options

 

 

742,114

 

 

 

1,770,739

 

Potentially diluted securities

 

 

24,510,530

 

 

 

1,770,739

 

XML 39 R16.htm IDEA: XBRL DOCUMENT v3.22.1
Stock-Based Compensation
12 Months Ended
Dec. 31, 2021
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]  
Stock-Based Compensation

10. Stock-based Compensation

On June 21, 2021, the 2021 Plan was adopted by the Company’s board of directors and approved by the Company’s stockholders. As of the adoption date, the 2019 Plan was terminated. No terms were changed for grants previously awarded under the 2019 Plan, and the Company concluded a modification did not occur. Under the 2019 Plan, the Company primarily granted employees incentive stock options, which had a maximum term of ten years from the date of the grant. Generally, the incentive stock options granted under the 2019 Plan have a four year, service-based vesting period. All of the options granted under the 2019 Plan had an exercise price equal to the fair value of a share of common stock on the date of the grant, according to Company policy.

The 2021 Plan permits the grant of incentive stock options, nonstatutory stock options, stock appreciation rights, restricted stock, restricted stock units, and stock bonus awards. The 2021 Plan initially reserved 3,444,343 shares of Common Stock, including the transfer of remaining shares reserved under the 2019 Plan. In addition, the number of shares reserved for issuance under the 2021 Plan will increase automatically on the first day of each fiscal year beginning with the 2022 fiscal year.

Under the 2021 Plan, the term of each stock option must be stated in the stock award agreement. In the case of an incentive stock option, the term will be ten years from the date of grant, or such shorter term as may be provided in the stock award agreement. Moreover, in the case of an incentive stock option granted to a participant who owns stock representing more than 10% of the total combined voting power of all classes of our stock or the stock of any of our affiliates, the term of the incentive stock option will be five years from the date of grant or such shorter term as may be provided in the stock award agreement. Under the 2021 Plan, the Company continues to have a policy to grant options with an exercise price equal to the fair value of a share of common stock, as determined by the closing price on NASDAQ on the grant date.

The following summarizes the Company’s stock option activity for the year ended December 31, 2021:

 

 

Shares

 

 

Weighted

 

Weighted Average

 

 

 

 

Issuable

 

 

Average

 

Remaining

 

Aggregate

 

 

under

 

 

Exercise

 

Contract

 

Intrinsic

 

 

Options

 

 

Price

 

Term

 

Value

 

Outstanding at December 31, 2019

 

 

586,662

 

 

0.13

 

9.6 years

 

$

5,500

 

Granted

 

 

263,976

 

 

0.20

 

 

 

 

 

Exercised

 

 

(75,851

)

 

0.13

 

 

 

 

 

Forfeited or cancelled

 

 

(32,740

)

 

0.12

 

 

 

 

 

Outstanding at December 31, 2020

 

 

742,047

 

 

0.16

 

9.1 years

 

$

39,078

 

Exercisable at December 31, 2020

 

 

88,531

 

 

0.15

 

9.0 years

 

$

5,413

 

 

 

 

 

 

 

 

 

 

 

 

Outstanding at December 31, 2020

 

 

742,047

 

 

0.16

 

9.1 years

 

$

39,078

 

Granted

 

 

1,249,287

 

 

4.16

 

 

 

 

 

Exercised

 

 

(206,455

)

 

0.13

 

 

 

 

 

Forfeited or cancelled

 

 

(14,140

)

 

0.19

 

 

 

 

 

Outstanding at December 31, 2021

 

 

1,770,739

 

 

2.96

 

9.0 years

 

$

1,124,215

 

Exercisable at December 31, 2021

 

 

41,084

 

 

0.17

 

7.9 years

 

$

87,522

 

The aggregate intrinsic value is calculated based on the difference between the exercise price of the underlying stock options and the fair value of the Company’s common stock for stock options as of the reporting date. The intrinsic value of stock options exercised during the years ended December 31, 2020 and 2021 was $6,032 and $447,115, respectively. The weighted-average fair value of options granted during the years ended December 31, 2020 and 2021 was $0.20 and $4.16 per share, respectively.

For stock option grants with service-based vesting, stock-based compensation expense represents the portion of the grant date fair value of employee stock option grants recognized over the requisite service period of the awards on a straight-line basis, net of estimated forfeitures. For options that vest upon the achievement of performance milestones, the Company estimates fair value at the date of grant and compensation expense is recognized using the accelerated attribution method when it is determined that the performance criteria is probable of being met.

In determining the grant date fair value of the stock-based awards, the Company uses the Black-Scholes option-pricing model and assumptions discussed below. Each of these inputs is subjective and its determination generally requires significant judgment.

Fair Value of Common Stock—Prior to our initial public offering, the estimated fair value of our common stock was determined by our board of directors as of the date of each option grant, with input from management, considering our most recently available third-party valuation of our common stock as well as our board of directors’ assessment of additional objective and subjective factors that it believed were relevant and which may have changed from the date of the most recent third-party valuation to the date of the grant. Since the completion of our initial public offering on July 19, 2021, the fair value of each share of common stock underlying stock option grants is based the quoted market price on the primary stock exchange on which our common stock is traded on the day the stock award or option is granted.

Expected term—The expected term of stock options is determined using the “simplified” method, whereby the expected life equals the arithmetic average of the vesting term and the original contractual term of the option due to the Company’s lack of sufficient historical data.

Expected volatility—We have limited information on the income volatility of our stock as shares of our common stock were not actively traded on any public markets prior to July 19, 2021. The expected volatility was derived from the historical stock volatilities of comparable peer public companies within our industry.

Risk-free interest rate—The risk-free interest rate is based on the U.S. Treasury Bond in effect at the time of grant for periods corresponding with the expected term.

Dividend yield—The expected dividend yield is 0% because the Company has not historically paid, and does not expect, for the foreseeable future, to pay a dividend on its common stock.

For the years ended December 31, 2020 and 2021, the fair value of employee and director stock option awards was estimated at the date of grant using a Black-Scholes option-pricing model with the following assumptions:

 

 

 

Years Ended December 31,

 

 

2020

 

2021

Expected term (years)

 

6.25

 

6.24

Expected volatility

 

87.30%

 

83.18%

Risk-free interest rate

 

0.50%

 

1.02%

Dividend yield

 

 

Fair value underlying common stock

 

$0.18

 

$2.95

For the year ended December 31, 2020, for options with service-based vesting conditions, the Company recognized $9,590 of employee stock-based compensation expense in research and development expenses and $12,285 of employee stock-based compensation in general and administrative expenses in the accompanying statements of operations. For the year ended December 31, 2021, for options with service-based vesting conditions, the Company recognized $25,239 of employee stock-based compensation expense in research and development expenses and $335,736 of employee stock-based compensation in general and administrative expenses in the accompanying statements of operations.

As of December 31, 2020, the Company had an aggregate of $103,045 of unrecognized employee stock-based compensation cost for options with service-based vesting, which is expected to be recognized over a weighted average vesting period of 5.12 years.

As of December 31, 2020 and 2021, there was no unrecognized employee stock-based compensation cost for options with performance-based vesting conditions, as no performance-based options were unvested. For the years ended December 31, 2020 and 2021, the Company recognized an aggregate of $6,750 and nil of employee stock-based compensation cost, respectively, for options with performance-based vesting conditions which vested immediately upon achieving the performance target, respectively.
XML 40 R17.htm IDEA: XBRL DOCUMENT v3.22.1
Employee Benefit Plan
12 Months Ended
Dec. 31, 2021
Compensation And Retirement Disclosure [Abstract]  
Employee Benefit Plans

11. Employee Benefit Plan

The Company offers a defined contribution savings plan (the “Benefit Plan”) under Section 401 of the Internal Revenue Code for all eligible employees. The Benefit Plan allows for discretionary contributions which are limited to the maximum allowable for federal tax purposes. The total expense related to the discretionary payments made by the Company to the Benefit Plan for the years ended December 31, 2020 and 2021 was $146,400 and $173,400, respectively.

XML 41 R18.htm IDEA: XBRL DOCUMENT v3.22.1
Collaborative Arrangements
12 Months Ended
Dec. 31, 2021
Organization Consolidation And Presentation Of Financial Statements [Abstract]  
Collaborative Arrangements

12. Collaborative Arrangements

In March 2020, the Company entered into two collaborative arrangements relating to IND-enabling activities which continued in 2021. Pursuant to these agreements, the Company supplied materials for the studies and reimbursed the collaboration partner costs in connection with the projects. In turn, the partner will provide written reports and a body of scientific data for the results of the projects.

XML 42 R19.htm IDEA: XBRL DOCUMENT v3.22.1
Income Taxes
12 Months Ended
Dec. 31, 2021
Income Tax Disclosure [Abstract]  
Income Taxes

13. Income Taxes

The Company did not have a provision for income taxes (current or deferred tax expense) for tax years ended December 31, 2020 and 2021.

The following table summarizes the differences between the statutory federal income tax rate and the Company's effective income tax rate (percent data):

 

Rate Reconciliation

 

2020

 

 

 

 

 

2021

 

 

 

 

Net Loss Before Taxes

 

$

(5,802,201

)

 

 

 

 

$

(12,862,468

)

 

 

 

Benefit at statutory rate

 

 

(1,218,462

)

 

 

21.00

%

 

 

(2,701,118

)

 

 

21.00

%

State tax benefit net of federal benefit

 

 

(264,152

)

 

 

4.55

%

 

 

(590,728

)

 

 

4.59

%

Permanent book/tax differences

 

 

10,161

 

 

 

(0.18

%)

 

 

(85,678

)

 

 

0.67

%

Other adjustments

 

 

(34,591

)

 

 

0.60

%

 

 

2,093

 

 

 

(0.02

%)

R&D credit carryforward

 

 

(46,608

)

 

 

0.80

%

 

 

(85,000

)

 

 

0.66

%

Change in valuation allowance

 

 

1,555,740

 

 

 

(26.81

%)

 

 

3,460,431

 

 

 

(26.90

%)

Other

 

 

(2,088

)

 

 

0.04

%

 

 

 

 

 

0.00

%

Income tax expense/(benefit)

 

$

 

 

 

0.00

%

 

$

 

 

 

0.00

%

 

 

The tax effects of temporary differences that give rise to significant portions of the deferred tax assets and deferred tax liabilities at December 31, 2020 and 2021 are presented below:

 

 

 

2020

 

 

2021

 

Deferred tax assets:

 

 

 

 

 

 

Federal net operating loss carryforward

 

$

3,102,649

 

 

$

5,479,664

 

State net operating loss carryforward

 

 

658,595

 

 

 

1,164,970

 

Accrued expenses

 

 

24,585

 

 

 

12,356

 

Stock-based compensation

 

 

2,821

 

 

 

84,612

 

Deferred rent

 

 

2,089

 

 

 

307

 

R&D credit

 

 

133,015

 

 

 

218,015

 

Unrealized gain/loss

 

 

 

 

 

16,708

 

Deferred revenue

 

 

 

 

 

397,464

 

Net deferred tax assets

 

 

3,923,754

 

 

 

7,374,096

 

Deferred tax liabilities:

 

 

 

 

 

 

Depreciable assets

 

 

(10,054

)

 

 

35

 

Net deferred tax liabilities

 

 

(10,054

)

 

 

35

 

Less: valuation allowance

 

 

(3,913,700

)

 

 

(7,374,131

)

Net deferred tax asset (after valuation allowance)

 

$

 

 

$

 

 

A valuation allowance is recorded to reduce the deferred tax asset if, based on the weight of the evidence, it is more likely than not that some portion or all of the deferred tax asset will not be realized. As of December 31, 2021, after consideration of all the evidence, both positive and negative, management has determined that a valuation allowance of $7.4 million is necessary to reduce the deferred tax asset to the amount that will more likely than not be realized. During the year ended December 31, 2021, the valuation allowance increased by $3.5 million.

On March 27, 2020, the Coronavirus Aid, Relief and Economic Security (“CARES”) Act was enacted and signed into law. Certain provisions of the CARES Act could impact the 2019 income tax provision computations of the Company and will be reflected in the period of enactment (tax year 2020). The CARES Act, among other things, contains modifications on the limitation of business interest expense under Section 163(j), allow for net operating loss ("NOL") carryovers and carrybacks to offset 100% of taxable income for taxable years before 2021, and includes a technical correction to the TCJA with respect to Qualified Improvement Property ("QIP") where such property has a 15-year recovery period for purposes of the general depreciation system of Section 168(a). The Company is currently evaluating the impact of the CARES Act, and aside from the 15-year QIP technical correction, it believes that none of other modifications or tax law changes will result in any material benefit or apply.

As of December 31, 2020 and 2021, the Company had available federal NOL carryforwards of $14.8 million and $26.1 million. The Company also has available state NOLs carryforwards of approximately $15.2 million and $26.8 million, as of December 31, 2020 and 2021, respectively. The federal and state NOLs will carry forward indefinitely and be available to offset up to 100% of taxable income for taxable years before 2021 and 80% of taxable years staring after 2020. In addition, the Company had federal research and development credits carryforwards of $133,015 and $218,015, as of December 31, 2020 and 2021, respectively, to reduce future federal income taxes, if any. These carryforwards expire from 2038 through 2041 and are subject to review and possible adjustment.

Under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, (the Code), substantial changes in the Company’s ownership may limit the amount of net operating loss and research and development credit carryforwards that could be used annually in the future to offset taxable income. A formal Section 382 study has not been completed to determine if an ownership change has occurred and if its net operating losses are subject to an annual limitation. Such annual limitations could affect the utilization of NOL and tax credit carryforwards in the future.

XML 43 R20.htm IDEA: XBRL DOCUMENT v3.22.1
Commitments and Contingencies
12 Months Ended
Dec. 31, 2021
Commitments And Contingencies Disclosure [Abstract]  
Commitments and Contingencies

14. Commitments and Contingencies

Leases

The Company leases its operating facilities in Miramar, Florida under non-cancelable operating lease agreements and a short-term sublease agreement for additional office space. Rent expense is recognized for leases with increasing annual rents on a straight-line basis over the term of the lease. The amount of rent expense in excess of cash payments is classified as deferred rent. Lease incentives received are deferred and amortized over the term of the lease.

The future minimum payments for the lease and sublease agreements at December 31, 2021 are as follows:

 

2022 (remaining 2 months)

 

$

36,000

 

 

For the year ended December 31, 2020 and 2021, rental expense, including common area maintenance costs, recognized by the Company was $183,943 and $208,348, of which $82,971 and $100,457, respectively, are included in Research and development, in the accompanying statements of operations.

Contractual Commitments

During the year ended December 31, 2021, the Company entered into several agreements with a third-party global contract development and manufacturer of biologics for the manufacture of the Company’s proprietary molecules for use in clinical trials. At December 31, 2020, the future minimum payments under such agreements were $3.9 million. At December 31, 2021, future payment obligations under such agreements were $2.5 million of which approximately $181,600 was paid in January 2022.

Legal

Management has no knowledge of any pending or unasserted claims against the Company.

Other

In March 2020, the World Health Organization declared the outbreak of a novel coronavirus (COVID-19) as a pandemic, which continues to spread throughout the United States and the world. The spread of COVID-19 has caused significant volatility in the U.S. and international markets. There is significant uncertainty around the breadth and duration of business disruptions related to COVID-19, as well as its impact on the U.S. and international economies and, as such, the Company is unable to determine if it will have a material impact to its operations.

XML 44 R21.htm IDEA: XBRL DOCUMENT v3.22.1
Subsequent Events
12 Months Ended
Dec. 31, 2021
Subsequent Events [Abstract]  
Subsequent Events

15. Subsequent Events

Subsequent events have been evaluated through the date the financial statements were issued. As of such date, there were no material subsequent events identified that required recognition or disclosure other than as disclosed below or in the footnotes herein.

Effective March 1, 2022, the Company entered into a non-cancelable operating lease agreement for its current location with a two-year term and future minimum payments of $339,300.

XML 45 R22.htm IDEA: XBRL DOCUMENT v3.22.1
Organization and Summary of Significant Accounting Policies (Policies)
12 Months Ended
Dec. 31, 2021
Accounting Policies [Abstract]  
Basis of Presentation

Basis of Presentation

The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”).

Segment Reporting

Segment Reporting

The Company has one operating segment. The Company’s chief operating decision maker, its Chief Executive Officer, reviews financial information on an aggregate basis for allocating capital and evaluating performance.
Use of Estimates

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts in the financial statements and accompanying notes. Management must apply significant judgment in this process. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ from estimates.

Cash and Cash Equivalents

Cash and Cash Equivalents

Cash and cash equivalents consist of demand deposits at financial institutions, money market funds, and highly liquid investments with original maturities of three months or less.

Fair Value Measurements

Fair Value Measurements

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 820, Fair Value Measurement (“Topic 820”), establishes a fair value hierarchy for those instruments measured at fair value that distinguishes between fair value measurements based on market data (observable inputs) and those based on the Company’s own assumptions (unobservable inputs). This hierarchy maximizes the use of observable inputs and minimizes the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows:

Level 1: Observable inputs such as quoted prices in active markets;

Level 2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and

Level 3: Unobservable inputs in which there is little or no market data, which require a reporting entity to develop its own assumptions.

Fair value measurements are classified based on the lowest level of input that is significant to the measurement. The Company’s assessment of the significance of a particular input to the fair value measurement requires judgment, which may affect the valuation of the assets and liabilities and their placement within the fair value hierarchy levels. The determination of the fair values, as disclosed in Note 3, takes into account the market for the Company’s financial assets and liabilities, the associated credit risk, and other factors as required. The Company considers active markets as those in which transactions for the assets or liabilities occur in sufficient frequency and volume to provide pricing information on an ongoing basis.

Concentration of Credit Risk and Other Risks and Uncertainties Concentration of Credit Risk and Other Risks and Uncertainties

Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash, cash equivalents, accounts receivable, and investments. The Company’s cash and cash equivalents are deposited in accounts with financial institutions that management believes are of high credit quality. Such deposits may, at times, exceed federally insured limits. The Company has not experienced any losses on its deposits of cash and cash equivalents.

Currently all of the Company's revenues are derived from the Wugen License. For the year ended December 31, 2020, the Company recognized revenues of $4.1 million, $1.6 million of which was consideration received in the form of shares of Wugen common stock. These shares have limited marketability, and there was no public market on which to trade these shares as of December 31, 2021. As of December 31, 2021, the Company received cash payments of $1.8 million for the sale of research and clinical-grade material, which are currently recognized as deferred revenue on the accompanying balance sheet since the criteria for revenue recognition have not been met.

The Company is highly dependent on a third-party manufacturer to supply drug products for its research and development activities of its programs, including clinical and non-clinical studies. These programs could be adversely affected by a significant interruption in the supply of such drug products. The Company has no off-balance sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts or other hedging arrangements.

Property and Equipment, Net

Property and Equipment, Net

Property and equipment is stated at cost less accumulated depreciation. Depreciation expense is calculated using the straight-line method over the estimated useful lives of the assets, which range from 3 to 7 years. Leasehold improvements are amortized on a straight-line method over the shorter of the useful life of the leasehold improvement or the term of the lease. Upon retirement or sale of the assets, the cost and related accumulated depreciation and amortization are removed from the accompanying balance sheets and the resulting gain or loss is recorded to the statements of operations. Repairs and maintenance are expensed as incurred.

Impairment of Long-Lived Assets

Impairment of Long-Lived Assets

Long-lived assets are reviewed for indications of possible impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. Recoverability is measured by comparison of the carrying amounts to the future undiscounted cash flows attributable to these assets. An impairment loss is recognized to the extent an asset group is not recoverable, and the carrying amount exceeds the projected discounted future cash flows arising from these assets. Impairment losses, if any, are recognized in earnings. There were no impairment losses for any of the periods presented.

Redeemable Preferred Stock

Redeemable Preferred Stock

The Company applied the relevant accounting standards to distinguish liabilities from equity when we assessed the classification and measurement of preferred stock. Preferred Stock subject to mandatory redemptions was considered a liability and measured at fair value. Conditionally redeemable preferred stock issued by the Company was considered mezzanine or temporary equity and presented outside of the equity section of the accompanying balance sheet as of December 31, 2020.

Cumulative Dividends on Preferred Stock

Cumulative Dividends on Preferred Stock

The Company’s Preferred Stock earned a 6% cumulative dividend that compounded annually, whether or not declared by the Board of Directors. The Company considered cumulative dividends a legal obligation that should be recognized and accrued until such time as the dividends were declared and paid or liquidation occurred.

If Preferred Stock was classified as other than equity, this obligation was presented within Redeemable preferred stock. If Preferred Stock was included within equity, this obligation was treated as a long-term liability and presented within other liabilities in the accompanying balance sheet. As of December 31, 2020, all of the Company’s Preferred Stock was classified as other than equity, or mezzanine equity. Holders of Preferred Stock earned cumulative dividends beginning on June 7, 2019, with the original issuance of Series B Preferred Stock. During the year ended December 31, 2020, Series A Preferred Stock earned $348,490 in cumulative dividends; Series B Preferred Stock earned $776,804 in cumulative dividends; and Series C Preferred Stock earned $146,381 in cumulative dividends. Upon the IPO, all of the Company’s preferred stock converted to common stock. At that time, Series A Preferred Stock forfeited $753,307 of cumulative dividends; Series B Preferred Stock forfeited $1,550,403 of cumulative dividends; and Series C Preferred Stock forfeited $518,371 of cumulative dividends. No dividends were declared as of the conversion date.
Collaborative Arrangements

Collaborative Arrangements

When the Company enters into collaboration arrangements, it assesses whether the arrangements fall within the scope of FASB issued ASC 808, Collaborative Arrangements, based on whether the arrangements involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. If the payments from the collaboration partner to the Company represent consideration from a customer, such as license fees and contract research and development activities, the Company accounts for those payments within the scope of FASB issued ASC 606, Revenue from Contracts with Customers (“Topic 606”). However, if the Company concludes that the payments are not from a customer, for certain activities and associated payments, such as for certain collaborative research, development, manufacturing, and commercial activities, these payments are presented as a reduction of research and development expense or general and administrative expense, based on where the Company presents the underlying expense.

Revenue Recognition

Revenue Recognition

The Company recognizes revenue when its customer or collaborator obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services.

To determine revenue recognition for arrangements that are within the scope of Topic 606, it performs the following five steps:

i.
identify the contract(s) with a customer;
ii.
identify the performance obligations in the contract;
iii.
determine the transaction price;
iv.
allocate the transaction price to the performance obligations within the contract; and
v.
recognize revenue when (or as) the entity satisfies a performance obligation.

 

At contract inception, once the contract is determined to be within the scope of Topic 606 and it is probable of collection, the Company assesses the goods or services promised within the contract to determine whether each promised good or service is a performance obligation. The promised goods or services in the Company’s arrangements may consist of a license, or options to license, the Company’s intellectual property and research, development, and manufacturing services. The Company may provide options to additional items in such arrangements, which are accounted for as separate contracts when the customer elects to exercise such options, unless the option provides a material right to the customer. Performance obligations are promises in a contract to transfer a distinct good or service to the customer that (i) the customer can benefit from on its own or together with other readily available resources, and (ii) is separately identifiable from other promises in the contract. Goods or services that are not individually distinct performance obligations are combined with other promised goods or services until such combined group of promises meet the requirements of a performance obligation.

The Company determines the transaction price based on the amount of consideration the Company expects to receive for transferring the promised goods or services in the contract. Consideration may be fixed, variable, or a combination of both. At contract inception for arrangements that include variable consideration, the Company estimates the probability and extent of consideration it expects to receive under the contract utilizing either the most likely amount method or expected amount method, whichever best estimates the amount expected to be received. The Company then considers any constraints on the variable consideration and includes in the transaction price variable consideration to the extent it is deemed probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved.

The Company then allocates the transaction price to each performance obligation based on the relative standalone selling price and recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) control is transferred to the customer and the performance obligation is satisfied. For performance obligations which consist of licenses and other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.

The Company records amounts as accounts receivable when the right to consideration is deemed unconditional. When consideration is received, or such consideration is unconditionally due, from a customer prior to transferring goods or services to the customer under the terms of a contract, a contract liability is recorded as deferred revenue.
Deferred Revenue

Deferred Revenue

Deferred revenue represents amounts billed, or in certain cases, yet to be billed to the Company’s customer for which the related revenues have not been recognized because one or more of the revenue recognition criteria have not been met. The current portion of deferred revenue represents the amount to be recognized within one year from the balance sheet date based on the estimated performance period of the underlying performance obligations. As December 31, 2021, current deferred revenue includes amounts of $1.8 million allocated to the development supply agreement performance obligation under the Wugen License that is included within Accrued liabilities and other current liabilities.

Investments

Investments

The Company holds a minority interest in Wugen. The underlying shares of common stock are not traded on any public market and thus have limited marketability. The Company does not have significant influence over the operating and financial policies of Wugen. As a result, the Company has accounted for this investment using the measurement alternative whereby the investment is recorded at cost less impairment, adjusted for observable price changes in orderly transactions for an identical or similar investment of the same investee. No impairment was recognized during the years ended December 31, 2020 and 2021.

The Company invests net proceeds of its IPO in bills and notes issued by the U.S. Treasury which are classified as trading securities. As of December 31, 2021, the Company holds, $25.0 million in U.S. Treasury bills included in Short-term investments and $9.9 million in U.S. Treasury notes included in Investments in the accompanying balance sheet.
Research and Development Expenses

Research and Development Expenses

Research and development costs are expensed as incurred and include salaries, benefits, and other operating costs such as outside services, supplies and allocated overhead expenses. The Company may perform research and development for its own proprietary drug candidates and technology development or for certain third parties under collaborative arrangements. For its proprietary drug candidates and its internal technology development programs, the Company invests its own funds without reimbursement from a third party. Where the Company performs research and development activities under a clinical joint development collaboration, it records the partner’s share of collaboration expenses as a reduction to research and development expense when reimbursement amounts are due under the agreement.

The Company records an accrued expense for the estimated costs of its contract manufacturing activities performed by third parties. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to vendors. Payments under the contracts include upfront payments and milestone payments, which depend on factors such as the achievement of the completion of certain stages of the manufacturing process. For purposes of recognizing expense, the Company assesses whether the production process is sufficiently defined to be considered the delivery of a good, as evidenced by predictive or contractually required yields in the production process, or the delivery of a service, where processes and yields are developing and less certain. If the Company considers the process to be the delivery of a good, the Company recognizes the expense when the drug product is delivered, or otherwise bears risk of loss. If the Company considers the process to be the delivery of a service, the expense is recognized based on its best estimates of the contract manufacturer’s progress towards completion of the stages in the contracts. The Company recognizes and amortizes upfront payments and accrues for liabilities based on the specific terms of each arrangement. Arrangements may provide upfront payments for certain stages of the arrangement and milestone payments for the completion of certain stages, and, accordingly, may result in advance payments for services that have not been completed or goods not delivered and liabilities for stages where the contract manufacturer is entitled to a milestone payment.

Advance payments for goods or services that will be used or rendered for future research and development activities are capitalized as prepaid expenses and recognized as expense as the related goods are delivered or the related services are performed. The Company bases its estimates on the best information available at the time. However, additional information may become available to the Company which may allow it to make a more accurate estimate in future periods. In this event, the Company may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain. Such increases or decreases in cost are generally considered to be changes in estimates and will be reflected in research and development expenses in the period identified.

Patent Costs

Patent Costs

Costs related to filing and pursuing patent applications are recorded as general and administrative expenses in the accompanying statements of operations, and expensed as incurred since recoverability of such expenditures is uncertain.

Stock-based Compensation

Stock-based Compensation

The Company measures its stock-based awards granted to employees and directors based on the estimated fair value of the option on the date of grant (grant date fair value) and recognizes compensation expense over the vesting period. Compensation expense is recorded as either research and development or general and administrative expenses in the accompanying statements of operations based on the function to which the related services are provided. Forfeitures are accounted for as they occur. The Company has granted options with service-based and performance-based vesting conditions.

The Company uses the Black-Scholes option pricing model for the respective grant to determine the grant date fair value. The Black-Scholes option pricing model requires the input of highly subjective assumptions. These variables include, but are not limited to, its stock price volatility over the term of the awards and actual and projected employee stock option exercise behaviors. Management will continue to assess the assumptions and methodologies used to calculate the estimated grant date fair value of stock-based compensation. Circumstances may change and additional data may become available over time, which could result in changes to these assumptions and methodologies and materially impact the Company’s grant date fair value determination.

For stock option grants with service-based vesting, stock-based compensation expense represents the portion of the grant date fair value of employee stock option grants recognized over the requisite service period of the awards on a straight-line basis, net of estimated forfeitures. For options that vest upon the achievement of performance milestones, the Company estimates fair value at the date of grant and compensation expense is recognized using the accelerated attribution method when it is determined that the performance criteria is probable of being met.

Deferred Offering Costs

Deferred Offering Costs

The Company defers offering costs consisting of legal, accounting and other fees and costs directly attributable to its IPO. The deferred offering costs will be offset against the proceeds received upon the completion of the IPO. Deferred offering costs will be recorded under other non-current assets on the accompanying balance sheets. In the event the IPO is terminated, all of the deferred offering costs will be expensed within the Company’s statements of operations. As of December 31, 2020, there were no deferred offering costs recorded on the accompanying balance sheets. As of December 31, 2021, deferred offering costs related to underwriting discounts and commissions and offering expenses of $6.8 million were offset against IPO proceeds upon the consummation of the IPO.

Income Taxes

Income Taxes

The Company accounts for income taxes using an asset and liability approach in accordance with applicable guidance prescribed by FASB issued ASC 740, Income Taxes (“Topic 740”). Topic 740 requires that the deferred tax consequences of temporary differences between the amounts recorded in the financial statements and the amounts included in the federal and state income tax returns to be recognized in the balance sheet.

The Company makes judgments regarding the realizability of its deferred tax assets. The balance sheet carrying value of its deferred tax assets is based on whether the Company believes it is more likely than not that the Company will generate sufficient future taxable income to realize these deferred tax assets after consideration of all available evidence. The Company regularly reviews its deferred tax assets for recoverability considering historical profitability, projected future taxable income, the expected timing of the reversals of existing temporary differences and tax planning strategies. In assessing the need for a valuation allowance, the Company considers both positive and negative evidence related to the likelihood of realization of the deferred tax assets. The weight given to the positive and negative evidence is commensurate with the extent to which the evidence may be objectively verified. As such, it is generally difficult for positive evidence regarding projected future taxable income exclusive of reversing taxable temporary differences to outweigh objective negative evidence of recent financial reporting losses. Generally, cumulative loss in recent years is a significant piece of negative evidence that is difficult to overcome in determining that a valuation allowance is not needed.

The Company’s tax positions may be subject to income tax audits. The Company recognizes the tax benefit of an uncertain tax position only if it is more likely than not that the position is sustainable upon examination by the taxing authority, based on the technical merits. The tax benefit recognized is measured as the largest amount of benefit which is more likely than not to be realized upon settlement with the taxing authority. The Company recognizes interest accrued and penalties related to unrecognized tax benefits in its tax provision. The Company evaluates uncertain tax positions on a regular basis. The evaluations are based on a number of factors, including changes in facts and circumstances, changes in tax law, correspondence with tax authorities during the course of the audit, and effective settlement of audit issues. The provision for income taxes includes the effects of any accruals that the Company believes are appropriate, as well as the related net interest and penalties.

Tax Credit Receivable

Tax Credit Receivable

The Company is eligible for research and development credits for its research and development activities, in accordance with Internal Revenue Code (“I.R.C.”) § 41(c). The credits are generally available to offset income tax liabilities. The Company has applied approximately $250,000 of research and development credits to offset its federal payroll tax expenses for both years ended December 31, 2020 and 2021, due to its small business status. As of December 31, 2020 and 2021, the current portion of outstanding payroll tax receivables is recorded in Other current assets in the accompanying balance sheets and the noncurrent portion is recorded in Other noncurrent assets.

Net Loss Per Share

Net Loss Per Share

Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period, without consideration of potential dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the sum of the weighted average number of common shares plus the potential dilutive effects of potential dilutive securities outstanding during the period. Potential dilutive securities are excluded from diluted earnings or loss per share if the effect of such inclusion is anti-dilutive. The Company’s potentially dilutive securities, which include convertible redeemable preferred stock and outstanding stock options under the 2019 Equity Incentive Plan (“2019 Plan”) and the 2021 Equity Incentive Plan (“2021 Plan”), have been excluded from the computation of diluted net loss per share as they would be anti-dilutive to the net loss per share. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company’s net loss position.
Recently Issued Accounting Pronouncements

Recently Issued Accounting Pronouncements

In June 2016, FASB issued Accounting Standards Update (“ASU”) No. 2016-13, Financial Instruments—Credit Losses: Measurement of Credit Losses on Financial Instruments, as clarified in subsequent amendments to the initial guidance (collectively, “Topic 326”). Topic 326 requires measurement and recognition of expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecast. The Company adopted Topic 326 using a modified retrospective approach which requires a cumulative effect adjustment as of the beginning of the reporting period in which the guidance is adopted. Topic 326 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019, with early adoption permitted. The Company adopted Topic 326 effective January 1, 2020. The adoption did not have a material impact on our financial statements.

In February 2016, the FASB issued ASU No. 2016-02, Leases (“Topic 842”), which requires an entity to recognize assets and liabilities arising from a lease for both financing and operating leases. The ASU will also require new qualitative and quantitative disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. Topic 842 is effective for the Company in the fiscal years beginning after December 15, 2021, with early adoption permitted. The Company will adopt Topic 842 for the fiscal year ended December 31, 2022. The Company plans to use a practical expedient provided by FASB, and it will not recast comparative periods to reflect the impact of the new lease standard. Effective March 1, 2022, the Company entered into a non-cancelable operating lease for its current location with a two-year term. This is the only lease in scope of Topic 842. The Company expects accounting for the new lease under Topic 842 will materially affect the reported amount of total assets and total liabilities within the balance sheet, but it does not expect a material impact to the statement of operations
XML 46 R23.htm IDEA: XBRL DOCUMENT v3.22.1
Property and Equipment, Net (Tables)
12 Months Ended
Dec. 31, 2021
Property Plant And Equipment [Abstract]  
Schedule of Property and Equipment, Net

Property and equipment, net consists of the following:

 

 

 

At December 31,

 

 

 

2020

 

 

2021

 

Laboratory equipment

 

$

1,924,596

 

 

$

1,949,318

 

Office equipment

 

 

152,003

 

 

 

175,245

 

Furniture and fixtures

 

 

292,866

 

 

 

292,165

 

Leasehold improvements

 

 

349,976

 

 

 

349,976

 

 

 

$

2,719,441

 

 

$

2,766,704

 

Less: Accumulated depreciation and amortization

 

 

(1,104,015

)

 

 

(1,647,614

)

Property and equipment, net

 

$

1,615,426

 

 

$

1,119,090

 

XML 47 R24.htm IDEA: XBRL DOCUMENT v3.22.1
Fair Value of Financial Instruments (Tables)
12 Months Ended
Dec. 31, 2021
Fair Value Disclosures [Abstract]  
Summary of assets and liabilities that are measured at fair value on a recurring basis The following table presents the Company’s assets which were measured at fair value at December 31, 2020 and 2021:

 

 

 

At December 31, 2020

 

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

 

Assets:

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

6,752,266

 

 

$

 

 

$

 

 

$

6,752,266

 

Investment in Wugen

 

 

 

 

 

 

 

 

1,599,750

 

 

 

 

Total

 

$

6,752,266

 

 

$

 

 

$

1,599,750

 

 

$

6,752,266

 

 

 

 

At December 31, 2021

 

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

 

Assets:

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

9,506,499

 

 

$

 

 

$

 

 

$

9,506,499

 

Treasury bills

 

 

24,983,520

 

 

 

 

 

 

 

 

 

24,983,520

 

Treasury notes

 

 

9,922,300

 

 

 

 

 

 

 

 

 

9,922,300

 

Total

 

$

44,412,319

 

 

$

 

 

$

 

 

$

44,412,319

 

XML 48 R25.htm IDEA: XBRL DOCUMENT v3.22.1
Net Loss Per Share (Tables)
12 Months Ended
Dec. 31, 2021
Earnings Per Share [Abstract]  
Summary of Basic and Diluted Net Income (Loss) Per Common Share

The following table summarizes the computation of the basic and diluted net loss per share:

 

 

 

Years Ended December 31,

 

 

 

2020

 

 

2021

 

Numerator:

 

 

 

 

 

 

Net loss

 

$

(5,802,201

)

 

$

(12,862,468

)

Less: cumulative preferred dividends earned in the
   period, net of forfeitures

 

 

(1,271,675

)

 

 

 

Net loss available for distribution to common stock
   holders

 

$

(7,073,876

)

 

$

(12,862,468

)

Denominator:

 

 

 

 

 

 

Weighted-average common shares outstanding

 

 

4,739,285

 

 

 

18,770,935

 

Net loss per share, basic and diluted

 

$

(1.49

)

 

$

(0.69

)

Summary of Outstanding Potentially Dilutive Securities

The following table summarizes the outstanding potentially dilutive securities that have been excluded in the calculation of diluted net loss per share because their inclusion would be anti-dilutive:

 

 

 

As of December 31,

 

 

 

2020

 

 

2021

 

Redeemable Preferred Stock

 

 

23,768,416

 

 

 

 

Common stock options

 

 

742,114

 

 

 

1,770,739

 

Potentially diluted securities

 

 

24,510,530

 

 

 

1,770,739

 

XML 49 R26.htm IDEA: XBRL DOCUMENT v3.22.1
Stock-Based Compensation (Tables)
12 Months Ended
Dec. 31, 2021
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]  
Summary of Stock Option Activities

The following summarizes the Company’s stock option activity for the year ended December 31, 2021:

 

 

Shares

 

 

Weighted

 

Weighted Average

 

 

 

 

Issuable

 

 

Average

 

Remaining

 

Aggregate

 

 

under

 

 

Exercise

 

Contract

 

Intrinsic

 

 

Options

 

 

Price

 

Term

 

Value

 

Outstanding at December 31, 2019

 

 

586,662

 

 

0.13

 

9.6 years

 

$

5,500

 

Granted

 

 

263,976

 

 

0.20

 

 

 

 

 

Exercised

 

 

(75,851

)

 

0.13

 

 

 

 

 

Forfeited or cancelled

 

 

(32,740

)

 

0.12

 

 

 

 

 

Outstanding at December 31, 2020

 

 

742,047

 

 

0.16

 

9.1 years

 

$

39,078

 

Exercisable at December 31, 2020

 

 

88,531

 

 

0.15

 

9.0 years

 

$

5,413

 

 

 

 

 

 

 

 

 

 

 

 

Outstanding at December 31, 2020

 

 

742,047

 

 

0.16

 

9.1 years

 

$

39,078

 

Granted

 

 

1,249,287

 

 

4.16

 

 

 

 

 

Exercised

 

 

(206,455

)

 

0.13

 

 

 

 

 

Forfeited or cancelled

 

 

(14,140

)

 

0.19

 

 

 

 

 

Outstanding at December 31, 2021

 

 

1,770,739

 

 

2.96

 

9.0 years

 

$

1,124,215

 

Exercisable at December 31, 2021

 

 

41,084

 

 

0.17

 

7.9 years

 

$

87,522

 

Summary of Assumptions Used in Black-Scholes Model

For the years ended December 31, 2020 and 2021, the fair value of employee and director stock option awards was estimated at the date of grant using a Black-Scholes option-pricing model with the following assumptions:

 

 

 

Years Ended December 31,

 

 

2020

 

2021

Expected term (years)

 

6.25

 

6.24

Expected volatility

 

87.30%

 

83.18%

Risk-free interest rate

 

0.50%

 

1.02%

Dividend yield

 

 

Fair value underlying common stock

 

$0.18

 

$2.95

XML 50 R27.htm IDEA: XBRL DOCUMENT v3.22.1
Income Taxes (Tables)
12 Months Ended
Dec. 31, 2021
Income Tax Disclosure [Abstract]  
Schedule of Effective Income Tax Rate Reconciliation

The following table summarizes the differences between the statutory federal income tax rate and the Company's effective income tax rate (percent data):

 

Rate Reconciliation

 

2020

 

 

 

 

 

2021

 

 

 

 

Net Loss Before Taxes

 

$

(5,802,201

)

 

 

 

 

$

(12,862,468

)

 

 

 

Benefit at statutory rate

 

 

(1,218,462

)

 

 

21.00

%

 

 

(2,701,118

)

 

 

21.00

%

State tax benefit net of federal benefit

 

 

(264,152

)

 

 

4.55

%

 

 

(590,728

)

 

 

4.59

%

Permanent book/tax differences

 

 

10,161

 

 

 

(0.18

%)

 

 

(85,678

)

 

 

0.67

%

Other adjustments

 

 

(34,591

)

 

 

0.60

%

 

 

2,093

 

 

 

(0.02

%)

R&D credit carryforward

 

 

(46,608

)

 

 

0.80

%

 

 

(85,000

)

 

 

0.66

%

Change in valuation allowance

 

 

1,555,740

 

 

 

(26.81

%)

 

 

3,460,431

 

 

 

(26.90

%)

Other

 

 

(2,088

)

 

 

0.04

%

 

 

 

 

 

0.00

%

Income tax expense/(benefit)

 

$

 

 

 

0.00

%

 

$

 

 

 

0.00

%

 

 

Schedule of Deferred Tax Assets and Liabilities

The tax effects of temporary differences that give rise to significant portions of the deferred tax assets and deferred tax liabilities at December 31, 2020 and 2021 are presented below:

 

 

 

2020

 

 

2021

 

Deferred tax assets:

 

 

 

 

 

 

Federal net operating loss carryforward

 

$

3,102,649

 

 

$

5,479,664

 

State net operating loss carryforward

 

 

658,595

 

 

 

1,164,970

 

Accrued expenses

 

 

24,585

 

 

 

12,356

 

Stock-based compensation

 

 

2,821

 

 

 

84,612

 

Deferred rent

 

 

2,089

 

 

 

307

 

R&D credit

 

 

133,015

 

 

 

218,015

 

Unrealized gain/loss

 

 

 

 

 

16,708

 

Deferred revenue

 

 

 

 

 

397,464

 

Net deferred tax assets

 

 

3,923,754

 

 

 

7,374,096

 

Deferred tax liabilities:

 

 

 

 

 

 

Depreciable assets

 

 

(10,054

)

 

 

35

 

Net deferred tax liabilities

 

 

(10,054

)

 

 

35

 

Less: valuation allowance

 

 

(3,913,700

)

 

 

(7,374,131

)

Net deferred tax asset (after valuation allowance)

 

$

 

 

$

 

XML 51 R28.htm IDEA: XBRL DOCUMENT v3.22.1
Commitments and Contingencies (Tables)
12 Months Ended
Dec. 31, 2021
Operating Leases Future Minimum Payments Due [Abstract]  
Summary of the future minimum payments for the lease and sublease agreements

The future minimum payments for the lease and sublease agreements at December 31, 2021 are as follows:

 

2022 (remaining 2 months)

 

$

36,000

 

XML 52 R29.htm IDEA: XBRL DOCUMENT v3.22.1
Organization and Summary of Significant Accounting Policies - Additional information (Details) - USD ($)
12 Months Ended
Jul. 22, 2021
Jun. 25, 2021
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Stockholders' Equity, Reverse Stock Split   a 3-for-7 reverse stock split for all issued and outstanding common stock      
Investments     $ 11,522,050 $ 1,599,750  
Accounts receivable, net     133,000 2,500,000  
Proceeds from initial public offering     $ 56,000,000 0  
Common stock issued to holder of redeemable preferred stock 23,768,416        
Cumulative Dividends $ 2,800,000        
Percentage of Cumulative Dividends     6.00%    
Cash and cash equivalents     $ 11,730,677 8,455,834 $ 7,355,834
Short-term investments     24,983,520  
Long Term Investments     11,522,050 1,599,750  
Research and development     27,900,000    
Revenue recognized     4,099,750  
Forfeiture Of Cumulative Dividends     2,822,081 0  
Deferred offering costs reclassified to stockholders equity     6,800,000    
federal payroll taxes     250,000 250,000  
Series A Preferred Stock          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Cumulative Dividends       348,490  
Forfeiture Of Cumulative Dividends     753,307    
Series B Preferred Stock          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Cumulative Dividends       776,804  
Forfeiture Of Cumulative Dividends     1,550,403    
Series C Preferred Stock          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Cumulative Dividends       146,381  
Forfeiture Of Cumulative Dividends     $ 518,371    
Minimum          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Property, Plant and Equipment, Useful Life     3 years    
Maximum          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Property, Plant and Equipment, Useful Life     7 years    
U S Government Backed Securities          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Investments     $ 9,900,000    
Short-term investments     25,000,000.0    
Long Term Investments     9,900,000    
IPO | US Treasury Notes Securities          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Proceeds from initial public offering     9,900,000    
IPO | US Treasury Bill Securities          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Proceeds from initial public offering     $ 25,000,000.0    
Common Stock [Member]          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Issuance of common stock upon initial public offering, net of issuance cost, Shares     7,000,000    
Common Stock [Member] | IPO          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Issuance of common stock upon initial public offering, net of issuance cost, Shares 7,000,000        
Share Price $ 8.00        
Proceeds from initial public offering $ 49,200,000        
Accounts Payable and Accrued Liabilities [Member]          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Deferred revenue, Current     $ 1,800,000    
Wugen License          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Investments     1,600,000 1,600,000  
Accounts receivable, net     2,500,000    
Long Term Investments     1,600,000 1,600,000  
Revenue recognized       4,100,000  
Consideration received in shares of common stock       $ 1,600,000  
Deferred Revenue     $ 1,800,000    
XML 53 R30.htm IDEA: XBRL DOCUMENT v3.22.1
Property and Equipment, Net - Schedule of Property and Equipment (Details) - USD ($)
Dec. 31, 2021
Dec. 31, 2020
Property Plant And Equipment [Line Items]    
Property, plant and equipment, gross $ 2,766,704 $ 2,719,441
Less: Accumulated depreciation and amortization (1,647,614) (1,104,015)
Property and equipment, net 1,119,090 1,615,426
Laboratory equipment    
Property Plant And Equipment [Line Items]    
Property, plant and equipment, gross 1,949,318 1,924,596
Office Equipment    
Property Plant And Equipment [Line Items]    
Property, plant and equipment, gross 175,245 152,003
Furniture and fixtures    
Property Plant And Equipment [Line Items]    
Property, plant and equipment, gross 292,165 292,866
Leasehold improvements    
Property Plant And Equipment [Line Items]    
Property, plant and equipment, gross $ 349,976 $ 349,976
XML 54 R31.htm IDEA: XBRL DOCUMENT v3.22.1
Property and Equipment, Net - Additional Information (Details) - USD ($)
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Property Plant And Equipment [Line Items]    
Depreciation and amortization expense $ 543,598 $ 572,867
Research and development expense $ 353,388 $ 362,892
XML 55 R32.htm IDEA: XBRL DOCUMENT v3.22.1
Fair Value of Financial Instruments - Summary of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail) - USD ($)
Dec. 31, 2021
Dec. 31, 2020
Assets:    
Assets $ 44,412,319 $ 6,752,266
Money Market Funds [Member]    
Assets:    
Assets 9,506,499 6,752,266
Treasury bills [Member]    
Assets:    
Assets 24,983,520  
Treasury notes [Member]    
Assets:    
Assets 9,922,300  
Investments [Member]    
Assets:    
Investment (Note 4)   0
Level 1 [Member]    
Assets:    
Assets 44,412,319 6,752,266
Level 1 [Member] | Money Market Funds [Member]    
Assets:    
Assets 9,506,499 6,752,266
Level 1 [Member] | Treasury bills [Member]    
Assets:    
Assets 24,983,520  
Level 1 [Member] | Treasury notes [Member]    
Assets:    
Assets 9,922,300  
Level 1 [Member] | Investments [Member]    
Assets:    
Investment (Note 4)   0
Level 2 [Member]    
Assets:    
Assets 0 0
Level 2 [Member] | Money Market Funds [Member]    
Assets:    
Assets 0 0
Level 2 [Member] | Treasury bills [Member]    
Assets:    
Assets 0  
Level 2 [Member] | Treasury notes [Member]    
Assets:    
Assets 0  
Level 2 [Member] | Investments [Member]    
Assets:    
Investment (Note 4)   0
Level 3 [Member]    
Assets:    
Assets 0 1,599,750
Level 3 [Member] | Money Market Funds [Member]    
Assets:    
Assets 0 0
Level 3 [Member] | Treasury bills [Member]    
Assets:    
Assets 0  
Level 3 [Member] | Treasury notes [Member]    
Assets:    
Assets $ 0  
Level 3 [Member] | Investments [Member]    
Assets:    
Assets   $ 1,599,750
XML 56 R33.htm IDEA: XBRL DOCUMENT v3.22.1
Investments - Additional Information (Details) - USD ($)
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Net Investment Income [Line Items]    
Investments $ 11,522,050 $ 1,599,750
Consideration received on fair value of securities 1,600,000  
Proceeds from initial public offering 56,000,000 0
Wugen License    
Net Investment Income [Line Items]    
Investments 1,600,000 $ 1,600,000
US Treasury Bill Securities [Member] | I P O [Member]    
Net Investment Income [Line Items]    
Proceeds from initial public offering 25,000,000.0  
U S Treasury Notes Securities [Member] | I P O [Member]    
Net Investment Income [Line Items]    
Proceeds from initial public offering $ 9,900,000  
XML 57 R34.htm IDEA: XBRL DOCUMENT v3.22.1
Accrued Liabilities and Other Current Liabilities - Additional Information (Details) - USD ($)
12 Months Ended
Jan. 08, 2021
Dec. 31, 2021
Dec. 31, 2020
May 20, 2020
Payables And Accruals [Line Items]        
Accrued liabilities and other current liabilities   $ 2,097,925 $ 845,741  
Debt instrument, decrease, forgiveness   567,311  
Accounts payable and accrued liabilities, current   2,100,000    
Accounts Payable and Accrued Liabilities [Member]        
Payables And Accruals [Line Items]        
Deferred revenue, Current   1,800,000    
Manufacturing materials   48,750    
Legal fees   51,000    
Other expense   $ 50,000    
SBA Paycheck Protection Loan [Member]        
Payables And Accruals [Line Items]        
Short-term debt     567,311 $ 563,590
Accrued Expenses Current [Member]        
Payables And Accruals [Line Items]        
Accrued expenses current     $ 273,907  
Debt instrument, decrease, forgiveness $ 567,311      
XML 58 R35.htm IDEA: XBRL DOCUMENT v3.22.1
License Agreement - Additional Information (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Disclosure - License Agreement - (Details) [Line Items]    
Amount Considered For Performance Obligations   $ 4.1
Selling Price $ 2.5  
License Agreement Description For revenue-based royalties, including milestone payments based on the level of sales, the Company will include royalties in the transaction price at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty is allocated has been satisfied (or partially satisfied).  
Residual Approach [Member]    
Disclosure - License Agreement - (Details) [Line Items]    
Selling Price $ 1.6  
XML 59 R36.htm IDEA: XBRL DOCUMENT v3.22.1
Redeemable Preferred Stock - Additional Information (Details) - USD ($)
Dec. 31, 2021
Jul. 22, 2021
Dec. 31, 2020
Class Of Stock [Line Items]      
Total redeemable preferred stock   $ 31,115,399
Cumulative Dividends   $ 2,800,000  
Preferred stock, shares authorized 10,000,000    
Preferred stock, shares issued 0    
Series C Redeemable preferred stock [Member]      
Class Of Stock [Line Items]      
Temporary Equity, Shares Issued 0   5,439,112
Share Price     $ 2.05
Total redeemable preferred stock   $ 11,294,301
Series C Redeemable preferred stock [Member] | Proceeds From Issuance Of Preferred Stock      
Class Of Stock [Line Items]      
Total redeemable preferred stock     $ 11,200,000
XML 60 R37.htm IDEA: XBRL DOCUMENT v3.22.1
Net Loss Per Share - Summary of Basic and Diluted Net Income (Loss) Per Common Share (Detail) - USD ($)
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Numerator:    
Net loss $ (12,862,468) $ (5,802,201)
Less: cumulative preferred dividends earned in the period, net of forfeitures 0 (1,271,675)
Net loss available for distribution to common stockholders $ (12,862,468) $ (7,073,876)
Denominator:    
Weighted average shares outstanding, basic and diluted 18,770,935 4,739,285
Net loss per share, basic and diluted $ (0.69) $ (1.49)
XML 61 R38.htm IDEA: XBRL DOCUMENT v3.22.1
Net Loss Per Share - Summary of Outstanding Potentially Dilutive Securities (Detail) - shares
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]    
Potentially diluted securities 1,770,739 24,510,530
Redeemable Preferred Stocks    
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]    
Potentially diluted securities 23,768,416
Common Stock Options    
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]    
Potentially diluted securities 1,770,739 742,114
XML 62 R39.htm IDEA: XBRL DOCUMENT v3.22.1
Stock-Based Compensation - Additional Information (Details) - USD ($)
12 Months Ended
Jun. 21, 2021
Dec. 31, 2021
Dec. 31, 2020
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]      
Dividend yield   0.00% 0.00%
Intrinsic value exercised   $ 447,115 $ 6,032
Weighted average fair value of options granted   $ 4.16 $ 0.20
Employee Benefits and Share-based Compensation   $ 6,750
Unrecognized employee stock based compensation     $ 103,045
Unrecognized compensation, weighted average amortization period     5 years 1 month 13 days
Unrecognized employee stock based compensation cost   0 $ 0
Research and Development Expense [Member]      
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]      
Employee Benefits and Share-based Compensation   25,239 9,590
General and Administrative Expense      
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]      
Employee Benefits and Share-based Compensation   $ 335,736 $ 12,285
2019 Plan [Member] | Maximum      
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]      
Incentive stock option period 10 years    
2019 Plan [Member] | Minimum      
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]      
Incentive stock option period 4 years    
2021 Plan [Member]      
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]      
Incentive stock option period 10 years    
2021 Plan [Member] | Series of Individually Immaterial Business Acquisitions [Member]      
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]      
Voting Power percentage 10.00%    
2021 Plan [Member] | Common Class A      
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]      
Common stock reserved 3,444,343    
XML 63 R40.htm IDEA: XBRL DOCUMENT v3.22.1
Stock-Based Compensation - Summary of Stock Option Activities (Details) - USD ($)
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]      
Number of options outstanding, beginning of period 742,047 586,662  
Number of options granted 1,249,287 263,976  
Number of options exercised (206,455) (75,851)  
Number of options, forfeited or cancelled (14,140) (32,740)  
Number of options outstanding, ending of period 1,770,739 742,047 586,662
Number of options exercisable, end of period 41,084 88,531  
Weighted average exercise price outstanding, beginning of period $ 0.16 $ 0.13  
Weighted average exercise price, options granted 4.16 0.20  
Weighted average exercise price, options exercised 0.13 0.13  
Weighted average exercise price, options forfeited or cancelled 0.19 0.12  
Weighted average exercise price outstanding, end of period 2.96 0.16 $ 0.13
Weighted average exercise price, options exercisable $ 0.17 $ 0.15  
Weighted average remaining contracted terms (in years) outstanding, beginning of period   9 years 1 month 6 days 9 years 7 months 6 days
Weighted average remaining contracted terms (in years) outstanding, ending of period 9 years 9 years 1 month 6 days  
Weighted average remaining contracted terms (in years) exercisable 7 years 10 months 24 days 9 years  
Aggregate intrinsic value outstanding, beginning of period $ 39,078 $ 5,500  
Aggregate intrinsic value outstanding, end of period 1,124,215 39,078 $ 5,500
Aggregate intrinsic value options exercisable $ 87,522 $ 5,413  
XML 64 R41.htm IDEA: XBRL DOCUMENT v3.22.1
Stock-Based Compensation - Summary of Assumptions Used in Black-Scholes Model (Details) - $ / shares
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]    
Expected term (years) 6 years 2 months 26 days 6 years 3 months
Expected volatility 83.18% 87.30%
Risk-free interest rate 1.02% 0.50%
Dividend yield 0.00% 0.00%
Fair value underlying common stock $ 2.95 $ 0.18
XML 65 R42.htm IDEA: XBRL DOCUMENT v3.22.1
Employee Benefit Plan - Additional Information (Details) - USD ($)
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Compensation And Retirement Disclosure [Abstract]    
Defined Contribution Plan, Employer Discretionary Contribution Amount $ 146,400 $ 173,400
XML 66 R43.htm IDEA: XBRL DOCUMENT v3.22.1
Income Taxes - Additional Information (Details) - USD ($)
12 Months Ended
Mar. 27, 2020
Dec. 31, 2021
Dec. 31, 2020
Income Tax Examination [Line Items]      
Income tax expense/(benefit)   $ 0 $ 0
Income tax provisions under CARES Act   The CARES Act, among other things, contains modifications on the limitation of business interest expense under Section 163(j), allow for net operating loss ("NOL") carryovers and carrybacks to offset 100% of taxable income for taxable years before 2021, and includes a technical correction to the TCJA with respect to Qualified Improvement Property ("QIP") where such property has a 15-year recovery period for purposes of the general depreciation system of Section 168(a). The Company is currently evaluating the impact of the CARES Act, and aside from the 15-year QIP technical correction, it believes that none of other modifications or tax law changes will result in any material benefit or apply.  
Increase in valuation allowance   $ 3,500,000  
Taxable income utilization percentage under CARES Act 100.00%    
Federal and state NOL taxable income offset percentage   80.00% 100.00%
Federal research and development credits carryforwards   $ 218,015 $ 133,015
Carryforwards expiration term   2038 through 2041  
Valuation allowance available to reduce deferred tax asset   $ 7,400,000  
Federal [Member]      
Income Tax Examination [Line Items]      
Net operating loss carryforwards   26,100,000 14,800,000
State [Member]      
Income Tax Examination [Line Items]      
Net operating loss carryforwards   $ 26,800,000 $ 15,200,000
XML 67 R44.htm IDEA: XBRL DOCUMENT v3.22.1
Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details) - USD ($)
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Reconciliation Of Effective Income Tax Rate [Line Items]    
Net Loss Before Taxes $ (12,862,468) $ (5,802,201)
Benefit at statutory rate (2,701,118) (1,218,462)
State tax benefit net of federal benefit (590,728) (264,152)
Permanent book/tax differences (85,678) 10,161
Other adjustments 2,093 (34,591)
R&D credit carryforward 85,000 46,608
Change in valuation allowance 3,460,431 1,555,740
Other 0 2,088
Income Tax Expense (Benefit), Total $ 0 $ 0
Benefit at statutory rate 21.00% 21.00%
State tax benefit net of federal benefit 4.59% 4.55%
Permanent book/tax differences 0.67% (0.18%)
Other adjustments (0.02%) 0.60%
R&D credit carryforward 0.66% 0.80%
Change in valuation allowance (26.90%) (26.81%)
Other 0.00% 0.04%
Income tax expense/(benefit) 0.00% 0.00%
XML 68 R45.htm IDEA: XBRL DOCUMENT v3.22.1
Income Taxes - Components of Net Deferred Taxes (Detail) - USD ($)
Dec. 31, 2021
Dec. 31, 2020
Deferred tax assets:    
Federal net operating loss carryforward $ 5,479,664 $ 3,102,649
State net operating loss carryforward 1,164,970 658,595
Accrued expenses 12,356 24,585
Stock option compensation 84,612 2,821
Deferred rent 307 2,089
R&D credit 218,015 133,015
Unrealized Gain/Loss 16,708  
Deferred revenue 397,464  
Net deferred tax assets 7,374,096 3,923,754
Deferred tax liabilities:    
Depreciable assets 35 (10,054)
Net deferred tax liabilities 35 10,054
Less: valuation allowance (7,374,131) (3,913,700)
Net deferred tax asset (after valuation allowance) $ 0 $ 0
XML 69 R46.htm IDEA: XBRL DOCUMENT v3.22.1
Commitments and Contingencies - Summary of the Future Minimum Payments for the Lease and Sublease Agreements (Detail)
Dec. 31, 2021
USD ($)
Operating Leases Future Minimum Payments Due [Abstract]  
2022 (remaining 3 months) $ 36,000
XML 70 R47.htm IDEA: XBRL DOCUMENT v3.22.1
Commitments and Contingencies - Additional Information (Details) - USD ($)
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Jan. 31, 2022
Operating Leased Assets [Line Items]      
Operating leases, rent expense $ 208,348 $ 183,943  
Contractual obligation 2,500,000 3,900,000 $ 181,600
Research and Development Expense [Member]      
Operating Leased Assets [Line Items]      
Operating leases, rent expense $ 100,457 $ 82,971  
XML 71 R48.htm IDEA: XBRL DOCUMENT v3.22.1
Subsequent Events - Additional Information (Details) - Subsequent Event [Member] - USD ($)
24 Months Ended
Feb. 29, 2024
Jan. 31, 2022
Subsequent Event [Line Items]    
Term of agreements renewal periods 2 years  
Future minimum payments   $ 339,300
XML 72 hcwb-20211231_htm.xml IDEA: XBRL DOCUMENT 0001828673 us-gaap:OfficeEquipmentMember 2020-12-31 0001828673 srt:MaximumMember 2021-01-01 2021-12-31 0001828673 us-gaap:CommonStockMember 2019-12-31 0001828673 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-12-31 0001828673 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001828673 us-gaap:RetainedEarningsMember 2020-12-31 0001828673 hcwb:TwoThousandTwentyOnePlanMember 2021-06-21 2021-06-21 0001828673 hcwb:TreasuryNotesMember 2021-12-31 0001828673 hcwb:TreasuryBillsMember 2021-12-31 0001828673 hcwb:SeriesARedeemablePreferredStockMember us-gaap:PreferredStockMember 2020-12-31 0001828673 hcwb:SeriesARedeemablePreferredStockMember us-gaap:PreferredStockMember 2019-12-31 0001828673 us-gaap:FairValueInputsLevel1Member 2021-12-31 0001828673 hcwb:SeriesARedeemablePreferredStockMember 2019-12-31 0001828673 us-gaap:FairValueInputsLevel3Member 2021-12-31 0001828673 hcwb:SbaPaycheckProtectionLoanMember 2020-05-20 0001828673 hcwb:ConversionOfSeriesCRedeemablePreferredStockMember hcwb:SeriesCRedeemablePreferredStockMember 2021-01-01 2021-12-31 0001828673 hcwb:TreasuryBillsMember us-gaap:FairValueInputsLevel1Member 2021-12-31 0001828673 us-gaap:DomesticCountryMember 2021-12-31 0001828673 hcwb:WugenLicenseMember 2020-12-31 0001828673 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2021-12-31 0001828673 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0001828673 hcwb:SeriesCRedeemablePreferredStockMember us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001828673 hcwb:TreasuryNotesMember us-gaap:FairValueInputsLevel1Member 2021-12-31 0001828673 us-gaap:PreferredStockMember 2019-12-31 0001828673 us-gaap:FairValueInputsLevel2Member 2020-12-31 0001828673 us-gaap:FurnitureAndFixturesMember 2020-12-31 0001828673 us-gaap:SeriesAPreferredStockMember 2021-01-01 2021-12-31 0001828673 us-gaap:CommonStockMember 2020-01-01 2020-12-31 0001828673 hcwb:WugenLicenseMember 2021-12-31 0001828673 hcwb:SeriesCRedeemablePreferredStockMember us-gaap:PreferredStockMember 2020-12-31 0001828673 hcwb:SeriesCRedeemablePreferredStockMember us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0001828673 2021-07-22 0001828673 hcwb:SeriesBRedeemablePreferredStockMember 2021-01-01 2021-12-31 0001828673 us-gaap:InvestmentsMember us-gaap:FairValueInputsLevel3Member 2020-12-31 0001828673 us-gaap:LeaseholdsAndLeaseholdImprovementsMember 2020-12-31 0001828673 us-gaap:SubsequentEventMember 2022-03-01 2024-02-29 0001828673 us-gaap:CommonStockMember 2021-12-31 0001828673 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-12-31 0001828673 hcwb:SeriesBRedeemablePreferredStockMember us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0001828673 hcwb:SeriesCRedeemablePreferredStockMember us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0001828673 hcwb:ConversionOfSeriesBRedeemablePreferredStockMember hcwb:SeriesBRedeemablePreferredStockMember 2021-01-01 2021-12-31 0001828673 hcwb:SeriesCRedeemablePreferredStockMember 2020-01-01 2020-12-31 0001828673 us-gaap:CommonStockMember 2021-12-31 0001828673 hcwb:SeriesARedeemablePreferredStockMember us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0001828673 hcwb:SeriesARedeemablePreferredStockMember 2021-12-31 0001828673 hcwb:ProceedsFromIssuanceOfPreferredStockMember hcwb:SeriesCRedeemablePreferredStockMember 2020-12-31 0001828673 us-gaap:RetainedEarningsMember 2021-12-31 0001828673 hcwb:TreasuryBillsMember us-gaap:FairValueInputsLevel3Member 2021-12-31 0001828673 hcwb:ResidualApproachMember 2021-01-01 2021-12-31 0001828673 us-gaap:StateAndLocalJurisdictionMember 2020-12-31 0001828673 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member 2021-12-31 0001828673 us-gaap:FairValueInputsLevel3Member 2020-12-31 0001828673 srt:MinimumMember hcwb:TwoThousandNineteenPlanMember 2021-06-21 2021-06-21 0001828673 hcwb:RedeemablePreferredStocksMember 2021-01-01 2021-12-31 0001828673 us-gaap:SeriesAPreferredStockMember 2020-12-31 0001828673 2020-12-31 0001828673 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member 2021-12-31 0001828673 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001828673 hcwb:TreasuryNotesMember us-gaap:FairValueInputsLevel2Member 2021-12-31 0001828673 hcwb:TreasuryNotesMember us-gaap:FairValueInputsLevel3Member 2021-12-31 0001828673 us-gaap:CommonStockMember us-gaap:IPOMember 2021-07-22 0001828673 hcwb:CommonStockOptionsMember 2020-01-01 2020-12-31 0001828673 2022-03-22 0001828673 srt:MinimumMember 2021-01-01 2021-12-31 0001828673 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-12-31 0001828673 us-gaap:SeriesBPreferredStockMember 2020-12-31 0001828673 hcwb:ConversionOfSeriesARedeemablePreferredStockMember hcwb:SeriesARedeemablePreferredStockMember 2021-01-01 2021-12-31 0001828673 2021-12-31 0001828673 hcwb:SeriesBRedeemablePreferredStockMember us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001828673 hcwb:USGovernmentBackedSecuritiesMember 2021-12-31 0001828673 us-gaap:MoneyMarketFundsMember 2021-12-31 0001828673 hcwb:TreasuryBillsMember us-gaap:FairValueInputsLevel2Member 2021-12-31 0001828673 hcwb:SeriesBRedeemablePreferredStockMember 2021-12-31 0001828673 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0001828673 us-gaap:RetainedEarningsMember 2019-12-31 0001828673 us-gaap:LeaseholdsAndLeaseholdImprovementsMember 2021-12-31 0001828673 hcwb:SeriesARedeemablePreferredStockMember us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001828673 us-gaap:SeriesBPreferredStockMember 2021-01-01 2021-12-31 0001828673 us-gaap:AccountsPayableAndAccruedLiabilitiesMember 2021-12-31 0001828673 hcwb:TwoThousandTwentyOnePlanMember us-gaap:CommonClassAMember 2021-06-21 0001828673 hcwb:ClassBConvertibleCommonStockMember 2021-12-31 0001828673 us-gaap:CommonStockMember us-gaap:IPOMember 2021-07-22 2021-07-22 0001828673 hcwb:WugenLicenseMember 2020-01-01 2020-12-31 0001828673 us-gaap:SeriesCPreferredStockMember 2020-12-31 0001828673 us-gaap:InvestmentsMember us-gaap:FairValueInputsLevel2Member 2020-12-31 0001828673 us-gaap:CommonStockMember 2020-12-31 0001828673 hcwb:RedeemablePreferredStocksMember 2020-01-01 2020-12-31 0001828673 hcwb:SeriesCRedeemablePreferredStockMember 2021-01-01 2021-12-31 0001828673 us-gaap:InvestmentsMember us-gaap:FairValueInputsLevel1Member 2020-12-31 0001828673 hcwb:SeriesBRedeemablePreferredStockMember 2020-12-31 0001828673 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember hcwb:TwoThousandTwentyOnePlanMember 2021-06-21 0001828673 us-gaap:MoneyMarketFundsMember 2020-12-31 0001828673 us-gaap:SubsequentEventMember 2022-01-31 0001828673 hcwb:SeriesARedeemablePreferredStockMember 2020-12-31 0001828673 hcwb:SeriesCRedeemablePreferredStockMember 2020-12-31 0001828673 hcwb:SeriesARedeemablePreferredStockMember 2020-01-01 2020-12-31 0001828673 us-gaap:FairValueInputsLevel1Member 2020-12-31 0001828673 hcwb:SeriesBRedeemablePreferredStockMember 2019-12-31 0001828673 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-12-31 0001828673 hcwb:SeriesARedeemablePreferredStockMember us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0001828673 hcwb:LaboratoryEquipmentMember 2021-12-31 0001828673 hcwb:SeriesBRedeemablePreferredStockMember us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0001828673 hcwb:SeriesBRedeemablePreferredStockMember 2020-01-01 2020-12-31 0001828673 2022-01-31 0001828673 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member 2020-12-31 0001828673 2020-03-27 2020-03-27 0001828673 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member 2020-12-31 0001828673 hcwb:AccruedExpensesCurrentMember 2021-01-08 2021-01-08 0001828673 hcwb:SeriesBRedeemablePreferredStockMember us-gaap:PreferredStockMember 2019-12-31 0001828673 2021-01-01 2021-12-31 0001828673 hcwb:SeriesARedeemablePreferredStockMember 2021-01-01 2021-12-31 0001828673 2019-01-01 2019-12-31 0001828673 hcwb:SeriesCRedeemablePreferredStockMember 2021-12-31 0001828673 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2020-12-31 0001828673 us-gaap:FairValueInputsLevel2Member 2021-12-31 0001828673 hcwb:CommonStockOptionsMember 2021-01-01 2021-12-31 0001828673 2019-12-31 0001828673 hcwb:SbaPaycheckProtectionLoanMember 2020-12-31 0001828673 us-gaap:USTreasuryBillSecuritiesMember us-gaap:IPOMember 2021-01-01 2021-12-31 0001828673 2021-06-25 2021-06-25 0001828673 us-gaap:InvestmentsMember 2020-12-31 0001828673 hcwb:ClassBConvertibleCommonStockMember 2020-12-31 0001828673 us-gaap:RetainedEarningsMember 2020-01-01 2020-12-31 0001828673 us-gaap:DomesticCountryMember 2020-12-31 0001828673 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-12-31 0001828673 2020-01-01 2020-12-31 0001828673 hcwb:LaboratoryEquipmentMember 2020-12-31 0001828673 us-gaap:AccountsPayableAndAccruedLiabilitiesMember 2021-01-01 2021-12-31 0001828673 hcwb:SeriesBRedeemablePreferredStockMember us-gaap:PreferredStockMember 2020-12-31 0001828673 srt:MaximumMember hcwb:TwoThousandNineteenPlanMember 2021-06-21 2021-06-21 0001828673 us-gaap:SeriesCPreferredStockMember 2021-01-01 2021-12-31 0001828673 hcwb:AccruedExpensesCurrentMember 2020-12-31 0001828673 us-gaap:StateAndLocalJurisdictionMember 2021-12-31 0001828673 us-gaap:OfficeEquipmentMember 2021-12-31 0001828673 us-gaap:USTreasuryNotesSecuritiesMember us-gaap:IPOMember 2021-01-01 2021-12-31 0001828673 us-gaap:CommonStockMember 2020-12-31 0001828673 us-gaap:FurnitureAndFixturesMember 2021-12-31 pure shares iso4217:USD shares iso4217:USD false 0001828673 --12-31 5792302 FY 10-K true 2021-12-31 2021 false 001-40591 HCW Biologics Inc. DE 82-5024477 2929 N Commerce Parkway Miramar FL 33025 954 842–2024 Common Stock HCWB NASDAQ No No Yes Yes Non-accelerated Filer true true true false false 91400000 35779489 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Part III incorporates by reference certain information from the registrant’s definitive proxy statement (the “Proxy Statement”) relating to its 2022 Annual Meeting of Stockholders. The Proxy Statement will be filed with the United States Securities and Exchange Commission within 120 days after the end of the fiscal year to which this report relates.</span></p> 248 GRANT THORNTON LLP Miami, FL 8455834 11730677 24983520 2500000 133000 538306 2196557 654528 1436617 12148668 40480371 1599750 11522050 1615426 1119090 34242 393318 15398086 53514829 155343 223664 845741 2097925 1001084 2321589 0.0001 0.0001 14738948 6316691 0 0 6140792 0.0001 0.0001 28029449 12012617 0 0 13680306 0.0001 0.0001 18181818 5439112 0 0 11294301 31115399 0.0001 0.0001 10000000 4285714 0 0 429 0 0.0001 0.0001 74950215 507680 250000000 35768264 3577 0 81827006 -16718877 -30637343 -16718397 51193240 15398086 53514829 4099750 4099750 7255227 8173624 2669048 5194210 9924275 13367834 -5824525 -13367834 22324 505366 -5802201 -12862468 1271675 0 -7073876 -12862468 -1.49 -0.69 4739285 18770935 6316691 12012617 12883859 0 4717542 472 -9676766 -9676294 75851 8 9895 9903 5439112 11144520 21871 21871 348490 776804 146381 31766 1239910 1271676 19643 3400 -5802201 -5802201 6316691 6140792 12012617 13680306 5439112 11294301 4793393 480 -16718877 -16718397 206455 20 29517 29537 193050 430319 336651 33053 926966 960019 7858 20398 7000000 700 49239247 49239947 -6316691 -6333842 6316691 632 6353474 -20265 6333841 -12012617 -14118483 12012613 1201 14170312 -53030 14118483 -5439112 -11651350 5439112 544 11706534 -55737 11651341 360975 360975 -12862468 -12862468 35768264 3577 81827006 -30637343 51193240 -5802201 -12862468 572868 543598 21875 360975 0 567311 0 -65832 23043 28256 2500000 -2367000 2118264 2799415 -628647 1887816 -10431326 -10975717 186682 47263 0 24987277 0 9984375 -186682 -35018915 563590 0 11144520 0 0 56000000 0 6760053 9898 29528 11718008 49269475 1100000 3274843 7355834 8455834 8455834 11730677 1599750 0 1271676 0 0 2822081 567311 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">1. Organization and Summary of Significant Accounting Policies</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Organization</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">HCW Biologics Inc. (the “Company”) is a biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The Company believes age-related low-grade chronic inflammation, or “inflammaging,” is a significant contributing factor to several chronic diseases and conditions, such as cancer, cardiovascular disease, diabetes, neurodegenerative diseases, and autoimmune diseases. The Company is located in Miramar, Florida and was incorporated in the state of Delaware in April 2018.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Reverse Stock Split</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In June 2021, the Company’s board of directors and stockholders approved an amendment to the Company’s certificate of incorporation to effect </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">a 3-for-7 reverse stock split for all issued and outstanding common stock</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, redeemable preferred stock, and stock options, that was effective on June 25, 2021 (the “Reverse Stock Split”). The number of authorized shares and the par values of the common stock and redeemable preferred stock were not adjusted as a result of the Reverse Stock Split. The accompanying financial statements and notes to the financial statements give retroactive effect to the Reverse Stock Split for all periods presented.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Liquidity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On December 24, 2020, the Company entered into the Exclusive Worldwide License Agreement with Wugen Inc. (“Wugen License”). As a result of this transaction, as of December 31, 2020 and 2021, the Company holds a minority interest in Wugen Inc. (“Wugen”) carried at $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, the fair value on the effective date of the Wugen License. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The underlying shares of common stock are not currently traded on any public market and thus have limited marketability. These shares were subject to an anti-dilution provision based on the terms of a subsequent financing. During the year ended December 31, 2021, the Company received additional shares in Wugen under the terms of the anti-dilution provision for no additional consideration. The Company deemed the additional shares to be a similar instrument to those shares already held. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During the year ended December 31, 2021, the Company received cash payments of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for amounts due under the terms of the Wugen License.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, the Company had not generated any revenue from sales of its immunotherapeutic products. In the course of its development activities, the Company has sustained operating losses and expects to continue to incur operating losses for the foreseeable future. Since inception, substantially all the Company’s activities have consisted of research, development, establishing large-scale cGMP production for clinical trials, and raising capital.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On July 19, 2021, the Company’s registration statement on Form S-1 for its initial public offering (“IPO”) was declared effective by the Securities and Exchange Commission (the “SEC”). On July 22, 2021, the Company closed its IPO with the sale of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock, at a public offering price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share, resulting in net proceeds of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">49.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, after deducting underwriting discounts and commissions and estimated offering expenses paid by the Company. The IPO met the provisions for mandatory conversion of all shares of redeemable preferred stock according to the designations for these securities. As a result of the conversion, the Company issued </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">23,768,416</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock to the former holders of redeemable preferred stock. In addition, as a result of conditions for mandatory conversion, the Company was relieved of its obligation to pay $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in cumulative dividends that were accrued and unpaid on the conversion date.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, the Company had cash and cash equivalents of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, short-term investments of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">25.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million held in U.S. government-backed securities, and long-term investments of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million held in U.S. government-backed securities. Since inception to December 31, 2021, the Company incurred cumulative net losses of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">27.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. Management expects to incur additional losses in the future to conduct product research and development and recognizes the need to raise additional capital to fully implement its business plan. The Company intends to raise capital through the issuance of additional equity financing, sale of investment, and/or third-party collaboration funding. However, if such financing is not available at adequate levels, the Company will need to reevaluate its operating plan and may be required to delay the development of some of its products. The Company expects its cash and cash equivalents and current and long-term investments in government-backed securities as of December 31, 2021 will be sufficient to fund operating expenses and capital expenditure requirements for a period of at least one year from the issuance date of the financial statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Summary of Significant Accounting Policies</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Basis of Presentation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”).</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Segment Reporting</span></p></div><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has one operating segment. The Company’s chief operating decision maker, its Chief Executive Officer, reviews financial information on an aggregate basis for allocating capital and evaluating performance.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Use of Estimates</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts in the financial statements and accompanying notes. Management must apply significant judgment in this process. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ from estimates.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Cash and Cash Equivalents</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash and cash equivalents consist of demand deposits at financial institutions, money market funds, and highly liquid investments with original maturities of three months or less.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Fair Value Measurements</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 820, </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Fair Value Measurement</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> (“Topic 820”), establishes a fair value hierarchy for those instruments measured at fair value that distinguishes between fair value measurements based on market data (observable inputs) and those based on the Company’s own assumptions (unobservable inputs). This hierarchy maximizes the use of observable inputs and minimizes the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 1: Observable inputs such as quoted prices in active markets;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 3: Unobservable inputs in which there is little or no market data, which require a reporting entity to develop its own assumptions.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Fair value measurements are classified based on the lowest level of input that is significant to the measurement. The Company’s assessment of the significance of a particular input to the fair value measurement requires judgment, which may affect the valuation of the assets and liabilities and their placement within the fair value hierarchy levels. The determination of the fair values, as disclosed in Note 3, takes into account the market for the Company’s financial assets and liabilities, the associated credit risk, and other factors as required. The Company considers active markets as those in which transactions for the assets or liabilities occur in sufficient frequency and volume to provide pricing information on an ongoing basis.</span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span><span style="font-size:12.0pt;font-family:Times New Roman;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Concentration of Credit Risk and Other Risks and Uncertainties</span></span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash, cash equivalents, accounts receivable, and investments. The Company’s cash and cash equivalents are deposited in accounts with financial institutions that management believes are of high credit quality. Such deposits may, at times, exceed federally insured limits. The Company has not experienced any losses on its deposits of cash and cash equivalents.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Currently all of the Company's revenues are derived from the Wugen License. For the year ended December 31, 2020, the Company recognized revenues of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.1</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.6</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of which was consideration received in the form of shares of Wugen common stock. These shares have limited marketability, and there was no public market on which to trade these shares as of December 31, 2021. As of December 31, 2021, the Company received cash payments of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.8</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for the sale of research and clinical-grade material, which are currently recognized as deferred revenue on the accompanying balance sheet since the criteria for revenue recognition have not been met.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company is highly dependent on a third-party manufacturer to supply drug products for its research and development activities of its programs, including clinical and non-clinical studies. These programs could be adversely affected by a significant interruption in the supply of such drug products. The Company has no off-balance sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts or other hedging arrangements.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Property and Equipment, Net</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment is stated at cost less accumulated depreciation. Depreciation expense is calculated using the straight-line method over the estimated useful lives of the assets, which range from </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</span></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> to </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7 </span></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">years. Leasehold improvements are amortized on a straight-line method over the shorter of the useful life of the leasehold improvement or the term of the lease. Upon retirement or sale of the assets, the cost and related accumulated depreciation and amortization are removed from the accompanying balance sheets and the resulting gain or loss is recorded to the statements of operations. Repairs and maintenance are expensed as incurred.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Impairment of Long-Lived Assets</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Long-lived assets are reviewed for indications of possible impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. Recoverability is measured by comparison of the carrying amounts to the future undiscounted cash flows attributable to these assets. An impairment loss is recognized to the extent an asset group is not recoverable, and the carrying amount exceeds the projected discounted future cash flows arising from these assets. Impairment losses, if any, are recognized in earnings. There were no impairment losses for any of the periods presented.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Redeemable Preferred Stock</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company applied the relevant accounting standards to distinguish liabilities from equity when we assessed the classification and measurement of preferred stock. Preferred Stock subject to mandatory redemptions was considered a liability and measured at fair value. Conditionally redeemable preferred stock issued by the Company was considered mezzanine or temporary equity and presented outside of the equity section of the accompanying balance sheet as of December 31, 2020.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Cumulative Dividends on Preferred Stock</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company’s Preferred Stock earned a </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% cumulative dividend that compounded annually, whether or not declared by the Board of Directors. The Company considered cumulative dividends a legal obligation that should be recognized and accrued until such time as the dividends were declared and paid or liquidation occurred.</span></p></div><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If Preferred Stock was classified as other than equity, this obligation was presented within Redeemable preferred stock. If Preferred Stock was included within equity, this obligation was treated as a long-term liability and presented within other liabilities in the accompanying balance sheet. As of December 31, 2020, all of the Company’s Preferred Stock was classified as other than equity, or mezzanine equity. Holders of Preferred Stock earned cumulative dividends beginning on June 7, 2019, with the original issuance of Series B Preferred Stock. During the year ended December 31, 2020, Series A Preferred Stock earned $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">348,490</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> in cumulative dividends; Series B Preferred Stock earned $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">776,804</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> in cumulative dividends; and Series C Preferred Stock earned $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">146,381</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> in cumulative dividends. Upon the IPO, all of the Company’s preferred stock converted to common stock. At that time, Series A Preferred Stock forfeited $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">753,307</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of cumulative dividends; Series B Preferred Stock forfeited $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,550,403</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of cumulative dividends; and Series C Preferred Stock forfeited $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">518,371</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of cumulative dividends. No dividends were declared as of the conversion date. </span></span><span style=""/><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Collaborative Arrangements</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">When the Company enters into collaboration arrangements, it assesses whether the arrangements fall within the scope of FASB issued ASC 808, </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Collaborative Arrangements,</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> based on whether the arrangements involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. If the payments from the collaboration partner to the Company represent consideration from a customer, such as license fees and contract research and development activities, the Company accounts for those payments within the scope of FASB issued ASC 606, </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Revenue from Contracts with Customers </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(“Topic 606”). However, if the Company concludes that the payments are not from a customer, for certain activities and associated payments, such as for certain collaborative research, development, manufacturing, and commercial activities, these payments are presented as a reduction of research and development expense or general and administrative expense, based on where the Company presents the underlying expense.</span></p></div><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Revenue Recognition</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company recognizes revenue when its customer or collaborator obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To determine revenue recognition for arrangements that are within the scope of Topic 606, it performs the following five steps:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="margin-left:6.667%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">i.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">identify the contract(s) with a customer;</span></div></div><div style="margin-left:6.667%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">ii.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">identify the performance obligations in the contract;</span></div></div><div style="margin-left:6.667%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">iii.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">determine the transaction price;</span></div></div><div style="margin-left:6.667%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">iv.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">allocate the transaction price to the performance obligations within the contract; and</span></div></div><div style="margin-left:6.667%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">v.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">recognize revenue when (or as) the entity satisfies a performance obligation.</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">At contract inception, once the contract is determined to be within the scope of Topic 606 and it is probable of collection, the Company assesses the goods or services promised within the contract to determine whether each promised good or service is a performance obligation. The promised goods or services in the Company’s arrangements may consist of a license, or options to license, the Company’s intellectual property and research, development, and manufacturing services. The Company may provide options to additional items in such arrangements, which are accounted for as separate contracts when the customer elects to exercise such options, unless the option provides a material right to the customer. Performance obligations are promises in a contract to transfer a distinct good or service to the customer that (i) the customer can benefit from on its own or together with other readily available resources, and (ii) is separately identifiable from other promises in the contract. Goods or services that are not individually distinct performance obligations are combined with other promised goods or services until such combined group of promises meet the requirements of a performance obligation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company determines the transaction price based on the amount of consideration the Company expects to receive for transferring the promised goods or services in the contract. Consideration may be fixed, variable, or a combination of both. At contract inception for arrangements that include variable consideration, the Company estimates the probability and extent of consideration it expects to receive under the contract utilizing either the most likely amount method or expected amount method, whichever best estimates the amount expected to be received. The Company then considers any constraints on the variable consideration and includes in the transaction price variable consideration to the extent it is deemed probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company then allocates the transaction price to each performance obligation based on the relative standalone selling price and recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) control is transferred to the customer and the performance obligation is satisfied. For performance obligations which consist of licenses and other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company records amounts as accounts receivable when the right to consideration is deemed unconditional. When consideration is received, or such consideration is unconditionally due, from a customer prior to transferring goods or services to the customer under the terms of a contract, a contract liability is recorded as deferred revenue.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Deferred Revenue</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred revenue represents amounts billed, or in certain cases, yet to be billed to the Company’s customer for which the related revenues have not been recognized because one or more of the revenue recognition criteria have not been met. The current portion of deferred revenue represents the amount to be recognized within one year from the balance sheet date based on the estimated performance period of the underlying performance obligations. As December 31, 2021, current deferred revenue includes amounts of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million allocated to the development supply agreement performance obligation under the Wugen License that is included within Accrued liabilities and other current liabilities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Investments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company holds a minority interest in Wugen. The underlying shares of common stock are not traded on any public market and thus have limited marketability. The Company does not have significant influence over the operating and financial policies of Wugen. As a result, the Company has accounted for this investment using the measurement alternative whereby the investment is recorded at cost less impairment, adjusted for observable price changes in orderly transactions for an identical or similar investment of the same investee. No impairment was recognized during the years ended December 31, 2020 and 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company invests net proceeds of its IPO in bills and notes issued by the U.S. Treasury which are classified as trading securities. As of December 31, 2021, the Company holds, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">25.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in U.S. Treasury bills included in Short-term investments and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in U.S. Treasury notes included in Investments in the accompanying balance sheet.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Research and Development Expenses</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development costs are expensed as incurred and include salaries, benefits, and other operating costs such as outside services, supplies and allocated overhead expenses. The Company may perform research and development for its own proprietary drug candidates and technology development or for certain third parties under collaborative arrangements. For its proprietary drug candidates and its internal technology development programs, the Company invests its own funds without reimbursement from a third party. Where the Company performs research and development activities under a clinical joint development collaboration, it records the partner’s share of collaboration expenses as a reduction to research and development expense when reimbursement amounts are due under the agreement.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company records an accrued expense for the estimated costs of its contract manufacturing activities performed by third parties. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to vendors. Payments under the contracts include upfront payments and milestone payments, which depend on factors such as the achievement of the completion of certain stages of the manufacturing process. For purposes of recognizing expense, the Company assesses whether the production process is sufficiently defined to be considered the delivery of a good, as evidenced by predictive or contractually required yields in the production process, or the delivery of a service, where processes and yields are developing and less certain. If the Company considers the process to be the delivery of a good, the Company recognizes the expense when the drug product is delivered, or otherwise bears risk of loss. If the Company considers the process to be the delivery of a service, the expense is recognized based on its best estimates of the contract manufacturer’s progress towards completion of the stages in the contracts. The Company recognizes and amortizes upfront payments and accrues for liabilities based on the specific terms of each arrangement. Arrangements may provide upfront payments for certain stages of the arrangement and milestone payments for the completion of certain stages, and, accordingly, may result in advance payments for services that have not been completed or goods not delivered and liabilities for stages where the contract manufacturer is entitled to a milestone payment.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Advance payments for goods or services that will be used or rendered for future research and development activities are capitalized as prepaid expenses and recognized as expense as the related goods are delivered or the related services are performed. The Company bases its estimates on the best information available at the time. However, additional information may become available to the Company which may allow it to make a more accurate estimate in future periods. In this event, the Company may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain. Such increases or decreases in cost are generally considered to be changes in estimates and will be reflected in research and development expenses in the period identified.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Patent Costs</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Costs related to filing and pursuing patent applications are recorded as general and administrative expenses in the accompanying statements of operations, and expensed as incurred since recoverability of such expenditures is uncertain.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Stock-based Compensation</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company measures its stock-based awards granted to employees and directors based on the estimated fair value of the option on the date of grant (grant date fair value) and recognizes compensation expense over the vesting period. Compensation expense is recorded as either research and development or general and administrative expenses in the accompanying statements of operations based on the function to which the related services are provided. Forfeitures are accounted for as they occur. The Company has granted options with service-based and performance-based vesting conditions.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company uses the Black-Scholes option pricing model for the respective grant to determine the grant date fair value. The Black-Scholes option pricing model requires the input of highly subjective assumptions. These variables include, but are not limited to, its stock price volatility over the term of the awards and actual and projected employee stock option exercise behaviors. Management will continue to assess the assumptions and methodologies used to calculate the estimated grant date fair value of stock-based compensation. Circumstances may change and additional data may become available over time, which could result in changes to these assumptions and methodologies and materially impact the Company’s grant date fair value determination.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For stock option grants with service-based vesting, stock-based compensation expense represents the portion of the grant date fair value of employee stock option grants recognized over the requisite service period of the awards on a straight-line basis, net of estimated forfeitures. For options that vest upon the achievement of performance milestones, the Company estimates </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">fair value at the date of grant and compensation expense is recognized using the accelerated attribution method when it is determined that the performance criteria is probable of being met.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Deferred Offering Costs</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company defers offering costs consisting of legal, accounting and other fees and costs directly attributable to its IPO. The deferred offering costs will be offset against the proceeds received upon the completion of the IPO. Deferred offering costs will be recorded under other non-current assets on the accompanying balance sheets. In the event the IPO is terminated, all of the deferred offering costs will be expensed within the Company’s statements of operations. As of </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2020, there were no deferred offering costs recorded on the accompanying balance sheets. As of December 31, 2021, deferred offering costs related to underwriting discounts and commissions and offering expenses of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.8</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million were offset against IPO proceeds upon the consummation of the IPO.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Income Taxes</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company accounts for income taxes using an asset and liability approach in accordance with applicable guidance prescribed by FASB issued ASC 740, </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Income Taxes</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> (“Topic 740”). Topic 740 requires that the deferred tax consequences of temporary differences between the amounts recorded in the financial statements and the amounts included in the federal and state income tax returns to be recognized in the balance sheet.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company makes judgments regarding the realizability of its deferred tax assets. The balance sheet carrying value of its deferred tax assets is based on whether the Company believes it is more likely than not that the Company will generate sufficient future taxable income to realize these deferred tax assets after consideration of all available evidence. The Company regularly reviews its deferred tax assets for recoverability considering historical profitability, projected future taxable income, the expected timing of the reversals of existing temporary differences and tax planning strategies. In assessing the need for a valuation allowance, the Company considers both positive and negative evidence related to the likelihood of realization of the deferred tax assets. The weight given to the positive and negative evidence is commensurate with the extent to which the evidence may be objectively verified. As such, it is generally difficult for positive evidence regarding projected future taxable income exclusive of reversing taxable temporary differences to outweigh objective negative evidence of recent financial reporting losses. Generally, cumulative loss in recent years is a significant piece of negative evidence that is difficult to overcome in determining that a valuation allowance is not needed.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company’s tax positions may be subject to income tax audits. The Company recognizes the tax benefit of an uncertain tax position only if it is more likely than not that the position is sustainable upon examination by the taxing authority, based on the technical merits. The tax benefit recognized is measured as the largest amount of benefit which is more likely than not to be realized upon settlement with the taxing authority. The Company recognizes interest accrued and penalties related to unrecognized tax benefits in its tax provision. The Company evaluates uncertain tax positions on a regular basis. The evaluations are based on a number of factors, including changes in facts and circumstances, changes in tax law, correspondence with tax authorities during the course of the audit, and effective settlement of audit issues. The provision for income taxes includes the effects of any accruals that the Company believes are appropriate, as well as the related net interest and penalties.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Tax Credit Receivable</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company is eligible for research and development credits for its research and development activities, in accordance with Internal Revenue Code (“I.R.C.”) § 41(c). The credits are generally available to offset income tax liabilities. The Company has applied approximate</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ly $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">250,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> o</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">f research and development credits to offset its federal payroll tax expenses for both years ended December 31, 2020 and 2021, due to its small business status. As of December 31, 2020 and 2021, the current portion of outstanding payroll tax receivables is recorded in Other current assets in the accompanying balance sheets and the noncurrent portion is recorded in Other noncurrent assets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Net Loss Per Share</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period, without consideration of potential dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the sum of the weighted average number of common shares plus the potential dilutive effects of potential dilutive securities outstanding during the period. Potential dilutive securities are excluded from diluted earnings or loss per share if the effect of such inclusion is anti-dilutive. The Company’s potentially dilutive securities, which include convertible redeemable preferred stock and outstanding stock options under the 2019 Equity Incentive Plan (“2019 Plan”) and the 2021 Equity Incentive Plan (“2021 Plan”), have been excluded from the computation of diluted net loss per share as they would be anti-dilutive to the net loss per share. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company’s net loss position.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Recently Issued Accounting Pronouncements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In June 2016, FASB issued Accounting Standards Update (“ASU”) No. 2016-13, </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Financial Instruments—Credit Losses: Measurement of Credit Losses on Financial Instruments</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, as clarified in subsequent amendments to the initial guidance (collectively, “Topic 326”). Topic 326 requires measurement and recognition of expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecast. The Company adopted Topic 326 using a modified retrospective approach which requires a cumulative effect adjustment as of the beginning of the reporting period in which the guidance is adopted. Topic 326 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019, with early adoption permitted. The Company adopted Topic 326 effective January 1, 2020. The adoption did not have a material impact on our financial statements.</span></p></div><span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In February 2016, the FASB issued ASU No. 2016-02, Leases (“Topic 842”), which requires an entity to recognize assets and liabilities arising from a lease for both financing and operating leases. The ASU will also require new qualitative and quantitative disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. Topic 842 is effective for the Company in the fiscal years beginning after December 15, 2021, with early adoption permitted. The Company will adopt Topic 842 for the fiscal year ended December 31, 2022. The Company plans to use a practical expedient provided by FASB, and it will not recast comparative periods to reflect the impact of the new lease standard. Effective March 1, 2022, the Company entered into a non-cancelable operating lease for its current location with a two-year term. This is the only lease in scope of Topic 842. The Company expects accounting for the new lease under Topic 842 will materially affect the reported amount of total assets and total liabilities within the balance sheet, but it does not expect a material impact to the statement of operations</span></span><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"/> a 3-for-7 reverse stock split for all issued and outstanding common stock 1600000 1600000 2500000 7000000 8.00 49200000 23768416 2800000 11700000 25000000.0 9900000 27900000 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Basis of Presentation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”).</span></p> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Segment Reporting</span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has one operating segment. The Company’s chief operating decision maker, its Chief Executive Officer, reviews financial information on an aggregate basis for allocating capital and evaluating performance.</span> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Use of Estimates</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts in the financial statements and accompanying notes. Management must apply significant judgment in this process. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ from estimates.</span></p> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Cash and Cash Equivalents</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash and cash equivalents consist of demand deposits at financial institutions, money market funds, and highly liquid investments with original maturities of three months or less.</span></p> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Fair Value Measurements</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 820, </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Fair Value Measurement</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> (“Topic 820”), establishes a fair value hierarchy for those instruments measured at fair value that distinguishes between fair value measurements based on market data (observable inputs) and those based on the Company’s own assumptions (unobservable inputs). This hierarchy maximizes the use of observable inputs and minimizes the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 1: Observable inputs such as quoted prices in active markets;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 3: Unobservable inputs in which there is little or no market data, which require a reporting entity to develop its own assumptions.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Fair value measurements are classified based on the lowest level of input that is significant to the measurement. The Company’s assessment of the significance of a particular input to the fair value measurement requires judgment, which may affect the valuation of the assets and liabilities and their placement within the fair value hierarchy levels. The determination of the fair values, as disclosed in Note 3, takes into account the market for the Company’s financial assets and liabilities, the associated credit risk, and other factors as required. The Company considers active markets as those in which transactions for the assets or liabilities occur in sufficient frequency and volume to provide pricing information on an ongoing basis.</span></p> <span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Concentration of Credit Risk and Other Risks and Uncertainties</span><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash, cash equivalents, accounts receivable, and investments. The Company’s cash and cash equivalents are deposited in accounts with financial institutions that management believes are of high credit quality. Such deposits may, at times, exceed federally insured limits. The Company has not experienced any losses on its deposits of cash and cash equivalents.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Currently all of the Company's revenues are derived from the Wugen License. For the year ended December 31, 2020, the Company recognized revenues of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.1</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.6</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of which was consideration received in the form of shares of Wugen common stock. These shares have limited marketability, and there was no public market on which to trade these shares as of December 31, 2021. As of December 31, 2021, the Company received cash payments of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.8</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for the sale of research and clinical-grade material, which are currently recognized as deferred revenue on the accompanying balance sheet since the criteria for revenue recognition have not been met.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company is highly dependent on a third-party manufacturer to supply drug products for its research and development activities of its programs, including clinical and non-clinical studies. These programs could be adversely affected by a significant interruption in the supply of such drug products. The Company has no off-balance sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts or other hedging arrangements.</span></p> 4100000 1600000 1800000 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Property and Equipment, Net</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment is stated at cost less accumulated depreciation. Depreciation expense is calculated using the straight-line method over the estimated useful lives of the assets, which range from </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</span></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> to </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7 </span></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">years. Leasehold improvements are amortized on a straight-line method over the shorter of the useful life of the leasehold improvement or the term of the lease. Upon retirement or sale of the assets, the cost and related accumulated depreciation and amortization are removed from the accompanying balance sheets and the resulting gain or loss is recorded to the statements of operations. Repairs and maintenance are expensed as incurred.</span></p> P3Y P7Y <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Impairment of Long-Lived Assets</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Long-lived assets are reviewed for indications of possible impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. Recoverability is measured by comparison of the carrying amounts to the future undiscounted cash flows attributable to these assets. An impairment loss is recognized to the extent an asset group is not recoverable, and the carrying amount exceeds the projected discounted future cash flows arising from these assets. Impairment losses, if any, are recognized in earnings. There were no impairment losses for any of the periods presented.</span></p> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Redeemable Preferred Stock</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company applied the relevant accounting standards to distinguish liabilities from equity when we assessed the classification and measurement of preferred stock. Preferred Stock subject to mandatory redemptions was considered a liability and measured at fair value. Conditionally redeemable preferred stock issued by the Company was considered mezzanine or temporary equity and presented outside of the equity section of the accompanying balance sheet as of December 31, 2020.</span></p> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Cumulative Dividends on Preferred Stock</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company’s Preferred Stock earned a </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% cumulative dividend that compounded annually, whether or not declared by the Board of Directors. The Company considered cumulative dividends a legal obligation that should be recognized and accrued until such time as the dividends were declared and paid or liquidation occurred.</span></p><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If Preferred Stock was classified as other than equity, this obligation was presented within Redeemable preferred stock. If Preferred Stock was included within equity, this obligation was treated as a long-term liability and presented within other liabilities in the accompanying balance sheet. As of December 31, 2020, all of the Company’s Preferred Stock was classified as other than equity, or mezzanine equity. Holders of Preferred Stock earned cumulative dividends beginning on June 7, 2019, with the original issuance of Series B Preferred Stock. During the year ended December 31, 2020, Series A Preferred Stock earned $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">348,490</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> in cumulative dividends; Series B Preferred Stock earned $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">776,804</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> in cumulative dividends; and Series C Preferred Stock earned $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">146,381</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> in cumulative dividends. Upon the IPO, all of the Company’s preferred stock converted to common stock. At that time, Series A Preferred Stock forfeited $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">753,307</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of cumulative dividends; Series B Preferred Stock forfeited $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,550,403</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of cumulative dividends; and Series C Preferred Stock forfeited $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">518,371</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of cumulative dividends. No dividends were declared as of the conversion date. </span> 0.06 348490 776804 146381 753307 1550403 518371 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Collaborative Arrangements</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">When the Company enters into collaboration arrangements, it assesses whether the arrangements fall within the scope of FASB issued ASC 808, </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Collaborative Arrangements,</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> based on whether the arrangements involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. If the payments from the collaboration partner to the Company represent consideration from a customer, such as license fees and contract research and development activities, the Company accounts for those payments within the scope of FASB issued ASC 606, </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Revenue from Contracts with Customers </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(“Topic 606”). However, if the Company concludes that the payments are not from a customer, for certain activities and associated payments, such as for certain collaborative research, development, manufacturing, and commercial activities, these payments are presented as a reduction of research and development expense or general and administrative expense, based on where the Company presents the underlying expense.</span></p> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Revenue Recognition</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company recognizes revenue when its customer or collaborator obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To determine revenue recognition for arrangements that are within the scope of Topic 606, it performs the following five steps:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="margin-left:6.667%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">i.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">identify the contract(s) with a customer;</span></div></div><div style="margin-left:6.667%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">ii.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">identify the performance obligations in the contract;</span></div></div><div style="margin-left:6.667%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">iii.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">determine the transaction price;</span></div></div><div style="margin-left:6.667%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">iv.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">allocate the transaction price to the performance obligations within the contract; and</span></div></div><div style="margin-left:6.667%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">v.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">recognize revenue when (or as) the entity satisfies a performance obligation.</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">At contract inception, once the contract is determined to be within the scope of Topic 606 and it is probable of collection, the Company assesses the goods or services promised within the contract to determine whether each promised good or service is a performance obligation. The promised goods or services in the Company’s arrangements may consist of a license, or options to license, the Company’s intellectual property and research, development, and manufacturing services. The Company may provide options to additional items in such arrangements, which are accounted for as separate contracts when the customer elects to exercise such options, unless the option provides a material right to the customer. Performance obligations are promises in a contract to transfer a distinct good or service to the customer that (i) the customer can benefit from on its own or together with other readily available resources, and (ii) is separately identifiable from other promises in the contract. Goods or services that are not individually distinct performance obligations are combined with other promised goods or services until such combined group of promises meet the requirements of a performance obligation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company determines the transaction price based on the amount of consideration the Company expects to receive for transferring the promised goods or services in the contract. Consideration may be fixed, variable, or a combination of both. At contract inception for arrangements that include variable consideration, the Company estimates the probability and extent of consideration it expects to receive under the contract utilizing either the most likely amount method or expected amount method, whichever best estimates the amount expected to be received. The Company then considers any constraints on the variable consideration and includes in the transaction price variable consideration to the extent it is deemed probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company then allocates the transaction price to each performance obligation based on the relative standalone selling price and recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) control is transferred to the customer and the performance obligation is satisfied. For performance obligations which consist of licenses and other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company records amounts as accounts receivable when the right to consideration is deemed unconditional. When consideration is received, or such consideration is unconditionally due, from a customer prior to transferring goods or services to the customer under the terms of a contract, a contract liability is recorded as deferred revenue.</span> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Deferred Revenue</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred revenue represents amounts billed, or in certain cases, yet to be billed to the Company’s customer for which the related revenues have not been recognized because one or more of the revenue recognition criteria have not been met. The current portion of deferred revenue represents the amount to be recognized within one year from the balance sheet date based on the estimated performance period of the underlying performance obligations. As December 31, 2021, current deferred revenue includes amounts of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million allocated to the development supply agreement performance obligation under the Wugen License that is included within Accrued liabilities and other current liabilities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p> 1800000 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Investments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company holds a minority interest in Wugen. The underlying shares of common stock are not traded on any public market and thus have limited marketability. The Company does not have significant influence over the operating and financial policies of Wugen. As a result, the Company has accounted for this investment using the measurement alternative whereby the investment is recorded at cost less impairment, adjusted for observable price changes in orderly transactions for an identical or similar investment of the same investee. No impairment was recognized during the years ended December 31, 2020 and 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company invests net proceeds of its IPO in bills and notes issued by the U.S. Treasury which are classified as trading securities. As of December 31, 2021, the Company holds, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">25.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in U.S. Treasury bills included in Short-term investments and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in U.S. Treasury notes included in Investments in the accompanying balance sheet.</span> 25000000.0 9900000 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Research and Development Expenses</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development costs are expensed as incurred and include salaries, benefits, and other operating costs such as outside services, supplies and allocated overhead expenses. The Company may perform research and development for its own proprietary drug candidates and technology development or for certain third parties under collaborative arrangements. For its proprietary drug candidates and its internal technology development programs, the Company invests its own funds without reimbursement from a third party. Where the Company performs research and development activities under a clinical joint development collaboration, it records the partner’s share of collaboration expenses as a reduction to research and development expense when reimbursement amounts are due under the agreement.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company records an accrued expense for the estimated costs of its contract manufacturing activities performed by third parties. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to vendors. Payments under the contracts include upfront payments and milestone payments, which depend on factors such as the achievement of the completion of certain stages of the manufacturing process. For purposes of recognizing expense, the Company assesses whether the production process is sufficiently defined to be considered the delivery of a good, as evidenced by predictive or contractually required yields in the production process, or the delivery of a service, where processes and yields are developing and less certain. If the Company considers the process to be the delivery of a good, the Company recognizes the expense when the drug product is delivered, or otherwise bears risk of loss. If the Company considers the process to be the delivery of a service, the expense is recognized based on its best estimates of the contract manufacturer’s progress towards completion of the stages in the contracts. The Company recognizes and amortizes upfront payments and accrues for liabilities based on the specific terms of each arrangement. Arrangements may provide upfront payments for certain stages of the arrangement and milestone payments for the completion of certain stages, and, accordingly, may result in advance payments for services that have not been completed or goods not delivered and liabilities for stages where the contract manufacturer is entitled to a milestone payment.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Advance payments for goods or services that will be used or rendered for future research and development activities are capitalized as prepaid expenses and recognized as expense as the related goods are delivered or the related services are performed. The Company bases its estimates on the best information available at the time. However, additional information may become available to the Company which may allow it to make a more accurate estimate in future periods. In this event, the Company may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain. Such increases or decreases in cost are generally considered to be changes in estimates and will be reflected in research and development expenses in the period identified.</span></p> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Patent Costs</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Costs related to filing and pursuing patent applications are recorded as general and administrative expenses in the accompanying statements of operations, and expensed as incurred since recoverability of such expenditures is uncertain.</span></p> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Stock-based Compensation</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company measures its stock-based awards granted to employees and directors based on the estimated fair value of the option on the date of grant (grant date fair value) and recognizes compensation expense over the vesting period. Compensation expense is recorded as either research and development or general and administrative expenses in the accompanying statements of operations based on the function to which the related services are provided. Forfeitures are accounted for as they occur. The Company has granted options with service-based and performance-based vesting conditions.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company uses the Black-Scholes option pricing model for the respective grant to determine the grant date fair value. The Black-Scholes option pricing model requires the input of highly subjective assumptions. These variables include, but are not limited to, its stock price volatility over the term of the awards and actual and projected employee stock option exercise behaviors. Management will continue to assess the assumptions and methodologies used to calculate the estimated grant date fair value of stock-based compensation. Circumstances may change and additional data may become available over time, which could result in changes to these assumptions and methodologies and materially impact the Company’s grant date fair value determination.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For stock option grants with service-based vesting, stock-based compensation expense represents the portion of the grant date fair value of employee stock option grants recognized over the requisite service period of the awards on a straight-line basis, net of estimated forfeitures. For options that vest upon the achievement of performance milestones, the Company estimates </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">fair value at the date of grant and compensation expense is recognized using the accelerated attribution method when it is determined that the performance criteria is probable of being met.</span></p> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Deferred Offering Costs</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company defers offering costs consisting of legal, accounting and other fees and costs directly attributable to its IPO. The deferred offering costs will be offset against the proceeds received upon the completion of the IPO. Deferred offering costs will be recorded under other non-current assets on the accompanying balance sheets. In the event the IPO is terminated, all of the deferred offering costs will be expensed within the Company’s statements of operations. As of </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2020, there were no deferred offering costs recorded on the accompanying balance sheets. As of December 31, 2021, deferred offering costs related to underwriting discounts and commissions and offering expenses of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.8</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million were offset against IPO proceeds upon the consummation of the IPO.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p> 6800000 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Income Taxes</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company accounts for income taxes using an asset and liability approach in accordance with applicable guidance prescribed by FASB issued ASC 740, </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Income Taxes</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> (“Topic 740”). Topic 740 requires that the deferred tax consequences of temporary differences between the amounts recorded in the financial statements and the amounts included in the federal and state income tax returns to be recognized in the balance sheet.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company makes judgments regarding the realizability of its deferred tax assets. The balance sheet carrying value of its deferred tax assets is based on whether the Company believes it is more likely than not that the Company will generate sufficient future taxable income to realize these deferred tax assets after consideration of all available evidence. The Company regularly reviews its deferred tax assets for recoverability considering historical profitability, projected future taxable income, the expected timing of the reversals of existing temporary differences and tax planning strategies. In assessing the need for a valuation allowance, the Company considers both positive and negative evidence related to the likelihood of realization of the deferred tax assets. The weight given to the positive and negative evidence is commensurate with the extent to which the evidence may be objectively verified. As such, it is generally difficult for positive evidence regarding projected future taxable income exclusive of reversing taxable temporary differences to outweigh objective negative evidence of recent financial reporting losses. Generally, cumulative loss in recent years is a significant piece of negative evidence that is difficult to overcome in determining that a valuation allowance is not needed.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company’s tax positions may be subject to income tax audits. The Company recognizes the tax benefit of an uncertain tax position only if it is more likely than not that the position is sustainable upon examination by the taxing authority, based on the technical merits. The tax benefit recognized is measured as the largest amount of benefit which is more likely than not to be realized upon settlement with the taxing authority. The Company recognizes interest accrued and penalties related to unrecognized tax benefits in its tax provision. The Company evaluates uncertain tax positions on a regular basis. The evaluations are based on a number of factors, including changes in facts and circumstances, changes in tax law, correspondence with tax authorities during the course of the audit, and effective settlement of audit issues. The provision for income taxes includes the effects of any accruals that the Company believes are appropriate, as well as the related net interest and penalties.</span></p> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Tax Credit Receivable</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company is eligible for research and development credits for its research and development activities, in accordance with Internal Revenue Code (“I.R.C.”) § 41(c). The credits are generally available to offset income tax liabilities. The Company has applied approximate</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ly $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">250,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> o</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">f research and development credits to offset its federal payroll tax expenses for both years ended December 31, 2020 and 2021, due to its small business status. As of December 31, 2020 and 2021, the current portion of outstanding payroll tax receivables is recorded in Other current assets in the accompanying balance sheets and the noncurrent portion is recorded in Other noncurrent assets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p> 250000 250000 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Net Loss Per Share</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period, without consideration of potential dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the sum of the weighted average number of common shares plus the potential dilutive effects of potential dilutive securities outstanding during the period. Potential dilutive securities are excluded from diluted earnings or loss per share if the effect of such inclusion is anti-dilutive. The Company’s potentially dilutive securities, which include convertible redeemable preferred stock and outstanding stock options under the 2019 Equity Incentive Plan (“2019 Plan”) and the 2021 Equity Incentive Plan (“2021 Plan”), have been excluded from the computation of diluted net loss per share as they would be anti-dilutive to the net loss per share. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company’s net loss position.</span> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Recently Issued Accounting Pronouncements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In June 2016, FASB issued Accounting Standards Update (“ASU”) No. 2016-13, </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Financial Instruments—Credit Losses: Measurement of Credit Losses on Financial Instruments</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, as clarified in subsequent amendments to the initial guidance (collectively, “Topic 326”). Topic 326 requires measurement and recognition of expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecast. The Company adopted Topic 326 using a modified retrospective approach which requires a cumulative effect adjustment as of the beginning of the reporting period in which the guidance is adopted. Topic 326 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019, with early adoption permitted. The Company adopted Topic 326 effective January 1, 2020. The adoption did not have a material impact on our financial statements.</span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In February 2016, the FASB issued ASU No. 2016-02, Leases (“Topic 842”), which requires an entity to recognize assets and liabilities arising from a lease for both financing and operating leases. The ASU will also require new qualitative and quantitative disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. Topic 842 is effective for the Company in the fiscal years beginning after December 15, 2021, with early adoption permitted. The Company will adopt Topic 842 for the fiscal year ended December 31, 2022. The Company plans to use a practical expedient provided by FASB, and it will not recast comparative periods to reflect the impact of the new lease standard. Effective March 1, 2022, the Company entered into a non-cancelable operating lease for its current location with a two-year term. This is the only lease in scope of Topic 842. The Company expects accounting for the new lease under Topic 842 will materially affect the reported amount of total assets and total liabilities within the balance sheet, but it does not expect a material impact to the statement of operations</span> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2. Property and Equipment, Net</span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment, net consists of the following:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.586%;"/> <td style="width:1.605%;"/> <td style="width:1.206%;"/> <td style="width:13.098%;"/> <td style="width:0.798%;"/> <td style="width:1.605%;"/> <td style="width:1.206%;"/> <td style="width:13.098%;"/> <td style="width:0.798%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">At December 31,</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Laboratory equipment</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,924,596</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,949,318</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Office equipment</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">152,003</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">175,245</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Furniture and fixtures</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">292,866</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">292,165</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Leasehold improvements</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">349,976</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">349,976</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,719,441</span></p></td> <td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,766,704</span></p></td> <td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less: Accumulated depreciation and amortization</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,104,015</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,647,614</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment, net</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,615,426</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,119,090</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Depreciation and amortization expense for the year ended December 31, 2020 was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">572,867</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of which $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">362,892</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> is included in research and development expenses. Depreciation and amortization expense for the year ended December 31, 2021 was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">543,598</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, of which $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">353,388</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> is included in research and development expenses.</span></p> <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment, net consists of the following:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.586%;"/> <td style="width:1.605%;"/> <td style="width:1.206%;"/> <td style="width:13.098%;"/> <td style="width:0.798%;"/> <td style="width:1.605%;"/> <td style="width:1.206%;"/> <td style="width:13.098%;"/> <td style="width:0.798%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">At December 31,</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Laboratory equipment</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,924,596</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,949,318</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Office equipment</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">152,003</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">175,245</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Furniture and fixtures</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">292,866</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">292,165</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Leasehold improvements</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">349,976</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">349,976</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,719,441</span></p></td> <td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,766,704</span></p></td> <td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less: Accumulated depreciation and amortization</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,104,015</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,647,614</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment, net</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,615,426</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,119,090</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table> 1924596 1949318 152003 175245 292866 292165 349976 349976 2719441 2766704 1104015 1647614 1615426 1119090 572867 362892 543598 353388 <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">3. Fair Value of Financial Instruments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The carrying amount of the Company’s financial instruments, including cash and cash equivalents, accounts receivable, prepaid expenses and other current assets, U.S. government backed securities with maturity dates up to one year, accounts payable and accrued liabilities, approximate fair value due to their short-term maturities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:10.267%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span> </p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Money market funds included in cash and cash equivalents and U.S. government backed securities are measured at fair value based on quoted prices in active markets, which are considered Level 1 inputs. No transfers between levels occurred during the periods presented.</span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> The following table presents the Company’s assets which were measured at fair value at December 31, 2020 and 2021: </span></span><span style=""/></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:49.759%;"/> <td style="width:1.206%;"/> <td style="width:1.197%;"/> <td style="width:9.584%;"/> <td style="width:0.594%;"/> <td style="width:1.206%;"/> <td style="width:1.197%;"/> <td style="width:9.501%;"/> <td style="width:0.594%;"/> <td style="width:1.206%;"/> <td style="width:1.197%;"/> <td style="width:9.584%;"/> <td style="width:0.594%;"/> <td style="width:1.206%;"/> <td style="width:1.197%;"/> <td style="width:9.584%;"/> <td style="width:0.594%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Calibri;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">At December 31, 2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Calibri;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Calibri;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Level 1</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Level 2</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Level 3</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Total</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Assets:</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Money market funds</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,752,266</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,752,266</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Investment in Wugen</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,599,750</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,752,266</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,599,750</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,752,266</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:49.763%;"/> <td style="width:1.206%;"/> <td style="width:1.206%;"/> <td style="width:9.6%;"/> <td style="width:0.594%;"/> <td style="width:1.206%;"/> <td style="width:1.206%;"/> <td style="width:9.507%;"/> <td style="width:0.594%;"/> <td style="width:1.206%;"/> <td style="width:1.206%;"/> <td style="width:9.507%;"/> <td style="width:0.594%;"/> <td style="width:1.206%;"/> <td style="width:1.206%;"/> <td style="width:9.6%;"/> <td style="width:0.594%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">At December 31, 2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Level 1</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Level 2</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Level 3</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Total</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Assets:</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Money market funds</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9,506,499</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9,506,499</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Treasury bills</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">24,983,520</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">24,983,520</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Treasury notes</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9,922,300</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9,922,300</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">44,412,319</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">44,412,319</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table></div> <span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> The following table presents the Company’s assets which were measured at fair value at December 31, 2020 and 2021: </span><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:49.759%;"/> <td style="width:1.206%;"/> <td style="width:1.197%;"/> <td style="width:9.584%;"/> <td style="width:0.594%;"/> <td style="width:1.206%;"/> <td style="width:1.197%;"/> <td style="width:9.501%;"/> <td style="width:0.594%;"/> <td style="width:1.206%;"/> <td style="width:1.197%;"/> <td style="width:9.584%;"/> <td style="width:0.594%;"/> <td style="width:1.206%;"/> <td style="width:1.197%;"/> <td style="width:9.584%;"/> <td style="width:0.594%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Calibri;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">At December 31, 2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Calibri;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Calibri;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Level 1</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Level 2</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Level 3</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Total</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Assets:</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Money market funds</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,752,266</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,752,266</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Investment in Wugen</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,599,750</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,752,266</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,599,750</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,752,266</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:49.763%;"/> <td style="width:1.206%;"/> <td style="width:1.206%;"/> <td style="width:9.6%;"/> <td style="width:0.594%;"/> <td style="width:1.206%;"/> <td style="width:1.206%;"/> <td style="width:9.507%;"/> <td style="width:0.594%;"/> <td style="width:1.206%;"/> <td style="width:1.206%;"/> <td style="width:9.507%;"/> <td style="width:0.594%;"/> <td style="width:1.206%;"/> <td style="width:1.206%;"/> <td style="width:9.6%;"/> <td style="width:0.594%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">At December 31, 2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Level 1</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Level 2</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Level 3</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Total</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Assets:</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Money market funds</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9,506,499</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9,506,499</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Treasury bills</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">24,983,520</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">24,983,520</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Treasury notes</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9,922,300</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9,922,300</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">44,412,319</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">44,412,319</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table> 6752266 0 0 6752266 0 0 1599750 0 6752266 0 1599750 6752266 9506499 0 0 9506499 24983520 0 0 24983520 9922300 0 0 9922300 44412319 0 0 44412319 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">4. Investments</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2020, Investments consisted of a balance of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.6</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. In December 2020, the Company entered into the Wugen License for limited rights to develop, manufacture and commercialize cellular therapy products based on two of the Company’s fusion protein molecules. As part of the consideration received for the Wugen License, the Company received shares of Wugen common stock, which were recognized at $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.6</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, the fair value of the securities as of December 24, 2020, the effective date for the Wugen License. Initial recognition was at fair value based on level 3 inputs, since there was no public market on which to trade these shares at the time they were received. The fair value was determined based primarily on the pricing and terms of a third-party financing completed by Wugen in 2020. So long as there continues to be no public market for these securities, the Company will classify this asset as a cost method investment, recorded at cost less impairment adjusted for observable market changes.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, Investments had a balance of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in the accompanying balance sheet, consisting of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for the investment in Wugen, which the Company continues to carry at cost since no public market exists for these securities, and no impairment adjusted was necessary. In addition, Investments include $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in U.S. Treasury notes as of December 31, 2021. These securities are classified as trading securities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p> 1600000 1600000 11500000 1600000 9900000 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">5. Related Party Transactions</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2020, related parties held capital stock in the Company. The Company's Founder and Chief Executive Officer, Hing C. Wong, PhD., held all Class B Common Stock and Series A Preferred Stock issued by the Company. In addition, Dr. Wong purchased shares of Series B Preferred Stock and Series C Preferred Stock on the same terms and conditions for third-party investors. All shares of Preferred Shares held by Dr. Wong earned cumulative dividends.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During the year ended December 31, 2021, all shares purchased by Dr. Wong prior to the IPO were converted to common stock, and the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Company was relieved of its obligation to pay cumulative dividends on Preferred Shares that were accrued and unpaid as of the conversion date.</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> Dr. Wong purchased additional shares of the Company's common stock in the IPO and in the open market post IPO, in compliance with SEC regulations and the Company's insider trading policies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">6. Accrued Liabilities and Other Current Liabilities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In May 2020, the Company received an SBA Paycheck Protection Loan (“PPP loan”) in the principal amount of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">563,590</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. As of December 31, 2020, the Company had $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">845,741</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of Accrued liabilities and other current liabilities, primarily consisting of the PPP loan of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">567,311</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, including principal and accrued but unpaid interest, and accrued liabilities of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">273,907</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, the Company had a balance of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in Accrued liabilities and other current liabilities, consisting of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million related to deferred revenue, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">48,750</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> related to manufacturing materials, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">51,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> related to legal fees, and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">50,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> for other expenses. On January 8, 2021, the Company received full loan forgiveness of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">567,311</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> for obligations related to the PPP loan. The Company accounted for the PPP loan as debt, and the loan forgiveness was accounted for as a debt extinguishment. The amount of loan and interest forgiven is recognized as a gain upon debt extinguishment and is reported within Interest and other income, net in the accompanying statement of operations for the year ended December 31, 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p> 563590 845741 567311 273907 2100000 1800000 48750 51000 50000 567311 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">7. License Agreement</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On December 24, 2020, the Company entered into the Wugen License transferring rights to Wugen to develop, manufacture, and commercialize certain cellular therapy products based on two of the Company’s fusion protein molecules. The term of the agreement will expire on a product-by-product and country-by-country basis, upon the later of (i) ten (10) years from the first commercial sale of the product or (ii) the expiration of the last-to-expire valid patent claim of such product.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company retained regulatory T cell-based cellular therapy, injectable rights, and manufacturing rights, not granted to Wugen under the terms of the Wugen License. The Company and Wugen will enter into two supply agreements under industry-standard terms, under which the Company will provide cGMP and non-cGMP grade materials, including a development supply agreement and a commercial supply agreement.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">According to the terms of the agreement, Wugen will fund all future clinical development and commercialization activities for cellular therapy treatments for any indications utilizing the licensed fusion protein molecules covered by the Wugen License. In January 2021, two Phase 2 clinical trials related to treatment for relapsed / refractory acute myeloid leukemia based on one of the licensed molecules were initiated by the School of Medicine at Washington University in St. Louis and supported by Wugen.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company concluded that Wugen is a customer and the Wugen License is a functional license under the provisions of Topic 606. The Company identified the following performance obligations at the inception of the agreement:</span></p><div style="margin-left:6.667%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Provide Wugen with exclusive worldwide license rights for certain fusion proteins.</span></div></div><div style="margin-left:6.667%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Sell vials of HCW9201 clinical grade product available immediately.</span></div></div><div style="margin-left:6.667%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Transfer R&amp;D know-how.</span></div></div><div style="margin-left:6.667%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Supply of cGMP and non-cGMP grade materials for development.</span></div></div><div style="margin-left:6.667%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Supply of cGMP grade materials for commercialization.</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For the year ended December 31, 2020 the Company recognized $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.1</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for performance obligations satisfied in the period. This is the first time the Company has entered into an out-license arrangement and the first time the Company has established prices for its goods and services. Accordingly, the standalone selling price of the various performance obligations is uncertain, and the Company determined that an observable standalone selling price is not available for the identified performance obligations under the Wugen License. Where a standalone selling price is not directly observable, then the Company estimates the standalone selling price considering marketing conditions, entity-specific factors, and information about the customer that is reasonably available. The process for determining a standalone selling price involves significant judgment and includes consideration of multiple factors, including assumptions related to the market opportunity and the time needed to commercialize a product candidate pursuant to the relevant license, estimated direct expenses and other costs.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company first determined the standalone selling price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.5</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for the vials of HCW9201 and the R&amp;D know-how. The price was determined based on the cost of developing the know-how and the costs incurred in producing the vials. The standalone selling price for the license was determined using the residual approach and was priced at $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.6</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2020, the Company and Wugen had not finalized the development supply agreement. Therefore, there was no contract for purchase of materials during Wugen's development phase. The Company will defer recognition of revenues and costs for supply of materials during development until a contract is in place. The commercial supply agreement will be entered into in the future, pursuant to the terms of the Wugen License.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For the year ended December 31, 2021, the Company entered into a master services agreement with Wugen related to the development supply agreement to provide cGMP and non-cGMP grade licensed material based on industry-standard terms. However, as of December 31, 2021, the Company and Wugen have not finalized any statements of work under the master services agreement, thus no contract exists. Until such time that the Company enters statements of work for Wugen orders related to licensed material for clinical development, the Company will defer recognition of revenues.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Wugen License includes milestone payments and royalties. The Company uses judgment to determine whether milestones or other variable consideration should be included in the transaction price. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For revenue-based royalties, including milestone payments based on the level of sales, the Company will include royalties in the transaction price at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty is allocated has been satisfied (or partially satisfied).</span></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> As part of management’s evaluation of the transaction price, the Company considers numerous factors, including whether the achievement of the milestones is outside of our control, contingent upon the efforts of others or subject to scientific risks of success. If the Company concludes it is probable that a significant revenue reversal would not occur, the associated milestone payment is included in the transaction price. Milestone payments that are not within our control, such as regulatory approvals, are generally not considered probable until those milestones are achieved. The Company reevaluates the transaction price, including estimated variable consideration included in the transaction price and all constrained amounts, in each reporting period and as uncertain events are resolved or other changes in circumstances occur.</span></p> 4100000 2500000 1600000 For revenue-based royalties, including milestone payments based on the level of sales, the Company will include royalties in the transaction price at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty is allocated has been satisfied (or partially satisfied). <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">8. Redeemable Preferred Stock</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In a series of closings which took place in 2020, the Company completed the private placement of Series C Preferred Stock. The terms of the redeemable preferred stock provided for an adjustment to the conversion price upon the occurrence of certain transactions or events, such as stock splits, split-up, certain dividends, or distributions. Cumulative dividends accrued whether or not declared by the Board of Directors. Giving effect to the Reverse Stock Split, a total of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,439,112</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of Series C Preferred Stock were issued at $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.05</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share, for $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, net of offering costs. The Company’s Series C Preferred Stock was convertible into shares of Class A common stock and earned cumulative dividends at a rate of 6% per annum and compound annually until converted or redeemed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On July 22, 2021, the Company closed on its IPO, and the requirements for mandatory conversion were met. All outstanding shares of Series A, Series B, and Series C Preferred Stock converted into an equal number of shares of common stock. As a result, the rights, preferences, and terms ascribed to these shares are no longer applicable. Cumulative dividends of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million accrued as of the conversion date were forfeited and such forfeiture was recognized through Additional paid-in capital.</span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">At December 31, 2021, the Company has </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of preferred stock authorized and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares issued.</span> 5439112 2.05 11200000 2800000 10000000 0 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">9. Net Loss Per Share</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:10.2%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table summarizes the computation of the basic and diluted net loss per share:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:58.735%;"/> <td style="width:1.234%;"/> <td style="width:1.963%;"/> <td style="width:15.387%;"/> <td style="width:1.3%;"/> <td style="width:1.234%;"/> <td style="width:1.963%;"/> <td style="width:16.886%;"/> <td style="width:1.3%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Years Ended December 31,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Numerator:</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net loss</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,802,201</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12,862,468</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less: cumulative preferred dividends earned in the <br/>   period, net of forfeitures</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,271,675</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net loss available for distribution to common stock<br/>   holders</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,073,876</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12,862,468</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Denominator:</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Weighted-average common shares outstanding</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,739,285</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18,770,935</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net loss per share, basic and diluted</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.49</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.69</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:10.267%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table summarizes the outstanding potentially dilutive securities that have been excluded in the calculation of diluted net loss per share because their inclusion would be anti-dilutive:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:61.541%;"/> <td style="width:1.339%;"/> <td style="width:0.809%;"/> <td style="width:16.545%;"/> <td style="width:0.809%;"/> <td style="width:1.339%;"/> <td style="width:0.809%;"/> <td style="width:16.002%;"/> <td style="width:0.809%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">As of December 31,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Redeemable Preferred Stock</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">23,768,416</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_ef2944fe-ae36-4c12-ac79-11fb21fd4d64;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></span></span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Common stock options</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">742,114</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,770,739</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Potentially diluted securities</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">24,510,530</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,770,739</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table></div> <p style="text-indent:10.2%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table summarizes the computation of the basic and diluted net loss per share:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:58.735%;"/> <td style="width:1.234%;"/> <td style="width:1.963%;"/> <td style="width:15.387%;"/> <td style="width:1.3%;"/> <td style="width:1.234%;"/> <td style="width:1.963%;"/> <td style="width:16.886%;"/> <td style="width:1.3%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Years Ended December 31,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Numerator:</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net loss</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,802,201</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12,862,468</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less: cumulative preferred dividends earned in the <br/>   period, net of forfeitures</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,271,675</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net loss available for distribution to common stock<br/>   holders</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,073,876</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12,862,468</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Denominator:</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Weighted-average common shares outstanding</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,739,285</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18,770,935</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net loss per share, basic and diluted</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.49</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.69</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> </table> -5802201 -12862468 1271675 0 -7073876 -12862468 4739285 18770935 -1.49 -0.69 <p style="text-indent:10.267%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table summarizes the outstanding potentially dilutive securities that have been excluded in the calculation of diluted net loss per share because their inclusion would be anti-dilutive:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:61.541%;"/> <td style="width:1.339%;"/> <td style="width:0.809%;"/> <td style="width:16.545%;"/> <td style="width:0.809%;"/> <td style="width:1.339%;"/> <td style="width:0.809%;"/> <td style="width:16.002%;"/> <td style="width:0.809%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">As of December 31,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Redeemable Preferred Stock</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">23,768,416</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_ef2944fe-ae36-4c12-ac79-11fb21fd4d64;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></span></span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Common stock options</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">742,114</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,770,739</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Potentially diluted securities</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">24,510,530</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,770,739</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table> 23768416 742114 1770739 24510530 1770739 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">10. Stock-based Compensation</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On June 21, 2021, the 2021 Plan was adopted by the Company’s board of directors and approved by the Company’s stockholders. As of the adoption date, the 2019 Plan was terminated. No terms were changed for grants previously awarded under the 2019 Plan, and the Company concluded a modification did not occur. Under the 2019 Plan, the Company primarily granted employees incentive stock options, which had a maximum term of </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ten years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> from the date of the grant. Generally, the incentive stock options granted under the 2019 Plan have a </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">four year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, service-based vesting period. All of the options granted under the 2019 Plan had an exercise price equal to the fair value of a share of common stock on the date of the grant, according to Company policy.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The 2021 Plan permits the grant of incentive stock options, nonstatutory stock options, stock appreciation rights, restricted stock, restricted stock units, and stock bonus awards. The 2021 Plan initially reserved </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,444,343</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of Common Stock, including the transfer of remaining shares reserved under the 2019 Plan. In addition, the number of shares reserved for issuance under the 2021 Plan will increase automatically on the first day of each fiscal year beginning with the 2022 fiscal year.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under the 2021 Plan, the term of each stock option must be stated in the stock award agreement. In the case of an incentive stock option, the term will be </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ten years</span></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> from the date of grant, or such shorter term as may be provided in the stock award agreement. Moreover, in the case of an incentive stock option granted to a participant who owns stock representing more than </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the total combined voting power of all classes of our stock or the stock of any of our affiliates, the term of the incentive stock option will be five years from the date of grant or such shorter term as may be provided in the stock award agreement. Under the 2021 Plan, the Company continues to have a policy to grant options with an exercise price equal to the fair value of a share of common stock, as determined by the closing price on NASDAQ on the grant date.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following summarizes the Company’s stock option activity for the year ended December 31, 2021:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.023%;"/> <td style="width:1.215%;"/> <td style="width:0.603%;"/> <td style="width:9.951%;"/> <td style="width:0.798%;"/> <td style="width:1.215%;"/> <td style="width:11.175%;"/> <td style="width:1.215%;"/> <td style="width:11.184%;"/> <td style="width:1.215%;"/> <td style="width:1.206%;"/> <td style="width:9.598%;"/> <td style="width:0.603%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="3" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Shares</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Weighted</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Weighted Average</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="3" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Issuable</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Average</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Remaining</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Aggregate</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="3" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">under</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Exercise</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Contract</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Intrinsic</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="3" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Options</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Price</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Term</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Value</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Outstanding at December 31, 2019</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">586,662</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.13</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9.6</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> years</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,500</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Granted</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">263,976</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.20</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exercised</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">75,851</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.13</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Forfeited or cancelled</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">32,740</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.12</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Outstanding at December 31, 2020</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">742,047</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.16</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9.1</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> years</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">39,078</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exercisable at December 31, 2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">88,531</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.15</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9.0</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> years</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,413</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Outstanding at December 31, 2020</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">742,047</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.16</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9.1</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> years</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">39,078</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Granted</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,249,287</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.16</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exercised</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">206,455</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.13</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Forfeited or cancelled</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14,140</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.19</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Outstanding at December 31, 2021</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,770,739</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.96</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9.0</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> years</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,124,215</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exercisable at December 31, 2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">41,084</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.17</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.9</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> years</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">87,522</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table></div><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The aggregate intrinsic value is calculated based on the difference between the exercise price of the underlying stock options and the fair value of the Company’s common stock for stock options as of the reporting date. The intrinsic value of stock options exercised during the years ended December 31, 2020 and 2021 was </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,032</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">447,115</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, respectively. The weighted-average fair value of options granted during the years ended December 31, 2020 and 2021 was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.20</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.16</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share, respectively.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For stock option grants with service-based vesting, stock-based compensation expense represents the portion of the grant date fair value of employee stock option grants recognized over the requisite service period of the awards on a straight-line basis, net of estimated forfeitures. For options that vest upon the achievement of performance milestones, the Company estimates </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">fair value at the date of grant and compensation expense is recognized using the accelerated attribution method when it is determined that the performance criteria is probable of being met.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In determining the grant date fair value of the stock-based awards, the Company uses the Black-Scholes option-pricing model and assumptions discussed below. Each of these inputs is subjective and its determination generally requires significant judgment.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Fair Value of Common Stock</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—Prior to our initial public offering, the estimated fair value of our common stock was determined by our board of directors as of the date of each option grant, with input from management, considering our most recently available third-party valuation of our common stock as well as our board of directors’ assessment of additional objective and subjective factors that it believed were relevant and which may have changed from the date of the most recent third-party valuation to the date of the grant. Since the completion of our initial public offering on July 19, 2021, the fair value of each share of common stock underlying stock option grants is based </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the quoted market price on the primary stock exchange on which our common stock is traded on the day the stock award or option is granted.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Expec</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">t</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">ed term</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—The expected term of stock options is determined using the “simplified” method, whereby the expected life equals the arithmetic average of the vesting term and the original contractual term of the option due to the Company’s lack of sufficient historical data.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Expected volatility</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—We have limited information on the income volatility of our stock as shares of our common stock were not actively traded on any public markets prior to July 19, 2021. The expected volatility was derived from the historical stock volatilities of comparable peer public companies within our industry.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Risk-free interest rate</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—The risk-free interest rate is based on the U.S. Treasury Bond in effect at the time of grant for periods corresponding with the expected term.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Dividend yield</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—The expected dividend yield is </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% because the Company has not historically paid, and does not expect, for the foreseeable future, to pay a dividend on its common stock.</span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For the years ended December 31, 2020 and 2021, the fair value of employee and director stock option awards was estimated at the date of grant using a Black-Scholes option-pricing model with the following assumptions:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:48.516%;"/> <td style="width:2.532%;"/> <td style="width:23.21%;"/> <td style="width:2.532%;"/> <td style="width:23.21%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Calibri;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Calibri;"> </span></p></td> <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Years Ended December 31,</span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Calibri;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Calibri;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected term (years)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.25</span></span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.24</span></span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected volatility</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">87.30</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">83.18</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Risk-free interest rate</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.50</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.02</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Dividend yield</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Fair value underlying common stock</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.18</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.95</span></p></td> </tr> </table></div><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For the year ended December 31, 2020, for options with service-based vesting conditions, the Company recognized $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9,590</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of employee stock-based compensation expense in research and development expenses and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12,285</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of employee stock-based compensation in general and administrative expenses in the accompanying statements of operations. For the year ended December 31, 2021, for options with service-based vesting conditions, the Company recognized $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">25,239</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of employee stock-based compensation expense in research and development expenses and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">335,736</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of employee stock-based compensation in general and administrative expenses in the accompanying statements of operations.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2020, the Company had an aggregate of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">103,045</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of unrecognized employee stock-based compensation cost for options with service-based vesting, which is expected to be recognized over a weighted average vesting period of </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.12</span></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> years.</span></p><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2020 and 2021, there was </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> unrecognized employee stock-based compensation cost for options with performance-based vesting conditions, as no performance-based options were unvested. For the years ended December 31, 2020 and 2021, the Company recognized an aggregate of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,750</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_e66dc82e-175b-499d-b8c8-89e4a464a879;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">nil</span></span></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of employee stock-based compensation cost, respectively, for options with performance-based vesting conditions which vested immediately upon achieving the performance target, respectively.</span> P10Y P4Y 3444343 P10Y 0.10 <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following summarizes the Company’s stock option activity for the year ended December 31, 2021:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.023%;"/> <td style="width:1.215%;"/> <td style="width:0.603%;"/> <td style="width:9.951%;"/> <td style="width:0.798%;"/> <td style="width:1.215%;"/> <td style="width:11.175%;"/> <td style="width:1.215%;"/> <td style="width:11.184%;"/> <td style="width:1.215%;"/> <td style="width:1.206%;"/> <td style="width:9.598%;"/> <td style="width:0.603%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="3" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Shares</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Weighted</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Weighted Average</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="3" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Issuable</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Average</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Remaining</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Aggregate</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="3" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">under</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Exercise</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Contract</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Intrinsic</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="3" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Options</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Price</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Term</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Value</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Outstanding at December 31, 2019</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">586,662</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.13</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9.6</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> years</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,500</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Granted</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">263,976</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.20</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exercised</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">75,851</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.13</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Forfeited or cancelled</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">32,740</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.12</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Outstanding at December 31, 2020</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">742,047</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.16</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9.1</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> years</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">39,078</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exercisable at December 31, 2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">88,531</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.15</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9.0</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> years</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,413</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Outstanding at December 31, 2020</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">742,047</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.16</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9.1</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> years</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">39,078</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Granted</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,249,287</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.16</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exercised</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">206,455</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.13</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Forfeited or cancelled</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14,140</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.19</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Outstanding at December 31, 2021</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,770,739</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.96</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9.0</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> years</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,124,215</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exercisable at December 31, 2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">41,084</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.17</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.9</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> years</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">87,522</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table> 586662 0.13 P9Y7M6D 5500 263976 0.20 75851 0.13 32740 0.12 742047 0.16 P9Y1M6D 39078 88531 0.15 P9Y 5413 742047 0.16 P9Y1M6D 39078 1249287 4.16 206455 0.13 14140 0.19 1770739 2.96 P9Y 1124215 41084 0.17 P7Y10M24D 87522 6032 447115 0.20 4.16 0 <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For the years ended December 31, 2020 and 2021, the fair value of employee and director stock option awards was estimated at the date of grant using a Black-Scholes option-pricing model with the following assumptions:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:48.516%;"/> <td style="width:2.532%;"/> <td style="width:23.21%;"/> <td style="width:2.532%;"/> <td style="width:23.21%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Calibri;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Calibri;"> </span></p></td> <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Years Ended December 31,</span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Calibri;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Calibri;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected term (years)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.25</span></span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.24</span></span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected volatility</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">87.30</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">83.18</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Risk-free interest rate</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.50</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.02</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Dividend yield</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Fair value underlying common stock</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.18</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.95</span></p></td> </tr> </table> P6Y3M P6Y2M26D 0.8730 0.8318 0.0050 0.0102 0 0 0.18 2.95 9590 12285 25239 335736 103045 P5Y1M13D 0 0 6750 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">11. Employee Benefit Plan</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company offers a defined contribution savings plan (the “Benefit Plan”) under Section 401 of the Internal Revenue Code for all eligible employees. The Benefit Plan allows for discretionary contributions which are limited to the maximum allowable for federal tax purposes. The total expense related to the discretionary payments made by the Company to the Benefit Plan for the years ended December 31, 2020 and 2021 was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">146,400</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">173,400</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, respectively.</span></p> 146400 173400 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">12. Collaborative Arrangements</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In March 2020, the Company entered into two collaborative arrangements relating to IND-enabling activities which continued in 2021. Pursuant to these agreements, the Company supplied materials for the studies and reimbursed the collaboration partner costs in connection with the projects. In turn, the partner will provide written reports and a body of scientific data for the results of the projects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">13. Income Taxes</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company did </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">t have a provision for income taxes (current or deferred tax expense) for tax years ended December 31, 2020 and 2021.</span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table summarizes the differences between the statutory federal income tax rate and the Company's effective income tax rate (percent data):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:43.426%;"/> <td style="width:1.318%;"/> <td style="width:1.188%;"/> <td style="width:10.717%;"/> <td style="width:0.789%;"/> <td style="width:1.318%;"/> <td style="width:0.575%;"/> <td style="width:9.595%;"/> <td style="width:2.765%;"/> <td style="width:1.318%;"/> <td style="width:1.188%;"/> <td style="width:10.764%;"/> <td style="width:0.789%;"/> <td style="width:1.318%;"/> <td style="width:0.575%;"/> <td style="width:9.595%;"/> <td style="width:2.765%;"/> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Rate Reconciliation</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net Loss Before Taxes</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,802,201</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12,862,468</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Benefit at statutory rate</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,218,462</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21.00</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,701,118</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21.00</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">State tax benefit net of federal benefit</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">264,152</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.55</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">590,728</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.59</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Permanent book/tax differences</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,161</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.18</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">85,678</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.67</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other adjustments</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">34,591</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.60</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,093</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.02</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">R&amp;D credit carryforward</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">46,608</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.80</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">85,000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.66</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Change in valuation allowance</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,555,740</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">26.81</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,460,431</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">26.90</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,088</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.04</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.00</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Income tax expense/(benefit)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.00</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.00</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> </tr> </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"> </span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The tax effects of temporary differences that give rise to significant portions of the deferred tax assets and deferred tax liabilities at December 31, 2020 and 2021 are presented below:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:66.589%;"/> <td style="width:1.605%;"/> <td style="width:1.206%;"/> <td style="width:13.097%;"/> <td style="width:0.798%;"/> <td style="width:1.605%;"/> <td style="width:1.206%;"/> <td style="width:13.097%;"/> <td style="width:0.798%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred tax assets:</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Federal net operating loss carryforward</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,102,649</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,479,664</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">State net operating loss carryforward</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">658,595</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,164,970</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued expenses</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">24,585</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12,356</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock-based compensation</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,821</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">84,612</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred rent</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,089</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">307</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">R&amp;D credit</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">133,015</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">218,015</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Unrealized gain/loss</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16,708</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred revenue</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">397,464</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net deferred tax assets</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,923,754</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,374,096</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred tax liabilities:</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Depreciable assets</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,054</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">35</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net deferred tax liabilities</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,054</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">35</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less: valuation allowance</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,913,700</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,374,131</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net deferred tax asset (after valuation allowance)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A valuation allowance is recorded to reduce the deferred tax asset if, based on the weight of the evidence, it is more likely than not that some portion or all of the deferred tax asset will not be realized. As of December 31, 2021, after consideration of all the evidence, both positive and negative, management has determined that a valuation allowance of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.4</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million is necessary to reduce the deferred tax asset to the amount that will more likely than not be realized. During the year ended December 31, 2021, the valuation allowance increased by $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.5</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On March 27, 2020, the Coronavirus Aid, Relief and Economic Security (“CARES”) Act was enacted and signed into law. Certain provisions of the CARES Act could impact the 2019 income tax provision computations of the Company and will be reflected in the period of enactment (tax year 2020). </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The CARES Act, among other things, contains modifications on the limitation of business interest expense under Section 163(j), allow for net operating loss ("NOL") carryovers and carrybacks to offset </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">100</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of taxable income for taxable years before 2021, and includes a technical correction to the TCJA with respect to Qualified Improvement Property ("QIP") where such property has a 15-year recovery period for purposes of the general depreciation system of Section 168(a). The Company is currently evaluating the impact of the CARES Act, and aside from the 15-year QIP technical correction, it believes that none of other modifications or tax law changes will result in any material benefit or apply.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2020 and 2021, the Company had available federal NOL carryforwards of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14.8</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">26.1</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. The Company also has available state NOLs carryforwards of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15.2</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">26.8</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, as of December 31, 2020 and 2021, respectively. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The federal and state NOLs will carry forward indefinitely and be available to offset up to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">100</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of taxable income for taxable years before 2021 and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">80</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of taxable years staring after 2020. In addition, the Company had federal research and development credits carryforwards of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">133,015</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">218,015</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, as of Decem</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ber 31, 2020 and 2021, respectively, to reduce future federal income taxes, if any. These carryforwards expire from </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2038 through 2041</span></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and are subject to review and possible adjustment.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, (the Code), substantial changes in the Company’s ownership may limit the amount of net operating loss and research and development credit carryforwards that could be used annually in the future to offset taxable income. A formal Section 382 study has not been completed to determine if an ownership change has occurred and if its net operating losses are subject to an annual limitation. Such annual limitations could affect the utilization of NOL and tax credit carryforwards in the future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p> 0 0 <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table summarizes the differences between the statutory federal income tax rate and the Company's effective income tax rate (percent data):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:43.426%;"/> <td style="width:1.318%;"/> <td style="width:1.188%;"/> <td style="width:10.717%;"/> <td style="width:0.789%;"/> <td style="width:1.318%;"/> <td style="width:0.575%;"/> <td style="width:9.595%;"/> <td style="width:2.765%;"/> <td style="width:1.318%;"/> <td style="width:1.188%;"/> <td style="width:10.764%;"/> <td style="width:0.789%;"/> <td style="width:1.318%;"/> <td style="width:0.575%;"/> <td style="width:9.595%;"/> <td style="width:2.765%;"/> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Rate Reconciliation</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net Loss Before Taxes</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,802,201</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12,862,468</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Benefit at statutory rate</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,218,462</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21.00</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,701,118</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21.00</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">State tax benefit net of federal benefit</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">264,152</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.55</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">590,728</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.59</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Permanent book/tax differences</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,161</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.18</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">85,678</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.67</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other adjustments</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">34,591</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.60</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,093</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.02</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">R&amp;D credit carryforward</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">46,608</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.80</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">85,000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.66</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Change in valuation allowance</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,555,740</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">26.81</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,460,431</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">26.90</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,088</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.04</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.00</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Income tax expense/(benefit)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.00</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.00</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> </tr> </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"> </span></p> -5802201 -12862468 -1218462 0.2100 -2701118 0.2100 -264152 0.0455 -590728 0.0459 10161 -0.0018 -85678 0.0067 -34591 0.0060 2093 -0.0002 46608 0.0080 85000 0.0066 1555740 -0.2681 3460431 -0.2690 2088 0.0004 0 0.0000 0 0.0000 0 0.0000 <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The tax effects of temporary differences that give rise to significant portions of the deferred tax assets and deferred tax liabilities at December 31, 2020 and 2021 are presented below:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:66.589%;"/> <td style="width:1.605%;"/> <td style="width:1.206%;"/> <td style="width:13.097%;"/> <td style="width:0.798%;"/> <td style="width:1.605%;"/> <td style="width:1.206%;"/> <td style="width:13.097%;"/> <td style="width:0.798%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred tax assets:</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Federal net operating loss carryforward</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,102,649</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,479,664</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">State net operating loss carryforward</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">658,595</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,164,970</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued expenses</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">24,585</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12,356</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock-based compensation</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,821</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">84,612</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred rent</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,089</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">307</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">R&amp;D credit</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">133,015</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">218,015</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Unrealized gain/loss</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16,708</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred revenue</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">397,464</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net deferred tax assets</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,923,754</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,374,096</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred tax liabilities:</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Depreciable assets</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,054</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">35</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net deferred tax liabilities</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,054</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">35</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less: valuation allowance</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,913,700</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,374,131</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net deferred tax asset (after valuation allowance)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table> 3102649 5479664 658595 1164970 24585 12356 2821 84612 2089 307 133015 218015 16708 397464 3923754 7374096 -10054 35 10054 35 3913700 7374131 0 0 7400000 3500000 The CARES Act, among other things, contains modifications on the limitation of business interest expense under Section 163(j), allow for net operating loss ("NOL") carryovers and carrybacks to offset 100% of taxable income for taxable years before 2021, and includes a technical correction to the TCJA with respect to Qualified Improvement Property ("QIP") where such property has a 15-year recovery period for purposes of the general depreciation system of Section 168(a). The Company is currently evaluating the impact of the CARES Act, and aside from the 15-year QIP technical correction, it believes that none of other modifications or tax law changes will result in any material benefit or apply. 1 14800000 26100000 15200000 26800000 1 0.80 133015 218015 2038 through 2041 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">14. Commitments and Contingencies</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Leases</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company leases its operating facilities in Miramar, Florida under non-cancelable operating lease agreements and a short-term sublease agreement for additional office space. Rent expense is recognized for leases with increasing annual rents on a straight-line basis over the term of the lease. The amount of rent expense in excess of cash payments is classified as deferred rent. Lease incentives received are deferred and amortized over the term of the lease.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The future minimum payments for the lease and sublease agreements at December 31, 2021 are as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:79.656%;"/> <td style="width:1.772%;"/> <td style="width:1.706%;"/> <td style="width:16.005%;"/> <td style="width:0.86%;"/> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2022 (remaining 2 months)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">36,000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For the year ended December 31, 2020 and 2021, rental expense, including common area maintenance costs, recognized by the Company was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">183,943</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">208,348</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, of which $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">82,971</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">100,457</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, respectively, are included in Research and development, in the accompanying statements of operations.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Contractual Commitments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During the year ended December 31, 2021, the Company entered into several agreements with a third-party global contract development and manufacturer of biologics for the manufacture of the Company’s proprietary molecules for use in clinical trials. At December 31, 2020, the future minimum payments under such agreements were $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.9</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. At December 31, 2021, future payment obligations under such agreements were $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.5</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of which approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">181,600</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> was paid in January 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Legal</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Management has no knowledge of any pending or unasserted claims against the Company.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Other</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In March 2020, the World Health Organization declared the outbreak of a novel coronavirus (COVID-19) as a pandemic, which continues to spread throughout the United States and the world. The spread of COVID-19 has caused significant volatility in the U.S. and international markets. There is significant uncertainty around the breadth and duration of business disruptions related to COVID-19, as well as its impact on the U.S. and international economies and, as such, the Company is unable to determine if it will have a material impact to its operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The future minimum payments for the lease and sublease agreements at December 31, 2021 are as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:79.656%;"/> <td style="width:1.772%;"/> <td style="width:1.706%;"/> <td style="width:16.005%;"/> <td style="width:0.86%;"/> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2022 (remaining 2 months)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">36,000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table> 36000 183943 208348 82971 100457 3900000 2500000 181600 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">15. Subsequent Events</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Subsequent events have been evaluated through the date the financial statements were issued. As of such date, there were no material subsequent events identified that required recognition or disclosure other than as disclosed below or in the footnotes herein.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Effective March 1, 2022, the Company entered into a non-cancelable operating lease agreement for its current location with a </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">two-year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> term and future minimum payments of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">339,300</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p> P2Y 339300 EXCEL 73 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 74 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 75 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 76 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 137 263 1 false 49 0 false 4 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://hcwbiologics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 100010 - Statement - Balance Sheets Sheet http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementBalanceSheets Balance Sheets Statements 2 false false R3.htm 100020 - Statement - Balance Sheets (Parenthetical) Sheet http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementBalanceSheetsParenthetical Balance Sheets (Parenthetical) Statements 3 false false R4.htm 100030 - Statement - Statements of Operations Sheet http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementStatementsOfOperations Statements of Operations Statements 4 false false R5.htm 100040 - Statement - Statement of Changes in Redeemable Preferred Stock and Stockholders' (Deficit) Equity Sheet http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementStatementOfChangesInRedeemablePreferredStockAndStockholdersDeficitEquity Statement of Changes in Redeemable Preferred Stock and Stockholders' (Deficit) Equity Statements 5 false false R6.htm 100050 - Statement - Statement of Cash Flows Sheet http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementStatementOfCashFlows Statement of Cash Flows Statements 6 false false R7.htm 100060 - Disclosure - Organization and Summary of Significant Accounting Policies Sheet http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies Organization and Summary of Significant Accounting Policies Notes 7 false false R8.htm 100070 - Disclosure - Property and Equipment, Net Sheet http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet Property and Equipment, Net Notes 8 false false R9.htm 100080 - Disclosure - Fair Value of Financial Instruments Sheet http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstruments Fair Value of Financial Instruments Notes 9 false false R10.htm 100090 - Disclosure - Investments Sheet http://hcwbiologics.com/20211231/taxonomy/role/DisclosureInvestments Investments Notes 10 false false R11.htm 100100 - Disclosure - Related Party Transactions Sheet http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactions Related Party Transactions Notes 11 false false R12.htm 100110 - Disclosure - Accrued Liabilities and Other Current Liabilities Sheet http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureAccruedLiabilitiesAndOtherCurrentLiabilities Accrued Liabilities and Other Current Liabilities Notes 12 false false R13.htm 100120 - Disclosure - License Agreement Sheet http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureLicenseAgreement License Agreement Notes 13 false false R14.htm 100130 - Disclosure - Redeemable Preferred Stock Sheet http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureRedeemablePreferredStock Redeemable Preferred Stock Notes 14 false false R15.htm 100140 - Disclosure - Net Loss Per Share Sheet http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShare Net Loss Per Share Notes 15 false false R16.htm 100150 - Disclosure - Stock-Based Compensation Sheet http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensation Stock-Based Compensation Notes 16 false false R17.htm 100160 - Disclosure - Employee Benefit Plan Sheet http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureEmployeeBenefitPlan Employee Benefit Plan Notes 17 false false R18.htm 100170 - Disclosure - Collaborative Arrangements Sheet http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureCollaborativeArrangements Collaborative Arrangements Notes 18 false false R19.htm 100180 - Disclosure - Income Taxes Sheet http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxes Income Taxes Notes 19 false false R20.htm 100190 - Disclosure - Commitments and Contingencies Sheet http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies Commitments and Contingencies Notes 20 false false R21.htm 100200 - Disclosure - Subsequent Events Sheet http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureSubsequentEvents Subsequent Events Notes 21 false false R22.htm 100210 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies) Sheet http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies Organization and Summary of Significant Accounting Policies (Policies) Policies http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies 22 false false R23.htm 100220 - Disclosure - Property and Equipment, Net (Tables) Sheet http://hcwbiologics.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetTables Property and Equipment, Net (Tables) Tables http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet 23 false false R24.htm 100230 - Disclosure - Fair Value of Financial Instruments (Tables) Sheet http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsTables Fair Value of Financial Instruments (Tables) Tables http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstruments 24 false false R25.htm 100240 - Disclosure - Net Loss Per Share (Tables) Sheet http://hcwbiologics.com/20211231/taxonomy/role/DisclosureNetLossPerShareTables Net Loss Per Share (Tables) Tables http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShare 25 false false R26.htm 100250 - Disclosure - Stock-Based Compensation (Tables) Sheet http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationTables Stock-Based Compensation (Tables) Tables http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensation 26 false false R27.htm 100260 - Disclosure - Income Taxes (Tables) Sheet http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesTables Income Taxes (Tables) Tables http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxes 27 false false R28.htm 100270 - Disclosure - Commitments and Contingencies (Tables) Sheet http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables Commitments and Contingencies (Tables) Tables http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies 28 false false R29.htm 100280 - Disclosure - Organization and Summary of Significant Accounting Policies - Additional information (Details) Sheet http://hcwbiologics.com/20211231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails Organization and Summary of Significant Accounting Policies - Additional information (Details) Details 29 false false R30.htm 100290 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment (Details) Sheet http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails Property and Equipment, Net - Schedule of Property and Equipment (Details) Details 30 false false R31.htm 100300 - Disclosure - Property and Equipment, Net - Additional Information (Details) Sheet http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails Property and Equipment, Net - Additional Information (Details) Details 31 false false R32.htm 100310 - Disclosure - Fair Value of Financial Instruments - Summary of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail) Sheet http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail Fair Value of Financial Instruments - Summary of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail) Details 32 false false R33.htm 100320 - Disclosure - Investments - Additional Information (Details) Sheet http://hcwbiologics.com/20211231/taxonomy/role/DisclosureInvestmentsAdditionalInformationDetails Investments - Additional Information (Details) Details 33 false false R34.htm 100330 - Disclosure - Accrued Liabilities and Other Current Liabilities - Additional Information (Details) Sheet http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureAccruedLiabilitiesAndOtherCurrentLiabilitiesAdditionalInformationDetails Accrued Liabilities and Other Current Liabilities - Additional Information (Details) Details 34 false false R35.htm 100340 - Disclosure - License Agreement - Additional Information (Details) Sheet http://hcwbiologics.com/20211231/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails License Agreement - Additional Information (Details) Details 35 false false R36.htm 100350 - Disclosure - Redeemable Preferred Stock - Additional Information (Details) Sheet http://hcwbiologics.com/20211231/taxonomy/role/DisclosureRedeemablePreferredStockAdditionalInformationDetails Redeemable Preferred Stock - Additional Information (Details) Details 36 false false R37.htm 100360 - Disclosure - Net Loss Per Share - Summary of Basic and Diluted Net Income (Loss) Per Common Share (Detail) Sheet http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetIncomeLossPerCommonShareDetail Net Loss Per Share - Summary of Basic and Diluted Net Income (Loss) Per Common Share (Detail) Details 37 false false R38.htm 100370 - Disclosure - Net Loss Per Share - Summary of Outstanding Potentially Dilutive Securities (Detail) Sheet http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfOutstandingPotentiallyDilutiveSecuritiesDetail Net Loss Per Share - Summary of Outstanding Potentially Dilutive Securities (Detail) Details 38 false false R39.htm 100380 - Disclosure - Stock-Based Compensation - Additional Information (Details) Sheet http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails Stock-Based Compensation - Additional Information (Details) Details 39 false false R40.htm 100390 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activities (Details) Sheet http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivitiesDetails Stock-Based Compensation - Summary of Stock Option Activities (Details) Details 40 false false R41.htm 100400 - Disclosure - Stock-Based Compensation - Summary of Assumptions Used in Black-Scholes Model (Details) Sheet http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedInBlackScholesModelDetails Stock-Based Compensation - Summary of Assumptions Used in Black-Scholes Model (Details) Details 41 false false R42.htm 100410 - Disclosure - Employee Benefit Plan - Additional Information (Details) Sheet http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureEmployeeBenefitPlanAdditionalInformationDetails Employee Benefit Plan - Additional Information (Details) Details 42 false false R43.htm 100420 - Disclosure - Income Taxes - Additional Information (Details) Sheet http://hcwbiologics.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails Income Taxes - Additional Information (Details) Details 43 false false R44.htm 100430 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details) Sheet http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details) Details 44 false false R45.htm 100440 - Disclosure - Income Taxes - Components of Net Deferred Taxes (Detail) Sheet http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfNetDeferredTaxesDetail Income Taxes - Components of Net Deferred Taxes (Detail) Details 45 false false R46.htm 100450 - Disclosure - Commitments and Contingencies - Summary of the Future Minimum Payments for the Lease and Sublease Agreements (Detail) Sheet http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumPaymentsForLeaseAndSubleaseAgreementsDetail Commitments and Contingencies - Summary of the Future Minimum Payments for the Lease and Sublease Agreements (Detail) Details 46 false false R47.htm 100460 - Disclosure - Commitments and Contingencies - Additional Information (Details) Sheet http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails Commitments and Contingencies - Additional Information (Details) Details 47 false false R48.htm 100470 - Disclosure - Subsequent Events - Additional Information (Details) Sheet http://hcwbiologics.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails Subsequent Events - Additional Information (Details) Details 48 false false All Reports Book All Reports hcwb-20211231.htm hcwb-20211231.xsd hcwb-20211231_cal.xml hcwb-20211231_def.xml hcwb-20211231_lab.xml hcwb-20211231_pre.xml hcwb-ex23_1.htm hcwb-ex31_1.htm hcwb-ex31_2.htm hcwb-ex32_1.htm hcwb-ex32_2.htm hcwb-ex4_2.htm img111359907_0.jpg img111359907_1.jpg img111359907_10.jpg img111359907_2.jpg img111359907_3.jpg img111359907_4.jpg img111359907_5.jpg img111359907_6.jpg img111359907_7.jpg img111359907_8.jpg img111359907_9.jpg http://fasb.org/us-gaap/2021-01-31 http://xbrl.sec.gov/dei/2021q4 true true JSON 79 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "hcwb-20211231.htm": { "axisCustom": 2, "axisStandard": 20, "contextCount": 137, "dts": { "calculationLink": { "local": [ "hcwb-20211231_cal.xml" ] }, "definitionLink": { "local": [ "hcwb-20211231_def.xml" ] }, "inline": { "local": [ "hcwb-20211231.htm" ] }, "labelLink": { "local": [ "hcwb-20211231_lab.xml" ] }, "presentationLink": { "local": [ "hcwb-20211231_pre.xml" ] }, "schema": { "local": [ "hcwb-20211231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 445, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2021-01-31": 14, "http://xbrl.sec.gov/dei/2021q4": 4, "total": 18 }, "keyCustom": 31, "keyStandard": 232, "memberCustom": 20, "memberStandard": 28, "nsprefix": "hcwb", "nsuri": "http://hcwbiologics.com/20211231", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "hcwb-20211231.htm", "contextRef": "C_db440d28-e320-4f9b-8127-4c735fdac1c7", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://hcwbiologics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "hcwb-20211231.htm", "contextRef": "C_db440d28-e320-4f9b-8127-4c735fdac1c7", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "hcwb-20211231.htm", "contextRef": "C_db440d28-e320-4f9b-8127-4c735fdac1c7", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100090 - Disclosure - Investments", "role": "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureInvestments", "shortName": "Investments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "hcwb-20211231.htm", "contextRef": "C_db440d28-e320-4f9b-8127-4c735fdac1c7", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "hcwb-20211231.htm", "contextRef": "C_db440d28-e320-4f9b-8127-4c735fdac1c7", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100100 - Disclosure - Related Party Transactions", "role": "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactions", "shortName": "Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "hcwb-20211231.htm", "contextRef": "C_db440d28-e320-4f9b-8127-4c735fdac1c7", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "hcwb-20211231.htm", "contextRef": "C_db440d28-e320-4f9b-8127-4c735fdac1c7", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100110 - Disclosure - Accrued Liabilities and Other Current Liabilities", "role": "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureAccruedLiabilitiesAndOtherCurrentLiabilities", "shortName": "Accrued Liabilities and Other Current Liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "hcwb-20211231.htm", "contextRef": "C_db440d28-e320-4f9b-8127-4c735fdac1c7", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "hcwb-20211231.htm", "contextRef": "C_db440d28-e320-4f9b-8127-4c735fdac1c7", "decimals": null, "first": true, "lang": "en-US", "name": "hcwb:LicenseAgreementTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100120 - Disclosure - License Agreement", "role": "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureLicenseAgreement", "shortName": "License Agreement", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "hcwb-20211231.htm", "contextRef": "C_db440d28-e320-4f9b-8127-4c735fdac1c7", "decimals": null, "first": true, "lang": "en-US", "name": "hcwb:LicenseAgreementTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "hcwb-20211231.htm", "contextRef": "C_db440d28-e320-4f9b-8127-4c735fdac1c7", "decimals": null, "first": true, "lang": "en-US", "name": "hcwb:RedeemablePreferredStockTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100130 - Disclosure - Redeemable Preferred Stock", "role": "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureRedeemablePreferredStock", "shortName": "Redeemable Preferred Stock", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "hcwb-20211231.htm", "contextRef": "C_db440d28-e320-4f9b-8127-4c735fdac1c7", "decimals": null, "first": true, "lang": "en-US", "name": "hcwb:RedeemablePreferredStockTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "hcwb-20211231.htm", "contextRef": "C_db440d28-e320-4f9b-8127-4c735fdac1c7", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100140 - Disclosure - Net Loss Per Share", "role": "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShare", "shortName": "Net Loss Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "hcwb-20211231.htm", "contextRef": "C_db440d28-e320-4f9b-8127-4c735fdac1c7", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "hcwb-20211231.htm", "contextRef": "C_db440d28-e320-4f9b-8127-4c735fdac1c7", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100150 - Disclosure - Stock-Based Compensation", "role": "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensation", "shortName": "Stock-Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "hcwb-20211231.htm", "contextRef": "C_db440d28-e320-4f9b-8127-4c735fdac1c7", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "hcwb-20211231.htm", "contextRef": "C_db440d28-e320-4f9b-8127-4c735fdac1c7", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100160 - Disclosure - Employee Benefit Plan", "role": "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureEmployeeBenefitPlan", "shortName": "Employee Benefit Plan", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "hcwb-20211231.htm", "contextRef": "C_db440d28-e320-4f9b-8127-4c735fdac1c7", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "hcwb-20211231.htm", "contextRef": "C_db440d28-e320-4f9b-8127-4c735fdac1c7", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100170 - Disclosure - Collaborative Arrangements", "role": "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureCollaborativeArrangements", "shortName": "Collaborative Arrangements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "hcwb-20211231.htm", "contextRef": "C_db440d28-e320-4f9b-8127-4c735fdac1c7", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "hcwb-20211231.htm", "contextRef": "C_db440d28-e320-4f9b-8127-4c735fdac1c7", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100180 - Disclosure - Income Taxes", "role": "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "hcwb-20211231.htm", "contextRef": "C_db440d28-e320-4f9b-8127-4c735fdac1c7", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "hcwb-20211231.htm", "contextRef": "C_fc760a79-3d32-45e3-bc49-8300974057a3", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100010 - Statement - Balance Sheets", "role": "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementBalanceSheets", "shortName": "Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "hcwb-20211231.htm", "contextRef": "C_fc760a79-3d32-45e3-bc49-8300974057a3", "decimals": "0", "lang": null, "name": "us-gaap:PrepaidExpenseCurrent", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "hcwb-20211231.htm", "contextRef": "C_db440d28-e320-4f9b-8127-4c735fdac1c7", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100190 - Disclosure - Commitments and Contingencies", "role": "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "hcwb-20211231.htm", "contextRef": "C_db440d28-e320-4f9b-8127-4c735fdac1c7", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "hcwb-20211231.htm", "contextRef": "C_db440d28-e320-4f9b-8127-4c735fdac1c7", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100200 - Disclosure - Subsequent Events", "role": "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureSubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "hcwb-20211231.htm", "contextRef": "C_db440d28-e320-4f9b-8127-4c735fdac1c7", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "div", "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "hcwb-20211231.htm", "contextRef": "C_db440d28-e320-4f9b-8127-4c735fdac1c7", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100210 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)", "role": "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies", "shortName": "Organization and Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "hcwb-20211231.htm", "contextRef": "C_db440d28-e320-4f9b-8127-4c735fdac1c7", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hcwb-20211231.htm", "contextRef": "C_db440d28-e320-4f9b-8127-4c735fdac1c7", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100220 - Disclosure - Property and Equipment, Net (Tables)", "role": "http://hcwbiologics.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetTables", "shortName": "Property and Equipment, Net (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hcwb-20211231.htm", "contextRef": "C_db440d28-e320-4f9b-8127-4c735fdac1c7", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "hcwb-20211231.htm", "contextRef": "C_db440d28-e320-4f9b-8127-4c735fdac1c7", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100230 - Disclosure - Fair Value of Financial Instruments (Tables)", "role": "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsTables", "shortName": "Fair Value of Financial Instruments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "hcwb-20211231.htm", "contextRef": "C_db440d28-e320-4f9b-8127-4c735fdac1c7", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "hcwb-20211231.htm", "contextRef": "C_db440d28-e320-4f9b-8127-4c735fdac1c7", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100240 - Disclosure - Net Loss Per Share (Tables)", "role": "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureNetLossPerShareTables", "shortName": "Net Loss Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "hcwb-20211231.htm", "contextRef": "C_db440d28-e320-4f9b-8127-4c735fdac1c7", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "hcwb-20211231.htm", "contextRef": "C_db440d28-e320-4f9b-8127-4c735fdac1c7", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100250 - Disclosure - Stock-Based Compensation (Tables)", "role": "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationTables", "shortName": "Stock-Based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "hcwb-20211231.htm", "contextRef": "C_db440d28-e320-4f9b-8127-4c735fdac1c7", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hcwb-20211231.htm", "contextRef": "C_db440d28-e320-4f9b-8127-4c735fdac1c7", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100260 - Disclosure - Income Taxes (Tables)", "role": "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesTables", "shortName": "Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hcwb-20211231.htm", "contextRef": "C_db440d28-e320-4f9b-8127-4c735fdac1c7", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "div", "us-gaap:CommitmentsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hcwb-20211231.htm", "contextRef": "C_db440d28-e320-4f9b-8127-4c735fdac1c7", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfPropertySubjectToOrAvailableForOperatingLeaseTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100270 - Disclosure - Commitments and Contingencies (Tables)", "role": "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables", "shortName": "Commitments and Contingencies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:CommitmentsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hcwb-20211231.htm", "contextRef": "C_db440d28-e320-4f9b-8127-4c735fdac1c7", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfPropertySubjectToOrAvailableForOperatingLeaseTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "hcwb-20211231.htm", "contextRef": "C_fdaadc8f-1550-4509-bfec-163a365086b2", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityReverseStockSplit", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100280 - Disclosure - Organization and Summary of Significant Accounting Policies - Additional information (Details)", "role": "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "shortName": "Organization and Summary of Significant Accounting Policies - Additional information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "hcwb-20211231.htm", "contextRef": "C_fdaadc8f-1550-4509-bfec-163a365086b2", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityReverseStockSplit", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "hcwb-20211231.htm", "contextRef": "C_563808fa-0b52-4fdb-bc1c-eb753963c11d", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesIssued", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100020 - Statement - Balance Sheets (Parenthetical)", "role": "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementBalanceSheetsParenthetical", "shortName": "Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "hcwb-20211231.htm", "contextRef": "C_563808fa-0b52-4fdb-bc1c-eb753963c11d", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesIssued", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hcwb-20211231.htm", "contextRef": "C_fc760a79-3d32-45e3-bc49-8300974057a3", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100290 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment (Details)", "role": "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails", "shortName": "Property and Equipment, Net - Schedule of Property and Equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hcwb-20211231.htm", "contextRef": "C_fc760a79-3d32-45e3-bc49-8300974057a3", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hcwb-20211231.htm", "contextRef": "C_db440d28-e320-4f9b-8127-4c735fdac1c7", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100300 - Disclosure - Property and Equipment, Net - Additional Information (Details)", "role": "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails", "shortName": "Property and Equipment, Net - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hcwb-20211231.htm", "contextRef": "C_db440d28-e320-4f9b-8127-4c735fdac1c7", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "hcwb-20211231.htm", "contextRef": "C_fc760a79-3d32-45e3-bc49-8300974057a3", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100310 - Disclosure - Fair Value of Financial Instruments - Summary of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail)", "role": "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail", "shortName": "Fair Value of Financial Instruments - Summary of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "hcwb-20211231.htm", "contextRef": "C_fc760a79-3d32-45e3-bc49-8300974057a3", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "hcwb-20211231.htm", "contextRef": "C_fc760a79-3d32-45e3-bc49-8300974057a3", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LongTermInvestments", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100320 - Disclosure - Investments - Additional Information (Details)", "role": "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureInvestmentsAdditionalInformationDetails", "shortName": "Investments - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:InvestmentTextBlock", "div", "body", "html" ], "baseRef": "hcwb-20211231.htm", "contextRef": "C_fc760a79-3d32-45e3-bc49-8300974057a3", "decimals": "-5", "lang": null, "name": "hcwb:ConsiderationReceivedOnFairValueOfSecurities", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "hcwb-20211231.htm", "contextRef": "C_fc760a79-3d32-45e3-bc49-8300974057a3", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100330 - Disclosure - Accrued Liabilities and Other Current Liabilities - Additional Information (Details)", "role": "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureAccruedLiabilitiesAndOtherCurrentLiabilitiesAdditionalInformationDetails", "shortName": "Accrued Liabilities and Other Current Liabilities - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hcwb-20211231.htm", "contextRef": "C_fc760a79-3d32-45e3-bc49-8300974057a3", "decimals": "-5", "lang": null, "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "p", "hcwb:LicenseAgreementTextBlock", "div", "body", "html" ], "baseRef": "hcwb-20211231.htm", "contextRef": "C_53694d7c-bb8b-4ce2-8e92-2d147f7f97d4", "decimals": "-5", "first": true, "lang": null, "name": "hcwb:AmountConsideredForPerformanceObligations", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100340 - Disclosure - License Agreement - Additional Information (Details)", "role": "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails", "shortName": "License Agreement - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "hcwb:LicenseAgreementTextBlock", "div", "body", "html" ], "baseRef": "hcwb-20211231.htm", "contextRef": "C_53694d7c-bb8b-4ce2-8e92-2d147f7f97d4", "decimals": "-5", "first": true, "lang": null, "name": "hcwb:AmountConsideredForPerformanceObligations", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "hcwb-20211231.htm", "contextRef": "C_563808fa-0b52-4fdb-bc1c-eb753963c11d", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RedeemableNoncontrollingInterestEquityPreferredCarryingAmount", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100350 - Disclosure - Redeemable Preferred Stock - Additional Information (Details)", "role": "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureRedeemablePreferredStockAdditionalInformationDetails", "shortName": "Redeemable Preferred Stock - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "ix:continuation", "span", "p", "body", "html" ], "baseRef": "hcwb-20211231.htm", "contextRef": "C_fc760a79-3d32-45e3-bc49-8300974057a3", "decimals": "0", "lang": null, "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "hcwb-20211231.htm", "contextRef": "C_db440d28-e320-4f9b-8127-4c735fdac1c7", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100360 - Disclosure - Net Loss Per Share - Summary of Basic and Diluted Net Income (Loss) Per Common Share (Detail)", "role": "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetIncomeLossPerCommonShareDetail", "shortName": "Net Loss Per Share - Summary of Basic and Diluted Net Income (Loss) Per Common Share (Detail)", "subGroupType": "details", "uniqueAnchor": null }, "R38": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "hcwb-20211231.htm", "contextRef": "C_db440d28-e320-4f9b-8127-4c735fdac1c7", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100370 - Disclosure - Net Loss Per Share - Summary of Outstanding Potentially Dilutive Securities (Detail)", "role": "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfOutstandingPotentiallyDilutiveSecuritiesDetail", "shortName": "Net Loss Per Share - Summary of Outstanding Potentially Dilutive Securities (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "hcwb-20211231.htm", "contextRef": "C_db440d28-e320-4f9b-8127-4c735fdac1c7", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "hcwb-20211231.htm", "contextRef": "C_db440d28-e320-4f9b-8127-4c735fdac1c7", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "reportCount": 1, "unitRef": "U_pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100380 - Disclosure - Stock-Based Compensation - Additional Information (Details)", "role": "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "shortName": "Stock-Based Compensation - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "hcwb-20211231.htm", "contextRef": "C_db440d28-e320-4f9b-8127-4c735fdac1c7", "decimals": "0", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "hcwb-20211231.htm", "contextRef": "C_53694d7c-bb8b-4ce2-8e92-2d147f7f97d4", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100030 - Statement - Statements of Operations", "role": "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementStatementsOfOperations", "shortName": "Statements of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "hcwb-20211231.htm", "contextRef": "C_53694d7c-bb8b-4ce2-8e92-2d147f7f97d4", "decimals": "0", "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "hcwb-20211231.htm", "contextRef": "C_563808fa-0b52-4fdb-bc1c-eb753963c11d", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100390 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activities (Details)", "role": "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivitiesDetails", "shortName": "Stock-Based Compensation - Summary of Stock Option Activities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "hcwb-20211231.htm", "contextRef": "C_db440d28-e320-4f9b-8127-4c735fdac1c7", "decimals": "0", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "hcwb-20211231.htm", "contextRef": "C_db440d28-e320-4f9b-8127-4c735fdac1c7", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100400 - Disclosure - Stock-Based Compensation - Summary of Assumptions Used in Black-Scholes Model (Details)", "role": "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedInBlackScholesModelDetails", "shortName": "Stock-Based Compensation - Summary of Assumptions Used in Black-Scholes Model (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "hcwb-20211231.htm", "contextRef": "C_db440d28-e320-4f9b-8127-4c735fdac1c7", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hcwb-20211231.htm", "contextRef": "C_db440d28-e320-4f9b-8127-4c735fdac1c7", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100410 - Disclosure - Employee Benefit Plan - Additional Information (Details)", "role": "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureEmployeeBenefitPlanAdditionalInformationDetails", "shortName": "Employee Benefit Plan - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hcwb-20211231.htm", "contextRef": "C_db440d28-e320-4f9b-8127-4c735fdac1c7", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hcwb-20211231.htm", "contextRef": "C_db440d28-e320-4f9b-8127-4c735fdac1c7", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100420 - Disclosure - Income Taxes - Additional Information (Details)", "role": "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails", "shortName": "Income Taxes - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hcwb-20211231.htm", "contextRef": "C_db440d28-e320-4f9b-8127-4c735fdac1c7", "decimals": null, "lang": "en-US", "name": "hcwb:IncomeTaxProvisionUnderCaresActDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hcwb-20211231.htm", "contextRef": "C_db440d28-e320-4f9b-8127-4c735fdac1c7", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100430 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)", "role": "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails", "shortName": "Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hcwb-20211231.htm", "contextRef": "C_db440d28-e320-4f9b-8127-4c735fdac1c7", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hcwb-20211231.htm", "contextRef": "C_fc760a79-3d32-45e3-bc49-8300974057a3", "decimals": "0", "first": true, "lang": null, "name": "hcwb:DeferredTaxAssetsOperatingLossCarryforwardsFederalStateAndLocal", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100440 - Disclosure - Income Taxes - Components of Net Deferred Taxes (Detail)", "role": "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfNetDeferredTaxesDetail", "shortName": "Income Taxes - Components of Net Deferred Taxes (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hcwb-20211231.htm", "contextRef": "C_fc760a79-3d32-45e3-bc49-8300974057a3", "decimals": "0", "first": true, "lang": null, "name": "hcwb:DeferredTaxAssetsOperatingLossCarryforwardsFederalStateAndLocal", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfPropertySubjectToOrAvailableForOperatingLeaseTextBlock", "div", "us-gaap:CommitmentsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hcwb-20211231.htm", "contextRef": "C_fc760a79-3d32-45e3-bc49-8300974057a3", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100450 - Disclosure - Commitments and Contingencies - Summary of the Future Minimum Payments for the Lease and Sublease Agreements (Detail)", "role": "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumPaymentsForLeaseAndSubleaseAgreementsDetail", "shortName": "Commitments and Contingencies - Summary of the Future Minimum Payments for the Lease and Sublease Agreements (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfPropertySubjectToOrAvailableForOperatingLeaseTextBlock", "div", "us-gaap:CommitmentsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hcwb-20211231.htm", "contextRef": "C_fc760a79-3d32-45e3-bc49-8300974057a3", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:CommitmentsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hcwb-20211231.htm", "contextRef": "C_db440d28-e320-4f9b-8127-4c735fdac1c7", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LeaseAndRentalExpense", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100460 - Disclosure - Commitments and Contingencies - Additional Information (Details)", "role": "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "shortName": "Commitments and Contingencies - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:CommitmentsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hcwb-20211231.htm", "contextRef": "C_db440d28-e320-4f9b-8127-4c735fdac1c7", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LeaseAndRentalExpense", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:SubsequentEventsTextBlock", "div", "body", "html" ], "baseRef": "hcwb-20211231.htm", "contextRef": "C_47429380-65c2-4a88-a8c1-19fd94a1323b", "decimals": null, "first": true, "lang": "en-US", "name": "hcwb:TermOfAgreementsRenewalPeriod", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100470 - Disclosure - Subsequent Events - Additional Information (Details)", "role": "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "shortName": "Subsequent Events - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:SubsequentEventsTextBlock", "div", "body", "html" ], "baseRef": "hcwb-20211231.htm", "contextRef": "C_47429380-65c2-4a88-a8c1-19fd94a1323b", "decimals": null, "first": true, "lang": "en-US", "name": "hcwb:TermOfAgreementsRenewalPeriod", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "hcwb-20211231.htm", "contextRef": "C_4015a6a8-6a2b-4f1d-9851-d2d840fe4afd", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100040 - Statement - Statement of Changes in Redeemable Preferred Stock and Stockholders' (Deficit) Equity", "role": "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementStatementOfChangesInRedeemablePreferredStockAndStockholdersDeficitEquity", "shortName": "Statement of Changes in Redeemable Preferred Stock and Stockholders' (Deficit) Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "hcwb-20211231.htm", "contextRef": "C_4015a6a8-6a2b-4f1d-9851-d2d840fe4afd", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "hcwb-20211231.htm", "contextRef": "C_db440d28-e320-4f9b-8127-4c735fdac1c7", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100050 - Statement - Statement of Cash Flows", "role": "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementStatementOfCashFlows", "shortName": "Statement of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "hcwb-20211231.htm", "contextRef": "C_db440d28-e320-4f9b-8127-4c735fdac1c7", "decimals": "0", "lang": null, "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "hcwb-20211231.htm", "contextRef": "C_db440d28-e320-4f9b-8127-4c735fdac1c7", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100060 - Disclosure - Organization and Summary of Significant Accounting Policies", "role": "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies", "shortName": "Organization and Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "hcwb-20211231.htm", "contextRef": "C_db440d28-e320-4f9b-8127-4c735fdac1c7", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "hcwb-20211231.htm", "contextRef": "C_db440d28-e320-4f9b-8127-4c735fdac1c7", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100070 - Disclosure - Property and Equipment, Net", "role": "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet", "shortName": "Property and Equipment, Net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "hcwb-20211231.htm", "contextRef": "C_db440d28-e320-4f9b-8127-4c735fdac1c7", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "hcwb-20211231.htm", "contextRef": "C_db440d28-e320-4f9b-8127-4c735fdac1c7", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100080 - Disclosure - Fair Value of Financial Instruments", "role": "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstruments", "shortName": "Fair Value of Financial Instruments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "hcwb-20211231.htm", "contextRef": "C_db440d28-e320-4f9b-8127-4c735fdac1c7", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 49, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r435", "r437", "r438" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "Auditor Firm Id", "terseLabel": "Auditor Firm ID" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r435", "r437", "r438" ], "lang": { "en-us": { "role": { "label": "Auditor Location", "terseLabel": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r435", "r437", "r438" ], "lang": { "en-us": { "role": { "label": "Auditor Name", "terseLabel": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "internationalNameItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r435", "r437", "r438" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report", "terseLabel": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r436" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r439" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r433" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated By Reference [Text Block]", "terseLabel": "Documents Incorporated by Reference" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address Address Line2", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r432" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r432" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r443" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r432" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r441" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float", "terseLabel": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r432" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r432" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r432" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r432" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers", "terseLabel": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r442" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well Known Seasoned Issuer", "terseLabel": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_IcfrAuditorAttestationFlag": { "auth_ref": [ "r435", "r437", "r438" ], "lang": { "en-us": { "role": { "label": "Icfr Auditor Attestation Flag", "terseLabel": "ICFR Auditor Attestation Flag" } } }, "localname": "IcfrAuditorAttestationFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r431" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security12b Title", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r434" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "hcwb_AccruedExpensesCurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued expenses current.", "label": "Accrued Expenses Current", "terseLabel": "Accrued expenses current", "verboseLabel": "Accrued expenses, current" } } }, "localname": "AccruedExpensesCurrent", "nsuri": "http://hcwbiologics.com/20211231", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureAccruedLiabilitiesAndOtherCurrentLiabilitiesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "hcwb_AccruedExpensesCurrentAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accrued expenses current.", "label": "Accrued Expenses Current [Axis]", "terseLabel": "Accrued Expenses Current" } } }, "localname": "AccruedExpensesCurrentAxis", "nsuri": "http://hcwbiologics.com/20211231", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureAccruedLiabilitiesAndOtherCurrentLiabilitiesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "hcwb_AccruedExpensesCurrentDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accrued expenses current.", "label": "Accrued Expenses Current [Domain]", "terseLabel": "Accrued Expenses Current" } } }, "localname": "AccruedExpensesCurrentDomain", "nsuri": "http://hcwbiologics.com/20211231", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureAccruedLiabilitiesAndOtherCurrentLiabilitiesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "hcwb_AccruedExpensesCurrentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accrued expenses current.", "label": "Accrued Expenses Current [Member]", "terseLabel": "Accrued Expenses Current [Member]" } } }, "localname": "AccruedExpensesCurrentMember", "nsuri": "http://hcwbiologics.com/20211231", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureAccruedLiabilitiesAndOtherCurrentLiabilitiesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "hcwb_AgreementAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agreement.", "label": "Agreement [Axis]", "terseLabel": "Agreement" } } }, "localname": "AgreementAxis", "nsuri": "http://hcwbiologics.com/20211231", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureInvestmentsAdditionalInformationDetails", "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "hcwb_AgreementDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agreement.", "label": "Agreement [Domain]", "terseLabel": "Agreement" } } }, "localname": "AgreementDomain", "nsuri": "http://hcwbiologics.com/20211231", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureInvestmentsAdditionalInformationDetails", "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "hcwb_AmountConsideredForPerformanceObligations": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount considered for performance obligations.", "label": "Amount Considered For Performance Obligations", "terseLabel": "Amount Considered For Performance Obligations" } } }, "localname": "AmountConsideredForPerformanceObligations", "nsuri": "http://hcwbiologics.com/20211231", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "hcwb_ClassBConvertibleCommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class B convertible common stock member.", "label": "Class B Convertible Common Stock [Member]", "terseLabel": "Class B Convertible Common Stock [Member]" } } }, "localname": "ClassBConvertibleCommonStockMember", "nsuri": "http://hcwbiologics.com/20211231", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementBalanceSheets", "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementBalanceSheetsParenthetical" ], "xbrltype": "domainItemType" }, "hcwb_CommonStockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock abstract.", "label": "Common Stock [Abstract]", "terseLabel": "Common stock:" } } }, "localname": "CommonStockAbstract", "nsuri": "http://hcwbiologics.com/20211231", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementBalanceSheets" ], "xbrltype": "stringItemType" }, "hcwb_CommonStockOptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common Stock Options.", "label": "Common Stock Options [Member]", "terseLabel": "Common Stock Options" } } }, "localname": "CommonStockOptionsMember", "nsuri": "http://hcwbiologics.com/20211231", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfOutstandingPotentiallyDilutiveSecuritiesDetail" ], "xbrltype": "domainItemType" }, "hcwb_ConsiderationReceivedInSharesOfCommonStock": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Consideration received in shares of common stock.", "label": "Consideration Received In Shares Of Common Stock.", "terseLabel": "Consideration received in shares of common stock" } } }, "localname": "ConsiderationReceivedInSharesOfCommonStock", "nsuri": "http://hcwbiologics.com/20211231", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "hcwb_ConsiderationReceivedOnFairValueOfSecurities": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Consideration received on fair value of securities.", "label": "Consideration Received On Fair Value Of Securities", "terseLabel": "Consideration received on fair value of securities" } } }, "localname": "ConsiderationReceivedOnFairValueOfSecurities", "nsuri": "http://hcwbiologics.com/20211231", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureInvestmentsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "hcwb_ConversionOfSeriesARedeemablePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Conversion of series A redeemable preferred stock member.", "label": "Conversion Of Series A Redeemable Preferred Stock [Member]", "terseLabel": "Conversion Of Series A Redeemable Preferred Stock [Member]" } } }, "localname": "ConversionOfSeriesARedeemablePreferredStockMember", "nsuri": "http://hcwbiologics.com/20211231", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementStatementOfChangesInRedeemablePreferredStockAndStockholdersDeficitEquity" ], "xbrltype": "domainItemType" }, "hcwb_ConversionOfSeriesBRedeemablePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Conversion of series B redeemable preferred stock member.", "label": "Conversion Of Series B Redeemable Preferred Stock [Member]", "terseLabel": "Conversion Of Series B Redeemable Preferred Stock [Member]" } } }, "localname": "ConversionOfSeriesBRedeemablePreferredStockMember", "nsuri": "http://hcwbiologics.com/20211231", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementStatementOfChangesInRedeemablePreferredStockAndStockholdersDeficitEquity" ], "xbrltype": "domainItemType" }, "hcwb_ConversionOfSeriesCRedeemablePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Conversion of series C redeemable preferred stock member.", "label": "Conversion Of Series C Redeemable Preferred Stock [Member]", "terseLabel": "Conversion Of Series C Redeemable Preferred Stock [Member]" } } }, "localname": "ConversionOfSeriesCRedeemablePreferredStockMember", "nsuri": "http://hcwbiologics.com/20211231", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementStatementOfChangesInRedeemablePreferredStockAndStockholdersDeficitEquity" ], "xbrltype": "domainItemType" }, "hcwb_CumulativeDividendsEarnedAndAccruedInTheReportingPeriod": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cumulative dividends earned and accrued in the reporting period.", "label": "Cumulative Dividends Earned And Accrued In The Reporting Period", "terseLabel": "Cumulative dividends earned, accrued and forfeited in the reporting period" } } }, "localname": "CumulativeDividendsEarnedAndAccruedInTheReportingPeriod", "nsuri": "http://hcwbiologics.com/20211231", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "hcwb_CumulativeDividendsOnPreferredStockPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of Cumulative Dividends on Preferred Stock", "label": "Cumulative Dividends On Preferred Stock Policy Policy [Text Block]", "terseLabel": "Cumulative Dividends on Preferred Stock" } } }, "localname": "CumulativeDividendsOnPreferredStockPolicyPolicyTextBlock", "nsuri": "http://hcwbiologics.com/20211231", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "hcwb_CumulativeLossesToConductProductResearchAndDevelopmentInFuture": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cumulative losses to conduct product research and development in future.", "label": "Cumulative Losses To Conduct Product Research And Development In Future", "terseLabel": "Research and development" } } }, "localname": "CumulativeLossesToConductProductResearchAndDevelopmentInFuture", "nsuri": "http://hcwbiologics.com/20211231", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "hcwb_DeferredOfferingCostsReclassifiedToStockholdersEquity": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred offering costs reclassified to stockholders equity.", "label": "Deferred Offering Costs Reclassified To Stockholders Equity", "terseLabel": "Deferred offering costs reclassified to stockholders equity" } } }, "localname": "DeferredOfferingCostsReclassifiedToStockholdersEquity", "nsuri": "http://hcwbiologics.com/20211231", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "hcwb_DeferredTaxAssetUnrealizedGainLoss": { "auth_ref": [], "calculation": { "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfNetDeferredTaxesDetail": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred tax asset unrealized gain (loss).", "label": "Deferred Tax Asset Unrealized Gain Loss", "terseLabel": "Unrealized Gain/Loss" } } }, "localname": "DeferredTaxAssetUnrealizedGainLoss", "nsuri": "http://hcwbiologics.com/20211231", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfNetDeferredTaxesDetail" ], "xbrltype": "monetaryItemType" }, "hcwb_DeferredTaxAssetsOperatingLossCarryforwardsFederalStateAndLocal": { "auth_ref": [], "calculation": { "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfNetDeferredTaxesDetail": { "order": 7.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred tax assets operating loss carryforwards federal state and local.", "label": "Deferred Tax Assets Operating Loss Carryforwards Federal State And Local", "terseLabel": "Federal net operating loss carryforward" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwardsFederalStateAndLocal", "nsuri": "http://hcwbiologics.com/20211231", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfNetDeferredTaxesDetail" ], "xbrltype": "monetaryItemType" }, "hcwb_DeferredTaxLiabilityDepreciableAssets": { "auth_ref": [], "calculation": { "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfNetDeferredTaxesDetail": { "order": 0.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred tax liability depreciable assets.", "label": "Deferred Tax Liability Depreciable Assets", "terseLabel": "Depreciable assets" } } }, "localname": "DeferredTaxLiabilityDepreciableAssets", "nsuri": "http://hcwbiologics.com/20211231", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfNetDeferredTaxesDetail" ], "xbrltype": "monetaryItemType" }, "hcwb_DenominatorAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Denominator", "label": "Denominator [Abstract]", "terseLabel": "Denominator:" } } }, "localname": "DenominatorAbstract", "nsuri": "http://hcwbiologics.com/20211231", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetIncomeLossPerCommonShareDetail" ], "xbrltype": "stringItemType" }, "hcwb_DisclosureLicenseAgreementDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure License Agreement Details [Line Items]", "terseLabel": "Disclosure - License Agreement - (Details) [Line Items]" } } }, "localname": "DisclosureLicenseAgreementDetailsLineItems", "nsuri": "http://hcwbiologics.com/20211231", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "hcwb_EffectiveIncomeTaxRateReconciliationPermanentDifferences": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Effective Income Tax Rate Reconciliation Permanent Differences", "label": "Effective Income Tax Rate Reconciliation Permanent Differences", "terseLabel": "Permanent book/tax differences" } } }, "localname": "EffectiveIncomeTaxRateReconciliationPermanentDifferences", "nsuri": "http://hcwbiologics.com/20211231", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "hcwb_FederalAndStateNolTaxableIncomeOffsetPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Federal and State NOL taxable income offset percentage.", "label": "Federal and State NOL Taxable Income Offset Percentage", "terseLabel": "Federal and state NOL taxable income offset percentage" } } }, "localname": "FederalAndStateNolTaxableIncomeOffsetPercentage", "nsuri": "http://hcwbiologics.com/20211231", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "hcwb_FederalPayrollTaxes": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Federal Payroll Taxes", "label": "Federal Payroll Taxes", "terseLabel": "federal payroll taxes" } } }, "localname": "FederalPayrollTaxes", "nsuri": "http://hcwbiologics.com/20211231", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "hcwb_ForfeitureOfCumulativeDividends": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Forfeiture of cumulative dividends, upon conversion.", "label": "Forfeiture Of Cumulative Dividends", "terseLabel": "Forfeiture of cumulative dividends, upon conversion of Preferred Stock" } } }, "localname": "ForfeitureOfCumulativeDividends", "nsuri": "http://hcwbiologics.com/20211231", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "hcwb_InKindPaymentForLicenseFee": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "In-kind payment for license fee.", "label": "In Kind Payment For License Fee", "terseLabel": "In-kind payment for license fee" } } }, "localname": "InKindPaymentForLicenseFee", "nsuri": "http://hcwbiologics.com/20211231", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "hcwb_IncomeTaxProvisionUnderCaresActDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Income tax provision under CARES Act description.", "label": "Income Tax Provision under CARES Act Description", "terseLabel": "Income tax provisions under CARES Act" } } }, "localname": "IncomeTaxProvisionUnderCaresActDescription", "nsuri": "http://hcwbiologics.com/20211231", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "hcwb_IncomeTaxReconciliationPermanentDifferences": { "auth_ref": [], "calculation": { "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Income tax reconciliation permanent differences.", "label": "Income Tax Reconciliation Permanent Differences", "terseLabel": "Permanent book/tax differences" } } }, "localname": "IncomeTaxReconciliationPermanentDifferences", "nsuri": "http://hcwbiologics.com/20211231", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "hcwb_IssuanceCostsOfInitialPublicOffering": { "auth_ref": [], "calculation": { "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementStatementOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Issuance Costs of Initial Public Offering.", "label": "Issuance Costs Of Initial Public Offering", "negatedLabel": "Issuance costs of initial public offering" } } }, "localname": "IssuanceCostsOfInitialPublicOffering", "nsuri": "http://hcwbiologics.com/20211231", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "hcwb_LaboratoryEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Laboratory equipment.", "label": "Laboratory Equipment [Member]", "terseLabel": "Laboratory equipment" } } }, "localname": "LaboratoryEquipmentMember", "nsuri": "http://hcwbiologics.com/20211231", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "hcwb_LicenseAgreementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "License agreement.", "label": "License Agreement [Abstract]" } } }, "localname": "LicenseAgreementAbstract", "nsuri": "http://hcwbiologics.com/20211231", "xbrltype": "stringItemType" }, "hcwb_LicenseAgreementDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "License agreement description.", "label": "License Agreement Description", "terseLabel": "License Agreement Description" } } }, "localname": "LicenseAgreementDescription", "nsuri": "http://hcwbiologics.com/20211231", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "hcwb_LicenseAgreementTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "License agreement table.", "label": "License Agreement [Table]", "terseLabel": "License Agreement [Table]" } } }, "localname": "LicenseAgreementTable", "nsuri": "http://hcwbiologics.com/20211231", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "hcwb_LicenseAgreementTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "License agreement text block.", "label": "License Agreement [Text Block]", "terseLabel": "License Agreement" } } }, "localname": "LicenseAgreementTextBlock", "nsuri": "http://hcwbiologics.com/20211231", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureLicenseAgreement" ], "xbrltype": "textBlockItemType" }, "hcwb_NumeratorAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Numerator.", "label": "Numerator [Abstract]", "terseLabel": "Numerator:" } } }, "localname": "NumeratorAbstract", "nsuri": "http://hcwbiologics.com/20211231", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetIncomeLossPerCommonShareDetail" ], "xbrltype": "stringItemType" }, "hcwb_OperatingLossCarryforwardsExpirationTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating loss carryforwards, expiration term.", "label": "Operating Loss Carryforwards, Expiration Term", "terseLabel": "Carryforwards expiration term" } } }, "localname": "OperatingLossCarryforwardsExpirationTerm", "nsuri": "http://hcwbiologics.com/20211231", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "hcwb_PatentCostsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of Patent costs.", "label": "Patent Costs Policy Policy [Text Block]", "terseLabel": "Patent Costs" } } }, "localname": "PatentCostsPolicyPolicyTextBlock", "nsuri": "http://hcwbiologics.com/20211231", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "hcwb_PayablesAndAccrualsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Payables and accruals.", "label": "Payables And Accruals [Line Items]", "terseLabel": "Payables And Accruals [Line Items]" } } }, "localname": "PayablesAndAccrualsLineItems", "nsuri": "http://hcwbiologics.com/20211231", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureAccruedLiabilitiesAndOtherCurrentLiabilitiesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "hcwb_PayablesAndAccrualsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Payables and accruals.", "label": "Payables And Accruals [Table]", "terseLabel": "Payables And Accruals [Table]" } } }, "localname": "PayablesAndAccrualsTable", "nsuri": "http://hcwbiologics.com/20211231", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureAccruedLiabilitiesAndOtherCurrentLiabilitiesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "hcwb_PercentageOfCumulativeDividends": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of cumulative dividends", "label": "Percentage of Cumulative Dividends", "terseLabel": "Percentage of Cumulative Dividends" } } }, "localname": "PercentageOfCumulativeDividends", "nsuri": "http://hcwbiologics.com/20211231", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "hcwb_ProceedsFromIssuanceOfPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Proceeds from Issuance of preferred stock,", "label": "Proceeds From Issuance Of Preferred Stock [Member]", "terseLabel": "Proceeds From Issuance Of Preferred Stock" } } }, "localname": "ProceedsFromIssuanceOfPreferredStockMember", "nsuri": "http://hcwbiologics.com/20211231", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureRedeemablePreferredStockAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "hcwb_ReconciliationOfEffectiveIncomeTaxRateLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Reconciliation of Effective Income Tax Rate [Line Items]", "label": "Reconciliation Of Effective Income Tax Rate [Line Items]", "terseLabel": "Reconciliation Of Effective Income Tax Rate [Line Items]" } } }, "localname": "ReconciliationOfEffectiveIncomeTaxRateLineItems", "nsuri": "http://hcwbiologics.com/20211231", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "stringItemType" }, "hcwb_ReconciliationOfEffectiveIncomeTaxRateTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Reconciliation of Effective Income Tax Rate [Table]", "label": "Reconciliation Of Effective Income Tax Rate [Table]", "terseLabel": "Reconciliation Of Effective Income Tax Rate [Table]" } } }, "localname": "ReconciliationOfEffectiveIncomeTaxRateTable", "nsuri": "http://hcwbiologics.com/20211231", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "stringItemType" }, "hcwb_RedeemablePreferredStockTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Redeemable preferred stock.", "label": "Redeemable Preferred Stock [Text Block]", "terseLabel": "Redeemable Preferred Stock" } } }, "localname": "RedeemablePreferredStockTextBlock", "nsuri": "http://hcwbiologics.com/20211231", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureRedeemablePreferredStock" ], "xbrltype": "textBlockItemType" }, "hcwb_RedeemablePreferredStocksMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Redeemable preferred stock.", "label": "Redeemable Preferred Stocks [Member]", "terseLabel": "Redeemable Preferred Stocks" } } }, "localname": "RedeemablePreferredStocksMember", "nsuri": "http://hcwbiologics.com/20211231", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfOutstandingPotentiallyDilutiveSecuritiesDetail" ], "xbrltype": "domainItemType" }, "hcwb_ResidualApproachMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Residual approach member.", "label": "Residual Approach [Member]", "terseLabel": "Residual Approach [Member]" } } }, "localname": "ResidualApproachMember", "nsuri": "http://hcwbiologics.com/20211231", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "hcwb_SbaPaycheckProtectionLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sba paycheck protection loan.", "label": "Sba Paycheck Protection Loan [Member]", "terseLabel": "SBA Paycheck Protection Loan [Member]" } } }, "localname": "SbaPaycheckProtectionLoanMember", "nsuri": "http://hcwbiologics.com/20211231", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureAccruedLiabilitiesAndOtherCurrentLiabilitiesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "hcwb_SellingPrice": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Selling price.", "label": "Selling Price", "terseLabel": "Selling Price" } } }, "localname": "SellingPrice", "nsuri": "http://hcwbiologics.com/20211231", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "hcwb_SeriesARedeemablePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series A redeemable preferred stock member.", "label": "Series A Redeemable Preferred Stock [Member]", "terseLabel": "Series A Redeemable preferred stock [Member]" } } }, "localname": "SeriesARedeemablePreferredStockMember", "nsuri": "http://hcwbiologics.com/20211231", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementBalanceSheets", "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementBalanceSheetsParenthetical", "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementStatementOfChangesInRedeemablePreferredStockAndStockholdersDeficitEquity" ], "xbrltype": "domainItemType" }, "hcwb_SeriesBRedeemablePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series B redeemable preferred stock member.", "label": "Series B Redeemable Preferred Stock [Member]", "terseLabel": "Series B Redeemable preferred stock [Member]" } } }, "localname": "SeriesBRedeemablePreferredStockMember", "nsuri": "http://hcwbiologics.com/20211231", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementBalanceSheets", "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementBalanceSheetsParenthetical", "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementStatementOfChangesInRedeemablePreferredStockAndStockholdersDeficitEquity" ], "xbrltype": "domainItemType" }, "hcwb_SeriesCRedeemablePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series C redeemable preferred stock member.", "label": "Series C Redeemable Preferred Stock [Member]", "terseLabel": "Series C Redeemable preferred stock [Member]" } } }, "localname": "SeriesCRedeemablePreferredStockMember", "nsuri": "http://hcwbiologics.com/20211231", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureRedeemablePreferredStockAdditionalInformationDetails", "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementBalanceSheets", "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementBalanceSheetsParenthetical", "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementStatementOfChangesInRedeemablePreferredStockAndStockholdersDeficitEquity" ], "xbrltype": "domainItemType" }, "hcwb_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExercisedWeightedAverageRemainingContractualTerms": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Option Exercised Weighted Average Remaining Contractual Terms", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Option Exercised Weighted Average Remaining Contractual Terms", "terseLabel": "Weighted average remaining contracted terms (in years) exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExercisedWeightedAverageRemainingContractualTerms", "nsuri": "http://hcwbiologics.com/20211231", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivitiesDetails" ], "xbrltype": "durationItemType" }, "hcwb_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionForfeitedOrCancelledWeightedAverageRemainingContractualTerms": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Option Forfeited or Cancelled Weighted Average Remaining Contractual Terms.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Option Forfeited Or Cancelled Weighted Average Remaining Contractual Terms", "terseLabel": "Weighted average remaining contracted terms (in years) forfeited or cancelled" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionForfeitedOrCancelledWeightedAverageRemainingContractualTerms", "nsuri": "http://hcwbiologics.com/20211231", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivitiesDetails" ], "xbrltype": "durationItemType" }, "hcwb_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionGrantedWeightedAverageRemainingContractualTerms": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Option Granted Weighted Average Remaining Contractual Terms.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Option Granted Weighted Average Remaining Contractual Terms", "terseLabel": "Weighted average remaining contracted terms (in years) granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionGrantedWeightedAverageRemainingContractualTerms", "nsuri": "http://hcwbiologics.com/20211231", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivitiesDetails" ], "xbrltype": "durationItemType" }, "hcwb_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanUnvestedOptionsGrantsInPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Unvested Options Grants In Period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Unvested Options Grants In Period", "terseLabel": "Granted, Number of shares unvested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanUnvestedOptionsGrantsInPeriod", "nsuri": "http://hcwbiologics.com/20211231", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "hcwb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award options outstanding weighted average remaining contractual term 3.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Remaining Contractual Term3", "terseLabel": "Weighted average remaining contracted terms (in years) outstanding, ending of period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3", "nsuri": "http://hcwbiologics.com/20211231", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivitiesDetails" ], "xbrltype": "durationItemType" }, "hcwb_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansPercentageOfExercisePriceRange": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share Based Compensation Shares Authorized Under Stock Option Plans Percentage of Exercise Price Range.", "label": "Share Based Compensation Shares Authorized Under Stock Option Plans Percentage Of Exercise Price Range", "terseLabel": "Exercise Price for incentive stock" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansPercentageOfExercisePriceRange", "nsuri": "http://hcwbiologics.com/20211231", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "hcwb_TaxCreditReceivablePolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of tax credit receivable.", "label": "Tax Credit Receivable Policy Policy [Text Block]", "terseLabel": "Tax Credit Receivable" } } }, "localname": "TaxCreditReceivablePolicyPolicyTextBlock", "nsuri": "http://hcwbiologics.com/20211231", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "hcwb_TaxableIncomeUtilizationPercentageUnderCaresAct": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Taxable income utilization percentage under CARES Act.", "label": "Taxable income utilization percentage under CARES Act", "terseLabel": "Taxable income utilization percentage under CARES Act" } } }, "localname": "TaxableIncomeUtilizationPercentageUnderCaresAct", "nsuri": "http://hcwbiologics.com/20211231", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "hcwb_TermOfAgreementsRenewalPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Term Of Agreements Renewal Period", "label": "Term Of Agreements Renewal Period", "terseLabel": "Term of agreements renewal periods" } } }, "localname": "TermOfAgreementsRenewalPeriod", "nsuri": "http://hcwbiologics.com/20211231", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "hcwb_TreasuryBillsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Treasury bills member.", "label": "Treasury Bills [Member]", "terseLabel": "Treasury bills [Member]" } } }, "localname": "TreasuryBillsMember", "nsuri": "http://hcwbiologics.com/20211231", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "hcwb_TreasuryNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Treasury notes member.", "label": "Treasury Notes [Member]", "terseLabel": "Treasury notes [Member]" } } }, "localname": "TreasuryNotesMember", "nsuri": "http://hcwbiologics.com/20211231", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "hcwb_TwoThousandNineteenPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand nineteen plan member", "label": "Two Thousand Nineteen Plan [Member]", "terseLabel": "2019 Plan [Member]" } } }, "localname": "TwoThousandNineteenPlanMember", "nsuri": "http://hcwbiologics.com/20211231", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "hcwb_TwoThousandTwentyOnePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand twenty one plan member.", "label": "Two Thousand Twenty One Plan [Member]", "terseLabel": "2021 Plan [Member]" } } }, "localname": "TwoThousandTwentyOnePlanMember", "nsuri": "http://hcwbiologics.com/20211231", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "hcwb_USGovernmentBackedSecuritiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "U S Government Backed Securities.", "label": "U S Government Backed Securities [Member]", "terseLabel": "U S Government Backed Securities" } } }, "localname": "USGovernmentBackedSecuritiesMember", "nsuri": "http://hcwbiologics.com/20211231", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "hcwb_ValuationAllowanceAvailableToReduceDeferredTaxAsset": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Valuation allowance available to reduce deferred tax asset.", "label": "Valuation Allowance Available To Reduce Deferred Tax Asset", "terseLabel": "Valuation allowance available to reduce deferred tax asset" } } }, "localname": "ValuationAllowanceAvailableToReduceDeferredTaxAsset", "nsuri": "http://hcwbiologics.com/20211231", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "hcwb_WugenLicenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Wugen license.", "label": "Wugen License [Member]", "terseLabel": "Wugen License" } } }, "localname": "WugenLicenseMember", "nsuri": "http://hcwbiologics.com/20211231", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureInvestmentsAdditionalInformationDetails", "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r182", "r203", "r242", "r244", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r402", "r403", "r428", "r429" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedInBlackScholesModelDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r182", "r203", "r242", "r244", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r402", "r403", "r428", "r429" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedInBlackScholesModelDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r182", "r203", "r222", "r242", "r244", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r402", "r403", "r428", "r429" ], "lang": { "en-us": { "role": { "label": "Range [Axis]", "terseLabel": "Statistical Measurement" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedInBlackScholesModelDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r182", "r203", "r222", "r242", "r244", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r402", "r403", "r428", "r429" ], "lang": { "en-us": { "role": { "label": "Range [Member]", "terseLabel": "Statistical Measurement" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedInBlackScholesModelDetails" ], "xbrltype": "domainItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r148", "r347" ], "lang": { "en-us": { "role": { "label": "Title Of Individual [Axis]", "terseLabel": "Title of Individual" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureRedeemablePreferredStockAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Title Of Individual With Relationship To Entity [Domain]", "terseLabel": "Title of Individual" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureRedeemablePreferredStockAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "auth_ref": [ "r38" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Accounts Payable And Accrued Liabilities Current", "terseLabel": "Accounts payable and accrued liabilities, current", "totalLabel": "Accounts Payable and Accrued Liabilities, Current, Total" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureAccruedLiabilitiesAndOtherCurrentLiabilitiesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r36" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.", "label": "Accounts Payable And Accrued Liabilities Disclosure [Text Block]", "terseLabel": "Accrued Liabilities and Other Current Liabilities" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureAccruedLiabilitiesAndOtherCurrentLiabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing accounts payable and accrued liabilities.", "label": "Accounts Payable And Accrued Liabilities [Member]", "terseLabel": "Accounts Payable and Accrued Liabilities [Member]" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureAccruedLiabilitiesAndOtherCurrentLiabilitiesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent": { "auth_ref": [], "calculation": { "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementBalanceSheets": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.", "label": "Accounts Payable And Other Accrued Liabilities Current", "terseLabel": "Accrued liabilities and other current liabilities" } } }, "localname": "AccountsPayableAndOtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureAccruedLiabilitiesAndOtherCurrentLiabilitiesAdditionalInformationDetails", "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r35", "r352" ], "calculation": { "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable Current", "terseLabel": "Accounts payable", "totalLabel": "Accounts Payable, Current, Total" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r33", "r163" ], "calculation": { "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails": { "order": 0.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation Depletion And Amortization Property Plant And Equipment", "negatedLabel": "Less: Accumulated depreciation and amortization", "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance", "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance", "terseLabel": "Less: Accumulated depreciation and amortization", "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r21", "r273", "r352" ], "calculation": { "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid In Capital", "periodEndLabel": "Additional Paid in Capital, Ending Balance", "periodStartLabel": "Additional Paid in Capital, Beginning Balance", "terseLabel": "Additional paid-in capital", "totalLabel": "Additional Paid in Capital, Total" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r85", "r86", "r87", "r270", "r271", "r272", "r323" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementStatementOfChangesInRedeemablePreferredStockAndStockholdersDeficitEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments Noncash Items To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementStatementOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r246", "r247", "r275", "r276" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value", "terseLabel": "Stock-based compensation , Value", "totalLabel": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementStatementOfChangesInRedeemablePreferredStockAndStockholdersDeficitEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "auth_ref": [ "r70", "r185", "r188", "r189", "r339" ], "calculation": { "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementStatementOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.", "label": "Amortization of Debt Issuance Costs and Discounts", "terseLabel": "Accretion of issuance costs", "totalLabel": "Amortization of Debt Issuance Costs and Discounts, Total" } } }, "localname": "AmortizationOfFinancingCostsAndDiscounts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r108" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount", "terseLabel": "Potentially diluted securities" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfOutstandingPotentiallyDilutiveSecuritiesDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r108" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfOutstandingPotentiallyDilutiveSecuritiesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfOutstandingPotentiallyDilutiveSecuritiesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r108" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities Name [Domain]", "terseLabel": "Antidilutive Securities, Name" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfOutstandingPotentiallyDilutiveSecuritiesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r81", "r129", "r138", "r143", "r153", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r317", "r319", "r331", "r350", "r352", "r374", "r390" ], "calculation": { "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r4", "r6", "r47", "r81", "r153", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r317", "r319", "r331", "r350", "r352" ], "calculation": { "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r325" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets Fair Value Disclosure", "terseLabel": "Assets" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets Fair Value Disclosure [Abstract]", "terseLabel": "Assets:" } } }, "localname": "AssetsFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureAccruedLiabilitiesAndOtherCurrentLiabilitiesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r321", "r322" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureAccruedLiabilitiesAndOtherCurrentLiabilitiesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis Of Accounting Policy Policy [Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r241", "r243" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r241", "r243", "r310", "r311" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": { "auth_ref": [ "r309" ], "lang": { "en-us": { "role": { "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.", "label": "Business Acquisition Percentage Of Voting Interests Acquired", "terseLabel": "Voting Power percentage" } } }, "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock": { "auth_ref": [ "r84", "r124" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the business description and accounting policies concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Accounting policies describe all significant accounting policies of the reporting entity.", "label": "Business Description And Accounting Policies [Text Block]", "terseLabel": "Organization and Summary of Significant Accounting Policies" } } }, "localname": "BusinessDescriptionAndAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis": { "auth_ref": [ "r368", "r369", "r370" ], "lang": { "en-us": { "role": { "documentation": "Information by project.", "label": "Capitalized Costs Of Unproved Properties Excluded From Amortization By Property Or Project [Axis]", "terseLabel": "Project" } } }, "localname": "CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r2", "r29", "r72" ], "calculation": { "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash And Cash Equivalents At Carrying Value", "periodEndLabel": "Cash and cash equivalents at the end of the period", "periodStartLabel": "Cash and cash equivalents at the beginning of the period", "terseLabel": "Cash and cash equivalents", "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementBalanceSheets", "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease": { "auth_ref": [], "calculation": { "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementStatementOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.", "label": "Cash And Cash Equivalents Period Increase Decrease", "totalLabel": "Net changes in cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r8", "r73" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash And Cash Equivalents Policy [Text Block]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r79", "r81", "r99", "r100", "r101", "r104", "r106", "r113", "r114", "r115", "r153", "r171", "r175", "r176", "r177", "r180", "r181", "r201", "r202", "r205", "r206", "r331", "r440" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class Of Stock [Domain]", "terseLabel": "Class of Stock" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureRedeemablePreferredStockAdditionalInformationDetails", "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementBalanceSheets", "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementBalanceSheetsParenthetical", "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementStatementOfChangesInRedeemablePreferredStockAndStockholdersDeficitEquity" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class Of Stock [Line Items]", "terseLabel": "Class Of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureRedeemablePreferredStockAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CollaborativeArrangementAccountingPolicy": { "auth_ref": [ "r314" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for collaborative arrangements.", "label": "Collaborative Arrangement Accounting Policy", "terseLabel": "Collaborative Arrangements" } } }, "localname": "CollaborativeArrangementAccountingPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CollaborativeArrangementDisclosureTextBlock": { "auth_ref": [ "r312", "r313", "r316" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.", "label": "Collaborative Arrangement Disclosure [Text Block]", "terseLabel": "Collaborative Arrangements" } } }, "localname": "CollaborativeArrangementDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureCollaborativeArrangements" ], "xbrltype": "textBlockItemType" }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]", "terseLabel": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]" } } }, "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r40", "r170", "r380", "r396" ], "calculation": { "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments And Contingencies", "terseLabel": "Commitments and contingencies (Note 14)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments And Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsDisclosureTextBlock": { "auth_ref": [ "r169" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.", "label": "Commitments Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonClassAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Classification of common stock representing ownership interest in a corporation.", "label": "Common Class A [Member]", "terseLabel": "Common Class A" } } }, "localname": "CommonClassAMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r42" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock Capital Shares Reserved For Future Issuance", "terseLabel": "Common stock reserved" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r85", "r86", "r323" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementBalanceSheets", "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementBalanceSheetsParenthetical", "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementStatementOfChangesInRedeemablePreferredStockAndStockholdersDeficitEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock Par Or Stated Value Per Share", "terseLabel": "Common Stock, Par or Stated Value Per Share" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock Shares Authorized", "terseLabel": "Common Stock, Shares Authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock Shares Issued", "terseLabel": "Common Stock, Shares, Issued", "totalLabel": "Common Stock, Shares, Issued, Total" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r19", "r352" ], "calculation": { "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock Value", "periodEndLabel": "Common Stock, Value, Issued, Ending Balance", "periodStartLabel": "Common Stock, Value, Issued, Beginning Balance", "terseLabel": "Common Stock, Value, Issued", "totalLabel": "Common Stock, Value, Issued, Total" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Compensation And Retirement Disclosure [Abstract]" } } }, "localname": "CompensationAndRetirementDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r118", "r387" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk Credit Risk", "terseLabel": "Concentration of Credit Risk and Other Risks and Uncertainties" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractualObligation": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.", "label": "Contractual Obligation", "terseLabel": "Contractual obligation", "totalLabel": "Contractual Obligation, Total" } } }, "localname": "ContractualObligation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConversionOfStockByUniqueDescriptionAxis": { "auth_ref": [ "r74", "r75", "r76" ], "lang": { "en-us": { "role": { "documentation": "Information by description of stock conversions.", "label": "Conversion Of Stock By Unique Description [Axis]", "terseLabel": "Stock Conversion Description" } } }, "localname": "ConversionOfStockByUniqueDescriptionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementStatementOfChangesInRedeemablePreferredStockAndStockholdersDeficitEquity" ], "xbrltype": "stringItemType" }, "us-gaap_ConversionOfStockNameDomain": { "auth_ref": [ "r74", "r75", "r76" ], "lang": { "en-us": { "role": { "documentation": "The unique name of a noncash or part noncash stock conversion.", "label": "Conversion Of Stock Name [Domain]", "terseLabel": "Conversion of Stock, Name" } } }, "localname": "ConversionOfStockNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementStatementOfChangesInRedeemablePreferredStockAndStockholdersDeficitEquity" ], "xbrltype": "domainItemType" }, "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": { "auth_ref": [ "r17", "r18", "r207", "r210", "r214" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued for each share of convertible preferred stock that is converted.", "label": "Convertible Preferred Stock Shares Issued Upon Conversion", "terseLabel": "Common stock issued to holder of redeemable preferred stock" } } }, "localname": "ConvertiblePreferredStockSharesIssuedUponConversion", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CumulativeDividends": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cumulative cash dividends distributed to shareholders.", "label": "Cumulative Dividends", "terseLabel": "Cumulative Dividends" } } }, "localname": "CumulativeDividends", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureRedeemablePreferredStockAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentDecreaseForgiveness": { "auth_ref": [ "r80" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Decrease for amounts of indebtedness forgiven by the holder of the debt instrument.", "label": "Debt Instrument Decrease Forgiveness", "terseLabel": "Debt instrument, decrease, forgiveness", "verboseLabel": "PPP loan forgiveness" } } }, "localname": "DebtInstrumentDecreaseForgiveness", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureAccruedLiabilitiesAndOtherCurrentLiabilitiesAdditionalInformationDetails", "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredChargesPolicyTextBlock": { "auth_ref": [ "r34" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges.", "label": "Deferred Charges Policy [Text Block]", "terseLabel": "Deferred Offering Costs" } } }, "localname": "DeferredChargesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DeferredIncomeTaxLiabilities": { "auth_ref": [ "r13", "r14", "r288", "r376", "r388" ], "calculation": { "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfNetDeferredTaxesDetail": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.", "label": "Deferred Tax Liabilities, Gross", "totalLabel": "Net deferred tax liabilities" } } }, "localname": "DeferredIncomeTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfNetDeferredTaxesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredOfferingCosts": { "auth_ref": [ "r46", "r159" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.", "label": "Deferred Offering Costs", "terseLabel": "Deferred offering costs" } } }, "localname": "DeferredOfferingCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureAccruedLiabilitiesAndOtherCurrentLiabilitiesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRentAssetNetCurrent": { "auth_ref": [ "r28", "r340" ], "calculation": { "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfNetDeferredTaxesDetail": { "order": 3.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of rental income recognized over rental payment required by lease, classified as current.", "label": "Deferred Rent Asset Net Current", "terseLabel": "Deferred rent" } } }, "localname": "DeferredRentAssetNetCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfNetDeferredTaxesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenue": { "auth_ref": [ "r27" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.", "label": "Deferred Revenue", "totalLabel": "Deferred Revenue, Total" } } }, "localname": "DeferredRevenue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenueCurrent": { "auth_ref": [ "r27" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.", "label": "Deferred Revenue Current", "terseLabel": "Deferred revenue, Current", "totalLabel": "Deferred Revenue, Current, Total" } } }, "localname": "DeferredRevenueCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureAccruedLiabilitiesAndOtherCurrentLiabilitiesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsDeferredIncome": { "auth_ref": [ "r296", "r297" ], "calculation": { "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfNetDeferredTaxesDetail": { "order": 0.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.", "label": "Deferred Tax Assets, Deferred Income", "terseLabel": "Deferred revenue", "totalLabel": "Deferred Tax Assets, Deferred Income, Total" } } }, "localname": "DeferredTaxAssetsDeferredIncome", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfNetDeferredTaxesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r289" ], "calculation": { "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfNetDeferredTaxesDetail": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Gross", "totalLabel": "Net deferred tax assets" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfNetDeferredTaxesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGrossAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets Gross [Abstract]", "terseLabel": "Deferred tax assets:" } } }, "localname": "DeferredTaxAssetsGrossAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfNetDeferredTaxesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "auth_ref": [ "r291" ], "calculation": { "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfNetDeferredTaxesDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.", "label": "Deferred Tax Assets, Net", "totalLabel": "Net deferred tax asset (after valuation allowance)" } } }, "localname": "DeferredTaxAssetsLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfNetDeferredTaxesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal": { "auth_ref": [ "r296", "r297" ], "calculation": { "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfNetDeferredTaxesDetail": { "order": 6.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.", "label": "Deferred Tax Assets Operating Loss Carryforwards State And Local", "terseLabel": "State net operating loss carryforward" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfNetDeferredTaxesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.", "label": "Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration", "terseLabel": "Net operating loss carryforwards" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": { "auth_ref": [ "r294", "r296", "r297" ], "calculation": { "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfNetDeferredTaxesDetail": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.", "label": "Deferred Tax Assets Tax Credit Carryforwards", "terseLabel": "R&D credit", "totalLabel": "Deferred Tax Assets, Tax Credit Carryforwards, Total" } } }, "localname": "DeferredTaxAssetsTaxCreditCarryforwards", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfNetDeferredTaxesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": { "auth_ref": [ "r294", "r296", "r297" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.", "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research", "terseLabel": "Federal research and development credits carryforwards" } } }, "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": { "auth_ref": [ "r296", "r297" ], "calculation": { "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfNetDeferredTaxesDetail": { "order": 4.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.", "label": "Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost", "terseLabel": "Stock option compensation" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfNetDeferredTaxesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": { "auth_ref": [ "r296", "r297" ], "calculation": { "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfNetDeferredTaxesDetail": { "order": 5.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.", "label": "Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities", "terseLabel": "Accrued expenses" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfNetDeferredTaxesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r290" ], "calculation": { "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfNetDeferredTaxesDetail": { "order": 0.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets Valuation Allowance", "negatedLabel": "Less: valuation allowance", "totalLabel": "Deferred Tax Assets, Valuation Allowance, Total" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfNetDeferredTaxesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Tax Liabilities [Abstract]", "terseLabel": "Deferred tax liabilities:" } } }, "localname": "DeferredTaxLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfNetDeferredTaxesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.", "label": "Defined Contribution Plan Employer Discretionary Contribution Amount", "terseLabel": "Defined Contribution Plan, Employer Discretionary Contribution Amount" } } }, "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureEmployeeBenefitPlanAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r70", "r161" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation and amortization expense", "totalLabel": "Depreciation, Total" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r70", "r127" ], "calculation": { "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementStatementOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation Depletion And Amortization", "terseLabel": "Depreciation and amortization", "totalLabel": "Depreciation, Depletion and Amortization, Total" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r277" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Disclosure Of Compensation Related Costs Share Based Payments [Text Block]", "terseLabel": "Stock-Based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DividendsPreferredStock": { "auth_ref": [ "r218", "r386" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).", "label": "Dividends, Preferred Stock", "negatedLabel": "6% cumulative dividends on redeemable preferred stock , Value", "totalLabel": "Dividends, Preferred Stock, Total" } } }, "localname": "DividendsPreferredStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementStatementOfChangesInRedeemablePreferredStockAndStockholdersDeficitEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_DomesticCountryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.", "label": "Domestic Tax Authority [Member]", "terseLabel": "Federal [Member]" } } }, "localname": "DomesticCountryMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasicAndDiluted": { "auth_ref": [ "r105" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share Basic And Diluted", "terseLabel": "Net loss per share, basic and diluted", "totalLabel": "Earnings Per Share, Basic and Diluted, Total" } } }, "localname": "EarningsPerShareBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetIncomeLossPerCommonShareDetail", "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementStatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r108", "r109" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share Policy [Text Block]", "terseLabel": "Net Loss Per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r108", "r109", "r110", "r111" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Net Loss Per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r282" ], "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Continuing Operations", "terseLabel": "Income tax expense/(benefit)", "totalLabel": "Income tax expense/(benefit)" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r82", "r282", "r303" ], "lang": { "en-us": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate", "terseLabel": "Benefit at statutory rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r282", "r303" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.", "label": "Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance", "terseLabel": "Change in valuation allowance" } } }, "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": { "auth_ref": [ "r282", "r303" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.", "label": "Effective Income Tax Rate Reconciliation Other Adjustments", "terseLabel": "Other adjustments" } } }, "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r282", "r303" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).", "label": "Effective Income Tax Rate Reconciliation State And Local Income Taxes", "terseLabel": "State tax benefit net of federal benefit" } } }, "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": { "auth_ref": [ "r282", "r303" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.", "label": "Effective Income Tax Rate Reconciliation Tax Credits", "terseLabel": "R&D credit carryforward", "totalLabel": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent, Total" } } }, "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther": { "auth_ref": [ "r282", "r303" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other tax credits.", "label": "Effective Income Tax Rate Reconciliation Tax Credits Other", "terseLabel": "Other" } } }, "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": { "auth_ref": [ "r282", "r303" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.", "label": "Effective Income Tax Rate Reconciliation Tax Credits Research", "terseLabel": "R&D credit payroll" } } }, "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeBenefitsAndShareBasedCompensation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for employee benefit and equity-based compensation.", "label": "Employee Benefits And Share Based Compensation", "terseLabel": "Employee Benefits and Share-based Compensation" } } }, "localname": "EmployeeBenefitsAndShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r268" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1", "terseLabel": "Unrecognized compensation, weighted average amortization period" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "auth_ref": [ "r268" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options", "terseLabel": "Unrecognized employee stock based compensation cost" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r268" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options", "terseLabel": "Unrecognized employee stock based compensation" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r51", "r52", "r53", "r85", "r86", "r87", "r89", "r94", "r96", "r112", "r156", "r209", "r218", "r270", "r271", "r272", "r299", "r300", "r323", "r332", "r333", "r334", "r335", "r336", "r337", "r404", "r405", "r406", "r444" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementStatementOfChangesInRedeemablePreferredStockAndStockholdersDeficitEquity" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r325", "r326", "r327", "r330" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]", "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "auth_ref": [ "r328" ], "lang": { "en-us": { "role": { "documentation": "Class of asset.", "label": "Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation By Asset Class [Domain]", "terseLabel": "Asset Class" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail", "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueByAssetClassAxis": { "auth_ref": [ "r325", "r330" ], "lang": { "en-us": { "role": { "documentation": "Information by class of asset.", "label": "Fair Value By Asset Class [Axis]", "terseLabel": "Asset Class" } } }, "localname": "FairValueByAssetClassAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail", "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r183", "r186", "r187", "r223", "r225", "r226", "r227", "r228", "r229", "r230", "r237", "r326", "r356", "r357", "r358" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value By Fair Value Hierarchy Level [Axis]", "terseLabel": "Fair Value Hierarchy and NAV" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r329" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value of Financial Instruments" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstruments" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r183", "r223", "r225", "r230", "r237", "r326", "r356" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value Inputs Level1 [Member]", "terseLabel": "Level 1 [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r183", "r186", "r187", "r223", "r225", "r230", "r237", "r326", "r357" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value Inputs Level2 [Member]", "terseLabel": "Level 2 [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r183", "r186", "r187", "r223", "r225", "r226", "r227", "r228", "r229", "r230", "r237", "r326", "r358" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value Inputs Level3 [Member]", "terseLabel": "Level 3 [Member]" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "Fair Value Measurement Policy Policy [Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r183", "r186", "r187", "r223", "r225", "r226", "r227", "r228", "r229", "r230", "r237", "r356", "r357", "r358" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Measurements Fair Value Hierarchy [Domain]", "terseLabel": "Fair Value Hierarchy and NAV" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture And Fixtures [Member]", "terseLabel": "Furniture and fixtures" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r70", "r190", "r191" ], "calculation": { "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementStatementOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Gains Losses On Extinguishment Of Debt", "negatedLabel": "Gain on extinguishment of debt", "totalLabel": "Gain (Loss) on Extinguishment of Debt, Total" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r59" ], "calculation": { "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General And Administrative Expense", "terseLabel": "General and administrative", "totalLabel": "General and Administrative Expense, Total" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r57" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General And Administrative Expense [Member]", "terseLabel": "General and Administrative Expense" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IPOMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First sale of stock by a private company to the public.", "label": "I P O [Member]", "terseLabel": "IPO" } } }, "localname": "IPOMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureInvestmentsAdditionalInformationDetails", "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureAccruedLiabilitiesAndOtherCurrentLiabilitiesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "auth_ref": [ "r160", "r166" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.", "label": "Impairment Or Disposal Of Long Lived Assets Policy [Text Block]", "terseLabel": "Impairment of Long-Lived Assets" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r55", "r129", "r137", "r139", "r142", "r144", "r372", "r381", "r383", "r399" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "terseLabel": "Net Loss Before Taxes", "totalLabel": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Total" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r165", "r168" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r168" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r284" ], "lang": { "en-us": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r82", "r283", "r286", "r293", "r301", "r304", "r306", "r307", "r308" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExaminationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Income Tax Examination [Line Items]" } } }, "localname": "IncomeTaxExaminationLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxExaminationTable": { "auth_ref": [ "r285" ], "lang": { "en-us": { "role": { "documentation": "A summary of income tax examinations that an enterprise is currently subject to or that have been completed in the current period typically including a description of the examination, the jurisdiction conducting the examination, the tax year(s) under examination, the likelihood of an unfavorable settlement, the range of possible losses, the liability recorded, the Increase or Decrease in the liability from the prior period, and any penalties and interest that have been incurred or accrued.", "label": "Income Tax Examination [Table]" } } }, "localname": "IncomeTaxExaminationTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r83", "r95", "r96", "r128", "r281", "r302", "r305", "r400" ], "calculation": { "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense Benefit", "terseLabel": "Income tax expense/(benefit)", "totalLabel": "Income Tax Expense (Benefit), Total" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails", "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r50", "r279", "r280", "r286", "r287", "r292", "r298" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax Policy [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r282" ], "calculation": { "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": { "order": 5.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.", "label": "Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance", "terseLabel": "Change in valuation allowance" } } }, "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r282" ], "calculation": { "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": { "order": 0.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate", "terseLabel": "Benefit at statutory rate" } } }, "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationOtherAdjustments": { "auth_ref": [ "r282" ], "calculation": { "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": { "order": 3.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.", "label": "Income Tax Reconciliation Other Adjustments", "terseLabel": "Other adjustments" } } }, "localname": "IncomeTaxReconciliationOtherAdjustments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r282" ], "calculation": { "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).", "label": "Income Tax Reconciliation State And Local Income Taxes", "terseLabel": "State tax benefit net of federal benefit" } } }, "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationTaxCredits": { "auth_ref": [ "r282" ], "calculation": { "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": { "order": 4.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.", "label": "Income Tax Reconciliation Tax Credits", "terseLabel": "R&D credit carryforward", "totalLabel": "Effective Income Tax Rate Reconciliation, Tax Credit, Amount, Total" } } }, "localname": "IncomeTaxReconciliationTaxCredits", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationTaxCreditsOther": { "auth_ref": [ "r282" ], "calculation": { "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": { "order": 6.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other tax credits.", "label": "Income Tax Reconciliation Tax Credits Other", "terseLabel": "Other" } } }, "localname": "IncomeTaxReconciliationTaxCreditsOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": { "auth_ref": [ "r282" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.", "label": "Income Tax Reconciliation Tax Credits Research", "terseLabel": "R&D credit payroll" } } }, "localname": "IncomeTaxReconciliationTaxCreditsResearch", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r69" ], "calculation": { "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementStatementOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase Decrease In Accounts Payable And Accrued Liabilities", "terseLabel": "Accounts payable and other liabilities", "totalLabel": "Increase (Decrease) in Accounts Payable and Accrued Liabilities, Total" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r69" ], "calculation": { "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementStatementOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase Decrease In Accounts Receivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase Decrease In Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementStatementOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r69" ], "calculation": { "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementStatementOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase Decrease In Prepaid Deferred Expense And Other Assets", "negatedLabel": "Prepaid expenses and other assets", "totalLabel": "Increase (Decrease) in Prepaid Expense and Other Assets, Total" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestAndOtherIncome": { "auth_ref": [], "calculation": { "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementStatementsOfOperations": { "order": 0.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).", "label": "Interest And Other Income", "terseLabel": "Interest and other income, net", "totalLabel": "Interest and Other Income, Total" } } }, "localname": "InterestAndOtherIncome", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryRawMaterialsAndSupplies": { "auth_ref": [ "r45" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Gross amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed.", "label": "Inventory Raw Materials And Supplies", "terseLabel": "Manufacturing materials", "totalLabel": "Inventory, Raw Materials and Supplies, Gross, Total" } } }, "localname": "InventoryRawMaterialsAndSupplies", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureAccruedLiabilitiesAndOtherCurrentLiabilitiesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentPolicyTextBlock": { "auth_ref": [ "r152", "r398" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for investment in financial asset.", "label": "Investment Policy [Text Block]", "terseLabel": "Investments" } } }, "localname": "InvestmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InvestmentTextBlock": { "auth_ref": [ "r150", "r151", "r154", "r155" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for investment.", "label": "Investment [Text Block]", "terseLabel": "Investments" } } }, "localname": "InvestmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureInvestments" ], "xbrltype": "textBlockItemType" }, "us-gaap_InvestmentTypeAxis": { "auth_ref": [ "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424" ], "lang": { "en-us": { "role": { "documentation": "Information by type of investments.", "label": "Investment Type [Axis]", "terseLabel": "Investment Type" } } }, "localname": "InvestmentTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureInvestmentsAdditionalInformationDetails", "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentTypeCategorizationMember": { "auth_ref": [ "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424" ], "lang": { "en-us": { "role": { "documentation": "Asset obtained to generate income or appreciate in value.", "label": "Investment Type Categorization [Member]", "terseLabel": "Investments" } } }, "localname": "InvestmentTypeCategorizationMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureInvestmentsAdditionalInformationDetails", "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InvestmentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investments [Abstract]" } } }, "localname": "InvestmentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_InvestmentsFairValueDisclosure": { "auth_ref": [ "r325" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.", "label": "Investments Fair Value Disclosure", "terseLabel": "Investment (Note 4)", "totalLabel": "Investments, Fair Value Disclosure, Total" } } }, "localname": "InvestmentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Assets held for their financial return, rather than for the entity's operations.", "label": "Investments [Member]" } } }, "localname": "InvestmentsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseAndRentalExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "Lease And Rental Expense", "terseLabel": "Operating leases, rent expense", "totalLabel": "Operating Leases, Rent Expense, Total" } } }, "localname": "LeaseAndRentalExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseholdsAndLeaseholdImprovementsMember": { "auth_ref": [ "r162" ], "lang": { "en-us": { "role": { "documentation": "Assets held by a lessee under a capital lease and any addition or improvement to assets held under a lease arrangement (including addition or improvement to assets held by lessee under an operating lease arrangement).", "label": "Leaseholds And Leasehold Improvements [Member]", "terseLabel": "Leasehold improvements" } } }, "localname": "LeaseholdsAndLeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LegalFees": { "auth_ref": [ "r58" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.", "label": "Legal Fees", "terseLabel": "Legal fees" } } }, "localname": "LegalFees", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureAccruedLiabilitiesAndOtherCurrentLiabilitiesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities [Abstract]", "terseLabel": "Liabilities" } } }, "localname": "LiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r25", "r81", "r153", "r331", "r352", "r377", "r393" ], "calculation": { "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities And Stockholders Equity", "totalLabel": "Total liabilities, redeemable preferred stock and stockholders\u2019 (deficit) equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities And Stockholders Equity [Abstract]", "terseLabel": "LIABILITIES, REDEEMABLE PREFERRED STOCK AND STOCKHOLDERS\u2019 (DEFICIT) EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r39", "r81", "r153", "r171", "r172", "r173", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r318", "r319", "r320", "r331", "r350", "r351", "r352" ], "calculation": { "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermInvestments": { "auth_ref": [ "r30" ], "calculation": { "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementBalanceSheets": { "order": 0.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).", "label": "Long Term Investments", "terseLabel": "Investments", "totalLabel": "Long-term Investments, Total" } } }, "localname": "LongTermInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureInvestmentsAdditionalInformationDetails", "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r223" ], "lang": { "en-us": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "terseLabel": "Money Market Funds [Member]" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r67" ], "calculation": { "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementStatementOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided By Used In Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided By Used In Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementStatementOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r67" ], "calculation": { "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementStatementOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided By Used In Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided By Used In Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementStatementOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r67", "r68", "r71" ], "calculation": { "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementStatementOfCashFlows": { "order": 0.0, "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided By Used In Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided By Used In Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementStatementOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r1", "r48", "r49", "r53", "r56", "r71", "r81", "r88", "r90", "r91", "r92", "r93", "r95", "r96", "r102", "r129", "r137", "r139", "r142", "r144", "r153", "r171", "r172", "r173", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r324", "r331", "r382", "r397" ], "calculation": { "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementStatementOfCashFlows": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income Loss", "terseLabel": "Net loss", "totalLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetIncomeLossPerCommonShareDetail", "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementStatementOfCashFlows", "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementStatementOfChangesInRedeemablePreferredStockAndStockholdersDeficitEquity", "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r90", "r91", "r92", "r93", "r97", "r98", "r103", "r106", "r129", "r137", "r139", "r142", "r144" ], "calculation": { "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementStatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net Income Loss Available To Common Stockholders Basic", "totalLabel": "Net loss available for distribution to common stockholders" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetIncomeLossPerCommonShareDetail", "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements Policy Policy [Text Block]", "terseLabel": "Recently Issued Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Noncash Investing And Financing Items [Abstract]", "terseLabel": "Non-cash operating, investing and financing activities:" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementStatementOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_OfficeEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.", "label": "Office Equipment [Member]", "terseLabel": "Office Equipment" } } }, "localname": "OfficeEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r129", "r137", "r139", "r142", "r144" ], "calculation": { "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income Loss", "terseLabel": "Loss from operations", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasedAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Operating Leased Assets [Line Items]", "terseLabel": "Operating Leased Assets [Line Items]" } } }, "localname": "OperatingLeasedAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Leases Future Minimum Payments Due [Abstract]" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals": { "auth_ref": [ "r341" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Contractually required future rental payments receivable on noncancelable subleasing arrangements.", "label": "Operating Leases, Future Minimum Payments Due, Future Minimum Sublease Rentals", "terseLabel": "Future minimum payments" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases Future Minimum Payments Remainder Of Fiscal Year", "terseLabel": "2022 (remaining 3 months)" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumPaymentsForLeaseAndSubleaseAgreementsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization Consolidation And Presentation Of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r46", "r352" ], "calculation": { "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementBalanceSheets": { "order": 0.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets Current", "terseLabel": "Other current assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r34" ], "calculation": { "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets", "totalLabel": "Other Assets, Noncurrent, Total" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherGeneralExpense": { "auth_ref": [ "r60" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of general expenses not normally included in Other Operating Costs and Expenses.", "label": "Other General Expense", "terseLabel": "Other expense" } } }, "localname": "OtherGeneralExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureAccruedLiabilitiesAndOtherCurrentLiabilitiesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherResearchAndDevelopmentExpense": { "auth_ref": [ "r278" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of other research and development expense.", "label": "Other Research And Development Expense", "terseLabel": "Research and development expense" } } }, "localname": "OtherResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Payables And Accruals [Abstract]" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_PaymentsToAcquireLongtermInvestments": { "auth_ref": [ "r64" ], "calculation": { "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementStatementOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, beyond the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the long-term.", "label": "Payments To Acquire Longterm Investments", "negatedLabel": "Purchases of long-term investments" } } }, "localname": "PaymentsToAcquireLongtermInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r63" ], "calculation": { "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementStatementOfCashFlows": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments To Acquire Property Plant And Equipment", "negatedLabel": "Purchases of property and equipment", "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireShortTermInvestments": { "auth_ref": [ "r64" ], "calculation": { "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementStatementOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.", "label": "Payments To Acquire Short Term Investments", "negatedLabel": "Purchases of short-term investments" } } }, "localname": "PaymentsToAcquireShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": { "auth_ref": [ "r222", "r224", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r245" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for retirement benefits.", "label": "Pension And Other Postretirement Benefits Disclosure [Text Block]", "terseLabel": "Employee Benefit Plans" } } }, "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureEmployeeBenefitPlan" ], "xbrltype": "textBlockItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r248", "r269" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockAmountOfPreferredDividendsInArrears": { "auth_ref": [ "r212" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate amount of cumulative preferred dividends in arrears.", "label": "Preferred Stock Amount Of Preferred Dividends In Arrears", "negatedTerseLabel": "Cumulative dividends on redeemable preferred stock , Value", "terseLabel": "Cumulative dividends on redeemable preferred stock , Value" } } }, "localname": "PreferredStockAmountOfPreferredDividendsInArrears", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementStatementOfChangesInRedeemablePreferredStockAndStockholdersDeficitEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockDividendsAndOtherAdjustments": { "auth_ref": [ "r98", "r107" ], "calculation": { "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementStatementsOfOperations": { "order": 0.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate value of preferred stock dividends and other adjustments necessary to derive net income apportioned to common stockholders.", "label": "Preferred Stock Dividends And Other Adjustments", "negatedLabel": "Less: cumulative preferred dividends earned in the period, net of forfeitures", "negatedTerseLabel": "6% cumulative dividends on redeemable preferred stock , Value", "totalLabel": "Preferred Stock Dividends and Other Adjustments, Total" } } }, "localname": "PreferredStockDividendsAndOtherAdjustments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetIncomeLossPerCommonShareDetail", "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock [Member]", "terseLabel": "Preferred Stock [Member]" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementStatementOfChangesInRedeemablePreferredStockAndStockholdersDeficitEquity" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock Shares Authorized", "terseLabel": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureRedeemablePreferredStockAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r18", "r201" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock Shares Issued", "terseLabel": "Preferred stock, shares issued", "totalLabel": "Preferred Stock, Shares Issued, Total" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureRedeemablePreferredStockAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r3", "r5", "r157", "r158" ], "calculation": { "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Expense Current", "terseLabel": "Prepaid expenses", "totalLabel": "Prepaid Expense, Current, Total" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceInitialPublicOffering": { "auth_ref": [ "r65" ], "calculation": { "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementStatementOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.", "label": "Proceeds From Issuance Initial Public Offering", "terseLabel": "Proceeds from initial public offering" } } }, "localname": "ProceedsFromIssuanceInitialPublicOffering", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureInvestmentsAdditionalInformationDetails", "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r65" ], "calculation": { "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementStatementOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds From Issuance Of Common Stock", "terseLabel": "Proceeds from issuance of common stock" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfLongTermDebt": { "auth_ref": [ "r66" ], "calculation": { "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementStatementOfCashFlows": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.", "label": "Proceeds From Issuance Of Long Term Debt", "terseLabel": "Proceeds from PPP loan", "totalLabel": "Proceeds from Issuance of Long-term Debt, Total" } } }, "localname": "ProceedsFromIssuanceOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock": { "auth_ref": [ "r65" ], "calculation": { "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementStatementOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.", "label": "Proceeds From Issuance Of Preferred Stock And Preference Stock", "terseLabel": "Proceeds from the sale of Series C Preferred Stock" } } }, "localname": "ProceedsFromIssuanceOfPreferredStockAndPreferenceStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProjectMember": { "auth_ref": [ "r371" ], "lang": { "en-us": { "role": { "documentation": "Planned program of work.", "label": "Project [Member]", "terseLabel": "Project" } } }, "localname": "ProjectMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property Plant And Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r33", "r164" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Property Plant And Equipment By Type [Axis]", "terseLabel": "Long-Lived Tangible Asset" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r167", "r425", "r426", "r427" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property Plant And Equipment Disclosure [Text Block]", "terseLabel": "Property and Equipment, Net" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r32", "r162" ], "calculation": { "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property Plant And Equipment Gross", "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance", "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance", "terseLabel": "Property, plant and equipment, gross", "totalLabel": "Property, Plant and Equipment, Gross, Total" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property Plant And Equipment [Line Items]", "terseLabel": "Property Plant And Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails", "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment [Member]", "terseLabel": "Property, Plant and Equipment [Member]" } } }, "localname": "PropertyPlantAndEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r9", "r10", "r164", "r352", "r385", "r395" ], "calculation": { "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property Plant And Equipment Net", "periodEndLabel": "Property, Plant and Equipment, Net, Ending Balance", "periodStartLabel": "Property, Plant and Equipment, Net, Beginning Balance", "terseLabel": "Property and equipment, net", "totalLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails", "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentOtherNet": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after depreciation of long-lived, physical assets used to produce goods and services and not intended for resale, classified as other.", "label": "Property, Plant and Equipment, Other, Net", "terseLabel": "Other noncurrent assets within property and equipment", "totalLabel": "Property, Plant and Equipment, Other, Net, Total" } } }, "localname": "PropertyPlantAndEquipmentOtherNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r31", "r164", "r425", "r426" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property Plant And Equipment Policy [Text Block]", "terseLabel": "Property and Equipment, Net" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r9", "r164" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property Plant And Equipment [Text Block]", "terseLabel": "Schedule of Property and Equipment, Net" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r9", "r162" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Property Plant And Equipment Type [Domain]", "terseLabel": "Long-Lived Tangible Asset" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property Plant And Equipment Useful Life", "terseLabel": "Property, Plant and Equipment, Useful Life" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ReceivablesNetCurrent": { "auth_ref": [ "r20", "r26", "r352", "r394", "r409" ], "calculation": { "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.", "label": "Receivables Net Current", "terseLabel": "Accounts receivable, net", "totalLabel": "Receivables, Net, Current, Total" } } }, "localname": "ReceivablesNetCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RedeemableNoncontrollingInterestEquityPreferredCarryingAmount": { "auth_ref": [ "r194", "r195", "r196", "r197" ], "calculation": { "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "As of the reporting date, the carrying amount of noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. The noncontrolling interest holder's ownership (or holders' ownership) may be in the form of preferred shares (regardless of class), preferred partnership units (regardless of class), preferential membership interests, or any other form of preferred equity regardless of investee entity legal form.", "label": "Redeemable Noncontrolling Interest Equity Preferred Carrying Amount", "terseLabel": "Total redeemable preferred stock" } } }, "localname": "RedeemableNoncontrollingInterestEquityPreferredCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureRedeemablePreferredStockAdditionalInformationDetails", "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r344", "r345", "r346", "r348", "r349" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "Related Party Transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r278", "r366", "r430" ], "calculation": { "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementStatementsOfOperations": { "order": 0.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research And Development Expense", "terseLabel": "Research and development", "totalLabel": "Research and Development Expense, Total" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research And Development Expense [Member]", "terseLabel": "Research and Development Expense [Member]" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r278" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research And Development Expense Policy", "terseLabel": "Research and Development Expenses" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchMember": { "auth_ref": [ "r295" ], "lang": { "en-us": { "role": { "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.", "label": "Research [Member]", "terseLabel": "Research Member" } } }, "localname": "ResearchMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r22", "r218", "r273", "r352", "r392", "r407", "r408" ], "calculation": { "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementBalanceSheets": { "order": 0.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings Accumulated Deficit", "periodEndLabel": "Retained Earnings (Accumulated Deficit), Ending Balance", "periodStartLabel": "Retained Earnings (Accumulated Deficit), Beginning Balance", "terseLabel": "Accumulated deficit", "totalLabel": "Retained Earnings (Accumulated Deficit), Total" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r85", "r86", "r87", "r89", "r94", "r96", "r156", "r270", "r271", "r272", "r299", "r300", "r323", "r404", "r406" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementStatementOfChangesInRedeemablePreferredStockAndStockholdersDeficitEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": { "auth_ref": [ "r125", "r126", "r136", "r140", "r141", "r145", "r146", "r147", "r220", "r221", "r367" ], "calculation": { "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementStatementsOfOperations": { "order": 0.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.", "label": "Revenue From Contract With Customer Including Assessed Tax", "terseLabel": "Revenues", "verboseLabel": "Revenue recognized" } } }, "localname": "RevenueFromContractWithCustomerIncludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueRecognitionDeferredRevenue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for recognizing unearned income or deferred revenue related to transactions involving the sale of a product or performance of services.", "label": "Revenue Recognition Deferred Revenue", "terseLabel": "Deferred Revenue" } } }, "localname": "RevenueRecognitionDeferredRevenue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r77", "r78" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.", "label": "Revenue Recognition Policy [Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r54", "r81", "r125", "r126", "r136", "r140", "r141", "r145", "r146", "r147", "r153", "r171", "r172", "r173", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r331", "r383" ], "calculation": { "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementStatementsOfOperations": { "order": 0.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "terseLabel": "Total revenues", "totalLabel": "Revenues, Total" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenues [Abstract]", "terseLabel": "Revenues:" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale Of Stock Name Of Transaction [Domain]", "terseLabel": "Sale of Stock" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureInvestmentsAdditionalInformationDetails", "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureAccruedLiabilitiesAndOtherCurrentLiabilitiesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r108" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]", "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfOutstandingPotentiallyDilutiveSecuritiesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r108" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]", "terseLabel": "Summary of Outstanding Potentially Dilutive Securities" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureNetLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "auth_ref": [ "r315" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]", "terseLabel": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r291" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule Of Deferred Tax Assets And Liabilities Table [Text Block]", "terseLabel": "Schedule of Deferred Tax Assets and Liabilities" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r106" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule Of Earnings Per Share Basic And Diluted Table [Text Block]", "terseLabel": "Summary of Basic and Diluted Net Income (Loss) Per Common Share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureNetLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r282" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block]", "terseLabel": "Schedule of Effective Income Tax Rate Reconciliation" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r325", "r326" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule Of Fair Value Assets And Liabilities Measured On Recurring Basis Table [Text Block]", "terseLabel": "Summary of assets and liabilities that are measured at fair value on a recurring basis" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Net Investment Income [Line Items]" } } }, "localname": "ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureInvestmentsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable": { "auth_ref": [ "r61", "r62", "r401" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about investment income, including, but not limited to, interest and dividend income and amortization of discount (premium) derived from debt and equity securities. Excludes realized and unrealized gain (loss) on investments.", "label": "Investment Income [Table]" } } }, "localname": "ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureInvestmentsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfOperatingLeasedAssetsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of long-lived, depreciable assets that are subject to a operating lease agreements and are used in the normal conduct of business to produce goods and services. Examples may include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Schedule Of Operating Leased Assets [Table]", "terseLabel": "Schedule Of Operating Leased Assets [Table]" } } }, "localname": "ScheduleOfOperatingLeasedAssetsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r33", "r164" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Schedule Of Property Plant And Equipment [Table]", "terseLabel": "Schedule Of Property Plant And Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails", "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfPropertySubjectToOrAvailableForOperatingLeaseTextBlock": { "auth_ref": [ "r164", "r342", "r343" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessor's underlying asset for which right to use has been conveyed to lessee under operating lease.", "label": "Schedule Of Property Subject To Or Available For Operating Lease [Text Block]", "terseLabel": "Summary of the future minimum payments for the lease and sublease agreements" } } }, "localname": "ScheduleOfPropertySubjectToOrAvailableForOperatingLeaseTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r248", "r269" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]", "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedInBlackScholesModelDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r251", "r258", "r261" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]", "terseLabel": "Summary of Stock Option Activities" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r263" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]", "terseLabel": "Summary of Assumptions Used in Black-Scholes Model" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r41", "r79", "r113", "r114", "r192", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r208", "r210", "r211", "r213", "r215", "r216", "r217", "r218" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule Of Stock By Class [Table]", "terseLabel": "Schedule Of Stock By Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureRedeemablePreferredStockAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SecurityOwnedAndSoldNotYetPurchasedAtFairValueAxis": { "auth_ref": [ "r373" ], "lang": { "en-us": { "role": { "documentation": "Group of financial instruments held by a broker-dealer for their own account (proprietary securities) for trading or investment purposes that are carried at fair value including securities sold, not yet purchased.", "label": "Security Owned And Sold Not Yet Purchased At Fair Value [Axis]", "terseLabel": "Security Owned and Sold, Not yet Purchased, at Fair Value" } } }, "localname": "SecurityOwnedAndSoldNotYetPurchasedAtFairValueAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SecurityOwnedAndSoldNotYetPurchasedFairValueSecurityNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of financial instrument held by a broker-dealer for their own account (proprietary securities) for trading or investment purposes that are carried at fair value including securities sold, not yet purchased.", "label": "Security Owned And Sold Not Yet Purchased Fair Value Security Name [Domain]", "terseLabel": "Security Owned and Sold, Not yet Purchased Fair Value, Security Name" } } }, "localname": "SecurityOwnedAndSoldNotYetPurchasedFairValueSecurityNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "auth_ref": [ "r130", "r131", "r132", "r133", "r134", "r135", "r146" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for segment reporting.", "label": "Segment Reporting Policy Policy [Text Block]", "terseLabel": "Segment Reporting" } } }, "localname": "SegmentReportingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SeriesAPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outstanding nonredeemable series A preferred stock or outstanding series A preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Series A Preferred Stock [Member]", "terseLabel": "Series A Preferred Stock" } } }, "localname": "SeriesAPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesBPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outstanding nonredeemable series B preferred stock or outstanding series B preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Series B Preferred Stock [Member]", "terseLabel": "Series B Preferred Stock" } } }, "localname": "SeriesBPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesCPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outstanding nonredeemable series C preferred stock or outstanding series C preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Series C Preferred Stock [Member]", "terseLabel": "Series C Preferred Stock" } } }, "localname": "SeriesCPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember": { "auth_ref": [ "r311" ], "lang": { "en-us": { "role": { "documentation": "Represents the aggregation and reporting of combined amounts of individually immaterial business combinations that were completed during the period.", "label": "Series of Individually Immaterial Business Acquisitions [Member]", "terseLabel": "Series of Individually Immaterial Business Acquisitions [Member]" } } }, "localname": "SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r69" ], "calculation": { "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementStatementOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation", "totalLabel": "Share-based Payment Arrangement, Noncash Expense, Total" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r249" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1", "terseLabel": "Incentive stock option period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r257" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period", "terseLabel": "Granted, Number of Shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price", "terseLabel": "Fair value underlying common stock" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedInBlackScholesModelDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r266" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate", "terseLabel": "Dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedInBlackScholesModelDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r265" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate", "terseLabel": "Expected volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedInBlackScholesModelDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum", "terseLabel": "Expected volatility, Maximum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedInBlackScholesModelDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum", "terseLabel": "Expected volatility, Minimum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedInBlackScholesModelDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r267" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate", "terseLabel": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedInBlackScholesModelDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum", "terseLabel": "Risk-free interest rate, Maximum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedInBlackScholesModelDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum", "terseLabel": "Risk-free interest rate, Minimum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedInBlackScholesModelDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]", "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedInBlackScholesModelDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r254" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number", "terseLabel": "Number of options exercisable, end of period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivitiesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r254" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price", "terseLabel": "Weighted average exercise price, options exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivitiesDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [ "r260" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value", "terseLabel": "Intrinsic value exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r256" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period", "negatedLabel": "Number of options, forfeited or cancelled" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivitiesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross", "terseLabel": "Number of options granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivitiesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r259" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average fair value of options granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r269" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value", "periodEndLabel": "Aggregate intrinsic value outstanding, end of period", "periodStartLabel": "Aggregate intrinsic value outstanding, beginning of period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r253", "r269" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number", "periodEndLabel": "Number of options outstanding, ending of period", "periodStartLabel": "Number of options outstanding, beginning of period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivitiesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r252" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price", "periodEndLabel": "Weighted average exercise price outstanding, end of period", "periodStartLabel": "Weighted average exercise price outstanding, beginning of period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivitiesDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price", "terseLabel": "Weighted average exercise price, options exercised" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivitiesDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price", "terseLabel": "Weighted average exercise price, options forfeited or cancelled" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivitiesDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price", "terseLabel": "Weighted average exercise price, options granted" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivitiesDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r248", "r250" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share Based Compensation Option And Incentive Plans Policy", "terseLabel": "Stock-based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share Price", "terseLabel": "Share Price" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureRedeemablePreferredStockAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r264", "r274" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1", "terseLabel": "Expected term (years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedInBlackScholesModelDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r269" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1", "terseLabel": "Aggregate intrinsic value options exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r269" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1", "terseLabel": "Weighted average remaining contracted terms (in years) exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivitiesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r262" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2", "terseLabel": "Weighted average remaining contracted terms (in years) outstanding, beginning of period" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivitiesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares Outstanding", "periodEndLabel": "Ending balance (in shares)", "periodStartLabel": "Beginning balance (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementStatementOfChangesInRedeemablePreferredStockAndStockholdersDeficitEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermBorrowings": { "auth_ref": [ "r11", "r352", "r375", "r391" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.", "label": "Short Term Borrowings", "terseLabel": "Short-term debt", "totalLabel": "Short-term Debt, Total" } } }, "localname": "ShortTermBorrowings", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureAccruedLiabilitiesAndOtherCurrentLiabilitiesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShortTermDebtTypeAxis": { "auth_ref": [ "r37" ], "lang": { "en-us": { "role": { "documentation": "Information by type of short-term debt arrangement.", "label": "Short Term Debt Type [Axis]", "terseLabel": "Short-term Debt, Type" } } }, "localname": "ShortTermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureAccruedLiabilitiesAndOtherCurrentLiabilitiesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShortTermDebtTypeDomain": { "auth_ref": [ "r35" ], "lang": { "en-us": { "role": { "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing.", "label": "Short Term Debt Type [Domain]", "terseLabel": "Short-term Debt, Type" } } }, "localname": "ShortTermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureAccruedLiabilitiesAndOtherCurrentLiabilitiesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShortTermInvestments": { "auth_ref": [ "r12", "r378", "r379", "r389" ], "calculation": { "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.", "label": "Short Term Investments", "terseLabel": "Short-term investments", "totalLabel": "Short-term Investments, Total" } } }, "localname": "ShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShortTermInvestmentsMember": { "auth_ref": [ "r421", "r422", "r423", "r424" ], "lang": { "en-us": { "role": { "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet.", "label": "Short Term Investments [Member]", "terseLabel": "Short-term Investments" } } }, "localname": "ShortTermInvestmentsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StateAndLocalJurisdictionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.", "label": "State and Local Jurisdiction [Member]", "terseLabel": "State [Member]" } } }, "localname": "StateAndLocalJurisdictionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r17", "r18", "r19", "r79", "r81", "r99", "r100", "r101", "r104", "r106", "r113", "r114", "r115", "r153", "r171", "r175", "r176", "r177", "r180", "r181", "r201", "r202", "r205", "r206", "r209", "r331", "r440" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Statement Class Of Stock [Axis]", "terseLabel": "Class of Stock" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureRedeemablePreferredStockAdditionalInformationDetails", "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementBalanceSheets", "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementBalanceSheetsParenthetical", "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementStatementOfChangesInRedeemablePreferredStockAndStockholdersDeficitEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r44", "r51", "r52", "r53", "r85", "r86", "r87", "r89", "r94", "r96", "r112", "r156", "r209", "r218", "r270", "r271", "r272", "r299", "r300", "r323", "r332", "r333", "r334", "r335", "r336", "r337", "r404", "r405", "r406", "r444" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Statement Equity Components [Axis]", "terseLabel": "Equity Components" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementStatementOfChangesInRedeemablePreferredStockAndStockholdersDeficitEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementBalanceSheets", "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementBalanceSheetsParenthetical", "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementStatementOfChangesInRedeemablePreferredStockAndStockholdersDeficitEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement Of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement Of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement Of Stockholders Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r85", "r86", "r87", "r112", "r367" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementBalanceSheets", "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementBalanceSheetsParenthetical", "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementStatementOfChangesInRedeemablePreferredStockAndStockholdersDeficitEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "auth_ref": [ "r43", "r184", "r209", "r210", "r218" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.", "label": "Stock Issued During Period Shares Conversion Of Convertible Securities", "terseLabel": "Conversion of Redeemable Preferred Stock, with forfeited cumulative dividends, Shares" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementStatementOfChangesInRedeemablePreferredStockAndStockholdersDeficitEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r18", "r19", "r209", "r218" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period Shares New Issues", "terseLabel": "Issuance of common stock upon initial public offering, net of issuance cost, Shares" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementStatementOfChangesInRedeemablePreferredStockAndStockholdersDeficitEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesOther": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued attributable to transactions classified as other.", "label": "Stock Issued During Period, Shares, Other", "terseLabel": "Issuance of Series C Redeemable Preferred Stock net of issuance costs share" } } }, "localname": "StockIssuedDuringPeriodSharesOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementStatementOfChangesInRedeemablePreferredStockAndStockholdersDeficitEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r18", "r19", "r209", "r218", "r255" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Stock Issued During Period Shares Stock Options Exercised", "negatedLabel": "Number of options exercised", "terseLabel": "Issuance of Class A Common Stock upon exercise of stock options , Shares" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivitiesDetails", "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementStatementOfChangesInRedeemablePreferredStockAndStockholdersDeficitEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "auth_ref": [ "r44", "r209", "r218" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.", "label": "Stock Issued During Period Value Conversion Of Convertible Securities", "terseLabel": "Conversion of Redeemable Preferred Stock, with forfeited cumulative dividends, Value" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementStatementOfChangesInRedeemablePreferredStockAndStockholdersDeficitEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r18", "r19", "r209", "r218" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period Value New Issues", "terseLabel": "Issuance of common stock upon initial public offering, net of issuance cost, Value" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementStatementOfChangesInRedeemablePreferredStockAndStockholdersDeficitEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueOther": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of shares of stock issued attributable to transactions classified as other.", "label": "Stock Issued During Period, Value, Other", "terseLabel": "Issuance of Series C Redeemable Preferred Stock, net of issuance costs value" } } }, "localname": "StockIssuedDuringPeriodValueOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementStatementOfChangesInRedeemablePreferredStockAndStockholdersDeficitEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r44", "r209", "r218" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period Value Stock Options Exercised", "terseLabel": "Issuance of Class A Common Stock upon exercise of stock options , Value" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementStatementOfChangesInRedeemablePreferredStockAndStockholdersDeficitEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r19", "r23", "r24", "r81", "r149", "r153", "r331", "r352" ], "calculation": { "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementBalanceSheets": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders Equity", "periodEndLabel": "Ending balance , Value", "periodStartLabel": "Beginning balance , Value", "totalLabel": "Total stockholders\u2019 (deficit) equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementBalanceSheets", "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementStatementOfChangesInRedeemablePreferredStockAndStockholdersDeficitEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders Equity [Abstract]", "terseLabel": "Stockholders\u2019 (deficit) equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy": { "auth_ref": [ "r15", "r16", "r198" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for redeemable preferred stock issued. This disclosure may include the accounting treatment for the difference, if there is any, between the carrying value and redemption amount. For example, describe whether the issuer accretes changes in the redemption value.", "label": "Stockholders Equity Note Redeemable Preferred Stock Issue Policy", "terseLabel": "Redeemable Preferred Stock" } } }, "localname": "StockholdersEquityNoteRedeemablePreferredStockIssuePolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StockholdersEquityReverseStockSplit": { "auth_ref": [ "r219" ], "lang": { "en-us": { "role": { "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.", "label": "Stockholders Equity Reverse Stock Split", "terseLabel": "Stockholders' Equity, Reverse Stock Split" } } }, "localname": "StockholdersEquityReverseStockSplit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r338", "r354" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r338", "r354" ], "lang": { "en-us": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r338", "r354" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r338", "r354" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r353", "r355" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureSubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Subsidiary Sale Of Stock [Axis]", "terseLabel": "Sale of Stock" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureInvestmentsAdditionalInformationDetails", "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureAccruedLiabilitiesAndOtherCurrentLiabilitiesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardAxis": { "auth_ref": [ "r295" ], "lang": { "en-us": { "role": { "documentation": "Information by specific tax credit related to an unused tax credit.", "label": "Tax Credit Carryforward [Axis]", "terseLabel": "Tax Credit Carryforward" } } }, "localname": "TaxCreditCarryforwardAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardNameDomain": { "auth_ref": [ "r295" ], "lang": { "en-us": { "role": { "documentation": "The name of the tax credit carryforward.", "label": "Tax Credit Carryforward Name [Domain]", "terseLabel": "Tax Credit Carryforward, Name" } } }, "localname": "TaxCreditCarryforwardNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TemporaryEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Temporary Equity [Abstract]", "terseLabel": "Redeemable preferred stock:" } } }, "localname": "TemporaryEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_TemporaryEquityAccretionToRedemptionValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of accretion of temporary equity to its redemption value during the period.", "label": "Temporary Equity Accretion To Redemption Value", "terseLabel": "Redeemable Preferred Stock , Accretion of issuance costs , Value" } } }, "localname": "TemporaryEquityAccretionToRedemptionValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementStatementOfChangesInRedeemablePreferredStockAndStockholdersDeficitEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquityParOrStatedValuePerShare": { "auth_ref": [ "r7", "r193" ], "lang": { "en-us": { "role": { "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.", "label": "Temporary Equity Par Or Stated Value Per Share", "terseLabel": "Temporary Equity, Par or Stated Value Per Share" } } }, "localname": "TemporaryEquityParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_TemporaryEquitySharesAuthorized": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity Shares Authorized", "terseLabel": "Temporary Equity, Shares Authorized" } } }, "localname": "TemporaryEquitySharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_TemporaryEquitySharesIssued": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity Shares Issued", "terseLabel": "Temporary Equity, Shares Issued" } } }, "localname": "TemporaryEquitySharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureRedeemablePreferredStockAdditionalInformationDetails", "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_USTreasuryBillSecuritiesMember": { "auth_ref": [ "r384" ], "lang": { "en-us": { "role": { "documentation": "This category includes information about negotiable debt securities issued by the United States Department of the Treasury which generally have maturities of one year or less, are interest bearing, and are backed by the full faith and credit of the United States government.", "label": "US Treasury Bill Securities [Member]", "terseLabel": "US Treasury Bill Securities" } } }, "localname": "USTreasuryBillSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureInvestmentsAdditionalInformationDetails", "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_USTreasuryNotesSecuritiesMember": { "auth_ref": [ "r384" ], "lang": { "en-us": { "role": { "documentation": "This category includes information about negotiable debt securities issued by the United States Department of the Treasury which generally have maturities of one to ten years, are interest bearing, and are backed by the full faith and credit of the United States government.", "label": "U S Treasury Notes Securities [Member]", "terseLabel": "US Treasury Notes Securities" } } }, "localname": "USTreasuryNotesSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureInvestmentsAdditionalInformationDetails", "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnrealizedGainLossOnInvestments": { "auth_ref": [ "r70" ], "calculation": { "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementStatementOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) on investment.", "label": "Unrealized Gain (Loss) on Investments", "negatedLabel": "Unrealized gain (loss) on investments, net", "terseLabel": "Unrealized gain (loss) on investments, net", "totalLabel": "Unrealized Gain (Loss) on Investments, Total" } } }, "localname": "UnrealizedGainLossOnInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r116", "r117", "r119", "r120", "r121", "r122", "r123" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use Of Estimates", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": { "auth_ref": [ "r291" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.", "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount", "terseLabel": "Increase in valuation allowance" } } }, "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).", "label": "Weighted Average Number Of Share Outstanding Basic And Diluted", "terseLabel": "Weighted average shares outstanding, basic and diluted" } } }, "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://hcwbiologics.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetIncomeLossPerCommonShareDetail", "http://hcwbiologics.com/20211231/taxonomy/role/Role_StatementStatementsOfOperations" ], "xbrltype": "sharesItemType" } }, "unitCount": 4 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r111": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r124": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "http://asc.fasb.org/topic&trid=2196928" }, "r151": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "321", "URI": "http://asc.fasb.org/topic&trid=75115024" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r154": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "323", "URI": "http://asc.fasb.org/topic&trid=2196965" }, "r155": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "325", "URI": "http://asc.fasb.org/topic&trid=2197064" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.A)", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=122040515&loc=d3e105025-122735" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.CC)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742" }, "r167": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r169": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12317-112629" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12355-112629" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(12)(c)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(16)(c)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "14", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "15", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467743&loc=d3e20905-112640" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.C)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(l)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(o)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(p)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(q)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "60", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "70", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r245": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "715", "URI": "http://asc.fasb.org/topic&trid=2235017" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(5))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907" }, "r277": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.12)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r308": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r316": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "808", "URI": "http://asc.fasb.org/topic&trid=5833765" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=123415192&loc=d3e39927-112707" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=123406913&loc=d3e41502-112717" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=123405975&loc=d3e41551-112718" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=124258985&loc=SL77919398-209981" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r349": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r355": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-10(a)(32))", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123726172&loc=d3e511914-122862" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-10(c)(3)(ii)(A))", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123726172&loc=d3e511914-122862" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-10(c)(7)(ii))", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123726172&loc=d3e511914-122862" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6806780-109447" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "320", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=35711157&loc=d3e42546-110969" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(4))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "405", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(15)(b)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(g))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(5))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(b))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04.2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-06(3))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e604059-122996" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.28,29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column A))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column B))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column C))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column D))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r431": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r432": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r433": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r434": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r435": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r436": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r437": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r438": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r439": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r441": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r442": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r443": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(4),(5))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.6)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(a),(b))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(27)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r84": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1377-109256" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256" } }, "version": "2.1" } ZIP 80 0000950170-22-004847-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-22-004847-xbrl.zip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�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�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
  •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�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

    LE;*U/,#UBJ\(G/[9>XE'CO%F2/U/"QF.M9 .]QS2O5BQUS;8U"/)"K MID&)Q-M6X_6_GWT\"R[J3[I9&$F%% 1AUFKX8K6LX-K/U?(R .F-O]\$BB_A ML]5UL*R#>F$-O=$JKOD-+L$:B%*"@%#!O.*BFIN;P3>OKYOZ"XC^)1B+R/F? M#.@\,ES,_F, MXFG$8$Y+HK.?67$2Q,1 M_X#S>O/A[>>6-SJXTAR5-YS%Y?BT"=["9V!&_GM5 M8TO?-9@8&I\>H/'U2;M%P7&U]C3>"JR*ME(:;_8S6C9!!-^_7BW!-0Q^@9/; M\$5;ZJ8-A%Y^UGH1S/%;;5!+(W+ 'H*%@2Q#"7@--DT-KWN-!A,8*VKGX;Z? MB;QN,0DNL,:@))QE"MROJ""%!!\L%%* R<227&P-#KF/Q?117FJUFNOW96\[ MG1L)"];RSX/\^X?;C_>+7W&CD" _\K9J?T.AN<_",LNK%B!*SY=W?:?_B2;+ M]@&JQK*>S^O/AA^,OG"]M M[OMN+5L$)OD.MKQ+]![9TFT@'[EN=][$%Y?=Z)(^EC'^PIZ;6/I>PL3\$!^FY_JM&M[RP.LSM]+V+Y M';['SM*"WN%[X5G*[O*]1UA?&$U[?5.GWP/6=TNM>O'-I>K?UJ>PC0/3R94[ MY;N+QT]W#P4GWR#IBBU!]QKN)IKJR9NX7@R![U6F!F3%O_[O[R+ZW2-0_5ZM MQ/T\0,+O+'I_O,/">^&C=H\?JY';[T4^C5T->#;T\ O?J)_;:YQ2UCPM\ M>85S_'-W;+"$%R/@'F9G>T%WPH(N]H+N1,^?%W1>T$U[>R8EZ!(OZ$[T_'E! MYP7=M+=G(H+NMWK)YU[,G=[IFP:X%)!T\DVITREQL:4_KSP@Q?$ *>ZLKU[6 M-),3AP/Q%/?BQ(L3S]R>XB=*\2G1UXL3S]R>XB=-\2G1UXL3S]R>XB<\0'"C MEQ/O=$5YD(1%:,T[#,&=YLMF8C.CGNN2<1+Q("(TC MC7 _"2ESQ2@70O)$;PW',:F('8 N]T?LR68Y&#-Q=DA0]&BVHL@(C[DD19:H0I6QH'H+VHSE-!5QJ$$!ZA"N MT9QP*4N29&$191I4;+P%U'$(??BG;FK%VTL4(@A107_PFM +;$_8YT38Z)0K$H>RY#GHR#S:\@SC,HE4$@J2BXP1JE1" M1!CGA)=QFJ><\1CQM+TF/+Y<\0+;$_:T"#L=>>DUX'[B#M$1-&!:$\5R21"BFM$K3DCZ*)O0Q MTJF*[4=OH/!YXR-)C7>+3[I=&OC;:A'\^_>W+B1Y(O^?S\%PG=]CB>"I:DGJJI[ST2TW?8<;\RX^[H].[%_ M;=0++:PI0DN0DK6?_F85P)=(M=02)8)4Q6YXU"0(%+(R?_FL3(-*9ZSP)1W$5G9'E;95AA[7PJ/*!?@V<)^(UT:BIBM M&54*XD6W73@3K/ T$^ M>(UX63*D#,/(82I8T(PXL^79/D-.@(R$UB,I<-:V&86RMAT>PV=M.[2-R-KV ML-HV$,R"$ 2)DBAP4[5$BAJ)G-/>J#($)+2EDA)[9$W MC+I@G:(69]\K9TYRSOW_'#]&'-$O2BS1XI6=41%3SS3Q.[CPN MDVHX$O+258Y?L8G9'#NL.>:Q5,95&$D'-ADW\0"X$ Q16S*E9&F5V@I^>.94 M4%8CZ\!PXYH;9!66""L>2JXD#K9\3061][-[-L6R9CYVPF;-G#7S<+;U]#4S M83*4P5KDI*T09PPCY4%'&QNL$;1T0=NMHPH5:',N#*(^GE>0 ;2YE P9;YAW M7G#.^.LXM)=U\H!41R;LX>%\Z'LP'#C..CGKY#MTLC859HZ6T>D%;YEXBG3I M#7(:EYJ18!VF6\F+2CAFM$ 4,X9XL!X9P33B5FKFO*XP/]92@:R9CUV!9,(> M'M2'O@?# >6LF;-FOO-XFA6\XB5R%07=*DH9^[R5B"@C+ [""BFWCJ>53&%5 M&82MH(A7WB+KB$/!QK:H)7,D5MGG.';6S \M*8"_#1#K;II\^]4D(2].$OH8 MDBP(D-Y_5RF#F<^:!8?%9]>3SV_PVW0Y&IN;9CY[4]5_!/_VNO:SR=@Z^[]S:ZZCJNZK6T]KFR M9-]&DMTESB,B/$\+_ZK]&SXGUPX<*&:<'(J*"8DCP\_/BD,:NC8>Y+ M)O1!U-%]X_&R-AJD-OI;N KC(BN@8Y6_#'09Z(:]/8,".IJ![DCE+P-=!KIA M;\^@@(YEH#M2^Y=]/A:C,?K*^>0.HCK-X;0F5LIO@147Q(],UPDID[4_RH*3XD^F8XR$.&<6M\YQA_"(CQ?5(X'+$M3[TR>,A<6R&[4S8XR?L<% SZ\/7I0]# M*4J/@T44BPKQ2F&DK;>(D J#?B,X*+,U3DLQ8XGBJ%1<("X$1DH8$^=P>47C M-"U.7D??RB'Q:@;L3-CC)^QP\#)KPM>E"2O/07-5$I6<8L3+."=!5!Z14I.2 M:6>PQEN>8>"<44.1H!2\28,=TLQJ1 VN>,6%K*JM*E)0)I"4X>]ZY"EG"+3-#!&(ZY\-76E"%EG0N:(/R%GG N0AEH" MD\F;*XQ.V,"A6CE1!0VV#0F(:S!P3) 8&:]<*9D,8+5L#88@E3"XE*@2UH"K M7U)D=0#/O^*$5]0:9N@+&#B4C[1B(T'W.1DB(\50D2*3-Y/W>,F;]=R!]1SS MH:Q 9W$;'7E947#IRX <_+/BH.24<+?U'"^ML,F;%=QA%9P4AC.)':*24\25@9T+M$2,,N5+BH,V M6Y%JKB6FC$OD="@1=Q4H."X5(N#2E8$\X%SMI9B&?WQV>\GT481_>ES5OP<&W(-M(A[612BY+L(4J MA V)QW,U1=KR@"BK*E)A45+*;]M(E0FNE*5 0BD"=I6 WR@AD: 5(Z0,HJS4 MBY2K:4I'#._31'H>;L^SA+-6/7;"9JUZ1%N0M>J!<\>BLA5G EFO.>)!$*0I M,\AC%8)2&'.V=1RJ"I0I2RT*Q+@86L=(\1"09%59.526(E(UQG?9KU:=:G)T'8K$^/: NR/CUP9EP80H3&B/&J M1)PYVNM3BQ57FI3*;>E3H2K#P'M%,H9^N: $&1I;6!FB>6 LMG+,4=^L58=S MKIGN*9=.D9%Q#G?S.TX')EE-1QI>4)7F)?9 MRFRA'=9",ZZTSCF%*L$"XE9*I$T0B"D-=IL+E25BJW;1.$H=E4@QY1'7&",5 M*_2]\\KAB@1)GR7B<+ ._F($,5Q)$;BLI"?;I705_+_E* A7(0[7(2ND04Q3:J(: ME_+XDOY95Y^2,LGD'0K #WTGA@/065=G7?WE@@(3&*$50T0JC7CE'5("M#:I M),:4EP';K;)W46%*O (?G)<.\3(VA+$,7M"0TC!25MP_2Y?6K*NS,LFZ>@CD MS;HZZ^JLJU]:5Q-*!-&8(\[CE"UPI)$J#4'<*6T(]Y6W5_=5%"_"W 6+])>UGY+EZ,C?]AOKZZB^+??YE M?A&FM>L_A1_?2<1OOYJ&Y,5I2!]#P_C2\/([,.DAM_O7#3HN0FS45#18BC ( M/^*L LYG(:"*"R.KBI:4V:WA"I9S[*E"@<711)6V2!$J 3XD$Y4WCKBM,4,_ M3ZY".[N '?H-;O3]N'&_?U.$UIG+N'_3>?B"4 QA/^\ CC79)H\$=MN,_==* M%S\K5@3=:+.PDX;E65G*+U.QYZ#C)>/C]..[MFBJXGUPX<*&:<'(J*"8XM$Z M>2/WMW4["SY>:PIKQF;B0OS'TM+:LZEP.(+L-A@X Y$&L48..X^XK112&OQV M[*VAI>3!7P^AL6>%<"0*S;M6'1V'HH?F@M8 M_DV1K&A@T'HR:](7_YQ_#I/B;S78UVV(I"G&]44=>3B9MVT!U_EP%<;-Y:B MA\TK( M89H69>-C("] 1K@8Y_I]0N# >S\=F&N\+KW537$X;/W=P#VO:*!23 M8G;=1'%86U$76-%OVZ*:MY&1X$>S4$^*BV8+7R8Q V,J M*?]B"B];7\'MX]JWWFCS[9?7MN=F&I)(=U?'%VGB[H*Z&16P2>Z\N 9"Q5\T MGR?P=KXPLUP(?J$S# M)[5(0MW%.Z.ERN@3W$5";20AW9)IL)LJBG*1VL8 M$*HJP%M?A<*;6=@M+]%>@%N9\8+S$U=O93H<<2&@@&@7,YG[:AH MZZCR(@*$]+-)4UR"CP-V)%@!OX=9_$TG7Q& IL:GBP%Z>I&$Q\1%S8 *\8^; MI1@F]@!\^VV3!O$9/@"H78!%XOMU74YAQZ= S80Y\ /XP-63SPFTXK5MIZ%G MYS5X]-3!_ HTO&L^-04XR;>J.W?L7=$0@)* M&[;?MR=SN[Y/FZAT#=M;N+%IV[JZB6N*^P@.<7R(@0>TL^(BS,Z;B-H+=3=* M^P,N9<*E= U 95O4<,MZ&J\HC/^O>3)&X@H:VX;I5?2?%NMRYV;R&=!UEP2\ M)',7ZU8I2&?XPXWG/CS6RB_W;IZN(D_#C.(1PC==O^@KGR_K^R_-Y] %*9"I MX$7>F/&UN6G??E/\>=B>U+-XQDD!?)G%ANX$'8+'=KL_9-/].3?^9;R>X01( M#14@?C&9*;1&7%.)K" !.6<4I::DG&WU.7U,@/39_!UR)IY@$QUB(Q;64-3) M48L:YSH]&E7W@OG:\Q! 1_8.>?SF5;!C:00OJ62H(C@@3G75S?56P58ZGN3' M7&V5KM,@B*042%P[E MNLVW838Z,YW>+.VXSH+>LB/#'\#)[1WF9+1KX1>[K+]DA -PMZV9WG3Q >-] MLNLWX1L>&[7B*Q 322RC2M%8^BD0P+=$NBHU$D)6N,1**[[5Q[2W'\ CFP(Z M[45X]-G=J:Z!"P](RC_./IT5FUV!;WNS"ZOC+/J [:;?&SVQSH.JHTO4)MVK'*%&$FO,P]J"Q+^N9&7AZKX\0] I12) PU0NS =%?\W@M4/9\4_P;0:%1_/WY^-ND>9\;CX(4); M\7V\9PQ3?TI/C;?[!((.:WI7?)P&4"4QLM]]68.ZZ0)8&RO;4/[OI]WCP-"8 MNO,4.%O%Q?L[?[]UY[7'_K#U91]N:TV,WJ4X6Y=+6 M5MWGR5JP LMEQW,-(;\W/QB#EN4XIKU50U\[@> ]5D4'TV\]_-H M$R5&NH$]+F!#89MW!!_,BF%6++S.(9?3.O);E^GZ^>.'+I@,[!AK=.#::'MO M9'Y2?!BN';;=M P<@YT#\%2'JR[E7(,5WX!=^;G+C,';79J;G?(1!75+P&;G MX((D"H%//8WP$C^&5*(]0I''%=S\Z+3S_^ +OU.>U% MA,(%KZV>5G<)L:7M>MF CS (R_40AFLH*X6%LDAS8A!7\)=Q6B,MRHH'7V*F MMF)KCS%8K^59T5.W M6"-ODH4/,:%6_# '2)K,UK_=&_<_9L''K\@/H:' SOP[J)[M^I-E!0:L^M/W M8+>:&W<> %P_QK*/+DCSMP:^_*XK#'%O/W[\6(SAD^[?_NV?%L +RGWBZDM M;W,1!?AUA'A=<$0$:Y%3%G -QWZLS'!D+9,2L]C*?*L.TU7*>2$YUU^GS'O0N*"8=TB&D"K06RKK)P&X6IKJBD8:LKSF,J^[:U M<=(+VRJY5Q2/9TK%Q4ARCM8J8S9Q89.0% MPKX. -7<,EI)A;P#'@9#$@Q,:TJD*RF4MB63C&XQ.1 ML54%/R25(549E*XV2B][ /GQC\M8\_=T**62C3261\:>!W>KLVNQSU*DVS;9 M*RM%LA4N*TH(DM['UM"Z0@H#A)"*.D&9\3JXO9S5?$"XY$Y >41:FYX=F]I; M3VL_PE1[;45+@C-#+67(!^T09R5'1C*&*A\'6EH-&G'+HR4^<&+*$I6<6/"" MG4'&A !.,36N5*6RJKK-N._[OX2I,YF&?/$K.U+'RZ"*]F8[Y]/F :4>A MT2M@/BR4)Z:*4>6(FI9CI!383UA@4]FR%(+Y?3!?++2:S)KIS:_F^N] \&D- M? 78^6E^>3G>><#EP0?=U4B*8PNMK+/=ZE!9A+R+!7%> _>!K<\9H27"FH/A M+J5!BGB'2NTE,Z5C8/1O<9_2(E;M@/,9JWA\ZLD02SZI(DX&ZKW>ZH7TM_#9 MC'\*3V$S04;X"Y,?AL]FXTB#H@J+D>NDKK=0^8K(*$R_L6=;MQ1CO>\+,! MQVM^&>M3MF_=W2;^Z+))-4"Q-@.N_WEQYY5W5D]<HXW,T1?E/:8*0IXM6T0L"7OTT@[>NL1AU:-.KJ+[NC8,=K9LF,ZBVCY;*T[(H['0N#%3\V">[I3[V M MU=,0;V\6CT3V!O5_]@L&)3"]B1_W?\8UU6#%)XA/FB;ZC/$)W]5_@J=-BN\( M_E."7UC:M+GH^B;4TW:V]OI%:\;+%@J+!P)R?U?'F\1V"7%M725E?]78M#-@ M6]2O^LK$@7.7\'!X'3_RNXU#"NEX^._3>##8MO)LVL^ PBU=L_G1AU1?NS\[#J&+&C M7<:&=00/Z+[NF#O*<"_!(#QM#/7#/3'Q9MIWJ!CU7V^? M'4PW!PZ+M;R%^^O?/_;'_R8H_>-S:JJQ%D=9)6'- AB2!-Y>4)=XW1"16U=D M?GY"WLK%?AVIL+W9YJHEB4?K'%3-)]T!D&J>>BXY(%IL+;FQC;=1O8.LZ(1< M=?F&:(]N ?P,'*#^X&>RQ"?Q+(:'FW_AHC8KO=5,EBB_?(W5NE.Y>YW.9,Y6R__DSIMF''_V]^!C MYY@03^?^T[3@*7R>P4W_,:E3#7PZP5)\ H?E;\V\[E([46@ZUV+1/B:+S7[4 M '@&Z8BR[XXJ]*UY4I,<0%#PU:9+YW/37$K7@#"YOMR_9X0UB$]PVB;6AUW_ MK;D$IZ7$Y2:^Q[,3L^Z$:;(HFO$X%?84X/NE $%*-J_YU'TSHWB@^W+=D%A* M^YMUSECSMM9GH/:\X>OV_ZZK:#1-HH&2?A=5S'3V-NT^ M@NVZ:-]$.8F_WUGYV_8&6/LVV.I$EC0JIXDLB22?=4-OD"\=9H( M2;#B1%'.&;BOW[[M!P50NNPYL[:IFZL:*NV^^9$ZYK3Q"-%U M,QW[Z_CU0HAZ]Z/3,IT[L:DF5N=7^CZ]Z;^9VS.W'YYVW_SE$UA&Q56R/ "= M_^\/_]3@U*Z,DLZ:7CJD5Z8>)Z>B!H/+1Z-A?)/9.[/W0&D']E,?*2I^_5_F MXO+M^^+W27.-SIOKS+69:P=*.P#E+O @'QO?",9'FO^\$Z^SGTE']-74N2^ MDH_K*YEA-,/HX6FW!:.[D',K2$Q)P%3IG>/GC(2LV]=,A:91%W@2(5-$74 MDSC5NM+2\\V37:EF9M%:/WC8F(^KX.2'56QR+W7O_$EG,P[?43\AX%W!VQ;^ MMTW!WD7# 8#-QL>0<-W&D/(JJ[SH5K]V_JC=3.''T[7S&5K$S,QT&KNO+_,W M]]VJC9G,NCWO>MN[/JD3^_U\;AK?YQW"]"I^E3IL=*FF\4U75=!E%LSZS;E75.P%U8P067<]&D1?JV0TP,DA.5;NB2LFK/B==3SH12VD["VS2M5E: MI#0235/%FFF;":ST9D6S+C]Q&?N,M@M/J-N,+MU[-QDF5\WX"EZL!143EV2 M$_]K[C^O:N2Z7$M[:]P*<,S%?#RK+^.&+=YB+DG(?A53ZY5CM0QY?7?7XJ:/NQTC5^".?3I5UJ//T'QXW1A= M51?&[@;1B(TCJ\;)AX[7?:FT+\',- #[=6;N:CA7%(/(;ITKU/?&3%;>,DSD MNV+)].S_W6X\YS)>O=GPN*M<2V>)-V:(P2W[<\6+IL"+<0;M,DJU]_CBX6OL5/N/?6TJ]K!GD=71L$=!;QGQ?]M MKN&IT]%=@PSNEN^K<$O XP7+\T;I;M?-]/VEN.D:+XC!M;LPXS>[8T##SZ,8O@Q7IN$MO$A?7 MYR&Y]LL;ML7R:&Z,+"*62XM8AXSAVE#'N]-3CYR4?CWH?63>L4K1DXZ_R4RK\3 M!O0G/I:LL1Y]VL%&&ZY;-ZPT'M(!\WS7%,[%#*3EW>]DA45M[\;9H^M% '$! MANDY1>/ !QPM#QIHGD\;EQZ2@P1 MVP W786LOXO67)Q8 5?=K#[_T\INN7WF\P@\C;4YT/")Z>+GJU-H(4Z$W3BP MM;5KFUN^P '0CI$,,0*^(Z2Y@)3N_.]Y[+:_./2;%.\*:6!3FODLWC*=")Y/ M.Y7;C$?]O*_/R8Y='%L+%>Q^IU(30"6H:NFR M&.H]*WZN;K]*#Z5U,HS!G+$)Z[J(_$:8MQ>D]+]3X%!0Z!$ H\'1'R^HFVX:@UG+Q!1Q'V?=>TU# M&^/Y?J7M^OF^:1)!/77SBVB=N@4:G=VN77F)COZ.F#(PPE!I D/<2%!R#%?( M"U)6H11&^*W S%.-0C-C9>#G2O?F]"\@L)J;? M5KB+R>I] _^KE,R+/UBHU+M&2_41GHV(S'3%69?+J[M9+;T[W[<9F?3C,!?^ MPFQSC$T'RDN]G !R&OK.H0NP74/QI*@[\%TIK.ZY[>6X3I_&_T7SR]'R]\O9 M.\D0]."!3VL[3[>#=_MAUY">11/DA04"OTNYZ^#&9NVPY?=-C#G$ $/*=';# MM/X*=XG*JJIZ:R*E/)+&#_VPKD]QC:!3X=LXRPQN%WNH]^1AF3-RW(U$%?T;; M*%J]'ZIWR5 S[YLQ8$N;?K+.EC__\E/,">.CFQ9^&8.B\6U&216FX#95AC0;;*#!VP&A$:<2]*Q'4?W0XV"=+NZ9BT?'O M)T#WM4@;F;159.-NS#3M8IQAG4XEQ@3)"FN[N:'O-L?813?R"Z,SBQ0OF$;# M#.Y0?ILDR$R ]HM.$Y=-:DL!'R4OO/.V5T,54Z@N\@9XV3E= MI717GBK:_'WB:]9VTPX7)2_3 $(_#:NV(ATO=V78USOFMW:B2*\?!6B+=BWKP%_MO]H MWM>)K)W6F)W#.WX^+]ZMAJ?&\3THAAF[H=@/"RT.%(P3$_<10;/N.#XT*CA, MEG@WNW]B2GOZ[C\1-.92P>GG@2(>","0Y@XQZ:T1RA+GMMS_Q\Q(V8P\=][_ MN_GLO)E&&7I2!(#@V!_[&'MDK_3O[6"=69(F(=#)LZ&)$^.HEA%,'.+8!Z1 M.I&$STDPVF*^E0?9%QL^(@B%VN B&UXW4]^&R3=_F31'RGM==&DC![Z.]3O? MXE#NRIU*,K[]\ [^UF\Q./"5/ Q4I"?+Q(^O*UWUXNQZ/K?SBSCO^'_Z@IX8 MM9S/-FK#8A-QE^Q-W^U&"LF.HR@LU/5?P3_MNOR(A.Q^NM=3'1=MN%-&RY-C'8O M7CL%_[I;?[-8 JQA:4_$-K%I6./-F\4]UBZ$*_V2*.FI0IT!5,2&,O_ZYYG_ MPH7DC#+^H.MTR1YRG3AC2C[HA@^ZW;Z75YXI53YR>?"/Z:[-Z5E<)7;;O2OW MX%9T(J3X&2SV>\14 M/:[SU1V[EPG]W(0&LL9O4SQ[_T3O@7+YX@+#HHNVB4,O-K7?T6W/"QC@#]GB M_T@32G[<.@'WPM)U[T:OE_P#A8]QQY]=(+-&&N:^9$(?1"/1K)&.42/%DNVL M?8Y4^#+*990;]O8,!^5(1KGC$[Y[;.P^^/DU1C;%WAZS1QVM!K]-]X7-'T+B?>JK)Y!Z)SH,AO@I MJ'\@ZF>*GPK%AT3?#">9N3/%GYOB^[*VVYN/*)7[I"SA>RK?+:N%U M$W8XG/\O+[PS1Z@LAK-9WYW\ 0?.E:4E4T@00Q&OI$;6$(:$=)A6E? ";YVS M^9I1-XM*2P#\GR>NN0BQ@G7[M-_&@8;8 >W_?(/N::^A,!U1?/=4FXQ\ Q.F M/^6=RLTY27AF' MB, .<5999%D0<52%*XVA1(NM8[2/">YL=J]8-G5Z-_$?8C?<=\N.OO<9@U^R M 4=4DE$I[VYKF8%MD&+VA+#/">_/D2N>3-ZLUT]8<7KG.;:50-3X"O&*&*2H M!Q4J-37!2%?%&:-/#Y0\B^+\GS!MO&G/(P?'MK3\;5:9P\",7*-R3(;+HD:E M,%>F'J?.%M6M>1"QK^QZB]J[@A[GS3@.K\K!RL$IZ4<1=O.("#VC A9:^&8> M>623-X>^!\,1MY?.E7W%)AZA.3:(* M,(DKOO\:FG<+I?1;\T/20,F$[!5-ZEZVA\2;'&')1DK>/>]^,,*Z?2IO2#(Z M;.C-E3G9,!G:'@Q'.K)AD@V3XS1,I+(A&,60-TPA7E4<:<)+A(.G'/Z_5,KL MO=[G10R3X50$9HETR!)L_4_R(*#XD M^F8XR&X#O],/PX>&2"C^1R6B=I^N-EJF&F.?@X.NO;@BG^I M'6/>@H-OP1%JF).*#5IF%/4QQ">-0!QKA[02# 6L>,4#,\;H?20M%S#\KD/A M7]*0YP]5&K+T887!M^8M/6GP)A])ID=4[;-4_'FDX?A"@T>+3)FP!X?\O 4' MWX*L=0^K=4,9-',RMZL[H(_X^E&,POMA^I=FO%M MWL=AO-,V_?B;H@61",FX7%F:=%4%]A=RQO4P#C#F4J^!%J%G0R4;*J](4K*A MD@V58S94-&5>V%(@!A8&XH9+I!58'EA+RK6I&+9^'T&P%S94\%F9#957 +\/ MJDF'O^,9B+\L&"*-5ZL=_-O75W>3^MNOIC1Y<9.#/LKD@-?> 68/N=>_;E"P MQY"RLJ53P:!@*& (=1(9ICGRM"( +Y9(LI>C+9_<>?#S<0!,F,SJ%%*KK\*G MX.;3>E:']L<_W'CN@_]IVES\T%QJNHK+ M9@:4K,UX?%,L-JYHESL'UYM9<6[@0QO"I C]3BX:F *JNM3N%/164RVBJ:EO MZ6;,%7[NS+P-\5?U%'X.]VGCKZZ;^=C#MX6!9:#%$M[LTN\O2,5B72I?'0XM MX+GGGNY)_>+B(MZ8^:Q9*-#X;."D-_AMNAR-S0TPV)NJ_B/XM]>UGYV_D8E8 M_?4NV@N7;7C3ADLS!5-B\=K)Y.QN_SFS>+>]R1:NF>6I(S MP2,,?V Z_"9P@^YCI3P8+'/&^Y_@1C31]_PGBR8>N8*W^WJ MZSQ/^#D)/2#"/@(!]STCO=SKC/2GU*8T]4\]YT=S)IGD)J'8HJSKLF8EC$M8]H)81K)F'9\F);K MEX\OH/]K\"%DGYB'?G[SD/76U>.NWJ T.U7^@\]K#2[WY MZ3]#137G54 FL#*J&(J,DQH14EE**L]!SPS70UA-L.I99_-_LIP>]Q'AKPN7 M9.?Z:_;RA[6Y5$5S&*KMF0L.O@6G;H$,!_+N.!<+;CC'58FP M=!IQ, &0\G H^=8!J2%=X@8PR0X[-8;.CS' M7'*P:@C/_5)4156%X:E@DIJ@2;;/DZ!9"1]O MA",7$3PWXGR\?XH]LIJ0_?2'>SP)ACE(T'P2# \C/*$4^S&<>2XE,?#O9@]] MB_\D7Y"Z(;#,'=MPT7=61IDXXX4ZYMV;PNH\JR\K_M8S[*OI_W8 MATGQ;_-)*"@9%?&4X"BU"8M_%1_'L.!KTQ;&-Y1YF9RTU4QZK=M M81LS]5T[L6EPLV;:IE$-YO)RVEQ]X7>IBNLK4B,.32U/7@X7>_-.G?;7$=IJ%PYV;R&1X*JKKX/#4@K@60ZZINYNWX MIC#7L%3X%B@?IILW'J5%KRTTBG/?/SG!L]/*X(;AHO+<7,38#/J231,4Q>W]:*V40$;[LZ+;OZH M+^87Z3TCD9[<3?4.W+5*TA"T1URR@#CG#AF#*?+&"Q/S6;K%47$EZPRGA--ME):*TQ=%^!WTVGZ[N'7I/_\>6H#9 MSV"\U8TG&U99K!1^X^?3:!FU83)8L9N%27$3S'05RK]M3FQO\'!67U1@4"<. MCP*ZD-K$VR"/?PV3,(V9BTX([F#PI2CL$,6N@:%Y-C8W%EO!I$$5#G%,9,60 MP0*<%$*5KCQ1A&V=:@JR4@K,"$09U8BS8$$TE$7,.%\:BD,IRLSFMZA?-?-I MXO.C9/-1T8;I50W0UAD;5]V&Q":9L"-18XW'"^9_&%<#EL>>G&'JZC9$M>!" M$?Y[;L;%K$D75Z:>%E=F/$]29?I>G/"GVRA\GNP6/E!AS@%+I$ZBS4K]-./: MW9P-OD5GML]VMX==66.7T>Z9M:L=C]M_IP4!@M;.S&P.%MG-[>^Z?T83+;BZ MLVI2- J^F@*; V>FE'.\:ON3%"=I.X.I^\ VDWG;65=@RFTNNH:+NTPVW <$ M"NYR\MW@@R4*+"F)A" 4M(432'-.D,16,R]<)T0_FLIZ9<5(H[:\]I7]JIC_-9^#?_MRV8P+0SD*FV M N"&ZZ;APM0Q2KCX[9)[=V [*(.?)^"W^#H2HS-\)FD^9;S5[1M$WZ3N-V3C M;DNOJP;- DN;!E \16RQ"QL2@WP@1#WX5_6TG8$*N(D/" 9+N]/U:PZN#XY?(>PC"O(XXOUCFVDZIEMXB(DCUC&_N)@#O]BH M)*+?O&@(WNN!"-R%^3P-R2P]B\S667MHXEFX_[,9[=CHRJ@2 M&? H 1X51D8IC2P7L;- A;'EMR&58>E8Z12XLA@,?6$<4HXK5%6.$ L(JXD? MM-%^. [;GX=ZN'?8]E-[,QGPMYU' 3EOIK,H2)&!35M< )S::)@W5[6_5TC^ MWDQ#D>@'5NBDL3,S?U9;3CKL^;HKF>]$$Q4!6745M,DK]Q M <^)C?TGSV4W'6Z'=EM/S&LKK'9(D "BCI5 1DJ'G";82T,4AU=]7TUHB=R_G:%!U$;XW1^5*^\.Y"GB&+U+<+AW/6@+$9W5(+ M) 3?N.E/C*$B(W!H(\J_GRUK_2P"TKG0 F0I>Y(T97YN;]NTWQ9^'G7Y\GKE- M?UYGL3WGKK&7F NP4UU96L0M*9%5LD1""V.L+K529+]#G'9;K,G!_= AS3M0 M,%?U[.:W6-'PE4.;LA/VL-%-MX8V[1WD@PKHGVC]$]!8*8R';^Q^"1# ^Q!0D 4^E[$%#ABAYV-"B$C_D?OI, MBX=,7\)G4JL]KH\ )\H'7?@5-U1\GS<\H[A\$ 7%@RBS>T?V/BOC%C#FB1E/ M+FA>MD%G][1!?TVD'TB+\R[O\81:VU>T90.8Q9#)G3/L/4L9([.]U#WIWL= ]J0CO.>GM M\I+)GQ)91(9*[H&(R*^+RO:\:\,1DNQN#U=@WGW^/ V?S2QKE6$( M3/;:A[P[V6L?.)RE$V<9RH8C+)GVP0E"7Q6"4QC^@]OL[,'^:S=F8FJ7>LF=WNVD+TRXY]NJB]'X?! M;]^13Y[+Y'U6\NX$XL$0_/2G]1%/K?"R0K@*&G'A%#*.,>0(\88%ZTE%;[B T1_;&M1"I;"NANH_@_X,_A/L7E]^Z%ZESINFO>QH]ZT&]&X M[,*,-YLP_P6?D;O'563TR>AS).ASUUP$9:TT0B-I+4.<6Z"7=!@%PH-P3)8T ME+>%GE2J5,$[5)6\0IPZ![\!DZ^D7%5,829*M5/H[?U";[]:Z)?GT19%;G,S MCI%ENG-\0NR4.MB@@#XKCW+462>UF_,>,C*>##(.G;S#$81_.;3FRH&/0PP< M$8I3Z0@R4M/8=;U"EH)-+#3E09N*!HD'9C@O"UQ3ZF?35/[T_BNB'R.![QY% MDE'J197 _O- 2QE;)VA_GTW';!A*LU-S+ M.+)6@0WD D4J@ 5%/>&RDI66GN_;!DIXVOX\Z48L_G7:M.V3TC^T9",MRSV: M0!E7AH0KF;#/#]BG&&X=.EZ;DC$GM45&4 UX;0FRAFGD,-6B]"4S>BON^RQX MW7X58+](PH?NTZ/-J#,DU,F$S81]3L(^N!X^$SES[Y (^^PUY#F">"#[;V$C M/6644"XISZG9UTC>(XPJ#@=XOMM5M')23K053!@E/-*^).!$.XNT!?\X&%&1 M(#2E?&M8]Z.T/2 M\W_*^W/2"BA'20]QI,EX2EQ N'0>\)QK M- >(7(]*!CV\WU3>@H-O08[0Y@CME\I2+6/;3E0?_I! NHR/)#U[&](CN;D.2WF$;(4^(]^8:B:-7=D<2 MB#DI95(2X3U1!&G,*.*Z%,Y,R]0R)L[M=\?-[6E_LUQQ-#N;AVD!CUA.35IC%)SZB(QJ1O MYG8<E=Z&TLKMB&O)%%:5 M0=@*<*PK#[]V\,-@I6"Z9+&#]+"[0$M.1YC+891#W2\MV0O.=1"G1-X<&#UL M,P'*G-,<5F=IA3C#'!DE"0J:R](S30 :!X;Y+Q,/W6=?F(P^&7V&U#F:4!XX MC2U#2J\1=Q5&-FB&B"%@5@2L,=X6^J_(AIR[:_N,$G]7VVAVC&VC26X;G6%Q M:+ X=/(.1Q!RV^C7&"GA566X<1;Y0*("M1@98P-BV 3I2J(KI@=F->^K;333 M(RQ5-HZ'H06>\8A"SD0]5S\7$X-Y^\U$Y6,(0\J3Y^S34>U!MJ8.:TU)K!03 MVB/BK$2<,8JL+ DJ U'6!,W*R@S!FEJ#[SWDG90:";;/5BW/)"8YX93KJXZ= ML"<>YATZP&MCI:HJ@'7E<)PZR,!=%B3UKI:EX=3*K?&D!P;XETDRB4/#_Y $ M(2/.\2#.'8DEIZBC&DPW2LN N!,2::DLDDQC4Y6&$;6_IDM/&$EZMZ#?E5LB MQYA;PJ\WMY31<$AH.'3"#H?YGY!/>JJ>RK&/ YC&E5:A+$N.2LL4XMI4R'H3 MYW,3S9@08 +[O9G&^]&8FYDD\I0)I'RO;0A/$II>/H?TJI-%QZ=B0\<$@+HQ"5HJ "-6E=\P:K.@0JFM. MN&W'D!C^!!$FDS[6^ZQ1/J/KZ^"P<]QDK) MW(4C(^/@D''HY!V.(.0N'*\Q\.&ELB6C#)%*:L2)]D@S*Y'WTA#*>>EI.3## M.7?A.$4MD >%GIY*^2M(]RQ/!AV@194K,H9$V&P$'=@($MK _U4(5P0,&J49 M4KS4B):668TU8]N3S;SE''NJ4& 4@Q&D+5*$2L2=9*+R!@PBN6\C*.'IZ95%3BRI080=\8B[2Q' M7--26,4XL>)%0/R^\92;*/X":2"^WS101OB,.OD,Q>OEX5R1?BH,G6E]B(KT M'(X\;.O@IP0DH:H8#O!\MZL$YJ2<;VNDM+@2B#C#$.>TC-TI M,7*E54'H4I;5?ISO6>-^_[EMY\&_GT_KR>?.B4[^;YN^W.RU$_R3 J04ER,N M]MEA\H01;C@\^J>\/R>M@8XDT'%:"$\D)]B72!+G$-<5;)PP'$E?2NTI]HZK M0817%\C_DA%6?+;7)FP9A#((G5*T-?/SB\5<,ZDS)P^5O+G$\_1> M6*:L51IY:BO$9:605KB,QU^-=UHQLGU$_A!%KKU&F4]7'OS3BESYB'!\Z/JG M>\7X^$;$#8?AGQ#OS85 1Z_LCB00 $25XZQ+F,P]N%0\)7I-04 M5(/8ZI=UD&CP#FWR,O%@G35.QK4<-LY%N@,/&.?"T8$S=*9U;AM]$E[:/6VC M2:[*':C)\X2DUZ812L^HB$:H;^9V''($>: [<80:YZ2<:U<2):1DR+/8C-K& MMM05^,VVTL$JCROIMR*UE9,E-E(CYAE%7 2&K.,:*8:QEAP+:=BPFU&3D91X M)-D^'>=GE9?L/^<*BE,B[_$%*4X*]3'W\/^51M)5%>+&.Z09):@T0C)"E='$ M#0SU7R"22L]T;F&=T>?HT>>.%M98!%DI7H*5%__#/>V$WGKM;$DT^,C54_(H MY^[:/J/$W]6_FAUC_^K5W*KCD'8X@Y/[5KS)6@AGEG@5D#/>@ M13%%5G"*@F"!8VFO?5OYJ,".4C2O+QY($H@F<\WY#34<_5#<;$ M>-Y^TU'Y#,.0\NY -J@-/0JUL$%HH)"D-B%=8(XTU1I6HK)&VQ!4; M1!AR#;[WD'SB9(05'U;)9LXYY;JKH=5=Y?K8D\3\$C,OB$&F4B7B1F@$4%\A M[:3FP3$9U%;WK@-C_LL4\>?!"*\ W4\1<>Y(-P5;2:.81B7'&'%'!5(*2X0M M#Y(SCE7)]W9LYPD34^\6]+LR3N3X,D[R3+_>C%-&PR&AX= ).QSF?T*6Z;5X M(2=E&I=ES##I@ SU%G'-XU09[) 3)2E5I57EMPHT'FT:[T=C;N:7R.,33$J. M!*79!#XTZ*_GE>#ON,<[3 9?7]U!J?*L+.6W7R05H3MH15X(Q]>#6N1%9?ZW M\U"8SY^GX3.XAT6]$)SB*DI.4;<%<*.;CTWL;Y4DKP!@F,&/?%U581HF+A0V MS*Y#Z#X.O1M:7$8_M&BJ]"F\;IB.;^*YIS:VJ"Z:3F8+,_'I@LK4T_Z9_4\B M")C)S?_Z?_^@F.BWL)#FXJ*9]+\'F;U]IW;QRVFX;$",X%D>EGU6%/$=;[\9 M7+OY^\7"?>%36^UTJV3B%0%6[[?28S@M/N;)BFMX^+ MUG_9M;R34E/>"EEZ M2I'S.$;M!3AV/E!DM7/*<^5+LC7!4K!2@<#B>CK#^7$!WNK>YH=%U:&VS MR+$H%J8LD1;2HU!Q[+7EF% YA#Y9SRM*G,L1^4)IT9"Y=01*L+T,L."K,+[I M5>!U'T="I@LDW5*Z"T7XN1M9_D@U^%IDA "[4VPP$L%KX'=)D :/!W'O%<>2 M"TZV9.00ZN:+HS;3E^_!2/H).&&'N#PA<4#O[C5%$ISYM56HAC<[GJ+N^_]"M,3ZXFO'OY*C"_L06 M;DG+)J\5ON[=V/2$Y,+>4M3AXG+OQU.RHF898>#"]VD2(!U:JGW%D1 M:;,P'F;G9I8H4,PO^T"!<>=UN$IR'F\"CTY&5PP< +'ATF82X!EK/O_R04/W MJM?V!5X[147B=L%;=IL7E+@PMXUP8 ZQ%&IL9V+%VGGYW$6;G ML%_7YP&P>Q9_[L,L3"]@CWQ'\\1 :Z1U4WCC:6WBM9?3QJ8B7UB8#?%9<+^, M!H_?]Y\G2_HO=NY.:8U?KB-!)VR;_#X''R9]\/T8WA1]>'S3 0;(=M'"CM05:$QXM_^:^\]1B(^?<5X>*KJ+XYK> MU."BUBZJE,@F_[Y@DQ^ZZ&8:X#=LT.LBLOSM1U AH%^:HIE/@7< MPMO!"U5AFI1@B@FO],:FQPD_W(CJ1@=R#=CL3;K$-B Q\7H//.EFS70]V+L MW)"X?DT5CCK=G/B_J*;-10'+-YV].8I&;5O[M,;TC(L&5!;<';X$_C=7IAXG MQ)R=UU./+LUT=I/6;18:>FOML*3K,!ZGI>U<]"*2':4WM.U"'QKOZWA3(%ZS M(:!K\EJ9[K43T@/^@Z1'E0H*(4RC>A^'JX6Z@4T'0ER8F^(]X4=C=VS]*Q#TKBD]U5#/QDZCAQF&=,'=P0[0P_FT.]"6Z.V R MVA'[3QN9K-?XKPT2WY%%6)@^@'$=Q!Z#D1Y?_+_G310*P+7?P<#J$R:=T03_ M@(]O^O<,?W3[&+_M-GB+_>#EP7+S:_D98(&E[NFT3K$TU.+E?9SG^.'\4)NX M"]1_! //'07_#7^1N^@;S5U0#\-?_$I/_I:RHM$+[Q>_G7OV MK0%AP0X+OOO$O^T]@E%T":;!WO2YU_XI<"W\Z[_G9MR9E0:<@7/X!6#Q(O;; MHWGOK';K6B1CFVD-D@GX[585ALN5IPLZ$/& V+V&V,K61D,VO>B\ ONQCBKF MO(:WCN&7<50HYFS7)AXB[72TP#<,._;'!===-6.P&L;U[.8X#-A_ALY&&M<7 M:7Q7/>FR0UE?KYMV:C'6+6/Z@[E89C34S3;;M90C3 MQ2+2QY-X3;2:ZTEOQOEY.YO>/*.DJE^HFH94$@,<&ET ,.^/ M3:-.=[_&R@GH)?@?9Y] A*;!M',PI[]O8N1C4@3P2-QL$;0#[W0M:!=+B[KX M:*PYFL8(>M.U;$X.Y>RV.L\&]#[9\WU]!7XY[-)-'<;^V+ARR1A^XS4B5[Z2 MG&(0S*LJ4.08-XA3ZI&N)$8^A,HXSW55OLQ8G+MRBLLTX;M5$'5APBR8[U= MDHTLXN5\+5&(Z&:F\$M%),>9!?^VL,&9>1LVHM3G8'!$J!AY>/[$[5,)F]'O/GL? MW<%5HF5G.KH++)F'9!F7IF[5C,?-=?K=BDO>W&ORGC)0+,ZAI&,HBR>MCTTW M\UFSZ&02GPW4>X/?ILO1V-PT\]F;JOXC^+?7M9^= W$2M?H?N%B;=-F&-VV( MCOHL+-X[G33K[OW-KAYK5W5;VQ0:>+.XQQV=UKK'TF.L""L_78>Z)A^?5H<[.WR,)VW&8'^!N=EH?6W>"$R7P MXYA=L\_=/9@V_([7RUH ^FCD@7N!03NSL[,>2CLL554K-5/I J;[U*LZ$]Y M$NQ FTOE^4Y?&?FNB"NE*0WR7&O$F71(Z\ 0BX5BSGEC;+FW@[*/:1_TI83@ MD?;5*\^HN*>Q7N;\IYA?&6J&"#7&>D-\*".V!,05JY )%B,G0T6MM( $G.4YNEV>6^>"S,87?&BT<JNQYHNVD/F2NOKW)1I\3;$\S3@ M,4>JC\\5N.?H4(Y5#TSKY0#2L>H^ NH+.VR1]7&F,Z4<&5XRY''P5DE*2XP' MYQI$>/@)T.'G'ASVI_EB&OE4%%\6VXR3&2?WA).N8MP33)$35B..'45&<((P MIL:6PG)K]W.LYCAP$CCFV)J_OZ"#D+,$S[>-NX]MYP3!8'1Y8(BZA1!IN /=L> _CH MX>A#1DAZIN\>E9G'>1^BX]A=#<>ZSHR+WO-W3S"+;-O-)KDUKFAM=-5K&97( M::5 T#F26CO$M2?(,J&0#2SV\5,NZ"TY#]@Q'T07?D"<,XPT4P'ITO' *:FT M5K?E_,>^W]OW81*J>M:^F_C=HO_XN;9Z)/1QMB7='G[WI>EZ]21./P0Y<.== M][QP%<;-99J[TU_3OJIQG[RDRDCC$#:@L#@UP,.65R@(Z[ERCLGMUKR5K@AS ME4*XTACT&Y; OM@B0@2CO.+"LZUTP@OP,*$CJHYS-//#F+A>CF/K!K[Y.&HN MSF9,\Z"6[%LO1BQV_?O[T4B@O2_25,DTU3F.$XP8W@UJO$^)R6 MVAQ L"A0E>D3%JRL'>XJI2HIUZ*D2!@,2$^51>"C.*2EQ2YP'#V:+0LG@%%4 M&0]<&^-#SH/W8Y1&WE1,A@H4B\0'8&+&Q$BR(QW>?##UD,=8/'K3WB5:[G"T M-MOGPT9-"O/Y\S1\[OLROQ9P85R6C)4"*45 VQEND,(!_L.5$8165+&M.LW' M!)(7X/*I,UEV \LOS20:,<&G $G[6S,SX_7O?VC:V2_-[#\"K&1ARZSW37^" MV8K9"//CM5OGDS7K[GZ4@_BM<]L>O(X5A2G!%Z3^^1(2^_&PNPH7=WQD#_GZ(8JD).4A+9O9[T$X,[ M.0'7DAKB)&(\3@'2U".K14#!@$-$@G RN/\D V>O.[3ZYKR&:4B3%UZ)'I>& M8&V$01)KB;C $AD.F\MB-[=025J)+?Q[3+KC^?3X\D[=CS[$+?SMW$R^6K[&+P'I)Q)I\,=269G#MN'9YJXA(\WZ;-T-^#YU LR.2]UK]EN"EY$QR MI,LR(!ZCY1I[C@B-;2M%T)+Y?=I[SQ@4*4?R28=H#RA>D3WW8=&O_S:"$:K_ M0.>U!UOJ#6QU67JG:$!$"M@VK<%D44XAI0/XJR4W2NJAQR$F]7AI36[\SY 7 M_;"(5\3,40S91ND:EX"(3VCF8'D$5]<1%\#:@VOBGFEW&:ECNOP]5B M /O:#8L9F,7AUAK.UMV/=3MX4+79T8'8/<_NT8XPK2BE7 ;D2@O2P@@XPJP" MH\X(CXEAEHJMWF6/J<[_" P0"UTF/MD='X$+IF%63[N:EQXMW]>M&S?M?/JU MD^OP?5/*CCZ>>:N__ .G1IX5"X54]#0N/H[-)$>('RV/OZW954U5!3#&#*CN M"LC@DYA,:SM/0->:B#YM<0D$+[Z+(-2=_W!OU[>B^\R__5-7K%]\"IW9PC&) M>!I_EHZ73\RX^#5(%HH*Y4HSKB[H/W<4E7)@_ZHOY17>?;OXKW*H*/F4N9N:/ MXG(^O6S:Q<-GT2%9INBF86S6;K:Y@LNNQJV%9\!;V9L-R[7_Q<:[5%]E"2>G M_K58N6#<6EM6''EA!>+4$60L*P&B.>/"6>*8VP>8O^_X_8=)\?=4V+1=A) . MC$2_=Q)MI.LF#A9=VP"SM@&=_94\X:;X^9?W*$S A$N3H",(@#<=%J9?[_FF M^R;SZ:SX.)^V\SATNK/%P)PSGZ>AN_/FDMKYY>6XAM_&R=73&F!T::NUL[FO M^SJL::@O+-PT&H3PU=JZ07UCK"^GS7_!9V!K M H%F\^FD6\?BM]H* MD,F;F5FN%Q!R/NX*:S8>.*1@P(NAM:H459YJ1+AS,>\3.YN#5>EQ97U9.DK9 M7@[P_SQQS47XS?QQHO#\M,-.CP)F%D4D4K4 LH9V;^S[F,4461'L)>K@ZST$ MT8?V@KO="%,1IJC'R#"A 4440:H$SY95I7?4J+(T:J_(\V,7L>CC#7O/(0=I M-"4E0Y2(*LXUHLB*TB.%E5;>&D;,=O7<(]RB_;_/J61X9\6YB>919Q_$B'32 M^74'DK,(DL5W;CZ=QO+Q&"T+59A&.RO&N/IXUI\Z,P$^>%@(:L/%VJV;Z6-U M?#S^X9++8 M&R>6&4Q[.X/\E\*^:&'E--GP*O[;S"W@SN$7;AU1C*#I, M'/S;AMEU")/>[C:S^:R9WBQCM2M.3RW?$Y.N&?'_&]AYL<%;UWYW&:;QI'JR ME?_TYEY]?J\YMNL@_?[W\[Z^!0\1OJV^!8M#S_UV=$_J%Q<7\<8 W1=#E..S M8>_>X+?IT9^H>R]D9I^6WD61W-6+HUW?&B'K0=40]Z#I\ M)HE\P(5PG=)[7" ^$U(\X#I])O1#KJ-GLGS(=<]!P)*?+ &?H?/8)H!_3>N0 M(;4*>5%_,ST7C,0^//.F:R@&;_.U.BS:",6FD?"$)C"/W\FCFU5_C_)ZR)SY M!_3< >+&;U/OPN).CW.5!-,!Z>>P[>8*_!/IEXF=NSP1_E03/QM7)&%^IX- K > M3]Y-41'-)=_,8Z9ND]6&OA/#D9Y_&?I6[M0*@]G6TBD4O$FEC,!*RM)I01G6UQ]*KJ&=^FC87/W3UU/7D\X=E?[Y._2RK M9T+[XQ^SJ0%&K^,IE9]GX:+]I9FD@WG-.)9I+\;+WE.^U0*?_9]OT!?/K8B1 MPG1$,1G&#(S[Q7O;LQV25 \;LO^4C9O#&3+WFS%Y2] MH.P%92]HLT&$]N#^@!?D6440EY(CXRN%;%E:A2W%G-K]':@9JA=$Z$B5=,3+ M@8P"S&Y0=H-.U+K);M#1&Y*9O/O/]BUQ,.?Y]H[WBV9A9K9V_"V>H7J\]'S= M=F6YR80]2L)FYS$[CU]JZE8RK7G%4&4#N'^VM,A4MD)>X$I*8FB@6V?-G]2] M8/.\V!U-#=[-?NJ.-G]:@/W&P?1]N(LC2A1XBW2/WN)) M]P&/@)/M])[LS1 MJJ1,V*SK3U*9.L^8"5(C3(F-C5LLTA0'5%'BK"\IYVIK#OFC!E(\H%W+UZC0 MR_D4/FB!G^ AB*ZK4_[E@;3 $WF=, ^DS8K$&'!R^G[RUS M(7CI&&AT$;NF,@R,Q22XS(%1+4-5@LK?:^_"@7C+="0Q&1&RS]SJ20+?\LGHI(R8;.N/TEE&@0NG7(:>4M+Q$NB08]JCHCF$CQ@\'[U7MJ<9F_YF.!D M.%Q[I[><#PH?WV9&N>ZZWMJ^E& 29G$4Q**';O]QKL89J(K/Y!TJ>8_0CAH. M+IU^S*3TUNN2"R2U58@;K6+,Q"!LHK7'.)7B.2L,$O"_F_B_-<"X:Z7I^XB* ME'Q$Q#XK"$X8Y(;#IKEV_ 254"9OUO$GK$15Q4 )6H&T\AIQHDJD.+>@1%F0 MG!/LU=:XMN>J+'B01GUTD(2?"9$UZG%IU"?4%9SP_APYY&?R9HTZ5, Y?:^9 M*VVX<@%9%\!K=EHCRR5%ACDGI3-6N/(9*PV>T6L6&H\D'<@I[2')W+!U?/:: M3U )9?)F'7_"2M0KS3DU!.G2&<3+RL:IO!72H N#ML)*@U^JPN#9O6:=->IQ M:=07K"_XNDJ17%GP-=OX,<"O)G&"KFV:W_\<2PS6)O?FZI[!*?1,V"$1-MM( M!SZS:"LI2F)0*:T >\=:I"OJD"76E4Q0XQ5[2F;AW%W;NZ(,2^A\__^W]ZW- M;>-8VM_W5Z"RV_,FNX+"^\69F2K'2;HSTYUD[?3T[JP!2%UMV?)%L@=+IJHYMB:+ \YP;S@U+A7E'A.%[+?U O&";0[!149BD*)"P M2-A^$;:'ILT<:[7_(7[A.S'W_)@&,K6HQSA8T< -:2(8\^/0M:) ;FQY[Q.: MN-,,?S\L<9^@OS7$WL'^;&E_P.;!/3%!2%BT[>;IE_VW[7Z4^([O1S2U/!=V MU8%%HU1(&B>1<",A/,;B33(/6]Y5W\>$1_X@"-&(]\:(HPW?$U.#A$4;OI=& MTDU3*TA#067J,C!S/AA)7[K4]Q+?C?V N2S=V$@^PP;XN_O>($23V1>3B1W_ M>P3FYV8D*\+$/Z=U,P82X;'@IAIO)*^IY.VAAV2. MK_*$?$ CM(THC:/$FI M%T6",C=UJ>U)YEB!F]J)_X2M_5K#'R\5_!:"'*XW\&-##M(V2=3,-O78F["' MM@?)BZ9]CVUGD,1@/,%BNM(+J.>D/F7S(]^)HZV,Q;E/_..[AG23 MV,QDW\/53V2%RWI'EO2,(BM@$E!HS"RJ2?2E,;<\ZB(4\]R MHX@S1SQAJ_P#=Z'?G;)OQ2Y:S -0&4A>)&]_R=M#@V>.#=O_J+ C(\^UXY@R MX4KJ)5%*$RE2&H:VY3BV[?/(?JZN^PUVMOW'=G K D26V'.BZ7 M:MIP2IF;P&+M(+ <'][UHR?,Z\,+)UJI;Q!+\8)!8&&W0F^L.78K[(EI0<*B MS=Y+HVC%@<4]85'73<# 65Y*$R%3&J<\D%YB"6EM-"CG(6&-6RSD!JGZ" \F M[(VMW"!)OY?(]%:E(V'15IJG7O9_?VM%21)R+Z1>;,,_GF?1V'QO(W]@X6'"_;'9N+_=$]."A$6;O9=&T6:6#-+44X?-"-C? M)HPR*XDI=T5@22\.&7NVM/WV][=!@+:R+[82V_#W",R3$2O.)<$*+K%4QE +CN0UE;SH)NUZ:J_O)DF:4,[]@'J)&U$6NA9-8BOB@0A< M;WUHT19SXZTZ_5B\DZFLP$6""X[K6C;U/^;:]7BN7#>8I#_P?7\0>MB^=P@: M!7MH#\TQY9@MF3.K9SWF0*_QX#U'-[A>1%=V"/[:V5VL(7D4^=0.77/0>V MQSR):>JE(;.X[=C.4YY;_RS;8W?@!=; <]&B'H)&0?(B>?M+WA[:0W-,W/YO MCV48,TOX+DWM4&V/8;^;F^TQ]O'W"4<] MH@-K<8QS.AY%V 3>DM7R67T+%DKJ,L\$N:*/;%=2%ALKMA+6VHSR[>"Q*4!"U+J659"691:-'02*TX#Q@/KV\7%UJ4PBV+72U/; H*:. MH"QP$RK2-$IBSQ7,?LJ# AZ_H?T_696"U2/%X9>.97MO=FUJ]W [VUL%A(1% MPO:+L&@(=VL(4VFG29SXU).JU9_[L+/DRAK&=L0]$40LW(HAW.5N%&?C]'\W MBOW^_0.S%772L$LB+R>RJ.7KEXDL9)HUV,]@JA7?@+Q7=P+.T/'53D"4TR27 M/0M!F"-$_V$ZE.C![=:#2P+A18$7TT"DDGIZ %+7)"\&-7IA$FW/CFT121KQ* +S9@D:!9%%G=!/ M'-=QA9.$3Y=B/X'[9L4T*\X_3V2E(QM;FUVXU5C&'BL0\:!)W:Q+].(7=:2# $(8^]6+'HRRR LI#3W K#7G"GS!]CSO= MW2L0/33!UM_^J72-I.G;#M> M(>&"H4:+^H\).Y>M*%.6PJ,HW+\CK?O.8\SC#OSF3]?WQP6)\FHYE ME7'X6V3?_OIG^.=1QG]A=+O[=38W#NT@29D*+(,1]3S&*7/CD$9)%$MA1T+& M6]F&GO&1%--B8*^F M\C;S%0R#(#2!$6XQV"O;4/M9-<[745>QI#V>FI0I:>1X4E:LFA&1P:N5+#A\ MJ!FQAIR#2T2JK(;/E'J^4):""U$T!#Z@W2']>;BEZ"#4]V8:1,(*NE;J6Y!$YN7%T4U3")Z1<,JV[W@! M9%47]%G[//:^.4N7@@T,J9 M>5X!NB^TZ_F/WF&,*@Y5'*HX U2IAU:KCQP&S/):SAC52E=:4P#&;G EI6\X@\&(<.[5OFAVW8P?,KN9H5;27AV4ON>-:S E2 MZ@L!]M(&L\?B4-)8"I&(R)$V&'W>D6+:Y/%WS ;)FI,58D+X:P]]@[ M\H/8B:+4HZX?^=2+A$V9Y\!BK< )N2=B<)XVB2;,^W$>X"!MR3,*_&C@QSXV MPNZS%L&8 K)NO\F+!G#'X73+=;W #6D8P"[?8X%%$\MQJ"]3/Q3"3;F(-@D/ M[,X V@,[\ 9QB+,@#-$C6)FPEZ&!8\ZKJ13S8QIJ+$$PSCYC1-,DPJ++LUN7 MQTU2+Q1N /Y*:*MY&C&-12!IX >>9R2IK67V3:B:' M5J/@UG3J=&5$Q^-=(,<;^-$V0P"H2(Q0)+CM1W;M'V'1[NUX!+(CHC 6$LQ7 M '9/"$!.VC;UTQ@L6^2F@;,V[W$K6_UGMWNV,W#] .W>KA6)L24!UPTH;OH? M7 ]0\C]HPFJIFJO&2JCU"%<%+6#SE6XGIH M8!"I&2.8&=E?_8)1 F3=?I,73>-N36.Q2QW+%B[\ M)8,D?J:(P3.:QL@;@/U'VVB&@L&J@;T,("RF;55 'RP9,,YJ8\33),*B([3C M-@$[D"ES!?5Y+*D728_&5F33)/8MQI+8#IF_S1C!*4"I/:%/LCF95DI';K+5 MMR*<)[!WJ@&W]\BN_2,L6K(=%[]9:RS?Y,X#H\=F\;2BF"GS@(:QZE+71[[;A+YP@_7_)MM9?-/M-*\TLNX00VC MZPXL&_OW]UIIX!X>6;??Y$5[MVM[QUU+>C8-+$? WIRY-$Y3L'R6]'TK]K@; M/5F*?JOVSK$CM'?F* U,N^_E_O[7 LB;P^6"G+.L>*UF^&'VW3B#C*%)DPC; M0Q_''(WSIW^_="S;0V'HNS#@7A79M7^$[:'NWJO]J;!9$ 5>0!WA)-1+78\R MS[(HXT'@<.D$8;A6.;7Q^/FEE_LC.+EJP-P&<=A@$%H1IIUWK1\P[;S'V]*5 M:O!OLIA*3#P;:H,WB*E=/5O>&3H^+)>('M$7KTE\D>FA=]FISGGH.9T$H:)!$MCH;SJ61%WO4 MM2+;"6S!([9V^LE6DL?S%SX6O!S+#0K"XW#@;?7P-[2XO=_78Z+9 (7S20+K MSW?U#;LD3 L^YIJ-,_48CS2)L.@2[?@\',E21\0N]66@IL&YG#(KY=3V+=<* M1!1'D?TD]>,_5ANE*=Q![+B#T,>#^/$_A"+/JNS.P0$SU[E]>."^P%\LL]P8IW@>*XRX(=BPLTXN*:YQ,307H5]KB;!K:%OJ21X7>:9P#(]G,.ZMR%$ M*PA=Y@M./9^GU+-LE\91XE 1VHD36F$:6^XFN;#KO3OSLQ]G*^:AC2G>$4ZL M@5W^\H)^OX\'*+C[[-B=LMF_$B%SN/@59N0.RGPA!#N'H(<>Q%Z9Z,"R/ $& MED91I,I5+$Z3B,;HHOT/M(@HB./$#J@5<9=ZZHA-QF1(4\M+ MW,@/_2!:J]7:I.BX;;M:<>= JV\P(67;D94]UF/F<.(&P1),WQMI9)"\:,/W MV$C:L1_;41A0AW,P>)+[*NCA@,WT(]]FS/,#OLV"YNT:R:T&.5!)&!6WV,L* M!'/4P<^RKH_(-Y9/]>'NA.5Y><$*OL&4L+U$S 3[NH7P*\YN,1R#'CI"YBBS M_0]F^*'# H^#D^7)E'IA%-+(3AAU8AEY<6@%@9T\20?U/^86XGAN(#9JI[;= M06A99J6F]F.HC#DI'%]F_Y#V\5NNS;Z#P?I/V#K?"_QO'EJ'7G)4C!3-X6@ MGCF+UA- 3?!B<):P6:+U'Z9#V4.W=*_\OC01D2NLA#+'#:@7)0%EJMLH3'C, M;2?TA.,]2=QH);\'^O\!/M__R:H4K!ZM3OHW(<>WCSY?7TT*!GX,8'6MWXT,$P",+O/[;M M;/VY[V_I5AG=?E8E=WQ3=(=D-:DD5_(I2%/"[V(*KS8C>5.4*$L')&$UO ;W M4->T"R)EJO^2WS+ @,L!R1IUXW%929)G?\A\!N\#98JR4;^HQL.Q)).RTHLI M*[6>^4UN^-J+#-Y6GTU 6W3'G@[)<:T^\DYR.4YD15Q[0!S+@7_;4!;HY1J6 M4[4/#%>J[[BZ2D!S!*NH0=-^DX05@A3RG*D_!@1HQL[E&%B*C%@-JX)[CH%C M1/L [$9BPK?\QQ-E+W;'-S<;Q]BS/69Y(>6I&X*ALP(:,3^BCA]Q6\B ,W>C M'(9NRUW/5QQ_8UFN-.'7\E2SZG7CN6XM:S!'<,-@U6Y2__NYC>'MS1XFBSB! MUW.-40VLS&5=LVIVMUC#!>H=-H8GZ014B]R-\GM%!M]-JZPXUY^>258162@] M/)M-$RO+P1O,:*F?Y^K::U1DYSJ5>5M8[9 M!'8'I5 ?T"Z[BC^%Q?:@?NRW^^&K2V6"ET\!C DY]HCQE6D)=P M#Y %UWOSZ?//^N:_?2?BIZU\B'*-%7>Q($8<8\G(4M305TW M5$7 OD5C*W*H$Z1Q;,=QXL7Q=28/@H3%J7"IG]@1]62J#JL0(8W@WPA8/K#\ M^ J3 WLK9[?E]5^;#-PN#?076:F0(.Q0KC#]%0,^F59R8<&ILVK"G3NZG6^O M"399D'[0&K*EV%R=*KZ>OZ147PW:,E5N;;=5+)3&Y/E4P+T8:20?%2I\!;B! MF]3"W7G'7T_^=@SZ%G:,0.N)Y-IM_N\I&,HI6*C)_!JUNV3$]JG6S&HO#N(UFRMPM7X $C:IE8W\<^ [@W3= M7+5$8FHO3=*J'.MWY\N%1[N1:#H"D"@K^PW6K7<4P$UZ@]QJMFN*K&HGL+ + MPK5'6K>6#2@]S1MET]3B@5^!*$P9O$*F\ 4J<#"9Y+.%R[86'$-/KJ>>W,W! M'4OSXG)'.6?K$0,.G4<&2"J%E@\P6ZV% B&Z8)6H#RD^8XG8LRWITR!B@GHV M"RD+7$8MQW-2.P@#QQ/7S5,2.7;DQCX-TP1\,!9QFL3PC^?X@9NR-$A%=&?R MXO/<@_@9'(B35?*?39-_@GKX6KZ_G&1M7&XK.T[;&T:]-%B+<(WBZD-A3!G$ MS+)=C\9"N?>2@0]D2>7W)^!$23^RTK7-02 ]Z4CN4.$X'FP.6$SCU':I] +! M$S?F4'=T'QAR2*]X#/'/9^BL+75O#QD,J35NOJUJPS55YF2FS MG1].<"_A432) ABZD5N M!!OFQ*>)E*!RX4]7! ;RM^T/G5[S]T$IWBB)W< #%\"))-CT( (69:!])8,= M:10[0LA@3?&ZEL4#X2A-JR+5/J>Q:Z4TM&S8LOI^S //0,8$Q=MOCP V77'T$LN\&L2=" M\.#!DL!GI$,C&3O4$;87IF$:A\*[$FKZT*)S7(@SA&_S[,/#!38]CSAPWB>RU+D8."SY@:G_ZF\*7-8G7/!/"M.@<$]AWHV\'NH)/-]SXM2V:>B!X@3G(J6)@(VL'2=, MI%& N6<_(#=FVK.TF4>=,=5Q M@I9?OV5PB7IG D!E^GQ-H>K.E5^R\^(M_._^_V%Z]-%\]NMJ*4]-P"'0$N%& M[CQ__U%5_Q2@RD_!:R^FRKT7.O]NQU&@K1FH/E6M.R O6^]?R%<#)6FP62@: ME6:?I^*[DK)N?] 6Q,5OP!Q>%+*J1]F$C-FLK4):K2.&[[JAHD@M\XY=Q34+ MHZL'VIJY1))IK4OOBBG+\]E\:9WU6@:&KF[0AX07WD-:N-!\UT!V17F9QYJ##7(&J3 MMS1W*>-=\[(R.K_ U@F>=T ^P HSP;HJ9-#-E*N.E#:ELV(LU2T).Z^D7 HZ M(_6HK!JJS+&RH=3"3J4["-(,]K7[T(3A Q;(&NFMW/"]4_Y+^7/<, MNK*SZT;2H=+6!E=Z#2I3#$A43-&-*JQ5&R3<2]5J:KNJ5]:Y7OJ.;=WETA6J MKJRB@%]5>Y9ZA[-Z1"9LUCZNJM#,&6QL=%6I[CSL^K74'89$RXU:*/R5J>)* M>!P)O[0;I<7%FFICU6"IGO,[R]RU)[ J@V"S@2RJ&/>Q2C38NC N)R^8*8ZV M8ZV0L.T6__-H,8UOPLYEVZ5/=?#_B.47;%:_>4%>F],U_ICV^OLX@3>TUZ^R MV):]2]]U/1V@BE*;JW$1C+(X#BB3,K9]*5U7;M3U,OD/]#_1]-U2Q-!N-6%7F(VGXZ7>UCG@N59M2QS6[!08 MLV:].58K;J;NH#IQZB.3-/+!:8CYN(VFJV[4W[1ZMBZ;-N5\GHGZ;A"O(^N- MOISF;%9.FZ,TNY3BS44FFM%1J(G570\HYFQ2RZ-:3AB(IIP_MIZET][ZQ4TS M555_6WLH]='\'K=,5NV^-1X&?O"#HMAM,U[:"^UA&#KWN\ZZU_W %O^/2ZT MAM'Z_79];E$?)IF9HPU!=SGD927'#'0A>,P.&A0Q.AMMM4480I99KB8C&@KG4"T1 $U=:5#A2AE&:\LA>&^3ZF**,JQY\ M_4'[GK^TKN>7SO,\U0H8W(O/Z8=,U;?]KV35!L<"!0-K]V<"F<3../S--"?] MT3O6YWEF<[37AVY3^IW93%>+@XJ&Y?,HY:#KC%>^'2_'8Q4$!;DE2MTTLM#C MFWA9-_5@-:2:S*X4DZJ!*?M?I&R/)ZL M%2@]I$!_;@^T&3@NQ*D&ZGV+TP:%GY$[B#VW9Z5X!U+XZ3J6Z\HPH3YS!/5@ MN301X#1P1UJAZ_(@8%L9$K9EGG*L:.!ZFW1?[::\LTP)W)N/#H"SO#0*8Y[$ M5*1J/%-@>Y0YGJ !#YTH90&HJS5M)2WN"NFWK$0]S[5H[$:2Q@'WI.?8:1RO MC0;8,F=%SB .-^FG1F7U9"PE/=\%1<.H;5L!]8074@9<05/!'<%2&?OK[3^! M)\!&II+Z:JBVE\#E,;. %SFP&J#N!.M-_=LV@)8U\/RP9SQUO8I;Y0^Z(49Z M_MOI+>5U@WD1&%"X=<^4:Z<[,=OLA)K.,^DFYM9#+&EY("ZJ'$EQD*H;6"E5 MPAJ7GA;9/FBX[7S#H\-Q\Y&0-0B?[GA>9@!UG0E3D_TJ02=,30 [S\M$3\]J MV>=*1:P285C--%5\5<&WJ@E_&=#@/./+I./*%=>F1"ZK==7 L2J3C9H(/"YS MR:>Y;.\P;2M2.."KQW@U:LA6/23'Z\G*;J#F;4G0MK9'SS=;?60U].Q0IBS8 ML1]+9J?4$DQU!SJPK8N93_W(% MG7 CX\*_'=-VS$K*!=60;]4\]\"5OA>K/L,T!B]?G5(F0_A3)+&K@MM^NG:F M_6-"VD_'MT[/!T\OMZ"'.3C)8U88!; 5L+W8IYY4\X\\-X1-@1"6L*5CI?(Z M![+02X0-FM-W$DF]4'(:L4!0/XY"V*/*4%IK@Y/NR8'W#Z+9@Z"G$U-U>';" M,KUM^!LX$W%.Q@SF.(OP[/AMWX=-UHW+7> )I_R*;6]Z]TN\WJ;:8%;\_'@/LP#:"^ER*$ M:+IXY71Y8M?B* .1U=5TTN[5*@E+:?MSYZO6[%\Z-R5=N"L.R-IQ-31874$=Y, M%?@HA;:2'[IH57H]71Z_J&-FZE-:;U:RO0:\V(5"K-<6H8Y?;-K^1CW;H8*W ML[;#49<1S0^%%(O>^<5Q.&IH0CU_0U4;275X#5P['V]0EDU1*G.G%I/A85Z] MY-OW>LR%.I.S=:[:$*[SG40+NW=#L>OI5,0> MLUW'3:Z>%P0.RN?T>!'#/I6%O&#Y%WV8S)4P%JTE/P)G2Q7AUO)^9V3M@A>: MBU(?-;/Q&*N=5'_H?FOE>MZ6,3N,B9G,#P)/6#2-I%".7$(9#U.:!*'';5M* MRUN+[ :>%[G"M:B(7$8]3_HT<> 6ELULZ8,DV>O5(?/^NZ--N* MDGJ#PGDW'KB]&V=LE(&\=5N"PP#N.PS 7J'GO]U[$L#C:6Q&%\&CVBT>_]!/ MYI!I?=F-75,.N !/=YF05@Z**MV:%FI"6VWHYO&C.H8N)B?+X7'*_KU;?9#6 MU3I>/HJ*U'1_MK-7!/FPV( L1V@-[X/>LSC4W1UZXU%_*HO[46_7O*]RLV5> M P=,JI)+<%"EV8Q^K*>0J35KMOVR6/7V+.NF 1,#P383T??+$^K5J.=E^.$6 MB(U11SW;WW^>7@GN\%7J+L6^&VC5';$-FWQ9Z,MUS"@K6E=<8;6('\$UB5R- M#LW(5%N@2D[*JNE&B5ZHZ)8*$:B*KT0-+6W+OU1PX?UE-]E3'WS:#0NK])14 MU0(W50627?*AA(<8+Y.W*@BA3U)NX''SF=XVU%W"XIQ5.H&[6.CRX=7$U3& MJ7OGVMFH:JE2:!O91;74+;L#86NB*K_;X%GW[MG[D_\'WZ++.?56$PA3FV,J M>\:;ORYXH9X"R;MSV-NSUILV2*JJ=C.>31::XBHKK/9-ZH#52)TU__Y2\JF. M:7W6T^FJ=H*E?F_IZW3O#123ZECM:I@6_IH'QHIN=EQY3TFJE[S7,ONI9A=; M#5'W7\I7^@.V+[J_;A:(6\ZDLH>$O&5*WG2^C36+@X47)XL\G +MT\/S=&T- M^KZ-GC]_3\VQH-6MRT83^7 3N2Q7 9USJG65@GTQ;;JSE.W$P26J[94@$?N@ MEG97K_=U!";IN)U,N23^![@7L2WZ=R)*VMO,ILZ)K/%I5*ND5I9+>IE1>Z5.\0<,VC:R; MN4&?KUGI-UA85K>Q_LDTR3-.V'*KF&;P[&*J\_.,-!4KZC9_U)V?KNX)GZE' MR];TUE)V;1)@/'5&H) 78+2[^[?=49E4/1"+J:*JTTK/&:U)7JI-JLJ'D7;\ MD7J EJC\#5!8\=DY <:Y:$;=S;I&#/&&7"79?!RY\Y*]6JP)]&35#E!MSU^O MN^/2E\_PM\]ON\/9+Z3&J] ^22E'$_F1 %_1Q-NVC(* M?$B//)\MS5MG*5JO1JE=!8(2356'UG'*'8" *OZFSHN_AFM7CW&C%;LWTZ': M?H3:/EY!X70A7>TY 4M@3Y? ?FF!70G*? !@S=_2HNW8GNU85\K-4EH?H@Y> M?CDY_OR6?'Q'/DVU"^9XT:N%UBY6%52K.-;TG-:\?_IWU[M%O2I=K=_>=3H# MXRZ/:9Q=QHH/RI'HY+P^RQ*I6<[[)_=<4-L7RUA[9UI%0 MQ:7SNB!UL*_V U1L195DJ"TJJTM5;:D.D_E#!5&:M@\PN%MR#H#EUE8DA?^^C ']OMBW M&BTL)V0UGW"ZV&N#_P6W+LC?0)76(NO.\_JJM.672M=+@GBUPS[@C>>J);G^ MG/9#*DE0^!XJ?(WJ^ 7'654NFE20@Z4W#RF]<;9"N8,LJ+GAH>]>P?8?.WKL M4V.5U?,PQ99TB'8E5!;O]RS+'J91]-UTF%GYO$?3R416G-7R^?R)+\>GCW # M=K_NK^3CQX]]\#%%5H&[55:UG";Y@/7RDG0E"WLH"N*>M M3O:ZA6!B2I/T^[\1\K[ *7-, % M6ZMY10WS:&?R/7P0X%U5#^1+SHK5'-&JX]V?MD=\%8IZMKOJ)#5W8.\J>M:[VXV M_*+'@Z\RXP'HNE[GO9Y6UTXJH&(V8?FRP"Z59O='VAXP9K?J*]6DLNM6.E,] M-KP7[9(8AGP*5;K0AXN(XM>+\HB_JPLN4#T)J8 MK7]@MMXU0]_O26(6L_7(%,^0K?_6PV3]UUYFZ\G'?QB2J_]>X;2\'&5)UM2+ MNN_EL$H^DD(U^AGM'/OD??<$@Y4>AZ4W@H:V"Q');YDKUZ:;^Z"?I=CMN]::7W8@&[W2"M\H [=..]98+M[)G4 MD -9%6J'\=/);^3M_'2W>9%#*K9%/GX-D-PE$&RT M4YCKO]5)->]8PZZV_:&"VKZ"K%1.J#*=9N MO[@O?(KEZBB)V94Z,1UK*A7(]6U*M OZM)/#M3HKZ[L^=&OH!77.YCK'?;7P MC%&]F _\X]3+;UT?LHZ@MDW JZZ&'NQ^ER>QZH\,NFDG+=^07'D^8CYTY,J9 MUQUO:5?IDF3CL119>]@B/!Z7B]%=:O8YZ,![[V'BL9V@4JI^A M-XS''CI3/($U>3XE\JCAK:LZ?8^4R:.+Z1OM.-_@G;!I4[Y)U%C32G\O6+LC MZXV^G.9L5DZ;HS2[E.+-12::$1!&4ZK[ ."9LTDMCVHY86==F[J!CV@;F <=6]X'C.I?;,CT#MZ&TO?W7 ST%*]\Y<7X8MM M4KI]R M:O=-J*VR[JK"^.D:)NZS"G*3MMO1QJ]3A%?!M8;^S>"BDMP&[ 8*QCP"^*D< M/I>C\QV6(VOSO@%K>/)>^4;;8:S[N%!SQIJ[4D\('*J+9T?59'6A"\]08:#" M0(6Q:Y%4=10&NK6H"% 1H")X[FC,JA^/R@"5 2J#?5 &&'5 =8'J M7%H:H+ M\&STT5FLP9@#JHOMI-'O5[IJ]:/D^3[)I.[.NR\CO _EGUX S.GC:-%L_W6' MMFGU)F; M8.I=CU46$^# R.C2J:@2)IF4A^]?GUQ<3&L)1^>E]]>'U=\E'V3 M]6LISEGU&DPT>VU'3A2$[FOX?MN.7=OQ'=MQ/-=R7@L[C"/7%O+2M8>C9KR1 M4';G =^7#?23"ZI591[Z$,#KUJ(-$.Q1K$V$0=SK&%$_XX6$$7%7!S,$14PK]2S_!A=1A08@W$P1V!P M=X6B8C0.YHB*%;YV@M=JKC)*S&%)S&,3*L^/R\T9%3.0P4!L_W3>U4"L@XKO ML!2?^3@\32#6V:] [-M9SBYJ#+FB )N-@SEV#T.N*"I&XV".J&#(%06F!SB8 M(S"XCT)1,1H'KZ0EUY_2U_/)I+#BT5[J.]JT2L&7%%\S<;!'*MW1NW7QVCK4%C,Q<$< M87%=ESI^X-L62@Q*C+DXF",QN)%"43$:!W-$Q0I?6S'&7 ]08C#FBC'7P]1Y M5V.NF)X],,5G/@Z+F"N_2*B\]'[O;X7J.UGS*IOH,[?+E)Q)/JVR)I-8GXJ2 MAS@@#H@#XH X( Z( ^* ." .B /BL+*V&J YU<[]D?*1ND#4U_(#/RZK6;XBLDKPIJWJ( 574!&;C8([5Q/I3%!;# M<3!'6+#^%"6F#SB8(S&X*4-9,1L'48FT5Y-QP'@KRK3A.)AC #'ZBJ)B- [FB I&7U%B^H"# M.1*C=EY2V+ET?X>W'_A8C^1NC :CCC$4!W,,,D:#452,QL$< M45F/!N^87Y!3=HT 2JS1$JMVFR@K*"OFXF".K& T^E E!J/1&(T^3)T'%_D8 MC3XP=6<^#D\3C0YZ&XU^/Y[DY4R'F1?C= <$'ET*\K=I/B/!@"C'9;"8L?M% M@IT@IZ-22!VP;D:2G,KSK&XJ5C18+HQB;S@.YMA(#!"CJ!B-@SFB@N7"*#%] MP,$Z@2@P%:#- >ILY3_@$&: ],W9F/P],,:PCW M,D#[F3=E(BL2#_0 AV6,]E0FDG-&WL[8&(.T*/K]P\$<.XE!6A05HW$P1U0P M2(L2TP<5-6Y*0<3V11ZWN3+V6>\1E&7E&> M#48L-Q,,?D8< 51<5H',P1%0RXHL3T 0=S)$8%7-&\H+ 8C(,YPH(! MUT.5& RX8L#U,'6>+I4UEJ6REZMBM6%LK]-SV4Q4$%]7._;@C7OL^J M'V6176+$%A5 'W PQV:N1&QWS"C((KM& $75:%'%B#%*3!]P,$=BU(;006%! M83$7!W.$!2/&ARHQ&#'&B/%AZCS'':*V.S!M9SX.BU QOTBHO'3XQT1J8G?Q6UE)0;Y,DSSCY)AS>)9&3:S]D%5CC.&B9"(.B /B M@#@@#H@#XH X( Z( ^* ..QK'-."@*,N* M." .B /B@#@@#H@#XH X( Z( \9#,1YJ#)1FQT-=&^.AAZ8&SY MX%,!D ($ZC8JLGDRRF1*E@=C?4[A75F1R;2JIZJ!ORG)Z32'V]@NH[;WDKW2 M/?WJ-6+[HGM)QT@EW(>/6'$NR3%O,":*PHPX( Z( ^* ." .B /B@#@@#H@# MXH Q48R)&@.E\3%1'))S8&K0?!S68Z+]'75Z2TST0U:P@FB@B9@Z0KC.T_Q.#HH>E!\W'X7I0U#G$ M0M%Y3#2Y,0"JXZ1V1'X=G@U/AN1,T51Z)F0!P0!\0!<4 <$ ?$ 7% M'! 'Q %QP @K1EB-$S%S@+0M>_CQTQG&6 ]+$_8+!W/$Y6.AGIS\S]O3G\G' MHFZ8.J_I7"A$*$>* ." .B /B@#@@#H@#XH X( Z( X8C,1QI!)1F MQU=4./+LY">,I!R6)NP7#N:(RVHX\BN[+(MR/"/O+QM9U*J0\HR/Y)AA?!*E M"G% '! 'Q %Q0!P0!\0!<4 <$ ?$ >.3&)\T"TJS RXJ/GER_#-&4@Y+$_8+ M!W/$Y8[XY G+^31O.\]_SHH_$E9C-27*&.* ." .B /B@#@@#H@#XH X( Z( M T8K,5II&)1FAU]4M/+=^P\823DL3=@O',P1ESNBE>]DFA49!BM1Q! 'Q %Q M0!P0!\0!<4 <$ ?$ 7% '#!8B<%*@Z$T._JB@I4_'[_%2,IA:<)^X6".N-P1 MK/R9)3+'."5*%^* ." .B /B@#@@#H@#XH X( Z( \8I,4YI*)1F!UY4G/++ MZ7N,I!R6)NP7#N:(RQUQRB^5K(&,V ..0H8X( Z( ^* ." .B /B@#@@#H@# MXH#A2@Q7]DW$S '2MCR,HMP$T>WTOC]QYVH-Z6NR")R40$SRA9U+\E%I7<:; M[)LD[UC#R(ZW2=XB" M81"$/VS(U<%CF!H)<2]"3)@067$^7[K]""E\%'424!>R6KX&4CQI2%WFF7@* MRCU.,3Z>AX+M4*E'VLEV?).DKU_L6AS-,A_D@_3JLCJD12$%8(494/2+)=BV"/% M8@XY_XM\+ 0XXPV\S@B\!I*I,@N$P\=49H*4%?P^GLBB9DU9S<@DA^> %UE5 ML:*]&$G_&-*#$G"]-^3K2)*: SM/<[B@*4DSRFKR_G*4)5E#1NR;)(F40/)Q MUC3 ]%E!&.?@&+&"2YT@(J?R?'YLV1G]._G8R#$)+/ME\NJE\VJHOP$NR6H M%)!EYY5LOREM)8G4T\DDUTBR/)\!'_!R,B-E"@(V6WSO?(WM$B4YDWQ:94VF M& ?D\/TE'RE^("?E>)S5NIA^.H%_LJ8FE?S75-9;XA/[J50>R<1?7J2 I6W] M44_'\)G9,S!/4N;BH:RC$;8#0C[ :HEM >AG[8+O0^'.5]X)C4T5QD]E(;?# MGH?HU <],@"&^6_HU!\>4WA#WW6?^[&?3XL\QJ*=??SQT_'77T_?GZ$%>YP6 M_C*MZJGR[SK_3/E<6:6]NEKYY C> [=P1CB;UN F:N_U5$[*2J\D ><6: =O=*Y@ M(DJ,OISF;E=/F*,TNI7ASD8EF!(31E.H^ M !CF;%++HUI.6 5;U*LQ7WWO%]?K?[]E-6R<\JR9'\' M1::;DEOM1?[0=N,[KG&'=N3<<8T7#%W/OW+1]NJ7'=\?S/\'3I_'ZSO6LJVL MN'\N;O[AJLN>M1_?9D;.'EI;Y^V^-!%L"ZF6-@C6IF#!4M3[?WGAO$#@>N3N M_'3R&WF;P?>=9[PF'PL^_%[BVQP-.\Z$R&5/X3=(;E%6$2P$"\$Z7+#,LVV] M!M4K+3YS3-N*QN*F-Z=MXSNR]X5P5,ICSTG,=U*\*DO)!5 MF3*XM"KD<_0B/++R\/-O[T_)YP_D^.O7SZ>?WO^OX<3=)4_=HW+U>43)'/9Y MS_B(3&15EP6Y&)5U6S'*FFDE"9M,)*M4U6A>7JB>M+K)FFG3]1S!NV6FREM7 M=R3ZG5.92,X9>3MCXP$9Z->D^IZVXG6L2UI5I6I9D1%H[:::2GU1SB[2:4[F M,@>PP<)YTW[=.2 X:%NNX**<: %5MZRG2;LP56"K+JWDZDL#DJKOR<;SKU.7 M9,7J @HVE@/56\?;==2-9&*@F[V*6?OM\(6D11ZM> RU1_5_M!?0=PCH!\W;W5K,7SMG"Z!E9O^TLEEW7-JEE7 MS2S*0M[^S,!5:AGZ8D5"X$Y-)/WETVH"W%UKUI,*^!I^C)7DM$V6TURHA<+- M6VD8*,Z0R8Q4K,G26=;Q-GQSFE5C_2=\13-BS7T(IEHVB]F27/ W_))5F@.! M418,JYAKS&:=*,"SP)K4^E1]]RH18&'?LJJ9RI8 97JO4F@LW7]XZ?XC:O27 M1?BJ0%\WD'9U^*TJ[>KOTS*'OQ0KM2Q7*PW1E>AW7[Q2Z]]-(EUJH58AM*\* MW4.<==W$O6K'QKKX:^7L[M"RW#OJV6$[YX9WU;R[PVW/]37W ;)QB$_%,%S>X#K$DQ,Q3NW0CWUZS) M4;I1NE&Z]U&Z5;GK _/'GGGIX\>B[^T*_6W Z_5,Q#?3Q<\ U5/IXOT "F6L MM] 9!!7*&,K8=J$SMM(-VP=ZT3Y@'E]L>QO;J](NK,/;#5CFR&Y7S#5X\DJN MS5@-F0PUPEZ#98Y&N+L;V]2,) 8KMQFL--6C.YPLPYK\]BW/T$NHGD43WW\( M\?LD83;X@PBN,^ M@V6:.&(*#%-@BAN,\Z8P?GL@FAAS7]=R7TO?2#7B'W,.B]13-# 5AO*)4&$J M#%-A& GNHS B5 @50H50(528"L-4V!9386<<%D^^#LF/K*IDTV G"Z;C,/YO M)%CF*(YY.HYE53>GMYL-^;9DE5!_O,LJR9NRJE&?]);?4#GT""S3E ,F!S$Y MJ+CAR?S+QPR7VP=K<,@Q=80*H4*H$*J#A0J3BIA4-$H8#SFFCE A5 @50G6P M4&%2$9.*-R85?\YJ1GX9DA^S7-9&Q%PPHX=!>_/ ,D=J6PSG63M,VO66I5#^ M>P26:?*/23M,VBENN-%_PXP=!JSWW1 @5 @50H508<8.,W9[*HR''+!&J! J MA JA.EBH,&.'&;N;)V)F_ ]R-B0_5E(6$N/_F#+$E(&18)FC-FY.&2*D*'_[ M#)9I\HFX) CU@@50H50(50'"Q6F[#!E9Y0P'G+$ M&J%"J! JA.I@H<*4':;L;DS9_VXSP.V;,,&)O'ECF2"UFS%#^ M#@\LT^0/,V:8,5/<<*/_A$UN&##>=T. 4"%4"!5"A1DSS)CMJ3 >G*ZSMTZT MVPGTT$3;2E8#'_I!#QUL_:%-+VBRG1#998L/??<*MO_8]PDBW_C4H\4V;<+. M96N2*$N!88]8?L%F]9L7Y#5<^>?722EF?_VW/[\>->/\K_\?4$L#!!0 ( M -T[?536FX]( A "6M 1 :&-W8BTR,#(Q,3(S,2YXMSVS82 M_WY_!RK_W6@4A(PH0"% "TK?[UMP#?X@.D M+"?4E/W0R,3N8A>_!;!8@,2OOSTO/?1(A*2NCR>GB+;LD3&CB*/I)+*AV/2U\0]&;RY2WZXWQ\@R;. M@BPQNN2.OR1,H1Y:*+4ZZ_>?GIX.W1EEDGN^@NKDH<.7?=3KA<(O!,'Z.;K$ MBJ"SDZ.3D][1:>_DE_OC#V='1V0*.^3C06C)PGF:4N[Q.74"(Z#6X^.3T^,#A)42=.HKBI]8K(N%+=?,]3X1UR,>]# M<5\7ZYJ/>D?'O9/CB),P?WD2<\4!VT3$'F5?BRT' M^M.^+IYB22)R7_;F&*_RBH<%!G1 M^WY0F":E%8J#]ROPR%CQYYRA8;,FKA:43;CP1-XIMWW+/+A,9DA MTZO/L' $]TAUW^^O!%\1H2B1Z3'/"%@(,@-N&'9[T5#[IX>GAS"P1"2Y"K(= M2Q?W@85X-XEZ$:^B2C/?Z&*)S$ 4E4![?#R0 ((7]LGO;N=*D*9V HN$6=>@ M56[N78JJ;4:[9-;4:&"AC%:;?!G3M,U@!WM-#086Q_"L;CGYBY*)"&4N)^[6\*V1#O2^*.V"?S>[-/A@T4)V"Q">'/L:>CH\F"$"53N)406) ZUDC%K/ [Y$8! M>X?,MLC<80&/%D11L,X*4Y;:@ME)-6;H34;:VP[#!AC&/^1H-EI%:]4B_$HH M+=B=;F*7B$%\AA)!'6K;H#::72PPFQ,Y9&/B$HC4IQZ!^&I&A"#N1''G*\QG MYM\%]UPBI(Y$'*JNOODP*57B_%+9%L]X5^H9VC'"JA%E**D!^7PTWB$%&3@=8C0@W3@F/Q!PS M^IB<4>@(&.)9Q^$^A*!L?L<]Z!HD#>E+)5E _]G$Q4D" MNX?2U03=-ZA(.T&J*I34A:+*.L]HXAEWP3)PK90/1*I4N 5%UDP^I##*,7<8=&DAXT)&$%<6#JJ M];W 3&)G<^E3@[@:K^.C'%ZA)&1$H;2L#KXF\$%\('SBWE \I1[5V4Z8O$9J M0<2%+W0V(%52"&DC 1:8CW,PA])12HB9$TT%**PA7=JAWP3]&^H0)LE@+HA9 M0A0BG".RH'B20S&4@&(1'4K-AMCBK$')$%M";$'MM&"(+3?"ZX)Z'IUSO5CR2@1 Z/5V^%B^GMF"7SZED1*&TK [ )@ .&="2>_Q< MLB!(EUM RJ=* F9DN#M8FO6KY9(&"0Q8@%UPD_,EK#1/745O@2V?/4D),\NS MC+@.QT:!B#^5Y)L/;7#U6#HLYHBJ$3O)YT\2"2@0T:'TZOM%N]\WJKE_=))/ MK+Q@_PB]B7YU1T3JIJU+=H;N]>HZE\BN)K9 G<^^5&PFH3>!T [(7>XJI5'= MBM,"<3Y54V.'J8.Z:9_=R,D4]]5B(@N ==(W'5X[S.-4],A*!@N.]7,Z'9HO M76M60)BGLN"63^RDUYT=5KM>@%9@9^>R8%F4Z*E8C';@-IT&MUJ8#%S7:*^C MF_AUC4NB,/5R4^CN*["X3#[M])+54 \ENB":**./T!IU.E?;Q8$[_@$BEL3!Q?")@#(,RG,@!EF\7^CFJV M.%\^]5P(A415AF9,(.B6%-D5(U\MW/=+R[@[WT!=,&\&\EP^(&^4QIQ=NHG3^\Z@'4..[4H9D#L\$E]7Q%7" + MTJ AL% ^9UNP9Y()6XT&9L8)=3 <8:;WC>9\:U@#5:)= MERY0W:&'C7REO\GFFL2=@B:"=8:W-G#01S+1BP0S\V_A7PU%6[PKGT6V>5>J M?I12 $4:H$2%SJEVN)77. #>0HS%6?+YX])MOVXJ^QX^D6P9Z.+1R@"L/_J: M&@&:.$<]>18OR:>&*[PDO=]@8J"@4I34VGG,JWC,0$I_:=I:/@#-D)U[V/DZ M<18@17[A+O%>X#[UA5?[TKN"\YNU?"FE -(:Z,_ &!UZH1+(:-'YUL[>/6D\ M/3658?&4?+JW\)V5;F+:9:HV/G[2+%5;C\T">%&J-G66IM8\"+A5I\))^;W?"1]+9T7&^*".FJ4;;NSH->[$%Z MXN8L^!0@K#38/&-?()VPS>2*K1WZ&5Q5$MT7*Y;W>[VN%P< M/U[["BB_@-Y+?WF'UX;ZFHL; G&?.2HU]Y36O6J'%R?+IW^I#>ID@ M5BT("A1#H68H4@W!?&;*C8+AR:U Q61_H?/0G7MHXRAW6UD6O\HGA6U^U45# M.XIZ-U]!;!+Z-N*UN$ ^_W(!+ EY+&59< M;!I06-0Z W*[\!M6E)>WSI3;X/:F/!(%!:U3/CS& L;@:73*M;(3+'R!\3A]!'G4@W&[*PYDW-1HS\0FZ@,,1-YS< 77=]2=X/H??8!?0/R"2R6APWA82G//Y3U/7XX07?D0!9-;,>]- M=TNE%(/W ,*K1MA55Q&TQWAZLU=FL M@8D$(C'];B'58P4!T7&#;,\?M%%\ Z\VV-'C\/<8:2L:).S$YF(;L.26>V"3 MEA48"*,E0'P7Z(KG\:33F*W=YM_AM>">%WXL+V-BMFA_)DM85JE[4/#""\T.N)@:,NB70$7865&^.;<'SW?(?5=Y,A MJ/;PU8AEGY#_+V5NN-FDM\&"E-LU(8GAY12ML=,^?0VE]#6M"5Y'LZ%.-L,0 MY4\]ZD2!;6QR+=H],GXSD5K0H2M)VM>#RV/KJ^<5#2JXA[X9F5>?OGVV)L% MY7QD)=M](%$[W*RP;D(\3^<@!#A@9$KV66LZFG4T-1FX_$'\Y$/,Y^N$)!Q2 M!]H+@S5SZO5T\P;I_0*SX)3TU3-@18'I=T+G"T7QI-XZ=HDT:I7&,0/C1?>O5VB>,#HD[@J (O,?S6@3>RY3[6^'X&22H%D'7 M6)^_"5H/YNL-X-'!NP"FF>2093/CW[_>3#1A]F?VMNU#"U-O!=9TPM,7-_]+ MJMX?_P_V[P:^6G"A4Z1F19UZ/TN_U2#345XT!YLX::P;L;JE=U)!2]-1F23: M@X+U^5_1 CTT)Y.@B!JJ,5M;S0=G'\V2 Z%CPL@3K%DSPY^%J(T]16_C!J.$ MY_$G':L,'C$UTN[YF+B^0S;W&")KMV+=GWQ\\?&/2ZX'PNHC(A'-IBN[YOF/ M/HL4)R"REFP^;J7RY1^8"4]AWE!&M([)-E$#CM:=&X,IVGQI-CI7@ L,K*9I MG4G9[&[9*THY*QNSM<[PXJ'B"UE.B:@>3B*:5O;("WU(X1RB0H@3%041J<-1 M6>/J4+;3Q$3/,$[>,*RTO*7F: 2DZ483D U#1]GGFC;M;,RX)PUPOFT#6!GW MI $NMFT *V,K&^ FN,2/BW7\X=RLH14$K33H3G"'$%=>"[Z,-M?T1ZG+H6S" MT4J3RQQO8W"VDK74.$E=".4&JY7@V%ELVE18N;>P@%6$F$3QACG51&TW[/X)2M8C1BHM*Z1JI6D/ MD\\<0F%F-E6P\Q5Z?/PB3-:\.I2M-/%W?TY8F#3+FE14TDH3-E-^YMZFL@-9 M8>$6B2-7G2W6>I_"GY+7?%VQ(-67L:B\O,5&UQLQ-)BTPL.D8U8-H0P M5T2M@__?DV=U[J5?4]R:?[.WJJCH1V]'Y3KEILT5!*TUZ@[K;_N:PZZ5>-KI M6FMB60BMSVS82_]Z_@J=^:>-S]-F;]H?#AN_?OCNEW\TF];@8?C)^H2V5L_Q\08-,'<(Y6N&K!^F MO_UH_7$W>;0>L??GS.;(&E!GO42>;S6MA>^O;EJM[79[YY5."8!!#T<]NMRW!$MK O]]F?I@5^$2=S81XT\7"/D<9 LNL6!H#N/" M@,UX$*&4[Q58_?T*W38X7JX(:K1>2^K#+WPT'ZT0"YRAHOC%8WQE'*-YW^:+ M!T*WIZ*0C/"J&%XRSIA14)^_[WGN_7_7>"6D^81\X<'NFJ#17$8P0+Z-B1K8 MRU[J*VD%,AM=HB=[A_B+>/?S.0KR]>';"9AO@AP*F9'@P 5/T\RE+O?UM=.G MRQ7UPC@$6P[0'#&&W."[4+C35:$^=AYNQR;.F@2:$M-IBAKM?.2YR(W'$$ O MFHZ%&!)!>LQ)R6$S)Q8!?DU)<3QE110MOEXN@]&:&"X=\\\97=XVUKSY;-NK M+SW.DZF=OGSS2+WG)\260V^#N!]DT89%F8O8;0,*ERT2TSE4,0UKS4$:NA)7 MLDFH69V0'K$] ]?W,>*0(Z8^=?Y<4 )R9 M![4F[SE0+ I1D0OQ@AWLUP-MZ*S]-02XY\N COP%8AFJ.@!+N&P!.C ;74,8 MCNV]/2,(G#O$ZSALC5S9&'7 KN;"/=?%H<1C&[M#KV^OL _BQQ [)D,\R;Q9 M(]8%H7+.G2 7P0((H'Z"8H5Z/EP-B)Z'GH\83#DAYYA%,WK?9FP/7_>60DOU M4$O^[!I7L6,H!OQ,K5LG; 7^#)9;0:S>[U;(X_5RYWR[)688X;494%V309T2 MHU!=+W%8_ %/'X(4(A#!T@+Q>H N]5)8*B&\$5F(0^AEO=1H;.HFI%Y ^[M- MUJ@>V$YQUH(*Z-IDK*4^.EU0YN>MQ6H 35KM2*OT&H IL)-HSXDT"3^$EVYL M$B1./RY=TO'W1A4KH6F 1+3&*V8B[+8BACTP9(&8))0JLT0:0@ M%!@UAVLF)4FC-J;1)JJL-R.55T)H0N@6"RTAU.<4E?M$BQ1 $8?&A"!MJ.0$NHQ6JP72K9)K3M-I* M6:Y^)=[P!G\KVRQXA+^UW?K/V8^DNZ\1B2+F5[&MXI%R:<=F@C;(6Z.:[ * M?/("I[>Q,1%IYHDF@C=:F-[9'#LRP(<"(Z >X UVP2/XH1!V_[,NV!C1-$\G M!T-'LW6.F3F"046(#<#BA ;U2,11#]N_>&JN%S\ @Y@PF>WX_\;^H@^F!&=A MX#-D+3;DBKH _HF-1/4 G7)X&?*X>H[]-Z2N(;C3HCFCGSKB3Z6IN )R:Z#(ZJH^CL-"B76'GM!]4!],=*-AOD13-HC!BF+K@&0S9' Q3^S%D5"-XQHV+F<._VGR%PA]XA%0=G+X.[7-*%TE6[ M;5SQ6062ZC*IIIC#7F#J$=W9:1-WIJI)'HB&ZI1AAU M$'*YF.N&G*_%B:71/-Y5,T S^>$"$Q7Q2AE"ZEJ2%9N)*CDO0PS0BB$G/EJX M(BB0'6:R)64^_BOXO.ZJ."M,TFL2T$SX 1*G_L0G=5?.J5FUD:P,YI# MHH!AI,HPT1->:7:5ZK,F*CDO.#[:V..B]D9\Y-WO!,,:\T6X[DH57M;XR^-72>#I(U]FA^<* @3$3?%?-P=^A!&?^JX62JJ(OL]#+TXKVQ+]O* M#GIX6],<<;(NHGV9\?-0HL;BX;Y(=,PGTLZ[_S?M'.]M/][6?M#.SQ72JOY- M=,6UE])>NIPA=-[+J&C]XQL=J@/\?KYV@NWUX,SBQ3V]PS)/O&6DG M)9Y9$H(AA&Z#UT'58@?' M);T@B /YA@UC"M,2O,=+2RFU?O$O,S$7@[[(-4Q35?XL7449N:-2_K:-51#](YL$ )B;[. ML2[>F7C76:7"/]I*7'-49!RF:RF$-7A7BU%5RYYR_-WU2$+N_G1 MY^*_&<3.A_\!4$L#!!0 ( -T[?50WET/4K"8 %W/ @ 5 :&-W8BTR M,#(Q,3(S,5]D968N>&UL[5U?<^,VDG_?3^'SONS6G MRV5[DMVG%$U"$C,4J8"D;>73'P!2$BD!($"!1$/62^*Q ;#[AT:CT=UH_.-? MK[/HZ!GA-$SBS\=G[]X?'Z'83X(PGGP^_OIP,GBX& Z/__7//_WCOTY.CBZO MA[='M^CE:.!GX3.Z#%,_2M(STZ.3DW+X"XP\^ONC2R]#1S]^ M>/_AP\G[CR3:7;T%_^O M1[07^78%>, M&1$.?HR6;+RFX8^I/T4S[R;Q&7F?CRO\O#[AZ%V")Z+KJ)6Q!_W6R M;'9"?W5R]N'DX]F[US0X/B*S$:?LVPH?63:G?PVR58=JX^].BS^NFFX-_?*1 MM3W[].G3*?OKJFD:\AJ20<].__WEYH%!9>6&\.[FU84Q3RP8_F:'9 M$\)M2>6-89C.*1D.^_D3.ED!TY):R4@BFI<$;U([]5^>PB1*)J%?J%&B]\[. M/GP\.\V\UR1.9HM31OP]^<^O#QE1J%07GWL17:T/4X2R=(,),N#)9C\:HJRT/:% M4:/$]_#I3B5L3?\=3HBJR1:$=CIK1 M,?>%GC"X]D+\LQ?E9&)6QO&06'&8&>OI2M(':4JT).'C)O2>PHB0C](OR*-# M!(-L/0K1(7Z.,5D&YUX:I@53FJCU2E/W>FL8/Z,T8Z2;T4:: _8D240!XAQ5 MYX+,S(ALJ?B"@$^(K?[%W!(S_=GNY>$F](FQAP83C-@&;$8HVHS:/:]"B\(( MS[N,WM.J(-K^)DG3.X0?IL3$7.FN49[1HW+ [(6,S!?1<='B,J1>B6?T0!46 M$]E6"M3L1WM"BLT<4= HN$AFIS_6$#A'665A:03$177;V0O&NASZS7^E^+3SD3RGZ M/2<$7CV;,S';C"KB-4#C,&:]:3"@UAB]DETH0,%R",J;49\6I6))1Y3XM8]' MU(&?<%R-Z=+]-_;2)^:^R].3B>?-&06G*,K2Y6\8?B?OSTJ7_9_+7Z_)(2RC M(?EQA5+D/:'H\[&DX:EUHA^I2=5$<-'(/K$7D9>FHW%A^+V&C4!OM;?&0I62 MRYIK?8-V3D,7B?YU&>YH0?R6KJ*_^?4!8:J(1>> +[4X0$F?1D=K()>>C::&29V/*TK43S9EM[PNRE4[JMD_]1_]RS%['-+KOP,%Z0C9[YCT3R MK=37&FMUATC5?5_X[1LF2KD[" ;5>8%$MMJ2D72PM^2+8$=ZYRVH\BSI$JUY M?F-KQ#^BV3S!Y&RKM!!$K:V1O]ZS;LD9C!Q(B!%,OC(9QAG"*"W#T1X5HG9B&23U]3>-I7$$S6Z>2VA;$S+4-!VD$AKRVH>QA[# M*\?,G1<&P_C"FX?9.H-EDR]!:T :7%ESFU8^%VV53U-'BY:"C\BYA-"5WJ), M+O'\MM9(7R9.W$4TM::>/2'@0-H%D+FO;.;;-0<$3F^)92#J85'^,R^,47#E MX9B0DQ+UG<_RR,M04*:P"1=#8T=K3!4;$7.C4%M=*E/\MN8L7>KA.R>3_4S6 M74B/=FO[4*PT%7I95#MH3C;&JU<:!FTXUO+;0C#AN=B+VT$093G4G(:6O9U2 M]Z9MXAIL6Q@X-CD86_HEZPRM0X\#7&?-P_[Q48))Q\_'9^1;+#7_1QK]1,'G MXPRS,W#Y2[*;H=?L*F+AH\_'*9K,*O"6]P*TKK2,<3*3Q@"7M";"P-O1'(<) M)AQ_/OYP?)2GA(!D7MCV;3!XOX7!V(M2I,VDY$Z#@.E:L)'+\':$#R;OHHLR M L9%@:C'*_"B%"18%W :F.@#B 2EG7"6LZ"X&:PML,@CK+ M+C^:N\WJ5CS(<8X%\:W:"E<+P#H+A&X4MHH--\"Y#T@HR(4HP.@L^PU!QRKO M.P;XG(5(;76(8VS.,=X4+JPIRJT(G5EVM\] ]@V@QG"@LQ H[X_\^*'C?$LW M/5[SG&M9_O(HN9F M6?\ T!QH#- ["X&R.2"(Z#O.N(QC>2* LXSKJ?_N%;P=UK5- 6EB@G.(Z&QY M*KD,9@'X"$D-"+(>G.588=-3R:YPEG_E'4^0D>$LX[MH/Z$/T2P:?X.R#"2I M+FE-Z_4"MERQAXH,AXH,C?9()Q49WE91@PWSE:B%$68R$+"(YK): MF0!QU=Z'*XEZT\!02P=Y-B7;RQ_K74 ._U:OPV6L-K /TS37@[SL<;C#H7(1 M0E/%J/2$P)8K]SLJI"AJ&5D/.&Q(5ZVH]>%>PN%>@OW4_#=X+^&0D6\L44G9 M@GBL8=\%!,BL+2-G W0O?7(K-K<*QVRG(WEO+VPI/:L M=ZWP>XS;M.1=5=.!"LP8>_7+>I!A:[(.81PSQ!833)^"2&+Z-)7^N"'$.8AA-F'@HG+U[%+X,X77^/P]QQ=HM3' M(=OW)>*BW!T.@[?>#,G%2-)C/]@P_VQ![6-MEXK^(&^ERJ>Q6G!-\R!M:K'F M,#V>5-YZ$X&]U6Z/A*C(M:-8?Q*[N+GP= MESE]0_>.T)L4KC[VMU'Q-N#5*\)^F KCXOKC@*D;*UT>@L;0YJM0]@8F3#80 M3*;938HV3!8=H3%5O&FMSU.EGS66+L/G,$!QD-9UG( 146L@)F%1<(D^:%_^ M=D7O,!Z0?WM8= [4'P=*VB*M.('HJG],Z(95O LK>S)$O3_(=7:+7MA?Q X@ ME;[06"O46TO>-CM#8XYA7S6P*H':]1/7+>:S>4QH4!1391@+U4$M'G)^R\O2 M48^)X/3"F'C:?//Z'A$EE88980,_ASXJ&*:/'4^*$)U,TW7^66N WJ*L>/V9 M/BHOX+[>YI#L"CWA3QJLZ37+P5*6JRS>5N5? !1X#)2*<.\$ O1:W(>4[T/* M]YM-^5::?]UP9GU?D(38P(,BTXX=H0)=7:JLFN:P:J5$LW:,TUE<5&W'KJLV M]GA+0-E^?).W(S@A6&O]GN6BQWLRRDJP(>[N+ #[ M?E?*H&Y0MRIA0M&YFG!41,R:AWJ)%LY>,E-6G*)4#&W[W3"7% M8\^OH"DDA)A%X._0$!#FCYCE^WMH?+=(/#&+R _0$-'(2S&+Q"=H2"BFKQ@^ M?,+TKBFDNAC& 9[K:;>L&,/PN&)E*V?*&,8'G.79??*,803!&:H;V3+ RP-< MABG%+<=HA"=>'/[!YI)>_<]G,[*]DM-Y2.9O'/KT_9WB&3*Z:I(HI*^NK"5D M&(\3/&.]+^FA+4JMU0BX2*+(>R+6018^(V(0T3H'RS=CV).J_#\_DI]2SV?G MJJT9WKHN:/ 3]M(&_2D*\@A1;;%-Q^2U!^*TQ] % S);F=+6P.BH&6HF;^$O-@@A%;FQQ(.0W,?Y>+!+>) MQ6^;Q_V7?(*(,>#3]Y#$-PPYK>Q7U3C4.#D4Q]$2G/PI#8.0F*$/'C4>&LNQ M"-O;8V%-"(V&C<852T8J/0H=]Y$I^S6 AG_H5#8C%ZB5% SVI) M1(SG[#\HN\NQ/Z4G\T%V[868';EE"T9_(,A,KRA=MFTL^[+CH _WM,S+&<-UO_6/TE< M!#?_"I,LXYN$$GE?PCBV#S7L>E;)+,E=HVR4K(<]\R=^1D4 MX)%\2R(WG(9 B+X@ CVA98F9_T-NS#5WW$>F[%O9#],$9X\(S];$RAV.D@Z MZMK=(QI +/+U'N91F F5;G//?C!&XGRROC0GME\'M8K+WF MH_"9AI326Y2M'H7F,L!O"[,(B_/%=B@A=SCTA2'>=0.+];D2'Z$@O<;)C )& M8V%#FCWA17?Y4Q3ZHS$1=7%%5/7^EBL;L[2D^L*M/DKQ=9[$ZUPFH9]??R1[ M;.>S/&)) :M<5Q%;G);&/%)D4?I$QW@3FLG02))2%WN0>NET$ ?T?]0"??8B M%E[++CR,%T3&9;6.U/J".EQH'"L,%HM=33A-!D/I8T(64Y#[&=$T]'_W*$4> M]BF6E\3^CY(Y)6 87^=9OO5,K8D1+>[KSRC.$=6LA. ,>W[V2YA-+_(T2V8( M#V,_RNE%Z0%E*D7!H_7&8_4_D#!,"YOH8PKL5/NY*GW MME>BL]P*2I@%D[#9"@JY(Q"NM"4MX>F+L9H6_*^-&$NDC1+ MB0Q2#VHX#LDZ21K+].\PD#F,$5U T9VWP$D4D<6]95(+F]FT2^?$U%K<132) M-@XH)DPO?TW1.(]NPK%HG:GT=+#87A<9NK4L_PX26YVM3M.<15B[ *"1&0H4 M$J7:5TW)H55,9 B"QT!6ZLH,"- K6ZE7<>@L'WY5]V C:Q8F8/(5),[^W>;2 MZ56BSRCTE2#9+63YS2MV>;G'0#D]5(,]E &63'Q39G'-FE1(=P4/AK0>L%DT M'-:".E.^#4TE=1@HYVJ+HW5Z<4U.=DQ1!8^@=$4!@' ?EJ&1-.>5^:*24 P4 M*^G"Y:894ZZWLFK!<\=;5*KL.2SP@O3G)9,;J<= V3O4G-^A6*92&C%0WI4F M7IQ87#.A%))>P:,@LPQ,P>"PLM-/<*[7UA9G#CL+1>$.\=>FWU7D%GN+._M5&QC>KJS>'2M9[F9\,X6KMY5>OAI]3#A M +;-]/J41(\BI:.,!9<9W.6]8^4CN#L!LU8ZM/4F#H' Q ^ O-DIN6NJX"GZW37:[KN/@K2O4NJQ;5?=U\(Z59*->X>&X9PCTYR6_>;#4.U1P<. MT=UJPXCM@6VL=OO;,&[[8B6WO)EN&,T],)[%]^,-A\SVR$Y6NIH/_ VO>_*? M7]2U9JG)SB[*U*X77P/:;7<)YV)H]U0H)-Y#>UQ)2J?9J5D-W>(4M?L+L M\3N]&2LZP6/F?-%0"EFE)SRV*&G2ZMHJ/?>3+?-O&=P4NU12/%C,/B=^PD#< MV.:#<85)BX)+-,?(#\NG'N<1>W>9U@F9)3@KL\.$& OFQ-CPU@ BUFOH(_GD MRMM:(_TZQS$[MQ DK\-7^I.\!JZD SQ]0$P?745 N]@KIHR\%-&S#C5Q5_\8 MSN8X>4:UVPY#:K+"G+T^T@Z8)NL-)APM8L=JUK<2-%5; M$"8^:K?Q-(Q=)5RJ5A=X7&3W\[H#9@]N[&D8W2N'E,3R=?8:23M]:\Z&WC_@ M^ +48%P[>Q.@)0PR0WW_L&AGNS!SW]F4_9:"H7YFV M7]B (PH+H83Q.\*Q4 MHP^ZIE7QZJ&$NB M&>+V]EEP6Z3M/[M8/7<(F*\UL>=.IVJ4GW=Y]3JG]6=%OO7FC@?/Y\'SV;CK M.XM(U[I2"4?@!9F47*2-^V;M:-X9ZN AE'E306 (W?':2T1#,A/[YTV4*O^Z M#?3&_&8J=I5;/J*58(_&UV'L$45 W4(IL<^8X^LAG\T\O!B-"Z5"_6/5AVP* M%5.IK+"I;0JWDC6OTH9.Y)-?H;E(B\4U%IH<4&:_ >60V(H-F3/+W/CV(3I? MK'[\WQ!AJ@P6-U05J/D%9)WM,U?.!5O^VY2JG?R5QG@[K-KW7*PH8R9?RN3M M3)ZE)NEAGXV#,^[-^I>_)#%:?/'P-Y1=YW$@S^<3-+:7",QF834I:SML\)2R M^[VB#-_&?O8%NJ(H/FBKE@_M9X:?,EZMHLF7$6$S>-*A*Q6PI.&CMC1\[$H: M6$7>9FFH-K,&9:7VA+I(-'2"P(Q4&K;;.1AOZ.38*?'U[7)8<]RI9_S8*O#Z M20]\,#'4]M,K'&JYZ*@=H\"#I.B)[Q(EZ+YVG0":SN&:"QCOJ H4ED-$;,]" MLZ)#YKZ 9]XD43C9.ALIZT2G?>A&IGI_.*@O"VQOXJY]Z#&Q"V1?8.M1@SD< MYNY$S-I#YMUQ8O.UK.25E/<85VD->4 MUCED:TJ',6$-W:-Y@C-$[Z#FA/KS1?G@UV)+X(6W?%H,">!JDS+5:E>=-(O6FY$?*Q46I>%[A8[V0CIW(WDH9_5W>[B+WR7CPRUL#R!P1B\Q MRUZ1%$;2A!VM,=7TR"67H89.0&9((EV\^2BNI/>N >/I=ZW^ .1& M\+1N@^#P>]F\*JOZ+A:7,?7^#@;139C:_.M\NA:K%#V\N-TG.LIF=LU?LK9C@7*N%%YNM'5KRE !*:!@ M[,?#Z_W*AMA$%3_DQ\<-)@HM[H"V%A98KV]*V\JB-8K2CS+%R8L%BQ;@V].P[JQ/?!]<@ZO1EX'<< NII=/C%7_ M8C:&QG<]W7D+*IF4#$8;D9"MF:FZFJ3MC3G$.%_A!:#D;0\!@T/ H+^ @2 T M5ZSWLKY$6BYR89Q.W+ICBB1Q4UE[D%29?\&&_S5QL%?:WM[R6+Z+?(F>FJ(= M_+9P2)>K44%KM\DW+]8/3Q[9/(GIYG\C!E>&V#YSDWC\T*12%VL0GWL1-1(? MI@AE-_0[U#@6R[>P.2@&I&(BZ6#SJ2QFYI;>>_GB90B'Y&Q, M<'[(Y_-H.Y5$N9O%]^$F7G2-A)2O_VZW>/-/9'%B+U*HUKS1TKJEN'DE24'5\K/ZW8'P4SI'8(MQ_"[2H!#25GZSI:(7%FP01 )?FHT4/7P#]L M$6@HD6$2 H?K7RC[(!N V O=*',3UO2BR*L%GGM9L9A=V7=X%2BZ*U=KH-%_ M"!0!I670Y%"LBH+,=P<4@V8I:'9(;CSPJ>SYW3]9EX4_H$"MI)&XZ_Q M'"?/*"A?BR/;R-6K'^5D!=!K!80E\KL_RM)2FZ77[)9A4# M2D33\]Z5-NZ0:CYC\AZ1!4 T^V!.)MSSI^)$24%+<[F;*"*-)G>8: W>]VM_ M[TR97:+4QR';GU146K6Y:_D"^CO/ZN OV +<=(/N@(/&%@03&S6?B'3'KUJ MG6Q9,)%3B[ETN(=OW"ZL;B3@$9.%*VU M@S?#%#AJ[;F6X MZ:,WN''7S!UG#NKW*"#DTTWH#I<^A\+U#K%&+RN/7,8&1&=Y>5L 57491><+ M1I]:X=SM'O;8R+R,27L57ME506%[>[Z "B72.U2="14\#Q,G ;6B%RKR=LDIBX@8OU0FW489XA@F!6 KN3CPL-X M05^W8+X( 5^[C6EOV\MG.5W&S^B2+FUB0PHM)TY+BW[=ZMHM1'^09U-:CDNX M8!HZ@6)&NO(E'1QRD2J9[_R"OAQC&:9;H45Y,.%!H :%V."&"83B/8*F3:4'#IA>:].[J62=P03 Y/Q73VK.>>FUN=WQR.=R%L8:$,*"+:*J@?B+9#;/,V;NC,97'H[I M!<$ENUN3O%D[R=3P ()E._*B%E\S\A%[Q;9VH_Y\P1] $M3K\HO 8*0U7:1! MPL9N^\90%WFS?#\'OQBD4A=@H"LO#6G@PO?F.;S,;'TSG1HO3O4D[H';9M,O-$R;Z:@[Z'JR*YGFH;E;@P90EX@)# MTV'WL*YU4TG;;; R]@P*,QN2(7O&62>KMIB)K2*W7"R%.]U+ZH0IZ&M+#*P/\]#]-"Z] ?,9*?D)O[V9MUECE0#7)%B^%L5A;-X! N?W"A M]7"@YE3RT(>@-2CRC8CD+EZ;]OG(]U0%<"5L\Z^]DO7%>PUG^4Q(6/WO_2,F MR)]?_\U> F/DQ=3XD:RI6A/KA$I7S48CEX@U[X5]?$D>ITF>>G%P2W1)AE!, M/RGVZD91,J=4E@7-I$M%I:?E!<]T3UEGH$@I MH43C9U; XSK/TU9J73L.?R!!9 M.HSOR$D[$=T.ZNWSYJX]FZ?X*WM3'@4JP-FAH6/T-E,9O\8!PA4'--4!U"'O M$Y*]"1J-KU[)/\*T2 EFATIUF$Q\S+WERO[S,YEBFEC()O7,])+D?0*2&ZHZ MIS\G626A.BT]32(MU7(P]Z3DV@OQSUZ4HP$Q5&:%*J ;E4\TPS+5^I[8J*9% M1_F[[D$Z6G)3*)&53GU,,AJ"RG 8IZ'/F#>-JLZGG06VOE/]@L+)E C-X)D8 M71/$_GA)!&WSN(#.7N% M]#$.'GFW26GPL%E,V9*H_IT6F[M-LO^@[![YR22FED(U)-X 3[??WC]HBW5# MSLGEKV@[D8'2,Q'[!_9ZI*+3YM&I=]ENHL?!%%MS&1V"JA*[ID0XFRNF'&"N M =5Z&H;=V0.QK3Q0P_@[>[*SGXJY M%S7 5M76*_;95])F&)]'GO^-'!#)*.F7)$#1H3+8H3(8@,I@ "OO.%T^J>L; M\087_U/S&GW2.8 ^(CR3WOWLYH-OH#P6C'N:/R?T:9R(;-%]W]3<^/(^PUHJ M"'OH+@G8:Y"+56H1Y)* _0#Y/DR_76.$EH[?OM0#][O["VF/JD'V^3T&N#^U M(/O\?@!\J.[0 6N5D'D_6%8_>+@L^U8NR^YQKNOAKJ##N=S.!^2Z]+LXEPIL M\\JP\_')7CP\AVS=OC%?G?$.&:>]0[\\_<',0MT/Z/FNHD,*:[^(=Z1EG$]O M[<_#=$B(/23$[A/B-<<4\$R>=1)/<>?GT7M%*'P *[@UMFU38S4&MMG_SRDE:V4'@XA-/<&@/D^_1VCG]! MWTW%"^GC"/RV@+!O?$9GJS$@XEL)COW'9MCESD$*1?[0 M8T,O8T\8K("[P\ES2'W+[!+E!;M8Z6>7*/5QR#;2#4IU>]M;P>7CTE0XTA1E MZ6B.:%F#>'*3I"DA%2_(WLOR@Q_RI]^(%?>8$/498EGAZ!T'M08&-:(*HRN* MDA=:V663DXLI-<:&\?*E:"[[VL.8>X;'>Z4;4*K M.X0QVJ]14);78,O[-HEJI(S&8P+[;I#P%EUY(<+\N\PJRV.9?$FU676 M,(JQJ1(OY_4JIB$0WAPI]S5&[?9R'#R3,P25B\?D'@7Y]OKD$=YF& ?C\TH' MG.TJ#=QCA+.AQEU J!]$W(= 8&)6N1<< X#RKE&"470\X$[]%E#@^6\NO+@+ M -#++2JGU#0Z2N1H.%X?3D<1-![GW$>A:4?0/C'S^J\T/$_K1,0^4; [AEWY/IGZZ"(:MN:JZH_1 M'<*8/TGMP[Q(JG9WRP$FJAFNR8JZ2&*B*'*B*TJED<3I.2+JHBI05Z\9]L@: M)^L,+QCDMX1/TI,(8E2I02>-477S16LP:[6+;&U T];+&SG*/E ;G-AK! MPEX2XQ6WA\7"KN)C/^B[5G0U52CPH0ZRTKBEEFU.:%K4%&53R-O(-Z!!5?.S M5#2B'AC"41F1>3H\AE2#8_C(BIQ=WB=;I#FR)636L0_):G&;MK MISHZTS\?;91X]GG8&A@;*>+[;JVDYV MT=D^SNYHCIKX"&2\U0:3,2,+9YWC\M;KD#.)2,MXN/?!7/T/)3 MPTS1D<1X=H6H%T^WAYY+\W"SOYK3/IJ&^*I0B%Q/<-$12TGLM&CWHA! M58+ (R'+CC0)15=YDCUDQYE5PL8B LZEU'6,H]A#X%Q*G1'+2"LLX5QF7 X,Y_+M>L/(P82[CK'1)//%"1&HDSNO[]5D,\P7 Y9^#K!0;?NX5PDLUE8;%O$5"HX MFI!=/P1:]7!]5PRQ]V+9VMZ:NXW0;$,G "^*RQ4TM5R"B SP*EH40N< MJ8.FNG;\'M#84*AP)^IC_<(,6>27Z!E%R9Q25Y['E6[1R'K:6T'Y4XI^SRE! MS^0_C^2#$B$3M89$OE2XQ.W=9\'^;: -TN2%'[EMK9'.=#]9H??T5GU4+DX! MZ?RVUDBG-@?V_"SWHM%3%$YDY1SY;1U*I](S8_COBLEL!9BI#"V>#&LVB+8= MS )[ R8F.L6_I(:4 @[ $UU4RR@&@RP"1 %\)SQAS"]-MM$-GDL1,VAW(XE/KF>$W-559'>#8:#R88%4_G$D6&7KSH#A%Y M#38H4N@ !E#W?1\N.0P<=YS5M7QZG6=$$98OUY4/4J67.:K]GC 1T=;%SJ\6 M*V@WLH,.B2;]+#,:(+L>] UH+NLJFG=? -BG$\2;/TNKGR D]LU^GQAT5)^1 M?:?ER:+\-?T/?0+^G_\/4$L#!!0 ( -T[?53<%F1A&H@ $: !@ 5 M:&-W8BTR,#(Q,3(S,5]L86(N>&UL[+U[<^2XE2?Z_WX*W)[8V>ZX*G=7]<3, MV![O1NI5H[%*J=&CO1['#0=%(B6ZF62:9$K*_O07!P\2(,%')O%@5D^$PZ66 MP(-S0! XS]_YM__SOD[0*\Z+.$O_\,W'W_SP#<)IF$5Q^OR';Q[O/RSNSZZN MOOD___M__-O_\^$#.K^\ND$W^ TMPC)^Q>=Q$299L7:/K M./WY*2@P.L_"[1JG)?J 7LIR\[OOOW][>_M-M(K3(DNV)9FP^$V8K;]''SYP M\F/[^4Z-OP.P1/D;G3%"?)#EW&:9"&<9"@>S'I";I*P]^@19*@ M.WBJ0'>XP/DKCG[#:"9$@M\E0HSW(OY=$;[@=7"=A92]/WPCR?/^E">_R?+G M[S_]\,./WU=/=8Z __H@AGV 7WWX^.G#CQ]_\UY$WR#R-M*"SCUB$C'\O37^ M[4__1Y&?)_B9_(*H^O@"2=D;DKB)<^F?^!__JO]R]!CD_)?HW.LO4&IP7]B!9Y M'J3/& Z(TUT]Y#;8P:\6;T$>709Q_E.0;/&B*+;K#?UX+]XW."2K^U.6$#)) M7.[NR&)_"=[C]78MV*$\:"?'?Q]RW9E_1E M%(MM^9+E\2\XZA!JZ"EOXEQCLI$6:71'ECQ(X+M+Z9VG$T(_=B+K!0Y_\YR] M?A_AF'+]]W^"'S^P'RFKY#__NMA&,:$CE(,&@[H1WE;T'*]PGF.R2J\XW7:M M97.4-W:7&YP'\)WQ]UDLGHHR#\*R@_'N\=Y$N$I?R;D'AT9172:UUMPAQ\!# MWH21KT-<%E_(-T?XB9;I'0ZW>4X6GAS]D./ROB2ZRTV6/ 3O;/E@LN5J11:,7-0A'*;/S5UZ$ ECO)]M MUUM0O,#X?(TCHMD6R_0VYT?6?4DNX#$W^C1:3NZ5BY3H];N+-K%::^"[91R:X%]5T],LB^70(\ M)J-S3"SAYGCQ&QC2(? > M!+P)28ZN=9;2(YBJ !VBM(8Y/)D7440,I8+>?\N#G@O=R!E]&3<9J+41QFO8+*J% M=$4^<,S4]='?RUAZ_BXF\!8L5Y2A7A^%9J#'VY1\"7D9MY:4N73IPD:/FRQE M XNVLW(*I;EXO1/AOGG(8(NQNZ=/AQS_O#<1_X0A3HVC!5GLX!G?;-=/ M.">[#M[&[E+TP\@KE08MUMNV\^B82];88GW'*_6Z+B*CQ,=P5H+IR&_4+AI?9 M(?.X9_WJN$_#NN934]=[2%W4CYQ)2(=^FI IJ M(A[,:LV5 ,@#;+1Q,90)])UX5L[@ LYQ<)9%.D^*\F>?>I;X=I=/2?RL"_OV MCS7F]+E_"LCY$[[@\.?;G"C5U&%QG06I]@,>]8B_+YCP%&T3S%61EDN!'C/\ MA(4MS0[EVKU M^E@!H?92;Q'\A^"=_9E?\Z[@XD=@^>BL=\&^3*G?M&('E6W M.*T&H+\B' ]@8%D1A!Q,23[HI^3](^ M%.;K1"VZO)G\0+C,\A6.RRV8P"E+9&OH=USS(U9SW H%>&/#:Q G+H6W':Y" MHE+@-.SVY?4],8.+:4'XB< >)E;3/>A(=&-?O(?)-L+199ZMX95N2_I&EZN+ M( ==OQ!'TOC+R=A$_B/-:CB<_.*,W$1Q64#.?9"'+T-QY\'G_?I)F2_L?)M7 MN:W,1W:#W^B?.JV0<0\;TQ35921;1IN[H#,E]G[-AEM&=N[\B' M_5W2:\@Y_H6O/R]K 4="0<]*\%C1*[CKAA[[^-P^)ZK4T<2+_;XDZ;E9BE2[ MSIG_8'B#M,T_-]0/5TJL^,R3IJCYZ!#G"X^M;GIS%'_ZA=6=<#V1QF MYS!VN3[>?\[(QY92WW 0_HRC^I/K]L2,>,K;RX1\@*!XH6E*1.,\W3V2S7:5 ML@1-6%BX_/N.J3T(^/-#"&7R+,CSW2K+:;'2>]PE4_?XN;A2!H[5KM'S>@,W MP1KW!MV'GIIK=.ZPN)S'3-.NO%#R<7?EEO8],H=L4CF#83BI5!EM[+H@BQ1B M'!5@QP-M*+5>KD9$X/9]VKM[NK(.I6MZP$FM?<17H*4>>4^$PHE;CKBNN*]VG*"V?#F)-3'=9W=Q7OX @+"^:T)^6F'F=K7 M15Y*>YK\5W,_DU_]]0ZFU7Z.S;_Z4[VW>4H=PN3$O8S?J6NX-X3?\X!/E;,N M=EN\!G%"8VV9=!SS)$*:FM2M=^Y%Q6.42.0_TC1T\@EF24(+_EAV-(]NB6.= MJCJ@-_=E-4VC::X4H2H5NHY#6CKSG&-Z@IWCDKR13C-OWZ?]N0.V3P7^^Y;P M= ')QP]DPEZ-M7N\D[-6(/$P5]%%&IVW4_Z[QWE.33K;.S5)_\1<7%_7' :@ MQ]#L>V(&Q9RP?<\(;\^ $$$YZWTI(QZ;TQ!:BHV?06;G6/]12*G)2?T:K!F:'LN MP6$!.+IO3G>/:4P4OW-9%&ISC%J[@L]-X- MB#^//3E-3&7.AU=AFRQ7P[?OJ$=FG?]76V5#B12'4O,FOCZ7A26?;M@N;^7Y+,/DC_C(._V070.M:9]]6)$=0^> MP:_D1/H(5OFE ;* MC0;2?/J?F5\\O-?]-?24L<^&&3]$[2B(0DGV//E4R:&_R@" +,1U^9E6.1W_ ML#\UE>D2_2DNC4%^P6LATD25'_$?5^M-GKVR-+[>33/Z<6.[YT_;9YSRVZ[[ MA-6,FEMV+?/*&DZO'4O4V.NHBP^3)'N#;U *9I(+;AOBIH&L>U^'D/'\@6L@ M;T=]\WW/S<6TWJN*SGO!G!3JV+-&<\R3\SPW#J@TD!^TQ@6<1S6_/!S,XAW M]ZMJ[7$>WP+[$J&@BRQ?DE$[@SO+>S':QCSI'S:=*L(1N^Z';,B!ASS;PY"= MQJ)9;2?Q*29F5WWT0OB+:#%93K[P(-]1]O7I7;W6M)T9G:8O0?I(3]82_;._ MR!A9NZ*,PS-0X?)=[Y&A'SL7);4"NIX, C% QK.A,2"-,L:*<'4#I:U#U)^QQ9 M7] ,K?GD9 Y><:IB\=2%87^X,MJ?1E8W0N@_134#_9G(C62A<7"I0T_-1"LN M+K=0Q?&%[//U=BU:/)QOAWQG^U(YUJRSTYV>0$^4S>:,\^D>H*'!Y!3U?DC+$IQK+LNYP=(XW.0Z9(Y/\G&"NF\DH M.?NVU3%&WK]2TN7I[7..CWQX9OK]B.K:;M2]O?3_:3/-(-G(0">=<0@XQB:: M3QKX(*1%WQ,S ;5^X"%_5\SMLC^8 M4OW=/^3#P7Z%'[6YB1[8\)@I-[ID=V8IFM;>DA%H8$.SSPU6K#IM:U2P@?/M M $*S\3L-B-8Y?![('-TO9%JK:M/JZK@OJIX'O):X-;M?]8\]6HU,'$*5+^4A*X/D"EJZ MI44<]G4&=#+UT2ZLI&RR'H+VE5H^C[^BCK&I,'-*=I%Z:HPOXAYXR%P9/]SQ'4UCVXY_"=XAP&WZQ-IW^N-;X/:9[.0F[9YO-A" ?:$-W5#?7OTN0[[Z ML\\RVQ; \9A8^?[/&^RN4[!C<[/)LR!\Z4[L[!AI$D&"VZDXQ/$K+8(?T05G MOV?G%J%6*GFD-/;]0M6=5 P#&RP.!388>O (W+J3W;DSB L-P6WS^#V.EOD9 MG#U),E-<\$F,6H-CD;#.=*O1-]P_QB!;\7%7';W&'4_PF?/-: MK;+W@>,S@75&/H110D XR #4,8&O$\Q\ED;OPLO0S\"1H!)T!<3W(V*NC4$C MA^HQS7&00.3S,]&)-+'PL4\=7[%7WY:#[[L92W(PH9-S]R$/P.=TOUL_98GF MM%7_[M&E0]/.;X.\W,EIL./]_?M0F)N9J>DI>%CV4!^A^8'.46/N@$YLU7,S MR0YDR'-2![,*$?D*3@HO(W0\X.?FH$^SVA5BD MVN"N=HA?1"?>UHE9TYTV=VO@; ((9,(^;T'':&/:CE*!<"@ Z_Y$YN9*/J-= MYJ[25@)]&TEO/^_R/H3]-61I*:O+=+@P=.BIF5PT(UI_]CPP/U3$7O^5;KPY M'\!;]O"2;8L@C1[>R"O>+5.*9M ]+_Q Q OH8T9-U(S\B,M$'-HE>-T QT MFH!"LWX[DD[JOSGTH=VO@R0YW1:QIB2\:Y3).Y;"*[.48AIDA38(U;<*EV8' M/NW^S\^G8$W;KWNH#_#0T_Y*"//G(.5%W/!"LB2.1 <:(ACOB*D4 M%W&)B1'R2G8;"S9(!YAG\HZ_YN$H9 MRH_VAIE&<09U7ZW[0VT^M&?)UW[4_*FQZPTY?*AW+R<*_R8K@H3%WJ]!16"L MCRO>/XB4]WJH4:5/OHV-!K1Q?PE!Q^#Y^:$?"[S:)M?QJNL\'?.D-[&$DD\A MK8IXH$%CUVA_[ <)>(SN7S >TUBZ<_BLM+$Q":O[/^]1C=&J$)W:AWZTP5QE MV2W95=5\W0&O?1")&:@%M?N&\7B'-T3;Q1&+&A6GNS/6EWS7);@1DMZOGC.B MMS[CD:K P$/S3=TI!LI)/D/67%65:0.HPR '_I8Y@%U>H5$M5U)B0+\A.?S@ MW,(^#*>V-OSVB^VTGO8FW@->DT,HR'Q>3KR0:SXR80,J?^L(8P FY5 M?P+VC9R9-;J7X3B#VWW/FHSAYV9P*G7 V-6(=05/]-[M&14ZF+#'(KW!CO&5 M)U6,'=3P)Q+UV[WF,TY!R>;'2%<^AF:D3>RC7J]K[_CYQ84&\PW&/#F[DIH! MG\3@8_Y/^HOW8!VG-5CIT G?&N_=B:VH* .^:W7LK&V&D3[(@TAYW'8,]DIT M@V1,=^XY[6"#)VY)5H-NA=&@.(//6%:!NW.J>\=;YJK'2=DW?F:H%HT",IIC M27Z!(41>=BN"!Q*SAIC2B9BH'S@S2VEO/%40PBKB:'N>N96\\NS?PY&5= 3F M@%!*/AO6H/J9?#>$J;IZ94#QVH^&YV*>KM0/]D?_N3A7Z69;%M>0X/FI-[.N M[PE_NM9ZDV0[++JDPG[8RT9?L3\@^RU64E]PR< M V0T[*.QA^D=; 6(HZ;I 5A5(:Q,.G2KRD MS^-]*,E9)7WV>EIZ'IB?WVC@HA]^SO\!M5R!SG699&]#_J+>1XY/4=?#]EAL M?#4\X=S2?GOUJ?YG9A!2&9WS.B[XNRDVV?QT%5@B[5FPS !AU*;E9&YX][&YT_NH'.H'#DM@=F=QDFBWR6=P_R__=-=NWR:OMF>;,.1#_L[Z 0 MF>H:[CK!.D;[C!C"5L'GF/U[E?)69@6/1(M -)9+8KO#B8<0FY]Y,I0E,N)! M_U^;=')^W/NL_>C[T&C=]=*.Z09$''IJUK'AZ;!DIF.3X#&=M61CMV6XIQJ6;R:'RQ,/"S-X#!-TR*+4=0'N'>XQ8)83' M+*?[3EKT?1KLC:<.7+]O^ODH03T.CYY(R&1RWA;@"[&A M=U^"_&=<7F[)K=^KQW8,]I>"K%2]% P^B>\IOAV+\RU6?G^_)682&7T'*'!) MUU%L@K+3X&(!"FD.-<@EY*?<2EYG68P)0?<_,P,-=T@MU(VT"PQ[E;(T'&+C4A1?G?-P MWZ?GA+-%SK@0+IQG8L7_E)6LMR]5L-BHO#-KZ4!B+K_ACM9M\E_]*1^K%3G8 M*L=DK^*D'SLK1'>.-?#+7JCNTD/'9R.U\Y1M8!@9FMUOF9\>L'1$U5__@TY! MU+F6KOU.VW^?6U(J*_^Z0D-#SUR?"?E4 ODAA_<]%&Y[_1.#>]%FFZ#9#"E5QDV'W?7Z,#7 MK!ONW.89Y"+UJF#JF",H13JL^UX?(8>>=NHX%VF'G7YV=93_HNZ1V-Y=PXU= M.MU>XSK9#EH,Z&Z?T<\Z/24OXR(,DC\37?"2_$87>>D:Z2_SF&S1*$ZVH'S4 M#6$NWL-D2[XWJ%J%:VPK6HDT?8[7 ^4UQLC/()]YHBSCLIR-3')\NM<8J%OZ MQW-RCE9Q-R?Y#L-<> 0>*0/RA41B%Q!;@5D2Q!K"JSB,NZ%'!A_T?T^-3Y#H M?<2A/G#Q3G%UON(=;.T%X1C^*'Y)8J.W^I[D? F MZ..]R!R_R4I]*\)J9G7$MH:#3!P[(E%*56> M;PE/.R5[>TAU,C*'OY23H(#H"_P#-^)KD( '=9RG8]RS#D]XLII7$>$A)IHX M?1M:!*/A\9Y;,H#QE:5= &#]8X_/@M57EV]P2&RJGS*([B1$SIXOT<7,WI85 MFKT7K$WD,KUX!\\=N=Q>&)H!]!#M6)3AY^:GS(\[=48_[O_ZJ1HTC,C:T@SW M#N[$.ZSJ/[";C"9KX8A^2\5#5@:)_'= #" MH+C$R]5CNLFS5W)>,@6D$5U:K"'#Z!=ZT)[NA)*RS'EB04]=GXV9',?R!^PL M:#W]ETPG/6/=A]7Z4!-H)Z=Q@T50K]SMR*VR"!] %M1?F,N)M-Y'&@ MI[IVL$>TM0KL7A3PPOY]R(0/#-]@#C(&IN=#IDM!JC)01NI]8 Z JAP58. 5]3S@$1E(!/9H>4YUX/#V(?2N M;9TWQ6"_YHE4;8"UBM7?B3Z+ /6C \'>X\&YJ+G]2&S:L5XQUKDAU\MV>]S\ MG'%]N"@##WF/')[C(LSC#2^"Y48H9/^#AY <44/?^/YT'.K;M]LG,OMED@6Z MA/+V&">LG1%S)>^X(]I_]Y^P<[ICW4ZA\>(X\+O&^#DXO$0;3]X.4,GF%955 M8_/U!ZCX]QGPAM$*0/MXW.>>9V>0(-L-9S=%H[4*>##E99M89Z]$:1Z<$5 :'8@177CYU) M=7A5=RG:R0WWUMN#@$K(Y;Q< MU04^'2/9=?Z5,J]'8XNYQ2B*$MXD6+@"I!!T!"2^L*RVA&SL#?T2R^)3=#'(+:#/6[<&J0)1_RT1Y*;;[7G5&"7F41\4RB09#%T01<5N?5 M#D..J;@MBS)(H2RMNU2O[Z$YA 'Y@C+FN,H#J-H23^4G),/Y"I8 MOEF-KU\S8#:@ZOO"J3O>I@NR8A&%AM+O3/7OL^MFT\@JZ>I5/OKQ&9AW].0^ MW=&;:EP$N_V$N:^..96XUZG*3NSZ!+M'^X\5#ILN\[)4]/7A"Y9B0G9L'Q35 MN&<]XC2^25]>GJ7DQY 9T.P['%?+NC<9IT@NM(6QW.86,$-H9@-X E[BS4/& M+E!M>>LA%+Z^BEW'QALL/N(P-N$C'_0IQ\A M\GM& >C#4LKAU#&XQ]-SR8@>3%_M'C_K<$J5@LC*>R:$3YJ4_!G$^#E(+G%G MG*S^^\QP3*%W1B]HP>!C\TMMNQXHY!OQH-\V"RR4"B50O9XU_5B_<8^GX?2 MI_Z( U@%5\0HC],B#JGVUP4<87%"KU< ^=Z"?'H+5:4V$/-3@;.-<@A?GR>\B'&40$%\2+\T=?#:_QSJDCP-'I?)^2G M]/D/W^#TP^/]-XJ49$MFV]Q\!Z#QZ%0<4?.OR5/5>#3/$LS6FBSUV]O;;^AR MPTI_^N&''[^'/W]/&?WF?]/9$9T>R2PBB4=TND/R.,XGHHPBX!115I'$*Q+, MHII;!.PBSN^_?5^OUZ]ES4N<%_B:+7RU/J\5Y9,9KPW]OY]8NV86^O_H;<>Q M_^?,(,[-U[EF\HXA)@^A3#1N5,!1A3*Z0]&&4K8H/GX&B>HF2CK7U*%[@=%& M%7'$Z(I__@(3(#K#_W=D$LIOKB6F/5D>\!IB6TL#>AR7ILKC0:PVX@0!:<0IGR"J M\\U<'K[?*"U$B"%&30@Q<^[EO56_C82_#3#$$;8EB-3Z]#IC>+8'+CZG@@29 M6?(J+[5]AMMI2Q11_< %%E00)S-;?N73I!%$W6>&2F["F)\HEL1];4K>\RL\(E+;GT8AV+ M/*KY(2BC;Z'1"/JG[^R)(9OBN"R^T%)"'"VA]_HVAXZUD.=?/*;9$V3#,F_M M9ENJD2 9MX,%)@Y\H:J/@S"$!$=HF:**)T290C)7B+*%5+[ O*5T$&4-_84Q M9_$4FLMZ*M=VO0(.CM\:(6X*S_ \6N79&F6,<);.F_G6Y<=((: U:\;E>\+- MJM., %YY1S.0@Q+?9,E#\,X^!Y!DN5J137N+ M]F\LR:YIG;Y,U3I'(UZPQB+4F@@1%=5,H(H+1&['B@]$&3GR)>!;7ROLLB6L M4P>HTW60CSYO;U[J)+G&^3.YH3[GV5OYPLM[#GRWC"(2)!&CB3C1V4NAA*4< MB]*V6\Q\;I*UXC268$P.O>EE2^T9DU='KL)U0)M-Q61TCM,0[ZW5->Z#:EIQ M]Y.)692X83!5 M.B-WH#AP[+E8B:2Q"&(V\BU72U!YSL5:+!IK<;2+\%NV""E^!KA+\1ESL85G MFK[ZC(H;6!:WA=W0F=0[9<>+65"9(3X/$A.=(#K5"16ZFLWZ9K-*0^:$M M,Q.9[NIJFJ,25;^-"0\O$+@%2W4C1(77BNT+*64D4J_MOF^-Y01=I$(81H\9 M52?,D7V"( $21R?H@@)FH-,@@73(N0MU7P9Y.4:L4TP,F/0H))-/EUZ9+!\C M4^5(VB(P">;+LN*5Z%YZFS;\(HK(F((Z!6D?K]>8[-9IK@A.DWL:ESD29.SICA?GOD>DBA9-5I,L2WO&(FL-(><.UU03:S)A9)=+?.!_@*<(,J* M1E33Z/X U5 MY%EJ!)_@!-%N: <)W]1RV??/6Y!QW M8J(327#RJF,.^(%"Z,N(3FR+W^B-<+,%Y#MR6L%&EY#J&PTK#GSG8C+$9T-L M.GH:4Q^,-",M4PFI+LHG/?9%D#=$M1(!7XF"G719/=L)>J(K 9'9'L%SO$J M3L&[!&A23UN:.45H<=2>'!*$V!X- '*Z'K18@\TWS1=.9T8R51JL/T%B=J1, MKXYD#'PM"Y,,K,DLEN0S3GE)PB):QVD,1@.XH7F:#@///%!R3IM^]BKU*C'I M+VP"BQJ;%0'E/2^D##JEM.Q*-@,]US@V64=+:-$"NQ&L[R !H.=)&#Q/X[SW M3QKG_;(">:HX1JT;J&(:25PCRO:O^AWT7E9YM6@AGP8T5C)-@;Z-4[3#05Y\ MAW#-I4U8'.B#=JKK?G8PW ]01*W%7*NULOI33X2!8-R=M^I30U\M9Z)V@^I2T9@-(FS:BADE+XVRXPJ/U.O2 M*7MHNUZ#$RQ;*8OQ"&M(K-'3) A__D#8S2"WY@NY#RU>)*VN\C1!9,J-",E MD3#;H-S4=GV:&1%J3R;C',I,15$E)>@LHG,;Y,NFU@@R3O)JIO*LA@\9+8O% B)[CQSA M<#"#[YOU&93L.0/)FE62()^'N<#93++IZ"Z)TZ+@28?,"[W,]G,^;;YD72;H M1GK) 10L#B%;($EL!H?GOHARO&B@W*/HK_<0ZK7$ M, 5)H"RW@T>":T39MEL_&I>B$@GL\YC(DX83LV0ELO03#67"'#_UHTT 58-R M)6V1X)A5:+HPAO1-YR[>PV0;X0A:^L#6W#('Q7+5V9C:@"TILX)J7I!@!@$W M2&(''A(,U6J=XY-4<[19F&%^"07VQ0I.BY/U(5A=401 M7)/FPKQSNB2-7 \A-MGA?1_!6UR^2)['L 9'CP0XNO5B):;VT.@3=3$: <"M MR#D)"^G"YOMZ5:>HT5W)!@"\&<4D5R^1W2/ZBD0FT.ZG6WE\YD7 MC'\A0P+93NLS+YB\@X>DL_<1 YQ14+Q0],T(1Z<[R 2[2EE_"OAHP8IIM=I:B:!M7S'*.LS1RT$ 3>\IRZN!(R<"!DY?T_"_)\1W10 MVK?^/3[T_=4A#213)/H?H6GQ=C$FAY*DI1?&'6#"-"6\E4[G0@DW)$('PD,# MHL-BTI9V0]T$:SP)(:?K\P#"#O!R# LUXELYH:)YJR>?L& C@:B;HJ_P.%N,5F%%V])\BU/K5G0Z.E2+.C"(7C=-6ZP;R<MUR9 +YH>(W$1*PSMQSZ M:ZCI)T(T#XD+M@XAES<5^K&].Q%3G^\;^^X691C5[9AS: MP7_AX9'=Q7OX DL)?JF#8 WBA,)P9))5R;L)4+#C"0%2GET%\Z!J M(H#VEJU-T5.!3G:T4C=U^ 1D#BJ95UF.(O#S"H#>,E,J6/C4-J$(1&R*=HXC M=UN6D''/H@$81Y 0YA,-C4#L> J$L10/4R>M6Z8)_(S*;!,36TTE?ISCNG)?XY+LDTG)WO5$R ^ ZJF0'P.%TE( M]@15(,MK:3]HY/V ON6S?>>J >/VJ?ZN5MB]H6L_?,BB+4H_4)9#=WGL% MA>M%"W0*' X =I M%F&9B'F0F.@XQ6W5:]# 20'5&K1T@P*\P0^XGMEF03-79N7NIQ.4_EHY;O9O MM:SS&Q/$91-7Z@MK>L .K7)HI"<(?U<@Z-I*"C#%/]]!;3^=BTJ3B5AVDUSP MIO#_;'OCO:R1DE(FH?KQ3INH<%"H*",[T)/@=/>8QG_?DCN@"/-X,]%1HD): ML.,2"A7I%$B:P_HA:DM0-;0-\DDR2[0=*F7D!_$[7BZB9,BDT2E.\2HN"WT* M#8#MF-/DZ(_5[T4#335%B:@%@J5N; -@Z^M>Q/968FC+$*FM"-M*G,7D#^2" M?2:6HV%3O28-ZH8;P]V&3,G7)4XS25T12P>MXQ<3O@YX3H7Z&XV%+\58W8#_ M.5J')G1>4VXPTUCJ)P?BE_]J3WH]AB5#S]X2;6NYP3G=K),2W'FD U+;,3O7 MO__VB1WE%E'&[ M!LCCIU.7AY7K %5G3:SH:2<5N:#R)2@1Z*!KL7;DOU>PTA1M$1%]+$ UN-$3 M\&*"?#/E;A%%9$S!_[F.4_SIT#."TD.<4O4O)3ES">17J(IQHLB!'MXR M2^H7.D3G=ZZT*7!5368OO$_T-L M'VN%EC1A\[0N6+ D<"30D][ZA*(/@X36:O_M2&E^ Z$=-W@UM;[9]L03Y/6 MJ\C8?(,N;R+<41L2WOLR2ZRL+H"V29:L0\%4XHAT<=.^Z M> _(,4K/E^N)I4622TVBZJBPIA/+R0B.23>>F(.OU;!HB5^IZ#G+,@'.LK2( MB<6&(Z(U$+N17-]K"D7SE,3/AWD_&Q MI]1@@")KZO 6_W&UWN39*U/>)QUY-7D6 1#_B>09'!SHML14S.9*N%BB:^GK M_]/V&:?<4#=BZ%""*&$4;9W+T[GF^XIQ*QP5EJ_.Z5PKT#HRZ\Z[)K&"( ^= MI'@ETBQ;25E:%(N]I*SV: 5#B"63)4GV!K>\! M"6-^&N)F5-F5IJNE0(.:3 M $+*#%PO9$H5_8_&2(]7_J0I>C65B@?#9D/M],7C%;UQ[QS^]BU<4JK^5GDC MZM0F,RJHY':14[F<*:8&!5-T54K<8DN'1AH:#X!-2;IJIMR=B,PRZV5W9F1) M]&((*>;.?B/AC\FP822=5%[?!ODRIV5,K)^DJ)LP44M.:$,@B5'GGWM5.')4 MTG77EX.,F7L9>_4XUSUP.UK@%L>V!(,Z? U_;KD)KCY54^WY7G7"*>YP@8,\ M?#&>H-IH,E\WR"F0F//8UT#ITO2/P7KS^W,4LB9 Y!@F0ZSVL28"@3LF"X/D M/\A&*Z(X- -%0DF[B.J9%2&1N8?H *6+9,(NA&)'R+8LRH!VIYF"_%P@B=", M>6[V[N%]>9Y8JQJ*<4P/],)F%K<9(>3&/'73':>2W#&\!SBMGM,8]JVP&OE? M#@;.I$\CB7!M&]_9!IDP+I46*\.Z&!).DR$X*Q<>?''#D=/VG*Q0DM&H*:^ MO,V2.-P=O*D891JAD&A7-:&,^E&)IG9?Y/(%>ODL^EO5O+2(.0BN)R8]-'+Q M(E%BXB;KP:Q(\GOR*U>- 6U.@HH!&4>9#FYJ8)\1_G3(P9/ M611 :Z$PV6QV1"?^5:Q"=:745K/D(9=!:0&J>BY-H']3V$2RTBKAU6*S %\E*AP\,9>!KSG8$6!3BB M+4OMZS]&6*\V!J/%PDD,&Q*Z2UL7HEU'3CU)[6)RP^[P154XKBLK=^TL-RZV MKFX^:=3-9U3\D-<,.6F>QO27B:^2Z4#V7]$47N6;AG4Q$.O,2GEMU0/FM!!X M=Y.5A[9;:=;\<8HH!9*6"QL,L,\W2<4V)64['<@ WTI-K;KF/@[A]D$TZ76, MQC$Y9EFUH4LA<.!-8#WH$^L?1Z0G>BV@N;UBR$ O)KE-.O&P>$<^>.G5=#3C MO;#N27$@?0L+Z\-3:PDL"_@TW%OPJ=E;D*V![%P>V4;P4$R'FHWAMH]/FJZ/ MG&$Y?+!/S,V#^LSHI MYM3]EI/]SGJFCR%YDDY1.,'92^ ?)XF970;,$FY,.C).IK.M^)D52]"6A5+E M,300:6D308AT,"S9*5]U&X[WA#5+9)$.-H'US]NP@$F7;%RT12W:T6F1;,C5\4UQ26(,O#-6 W]7%^79JGF\CE%,@-@_B$PE5 MIT#G6T=YO]-@I$]W>@(3ZM1- 7 3';*+E.V2]ADMJF*-ZI?#8K4TW\T/V2+\ M^S;.\766/H-"*64('%HR+3Z4APQQXDA01TX:3AD5[K=,N!0_0[XL?U\"BH V M/4@(]0]4NMB%=.?XJ:P;SHOV&I>$7;)Y4ESL_=Z(C?&4U77\M[=$HB"%>B9! M\8B$$>$20A?5A*M>*.CR**52LXZ(:'%%_01%G/Z)W5=&':DBSQH@R8OEZ@IR MJH+D=ON4Q.%RM<+Y 2EP#8=VE"'G7\T,M4@" MB8NO:#DZTI[EI9 9@;9GG!46W)"8.4$-8)L3%=GF!/%DZE.6@ORUKJ*<=VUG M'>ML[J]V*1O%F186T7Y=IY>%2_K73%JR16/):@1,!DNUD-?KZULH%;)E)N=_ M7>354> UI:)/KFOK+FFS7--G1\*67]MU;+D=]COM"/M=,DB/+9GF*F4%E=.4 MEYLMY!* 5LRZ,14G$FQ(EJ,0;H@DL>E-];DF([,1=/%F/DX?<)9X(@85+WUU M@?%[EB7D;UE.P5XDM@&RBF8@Z__\0'XJ EH#6Y4199 MY@?]A7+D!"+9U_(I"2%'N8:M#H1@^IUGD"5@L+LBLX 9V>,0IAN_B:,?V#61 MV^6&+&-I*OBYKHB2478$:VY<,+7:K26=@VBB**6;'"]T6)-W*,_M;.>L8A]; M9[_5#_-SGA53H4%U[4$I72?!6;,B:8N**] LF_!,5[?+:07%Z!8M'>3('LRG MDL!TN[2%B#]1J=X_O_#'J4T2J%+-LCCEEK HD'2:IQU+]^#C> <)%%#EFULP MAM.7(1L3QHL_=%:]X7YOPSC%M"!*;<__GI?@>E\6\P6WT&RK>EN&^ZZ MAYB4(/'%O+V]??&.\S N\&T>AP>[!-P<*8)51'G]U2UV,P;7.D"P6)\-D&^= M%"Z.B5DOG1QXVVOQG)8UW.#R+"A>;O,,4)RCT]TC6:JKM#+'%H#VQA( IQDS MD&$+,R$Q%7RB,!FX,VM+LY[/B9%C7WS%70/RKY+LK6!@#[6%&E3S6+2$FJF> M$]^H)NW5T2NKX3PF;$8>?P(J,V56EZ ^5U8E[XM]5FOW^C@\2L-]Q/? YO31 M,MS^FFB#"]GXA7%JDC'\0HXG\@N.:#=BJDDS+8!5W5:]@\GZR7?_':@21AP1 M&H658U'6O"'*'-?S><4RKU&NFQO#0BNZ*:),NO4U>%C5(?7_L-5CD*01 MXI/$(=^^) Q-!6*%D_"?#%+GD8S/RR!.[9;7],)#3O?8#,%#^L;VG.31&<3V MM"><#(_&6K2S5))+\KN#*U$$3!KO^;JA M71-$@J)5NPS>QP69K]PMHHB,*?@_UW&*/QYJ6E)ZB%.J_J4D9RZ!'??5DS6&7$LCQI5C-INGSS'=58! M+<1"O-(N*,+O>!Q.699+ZGV?R6$"QM)7O'I-OW\KG]=73' F*R.[]0?6QJDC MWQA,J5,,4@,HHYTHET[01*'Q5,SJX>NV=5.=C1)1I16?$T>B68F:3;J$6 M,:SK9YR&5EX1=;AP[,-"8"P&R6'YU V7GB#+BG$X85L>.%,R\-U5\5X!8!*" M]O*YC8J@)'6XE:-E)=QFY*A/_BO>G&71H>^B8>@PDHC01$!T[D+TV3K612GR M\J\/<0D1CZN4-B$F[W]"03REQ? *!#5KI?'&>%<@>ZD F2S #+6QJLOKHBBV M:Z8V@?/R,L=8M#" D-&7X!U J;PI_U(W7(E3YG8%7JM^"RS Q=G]]2VXXK0E M9#^L8'%BL3@YH7PRX]5I&P+Y.:?EIK##%,_&D>>? MF5@F!>IAW$(Y-5'OMT\%_OL6@BBO4.,XI2RT(H4H+?OEB+R":U)FC*!A'>[A M4&83E<_Y,:CH.]3:SZWS>IMG(<81;1TEL)],(F8)^@Q;LD*7<@:;95U.-1.? M"TL3()T!9U$C] X73-'>;/(L"%^,1*F9H2!(VN[R84:$AC.CDB(04MAML6)& MB,33*ZBP0>YPB.-7N'98H?#$HL"R!\GMB(O%'9D,K^F&-5!EUDQ6I7.@!3EGQ"QH M4U6@T6Q R]>#%2F%W2"DJZDC=_5U]L13-JE&QN8;M)\]-[ZRQE5!T3'*VJRK M"$'@+0@9I]KRH;E5.P,@7KFKD:(9H-K#2\#[7UT*;+!E?B:0P4;60^^]F&/3 M\D?[Z)AP$@@WQZM#()_(.+^4T<\J&?;W-YZ-O\[Y=I M%;+ %=H@7?3K.(2$[<5SCC$#PB_"/*;+-O%TXI11($BCJ*9MZT P* [_+(48 M%4DDT9R_% HLJUM1*J\YV!RT\H!^I_!Q9RE%$#P\UEW1%(=>3=4Z'+Q1>90, MA*8H;EVERQ7T8(%3#]I73%'T5!]IY1 F9N9UU8<%YK >1C O9K_+>\DDI-!N3DL#JVE9 O$TQ;8F\0KII.31?B ]A>#KF&?EQF3]D;X>J\8T\5: '!C!0 MG#7[?1FJ5(C,EA LQD1TB>6J,AB*.YSB-U&P.BFP!!H240@KZ[ @UC&ES;-X M;'D9C$J42,(0W:^FBCA9:SCWYF5IF.\>9+*2*0H5Z>!G^2E+")D$- ?(%64= M8^>6G"N8136W/#N7\?MK7',5Z(.OSVM%^<3^VHS#(Q(-5Z88SF/QATZD%C,G M @S&?DMNJ^N0[+<$#DR=)4'X7FSCUZ.&6);0]RR)U0"5 ?>[]5.6'*K/,QJ($9DAGXHE99G9.N.=MO*[#?)R)S=2 M,E$.,;F:;B:(R0;%[T-,CBNQ MG2 F=[;WI"D29"DF=X9$*5&%E6@%>HO+%Z([;$3_4X 8P/8[GQJ7M8[UR9UO MFXUO*?431.@?D6B-:.TX^1R$:^4HPF(-,'#+5?7;,DJM-7A]F MO@/N7[*\!'V;W4?4\3HM-@@$64*"1-))#Q93DBB!0:#*,D@DNG94=%IXK9"SB0K])64UTXW9F/ M.4FR-SCRC5?ELKG!#-$U%*X80!4'7]/J*/N%+42<4B0P/@WXMXB4MR6@D]-MK(9E5P\S6.Y-TP%&2 M.7:&L0X[D.B/]\^[4YQ]RH5R(IH.,T"@PI%%Z3/ (IY%?"B-K*WWS+'EZR;1&DT<,;.51VRQ2##]Z( M24&(HY)31R4EC\"=LR$36+8>S,K%-Q7((Z@B1A9:D-"@A77()*,"R?OKTP^? M/MH6H59>Q>UE)';MY)HWP'/29-V.1>NIR*.,.^_2-'6<+1,*X4&'%+A-C\(AJ?M M;JRGXH!\@#>1HA7H;!QG%QR18D*+CD9K0M<^1DE8,0?1'60%E?K?Q$1'*&O# MK;CGV[5WE;0\8E6V_)F4X3[)7-7Z"*1,9-W"M21PTBEKIZA')V-W.80] M49;Y,@J? _IN9'RG,C97(* M02E/#^=3Q0"J.7"2,4G=&[2U\J1Z.4IACERJ^24.6*U.?$F'JQT7_QZ3HSL/ M7W;G&=5$Z"]L*HM[R*K(\@O4R@+2 MD]Z=E+,%]'C$WOH[,B1$1[H6!_RQ$K.O7(#1W[;<)?&0+2)R]Q_DH^?E;C#%&^YY12.:R3J:2F+&ZOSKB[_4.C M<*BNSCF!JL>UE;@LH',HU6V0%4,T8 LX@,LQY0UWE M6Q5[B/,G^NU*'-K.5)K;XJJ>A2S\F>_+4%XX:_E;S"2J4G AQH;)NA ]*-J& MY6V>P3]WVA;V5^GEMCS L=^T@NO\WX3.CLH,D!EA8JA>H/_FHM4]W"&1U.H^ M)N84Y<*::>QT;82Q7*\)FQ6^-SXOXA,C,3-54Z6YX4-DLW\52])HE*'=!A9O MX_ %1UOHL--81PYB^=)DO3/;9/K>'5P MEVM1/LNJ,A=R529BU!&0/RK9&ABS?76G3D04(;U%R PL

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ǫ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ⅅ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ɝ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

    V[=NZ'!4:@:4"[. H#TM1!#&$@[ M'0*&F0D-J9>E'/?LU[/1BVU'9>@<*Y'L'6>"/[D+WM^)"UJ 1=!:BB)=1(XNK7WM%.(V8 MO#?EWT%ZF4]W[AA&/1&M"%!5X"4:O4 .KM50"@2'WZ(W[IYW[H?=U3AKN=RG MX?-$L9F!4_)K*;_S/\?0OXCY!-4P MHU@X5/[6@NU;7%'$F-)OJWYR56HU\RM=YNGBII6E;0,1M3--1V^.DS%R5-W5 M/@D"H4TSTY[GU'P6OW;;T%MLHHWC+M=ZW7\F9LT,[%IQDBG.\_OS*!1M3 (G M#@^P,4N[(;6_?;S>CN]M_D1^KFQT^@T[&_K1[WK(/[5Q4/7V\T]LJ&KE6,6O M-U7)MQOO[*XK'[ OT_P,,M7I'* VV6JB=BDQ%CUJD/ KO"+:3;(;\]$4S\XV M]AW?5UM?S4Q6GJW>GI.&Z6/DR8R]JH1[=($RI9:Z(N65%Z),U")4QGB^:F3& M91MA]J^V@>),#X^C%-EQVM_P_6A'6-*I4^TM37GMF[:.E.4_XB+W[@;%RS$G M'R42@-C9H MH,DP UN\V^"XX)[ID(R0&GU%79T0PWPLF'K;O%'+E,/=( O:DGJ7O/^KO>^,:C+J MUGPA2!.-TGM44+HH52D)B#01P4*1*B+21(J E$ 0E"9%0$!!"!V1$I'>I0N( M5(ETDH!T2) 2(&7"-S-K[O?-NC/K_KASYX<_GB3O2B [[SZ[/&>?L\_4\D%U M^Z=?G\J3-6ZK.<;^$N(]_>/25:ZEB:82Y0G%G?PVIG!7?Q$?D4_)9]#?J4!% MA1Q)KPZ84TH7A^+@C@?&3*./7MWYK@$\2IIH=B=T=P4A;-'(:_C;B5((A7;! ML9[FP-P1J>[>NN6XP,7/.U0@>J(R3;9=R&N%6TI*X\RU0@;_F%-O@C0>(EC_ M0,8;VGRDE]%P.2!JX.N!Q :\&\ M\+-X*A +UQ(N_]COSU;,WK7\I#?'BB.THVB12="7/D0UO:\A\+C$YL7?YFY9 M,3W2<1Y<&CUB>%3:D<0V\L176.XA$G>J;W4AU,JW17I8G**<1&0:#)$/-0P M=S<9;B/"$YP'51_O8E4?GV^VYP_M7NW]"+/ -I^&:^*-0M6D";8]*B[HN_)3 M]98I^YIMXG:_3GJN=(7(YQ.="0&]H" N,NX'XPW-3S7IFR0-R-6V*)0B-#NU[M8MI),:PA7K(AVBN9N964(%7>W-&^Z1&6J)DBN(B M=F/=V8@--E]^PJ'#"OTLT6N-%]221>P6BUI%H&TAT!I4AEH00<06/]OUOI2Q MU#OM?&E_;I\K[QTV&RNW=V!#L M)^ #!-_16;C':$F[FWR_*_>FX6"'_,$@X^$LW(18(9I:;X8L7.I\_]"\##K M3==UW&-8N&-+#@S*?^ 22U#%!&W+S[CPX#M%'EX],8!TEU@-91&!=H#07#L^ ML[N_)WLXA@3':!,%B>39X9@]6E1]'JHMZ U;:[7&#\:Q))U MO.5$HTNS*C[&(KTKP>;Z[^,?1U2OAX"2!QXRJQ,^/,(V;N+<26((]WI*]Z$C M200Q/KN<:3,K6^S^P_^P-H^<9AT7C^HRZKUX[DQ@\A,J<-8F@\!!T>^.I )K M0LJ4$"?0@CL=%6CS7+1%M''MMLB[!!6N308\JU%MF3/9'K9>38$P;K@K2CQ^ M;54SM)BB#Q$8=HB-A+YG8-W:',^EP!IUJ8#5.A7XD+Q&4:$"B8%8V\-CUHBE M@BQP>B7D-?1J0WG3D!OJ8M4)VSN)XJ6B$\>OY0:3:[MX%ZZJ 2RXTJ?.F=RZ>((\8M;R24 M4AZ=4==2I4L@,D)B@Y0U!(TZ!B)/D6#X+:L2?<^/TY?CAIFN,,0W]L^ZS#L* MZ8-BYOU\,Z$R\%M@A&M00+7T]^PQW-KG(/I09?L"CZ#^P-2X9CZG&5C*A-N- MWP]* MCP+=']/BN9;7PJ=KW&[:N,BRB< 3QU?8#H$-LZLB97XB?/T!8JV(Z+2(Z++\ M0<7?]U&YD7W'!HT+3!CH2Y@$PI\EC#JJ7]WP,8J:81[.M??!&JH36@W\U78/ M[.1<%P?"]I1:\ VEL3D/)Y[7GP(NO_JU=N6 %=B#15,!?"I-73!'*L#L/M$\ MO9O]FXQ\"F\J1:M71.\'&E"!E^D4CGAB:E NA=VHTF#O\F__%B5*H^.FV>3/ M+6088A[7LB'E3\K/ KL0#6FI%W+W5O;1TT3SS\5XD76!9Q7N5[J;_&OBX<^Q ML?*XF_7J*16>)S]<=#ME6::$291K+_3J_H/*65V0C4)N>231",E"*N5U= BT M%,5$S"?D' R8IK9GGO:H.0U+]O3[*-3X?2[OP;S/W >?Y1'%-:C$3X@V/@55 MU$VI'OMQWYX*^$E('6";_-Y95^7HQRI/;A V%O>^L(,@'EPM')FC M=%S_%/9B_VW8DT@SZW"'P!71]B.-MVI23=O)#E5_W!^VS,39/(LOLIDU*G+] MT:Q(])JU)OH$>0W%5RWGKAOKQ]T#-T-?/2.&!!HSN>:XFD+/#KGYN"G9R>3W MNNMLJ)X*8K[*X'L&'0/W(2 C&^6QZG*S.C\+*\(MKVTDX-@FOPV(#!>2TWW\ MGRH(.>HE1!GH#SNUJC.$A#)AWY-;)Z(T1O9#(":>\4ZEJ7EOS7@%K=P>WU5TST-Z0:!C8WM!B\?8H^]2E$Y[N M <,YF:U= ;[[X5<[@WCPJWIAUXF!V1,:T765W^ZH)3+M6J\&[-RIL15^"^5QE.75GR M^\%48/8=5A$3HX;XV '^-F%?+IQG( Q[CRK\QVYLT((,#^66J>TAF&;(7F8_ MJ[92:#Q43$J6'%'6LGU5:H662JQBS3ID ML1/'>&96Q^GQ"^4.V?%4//>BK_ MT#$AK1=I2DPF!-ZN3=<\-$R)%4C6CD.<.R\4=NE,@_> 50!K-B&QS= ,=W\D MYTKBZMKGLUT>YI+QB[:&2P>&F:]R)YQ]3T66NN6>[LH=? [-VQ&K4Z#;^IT- MZX2\>OYYRL;6]GQ#\Z@CXQD*R(_D!)JBB"%ZY A@LG^3GUFK-8N:019Q M5L>CKKXBZM3G;_?E%L!SK488F]7_->?? WL<3Z0"! C9*VR_"5#>?8861IO_ M)"E[W(>/\ES.]:P:7/>,OT-3X*SBMB&\"7N;"K#B=D/C;]_4=53LG1;VVRKH M[=EG)QZP'O@Z8VNJ$[%FQSF=K']MLS+J9X$SF^6G^K";T2J0L%+>Y)&"U:48%U.@;?9O4O-:_HM;G?LYZ+"V'T..8-87J0U 7C5AS@MF';;$1F,B^$51 TV7/Y=^4[^OB(Y^G_4;.6=]8;7=5=5E> M('_0!-[_>&3\Z]K)X#O334N@PISF!S1GUH=#D@Y6D<1SMA1Y7=(%6T$JL(BF M_=)6=MH]3@,.@J/WPR@]<8?**NC J'G:?Q> ='F0!B@!/D,D$[+4@&^_WE^M!QQD0I ZQAP"1?X5[*]@?P7[*]A?P?Z#@IT\CF4BO76G M_>-?MW!'72">)3\W1QK7C:$*?[X,NYWX/#!;--B2A47U2ZW K6==C)+)@-5( ME;6N;IVRB@/Y9\S"#3ZW J=W-&XGJ=D-BG?90;$%#_'OO'S3BA704U2]W3[ MOG]W:S8P/N&SW.6J9UV615!Y;2 H P.)%N8FO#?W7MV\L-.RT+O&_%L]>*D' MW):TE?0"S?4+_95K#<:F*/O::W(2%9%B4,JOS JK_'IXR;9NJ^'4@IG[= PA M[L-<2)"ZMO831U?SM)4KN%IQMBB.5.TG7J!3+'P;&@?W*O\S%_?3]9%H/"OQ MV5&X34>_@=/C?[Q".1TTIE4G.,()4Y*Y5M?*[KDMR=NT_)M*KNNA(A7X!J;% M:=1;6HAV HW ,-9^LI17;B)4@(Z#) 7N"@;ADY&A5<7I[B>6/0:XWJ($HYYD M)X=^..4YUL1:MRF,^!9V])4O9P]8LL#GR6D('-J6"@3+SO]\CW+%E@FM6$3:2!10;OL6+T"4( MACPH#F 4(O<#01PV#H3Y:\&\5OZU4QD],NOF9'#&X" P5[GV 5MJ07BBT'^T9DQJ8+Z#8I.WQ_HQ2( M$;&V5PT>Y.-CGJ8"08+H,-(YP@*R?=KVWA#I>N*DIO0[9[6<+CZ>,^&W?X _ MXSCI=KC@(_B;BSBE,EVC"BO$TBA*DV#4#3YIX1S/%+X!,?VY*&Q=:=R&,9D, MT3_CN"2GCXNK^DV[S6X;,E"I%>X]SW<;]N7O';1^FNN]YZ1[ODLC3@D1.C35 MT##8'\3QF/[75TZ P34$FORG9EV,"HBP(XI'Y]@,&2@2P"SUXD"-7L;%+]?3Q)%.$X_ MU=J)*D<>SJ,]";D=-@KX@J("EP#MM:@8GSORX_A.));]^\-JWE+H[S0JJ M<10Y$_J>%Z4?S\CJ82! [^VU YHD<=" &HPPV9%VH9@[ ^>F4.E_7+I@JE4- ML<[9Q1L(P/*#3K,-36D*#EURFC?N;:]5_"/6&<^]/,NAII7K+,Q=D[+E]#[7 M,EZ\Z&WS%2!VTHQA'E=T@![FEWDQO*TJP/CP]PQ#9/EFR#' !G6*G$<%YFV' M8*M8(S*#60TZ,G@8L26[A-PAB%%"Q4'H;Z\VZ/T\FVG^H:0%*%%8 NH\2^MPX&LP$-Z@WF'0N'+ZX)5=+7KO?6Y^9GBHF M,C7(-*KXIW#]_,+%JNSZ4Q<93B2JK$]WKZ9M%Q+'YSA'*&.*.1TQD=PS1O+0 M=Y,'B\([\Z:("5O^9BFMHJ $S-#:M)?Y(UWV#Z_$"GZK-PWD X&(P'6Z M5;-P1F^PG[_DC=6Y^:[)(-6P*;,H WP--CZTP%E-/4@:+\5^$NE[5X3\\5<, M&>JR;11;7_BZ43WWO@M4L#EEHI4E;DV;O5RK:TPT5&/]E_=.4>-EPD";1682 MW<_-N/2/#/1.^;&]*4(WOH0R'\P=&C,AG1$"C#$(HWXXR' M_*@')\7J -TBI#-IAJ]84?+R3T$KQ4J[K>3K<\TA>"EGG#*OA-T:;%063(O] MBO2K-;_OK\:@H8/+)-<*!0;JOO*6*N7 =*;$PY0]S?>?9LTS27V#1&6!(>0/ M+?,/"3SD9S3.++ M,S91@'1'.(JG3& OB]ZA:Y?@8TH#RFW A[3@U1T1 5LM[=ZZL1>-I]U_>T(:$^N' +52"U"'MMPS]*XL(5 M(X26$I 5/9=2KA4G"+9T"(R'^^\I+C=S$%LQ1NR_=/ZLF!XX; ")$UN:P@+D M%+5+V]W0MA#5@]]5FQ _QW;^2O['%46E^=\)^U'-2E(UHEY?3ZD(UWZJIP(= MF\Q^ 3_T-Q0;#*+NP:MWOY1\N;QV*0^WXB'51E(L7&GA;1:O;@@\KEU@V?OE MAJYX=.WX*?6>KP/8P$&F$3-CK2+G"LMFX>/O+)3V3'DI.HV0.<.1):@,03E" M5E#GX?=T50F=L_'SILTA)JS9&E]!@-EW!.?YU%8(=]6):^-Z\??*$0VM9"R7 M/R_+[5OI#Z1G>>D^*P%7QT*;YF+M3>4JLNO M?ACRW&<_=8>^-CZ$7V*DD1Z])<&^PE'9UONY=F'A@YNMO[ 7RX!/F!HOQ(TSP\68'J?>=:]%+<*&=+CV0)>>7__'4: MXA@1U5G/9O!EAKAFW#(U(P2[<6"&B8LBO\#_T:N0J+[+G'*;,DGJWE&@&W:Q M\"E %4PY[PV6C-4PW]&;S&9LO' XIQOE+7-_4XT+:U31T?U">I/A$ZS^/AT; MM/; K(!T%[^S&*7&XN]:R'=L6]1*H[S\6.^B5/='L7@KLPR2-+$USSF-WDE8 MLBZE=^/[VSC_V^\?V6J%W/B\/+ X$2*S/,NB:(H\#,1"(F=-+!F%EWDO@#0>Y;3\3U65['/W)DBG<%;S9S N^@&"O?K$!H/7_WP??1 =NXR M\7>(:H4G4,O]VZFCX^GI#8'(G6Z+)*=67EYU;7@/[KCU78QMYRQ1/[O&OW*U M*,W$'>/CWL*G'DD);7H\B7L>4CCR:C2M78/8IWF^,?,!]!VKYD%8-/ '')4#F9*AY919<4>()\M^GONU0+"=K<8JE*OZI]H)3TQ^ M6]MN#O. @R3CR/X+#5[8L;*Q3L!?U MX*I02-9)5GTK M/-,.='JU-YB>J+*J.U161;YQ(6[UCDB?+J\=[SR[ZJ/$X'((+IS \[KE MLRD&.[2]WUC'9J\Z>\6QFZ_[#&)G"6300;E*$.NX]4 M%EOK\Y1\27]@8[KQ_?DSLE0@A9^C%38]2@7PO C"/;J52A,AB$DU6L%5W70 M,5Z&O9\[RB1&=B&.-MY_9/W>RX($U5[Y-X)SS3E3JIJA! M7WJ&T.WT<\U/(-:/SZT6>Z ]5[COQ'W$1T!>W/&"9IE)X(PFN)Z6G"_'Y^=W ML-_(MSA89/T&^V5L!)TG+&MP-]H1*JR&H2)32P!J M%/O^)=SA[$)299YPM$K\W;#!9]O7_]%.0?R1A\G;.&9U;0"^1S#!3K@4J4*%>\0)K\"7O[*&:2R"[6AM"&K5HA>R 1:5%=*SV63-I MC92)E,N#."$!KN]5Z+]Z #TXL5&DD1_1;JYB#L'87GC+!%7PS-.WUTNM#9A0 M#P$"WQ@% %NV$V84K0 P^:C>DEDNZC!=X6] -%5YSY>C57" M%Y0_X?4OGV7A"^)Z R ((_MF*)<#Z^:J7)OEYP_2 VLM^"Z/,O)^VT,E;[N9 M61-%<*O%@0VF:>-4X+G"(T[+=Q7)">"/),]O"G0[I<]L1 F;X2210%?G,A>( M0^*"01>\T#/$\\>@)Q'-/ULI%G;L1<;=._+KWZJW@"<'CKZS8XU!+=449;C! M_>LG3M1-Q-8D5U;?":B^JE:^6"S?4+?MR11')., M>UBXI$%VE<78TC(-1F+WUY2)C&UE=MN2+UH>]K4.=&'LC$Q&;PH7;>IP8"8+ M(O(K&BIH^%GV;<[/\HY;[\:)GD=V,3V'Y%^U96[4#RQ8"8"7/MG@WNC_,7;G M"KN.$5_W7+O@]AG01 OFFA\'!;X)PTL41 M(\I(PXDC=Q,?7JDYO'(">>VY&]G0[T=Q$3$"!^O@/991H?M!E^%&1WZ>QM;: M5)#^RBU@31RT0A;0KQRL#+2^V'G?S4?1-:5S:BN?(1( _F^.%%,W@L[0!@J>E>#(VV?]4277MHP*/D?O' MB!&4AO:CY>X!J+CU_ 8\4^2#%P:]!W#,O9/F:VK@ (" ^C\63E'IS6Q^AWIX MI?Q/B"=18P+?<,>E]5N8SX?%J[ M4W )D_F /\_:3RIP=CJ0TI1+RR)C@P1LKP;WVVX)H5M6)V!D9O10)1W65H B MM@(5KHMO#^#L=_,1O6:97GGXK?#,.>'NF"1T0C1V&Q9"D2:<;PPH0'W4>OA4 M(XE'>OB'YI*Y-Q/O7'60)\T->!_O@_%WE_*^+T%E7;^OL6]ZG5 M05R\WA6XY01:K=\W:FW9\IS=XVJDW$'_3-YB=R$0Y7&E,X5%6E+:SI^F%%[S M[D>7>_ Z\F%>[&6!4:[_4MALCL;'QRD8"6CZ*+V6_G*^0E+_M\Y=AI@X\'"S M#_$]%1!C@9&#[R.6:C^"EA"1O@//\8L=E[J.7_V<' )*JC*PWT8)D=,NX@QU M.TROQRN99R7K!)[U0&Q?MM52P1?R^084Q*I%81X@/.!($>K^$Z!7R507F+H?3W6W5CF 5_$F^!2JY2, M0RT_G=\=!D$GR!G?( I0XS<<\9@'_A KLW=P+6+Z1_BMAJI!!745K"K'IP5U25G23 !;IER0_C:P0ANU@8X0?,)T\EGP.,YTS6B3A?2E)>,19=AV2\F) M9DE8Q+:]63E<%G\?#PNS&UF41(]+5<5>4PC M9#9B1S-[0" 5>-4R?WL(L=H%)@,F&?84#9H;W5FGT7B7FG_O'2?0[X'Q/LJ- M\T?'+L__X]CE4:XMFGW1O/%Y=BI :?5"+/TJ7F']1Q5IWT";"B0EIU+:T4LN]\A*X39;0L*O\JLB@[+P02:[?Z^H&##;L;E_P8;FB%#* M*%%R&@Q'HVB(G5[P[VVZTD-=(F*=7RD5RYRT6/5V\J8&A6E!?Y?A-!4 %:P& M0^4I/[C1P;[N*'MKF3\]TG)EM]2/=AN^ .<'(&.WZ;"(8RX3.H/#1D_A)51@ M0'N?9@?"],TJP^=&??HRY-N&5",+6GIUF/1%?\5T!#) ;O(#!ZYSMA%4H!PJ M:#GU+?VIH@3_<@7:&0,[D04AQ_KN9+ '2 =X7GZ'9PN>,;DJ,RZ+42!4R0EB2@.B G3;,6[XC(/_I1\'& MPW.1("EZ3?=F.B95K=-Q&5)#:K*'*LZF=W0]L8;:.V(3+)4UC+QA#S:._:D+ MUVL54/&ZV@G 5QWLGQ=9=SO;NZK__/Y^G.UTJN_7GK8X(P#9UF39CJA 1U49 M;I9.:>9TR''=NBAJWW7RIUNVOUK*#]U;SVSUG.I/)F.FU9\H!#)+EZ9"1 UB M.P#ERRO](="'^E=6+13HVHCV&)ZP1AE19>X#]TG9G(6G*,O^)QM3S+:U>:!9K6D&Z:XES*K_/"I_,TU/=Y\*EDJ&XA/O!W'B;B+E) M_[G!=9N9J[_47N0[]H @'8;N0QK'3$>E978,57ZWK1^?G-(9TLN.[$T(E5,Q M21,'9>!K7FQ#&,_W+OG&/[W(+/?T/?+*\EY4M\5,)O/3++^+Y_3MWKCY'AL,P,J"V05YOPXLS MWR^UR]%;-Y=Y=1,4*[0!KN_$>,SF*[B9>+KY$"9M#M'G_3A.:\?A#+);<>2V MAB JHEF :-"&IE^\,90=-^^=J>-L'?RJIQL3G:J/YXFH-&*W]@MMZ\>-EH5% M..$0_&S,64/:L?6,K'F'(\<'+V__D"\C%Y.8'#Z MF,N:"UJ^E1-RMKZRNKDJ<6R#N4QF7L!&PECN\_89O&MX/5%B[GA1VMUL_YO= MHMK/)&7G!4#X,DHTT(K?"R5=Q1@CRKU?!^K:A;^A'SZ]9!WU)%BQZ:B-S3]- MXDI-KKXBIN-WC2)5?&)+ A+-TYWY^A2@C]="+H\&&#.80D'X@=>-/-G0JGQM M3SGS#FX'&<$0-\&G=UB$NZ/'\)OM2!:B*:+2647ALM4N[;=;!1U/JL%WNCFE M>0XKJ I=S6-/-V<_-V?O.Q2#J[+-HO_H,G'Q/>J^@+IIV_$^KV=?'K'1[0A' M3)DVV)'X\=[;'2$]6WJUNL6]I>FC*ONE7 MTK'G-,4K8C8C*%SXRE!KB$Y-*-Q^X$F/F'KP8]'XMGH+\:R34O>)!G,9@<:! MA]-,>SH;C_K%Q[([\9@S8I<*Y.@[YW*S2__K"R.D:7TZ'/[?;@HT1# MRYP0UL5&D[E8IJZ$B>XR"_6VB93+QY*3CI4CZW4"6)><:,/]<;IK[K)OO5LB M[[K;0_.<:YV?LQZP9=+^E*8C@FZ8MQ&?I:9[Z415A_%EO[;>GM \K"4KOYP MJ8*AY*3AYYANUR>A5]Z4/^3TGM]R6>>D$^IL5/;=LIQJ%QS\EF]SE5/NLWJD MNK9_9CD>W&J1UZ_8^+S>]7*/I7[X=RI0CRG?YD49YX2HI1J1,]6$G*\DK@3= MVM&D F;2O='!#9R0L2;5F\,E"I;,:]Z3>J5N]KSF.59T-*^^5_SVJ'5/-!R$ M&> S<+]8\PC-;EED/O[8^XSPK 1?65HT4)CO[)MV,=6MX)?V@L6DCDB4W*U_ MR+C :)@^TT9\BK@!"==1JX3OU%$":4GSWEWUWCQO)V&,N1.0-*& MJ\[1N18=-JSXQ=>G=6KR6KU7+GWYD!>M#BHZ$?]D#)J$?_UU0G%BVM+IMEJO M5ZFGR'?.0REVF*"9FS8 )<8 12L@2@SY[K:4U:F4)?I_*&AO"$U,0#99/-" M&_ ?((FW (C!<^XD-EI6%9U+X;0-@2V=5J8PTJARIUGN;0TNA28EM,[PNO&J0]@7EXF@IC6^;_JX$Y4'\5H; M4M>B@3^!\2]LZ-*N]108G42$J]9=/DBRJ(>T(8_Y!6">/JF\8H/Q,+5,<8X4 MR::+ @Y#I"K^^SY821<+Z_#RA[L6R1]X?%%[.1F@HNTKZN35,.2<64C!NV_U MCPCT7G=4BY0H>4=M]'F%!?%&X:0++YW2;G*7M9^0E14!7ULSL)^\4GH@GL7F MYMH6P!2Y$&UM?Z.ZR>]>B9O*C#\Y]_ KZ M17?WM@9SK]"-S[20HJYMMT0YCI^-V#3\G91K<7_J[>7WYVX*%3+$#YJNMDJ&? HKV&$PS..E^S^)SX*#%?>1XC< S"FK= MRXWB3W:M':H4DFJO/M>G]SGTQY37G?-=N!6C.T$#BKFTJ/(:"V%>$I9\]7!L MNSBP/Y=YX]*2.E<7;S!C]<RHDMV], M_^$0@$G.TNYS\KI]QV&MHM= M)\!48$S!40N>8D'O_A MN9EY]L.:01U-Y6PN.='$21 M=AZ5@=V.B?.Y+E"7_MT,))00HQ2D<^PH>? *%B>Z86QYK65F4 41#2:3NY%Y M3E/Q6I68%D%L?:\X* V?&K(-9I 9')+)BYQ^\B=-_WV?VW1-T=RRG]H9P+OZBVSD;?KN5(1N_*1LW\WR M@48PM331XH(:%O$BF#[3_MQR4AM+C]Y&WN1!DK5NA!H'IH4EF_]BTK'BS^T& M?=_:!QO8?^W^D J.!J1X+/ 1$8W:GD)=Y7D3,WW\3W3?>YD\^P#NH@T'YO6Y MZ+$9*;]3NFQZIT\'2+X(.::B-^R4*<$IIY+LH-ZZ(C%JS"@<.S=[TB^ L+$= M*SSV X.[7/FF@.6.ILCR&YCDU/]8Y_>_,[1Q+"QT1JF94( J<>YWYK>:[?<$ MOW_%J,"QLK;0?\*_I MRN9:4Q_;E/YW)B)&/HEJ1B_H7-^'(4 MJS=&(OW?O-CIA/=YXEVQ;J-&; &UL4$L! A0#% @ W3M]5-P69&$:B 1H & !4 ( ! M1#\$ &AC=V(M,C R,3$R,S%?;&%B+GAM;%!+ 0(4 Q0 ( -T[?51L^CPZ M7CX $C!! 5 " 9''! !H8W=B+3(P,C$Q,C,Q7W!R92YX M;6Q02P$"% ,4 " #=.WU4&6!YA94" M$P #P @ $B M!@4 :&-W8BUE>#(S7S$N:'1M4$L! A0#% @ W3M]5)%LB]HM" F3D M \ ( !Y @% &AC=V(M97@S,5\Q+FAT;5!+ 0(4 Q0 ( M -T[?50O>J>Z(0@ (TY / " 3X1!0!H8W=B+65X,S%? M,BYH=&U02P$"% ,4 " #=.WU4;&>9LZ<$ #P*0 #P M@ &,&04 :&-W8BUE>#,R7S$N:'1M4$L! A0#% @ W3M]5""9E5VIP$ ]U<" !( M ( ! .T( &EM9S$Q,3,U.3DP-U\V+FIP9U!+ 0(4 Q0 ( -T[?5046L34 M6RD ! M 2 " 0Z5"@!I;6

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

  •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